name1,name2,name3,name4,name5,mean_cp,mean_odds,uniq_a,uniq_b,shared,score,treeLevel
Body mass index (clna),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,66.01,91,33,0,44.97,1.0
Body mass index (clna),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,66.55,91,16,0,18.81,9.0
Body mass index (clna),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.33e-25,66.36,91,71,0,126.4,5.0
Body mass index (clna),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.96e-32,80.2,91,35,0,48.46,21.0
Body mass index (clna),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.09e-38,66.28,91,110,0,166.28,21.0
Body mass index (clna),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,65.62,91,37,0,52.04,1.0
Intravenous Glucose Tolerance Test (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.71e-06,39.14,5,18,0,6.39,6.0
Ambulatory Care Facilities (hcro),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),3.28e-08,64.82,17,13,0,22.94,2.0
Ambulatory Care Facilities (hcro),LOCATION_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),3.25e-08,67.75,17,11,0,18.12,2.0
Ambulatory Care Facilities (hcro),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),3.42e-10,68.96,17,13,0,22.94,2.0
Ambulatory Care Facilities (hcro),LOCATION_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),2.75e-16,64.25,17,27,0,27.7,2.0
Breast cancer invasive NOS (neop),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.18e-06,24.52,6,18,0,8.0,1.0
Coronary Arteriosclerosis (dsyn),AFFECTS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),4.82e-07,26.23,6,33,0,7.09,1.0
Coronary Arteriosclerosis (dsyn),AFFECTS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.91e-06,26.77,6,16,0,8.25,7.0
Coronary Arteriosclerosis (dsyn),AFFECTS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),4.81e-07,26.57,6,71,0,6.51,5.0
Coronary Arteriosclerosis (dsyn),AFFECTS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.81e-07,40.42,6,35,0,7.03,7.0
Coronary Arteriosclerosis (dsyn),AFFECTS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.81e-07,26.5,6,110,0,6.33,7.0
Coronary Arteriosclerosis (dsyn),AFFECTS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),4.83e-07,25.84,6,37,0,6.97,1.0
Knee pain (sosy),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,20.15,14,18,0,24.89,1.0
"Surgical Procedures, Laparoscopic (topp)",compared_with,Open approach (topp),TREATS,"Aortic Aneurysm, Abdominal (dsyn)",4.66e-08,11.68,17,32,0,26.03,4.0
"Surgical Procedures, Laparoscopic (topp)",compared_with,Open approach (topp),TREATS,Malignant tumor of colon (neop),4.66e-08,10.92,15,27,2,23.33,4.0
"Surgical Procedures, Laparoscopic (topp)",compared_with,Open approach (topp),TREATS,Primary carcinoma of the liver cells (neop),9.29e-08,12.57,17,11,0,18.12,4.0
"Surgical Procedures, Laparoscopic (topp)",compared_with,Open approach (topp),TREATS,Carcinoma of the Large Intestine (neop),4.66e-08,9.49,15,50,2,19.5,4.0
"Surgical Procedures, Laparoscopic (topp)",compared_with,Open approach (topp),TREATS,Octogenarians (aggp),6.04e-08,17.42,17,10,0,15.88,4.0
"Surgical Procedures, Laparoscopic (topp)",compared_with,Open approach (topp),TREATS,Aneurysm (anab),2.8e-06,8.92,17,11,0,18.12,4.0
"Surgical Procedures, Laparoscopic (topp)",compared_with,Open approach (topp),TREATS,Ruptured abdominal aortic aneurysm (dsyn),9.86e-07,13.1,17,9,0,13.76,4.0
"Surgical Procedures, Laparoscopic (topp)",compared_with,Open approach (topp),TREATS,Cancer of Rectum (neop),4.66e-08,7.88,16,33,1,23.76,4.0
"Surgical Procedures, Laparoscopic (topp)",compared_with,Open approach (topp),TREATS,Malignant neoplasm of stomach (neop),2.23e-07,9.01,17,13,0,22.94,4.0
Alanine Transaminase (aapp),PREDISPOSES,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.79e-10,44.83,12,23,0,18.26,21.0
Alanine Transaminase (aapp),PREDISPOSES,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),3.33e-16,44.27,12,57,0,14.53,11.0
Alanine Transaminase (aapp),PREDISPOSES,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,52.74,12,9,0,15.75,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,15.74,34,9,0,11.38,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.37e-25,14.8,34,194,0,39.96,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,13.52,34,17,0,25.5,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,14.79,34,29,0,53.74,11.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,16.97,34,14,0,19.76,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,12.78,34,12,0,16.24,5.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),9.83e-23,11.6,34,48,0,58.08,11.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.51e-19,14.99,34,29,0,53.74,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.37e-25,12.04,34,98,0,45.8,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,10.7,34,24,0,40.94,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,17.11,34,10,0,12.94,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,9.47,34,37,0,65.24,7.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,11.28,34,20,0,31.76,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.37e-25,12.93,34,94,0,46.3,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,18.72,34,8,0,9.88,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,15.59,34,19,0,29.62,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,12.75,34,21,0,33.97,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,17.93,34,12,0,16.24,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,25.65,34,10,0,12.94,21.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,18.23,34,10,0,12.94,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,12.55,34,21,0,33.97,21.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,14.16,34,21,0,33.97,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,12.28,34,32,0,62.12,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,19.64,34,10,0,12.94,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.37e-25,18.61,34,39,0,63.64,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),2.37e-25,22.59,34,44,0,60.27,11.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.37e-25,15.46,34,113,0,44.23,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,12.99,34,11,0,14.56,11.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,12.72,34,11,0,14.56,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,13.18,34,12,0,16.24,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,11.07,34,25,0,43.38,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.37e-25,16.75,34,87,0,47.29,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,11.74,34,33,0,65.03,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.46e-25,14.47,34,41,0,62.2,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,14.64,34,21,0,33.97,1.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,12.31,34,21,0,33.97,9.0
Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.37e-25,13.25,33,1020,1,34.07,11.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),5.11e-06,24.87,6,9,0,10.0,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.52e-06,23.93,6,194,0,6.19,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),2.52e-06,22.66,6,17,0,8.12,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.52e-06,23.92,6,29,0,7.24,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2.52e-06,26.11,6,14,0,8.57,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),3.58e-06,21.91,6,12,0,9.0,5.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),2.52e-06,20.73,6,48,0,6.75,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.52e-06,24.12,6,29,0,7.24,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.52e-06,21.17,6,98,0,6.37,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.52e-06,19.83,6,24,0,7.5,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),2.7e-06,26.25,6,10,0,9.6,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),2.53e-06,18.61,6,37,0,6.97,7.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.53e-06,20.41,6,20,0,7.8,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.52e-06,22.06,6,94,0,6.38,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),4.86e-06,27.85,6,8,0,10.5,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),2.52e-06,24.73,6,19,0,7.89,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),2.52e-06,21.88,6,21,0,7.71,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.52e-06,27.06,6,12,0,9.0,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.52e-06,34.78,6,10,0,9.6,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),2.6e-06,27.36,6,10,0,9.6,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.52e-06,21.68,6,21,0,7.71,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.52e-06,23.29,6,21,0,7.71,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.52e-06,21.42,6,32,0,7.12,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),2.55e-06,28.77,6,10,0,9.6,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.52e-06,27.74,6,39,0,6.92,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),2.52e-06,31.72,6,44,0,6.82,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.52e-06,24.6,6,113,0,6.32,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),5.27e-06,22.12,6,11,0,9.27,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),6.69e-06,21.85,6,11,0,9.27,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),3.08e-06,22.31,6,12,0,9.0,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),2.52e-06,20.21,6,25,0,7.44,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.52e-06,25.88,6,87,0,6.41,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),2.52e-06,20.87,6,33,0,7.09,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.52e-06,23.61,6,41,0,6.88,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),2.52e-06,23.77,6,21,0,7.71,1.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",2.52e-06,21.44,6,21,0,7.71,8.0
Obese build (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.52e-06,22.38,6,1021,0,6.04,8.0
Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.2e-09,13.36,14,18,0,24.89,1.0
Obese build (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.98e-11,39.29,9,22,0,12.68,8.0
Obese build (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.43e-10,38.72,9,17,0,13.76,1.0
Obese build (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.29e-08,34.78,9,27,0,12.0,1.0
Obese build (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.38e-08,37.74,9,15,0,14.4,1.0
Obese build (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.56e-10,35.94,9,24,0,12.38,8.0
Obese build (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.99e-11,35.56,9,34,0,11.38,1.0
Obese build (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),1.98e-11,36.99,9,40,0,11.03,1.0
Obese build (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.24e-09,43.72,9,12,0,15.75,8.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,52.7,26,9,0,12.12,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),5.04e-36,51.76,26,194,0,29.48,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,50.48,26,17,0,28.12,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,51.75,26,29,0,49.31,11.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,53.93,26,14,0,21.54,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,49.74,26,12,0,17.54,5.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),9.81e-23,48.56,26,48,0,40.08,11.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.51e-19,51.95,26,29,0,49.31,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),5.04e-36,49.0,25,97,1,31.44,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,47.66,26,24,0,46.15,9.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,54.07,26,10,0,13.85,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,46.43,26,37,0,44.27,7.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,48.23,26,20,0,35.38,9.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),5.04e-36,49.89,26,94,0,33.19,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,55.68,26,8,0,10.46,9.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,52.55,26,19,0,32.88,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,49.71,26,21,0,37.96,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,54.89,26,12,0,17.54,9.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,62.6,26,10,0,13.85,21.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,55.19,26,10,0,13.85,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,49.51,26,21,0,37.96,21.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,51.12,26,21,0,37.96,9.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,49.24,25,31,1,45.16,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,56.6,26,10,0,13.85,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.28e-31,55.57,26,39,0,43.33,9.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),5.04e-36,59.55,26,44,0,41.36,11.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.04e-36,52.42,26,113,0,31.98,9.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,49.95,26,11,0,15.65,11.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,49.68,26,11,0,15.65,9.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,50.14,26,12,0,17.54,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,48.03,26,25,0,49.04,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",5.04e-36,53.71,26,87,0,33.77,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,48.69,26,33,0,46.48,9.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),9.09e-27,51.43,26,41,0,42.49,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,51.6,26,21,0,37.96,1.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,49.27,26,21,0,37.96,9.0
Overweight (sosy),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),5.04e-36,50.21,26,1021,0,26.66,11.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,28.99,16,18,0,30.22,1.0
Forearm (blor),LOCATION_OF,Entire radius (bpoc),LOCATION_OF,Fracture (inpo),3.33e-07,11.25,8,6,0,10.5,2.0
Combined Modality Therapy (topp),USES,Metformin (phsu),TREATS,Pancreatic carcinoma (neop),4.72e-06,14.7,27,9,0,12.0,4.0
Combined Modality Therapy (topp),USES,Metformin (phsu),TREATS,Heart failure (dsyn),1.36e-08,13.48,27,14,0,21.26,4.0
Combined Modality Therapy (topp),USES,Metformin (phsu),CAUSES,"Acidosis, Lactic (dsyn)",6.32e-13,12.99,27,22,0,39.93,6.0
Combined Modality Therapy (topp),USES,Metformin (phsu),TREATS,Diabetic (fndg),1.59e-10,9.17,27,45,0,43.2,4.0
Combined Modality Therapy (topp),USES,Metformin (phsu),ISA,Antidiabetics (phsu),6.82e-08,8.84,27,44,0,43.57,5.0
Combined Modality Therapy (topp),USES,Metformin (phsu),TREATS,Malignant neoplasm of prostate (neop),1.91e-08,14.22,27,13,0,19.26,4.0
Osteocalcin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.29e-07,24.68,7,16,0,10.06,8.0
Osteocalcin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.02e-06,29.85,7,9,0,12.44,8.0
Osteocalcin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),2e-07,22.24,7,31,0,8.58,8.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,22.52,89,9,0,9.91,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.53e-88,21.58,88,193,1,128.12,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,20.31,89,17,0,20.25,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,21.57,88,28,1,36.91,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,23.76,89,14,0,16.2,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,19.56,89,12,0,13.62,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),9.81e-23,18.38,89,48,0,73.89,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.51e-19,21.77,89,29,0,38.45,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.74e-50,18.82,89,98,0,169.83,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,23.9,89,10,0,11.12,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,16.25,89,37,0,52.38,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,18.06,89,20,0,24.49,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),6.68e-54,19.71,89,94,0,173.27,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,25.5,89,8,0,8.72,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,22.38,89,19,0,23.06,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,19.53,89,21,0,25.96,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,24.71,89,12,0,13.62,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,32.43,89,10,0,11.12,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,25.01,89,10,0,11.12,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,19.33,89,21,0,25.96,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,20.94,89,21,0,25.96,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,19.07,89,32,0,43.51,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,26.42,89,10,0,11.12,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.28e-31,25.39,89,39,0,56.09,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.34e-39,29.37,89,44,0,65.75,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.12e-79,22.25,89,113,0,159.1,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,19.77,89,11,0,12.36,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,19.5,89,11,0,12.36,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,19.96,89,12,0,13.62,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,17.86,89,25,0,32.02,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.68e-65,23.53,89,87,0,172.04,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,18.52,89,33,0,45.24,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),9.09e-27,21.26,89,41,0,59.89,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,21.42,89,21,0,25.96,1.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,19.09,89,21,0,25.96,5.0
Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.53e-88,20.03,89,1021,0,96.76,5.0
Boys (popg),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Ischemic stroke (dsyn),4.17e-06,49.1,7,11,0,11.45,2.0
Boys (popg),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),1.64e-09,46.33,7,34,0,8.44,2.0
Boys (popg),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Septicemia (dsyn),1.34e-09,50.69,7,20,0,9.45,2.0
Boys (popg),LOCATION_OF,C-reactive protein (aapp),ISA,Albumins (aapp),1.34e-09,47.93,7,30,0,8.63,2.0
Boys (popg),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),1.25e-07,48.45,7,15,0,10.27,2.0
Boys (popg),LOCATION_OF,C-reactive protein (aapp),ISA,Acute-Phase Proteins (aapp),1.34e-09,45.52,7,77,0,7.64,2.0
Boys (popg),LOCATION_OF,C-reactive protein (aapp),compared_with,procalcitonin (aapp),1.95e-08,48.74,7,16,0,10.06,2.0
Boys (popg),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Myocardial Infarction (dsyn),2.06e-06,47.78,7,14,0,10.5,2.0
Overweight (sosy),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,30.7,15,33,0,21.82,1.0
Overweight (sosy),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,31.24,15,16,0,29.06,8.0
Overweight (sosy),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),2.22e-18,31.04,15,71,0,18.17,5.0
Overweight (sosy),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.22e-18,44.89,15,35,0,21.43,8.0
Overweight (sosy),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.22e-18,30.97,15,110,0,17.05,8.0
Overweight (sosy),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,30.31,15,37,0,21.08,1.0
CANADIAN (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),7.33e-08,8.67,14,20,0,23.8,1.0
CANADIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),7.49e-08,5.86,14,65,0,17.02,1.0
CANADIAN (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),4.48e-07,8.18,14,16,0,26.25,1.0
CANADIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.17e-06,8.44,14,13,0,25.07,1.0
CANADIAN (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),8.46e-08,9.42,14,16,0,26.25,1.0
CANADIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.54e-06,14.82,14,8,0,12.57,1.0
CANADIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),7.25e-08,8.3,14,23,0,22.52,1.0
CANADIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),7.24e-08,9.2,14,22,0,22.91,1.0
CANADIAN (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),9.57e-07,9.12,14,13,0,25.07,1.0
CANADIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),7.39e-08,11.12,14,15,0,27.07,1.0
Revision procedure (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.07e-06,45.78,7,12,0,11.08,1.0
Revision procedure (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.23e-08,43.15,7,24,0,9.04,4.0
Metformin (phsu),PREVENTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.6e-08,18.2,11,16,0,18.56,9.0
Metformin (phsu),PREVENTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,23.37,11,9,0,16.36,9.0
Metformin (phsu),PREVENTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.18e-07,15.75,11,31,0,14.9,21.0
Antihypertensive Agents (phsu),TREATS,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.21e-06,41.05,5,62,0,5.4,4.0
Antihypertensive Agents (phsu),TREATS,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.21e-06,51.65,5,17,0,6.47,4.0
Antihypertensive Agents (phsu),TREATS,Dyslipidemias (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.21e-06,43.34,5,19,0,6.32,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Survivors (humn),8.97e-09,14.41,10,34,0,12.94,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Fibrosis (patf),9.27e-09,14.78,10,21,0,14.76,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Septicemia (dsyn),8.97e-09,18.15,10,38,0,12.63,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Critical Illness (dsyn),8.97e-09,13.72,10,35,0,12.86,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,cohort (humn),8.97e-09,12.65,10,49,0,12.04,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Pneumonia (dsyn),8.97e-09,18.01,10,25,0,14.0,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Acute heart failure (dsyn),1.35e-06,19.63,10,9,0,17.1,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Surgical Patients (podg),6.38e-08,14.55,10,17,0,15.88,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),9.34e-09,12.99,10,33,0,13.03,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,End stage renal failure (dsyn),9.05e-09,16.52,10,18,0,15.56,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Pancreatitis (dsyn),2.99e-06,14.67,10,13,0,17.69,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Pulmonary Embolism (dsyn),4.85e-07,14.98,10,14,0,17.14,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Aortic Valve Stenosis (dsyn),4.86e-07,14.54,10,15,0,16.67,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Coronary heart disease (dsyn),1.78e-08,13.98,10,21,0,14.76,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Frailty (fndg),1.88e-06,19.16,10,9,0,17.1,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),USES,Brain natriuretic peptide (aapp),1.56e-08,15.77,10,16,0,16.25,5.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Chronic heart failure (dsyn),1.1e-08,15.26,10,18,0,15.56,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Heart failure (dsyn),8.97e-09,14.57,10,67,0,11.49,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,CARDIAC EVENT (dsyn),3.48e-06,20.92,10,8,0,14.4,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,Acute coronary syndrome (dsyn),9.67e-09,14.87,10,20,0,15.0,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),TREATS,End stage liver disease (dsyn),8.97e-09,23.38,10,17,0,15.88,4.0
Polysomnography (diap),ISA,Assessment procedure (hlca),METHOD_OF,Transplantation (topp),9.91e-09,13.21,10,29,0,13.45,5.0
Polysomnography (diap),ISA,Assessment procedure (hlca),METHOD_OF,Percutaneous coronary intervention (topp),3.48e-06,20.92,10,8,0,14.4,5.0
Ultrasonography (diap),METHOD_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),3.28e-08,49.16,13,13,0,26.0,16.0
Ultrasonography (diap),METHOD_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),3.25e-08,52.09,13,11,0,20.31,7.0
Ultrasonography (diap),METHOD_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),3.42e-10,53.3,13,13,0,26.0,16.0
Ultrasonography (diap),METHOD_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),2.85e-16,48.58,13,27,0,19.26,5.0
Frailty (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.97e-09,15.06,11,20,0,17.05,1.0
Frailty (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.51e-09,12.25,11,65,0,12.86,1.0
Frailty (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.76e-07,14.57,11,16,0,18.56,1.0
Frailty (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.1e-06,14.82,11,13,0,20.31,1.0
Frailty (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.32e-08,15.81,11,16,0,18.56,1.0
Frailty (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,21.21,11,8,0,13.82,1.0
Frailty (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.15e-09,14.69,11,23,0,16.26,1.0
Frailty (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),9.84e-10,15.58,11,22,0,16.5,1.0
Frailty (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,15.51,11,13,0,20.31,1.0
Frailty (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.51e-09,17.51,11,15,0,19.07,1.0
Body Composition (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),4.63e-10,37.91,8,33,0,9.94,1.0
Body Composition (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,38.45,8,16,0,12.0,8.0
Body Composition (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),2.04e-10,38.26,8,71,0,8.9,5.0
Body Composition (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.04e-10,52.1,8,35,0,9.83,8.0
Body Composition (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.04e-10,38.18,8,110,0,8.58,8.0
Body Composition (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.56e-09,37.52,8,37,0,9.73,1.0
Twin birth (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),7.68e-07,25.7,6,20,0,7.8,1.0
Twin birth (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),7.7e-07,22.88,6,65,0,6.55,1.0
Twin birth (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),1.14e-06,25.21,6,16,0,8.25,1.0
Twin birth (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.86e-06,25.46,6,13,0,8.77,1.0
Twin birth (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),7.8e-07,26.44,6,16,0,8.25,1.0
Twin birth (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),4.24e-06,31.85,6,8,0,10.5,1.0
Twin birth (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),7.67e-07,25.33,6,23,0,7.57,1.0
Twin birth (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),7.67e-07,26.22,6,22,0,7.64,1.0
Twin birth (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),1.65e-06,26.15,6,13,0,8.77,1.0
Twin birth (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),7.69e-07,28.15,6,15,0,8.4,1.0
Body mass index procedure (diap),AFFECTS,Pregnancy (orgf),PROCESS_OF,Survivors (humn),1.11e-08,72.36,31,15,0,22.26,1.0
Body mass index procedure (diap),AFFECTS,Pregnancy (orgf),PROCESS_OF,"Twins, Dizygotic (humn)",2.41e-15,68.84,31,60,0,47.02,1.0
Body mass index procedure (diap),AFFECTS,Pregnancy (orgf),PROCESS_OF,Monoamniotic twins (podg),4.11e-12,69.7,31,33,0,60.12,1.0
Body mass index procedure (diap),AFFECTS,Pregnancy (orgf),PROCESS_OF,Singleton (humn),5.7e-47,68.35,31,357,0,33.69,1.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Atrial Fibrillation (patf),3.39e-07,7.49,31,21,0,35.23,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Primary Prevention (topp),1.5e-07,7.37,31,23,0,40.06,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,STEMI (dsyn),6.17e-18,12.1,31,47,0,51.45,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,General Population (humn),1.67e-08,7.6,31,24,0,42.58,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),PREVENTS,Premature Birth (patf),2.44e-16,9.82,31,30,0,59.03,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),PREVENTS,Death (finding) (fndg),6.17e-18,16.23,31,94,0,41.22,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,"Aortic Aneurysm, Abdominal (dsyn)",1.04e-14,13.87,31,20,0,32.9,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Hemorrhage (fndg),6.17e-18,8.97,31,65,0,45.78,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Pulmonary Embolism (dsyn),2.22e-08,10.73,31,14,0,20.32,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cerebrovascular accident (dsyn),6.7e-11,9.12,31,22,0,37.61,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Septicemia (dsyn),6.17e-18,12.56,31,41,0,54.44,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Malaria (dsyn),6.17e-18,8.04,31,56,0,48.16,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),PREVENTS,Stillbirth (patf),1.21e-08,13.51,31,12,0,16.65,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),6.17e-18,7.71,31,60,0,47.02,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Critical limb ischemia (patf),6.17e-18,11.72,31,40,0,55.02,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,"Shock, Cardiogenic (patf)",5.68e-10,13.27,31,14,0,20.32,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Cardiovascular Diseases (dsyn),9.55e-15,8.53,31,33,0,60.12,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Pneumonia (dsyn),9.32e-10,9.37,31,19,0,30.65,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Chronic heart failure (dsyn),3.58e-15,10.87,31,25,0,45.16,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),PREVENTS,"Death, Sudden, Cardiac (patf)",6.63e-07,12.69,31,10,0,13.23,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,high-risk group (humn),1.79e-11,8.29,31,27,0,50.52,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,"Pancreatitis, Acute Necrotizing (dsyn)",5.74e-14,12.87,31,20,0,32.9,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,"Stenosis, unspecified (patf)",8.57e-11,8.18,31,26,0,47.81,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Deglutition Disorders (dsyn),7.56e-07,8.62,31,15,0,22.26,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Depressed mood (fndg),1.87e-06,6.57,31,30,0,59.03,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,High Risk Populations (popg),3.35e-09,7.87,31,24,0,42.58,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Octogenarians (aggp),1.21e-07,14.87,31,10,0,13.23,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Acute myocardial infarction (dsyn),6.17e-18,9.69,31,104,0,40.24,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),USES,Losartan (orch),6.17e-18,10.07,31,65,0,45.78,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Peripheral Vascular Diseases (dsyn),6.17e-18,9.94,31,40,0,55.02,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Postpartum Hemorrhage (patf),6.54e-08,13.48,31,11,0,14.9,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Coronary Arteriosclerosis (dsyn),6.17e-18,9.15,31,60,0,47.02,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Anemia (dsyn),3.7e-07,8.23,31,17,0,26.32,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),PREVENTS,Adverse event (fndg),2.4e-07,8.66,31,16,0,24.26,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Ischemia (dsyn),5.68e-12,9.47,31,23,0,40.06,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Endoleak (patf),6.18e-18,12.47,31,30,0,59.03,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Carotid Stenosis (dsyn),1.76e-07,9.15,31,15,0,22.26,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Secondary prevention (topp),3.09e-06,8.16,31,15,0,22.26,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Malnutrition (dsyn),5.8e-09,8.54,31,20,0,32.9,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Systemic arterial pressure (fndg),1.25e-11,6.95,31,43,0,53.35,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Pre-Eclampsia (dsyn),1.09e-09,14.23,31,13,0,18.45,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,"Kidney Failure, Chronic (dsyn)",6.17e-18,9.74,31,52,0,49.48,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Myocardial Infarction (dsyn),6.17e-18,10.78,31,91,0,41.56,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Maternal Mortality (fndg),3.11e-17,21.16,31,19,0,30.65,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Mitral Valve Insufficiency (dsyn),6.68e-07,9.07,31,14,0,20.32,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Survivors (humn),2.27e-09,6.36,31,53,0,49.13,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,"Stroke, Acute (dsyn)",1.02e-06,8.51,31,15,0,22.26,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),PREVENTS,Perinatal death (fndg),6.11e-15,19.44,31,17,0,26.32,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,End stage renal failure (dsyn),1.25e-12,10.77,31,21,0,35.23,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Diabetic (fndg),1.71e-15,8.35,31,36,0,57.69,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),PREVENTS,Newborn death (patf),2.24e-08,17.73,31,10,0,13.23,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,"Hepatitis C, Chronic (dsyn)",6.5e-07,14.99,31,9,0,11.61,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),PREVENTS,Maternal Mortality (fndg),6.17e-18,20.36,31,80,0,43.01,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cardiovascular event (fndg),3.04e-17,11.09,31,28,0,53.29,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Death (finding) (fndg),4.01e-14,14.11,31,19,0,30.65,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Acute coronary syndrome (dsyn),6.17e-18,10.08,31,60,0,47.02,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Heart Arrest (patf),1.06e-16,11.1,31,27,0,50.52,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Disease Progression (patf),3.47e-07,8.9,31,15,0,22.26,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Critical Illness (dsyn),6.17e-18,10.12,31,42,0,53.88,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Diarrhea (sosy),2.07e-09,9.49,31,18,0,28.45,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Congestive heart failure (dsyn),6.68e-07,9.07,31,14,0,20.32,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),USES,Pravastatin (phsu),6.22e-18,12.07,31,30,0,59.03,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Septic Shock (patf),2.2e-09,13.53,31,13,0,18.45,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Control Groups (humn),3.03e-06,6.01,31,57,0,47.86,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Coronary heart disease (dsyn),6.17e-18,8.91,31,49,0,50.61,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),PREVENTS,Hemorrhage (fndg),2.4e-07,8.66,31,16,0,24.26,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Claudication (dsyn),1.74e-12,13.87,31,17,0,26.32,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,"Respiratory Distress Syndrome, Adult (dsyn)",8.54e-10,10.33,31,17,0,26.32,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Ischemic stroke (dsyn),4.76e-07,7.57,31,20,0,32.9,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),6.17e-18,6.69,31,123,0,38.81,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Upper gastrointestinal hemorrhage (dsyn),3.09e-14,15.67,31,18,0,28.45,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Revascularization - action (topp),4.23e-16,12.19,31,24,0,42.58,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),4.43e-16,8.84,31,34,0,59.26,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,cohort (humn),3.64e-14,7.78,31,38,0,56.29,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cardiovascular morbidity (dsyn),6.17e-18,19.77,31,24,0,42.58,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Aortic Valve Stenosis (dsyn),4.67e-17,10.94,31,28,0,53.29,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Heart failure (dsyn),6.17e-18,9.56,31,103,0,40.33,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),PREVENTS,Malaria (dsyn),1.19e-07,8.28,31,18,0,28.45,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),AFFECTS,Maternal Mortality (fndg),1.4e-12,20.62,31,14,0,20.32,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),ISA,Procedures (hlca),6.17e-18,6.82,31,125,0,38.69,5.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,Fetofetal Transfusion (dsyn),4.39e-07,15.67,31,9,0,11.61,4.0
Primary Health Care (hlca),ISA,Intervention regimes (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",1.33e-11,8.52,31,26,0,47.81,4.0
dietary intervention (topp),TREATS,Participant (humn),USES,Medicare (rnlw),8.7e-08,39.67,6,18,0,8.0,4.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),2.72e-08,16.02,11,15,0,19.07,21.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),4.39e-08,18.37,11,12,0,21.08,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),7.92e-09,16.67,11,15,0,19.07,5.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),9.69e-10,15.91,11,28,0,15.32,5.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),1.01e-09,14.07,11,28,0,15.32,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),9.69e-10,16.87,11,66,0,12.83,5.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),9.69e-10,14.72,11,47,0,13.57,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),1.12e-09,14.0,11,27,0,15.48,9.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),8.96e-07,18.43,11,10,0,19.09,9.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),5.23e-09,19.0,11,13,0,20.31,9.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1e-09,14.42,11,26,0,15.65,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),1.44e-07,14.06,11,19,0,17.37,5.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),1.04e-07,15.42,11,15,0,19.07,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (humn),1.86e-09,14.35,11,23,0,16.26,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),3.13e-06,13.96,11,16,0,18.56,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),2.14e-06,15.1,11,13,0,20.31,5.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),2.35e-06,13.81,11,17,0,18.12,5.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),9.69e-10,14.45,11,51,0,13.37,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),9.69e-10,14.95,11,145,0,11.83,11.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),9.69e-10,15.8,11,39,0,14.1,11.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.42e-06,15.42,11,12,0,21.08,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.64e-07,18.75,11,10,0,19.09,9.0
Periodicals (inpr),ISA,Measurement (ftcn),ISA,Techniques (ftcn),2.44e-08,1.34,72,116,0,116.69,5.0
Periodicals (inpr),ISA,Measurement (ftcn),ISA,Health (idcn),2.44e-08,3.11,72,94,0,127.15,5.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.11e-09,13.39,13,20,0,21.45,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.65e-09,10.58,13,65,0,15.6,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.76e-07,12.9,13,16,0,23.56,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,13.16,13,13,0,26.0,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.23e-08,14.14,13,16,0,23.56,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,19.55,13,8,0,12.92,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.86e-10,13.02,13,23,0,20.35,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.25e-10,13.92,13,22,0,20.68,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,13.85,13,13,0,26.0,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.65e-09,15.84,13,15,0,24.27,1.0
Roux-en-Y Gastric Bypass (topp),ISA,Gastric Bypass (topp),TREATS,Body Weight decreased (fndg),2.38e-06,42.95,13,14,0,25.07,4.0
Roux-en-Y Gastric Bypass (topp),ISA,Gastric Bypass (topp),TREATS,"Obesity, Morbid (dsyn)",5.27e-16,41.81,12,47,1,15.06,4.0
Lymphedema (dsyn),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),1.99e-10,16.59,15,25,0,24.0,1.0
Lymphedema (dsyn),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),6.08e-09,14.38,15,13,0,24.27,1.0
Lymphedema (dsyn),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),1.99e-10,18.84,15,32,0,22.03,1.0
Atherosclerosis (dsyn),PROCESS_OF,South Asian (popg),ISA,Ethnic group (popg),6.7e-13,21.63,12,49,0,14.94,1.0
Control Groups (humn),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Ischemic stroke (dsyn),4.32e-06,11.42,11,11,0,22.0,2.0
Control Groups (humn),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),1.48e-07,8.65,11,34,0,14.56,2.0
Control Groups (humn),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Septicemia (dsyn),1.48e-07,13.01,11,20,0,17.05,2.0
Control Groups (humn),LOCATION_OF,C-reactive protein (aapp),ISA,Albumins (aapp),1.48e-07,10.25,11,30,0,15.03,2.0
Control Groups (humn),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),2.71e-07,10.76,11,15,0,19.07,2.0
Control Groups (humn),LOCATION_OF,C-reactive protein (aapp),ISA,Acute-Phase Proteins (aapp),1.48e-07,7.83,11,77,0,12.57,2.0
Control Groups (humn),LOCATION_OF,C-reactive protein (aapp),compared_with,procalcitonin (aapp),1.66e-07,11.06,11,16,0,18.56,2.0
Control Groups (humn),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Myocardial Infarction (dsyn),2.21e-06,10.1,11,14,0,19.64,2.0
"Milk, Human (bdsu)",LOCATION_OF,Insulin (horm),TREATS,Hospitalized Patients (humn),4.86e-06,22.77,6,11,0,9.27,2.0
"Milk, Human (bdsu)",LOCATION_OF,Insulin (horm),TREATS,Hyperglycemia (dsyn),2.11e-06,20.55,6,57,0,6.63,2.0
Intervention regimes (hlca),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,15.23,34,33,0,65.03,1.0
Intervention regimes (hlca),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,15.77,34,16,0,23.53,4.0
Intervention regimes (hlca),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.33e-25,15.57,34,71,0,50.28,4.0
Intervention regimes (hlca),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),6.91e-32,29.42,34,35,0,67.03,4.0
Intervention regimes (hlca),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.95e-32,15.5,34,110,0,44.51,4.0
Intervention regimes (hlca),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,14.84,34,37,0,65.24,1.0
Plasminogen Activator Inhibitor 1 (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),1.53e-07,20.61,7,33,0,8.48,1.0
Plasminogen Activator Inhibitor 1 (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.58e-06,21.16,7,16,0,10.06,8.0
Plasminogen Activator Inhibitor 1 (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.53e-07,20.96,7,71,0,7.69,5.0
Plasminogen Activator Inhibitor 1 (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.53e-07,34.8,7,35,0,8.4,8.0
Plasminogen Activator Inhibitor 1 (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.53e-07,20.89,7,110,0,7.45,8.0
Plasminogen Activator Inhibitor 1 (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.54e-07,20.22,7,37,0,8.32,1.0
Normal blood pressure (fndg),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),3.29e-11,23.32,10,98,0,11.02,1.0
Normal blood pressure (fndg),PROCESS_OF,African American (popg),ISA,Racial group (popg),3.29e-11,24.25,10,324,0,10.31,1.0
Age (orga),ASSOCIATED_WITH,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),9.82e-14,47.71,10,62,0,11.61,8.0
Age (orga),ASSOCIATED_WITH,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.09e-13,58.31,10,17,0,15.88,8.0
Age (orga),ASSOCIATED_WITH,Dyslipidemias (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.18e-11,50.0,10,19,0,15.26,8.0
Upper Extremity (bpoc),LOCATION_OF,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.11e-06,28.11,7,12,0,11.08,1.0
Upper Extremity (bpoc),LOCATION_OF,Body Weight decreased (fndg),ISA,Physical findings (sosy),1.12e-07,25.48,7,24,0,9.04,2.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.6e-06,21.42,9,9,0,18.0,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.2e-08,20.48,9,194,0,9.42,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),1.23e-08,19.2,9,17,0,13.76,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.2e-08,20.47,9,29,0,11.79,11.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.22e-08,22.65,9,14,0,14.79,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.08e-06,18.46,9,12,0,15.75,5.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.2e-08,17.28,9,48,0,10.69,11.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.2e-08,20.67,9,29,0,11.79,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.2e-08,17.72,9,98,0,9.83,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),1.43e-08,16.38,9,24,0,12.38,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.88e-07,22.79,9,10,0,17.1,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),2.41e-08,15.15,9,37,0,11.19,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.87e-08,16.96,9,20,0,13.05,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.2e-08,18.61,9,94,0,9.86,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.35e-06,24.4,9,8,0,15.11,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),1.2e-08,21.27,9,19,0,13.26,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-08,18.43,9,21,0,12.86,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),1.47e-08,23.61,9,12,0,15.75,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.46e-08,31.32,9,10,0,17.1,21.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),9.37e-08,23.91,9,10,0,17.1,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.2e-08,18.23,9,21,0,12.86,21.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.2e-08,19.84,9,21,0,12.86,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.2e-08,17.96,9,32,0,11.53,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),4.73e-08,25.32,9,10,0,17.1,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.2e-08,24.29,9,39,0,11.08,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.2e-08,28.27,9,44,0,10.84,11.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.2e-08,21.14,9,113,0,9.72,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.76e-06,18.67,9,11,0,16.36,11.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.71e-07,18.86,9,12,0,15.75,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.21e-08,16.75,9,25,0,12.24,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.2e-08,22.43,9,87,0,9.93,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.2e-08,17.42,9,33,0,11.45,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.2e-08,20.15,9,41,0,10.98,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.2e-08,20.32,9,21,0,12.86,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",1.2e-08,17.99,9,21,0,12.86,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.2e-08,18.93,9,1021,0,9.08,11.0
"Diabetes, Gestational (dsyn)",COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",9.9e-08,26.38,7,16,0,10.06,9.0
"Diabetes, Gestational (dsyn)",COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.92e-07,31.54,7,9,0,12.44,9.0
"Diabetes, Gestational (dsyn)",COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.71e-07,23.93,7,31,0,8.58,9.0
Interleukin-6 (aapp),INTERACTS_WITH,C-reactive protein (aapp),ASSOCIATED_WITH,Ischemic stroke (dsyn),4.25e-06,19.12,8,11,0,13.82,8.0
Interleukin-6 (aapp),INTERACTS_WITH,C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),7.43e-08,16.35,8,34,0,9.88,10.0
Interleukin-6 (aapp),INTERACTS_WITH,C-reactive protein (aapp),PREDISPOSES,Septicemia (dsyn),7.4e-08,20.71,8,20,0,11.2,10.0
Interleukin-6 (aapp),INTERACTS_WITH,C-reactive protein (aapp),ISA,Albumins (aapp),7.4e-08,17.95,8,30,0,10.13,5.0
Interleukin-6 (aapp),INTERACTS_WITH,C-reactive protein (aapp),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),1.98e-07,18.47,8,15,0,12.27,8.0
Interleukin-6 (aapp),INTERACTS_WITH,C-reactive protein (aapp),ISA,Acute-Phase Proteins (aapp),7.4e-08,15.54,8,77,0,8.83,5.0
Interleukin-6 (aapp),INTERACTS_WITH,C-reactive protein (aapp),compared_with,procalcitonin (aapp),9.22e-08,18.76,8,16,0,12.0,10.0
Interleukin-6 (aapp),INTERACTS_WITH,C-reactive protein (aapp),PREDISPOSES,Myocardial Infarction (dsyn),2.13e-06,17.8,8,14,0,12.57,10.0
Pancreatic carcinoma (neop),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.18e-09,27.03,10,18,0,15.56,1.0
tomography (diap),METHOD_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),3.28e-08,59.33,14,13,0,25.07,16.0
tomography (diap),METHOD_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),3.25e-08,62.26,14,11,0,19.64,7.0
tomography (diap),METHOD_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),3.42e-10,63.47,14,13,0,25.07,16.0
tomography (diap),METHOD_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),2.75e-16,58.76,14,27,0,21.26,5.0
DMD|BEST1 (gngm),PART_OF,Femur (bpoc),LOCATION_OF,Head (blor),1.67e-06,7.1,17,6,0,8.12,2.0
DMD|BEST1 (gngm),PART_OF,Femur (bpoc),LOCATION_OF,Neck (blor),6.63e-07,7.39,17,393,0,17.74,2.0
DMD|BEST1 (gngm),PART_OF,Femur (bpoc),LOCATION_OF,Slipped Epiphyses (dsyn),3.52e-12,7.02,17,1,0,1.06,2.0
Metabolic syndrome (dsyn),PREDISPOSES,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),6.05e-07,17.94,7,23,0,9.13,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),6.04e-07,17.39,7,57,0,7.86,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),8.95e-07,25.85,7,9,0,12.44,9.0
Feeding behaviors (inbe),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.19e-09,17.42,12,18,0,20.0,1.0
Waist circumference (fndg),PREDISPOSES,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular morbidity (dsyn),5.53e-10,62.03,7,23,0,9.13,21.0
Waist circumference (fndg),PREDISPOSES,Systemic arterial pressure (fndg),PREDISPOSES,Cerebrovascular accident (dsyn),2.32e-07,56.07,7,18,0,9.72,21.0
Waist circumference (fndg),PREDISPOSES,Systemic arterial pressure (fndg),PROCESS_OF,General Population (humn),1.36e-06,54.72,7,27,0,8.81,1.0
Waist circumference (fndg),PREDISPOSES,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),5.62e-10,55.69,7,32,0,8.53,21.0
Waist circumference (fndg),PREDISPOSES,Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),5.64e-10,55.12,7,39,0,8.26,1.0
Waist circumference (fndg),PREDISPOSES,Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),7.19e-07,54.26,7,41,0,8.2,1.0
Waist circumference (fndg),PREDISPOSES,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular event (fndg),6.32e-10,56.0,7,27,0,8.81,21.0
PREDICTED (clna),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),1.3e-08,22.92,8,77,0,8.83,1.0
PREDICTED (clna),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),2.3e-08,23.26,8,16,0,12.0,1.0
PREDICTED (clna),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Young adult (aggp),4.09e-06,22.7,8,12,0,13.33,1.0
PREDICTED (clna),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Middle Aged (aggp),1.34e-08,23.05,8,19,0,11.37,1.0
PREDICTED (clna),PREDISPOSES,Coronary heart disease (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.44e-08,21.83,8,22,0,10.91,21.0
PREDICTED (clna),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Outpatients (podg),7.06e-08,20.84,8,24,0,10.67,1.0
PREDICTED (clna),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,General Population (humn),1.3e-08,22.54,8,42,0,9.52,1.0
PREDICTED (clna),PREDISPOSES,Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),1.3e-08,23.79,8,102,0,8.63,5.0
PREDICTED (clna),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Heart failure (dsyn),3.47e-07,23.38,8,13,0,12.92,11.0
PREDICTED (clna),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),1.3e-08,23.13,8,83,0,8.77,1.0
PREDICTED (clna),PREDISPOSES,Coronary heart disease (dsyn),ISA,Death (finding) (fndg),1.3e-08,25.71,8,250,0,8.26,5.0
PREDICTED (clna),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),1.3e-08,22.89,8,194,0,8.33,11.0
Essential Hypertension (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.67e-07,21.35,7,18,0,9.72,1.0
Fatty Acids (bacs),PART_OF,Erythrocytes (cell),PART_OF,Sheep (mamm),7.84e-13,5.77,20,20,0,40.0,3.0
Fatty Acids (bacs),PART_OF,Erythrocytes (cell),LOCATION_OF,Folate (orch),1.89e-07,5.92,20,26,0,35.38,2.0
Fatty Acids (bacs),PART_OF,Erythrocytes (cell),LOCATION_OF,hemolysis (celf),5.94e-09,5.87,20,16,0,28.8,2.0
Fatty Acids (bacs),PART_OF,Erythrocytes (cell),LOCATION_OF,Cytolysis (celf),1.59e-07,5.87,20,13,0,21.45,2.0
Body mass index (clna),PREDISPOSES,Pancreatitis (dsyn),ISA,Inflammatory disorder (dsyn),4.02e-06,80.4,4,37,0,4.43,5.0
Body mass index (clna),PREDISPOSES,Pancreatitis (dsyn),CAUSES,Hospitalization (hlca),4.25e-06,82.8,4,11,0,5.45,11.0
Body mass index (clna),PREDISPOSES,Pancreatitis (dsyn),CAUSES,Multiple Organ Failure (patf),4.02e-06,86.13,4,16,0,5.0,11.0
Body mass index (clna),PREDISPOSES,Pancreatitis (dsyn),CAUSES,Cessation of life (orgf),4.02e-06,81.57,4,19,0,4.84,11.0
Body mass index (clna),PREDISPOSES,Pancreatitis (dsyn),COEXISTS_WITH,Sepsis Syndrome (dsyn),4.09e-06,90.2,4,9,0,5.78,9.0
Waist circumference (fndg),PREDISPOSES,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.14e-06,32.69,5,23,0,6.09,21.0
Waist circumference (fndg),PREDISPOSES,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),3.14e-06,32.13,5,57,0,5.44,11.0
Waist circumference (fndg),PREDISPOSES,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),3.43e-06,40.6,5,9,0,7.78,9.0
cohort (humn),LOCATION_OF,Gamma-glutamyl transferase (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),3.63e-06,40.48,6,8,0,10.5,2.0
adiposity (orga),ISA,Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),1.38e-09,58.67,251,22,0,23.93,5.0
cohort (humn),LOCATION_OF,Prostate-Specific Antigen (aapp),PART_OF,Malignant neoplasm of prostate (neop),3.37e-06,14.32,7,38,0,8.29,2.0
cohort (humn),LOCATION_OF,Prostate-Specific Antigen (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.37e-06,12.16,7,47,0,8.04,2.0
Entire thigh (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Pulmonary Embolism (dsyn),9.5e-08,22.6,7,29,0,8.69,2.0
Entire thigh (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Secondary malignant neoplasm of liver (neop),8.06e-07,22.34,7,26,0,8.88,2.0
Entire thigh (bpoc),LOCATION_OF,tomography (diap),ISA,Medical Imaging (diap),2.35e-06,20.69,7,318,0,7.15,2.0
Entire thigh (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Malignant neoplasm of lung (neop),8.29e-08,25.82,7,129,0,7.38,2.0
Entire thigh (bpoc),LOCATION_OF,tomography (diap),ISA,Diagnosis (hlca),8.29e-08,21.46,7,112,0,7.44,2.0
Entire thigh (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Solid tumor (neop),9.61e-08,23.58,7,21,0,9.33,2.0
Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,14.75,45,20,0,28.89,1.0
Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,11.94,45,65,0,76.15,1.0
Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,14.26,45,16,0,21.69,1.0
Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,14.52,45,13,0,16.76,1.0
Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,15.5,45,16,0,21.69,1.0
Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,20.9,45,8,0,9.42,1.0
Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,14.38,45,23,0,34.76,1.0
Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,15.27,45,22,0,32.76,1.0
Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,15.2,45,13,0,16.76,1.0
Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,17.2,45,15,0,20.0,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.72e-06,26.97,7,9,0,12.44,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.25e-07,26.03,7,194,0,7.25,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),1.26e-07,24.75,7,17,0,9.88,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.25e-07,26.02,7,29,0,8.69,11.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.25e-07,28.2,7,14,0,10.5,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.19e-06,24.01,7,12,0,11.08,5.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.25e-07,22.83,7,48,0,8.02,11.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.25e-07,26.22,7,29,0,8.69,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.25e-07,23.27,7,98,0,7.5,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),1.28e-07,21.93,7,24,0,9.04,9.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),3.01e-07,28.34,7,10,0,11.9,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.37e-07,20.7,7,37,0,8.32,7.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.32e-07,22.5,7,20,0,9.45,9.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.25e-07,24.16,7,94,0,7.52,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.47e-06,29.95,7,8,0,13.12,9.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),1.25e-07,26.82,7,19,0,9.58,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.25e-07,23.98,7,21,0,9.33,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),1.28e-07,29.16,7,12,0,11.08,9.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.28e-07,36.87,7,10,0,11.9,21.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),2.07e-07,29.46,7,10,0,11.9,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.25e-07,23.78,7,21,0,9.33,21.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.25e-07,25.39,7,21,0,9.33,9.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.25e-07,23.51,7,32,0,8.53,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),1.61e-07,30.87,7,10,0,11.9,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.25e-07,29.84,7,39,0,8.26,9.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.25e-07,33.82,7,44,0,8.11,11.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.25e-07,26.69,7,113,0,7.43,9.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.87e-06,24.22,7,11,0,11.45,11.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.3e-06,23.94,7,11,0,11.45,9.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),6.85e-07,24.41,7,12,0,11.08,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.25e-07,22.3,7,25,0,8.96,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.25e-07,27.98,7,87,0,7.56,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.25e-07,22.96,7,33,0,8.48,9.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.25e-07,25.7,7,41,0,8.2,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.25e-07,25.87,7,21,0,9.33,1.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",1.25e-07,23.53,7,21,0,9.33,9.0
Insulin (horm),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.25e-07,24.48,7,1021,0,7.05,11.0
"TNF protein, human|TNF (aapp)",PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,26.56,10,16,0,16.25,9.0
"TNF protein, human|TNF (aapp)",PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,31.73,10,9,0,17.1,9.0
"TNF protein, human|TNF (aapp)",PREDISPOSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,24.11,10,31,0,13.23,21.0
Adiponectin (aapp),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,18.74,12,16,0,21.0,7.0
Adiponectin (aapp),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,23.91,12,9,0,15.75,7.0
Adiponectin (aapp),AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,16.29,12,31,0,16.65,7.0
Calcium (bacs),PART_OF,Protoplasm (celc),LOCATION_OF,Compartments (bsoj),1.91e-26,0.16,14,23,0,22.52,2.0
Alcohol consumption (inbe),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.38e-09,10.07,17,18,0,33.06,1.0
Menarche (orgf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,24.35,15,20,0,26.25,1.0
Menarche (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,21.54,15,65,0,18.46,1.0
Menarche (orgf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,23.86,15,16,0,29.06,1.0
Menarche (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,24.12,15,13,0,24.27,1.0
Menarche (orgf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,25.1,15,16,0,29.06,1.0
Menarche (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,30.5,15,8,0,12.27,1.0
Menarche (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,23.98,15,23,0,24.78,1.0
Menarche (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,24.88,15,22,0,25.23,1.0
Menarche (orgf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,24.8,15,13,0,24.27,1.0
Menarche (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,26.8,15,15,0,30.0,1.0
"Diabetes Mellitus, Insulin-Dependent (dsyn)",PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.21e-09,9.28,20,18,0,34.2,1.0
Supplementation (topp),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),7.65e-09,19.29,9,18,0,13.5,6.0
Primary Schools (orgt),LOCATION_OF,Clinical Trials (resa),USES,Stents (medd),2.38e-07,13.78,9,78,0,10.04,2.0
Primary Schools (orgt),LOCATION_OF,Clinical Trials (resa),USES,Probes (medd),2.76e-07,9.01,9,5,0,7.78,2.0
Primary Schools (orgt),LOCATION_OF,Clinical Trials (resa),USES,Metal stent (medd),2.38e-07,16.14,9,34,0,11.38,2.0
Primary Schools (orgt),LOCATION_OF,Clinical Trials (resa),USES,Treatment Protocols (resa),2.38e-07,12.37,9,147,0,9.55,2.0
Primary Schools (orgt),LOCATION_OF,Clinical Trials (resa),USES,Drug eluting stent (medd),2.38e-07,14.59,9,38,0,11.13,2.0
Primary Schools (orgt),LOCATION_OF,Clinical Trials (resa),USES,"Defibrillators, Implantable (medd)",2.38e-07,16.94,9,40,0,11.03,2.0
Primary Schools (orgt),LOCATION_OF,Clinical Trials (resa),USES,"Stents, Vascular, Coronary (medd)",2.44e-07,16.74,9,13,0,15.23,2.0
LDL Cholesterol Lipoproteins (bacs),ISA,Lipids (lipd),PART_OF,Stratum corneum (tisu),8.06e-07,18.91,8,2,0,2.5,3.0
Diet good (topp),PREVENTS,Chronic Disease (dsyn),CAUSES,Cessation of life (orgf),3.72e-07,30.79,6,66,0,6.55,11.0
Diet good (topp),PREVENTS,Chronic Disease (dsyn),PROCESS_OF,cohort (humn),6.51e-07,28.9,6,16,0,8.25,1.0
Diet good (topp),PREVENTS,Chronic Disease (dsyn),CAUSES,Disability NOS (patf),5.22e-06,27.71,6,18,0,8.0,11.0
Plication (topp),compared_with,Gastrectomy (topp),TREATS,Gastric Adenocarcinoma (neop),7e-12,46.02,9,64,0,10.27,4.0
Plication (topp),compared_with,Gastrectomy (topp),TREATS,Malignant neoplasm of stomach (neop),7e-12,42.88,9,578,0,9.14,4.0
Plication (topp),compared_with,Gastrectomy (topp),TREATS,Advanced cancer (neop),7e-12,45.59,9,24,0,12.38,4.0
Plication (topp),compared_with,Gastrectomy (topp),TREATS,Adenocarcinoma (neop),7e-12,44.09,9,30,0,11.7,4.0
Plication (topp),compared_with,Gastrectomy (topp),TREATS,"Obesity, Morbid (dsyn)",7e-12,41.77,9,80,0,10.01,4.0
Plication (topp),compared_with,Gastrectomy (topp),USES,Sleeves (medd),7e-12,38.84,8,532,1,8.12,6.0
Plication (topp),compared_with,Gastrectomy (topp),TREATS,Body Weight decreased (fndg),7e-12,42.05,9,30,0,11.7,4.0
Plication (topp),compared_with,Gastrectomy (topp),TREATS,Stomach Carcinoma (neop),7e-12,42.77,9,49,0,10.65,4.0
Plication (topp),compared_with,Gastrectomy (topp),ADMINISTERED_TO,Surgeon (humn),2.01e-09,45.15,9,14,0,14.79,15.0
Plication (topp),compared_with,Gastrectomy (topp),TREATS,Malignant neoplasm of stomach stage III (neop),2.07e-06,44.4,9,10,0,17.1,4.0
Plication (topp),compared_with,Gastrectomy (topp),TREATS,Early gastric cancer (neop),7e-12,41.32,9,71,0,10.14,4.0
Adipose tissue (tisu),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Carcinoma of the Large Intestine (neop),4.44e-06,22.17,6,11,0,9.27,2.0
Adipose tissue (tisu),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),4.13e-06,19.7,6,21,0,7.71,2.0
Adipose tissue (tisu),LOCATION_OF,Vitamin D (phsu),TREATS,Cardiovascular Diseases (dsyn),6.82e-06,21.52,6,10,0,9.6,2.0
Adipose tissue (tisu),LOCATION_OF,Vitamin D (phsu),TREATS,"Hyperparathyroidism, Secondary (dsyn)",4.14e-06,19.25,6,18,0,8.0,2.0
Adipose tissue (tisu),LOCATION_OF,Vitamin D (phsu),TREATS,Critical Illness (dsyn),4.22e-06,23.35,6,11,0,9.27,2.0
Adipose tissue (tisu),LOCATION_OF,Vitamin D (phsu),TREATS,"Kidney Failure, Chronic (dsyn)",4.13e-06,19.37,6,24,0,7.5,2.0
Adipose tissue (tisu),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",4.13e-06,19.29,6,28,0,7.29,2.0
Exercise (dora),TREATS,cohort (humn),USES,Medicare (rnlw),1.24e-06,13.29,8,20,0,11.2,4.0
Exercise (dora),TREATS,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.24e-06,10.47,8,65,0,8.98,2.0
Exercise (dora),TREATS,cohort (humn),USES,Treats (clas),1.61e-06,12.79,8,16,0,12.0,4.0
Exercise (dora),TREATS,cohort (humn),LOCATION_OF,Calcium (bacs),5.33e-06,13.05,8,13,0,12.92,2.0
Exercise (dora),TREATS,cohort (humn),USES,Classification (clas),1.25e-06,14.03,8,16,0,12.0,4.0
Exercise (dora),TREATS,cohort (humn),LOCATION_OF,Sodium (elii),4.71e-06,19.44,8,8,0,16.0,2.0
Exercise (dora),TREATS,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.24e-06,12.91,8,23,0,10.78,2.0
Exercise (dora),TREATS,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.24e-06,13.81,8,22,0,10.91,2.0
Exercise (dora),TREATS,cohort (humn),USES,Tissue Microarray (resd),2.12e-06,13.74,8,13,0,12.92,4.0
Exercise (dora),TREATS,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.24e-06,15.74,8,15,0,12.27,2.0
Entire right knee (bpoc),LOCATION_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Glioblastoma (neop),1.7e-07,16.57,8,18,0,11.56,2.0
Entire right knee (bpoc),LOCATION_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Congenital diaphragmatic hernia (cgab),3.84e-07,21.85,8,10,0,14.4,2.0
Fasting (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.3e-09,13.84,13,18,0,22.39,1.0
Screening procedure (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.07e-11,16.06,14,22,0,22.91,4.0
Screening procedure (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.43e-10,15.49,14,17,0,25.53,1.0
Screening procedure (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.29e-08,11.55,14,27,0,21.26,1.0
Screening procedure (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.38e-08,14.51,14,15,0,27.07,1.0
Screening procedure (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.57e-10,12.71,14,24,0,22.17,4.0
Screening procedure (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),2.08e-11,12.33,14,34,0,19.76,1.0
Screening procedure (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),2.07e-11,13.76,14,40,0,18.9,1.0
Screening procedure (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.24e-09,20.48,14,12,0,22.29,4.0
Fatty Liver (dsyn),COEXISTS_WITH,"Hepatitis C, Chronic (dsyn)",ISA,Virus Diseases (dsyn),3.69e-14,26.0,23,301,0,24.76,5.0
Fatty Liver (dsyn),COEXISTS_WITH,"Hepatitis C, Chronic (dsyn)",CAUSES,Liver diseases (dsyn),3.31e-10,30.47,23,18,0,32.09,9.0
Lower Extremity (blor),LOCATION_OF,Physical function (fndg),PROCESS_OF,Survivors (humn),2.94e-06,10.76,9,16,0,14.06,1.0
Training (edac),AFFECTS,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.43e-06,25.82,6,22,0,7.64,7.0
Training (edac),AFFECTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.43e-06,25.24,6,17,0,8.12,1.0
Training (edac),AFFECTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.44e-06,21.31,6,27,0,7.33,1.0
Training (edac),AFFECTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.45e-06,24.27,6,15,0,8.4,1.0
Training (edac),AFFECTS,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.43e-06,22.47,6,24,0,7.5,7.0
Training (edac),AFFECTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.43e-06,22.09,6,34,0,7.06,1.0
Training (edac),AFFECTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),1.43e-06,23.51,6,40,0,6.9,1.0
Training (edac),AFFECTS,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.43e-06,30.24,6,12,0,9.0,7.0
Waist circumference (fndg),PREDISPOSES,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.2e-14,55.25,16,22,0,27.64,9.0
Waist circumference (fndg),PREDISPOSES,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.23e-10,54.68,16,17,0,31.06,1.0
Waist circumference (fndg),PREDISPOSES,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.29e-08,50.74,16,27,0,25.48,1.0
Waist circumference (fndg),PREDISPOSES,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.38e-08,53.7,16,15,0,29.06,1.0
Waist circumference (fndg),PREDISPOSES,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.37e-10,51.9,16,24,0,26.67,21.0
Waist circumference (fndg),PREDISPOSES,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),8.91e-14,51.52,16,34,0,23.53,1.0
Waist circumference (fndg),PREDISPOSES,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),5.4e-21,52.95,16,40,0,22.4,1.0
Waist circumference (fndg),PREDISPOSES,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.22e-09,59.67,16,12,0,21.0,9.0
Pancreatic carcinoma (neop),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,17.37,17,20,0,31.45,1.0
Pancreatic carcinoma (neop),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,14.55,17,65,0,21.45,1.0
Pancreatic carcinoma (neop),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,16.87,17,16,0,31.06,1.0
Pancreatic carcinoma (neop),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,17.13,17,13,0,22.94,1.0
Pancreatic carcinoma (neop),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,18.11,17,16,0,31.06,1.0
Pancreatic carcinoma (neop),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,23.52,17,8,0,11.76,1.0
Pancreatic carcinoma (neop),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,16.99,17,23,0,29.57,1.0
Pancreatic carcinoma (neop),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,17.89,17,22,0,30.14,1.0
Pancreatic carcinoma (neop),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,17.82,17,13,0,22.94,1.0
Pancreatic carcinoma (neop),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,19.81,17,15,0,28.24,1.0
Binge Eating (mobd),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,24.83,40,18,0,26.1,1.0
Dietary Habits (inbe),PROCESS_OF,student (prog),USES,Grade (clas),1.43e-06,18.91,6,7,0,11.14,1.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),1.84e-08,48.12,16,20,0,28.8,1.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Disability NOS (patf),5.41e-22,51.27,16,36,0,23.11,8.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Respiration Disorders (dsyn),4.93e-22,47.9,16,59,0,20.34,5.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Respiratory physiology (ortf),2.06e-08,47.56,16,23,0,27.13,1.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Acute respiratory failure (dsyn),3.54e-07,50.56,16,12,0,21.0,8.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),4.83e-22,48.27,15,71,1,18.17,1.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Lung diseases (dsyn),4.83e-22,47.74,16,73,0,19.51,5.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Hospitalized Patients (humn),4.83e-22,49.07,16,50,0,21.12,1.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospital admission (hlca),3.35e-09,50.86,16,15,0,29.06,8.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Cessation of life (orgf),4.83e-22,50.79,16,184,0,17.39,8.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Outpatients (podg),1.87e-08,46.33,16,43,0,21.95,1.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,General Population (humn),7.58e-12,48.3,16,27,0,25.48,1.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Diagnosis (hlca),1.7e-07,52.34,16,11,0,18.56,8.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospitalization (hlca),2e-18,50.48,16,31,0,24.26,8.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Participant (humn),4.83e-22,47.63,16,70,0,19.66,1.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),COEXISTS_WITH,Smoker (fndg),2.39e-07,46.81,16,27,0,25.48,8.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Chronic Disease (dsyn),8.67e-22,48.78,16,46,0,21.57,5.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Malignant neoplasm of lung (neop),8.79e-08,48.5,16,17,0,31.06,8.0
Body Composition (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Pneumonia (dsyn),4.46e-07,50.41,16,12,0,21.0,8.0
follow-up (hlca),TREATS,Participant (humn),USES,Medicare (rnlw),1.16e-09,11.09,29,18,0,29.17,4.0
Vital capacity (ortf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.22e-08,17.19,9,18,0,13.5,1.0
DMD|BEST1 (gngm),PART_OF,Bone structure of ischium (bpoc),LOCATION_OF,Fracture (inpo),6.57e-27,10.36,46,97,0,67.81,2.0
DMD|BEST1 (gngm),PART_OF,Bone structure of ischium (bpoc),LOCATION_OF,Bone Screws (medd),1.27e-17,9.63,46,111,0,65.06,2.0
DMD|BEST1 (gngm),PART_OF,Bone structure of ischium (bpoc),LOCATION_OF,Fracture with displacement (inpo),4.29e-08,15.68,46,12,0,15.13,2.0
DMD|BEST1 (gngm),PART_OF,Bone structure of ischium (bpoc),LOCATION_OF,Arthroscopy (diap),5.63e-20,8.27,46,6,0,6.78,2.0
DMD|BEST1 (gngm),PART_OF,Bone structure of ischium (bpoc),LOCATION_OF,Intertrochanteric Fractures (inpo),1e-10,10.3,46,40,0,74.78,2.0
DMD|BEST1 (gngm),PART_OF,Bone structure of ischium (bpoc),LOCATION_OF,[X]Unspecified osteoporosis with pathological fracture (dsyn),1.68e-10,10.53,46,35,0,61.63,2.0
DMD|BEST1 (gngm),PART_OF,Bone structure of ischium (bpoc),LOCATION_OF,Degenerative polyarthritis (dsyn),1.25e-09,8.37,46,19,0,26.85,2.0
DMD|BEST1 (gngm),PART_OF,Bone structure of ischium (bpoc),LOCATION_OF,Congenital dislocation (cgab),3.86e-16,8.25,46,2,0,2.09,2.0
Health behavior (inbe),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),6.01e-08,18.48,10,25,0,14.0,1.0
Health behavior (inbe),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),6.6e-08,16.28,10,13,0,17.69,1.0
Health behavior (inbe),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),6.01e-08,20.74,10,32,0,13.12,1.0
Snoring (sosy),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,23.87,14,16,0,26.25,8.0
Snoring (sosy),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.58e-15,34.09,14,26,0,21.54,8.0
Behavior (inbe),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),6.84e-07,7.57,18,18,0,36.0,1.0
Roux-en-Y Gastric Bypass (topp),TREATS,Female (orga),ISA,Gender (orga),7.97e-06,28.14,5,51,0,5.49,4.0
Body Weight decreased (fndg),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),1.65e-18,31.38,15,98,0,17.3,1.0
Body Weight decreased (fndg),PROCESS_OF,African American (popg),ISA,Racial group (popg),1.65e-18,32.32,15,324,0,15.69,1.0
Bulimia (mobd),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,14.77,15,18,0,27.5,1.0
Body mass index (clna),PREDISPOSES,Hyperglycemia (dsyn),COEXISTS_WITH,Diabetic (fndg),8.68e-07,44.17,5,28,0,5.89,9.0
Body mass index (clna),PREDISPOSES,Hyperglycemia (dsyn),PROCESS_OF,cohort (humn),2.14e-06,46.95,5,12,0,7.08,1.0
Body mass index (clna),PREDISPOSES,Hyperglycemia (dsyn),COEXISTS_WITH,Ischemic stroke (dsyn),8.6e-07,49.93,5,12,0,7.08,9.0
Body mass index (clna),PREDISPOSES,Hyperglycemia (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),4.29e-06,48.13,5,10,0,7.5,9.0
Body mass index (clna),PREDISPOSES,Hyperglycemia (dsyn),PROCESS_OF,Hospitalized Patients (humn),8.37e-07,47.09,5,62,0,5.4,1.0
Body mass index (clna),PREDISPOSES,Hyperglycemia (dsyn),PROCESS_OF,Critically ill children (podg),8.37e-07,51.24,5,30,0,5.83,1.0
Body mass index (clna),PREDISPOSES,Hyperglycemia (dsyn),COEXISTS_WITH,Traumatic Brain Injury (inpo),1.44e-06,56.33,5,8,0,8.12,9.0
Body mass index (clna),PREDISPOSES,Hyperglycemia (dsyn),PROCESS_OF,inpatient (humn),8.37e-07,45.95,5,36,0,5.69,1.0
Body mass index (clna),PREDISPOSES,Hyperglycemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),8.37e-07,45.91,5,25,0,6.0,21.0
Body mass index (clna),PREDISPOSES,Hyperglycemia (dsyn),COEXISTS_WITH,Critical Illness (dsyn),8.37e-07,52.17,5,37,0,5.68,9.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,16.94,13,9,0,15.23,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.81e-10,16.0,13,194,0,13.87,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),5.17e-10,14.73,13,17,0,22.94,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.81e-10,15.99,13,29,0,18.83,11.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),3.8e-10,18.18,13,14,0,25.07,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,13.98,13,12,0,23.08,5.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.81e-10,12.8,13,48,0,16.52,11.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.81e-10,16.19,13,29,0,18.83,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.81e-10,13.24,13,98,0,14.72,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.51e-09,11.9,13,24,0,20.04,9.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,18.32,13,10,0,17.69,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.23e-08,10.67,13,37,0,17.57,7.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.91e-09,12.48,13,20,0,21.45,9.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.81e-10,14.13,13,94,0,14.8,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,19.92,13,8,0,12.92,9.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),1.81e-10,16.8,13,19,0,21.89,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.93e-10,13.95,13,21,0,21.05,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.96e-09,19.13,13,12,0,23.08,9.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.82e-09,26.85,13,10,0,17.69,21.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.2e-08,19.43,13,10,0,17.69,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.03e-10,13.75,13,21,0,21.05,21.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.81e-10,15.36,13,21,0,21.05,9.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.81e-10,13.49,13,32,0,18.28,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.55e-08,20.84,13,10,0,17.69,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.81e-10,19.81,13,39,0,17.33,9.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.81e-10,23.79,13,44,0,16.84,11.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.81e-10,16.67,13,113,0,14.5,9.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,14.19,13,11,0,20.31,11.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,13.92,13,11,0,20.31,9.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.6e-07,14.38,13,12,0,23.08,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),2.98e-10,12.27,13,25,0,19.76,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.81e-10,17.95,13,87,0,14.94,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.81e-10,12.94,13,33,0,18.12,9.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.81e-10,15.67,13,41,0,17.12,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.81e-10,15.84,13,21,0,21.05,1.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",2.31e-10,13.51,13,21,0,21.05,9.0
Hyperlipidemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.81e-10,14.45,13,1021,0,13.17,11.0
Anorexia Nervosa (mobd),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,24.01,47,18,0,24.89,1.0
Drowsiness (sosy),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,22.07,13,16,0,23.56,8.0
Drowsiness (sosy),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),5.54e-14,32.28,13,26,0,19.5,8.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,16.55,16,9,0,14.06,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.42e-12,15.6,16,194,0,17.32,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.38e-10,14.33,16,17,0,31.06,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.42e-12,15.6,16,29,0,24.83,11.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2.01e-10,17.78,16,14,0,26.25,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,13.59,16,12,0,21.0,5.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.42e-12,12.41,16,48,0,21.33,11.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.42e-12,15.8,16,29,0,24.83,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.42e-12,12.85,15,97,1,17.32,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,11.51,16,24,0,26.67,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,17.92,16,10,0,16.25,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,10.28,16,37,0,22.92,7.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,12.08,16,20,0,28.8,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.42e-12,13.73,16,94,0,18.72,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,19.53,16,8,0,12.0,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),1.73e-12,16.4,16,19,0,29.47,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.35e-11,13.55,16,21,0,28.19,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,18.73,16,12,0,21.0,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.64e-09,26.45,16,10,0,16.25,21.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,19.04,16,10,0,16.25,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.39e-11,13.36,16,21,0,28.19,21.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.69e-12,14.96,16,21,0,28.19,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.42e-12,13.09,15,31,1,22.26,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,20.45,16,10,0,16.25,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.42e-12,19.42,16,39,0,22.56,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.42e-12,23.39,16,44,0,21.82,11.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.42e-12,16.27,16,113,0,18.27,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,13.8,16,11,0,18.56,11.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,13.52,16,11,0,18.56,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,13.98,16,12,0,21.0,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.19e-10,11.88,16,25,0,26.24,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.42e-12,17.55,16,87,0,18.94,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.42e-12,12.54,16,33,0,23.76,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.42e-12,15.28,16,41,0,22.24,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.51e-12,15.45,16,21,0,28.19,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5.14e-11,13.11,16,21,0,28.19,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.42e-12,14.06,16,1021,0,16.25,11.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),3e-07,51.2,7,18,0,9.72,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),8.79e-10,53.64,7,77,0,7.64,21.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),8.79e-10,51.71,7,33,0,8.48,5.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),2.59e-09,52.72,7,18,0,9.72,21.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),1.08e-09,55.97,7,15,0,10.27,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",8.79e-10,53.7,7,41,0,8.2,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),8.79e-10,52.24,7,30,0,8.63,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),8.79e-10,51.89,7,35,0,8.4,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),8.79e-10,56.26,7,27,0,8.81,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),3.96e-06,50.99,7,16,0,10.06,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),8.8e-10,53.68,7,22,0,9.23,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),2.11e-08,51.93,7,18,0,9.72,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),8.79e-10,55.8,7,19,0,9.58,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),1.01e-07,54.77,7,12,0,11.08,7.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),1.88e-07,60.49,7,9,0,12.44,11.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),8.79e-10,51.37,7,97,0,7.51,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),8.79e-10,52.38,7,68,0,7.72,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),8.79e-10,65.39,7,27,0,8.81,21.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),8.96e-07,55.53,7,10,0,11.9,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),8.79e-10,59.28,7,20,0,9.45,9.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),8.79e-10,56.37,7,19,0,9.58,9.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),8.79e-10,52.62,7,93,0,7.53,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),3.3e-08,52.52,7,16,0,10.06,5.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),4.84e-07,51.31,7,17,0,9.88,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),6.64e-07,55.85,7,10,0,11.9,21.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),3.68e-09,51.41,7,22,0,9.23,1.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),8.79e-10,53.23,7,24,0,9.04,11.0
Waist circumference (fndg),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),2.69e-06,54.45,7,10,0,11.9,9.0
Adenocarcinoma (neop),PART_OF,Esophagus (bpoc),PART_OF,African race (popg),1.17e-10,4.82,47,31,0,51.45,3.0
Adenocarcinoma (neop),PART_OF,Esophagus (bpoc),LOCATION_OF,Carcinoma (neop),1.03e-06,4.82,47,17,0,23.15,2.0
Intervention regimes (hlca),TREATS,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),3.57e-18,14.15,35,25,0,42.86,2.0
Intervention regimes (hlca),TREATS,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),5.88e-09,11.95,35,13,0,17.83,2.0
Intervention regimes (hlca),TREATS,Survivors (humn),LOCATION_OF,procalcitonin (aapp),3.28e-18,16.41,35,32,0,61.26,2.0
Subcutaneous Fat (tisu),PART_OF,Entire trunk (bpoc),LOCATION_OF,Hemorrhage (fndg),1.7e-07,26.63,18,12,0,20.0,2.0
Subcutaneous Fat (tisu),PART_OF,Entire trunk (bpoc),PART_OF,Elephants (mamm),6.31e-20,24.94,18,140,0,20.31,3.0
Subcutaneous Fat (tisu),PART_OF,Entire trunk (bpoc),PART_OF,Aorta (bpoc),2.04e-09,22.35,18,35,0,27.26,3.0
Intervention regimes (hlca),METHOD_OF,Primary Prevention (topp),USES,"Defibrillators, Implantable (medd)",1.33e-07,13.67,12,149,0,12.97,6.0
Intervention regimes (hlca),METHOD_OF,Primary Prevention (topp),USES,Hydroxymethylglutaryl-CoA Reductase Inhibitors (phsu),1.33e-07,9.36,12,61,0,14.36,6.0
Intervention regimes (hlca),METHOD_OF,Primary Prevention (topp),USES,Aspirin (phsu),1.33e-07,8.8,12,79,0,13.82,6.0
Excretory function (phsf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1e-09,16.1,13,20,0,21.45,1.0
Excretory function (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.55e-09,13.29,13,65,0,15.6,1.0
Excretory function (phsf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,15.61,13,16,0,23.56,1.0
Excretory function (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,15.87,13,13,0,26.0,1.0
Excretory function (phsf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,16.85,13,16,0,23.56,1.0
Excretory function (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,22.25,13,8,0,12.92,1.0
Excretory function (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.83e-10,15.73,13,23,0,20.35,1.0
Excretory function (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),2.19e-11,16.62,13,22,0,20.68,1.0
Excretory function (phsf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,16.55,13,13,0,26.0,1.0
Excretory function (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.55e-09,18.55,13,15,0,24.27,1.0
Postoperative Complications (patf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),2.95e-09,14.26,11,20,0,17.05,1.0
Postoperative Complications (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),4.49e-09,11.45,11,65,0,12.86,1.0
Postoperative Complications (patf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.77e-07,13.77,11,16,0,18.56,1.0
Postoperative Complications (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.1e-06,14.03,11,13,0,20.31,1.0
Postoperative Complications (patf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.42e-08,15.01,11,16,0,18.56,1.0
Postoperative Complications (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,20.41,11,8,0,13.82,1.0
Postoperative Complications (patf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.13e-09,13.89,11,23,0,16.26,1.0
Postoperative Complications (patf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.97e-09,14.78,11,22,0,16.5,1.0
Postoperative Complications (patf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.86e-07,14.71,11,13,0,20.31,1.0
Postoperative Complications (patf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),3.5e-09,16.71,11,15,0,19.07,1.0
Calcium (bacs),PART_OF,Extracellular (celc),LOCATION_OF,Vesicle (acab),2.96e-12,0.22,2,57,0,2.07,2.0
Calcium (bacs),PART_OF,Extracellular (celc),LOCATION_OF,Polysaccharides (carb),1.37e-19,0.04,2,3,0,3.33,2.0
Testosterone (phsu),ISA,Lipids (lipd),PART_OF,Stratum corneum (tisu),7.96e-07,40.29,8,2,0,2.5,3.0
hypoglycemia (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),4.37e-06,12.38,8,18,0,11.56,1.0
Column (bpoc),LOCATION_OF,Diastasis (patf),PROCESS_OF,Magnetism (npop),2.12e-07,0.1,1,6,0,1.17,1.0
Atrial Fibrillation (patf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,12.43,31,18,0,28.45,1.0
Lower Extremity (blor),LOCATION_OF,Peripheral Vascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),2.09e-06,8.92,27,10,0,13.7,2.0
Lower Extremity (blor),LOCATION_OF,Peripheral Vascular Diseases (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.82e-08,10.69,27,15,0,23.33,2.0
Lower Extremity (blor),LOCATION_OF,Peripheral Vascular Diseases (dsyn),ISA,Vascular Diseases (dsyn),1.82e-08,8.6,27,18,0,30.0,2.0
Lower Extremity (blor),LOCATION_OF,Peripheral Vascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.03e-07,7.39,27,14,0,21.26,1.0
Lower Extremity (blor),LOCATION_OF,Peripheral Vascular Diseases (dsyn),ISA,Cardiovascular Diseases (dsyn),1.81e-08,7.07,27,30,0,51.3,2.0
Lower Extremity (blor),LOCATION_OF,Peripheral Vascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.81e-08,7.39,27,26,0,51.04,1.0
Lower Extremity (blor),LOCATION_OF,Peripheral Vascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.88e-08,8.51,27,16,0,25.48,2.0
Lower Extremity (blor),LOCATION_OF,Peripheral Vascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.81e-08,4.9,24,31,3,42.58,1.0
Energy Metabolism (phsf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.22e-09,19.66,11,18,0,17.72,1.0
Waist circumference (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,57.49,41,20,0,29.76,1.0
Waist circumference (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,54.68,41,65,0,66.86,1.0
Waist circumference (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,57.0,41,16,0,22.24,1.0
Waist circumference (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,57.26,41,13,0,17.12,1.0
Waist circumference (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,58.24,41,16,0,22.24,1.0
Waist circumference (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,63.64,41,8,0,9.56,1.0
Waist circumference (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,57.12,41,23,0,35.9,1.0
Waist circumference (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,58.02,41,22,0,33.8,1.0
Waist circumference (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,57.94,41,13,0,17.12,1.0
Waist circumference (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,59.94,41,15,0,20.49,1.0
olanzapine (orch),ISA,Antipsychotic Agents (phsu),TREATS,Dementia (mobd),3.42e-06,6.01,19,46,0,26.85,4.0
Overweight (sosy),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.2e-14,47.59,14,22,0,22.91,8.0
Overweight (sosy),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.23e-10,47.01,14,17,0,25.53,1.0
Overweight (sosy),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.29e-08,43.08,14,27,0,21.26,1.0
Overweight (sosy),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.38e-08,46.04,14,15,0,27.07,1.0
Overweight (sosy),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.37e-10,44.24,14,24,0,22.17,8.0
Overweight (sosy),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),8.91e-14,43.86,14,34,0,19.76,1.0
Overweight (sosy),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),7.6e-19,45.28,14,40,0,18.9,1.0
Overweight (sosy),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.22e-09,52.01,14,12,0,22.29,8.0
Pelvic organ (bpoc),LOCATION_OF,Ptosis (dsyn),CAUSES,Mitral Valve Insufficiency (dsyn),4.36e-08,5.91,22,24,0,42.17,2.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,22.48,18,16,0,30.22,9.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,27.65,18,9,0,13.5,9.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,20.03,18,31,0,28.45,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular arteriosclerosis unspecified (dsyn),CAUSES,Cessation of life (orgf),6.04e-07,18.97,7,24,0,9.04,11.0
Intervention regimes (hlca),NEG_TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.12e-06,42.88,6,12,0,9.0,1.0
Intervention regimes (hlca),NEG_TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),1.31e-07,40.24,6,24,0,7.5,5.0
"Osteoarthritis, Knee (dsyn)",PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,23.83,18,20,0,34.2,1.0
"Osteoarthritis, Knee (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,21.01,18,65,0,22.98,1.0
"Osteoarthritis, Knee (dsyn)",PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,23.33,18,16,0,30.22,1.0
"Osteoarthritis, Knee (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,23.59,18,13,0,22.39,1.0
"Osteoarthritis, Knee (dsyn)",PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,24.57,18,16,0,30.22,1.0
"Osteoarthritis, Knee (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,29.98,18,8,0,11.56,1.0
"Osteoarthritis, Knee (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,23.45,18,23,0,32.09,1.0
"Osteoarthritis, Knee (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,24.35,18,22,0,32.73,1.0
"Osteoarthritis, Knee (dsyn)",PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,24.28,18,13,0,22.39,1.0
"Osteoarthritis, Knee (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,26.28,18,15,0,27.5,1.0
ghrelin (aapp),COEXISTS_WITH,Insulin (horm),TREATS,Hospitalized Patients (humn),5.89e-06,34.38,5,11,0,7.27,4.0
ghrelin (aapp),COEXISTS_WITH,Insulin (horm),TREATS,Hyperglycemia (dsyn),3.14e-06,32.16,5,57,0,5.44,4.0
Total cholesterol (strd),ISA,Cholesterol (bacs),PART_OF,Membrane (celc),6.47e-15,13.85,92,5,0,5.27,3.0
tomography (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.16e-09,27.78,38,18,0,26.53,6.0
Caloric Restriction (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,25.63,19,12,0,19.58,1.0
Caloric Restriction (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,23.0,19,24,0,34.04,4.0
Compartments (bsoj),PART_OF,Bone structure of tibia (bpoc),LOCATION_OF,SLOPE (fndg),1.07e-06,7.33,9,2,0,2.44,2.0
Metformin (phsu),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),6.68e-10,17.8,10,33,0,13.03,1.0
Metformin (phsu),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,18.34,10,16,0,16.25,4.0
Metformin (phsu),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),4.1e-10,18.14,10,71,0,11.41,4.0
Metformin (phsu),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.1e-10,31.99,10,35,0,12.86,4.0
Metformin (phsu),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.1e-10,18.07,10,110,0,10.91,4.0
Metformin (phsu),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.76e-09,17.41,10,37,0,12.7,1.0
Systolic blood pressure (ortf),PROCESS_OF,student (prog),USES,Grade (clas),1.42e-11,34.01,9,7,0,12.44,1.0
Intervention regimes (hlca),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular morbidity (dsyn),5.05e-13,13.88,23,23,0,46.0,4.0
Intervention regimes (hlca),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cerebrovascular accident (dsyn),2.32e-07,7.92,23,18,0,32.09,4.0
Intervention regimes (hlca),TREATS,Systemic arterial pressure (fndg),PROCESS_OF,General Population (humn),1.36e-06,6.57,23,27,0,42.59,1.0
Intervention regimes (hlca),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),9.27e-12,7.55,23,32,0,39.53,4.0
Intervention regimes (hlca),TREATS,Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),1.2e-11,6.97,23,39,0,36.56,1.0
Intervention regimes (hlca),TREATS,Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),7.18e-07,6.12,23,41,0,35.9,1.0
Intervention regimes (hlca),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular event (fndg),7.95e-11,7.86,23,27,0,42.59,4.0
Bone structure of ischium (bpoc),LOCATION_OF,Fracture (inpo),PROCESS_OF,Geriatric Patients (humn),3.97e-07,6.43,24,15,0,24.38,1.0
Feeding behaviors (inbe),ISA,Behavior (inbe),PROCESS_OF,network (popg),2.21e-06,7.02,14,4,0,5.14,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,Kidney Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.57e-07,24.52,69,8,0,8.93,18.0
Glomerular Filtration Rate (ortf),DIAGNOSES,Kidney Diseases (dsyn),AFFECTS,Systemic arterial pressure (fndg),1.14e-09,12.33,69,21,0,27.39,7.0
Glomerular Filtration Rate (ortf),DIAGNOSES,Kidney Diseases (dsyn),CAUSES,"Kidney Failure, Acute (dsyn)",2.05e-11,12.78,69,23,0,30.67,11.0
Glomerular Filtration Rate (ortf),DIAGNOSES,Kidney Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",9.63e-07,10.44,69,27,0,37.57,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,Kidney Diseases (dsyn),CAUSES,End stage renal failure (dsyn),2.19e-08,11.49,69,22,0,29.01,11.0
Glomerular Filtration Rate (ortf),DIAGNOSES,Kidney Diseases (dsyn),PROCESS_OF,cohort (humn),8.91e-10,12.15,69,22,0,29.01,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,Kidney Diseases (dsyn),CAUSES,Cessation of life (orgf),9.14e-22,14.75,69,35,0,52.75,11.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.09e-13,37.7,11,22,0,16.5,8.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.23e-10,37.12,11,17,0,18.12,1.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.29e-08,33.19,11,27,0,15.48,1.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.38e-08,36.15,11,15,0,19.07,1.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.37e-10,34.35,11,24,0,16.04,8.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.76e-13,33.97,11,34,0,14.56,1.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),8.71e-14,35.39,11,40,0,14.03,1.0
adiposity (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.22e-09,42.12,11,12,0,21.08,8.0
Overweight (sosy),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),4.09e-30,41.6,26,98,0,32.9,1.0
Overweight (sosy),PROCESS_OF,African American (popg),ISA,Racial group (popg),6.47e-35,42.54,26,324,0,28.09,1.0
Left ventricular mass (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.09e-09,22.55,10,20,0,15.0,1.0
Left ventricular mass (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.63e-09,19.73,10,65,0,11.54,1.0
Left ventricular mass (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.76e-07,22.05,10,16,0,16.25,1.0
Left ventricular mass (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,22.31,10,13,0,17.69,1.0
Left ventricular mass (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.23e-08,23.29,10,16,0,16.25,1.0
Left ventricular mass (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,28.7,10,8,0,14.4,1.0
Left ventricular mass (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.72e-10,22.17,10,23,0,14.35,1.0
Left ventricular mass (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.1e-10,23.07,10,22,0,14.55,1.0
Left ventricular mass (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,23.0,10,13,0,17.69,1.0
Left ventricular mass (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.64e-09,24.99,10,15,0,16.67,1.0
Body mass index procedure (diap),DIAGNOSES,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,53.17,7,12,0,11.08,1.0
Body mass index procedure (diap),DIAGNOSES,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.11e-08,50.53,7,24,0,9.04,5.0
Assessment procedure (hlca),TREATS,Well adult (fndg),PROCESS_OF,Voluntary Workers (humn),3.84e-09,9.55,11,15,0,19.07,1.0
Body Weight decreased (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.68e-13,28.51,12,22,0,18.55,9.0
Body Weight decreased (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.23e-10,27.94,12,17,0,20.47,1.0
Body Weight decreased (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.29e-08,24.0,12,27,0,17.33,1.0
Body Weight decreased (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.38e-08,26.96,12,15,0,21.6,1.0
Body Weight decreased (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.37e-10,25.16,12,24,0,18.0,9.0
Body Weight decreased (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),2.35e-13,24.78,12,34,0,16.24,1.0
Body Weight decreased (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),1.46e-13,26.21,12,40,0,15.6,1.0
Body Weight decreased (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.22e-09,32.93,12,12,0,24.0,9.0
treatment program (hlca),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),2.77e-06,39.45,5,12,0,7.08,1.0
treatment program (hlca),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),1.77e-06,36.81,5,24,0,6.04,4.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),COEXISTS_WITH,Heart failure (dsyn),1.91e-08,28.99,8,15,0,12.27,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.91e-08,31.47,8,15,0,12.27,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),CAUSES,"Kidney Failure, Chronic (dsyn)",1.91e-08,22.97,8,20,0,11.2,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.91e-08,22.23,8,52,0,9.23,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,Hospitalized Patients (humn),5.78e-07,21.11,8,15,0,12.27,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.68e-08,20.63,8,21,0,11.05,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),CAUSES,End stage renal failure (dsyn),1.91e-08,21.91,8,51,0,9.25,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,Survivors (humn),9.52e-08,24.22,8,12,0,13.33,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),CAUSES,Kidney Failure (dsyn),1.91e-08,26.56,8,15,0,12.27,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),CAUSES,Cessation of life (orgf),1.91e-08,23.81,8,43,0,9.49,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),2.38e-08,24.06,8,14,0,12.57,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),1.91e-08,22.23,8,26,0,10.46,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,General Population (humn),1.92e-08,21.42,8,22,0,10.91,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),ISA,Metabolic Diseases (dsyn),1.65e-06,18.6,8,43,0,9.49,5.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),1.91e-08,21.06,8,44,0,9.45,1.0
Skeletal muscle structure (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,melanoma (neop),4.63e-09,6.73,19,45,0,27.02,2.0
Skeletal muscle structure (bpoc),LOCATION_OF,Biopsy (diap),ISA,Diagnosis (hlca),5.04e-09,4.53,19,161,0,21.24,2.0
Skeletal muscle structure (bpoc),LOCATION_OF,Biopsy (diap),ISA,Procedures (hlca),4.89e-07,4.65,19,81,0,23.46,2.0
Snoring (sosy),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.58e-08,32.64,7,18,0,9.72,1.0
Insulin Resistance (patf),AFFECTS,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.7e-06,41.25,5,22,0,6.14,7.0
Insulin Resistance (patf),AFFECTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.7e-06,40.68,5,17,0,6.47,1.0
Insulin Resistance (patf),AFFECTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.72e-06,36.74,5,27,0,5.93,1.0
Insulin Resistance (patf),AFFECTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.72e-06,39.7,5,15,0,6.67,1.0
Insulin Resistance (patf),AFFECTS,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.7e-06,37.9,5,24,0,6.04,7.0
Insulin Resistance (patf),AFFECTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.7e-06,37.52,5,34,0,5.74,1.0
Insulin Resistance (patf),AFFECTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),1.7e-06,38.95,5,40,0,5.62,1.0
Insulin Resistance (patf),AFFECTS,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.71e-06,45.67,5,12,0,7.08,7.0
Reactive Oxygen Species (bacs),PART_OF,Protoplasm (celc),LOCATION_OF,Compartments (bsoj),1.22e-15,0.11,2,23,0,2.17,2.0
Carcinoma (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Cancer Diagnosis (diap),1.21e-06,2.37,2,179,0,2.02,2.0
Carcinoma (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Localized Malignant Neoplasm (neop),1.21e-06,3.23,2,29,0,2.14,2.0
C-Peptide (aapp),ISA,Insulin (horm),TREATS,Hospitalized Patients (humn),2.75e-06,19.21,69,11,0,12.75,4.0
C-Peptide (aapp),ISA,Insulin (horm),TREATS,Hyperglycemia (dsyn),1.13e-22,16.99,69,57,0,104.09,4.0
Female (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,31.61,12,33,0,16.36,1.0
Female (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,32.15,12,16,0,21.0,8.0
Female (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),7.81e-15,31.96,12,71,0,14.03,5.0
Female (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),7.81e-15,45.8,12,35,0,16.11,8.0
Female (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),7.81e-15,31.88,12,110,0,13.31,8.0
Female (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,31.22,12,37,0,15.89,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.11e-09,22.11,10,20,0,15.0,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.65e-09,19.29,10,65,0,11.54,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.76e-07,21.61,10,16,0,16.25,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,21.87,10,13,0,17.69,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.24e-08,22.85,10,16,0,16.25,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,28.26,10,8,0,14.4,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.91e-10,21.73,10,23,0,14.35,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.3e-10,22.63,10,22,0,14.55,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,22.56,10,13,0,17.69,1.0
Fatty Liver (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.66e-09,24.56,10,15,0,16.67,1.0
Introduction procedure (hlca),ISA,Procedures (hlca),METHOD_OF,Aortic valve replacement NOS (topp),3.49e-08,10.25,18,21,0,33.43,5.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,Atrial Fibrillation (patf),3.49e-08,6.42,18,35,0,27.26,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,End stage liver disease (dsyn),7.45e-08,8.29,18,15,0,27.5,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,Congenital heart disease (dsyn),1.1e-06,8.52,18,12,0,20.0,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,cohort (humn),3.12e-07,6.19,18,20,0,34.2,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,Heart failure (dsyn),3.63e-08,7.77,18,19,0,35.05,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,Aortic Valve Stenosis (dsyn),3.49e-08,10.82,18,43,0,25.53,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,Octogenarians (aggp),1.52e-07,16.88,18,9,0,13.5,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),ADMINISTERED_TO,Surgeon (humn),3.49e-08,5.24,18,61,0,23.31,5.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,Coronary Arteriosclerosis (dsyn),3.52e-08,7.3,18,22,0,32.73,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,"Pancreatitis, Chronic (dsyn)",3.49e-08,7.52,18,29,0,29.17,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,Need for isolation (fndg),3.49e-08,3.4,18,2,0,2.22,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,Diabetic (fndg),3.71e-06,6.93,18,14,0,24.89,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,Aortic valve disorder (dsyn),3.49e-08,9.87,18,22,0,32.73,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,Septicemia (dsyn),1.61e-06,10.31,18,10,0,15.56,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,Hypoplastic Left Heart Syndrome (dsyn),3.49e-08,10.31,18,72,0,22.5,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,Rectal Prolapse (dsyn),6.22e-07,6.21,18,19,0,35.05,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,Dissection of aorta (dsyn),4.44e-07,8.36,18,13,0,22.39,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,Hemorrhage (fndg),3.51e-08,5.61,18,36,0,27.0,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,Body Weight decreased (fndg),3.86e-08,7.17,18,20,0,34.2,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),TREATS,"Obesity, Morbid (dsyn)",3.49e-08,6.83,18,41,0,25.9,4.0
Introduction procedure (hlca),ISA,Procedures (hlca),METHOD_OF,Coronary Artery Bypass Surgery (topp),3.8e-08,11.74,18,13,0,22.39,5.0
Carcinoma (neop),PART_OF,Breast (bpoc),LOCATION_OF,In complete remission (fndg),2.12e-06,2.69,3,19,0,3.47,2.0
Carcinoma (neop),PART_OF,Breast (bpoc),LOCATION_OF,Advanced cancer (neop),5.87e-07,4.56,3,19,0,3.47,2.0
deceased (fndg),PROCESS_OF,Donor person (humn),LOCATION_OF,Antithymoglobulin (phsu),1.21e-07,10.93,35,17,0,25.26,1.0
deceased (fndg),PROCESS_OF,Donor person (humn),LOCATION_OF,Cyclophosphamide (opco),3.62e-06,9.37,35,9,0,11.31,1.0
Leptin|LEP (aapp),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,26.32,13,33,0,18.12,1.0
Leptin|LEP (aapp),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,26.87,13,16,0,23.56,4.0
Leptin|LEP (aapp),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.59e-15,26.67,13,71,0,15.38,4.0
Leptin|LEP (aapp),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.59e-15,40.51,13,35,0,17.83,4.0
Leptin|LEP (aapp),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.59e-15,26.6,13,110,0,14.54,4.0
Leptin|LEP (aapp),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,25.94,13,37,0,17.57,1.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,29.06,18,16,0,30.22,9.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,34.23,18,9,0,13.5,9.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,26.62,18,31,0,28.45,9.0
Fat tissue increased (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.88e-09,52.16,7,20,0,9.45,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.42e-09,49.35,7,65,0,7.75,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.76e-07,51.67,7,16,0,10.06,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.1e-06,51.92,7,13,0,10.77,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.31e-08,52.91,7,16,0,10.06,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,58.31,7,8,0,13.12,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.06e-09,51.79,7,23,0,9.13,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),8.94e-10,52.68,7,22,0,9.23,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,52.61,7,13,0,10.77,1.0
Fat tissue increased (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.42e-09,54.61,7,15,0,10.27,1.0
Screening procedure (hlca),TREATS,Participant (humn),USES,Medicare (rnlw),1.16e-08,10.2,14,18,0,24.89,4.0
Physical Examination (hlca),TREATS,Participant (humn),USES,Medicare (rnlw),1.16e-09,17.87,53,18,0,24.11,4.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),3.11e-06,22.78,7,9,0,12.44,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),5.19e-07,21.83,7,194,0,7.25,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),5.19e-07,20.56,7,17,0,9.88,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),5.19e-07,21.83,7,29,0,8.69,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),5.19e-07,24.01,7,14,0,10.5,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.58e-06,19.82,7,12,0,11.08,5.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),5.19e-07,18.64,7,48,0,8.02,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),5.19e-07,22.03,7,29,0,8.69,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),5.19e-07,19.07,7,98,0,7.5,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),5.21e-07,17.74,7,24,0,9.04,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),6.95e-07,24.15,7,10,0,11.9,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),5.31e-07,16.51,7,37,0,8.32,7.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),5.25e-07,18.31,7,20,0,9.45,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),5.19e-07,19.96,7,94,0,7.52,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.86e-06,25.76,7,8,0,13.12,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),5.19e-07,22.63,7,19,0,9.58,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),5.19e-07,19.78,7,21,0,9.33,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),5.21e-07,24.96,7,12,0,11.08,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),5.21e-07,32.68,7,10,0,11.9,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),6e-07,25.27,7,10,0,11.9,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),5.19e-07,19.58,7,21,0,9.33,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),5.19e-07,21.19,7,21,0,9.33,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),5.19e-07,19.32,7,32,0,8.53,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),5.54e-07,26.68,7,10,0,11.9,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),5.19e-07,25.65,7,39,0,8.26,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),5.19e-07,29.62,7,44,0,8.11,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.19e-07,22.5,7,113,0,7.43,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),3.27e-06,20.03,7,11,0,11.45,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.69e-06,19.75,7,11,0,11.45,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),1.08e-06,20.21,7,12,0,11.08,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),5.19e-07,18.11,7,25,0,8.96,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",5.19e-07,23.78,7,87,0,7.56,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),5.19e-07,18.77,7,33,0,8.48,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),5.19e-07,21.51,7,41,0,8.2,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),5.19e-07,21.68,7,21,0,9.33,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5.19e-07,19.34,7,21,0,9.33,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),5.19e-07,20.29,7,1021,0,7.05,9.0
High Density Lipoprotein Cholesterol (bacs),ISA,Lipids (lipd),PART_OF,Stratum corneum (tisu),7.96e-07,12.43,11,2,0,2.36,3.0
Dyslipidemias (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),6.77e-09,18.12,9,23,0,12.52,9.0
Dyslipidemias (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),6.49e-09,17.56,9,57,0,10.42,9.0
Dyslipidemias (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.97e-07,26.03,9,9,0,18.0,9.0
Clamp (medd),USES,Insulin (horm),TREATS,Hospitalized Patients (humn),2.75e-06,11.96,33,11,0,14.67,4.0
Clamp (medd),USES,Insulin (horm),TREATS,Hyperglycemia (dsyn),1.98e-22,9.75,33,57,0,52.11,4.0
Metformin (phsu),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,29.67,13,12,0,23.08,1.0
Metformin (phsu),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,27.04,13,24,0,20.04,4.0
Diabetes Mellitus (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",9.96e-07,24.95,6,16,0,8.25,9.0
Diabetes Mellitus (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.89e-06,30.11,6,9,0,10.0,9.0
Diabetes Mellitus (dsyn),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.07e-06,22.5,6,31,0,7.16,9.0
abnormal glucose tolerance test (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),2.88e-07,29.02,6,136,0,6.26,1.0
abnormal glucose tolerance test (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),2.88e-07,28.15,6,188,0,6.19,1.0
abnormal glucose tolerance test (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Population Group (humn),2.82e-06,29.03,6,20,0,7.8,1.0
Atypical antipsychotic (phsu),TREATS,Schizophrenia (mobd),PROCESS_OF,Outpatients (podg),7.04e-08,2.81,23,12,0,18.26,1.0
Albuminuria (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,17.7,15,18,0,27.5,1.0
FAVOR (phsu),COEXISTS_WITH,Lipids (lipd),PART_OF,Stratum corneum (tisu),7.99e-07,15.48,9,2,0,2.44,3.0
Metabolic syndrome (dsyn),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),3.58e-08,13.86,9,98,0,9.83,1.0
Metabolic syndrome (dsyn),PROCESS_OF,African American (popg),ISA,Racial group (popg),3.58e-08,14.8,9,324,0,9.25,1.0
Metabolic syndrome (dsyn),AFFECTS,Renal function (ortf),PROCESS_OF,Survivors (humn),1.7e-06,41.45,5,27,0,5.93,1.0
Metabolic syndrome (dsyn),AFFECTS,Renal function (ortf),PROCESS_OF,cohort (humn),1.71e-06,37.64,5,23,0,6.09,1.0
Metabolic syndrome (dsyn),AFFECTS,Renal function (ortf),PROCESS_OF,"Recipient, Transplant (podg)",1.74e-06,35.93,5,41,0,5.61,1.0
Metabolic syndrome (dsyn),AFFECTS,Renal function (ortf),PROCESS_OF,Glomerular Filtration Rate (ortf),1.7e-06,37.66,5,30,0,5.83,1.0
Metabolic syndrome (dsyn),AFFECTS,Renal function (ortf),PROCESS_OF,Hospitalized Patients (humn),5.78e-06,38.71,5,12,0,7.08,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Schizophrenia (mobd),PROCESS_OF,Outpatients (podg),1.19e-06,9.41,8,12,0,13.33,1.0
"Diabetes, Gestational (dsyn)",AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.64e-07,32.66,6,16,0,8.25,7.0
"Diabetes, Gestational (dsyn)",AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.16e-06,37.83,6,9,0,10.0,7.0
"Diabetes, Gestational (dsyn)",AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),3.35e-07,30.22,6,31,0,7.16,7.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),NEG_TREATS,Hemorrhage (fndg),1.12e-06,56.31,6,11,0,9.27,22.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),TREATS,Left ventricular outflow tract obstruction (cgab),1.18e-07,57.06,6,12,0,9.0,4.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),TREATS,Mitral Valve Insufficiency (dsyn),1.78e-08,56.61,6,28,0,7.29,4.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),TREATS,Aortic Valve Insufficiency (dsyn),1.78e-08,57.1,6,20,0,7.8,4.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),METHOD_OF,Aortic valve replacement NOS (topp),1.78e-08,57.44,6,19,0,7.89,16.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),TREATS,Postoperative Complications (patf),4.19e-06,55.39,6,11,0,9.27,4.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),TREATS,Tricuspid Valve Insufficiency (dsyn),1.78e-08,61.27,6,14,0,8.57,4.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),TREATS,"Etiology, operative procedure, as cause of (fndg)",1.89e-06,58.84,6,9,0,10.0,4.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),TREATS,Hemorrhage (fndg),1.78e-08,57.92,6,394,0,6.09,4.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),TREATS,cohort (humn),1.78e-08,56.4,6,23,0,7.57,4.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),TREATS,Endocarditis (dsyn),1.78e-08,59.89,6,25,0,7.44,4.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),TREATS,Survivors (humn),5.04e-07,58.49,6,10,0,9.6,4.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),TREATS,Necrosis (patf),2.69e-07,59.31,6,10,0,9.6,4.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),TREATS,Extravasation (patf),1.82e-08,56.08,6,17,0,8.12,4.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),TREATS,Glioblastoma (neop),1.79e-06,55.97,6,11,0,9.27,4.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),TREATS,"Stenosis, unspecified (patf)",2.66e-08,53.66,6,21,0,7.71,4.0
Bariatric Surgery (topp),PRECEDES,Repeat Surgery (topp),TREATS,Postoperative Hemorrhage (patf),1.96e-06,55.11,6,12,0,9.0,4.0
Insulin Resistance (patf),COEXISTS_WITH,"Hepatitis C, Chronic (dsyn)",ISA,Virus Diseases (dsyn),3.69e-14,21.42,18,301,0,19.08,5.0
Insulin Resistance (patf),COEXISTS_WITH,"Hepatitis C, Chronic (dsyn)",CAUSES,Liver diseases (dsyn),3.31e-10,25.9,18,18,0,36.0,9.0
Intervention regimes (hlca),PREVENTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.32e-07,18.09,8,16,0,12.0,9.0
Intervention regimes (hlca),PREVENTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.02e-06,23.25,8,9,0,15.11,9.0
Intervention regimes (hlca),PREVENTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),2.03e-07,15.64,8,31,0,10.06,21.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),NEG_TREATS,Hemorrhage (fndg),1.71e-06,28.64,6,11,0,9.27,22.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),TREATS,Left ventricular outflow tract obstruction (cgab),7.09e-07,29.39,6,12,0,9.0,4.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),TREATS,Mitral Valve Insufficiency (dsyn),6.08e-07,28.94,6,28,0,7.29,4.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),TREATS,Aortic Valve Insufficiency (dsyn),6.08e-07,29.43,6,20,0,7.8,4.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),METHOD_OF,Aortic valve replacement NOS (topp),6.08e-07,29.77,6,19,0,7.89,16.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),TREATS,Postoperative Complications (patf),4.78e-06,27.72,6,11,0,9.27,4.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),TREATS,Tricuspid Valve Insufficiency (dsyn),6.08e-07,33.6,6,14,0,8.57,4.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),TREATS,"Etiology, operative procedure, as cause of (fndg)",2.48e-06,31.17,6,9,0,10.0,4.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),TREATS,Hemorrhage (fndg),6.08e-07,30.26,6,394,0,6.09,4.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),TREATS,cohort (humn),6.08e-07,28.73,6,23,0,7.57,4.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),TREATS,Endocarditis (dsyn),6.08e-07,32.22,6,25,0,7.44,4.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),TREATS,Survivors (humn),1.09e-06,30.82,6,10,0,9.6,4.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),TREATS,Necrosis (patf),8.59e-07,31.64,6,10,0,9.6,4.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),TREATS,Extravasation (patf),6.09e-07,28.41,6,17,0,8.12,4.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),TREATS,Glioblastoma (neop),2.38e-06,28.3,6,11,0,9.27,4.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),TREATS,"Stenosis, unspecified (patf)",6.17e-07,25.99,6,21,0,7.71,4.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Repeat Surgery (topp),TREATS,Postoperative Hemorrhage (patf),2.55e-06,27.44,6,12,0,9.0,4.0
Valproate (phsu),TREATS,Epilepsy (dsyn),CAUSES,Cessation of life (orgf),1.02e-10,12.3,19,55,0,25.56,4.0
Valproate (phsu),TREATS,Epilepsy (dsyn),PROCESS_OF,Survivors (humn),5.46e-08,10.79,19,13,0,21.89,1.0
Intervention regimes (hlca),TREATS,African American (popg),ISA,Ethnic group (popg),2.08e-12,10.57,16,98,0,18.61,4.0
Intervention regimes (hlca),TREATS,African American (popg),ISA,Racial group (popg),2.08e-12,11.51,16,324,0,16.79,4.0
Polycystic Ovary Syndrome (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,34.55,24,16,0,26.67,9.0
Polycystic Ovary Syndrome (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,39.72,24,9,0,12.38,9.0
Polycystic Ovary Syndrome (dsyn),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,32.11,24,31,0,42.58,9.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,28.29,16,20,0,28.8,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,25.47,16,65,0,19.94,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,27.8,16,16,0,32.0,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,28.05,16,13,0,23.56,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,29.03,16,16,0,32.0,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,34.44,16,8,0,12.0,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,27.91,16,23,0,27.13,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,28.81,16,22,0,27.64,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,28.74,16,13,0,23.56,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,30.74,16,15,0,29.06,1.0
Oral Glucose Tolerance Test (diap),DIAGNOSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.6e-08,28.62,9,16,0,14.06,9.0
Oral Glucose Tolerance Test (diap),DIAGNOSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,33.79,9,9,0,18.0,9.0
Oral Glucose Tolerance Test (diap),DIAGNOSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.18e-07,26.17,9,31,0,11.61,18.0
Osteoporosis (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,16.63,15,18,0,27.5,1.0
Pre-diabetic (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),3.01e-09,44.77,7,20,0,9.45,1.0
Pre-diabetic (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),4.55e-09,41.96,7,65,0,7.75,1.0
Pre-diabetic (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.77e-07,44.28,7,16,0,10.06,1.0
Pre-diabetic (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.1e-06,44.54,7,13,0,10.77,1.0
Pre-diabetic (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.42e-08,45.52,7,16,0,10.06,1.0
Pre-diabetic (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,50.92,7,8,0,13.12,1.0
Pre-diabetic (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.19e-09,44.4,7,23,0,9.13,1.0
Pre-diabetic (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),2.03e-09,45.29,7,22,0,9.23,1.0
Pre-diabetic (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.87e-07,45.22,7,13,0,10.77,1.0
Pre-diabetic (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),3.55e-09,47.22,7,15,0,10.27,1.0
High Density Lipoprotein Cholesterol (bacs),AFFECTS,Systolic blood pressure (ortf),PROCESS_OF,cohort (humn),3.79e-06,29.89,6,15,0,8.4,1.0
High Density Lipoprotein Cholesterol (bacs),AFFECTS,Systolic blood pressure (ortf),PROCESS_OF,Survivors (humn),2.89e-07,35.64,6,13,0,8.77,1.0
Hypertriglyceridemia (fndg),ISA,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.55e-16,13.94,19,62,0,24.82,5.0
Hypertriglyceridemia (fndg),ISA,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.05e-14,24.54,19,17,0,32.21,5.0
Hypertriglyceridemia (fndg),ISA,Dyslipidemias (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.17e-11,16.23,19,19,0,38.0,5.0
"Sleep Apnea, Obstructive (dsyn)",COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.78e-10,34.74,9,33,0,11.45,1.0
"Sleep Apnea, Obstructive (dsyn)",COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,35.28,9,16,0,14.06,9.0
"Sleep Apnea, Obstructive (dsyn)",COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.98e-11,35.09,9,71,0,10.14,5.0
"Sleep Apnea, Obstructive (dsyn)",COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.98e-11,48.93,9,35,0,11.31,9.0
"Sleep Apnea, Obstructive (dsyn)",COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.98e-11,35.01,9,110,0,9.74,9.0
"Sleep Apnea, Obstructive (dsyn)",COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.37e-09,34.35,9,37,0,11.19,1.0
Anemia (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),2.22e-07,10.2,11,20,0,17.05,1.0
Anemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.23e-07,7.38,11,65,0,12.86,1.0
Anemia (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),5.96e-07,9.71,11,16,0,18.56,1.0
Anemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.31e-06,9.96,11,13,0,20.31,1.0
Anemia (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),2.33e-07,10.94,11,16,0,18.56,1.0
Anemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.69e-06,16.35,11,8,0,13.82,1.0
Anemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.21e-07,9.82,11,23,0,16.26,1.0
Anemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),2.21e-07,10.72,11,22,0,16.5,1.0
Anemia (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),1.11e-06,10.65,11,13,0,20.31,1.0
Anemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.22e-07,12.65,11,15,0,19.07,1.0
follow-up (hlca),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,38.69,12,12,0,24.0,1.0
follow-up (hlca),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,36.05,12,24,0,18.0,4.0
Physical Examination (hlca),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),3.24e-09,13.15,12,18,0,20.0,6.0
Systemic arterial pressure (fndg),PROCESS_OF,student (prog),USES,Grade (clas),7.35e-21,24.52,24,7,0,9.04,1.0
Physical activity (dora),TREATS,Participant (humn),USES,Medicare (rnlw),1.16e-09,19.1,41,18,0,25.9,4.0
Insulin Resistance (patf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,28.72,62,18,0,23.23,1.0
Male gender (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.14e-06,32.69,5,23,0,6.09,8.0
Male gender (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),3.14e-06,32.13,5,57,0,5.44,8.0
Male gender (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),3.43e-06,40.6,5,9,0,7.78,8.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Residual Tumor (neop),7.56e-07,7.86,1014,15,0,15.22,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Anastomosis (acab),3.53e-14,8.08,1014,30,0,30.89,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,"[M]Squamous cell carcinoma, metastatic NOS (neop)",1.7e-16,6.54,1014,52,0,54.67,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Rhabdomyosarcoma (neop),7.71e-07,6.37,1014,23,0,23.52,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Malignant Squamous Cell Neoplasm (neop),5.85e-14,6.18,1014,52,0,54.67,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Adenoid Cystic Carcinoma (neop),2.25e-13,8.14,1014,28,0,28.77,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Fracture with displacement (inpo),1.44e-10,6.64,1014,32,0,33.01,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),6.13e-95,5.62,1014,526,0,798.86,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,sarcoma (neop),3.6e-18,6.7,1014,54,0,56.88,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Secondary malignant neoplasm of lymph node (neop),2.54e-14,6.04,1014,58,0,61.32,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,"[X]Malignant melanoma of skin, unspecified (neop)",3.04e-09,6.64,1014,28,0,28.77,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Squamous cell carcinoma of skin (neop),3.1e-22,8.63,1014,43,0,44.82,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,melanoma (neop),5.17e-30,6.83,1014,85,0,92.13,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Merkel cell carcinoma (neop),1.93e-12,7.93,1014,27,0,27.72,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Neoplasm Metastasis (neop),1.85e-06,6.16,1014,24,0,24.57,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Necrotizing fasciitis (dsyn),7.51e-19,8.95,1014,35,0,36.21,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Wounds and Injuries (inpo),1.61e-07,5.51,1014,47,0,49.18,2.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),8.58e-08,38.64,6,25,0,7.44,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),8.61e-08,42.55,6,15,0,8.4,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),8.58e-08,47.93,6,24,0,7.5,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),8.58e-08,38.56,6,46,0,6.78,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),PROCESS_OF,General Population (humn),8.65e-08,38.13,6,24,0,7.5,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),8.63e-08,39.97,6,18,0,8.0,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),8.58e-08,36.7,6,73,0,6.49,5.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),1.8e-07,37.3,6,24,0,7.5,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",8.58e-08,38.62,6,41,0,6.88,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),8.66e-08,39.39,6,19,0,7.89,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",8.58e-08,40.27,6,26,0,7.38,8.0
Insulin Resistance (patf),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),4.09e-30,29.04,35,98,0,47.5,1.0
Insulin Resistance (patf),PROCESS_OF,African American (popg),ISA,Racial group (popg),1.95e-42,29.97,35,324,0,38.78,1.0
Overweight (sosy),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,34.82,58,18,0,23.59,1.0
"Tomography, Optical Coherence (diap)",ISA,Medical Imaging (diap),USES,Transmission Electron Microscopes (medd),4.08e-06,0.17,3,9,0,4.0,5.0
"Tomography, Optical Coherence (diap)",ISA,Medical Imaging (diap),USES,"Microscopes, Electron, Scanning (medd)",2.98e-06,0.08,3,2,0,3.33,5.0
Notch (bsoj),PART_OF,Sternum (bpoc),LOCATION_OF,Wound complication (inpo),3.2e-06,6.17,14,36,0,19.44,2.0
Notch (bsoj),PART_OF,Sternum (bpoc),LOCATION_OF,Injury wounds (inpo),3.23e-06,6.35,14,21,0,23.33,2.0
Notch (bsoj),PART_OF,Sternum (bpoc),LOCATION_OF,Instability (fndg),3.2e-06,6.78,14,32,0,20.12,2.0
interferon therapy (topp),USES,Ribavirin (phsu),TREATS,"Hemorrhagic Fever, Crimean (dsyn)",2.23e-06,8.0,15,13,0,24.27,4.0
interferon therapy (topp),USES,Ribavirin (phsu),TREATS,Respiratory Syncytial Virus Infections (dsyn),1.81e-06,6.65,15,18,0,27.5,4.0
Oral Glucose Tolerance Test (diap),USES,Insulin (horm),TREATS,Hospitalized Patients (humn),2.75e-06,26.71,15,11,0,19.07,4.0
Oral Glucose Tolerance Test (diap),USES,Insulin (horm),TREATS,Hyperglycemia (dsyn),6.74e-17,24.5,15,57,0,18.95,4.0
Weight maintenance regimen (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,36.59,10,12,0,18.33,1.0
Weight maintenance regimen (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,33.96,10,24,0,14.17,4.0
Cerebrovascular accident (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),7.66e-09,7.05,29,18,0,29.17,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),1.93e-08,30.0,7,78,0,7.63,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),1.14e-07,29.13,7,22,0,9.23,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),2.34e-08,36.23,7,12,0,11.08,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),6.29e-08,30.1,7,18,0,9.72,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (humn),1.93e-08,28.1,7,67,0,7.73,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),2.14e-08,30.08,7,21,0,9.33,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),1.93e-08,29.58,7,35,0,8.4,1.0
Respiration (phsf),PROCESS_OF,Chamber (bpoc),LOCATION_OF,Pathological Dilatation (patf),5.34e-08,8.46,24,25,0,47.04,1.0
Exercise (dora),TREATS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,14.01,17,16,0,31.06,4.0
Exercise (dora),TREATS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,19.18,17,9,0,13.76,4.0
Exercise (dora),TREATS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,11.56,17,31,0,26.32,4.0
Body mass index (clna),PREDISPOSES,Tuberculosis (dsyn),ISA,Opportunistic Infections (dsyn),1.42e-10,41.86,8,53,0,9.21,5.0
Body mass index (clna),PREDISPOSES,Tuberculosis (dsyn),CAUSES,Hospitalization (hlca),1.03e-08,48.74,8,11,0,13.82,11.0
Body mass index (clna),PREDISPOSES,Tuberculosis (dsyn),CAUSES,Cessation of life (orgf),1.42e-10,41.81,8,178,0,8.36,11.0
Body mass index (clna),PREDISPOSES,Tuberculosis (dsyn),PROCESS_OF,General Population (humn),9.37e-09,40.88,8,22,0,10.91,1.0
Body mass index (clna),PREDISPOSES,Tuberculosis (dsyn),PROCESS_OF,Males (popg),3.5e-06,45.45,8,9,0,15.11,1.0
Body mass index (clna),PREDISPOSES,Tuberculosis (dsyn),PROCESS_OF,cohort (humn),1.43e-10,40.93,8,33,0,9.94,1.0
Body mass index (clna),PREDISPOSES,Tuberculosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.42e-10,42.13,8,62,0,9.03,1.0
Body mass index (clna),PREDISPOSES,Tuberculosis (dsyn),OCCURS_IN,"Recipient, Transplant (podg)",7.63e-08,44.7,8,12,0,13.33,21.0
Body mass index (clna),PREDISPOSES,Tuberculosis (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.43e-10,41.68,8,30,0,10.13,1.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),1.84e-08,22.75,10,20,0,15.0,1.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Disability NOS (patf),6.29e-11,25.9,10,36,0,12.78,9.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Respiration Disorders (dsyn),6.29e-11,22.53,10,59,0,11.69,5.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Respiratory physiology (ortf),2.07e-08,22.19,10,23,0,14.35,1.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Acute respiratory failure (dsyn),3.54e-07,25.19,10,12,0,18.33,9.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),6.29e-11,22.9,10,72,0,11.39,1.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Lung diseases (dsyn),6.29e-11,22.37,10,73,0,11.37,5.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Hospitalized Patients (humn),6.29e-11,23.7,10,50,0,12.0,1.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospital admission (hlca),3.41e-09,25.49,10,15,0,16.67,9.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Cessation of life (orgf),6.29e-11,25.42,10,184,0,10.54,9.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Outpatients (podg),1.88e-08,20.96,10,43,0,12.33,1.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,General Population (humn),7.05e-11,22.92,10,27,0,13.7,1.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Diagnosis (hlca),1.7e-07,26.97,10,11,0,19.09,9.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospitalization (hlca),6.29e-11,25.11,10,31,0,13.23,9.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Participant (humn),6.29e-11,22.26,10,70,0,11.43,1.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),COEXISTS_WITH,Smoker (fndg),2.39e-07,21.44,10,27,0,13.7,9.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Chronic Disease (dsyn),6.29e-11,23.41,10,46,0,12.17,5.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Malignant neoplasm of lung (neop),8.79e-08,23.13,10,17,0,15.88,9.0
Muscular Atrophy (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Pneumonia (dsyn),4.46e-07,25.04,10,12,0,18.33,9.0
Calcium (bacs),PART_OF,Coronary artery (bpoc),LOCATION_OF,Stable Disease (fndg),8.99e-18,5.67,146,47,0,62.13,2.0
Calcium (bacs),PART_OF,Coronary artery (bpoc),LOCATION_OF,Senile Plaques (acab),6.08e-07,4.03,146,49,0,65.45,2.0
Calcium (bacs),PART_OF,Coronary artery (bpoc),LOCATION_OF,Pre-existing disease (sosy),1.35e-15,7.86,146,28,0,33.37,2.0
Calcium (bacs),PART_OF,Coronary artery (bpoc),LOCATION_OF,"Stenosis, unspecified (patf)",8.77e-14,4.09,146,90,0,145.48,2.0
Calcium (bacs),PART_OF,Coronary artery (bpoc),LOCATION_OF,Metal stent (medd),4.43e-06,5.65,146,16,0,17.75,2.0
Calcium (bacs),PART_OF,Coronary artery (bpoc),LOCATION_OF,Drug eluting stent (medd),2.79e-07,6.45,146,16,0,17.75,2.0
Adiponectin (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,"Energy, Physics (npop)",1.85e-08,8.23,11,79,0,12.53,1.0
Adiponectin (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,Oxidation-Reduction (npop),3.44e-06,8.19,11,29,0,15.17,1.0
Physical activity (dora),TREATS,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),1.02e-06,12.3,8,25,0,10.56,1.0
Physical activity (dora),TREATS,Diabetic (fndg),PROCESS_OF,Participant (humn),1.06e-06,10.84,8,50,0,9.28,1.0
Physical activity (dora),TREATS,Diabetic (fndg),PROCESS_OF,cohort (humn),1.02e-06,12.83,8,65,0,8.98,1.0
Physical activity (dora),TREATS,Diabetic (fndg),PROCESS_OF,Population Group (humn),2.12e-06,15.44,8,11,0,13.82,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.9e-09,15.09,11,18,0,17.72,1.0
Menopause (phsf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),9.51e-07,25.42,6,18,0,8.0,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,20.12,18,9,0,13.5,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.69e-16,19.18,18,194,0,19.67,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,17.91,18,17,0,33.06,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.69e-16,19.18,18,29,0,29.17,11.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,21.36,18,14,0,24.89,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,17.17,18,12,0,20.0,5.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.69e-16,15.99,18,48,0,24.75,11.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.69e-16,19.38,18,29,0,29.17,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.69e-16,16.42,18,98,0,21.31,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,15.09,18,24,0,31.5,9.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,21.5,18,10,0,15.56,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,13.86,18,37,0,26.76,7.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,15.66,18,20,0,34.2,9.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.69e-16,17.31,18,94,0,21.45,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,23.1,18,8,0,11.56,9.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,19.98,18,19,0,35.05,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,17.13,18,21,0,33.43,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,22.31,18,12,0,20.0,9.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,30.03,18,10,0,15.56,21.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,22.61,18,10,0,15.56,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,16.93,18,21,0,33.43,21.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.7e-13,18.54,18,21,0,33.43,9.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.59e-16,16.67,18,32,0,28.12,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,24.03,18,10,0,15.56,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.69e-16,23.0,18,39,0,26.31,9.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.69e-16,26.97,18,44,0,25.36,11.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.69e-16,19.85,18,113,0,20.87,9.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,17.38,18,11,0,17.72,11.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,17.1,18,11,0,17.72,9.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,17.56,18,12,0,20.0,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,15.46,18,25,0,30.96,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.69e-16,21.13,18,87,0,21.72,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),7.85e-16,16.12,18,33,0,27.82,9.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.69e-16,18.86,18,41,0,25.9,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.89e-14,19.02,18,21,0,33.43,1.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,16.69,18,21,0,33.43,9.0
Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.69e-16,17.64,18,1021,0,18.32,11.0
Insulin (horm),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,20.29,27,16,0,25.48,8.0
Insulin (horm),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,25.45,27,9,0,12.0,8.0
Insulin (horm),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,17.84,27,31,0,50.52,8.0
Physical activity (dora),TREATS,student (prog),USES,Grade (clas),1.35e-13,11.72,15,7,0,10.27,4.0
High weight (sosy),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),3.98e-09,28.06,8,18,0,11.56,1.0
Italians (popg),ISA,Caucasoid Race (popg),ISA,Racial group (popg),1.44e-07,11.95,9,136,0,9.6,5.0
Italians (popg),ISA,Caucasoid Race (popg),ISA,Ethnic group (popg),1.44e-07,11.08,9,188,0,9.43,5.0
Italians (popg),ISA,Caucasoid Race (popg),ISA,Population Group (humn),2.68e-06,11.97,9,20,0,13.05,5.0
Dietary intake (orgf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,22.39,20,18,0,34.2,1.0
Cartilage (tisu),PART_OF,Bone structure of tibia (bpoc),LOCATION_OF,SLOPE (fndg),3.07e-09,3.5,20,2,0,2.2,2.0
Hypertriglyceridemia (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.24e-06,17.42,7,18,0,9.72,1.0
Gamma-glutamyl transferase (aapp),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),9.5e-07,22.98,6,33,0,7.09,1.0
Gamma-glutamyl transferase (aapp),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),5.38e-06,23.52,6,16,0,8.25,9.0
Gamma-glutamyl transferase (aapp),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),9.5e-07,23.32,6,71,0,6.51,5.0
Gamma-glutamyl transferase (aapp),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),9.5e-07,37.17,6,35,0,7.03,21.0
Gamma-glutamyl transferase (aapp),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),9.5e-07,23.25,6,110,0,6.33,21.0
Gamma-glutamyl transferase (aapp),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),9.52e-07,22.59,6,37,0,6.97,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,23.76,26,20,0,35.38,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,20.95,26,65,0,36.4,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,23.27,26,16,0,25.85,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,23.52,26,13,0,19.5,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,24.51,26,16,0,25.85,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,29.91,26,8,0,10.46,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,23.39,26,23,0,43.35,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,24.28,26,22,0,40.62,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,24.21,26,13,0,19.5,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,26.21,26,15,0,23.65,1.0
Waist circumference (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,34.01,31,33,0,60.12,1.0
Waist circumference (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,34.56,31,16,0,24.26,9.0
Waist circumference (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.33e-25,34.36,31,71,0,44.54,5.0
Waist circumference (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.96e-32,48.2,31,35,0,58.46,9.0
Waist circumference (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.3e-38,34.29,31,110,0,39.74,9.0
Waist circumference (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,33.62,31,37,0,56.97,1.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Atrial Fibrillation (patf),3.41e-07,4.78,32,21,0,34.78,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Primary Prevention (topp),1.51e-07,4.67,32,23,0,39.53,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,STEMI (dsyn),1.44e-09,9.39,32,47,0,53.79,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,General Population (humn),1.82e-08,4.89,32,24,0,42.0,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),PREVENTS,Premature Birth (patf),1.44e-09,7.11,32,30,0,58.12,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),PREVENTS,Death (finding) (fndg),1.44e-09,13.52,32,94,0,42.89,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,"Aortic Aneurysm, Abdominal (dsyn)",1.44e-09,11.16,32,20,0,32.5,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Hemorrhage (fndg),1.44e-09,6.27,32,65,0,47.75,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Pulmonary Embolism (dsyn),2.36e-08,8.02,32,14,0,20.12,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cerebrovascular accident (dsyn),1.51e-09,6.42,32,22,0,37.12,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Septicemia (dsyn),1.44e-09,9.85,32,41,0,56.98,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Malaria (dsyn),1.44e-09,5.33,32,56,0,50.29,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),PREVENTS,Stillbirth (patf),1.35e-08,10.8,32,12,0,16.5,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),1.44e-09,5.0,31,59,1,47.29,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Critical limb ischemia (patf),1.44e-09,9.02,32,40,0,57.6,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,"Shock, Cardiogenic (patf)",2.01e-09,10.56,32,14,0,20.12,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Cardiovascular Diseases (dsyn),1.44e-09,5.83,32,33,0,63.03,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Pneumonia (dsyn),2.37e-09,6.66,32,19,0,30.28,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Chronic heart failure (dsyn),1.44e-09,8.16,32,25,0,44.53,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),PREVENTS,"Death, Sudden, Cardiac (patf)",6.65e-07,9.99,32,10,0,13.12,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,high-risk group (humn),1.46e-09,5.58,32,27,0,49.78,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,"Pancreatitis, Acute Necrotizing (dsyn)",1.44e-09,10.16,32,20,0,32.5,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,"Stenosis, unspecified (patf)",1.52e-09,5.48,32,26,0,47.12,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Deglutition Disorders (dsyn),7.57e-07,5.91,32,15,0,22.03,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Depressed mood (fndg),1.87e-06,3.87,32,30,0,58.12,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,High Risk Populations (popg),4.79e-09,5.16,32,24,0,42.0,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Octogenarians (aggp),1.23e-07,12.16,32,10,0,13.12,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Acute myocardial infarction (dsyn),1.44e-09,6.99,32,104,0,41.85,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),USES,Losartan (orch),1.44e-09,7.36,32,65,0,47.75,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Peripheral Vascular Diseases (dsyn),1.44e-09,7.23,32,40,0,57.6,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Postpartum Hemorrhage (patf),6.68e-08,10.77,32,11,0,14.78,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Coronary Arteriosclerosis (dsyn),1.44e-09,6.45,32,60,0,49.07,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Anemia (dsyn),3.71e-07,5.52,32,17,0,26.03,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),PREVENTS,Adverse event (fndg),2.41e-07,5.95,32,16,0,24.0,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Ischemia (dsyn),1.44e-09,6.76,32,23,0,39.53,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Endoleak (patf),1.44e-09,9.77,32,30,0,58.12,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Carotid Stenosis (dsyn),1.78e-07,6.45,32,15,0,22.03,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Secondary prevention (topp),3.09e-06,5.45,32,15,0,22.03,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Malnutrition (dsyn),7.24e-09,5.83,32,20,0,32.5,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Systemic arterial pressure (fndg),1.45e-09,4.25,32,43,0,55.81,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Pre-Eclampsia (dsyn),2.52e-09,11.52,32,13,0,18.28,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,"Kidney Failure, Chronic (dsyn)",1.44e-09,7.04,32,52,0,51.69,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Myocardial Infarction (dsyn),1.44e-09,8.07,32,91,0,43.25,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Maternal Mortality (fndg),1.44e-09,18.45,32,19,0,30.28,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Mitral Valve Insufficiency (dsyn),6.7e-07,6.36,32,14,0,20.12,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Survivors (humn),3.71e-09,3.66,32,53,0,51.32,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,"Stroke, Acute (dsyn)",1.02e-06,5.81,32,15,0,22.03,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),PREVENTS,Perinatal death (fndg),1.44e-09,16.74,32,17,0,26.03,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,End stage renal failure (dsyn),1.44e-09,8.07,32,21,0,34.78,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Diabetic (fndg),1.44e-09,5.64,32,36,0,60.44,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),PREVENTS,Newborn death (patf),2.38e-08,15.02,32,10,0,13.12,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,"Hepatitis C, Chronic (dsyn)",6.52e-07,12.29,32,9,0,11.53,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),PREVENTS,Maternal Mortality (fndg),1.44e-09,17.65,32,80,0,44.8,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cardiovascular event (fndg),1.44e-09,8.38,32,28,0,52.5,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Death (finding) (fndg),1.44e-09,11.41,32,19,0,30.28,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Acute coronary syndrome (dsyn),1.44e-09,7.38,32,60,0,49.07,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Heart Arrest (patf),1.44e-09,8.39,32,27,0,49.78,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Disease Progression (patf),3.48e-07,6.19,32,15,0,22.03,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Critical Illness (dsyn),1.44e-09,7.41,32,42,0,56.38,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Diarrhea (sosy),3.51e-09,6.79,32,18,0,28.12,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Congestive heart failure (dsyn),6.7e-07,6.36,32,14,0,20.12,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),USES,Pravastatin (phsu),1.44e-09,9.36,32,30,0,58.12,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Septic Shock (patf),3.64e-09,10.83,32,13,0,18.28,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Control Groups (humn),3.04e-06,3.31,32,57,0,49.96,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Coronary heart disease (dsyn),1.44e-09,6.21,32,49,0,52.9,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),PREVENTS,Hemorrhage (fndg),2.41e-07,5.95,32,16,0,24.0,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Claudication (dsyn),1.44e-09,11.16,32,17,0,26.03,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,"Respiratory Distress Syndrome, Adult (dsyn)",2.29e-09,7.62,32,17,0,26.03,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Ischemic stroke (dsyn),4.77e-07,4.87,32,20,0,32.5,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),1.44e-09,3.98,32,123,0,40.33,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Upper gastrointestinal hemorrhage (dsyn),1.44e-09,12.96,32,18,0,28.12,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Revascularization - action (topp),1.44e-09,9.48,32,24,0,42.0,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),1.44e-09,6.13,32,34,0,62.12,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,cohort (humn),1.44e-09,5.07,32,38,0,58.95,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cardiovascular morbidity (dsyn),1.44e-09,17.06,32,24,0,42.0,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Aortic Valve Stenosis (dsyn),1.44e-09,8.23,32,28,0,52.5,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Heart failure (dsyn),1.44e-09,6.85,32,103,0,41.94,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),PREVENTS,Malaria (dsyn),1.21e-07,5.57,32,18,0,28.12,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),AFFECTS,Maternal Mortality (fndg),1.44e-09,17.92,32,14,0,20.12,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),ISA,Procedures (hlca),1.44e-09,4.11,32,125,0,40.19,5.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,Fetofetal Transfusion (dsyn),4.41e-07,12.96,32,9,0,11.53,4.0
Self-Management (hlca),ISA,Intervention regimes (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",1.45e-09,5.82,32,26,0,47.12,4.0
Body mass index (clna),PREDISPOSES,Primary carcinoma of the liver cells (neop),ISA,Common Neoplasm (neop),3.48e-10,62.06,7,28,0,8.75,5.0
Body mass index (clna),PREDISPOSES,Primary carcinoma of the liver cells (neop),ISA,Liver and Intrahepatic Biliary Tract Carcinoma (neop),3.38e-10,62.03,7,68,0,7.72,5.0
Body mass index (clna),PREDISPOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,Hispanics (humn),4.66e-08,67.7,7,11,0,11.45,1.0
Body mass index (clna),PREDISPOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,cohort (humn),3.38e-10,64.43,7,85,0,7.58,1.0
Body mass index (clna),PREDISPOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,"Recipient, Transplant (podg)",3.38e-10,64.7,7,25,0,8.96,1.0
Body mass index (clna),PREDISPOSES,Primary carcinoma of the liver cells (neop),ISA,Chronic liver disease NOS (dsyn),4.98e-06,61.6,7,16,0,10.06,5.0
Body mass index (clna),PREDISPOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,Hepatitis C virus (virs),6.81e-08,62.26,7,18,0,9.72,1.0
Body mass index (clna),PREDISPOSES,Primary carcinoma of the liver cells (neop),ISA,Liver neoplasms (neop),1.3e-08,61.24,7,26,0,8.88,5.0
Body mass index (clna),PREDISPOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,African American (popg),6.57e-08,67.31,7,11,0,11.45,1.0
Body mass index (clna),PREDISPOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,cohort (humn),3.38e-10,63.03,7,26,0,8.88,1.0
Body mass index (clna),PREDISPOSES,Primary carcinoma of the liver cells (neop),COEXISTS_WITH,Fibrosis (patf),3.38e-10,61.45,7,69,0,7.71,9.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),5.26e-06,19.11,7,9,0,12.44,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.67e-06,18.17,7,194,0,7.25,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),2.67e-06,16.89,7,17,0,9.88,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.67e-06,18.16,7,29,0,8.69,11.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2.67e-06,20.34,7,14,0,10.5,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),3.73e-06,16.15,7,12,0,11.08,5.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),2.67e-06,14.97,7,48,0,8.02,11.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.67e-06,18.36,7,29,0,8.69,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.67e-06,15.41,7,98,0,7.5,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.67e-06,14.07,7,24,0,9.04,9.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),2.85e-06,20.48,7,10,0,11.9,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),2.68e-06,12.84,7,37,0,8.32,7.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.68e-06,14.64,7,20,0,9.45,9.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.67e-06,16.3,7,94,0,7.52,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),5.01e-06,22.09,7,8,0,13.12,9.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),2.67e-06,18.96,7,19,0,9.58,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),2.67e-06,16.12,7,21,0,9.33,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.67e-06,21.3,7,12,0,11.08,9.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.67e-06,29.01,7,10,0,11.9,21.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),2.75e-06,21.6,7,10,0,11.9,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.67e-06,15.92,7,21,0,9.33,21.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.67e-06,17.53,7,21,0,9.33,9.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.67e-06,15.65,7,32,0,8.53,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),2.71e-06,23.01,7,10,0,11.9,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.67e-06,21.98,7,39,0,8.26,9.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),2.67e-06,25.96,7,44,0,8.11,11.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.67e-06,18.83,7,113,0,7.43,9.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),5.42e-06,16.36,7,11,0,11.45,11.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),6.84e-06,16.08,7,11,0,11.45,9.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),3.23e-06,16.55,7,12,0,11.08,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),2.67e-06,14.44,7,25,0,8.96,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.67e-06,20.11,7,87,0,7.56,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),2.67e-06,15.1,7,33,0,8.48,9.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.67e-06,17.84,7,41,0,8.2,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),2.67e-06,18.01,7,21,0,9.33,1.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",2.67e-06,15.67,7,21,0,9.33,9.0
Vitamin D (phsu),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.67e-06,16.62,7,1021,0,7.05,11.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),1.01e-07,23.71,7,20,0,9.45,1.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Disability NOS (patf),8.29e-08,26.87,7,36,0,8.36,8.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Respiration Disorders (dsyn),8.29e-08,23.5,7,59,0,7.83,5.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Respiratory physiology (ortf),1.03e-07,23.15,7,23,0,9.13,1.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Acute respiratory failure (dsyn),4.36e-07,26.16,7,12,0,11.08,8.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),8.29e-08,23.87,7,72,0,7.68,1.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Lung diseases (dsyn),8.29e-08,23.33,7,73,0,7.67,5.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Hospitalized Patients (humn),8.29e-08,24.67,7,50,0,7.98,1.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospital admission (hlca),8.62e-08,26.46,7,15,0,10.27,8.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Cessation of life (orgf),8.29e-08,26.39,7,184,0,7.27,8.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Outpatients (podg),1.02e-07,21.93,7,43,0,8.14,1.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,General Population (humn),8.29e-08,23.89,7,27,0,8.81,1.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Diagnosis (hlca),2.53e-07,27.94,7,11,0,11.45,8.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospitalization (hlca),8.29e-08,26.07,7,31,0,8.58,8.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Participant (humn),8.29e-08,23.23,7,70,0,7.7,1.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),COEXISTS_WITH,Smoker (fndg),3.22e-07,22.4,7,27,0,8.81,8.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Chronic Disease (dsyn),8.29e-08,24.38,7,46,0,8.07,5.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Malignant neoplasm of lung (neop),1.71e-07,24.1,7,17,0,9.88,8.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Pneumonia (dsyn),5.29e-07,26.0,7,12,0,11.08,8.0
Cholesterol (bacs),ISA,Lipids (lipd),PART_OF,Stratum corneum (tisu),5.68e-06,5.0,10,2,0,2.4,3.0
"Arthroplasty, Replacement, Knee (topp)",PRECEDES,Revision procedure (topp),TREATS,Hemorrhage (fndg),1.83e-06,15.47,8,19,0,11.37,4.0
Triglycerides (bacs),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,33.3,23,16,0,27.13,9.0
Triglycerides (bacs),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,38.46,23,9,0,12.52,9.0
Triglycerides (bacs),PREDISPOSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,30.85,23,31,0,40.06,21.0
Gastrectomy (topp),TREATS,Malignant neoplasm of stomach (neop),PROCESS_OF,cohort (humn),3.86e-17,8.02,79,31,0,43.16,1.0
Gastrectomy (topp),TREATS,Malignant neoplasm of stomach (neop),ISA,Malignant disease (dsyn),3.28e-08,9.45,79,13,0,15.14,4.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),4.78e-08,21.11,8,15,0,12.27,1.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic heart failure (dsyn),PROCESS_OF,Outpatients (podg),3.91e-08,20.99,8,86,0,8.74,1.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic heart failure (dsyn),CAUSES,Hospitalization (hlca),3.91e-08,24.48,8,17,0,11.76,8.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic heart failure (dsyn),ISA,Heart failure (dsyn),3.91e-08,25.08,8,16,0,12.0,5.0
Cachexia (sosy),ASSOCIATED_WITH,Chronic heart failure (dsyn),PROCESS_OF,cohort (humn),3.92e-08,25.18,8,14,0,12.57,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,18.78,15,9,0,14.4,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),4.24e-13,17.84,15,194,0,16.16,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,16.57,15,17,0,28.24,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),4.24e-13,17.83,15,29,0,22.76,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2e-10,20.02,15,14,0,27.07,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,15.82,15,12,0,21.6,5.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),4.24e-13,14.64,15,48,0,19.69,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),4.24e-13,18.03,15,29,0,22.76,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),4.24e-13,15.08,15,98,0,17.3,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,13.74,15,24,0,24.38,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,20.16,15,10,0,16.67,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,12.51,15,37,0,21.08,7.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,14.32,15,20,0,26.25,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),4.24e-13,15.97,15,94,0,17.39,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,21.76,15,8,0,12.27,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),7.37e-13,18.64,15,19,0,26.84,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.25e-11,15.79,15,21,0,25.71,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,20.97,15,12,0,21.6,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,28.69,15,10,0,16.67,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,21.27,15,10,0,16.67,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.29e-11,15.59,15,21,0,25.71,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),6.93e-13,17.2,15,21,0,25.71,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),4.24e-13,15.33,15,32,0,22.03,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,22.68,15,10,0,16.67,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),4.24e-13,21.65,15,39,0,20.77,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),4.24e-13,25.63,15,44,0,20.11,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.24e-13,18.51,15,113,0,16.99,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,16.03,15,11,0,19.07,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,15.76,15,11,0,19.07,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,16.22,15,12,0,21.6,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,14.12,15,25,0,24.0,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",4.24e-13,19.79,15,87,0,17.59,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),4.24e-13,14.78,15,33,0,21.82,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),4.24e-13,17.52,15,41,0,20.49,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),5.13e-13,17.68,15,21,0,25.71,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5.04e-11,15.35,15,21,0,25.71,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),4.24e-13,16.29,15,1021,0,15.22,8.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,23.77,11,9,0,16.36,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.55e-11,22.82,11,194,0,11.62,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.72e-10,21.55,11,17,0,18.12,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),3.55e-11,22.82,11,29,0,15.17,11.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2.35e-10,25.0,11,14,0,19.64,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,20.81,11,12,0,21.08,5.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),3.55e-11,19.63,11,48,0,13.52,11.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),3.55e-11,23.02,11,29,0,15.17,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.55e-11,20.06,11,98,0,12.23,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.36e-09,18.73,11,24,0,16.04,9.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,25.14,11,10,0,19.09,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.22e-08,17.5,11,37,0,14.27,7.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.77e-09,19.3,11,20,0,17.05,9.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),3.55e-11,20.95,11,94,0,12.29,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,26.74,11,8,0,13.82,9.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.58e-11,23.62,11,19,0,17.37,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),4.75e-11,20.77,11,21,0,16.76,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.81e-09,25.95,11,12,0,21.08,9.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.67e-09,33.67,11,10,0,19.09,21.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,26.26,11,10,0,19.09,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),5.8e-11,20.57,11,21,0,16.76,21.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),3.57e-11,22.18,11,21,0,16.76,9.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.55e-11,20.31,11,32,0,14.78,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,27.67,11,10,0,19.09,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),3.55e-11,26.64,11,39,0,14.1,9.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),3.55e-11,30.61,11,44,0,13.75,11.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.55e-11,23.49,11,113,0,12.07,9.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,21.02,11,11,0,22.0,11.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,20.74,11,11,0,22.0,9.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,21.2,11,12,0,21.08,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.53e-10,19.1,11,25,0,15.84,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.55e-11,24.77,11,87,0,12.39,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),3.55e-11,19.76,11,33,0,14.67,9.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.55e-11,22.5,11,41,0,13.95,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),3.55e-11,22.67,11,21,0,16.76,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",8.54e-11,20.33,11,21,0,16.76,9.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),3.55e-11,21.28,11,1021,0,11.12,11.0
body mass (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,42.57,25,18,0,30.96,1.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,Octogenarians (aggp),6.5e-07,13.59,22,8,1,10.91,1.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,Surgical Patients (podg),1.24e-08,8.35,23,16,0,27.13,1.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,General Population (humn),1.42e-10,8.08,23,31,0,40.06,1.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),1.42e-10,7.5,23,28,0,41.89,1.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,African American (popg),1.42e-10,10.0,23,53,0,32.98,1.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,Caucasoid Race (popg),1.24e-06,6.14,23,19,0,34.7,1.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,Participant (humn),1.42e-10,7.9,23,33,0,39.03,1.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,Long-Term Survivors (podg),9.96e-10,8.93,23,17,0,29.57,1.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),1.42e-10,5.59,23,100,0,28.29,1.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Carcinoma of the Large Intestine (neop),ISA,Common Neoplasm (neop),3.8e-09,7.26,23,20,0,37.39,4.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,cohort (humn),6.79e-08,7.03,23,18,0,32.09,1.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,cohort (humn),1.42e-10,7.27,23,63,0,31.4,1.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,Black race (popg),2.23e-08,9.33,23,14,0,22.52,1.0
Cardiovascular event (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,13.13,19,18,0,35.05,1.0
Jumping (dora),ISA,Performance (inbe),PROCESS_OF,cohort (humn),3.73e-10,5.55,27,150,0,31.86,1.0
Jumping (dora),ISA,Performance (inbe),PROCESS_OF,athlete (humn),4.28e-10,2.78,27,5,0,5.93,1.0
Jumping (dora),ISA,Performance (inbe),PROCESS_OF,student (prog),3.73e-10,2.75,27,4,0,4.59,1.0
Jumping (dora),ISA,Performance (inbe),PROCESS_OF,Surgeon (humn),1.11e-06,4.64,27,27,0,54.0,1.0
Jumping (dora),ISA,Performance (inbe),PREDISPOSES,Septicemia (dsyn),2.59e-06,10.83,27,9,0,12.0,5.0
Sedentary (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,15.54,39,18,0,26.31,1.0
Biomedical tape (medd),TREATS,"Urinary Incontinence, Stress (dsyn)",PROCESS_OF,Urodynamics (ortf),3.65e-07,2.98,19,1,0,1.05,1.0
Vertical-Banded Gastroplasty (topp),PRECEDES,Roux-en-Y Gastric Bypass (topp),TREATS,"Obesity, Morbid (dsyn)",5.58e-07,49.79,5,54,0,5.46,4.0
Disability NOS (patf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.26e-07,7.93,18,18,0,36.0,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,14.59,126,20,0,23.17,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,11.78,126,65,0,98.53,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,14.1,126,16,0,18.03,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,14.36,126,13,0,14.34,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,15.34,126,16,0,18.03,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,20.75,126,8,0,8.51,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,14.22,126,23,0,27.2,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,15.12,126,22,0,25.84,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,15.05,126,13,0,14.34,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,17.04,126,15,0,16.79,1.0
Smoking (inbe),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,10.5,29,20,0,33.79,1.0
Smoking (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,7.69,29,65,0,41.94,1.0
Smoking (inbe),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,10.01,29,16,0,24.83,1.0
Smoking (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,10.26,29,13,0,18.83,1.0
Smoking (inbe),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,11.25,29,16,0,24.83,1.0
Smoking (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,16.65,29,8,0,10.21,1.0
Smoking (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,10.13,29,23,0,41.24,1.0
Smoking (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,11.02,29,22,0,38.69,1.0
Smoking (inbe),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,10.95,29,13,0,18.83,1.0
Smoking (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,12.95,29,15,0,22.76,1.0
Blood Pressure (orgf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.19e-07,33.14,6,18,0,8.0,1.0
Adiponectin (aapp),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),8.67e-09,24.1,8,77,0,8.83,1.0
Adiponectin (aapp),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),1.87e-08,24.44,8,16,0,12.0,1.0
Adiponectin (aapp),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Young adult (aggp),4.09e-06,23.88,8,12,0,13.33,1.0
Adiponectin (aapp),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Middle Aged (aggp),9.11e-09,24.23,8,19,0,11.37,1.0
Adiponectin (aapp),PREDISPOSES,Coronary heart disease (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.01e-08,23.01,8,22,0,10.91,21.0
Adiponectin (aapp),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Outpatients (podg),6.63e-08,22.02,8,24,0,10.67,1.0
Adiponectin (aapp),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,General Population (humn),8.67e-09,23.72,8,42,0,9.52,1.0
Adiponectin (aapp),PREDISPOSES,Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),8.67e-09,24.97,8,102,0,8.63,5.0
Adiponectin (aapp),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Heart failure (dsyn),3.43e-07,24.56,8,13,0,12.92,11.0
Adiponectin (aapp),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),8.67e-09,24.31,8,83,0,8.77,1.0
Adiponectin (aapp),PREDISPOSES,Coronary heart disease (dsyn),ISA,Death (finding) (fndg),8.67e-09,26.89,8,250,0,8.26,5.0
Adiponectin (aapp),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),8.67e-09,24.07,8,194,0,8.33,11.0
Microalbuminuria (dsyn),COEXISTS_WITH,Hypertensive (fndg),PROCESS_OF,Participant (humn),3.78e-12,17.6,12,53,0,14.72,1.0
Diagnosis (hlca),TREATS,Diabetes Mellitus (dsyn),COEXISTS_WITH,Heart failure (dsyn),2.21e-06,20.13,8,15,0,12.27,4.0
Diagnosis (hlca),TREATS,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.21e-06,22.6,8,15,0,12.27,4.0
Diagnosis (hlca),TREATS,Diabetes Mellitus (dsyn),CAUSES,"Kidney Failure, Chronic (dsyn)",2.21e-06,14.1,8,20,0,11.2,4.0
Diagnosis (hlca),TREATS,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.21e-06,13.37,8,52,0,9.23,4.0
Diagnosis (hlca),TREATS,Diabetes Mellitus (dsyn),PROCESS_OF,Hospitalized Patients (humn),2.77e-06,12.24,8,15,0,12.27,1.0
Diagnosis (hlca),TREATS,Diabetes Mellitus (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.22e-06,11.76,8,21,0,11.05,1.0
Diagnosis (hlca),TREATS,Diabetes Mellitus (dsyn),CAUSES,End stage renal failure (dsyn),2.21e-06,13.05,8,51,0,9.25,4.0
Diagnosis (hlca),TREATS,Diabetes Mellitus (dsyn),PROCESS_OF,Survivors (humn),2.29e-06,15.36,8,12,0,13.33,1.0
Diagnosis (hlca),TREATS,Diabetes Mellitus (dsyn),CAUSES,Kidney Failure (dsyn),2.21e-06,17.7,8,15,0,12.27,4.0
Diagnosis (hlca),TREATS,Diabetes Mellitus (dsyn),CAUSES,Cessation of life (orgf),2.21e-06,14.95,8,43,0,9.49,4.0
Diagnosis (hlca),TREATS,Diabetes Mellitus (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),2.22e-06,15.2,8,14,0,12.57,4.0
Diagnosis (hlca),TREATS,Diabetes Mellitus (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),2.21e-06,13.37,8,26,0,10.46,4.0
Diagnosis (hlca),TREATS,Diabetes Mellitus (dsyn),PROCESS_OF,General Population (humn),2.21e-06,12.56,8,22,0,10.91,1.0
Diagnosis (hlca),TREATS,Diabetes Mellitus (dsyn),ISA,Metabolic Diseases (dsyn),3.84e-06,9.74,8,43,0,9.49,4.0
Diagnosis (hlca),TREATS,Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),2.21e-06,12.19,8,44,0,9.45,1.0
Diagnosis (hlca),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.52e-06,19.17,6,33,0,7.09,1.0
Diagnosis (hlca),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),6.95e-06,19.71,6,16,0,8.25,4.0
Diagnosis (hlca),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),2.52e-06,19.51,6,71,0,6.51,4.0
Diagnosis (hlca),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.52e-06,33.36,6,35,0,7.03,4.0
Diagnosis (hlca),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.52e-06,19.44,6,110,0,6.33,4.0
Diagnosis (hlca),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),2.52e-06,18.78,6,37,0,6.97,1.0
Overweight (sosy),PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),3.18e-42,40.12,32,136,0,39.53,1.0
Overweight (sosy),PROCESS_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),1.23e-33,39.25,32,188,0,37.45,1.0
Overweight (sosy),PROCESS_OF,Caucasoid Race (popg),ISA,Population Group (humn),2.53e-06,40.14,32,20,0,32.5,1.0
Ultrasonography (diap),DIAGNOSES,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.79e-10,31.54,40,22,1,34.1,18.0
Ultrasonography (diap),DIAGNOSES,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),1.67e-22,30.99,41,57,0,70.49,11.0
Ultrasonography (diap),DIAGNOSES,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,39.46,41,9,0,10.98,9.0
Exercise stress test (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.16e-09,15.32,25,18,0,30.96,6.0
oxidized low density lipoprotein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.88e-07,29.03,6,33,0,7.09,1.0
oxidized low density lipoprotein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.72e-06,29.57,6,16,0,8.25,8.0
oxidized low density lipoprotein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),2.88e-07,29.38,6,71,0,6.51,5.0
oxidized low density lipoprotein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.88e-07,43.22,6,35,0,7.03,8.0
oxidized low density lipoprotein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.88e-07,29.3,6,110,0,6.33,8.0
oxidized low density lipoprotein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),2.89e-07,28.64,6,37,0,6.97,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,20.42,121,9,0,9.67,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),5.13e-113,19.47,120,193,1,194.61,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,18.2,121,17,0,19.39,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,19.47,121,29,0,35.95,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,21.65,121,14,0,15.62,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,17.46,121,12,0,13.19,5.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),9.81e-23,16.28,121,48,0,67.04,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.51e-19,19.67,121,29,0,35.95,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.74e-50,16.71,121,98,0,177.37,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,21.79,121,10,0,10.83,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,14.15,121,37,0,48.31,7.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,15.95,121,20,0,23.31,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),6.68e-54,17.6,121,94,0,167.02,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,23.39,121,8,0,8.53,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,20.27,121,19,0,21.98,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,17.42,121,21,0,24.64,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,22.6,121,12,0,13.19,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,30.32,121,10,0,10.83,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,22.91,121,10,0,10.83,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,17.22,121,21,0,24.64,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,18.83,121,21,0,24.64,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,16.96,121,32,0,40.46,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,24.32,121,10,0,10.83,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.28e-31,23.29,121,39,0,51.57,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.34e-39,27.26,121,44,0,60.0,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.12e-79,20.14,121,113,0,218.53,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,17.67,121,11,0,12.0,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,17.39,121,11,0,12.0,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,17.85,121,12,0,13.19,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,15.75,121,25,0,30.17,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.68e-65,21.42,121,87,0,149.55,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,16.41,121,33,0,42.0,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),9.09e-27,19.15,121,41,0,54.89,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,19.32,121,21,0,24.64,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,16.98,121,21,0,24.64,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),5.13e-113,17.93,121,1021,0,135.34,11.0
Physically active (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.17e-09,14.36,14,18,0,24.89,1.0
Leptin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),8.57e-10,22.37,9,33,0,11.45,1.0
Leptin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,22.92,9,16,0,14.06,8.0
Leptin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),5.98e-10,22.72,9,71,0,10.14,5.0
Leptin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),5.98e-10,36.56,9,35,0,11.31,8.0
Leptin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.98e-10,22.65,9,110,0,9.74,8.0
Leptin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.95e-09,21.98,9,37,0,11.19,1.0
alpha-Fetoproteins (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.64e-08,24.95,9,16,0,14.06,8.0
alpha-Fetoproteins (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,30.11,9,9,0,18.0,8.0
alpha-Fetoproteins (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.18e-07,22.5,9,31,0,11.61,8.0
rosiglitazone (phsu),TREATS,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),3.19e-09,17.96,17,25,0,28.56,1.0
rosiglitazone (phsu),TREATS,Diabetic (fndg),PROCESS_OF,Participant (humn),4.47e-08,16.5,17,50,0,22.78,1.0
rosiglitazone (phsu),TREATS,Diabetic (fndg),PROCESS_OF,cohort (humn),5.18e-17,18.49,17,65,0,21.45,1.0
rosiglitazone (phsu),TREATS,Diabetic (fndg),PROCESS_OF,Population Group (humn),1.11e-06,21.1,17,11,0,18.12,1.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Residual Tumor (neop),7.56e-07,10.55,40,15,0,20.62,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Anastomosis (acab),3.53e-14,10.77,40,30,0,52.5,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,"[M]Squamous cell carcinoma, metastatic NOS (neop)",1.7e-16,9.24,40,52,0,70.77,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Rhabdomyosarcoma (neop),7.71e-07,9.06,40,23,0,36.22,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Malignant Squamous Cell Neoplasm (neop),5.85e-14,8.88,40,52,0,70.77,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Adenoid Cystic Carcinoma (neop),2.25e-13,10.83,40,28,0,47.6,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Fracture with displacement (inpo),1.44e-10,9.34,40,32,0,57.6,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),4.2e-28,8.32,40,526,0,43.04,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,sarcoma (neop),3.6e-18,9.39,40,54,0,69.63,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Secondary malignant neoplasm of lymph node (neop),2.54e-14,8.73,40,58,0,67.59,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,"[X]Malignant melanoma of skin, unspecified (neop)",3.04e-09,9.33,40,28,0,47.6,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Squamous cell carcinoma of skin (neop),3.1e-22,11.33,40,43,0,77.21,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,melanoma (neop),4.25e-28,9.52,40,85,0,58.82,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Merkel cell carcinoma (neop),1.93e-12,10.63,40,27,0,45.23,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Neoplasm Metastasis (neop),1.85e-06,8.86,40,24,0,38.4,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Necrotizing fasciitis (dsyn),7.51e-19,11.65,40,35,0,65.62,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Wounds and Injuries (inpo),1.61e-07,8.2,40,47,0,74.04,2.0
Birth (orgf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,10.99,157,20,0,22.55,1.0
Birth (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,8.18,157,65,0,91.91,1.0
Birth (orgf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,10.5,157,16,0,17.63,1.0
Birth (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,10.76,157,13,0,14.08,1.0
Birth (orgf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,11.74,157,16,0,17.63,1.0
Birth (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,17.14,157,8,0,8.41,1.0
Birth (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,10.62,157,23,0,26.37,1.0
Birth (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,11.51,157,22,0,25.08,1.0
Birth (orgf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,11.44,157,13,0,14.08,1.0
Birth (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,13.44,157,15,0,16.43,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Participant (humn),3.5e-15,54.98,17,84,0,20.44,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Hyperglycemia (dsyn),3.52e-07,62.03,17,10,0,15.88,21.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Atrial Fibrillation (patf),2.24e-08,66.32,17,10,0,15.88,11.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Human Age Group (aggp),2.07e-09,58.09,17,18,0,33.06,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Population Group (humn),3.41e-06,58.67,17,11,0,18.12,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Vascular Diseases (dsyn),1.44e-16,57.0,17,38,0,24.61,5.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Cessation of life (orgf),2.11e-24,57.66,17,449,0,17.64,11.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Black race (popg),7.53e-12,57.69,17,24,0,29.04,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),5.63e-22,60.18,17,34,0,25.5,21.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Neurologist (humn),1.86e-10,56.05,17,31,0,26.32,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),2.11e-24,58.02,17,140,0,19.06,5.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),1.12e-09,57.9,17,19,0,32.21,21.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Survivors (humn),1.29e-22,54.4,17,330,0,17.88,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.21e-07,60.06,17,11,0,18.12,9.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Deglutition Disorders (dsyn),6.17e-07,55.86,17,22,0,30.14,21.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Depressive disorder (mobd),1.75e-09,55.28,17,41,0,24.05,21.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,Myocardial Infarction (dsyn),2.51e-08,60.14,17,13,0,22.94,9.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Young adult (aggp),2.79e-10,55.17,17,48,0,23.02,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,inpatient (humn),4.69e-06,55.22,17,27,0,27.7,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,VICTIM (humn),2.49e-07,55.04,17,38,0,24.61,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),OCCURS_IN,cohort (humn),6.44e-10,59.72,17,16,0,31.06,21.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Disability NOS (patf),2.11e-24,56.12,17,163,0,18.77,11.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,General Population (humn),1.25e-19,57.11,17,44,0,23.57,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),AFFECTS,Systemic arterial pressure (fndg),1.93e-12,57.28,17,27,0,27.7,7.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Heart failure (dsyn),1.08e-11,66.06,17,14,0,25.53,21.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Octogenarians (aggp),1.27e-12,66.32,17,15,0,28.24,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Control Groups (humn),1.24e-06,56.13,17,19,0,32.21,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Disability NOS (patf),1.2e-18,56.59,17,47,0,23.15,21.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),AFFECTS,Cessation of life (orgf),4.46e-07,59.14,17,12,0,20.47,7.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Hospitalization (hlca),2.23e-17,62.1,17,24,0,29.04,11.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,Diabetic (fndg),1.72e-11,57.77,17,23,0,29.57,9.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Pneumonia (dsyn),6.95e-07,58.86,17,12,0,20.47,21.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Ethnic group (popg),2.74e-09,59.0,17,16,0,31.06,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),2.11e-24,57.67,16,154,1,17.66,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Teams (humn),2.45e-14,56.09,17,42,0,23.88,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.72e-09,57.63,17,19,0,32.21,21.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Thrombosis (patf),7.33e-11,58.01,17,21,0,30.76,5.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Cerebrovascular Disorders (patf),2.8e-16,56.6,17,41,0,24.05,5.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Hospitalized Patients (humn),2.11e-24,57.98,17,64,0,21.52,1.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),2.11e-24,57.33,17,129,0,19.24,9.0
Body mass index (clna),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),1.66e-19,57.76,17,39,0,24.41,1.0
long-term care (hlca),USES,Metformin (phsu),TREATS,Pancreatic carcinoma (neop),4.73e-06,19.35,10,9,0,17.1,4.0
long-term care (hlca),USES,Metformin (phsu),TREATS,Heart failure (dsyn),1.69e-08,18.13,10,14,0,17.14,4.0
long-term care (hlca),USES,Metformin (phsu),CAUSES,"Acidosis, Lactic (dsyn)",3.31e-09,17.64,10,22,0,14.55,6.0
long-term care (hlca),USES,Metformin (phsu),TREATS,Diabetic (fndg),3.46e-09,13.82,10,45,0,12.22,4.0
long-term care (hlca),USES,Metformin (phsu),ISA,Antidiabetics (phsu),7.15e-08,13.49,10,44,0,12.27,5.0
long-term care (hlca),USES,Metformin (phsu),TREATS,Malignant neoplasm of prostate (neop),2.24e-08,18.86,10,13,0,17.69,4.0
Knee (blor),LOCATION_OF,Bone Marrow (bpoc),LOCATION_OF,Micrometastasis (fndg),2.55e-06,13.98,7,41,0,8.2,2.0
Knee (blor),LOCATION_OF,Bone Marrow (bpoc),LOCATION_OF,Infiltration (patf),1.24e-06,13.95,7,127,0,7.39,2.0
Knee (blor),LOCATION_OF,Bone Marrow (bpoc),LOCATION_OF,Histiocytosis haematophagic (dsyn),1.29e-06,16.5,7,17,0,9.88,2.0
Adiponectin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,20.88,48,33,0,55.69,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,21.42,48,16,0,21.33,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.33e-25,21.23,48,71,0,80.45,5.0
Adiponectin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.96e-32,35.07,48,35,0,60.52,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.09e-38,21.15,48,110,0,68.95,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,20.49,48,37,0,65.52,1.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),2.64e-08,16.28,12,15,0,21.6,8.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),4.3e-08,18.63,12,12,0,24.0,1.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),7.06e-09,16.93,12,15,0,21.6,5.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),1.04e-10,16.17,12,28,0,17.14,5.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),1.41e-10,14.33,12,28,0,17.14,1.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),1.04e-10,17.12,12,66,0,14.18,5.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),1.04e-10,14.98,12,47,0,15.06,1.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),2.53e-10,14.26,12,27,0,17.33,8.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),8.95e-07,18.68,12,10,0,18.33,8.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),4.37e-09,19.25,12,13,0,23.08,8.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.36e-10,14.67,12,26,0,17.54,1.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),1.43e-07,14.32,12,19,0,19.58,5.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),1.03e-07,15.68,12,15,0,21.6,1.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (humn),9.94e-10,14.6,12,23,0,18.26,1.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),3.12e-06,14.21,12,16,0,21.0,1.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),2.14e-06,15.36,12,13,0,23.08,5.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),2.35e-06,14.07,12,17,0,20.47,5.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),1.04e-10,14.71,12,51,0,14.82,1.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),1.04e-10,15.2,12,145,0,12.99,8.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),1.04e-10,16.06,12,39,0,15.69,8.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.42e-06,15.68,12,12,0,24.0,1.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.76e-06,14.83,12,14,0,22.29,8.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.63e-07,19.01,12,10,0,18.33,8.0
participation (inbe),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),3.29e-07,9.26,13,18,0,22.39,1.0
Knee (blor),LOCATION_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Glioblastoma (neop),3.75e-08,8.49,79,18,0,22.1,2.0
Knee (blor),LOCATION_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Congenital diaphragmatic hernia (cgab),2.51e-07,13.77,79,10,0,11.27,2.0
Dyslipidemias (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",7.04e-08,13.8,10,16,0,16.25,9.0
Dyslipidemias (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.63e-07,18.97,10,9,0,17.1,9.0
Dyslipidemias (dsyn),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.42e-07,11.35,10,31,0,13.23,9.0
Cholesterol (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),5.19e-07,17.07,7,33,0,8.48,1.0
Cholesterol (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.95e-06,17.61,7,16,0,10.06,8.0
Cholesterol (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),5.19e-07,17.42,7,71,0,7.69,5.0
Cholesterol (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),5.19e-07,31.26,7,35,0,8.4,8.0
Cholesterol (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.19e-07,17.34,7,110,0,7.45,8.0
Cholesterol (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),5.2e-07,16.68,7,37,0,8.32,1.0
Health behavior (inbe),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),4.13e-06,19.23,6,20,0,7.8,1.0
Health behavior (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),4.13e-06,16.42,6,65,0,6.55,1.0
Health behavior (inbe),PROCESS_OF,cohort (humn),USES,Treats (clas),4.51e-06,18.74,6,16,0,8.25,1.0
Health behavior (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),8.23e-06,18.99,6,13,0,8.77,1.0
Health behavior (inbe),PROCESS_OF,cohort (humn),USES,Classification (clas),4.14e-06,19.98,6,16,0,8.25,1.0
Health behavior (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),7.6e-06,25.38,6,8,0,10.5,1.0
Health behavior (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),4.13e-06,18.86,6,23,0,7.57,1.0
Health behavior (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),4.13e-06,19.75,6,22,0,7.64,1.0
Health behavior (inbe),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),5.02e-06,19.68,6,13,0,8.77,1.0
Health behavior (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),4.13e-06,21.68,6,15,0,8.4,1.0
"Osteoarthritis, Hip (dsyn)",PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.41e-08,21.61,8,18,0,11.56,1.0
activity level (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.36e-09,21.61,10,18,0,15.56,1.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),1.07e-07,9.15,15,15,0,30.0,18.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),1.24e-07,11.51,15,12,0,21.6,1.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),8.76e-08,9.8,15,15,0,30.0,5.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),8.06e-08,9.05,15,28,0,23.04,5.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),8.07e-08,7.21,15,28,0,23.04,1.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),8.06e-08,10.0,15,66,0,18.41,5.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),8.06e-08,7.85,15,47,0,19.79,1.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),8.08e-08,7.13,15,27,0,23.33,9.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),9.76e-07,11.56,15,10,0,16.67,9.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),8.49e-08,12.13,15,13,0,24.27,9.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",8.06e-08,7.55,15,26,0,23.65,1.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),2.23e-07,7.2,15,19,0,26.84,5.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),1.84e-07,8.56,15,15,0,30.0,1.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (humn),8.15e-08,7.48,15,23,0,24.78,1.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),3.2e-06,7.09,15,16,0,29.06,1.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),2.22e-06,8.24,15,13,0,24.27,5.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),2.43e-06,6.95,15,17,0,28.24,5.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),8.06e-08,7.59,15,51,0,19.41,1.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),8.06e-08,8.08,15,145,0,16.55,11.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),8.06e-08,8.93,15,39,0,20.77,11.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.5e-06,8.56,15,12,0,21.6,1.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.84e-06,7.71,15,14,0,27.07,9.0
angiogram (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",7.44e-07,11.89,15,10,0,16.67,9.0
Abdominal obesity (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,37.23,12,33,0,16.36,1.0
Abdominal obesity (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,37.77,12,16,0,21.0,9.0
Abdominal obesity (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.5e-15,37.57,12,71,0,14.03,5.0
Abdominal obesity (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.5e-15,51.42,12,35,0,16.11,21.0
Abdominal obesity (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.5e-15,37.5,12,110,0,13.31,21.0
Abdominal obesity (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,36.84,12,37,0,15.89,1.0
"Hemoglobin, Glycosylated (aapp)",ISA,Lipids (lipd),PART_OF,Stratum corneum (tisu),1.35e-06,47.2,5,2,0,2.8,3.0
Age (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.8e-10,45.59,9,22,1,12.68,8.0
Age (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),1.49e-13,45.04,10,57,0,11.75,8.0
Age (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,53.5,10,9,0,17.1,8.0
Intervention regimes (hlca),TREATS,Participant (humn),USES,Medicare (rnlw),1.17e-09,11.38,17,18,0,33.06,4.0
Fetal Growth (phsf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Survivors (humn),1.11e-08,11.61,24,15,0,24.38,1.0
Fetal Growth (phsf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,"Twins, Dizygotic (humn)",3.06e-15,8.09,24,60,0,33.6,1.0
Fetal Growth (phsf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Monoamniotic twins (podg),4.11e-12,8.96,24,33,0,41.45,1.0
Fetal Growth (phsf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Singleton (humn),6.53e-16,7.6,24,357,0,25.61,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,28.28,19,16,0,29.47,9.0
Insulin Resistance (patf),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),3.6e-22,38.49,19,26,0,32.88,9.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),2.99e-07,14.59,13,18,0,22.39,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.11e-11,17.02,13,77,0,15.19,8.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),1.11e-11,15.1,13,33,0,18.12,5.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),1.73e-09,16.11,13,18,0,22.39,8.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),2.11e-10,19.35,13,15,0,24.27,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",1.11e-11,17.09,13,41,0,17.12,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),1.11e-11,15.63,13,30,0,18.63,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),1.11e-11,15.27,13,35,0,17.83,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),1.11e-11,19.65,13,27,0,19.26,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),3.96e-06,14.38,13,16,0,23.56,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),1.17e-11,17.07,13,22,0,20.68,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),2.02e-08,15.31,13,18,0,22.39,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),1.15e-11,19.18,13,19,0,21.89,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),1.01e-07,18.16,13,12,0,23.08,7.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),1.87e-07,23.87,13,9,0,15.23,8.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),1.11e-11,14.75,13,97,0,14.74,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),1.11e-11,15.77,13,68,0,15.49,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.11e-11,28.77,13,27,0,19.26,8.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),8.95e-07,18.91,13,10,0,17.69,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),1.11e-11,22.66,13,20,0,21.45,8.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),1.13e-11,19.75,13,19,0,21.89,8.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),1.11e-11,16.01,13,93,0,14.82,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),3.21e-08,15.91,13,16,0,23.56,5.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),4.83e-07,14.7,13,17,0,22.94,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),6.63e-07,19.24,13,10,0,17.69,8.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),2.81e-09,14.79,13,22,0,20.68,1.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),1.13e-11,16.61,13,24,0,20.04,8.0
Age (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),2.69e-06,17.84,13,10,0,17.69,8.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.2e-07,11.61,9,62,0,10.31,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.2e-07,22.2,9,17,0,13.76,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Dyslipidemias (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.2e-07,13.89,9,19,0,13.26,9.0
Sleep (orgf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,17.56,16,20,0,28.8,1.0
Sleep (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,14.74,16,65,0,19.94,1.0
Sleep (orgf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,17.06,16,16,0,32.0,1.0
Sleep (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,17.32,16,13,0,23.56,1.0
Sleep (orgf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,18.3,16,16,0,32.0,1.0
Sleep (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,23.71,16,8,0,12.0,1.0
Sleep (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,17.18,16,23,0,27.13,1.0
Sleep (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,18.08,16,22,0,27.64,1.0
Sleep (orgf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,18.01,16,13,0,23.56,1.0
Sleep (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,20.0,16,15,0,29.06,1.0
Skeletal muscle structure (bpoc),LOCATION_OF,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,7.75,25,16,0,26.24,2.0
Skeletal muscle structure (bpoc),LOCATION_OF,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,12.91,25,9,0,12.24,2.0
Skeletal muscle structure (bpoc),LOCATION_OF,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,5.3,25,31,0,45.16,2.0
Intervention regimes (hlca),TREATS,Participant (humn),USES,Medicare (rnlw),1.16e-09,10.79,52,18,0,24.23,4.0
Fibrosis (patf),COEXISTS_WITH,Diabetes Mellitus (dsyn),COEXISTS_WITH,Heart failure (dsyn),8.08e-09,42.82,7,15,0,10.27,9.0
Fibrosis (patf),COEXISTS_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),8.07e-09,45.29,7,15,0,10.27,9.0
Fibrosis (patf),COEXISTS_WITH,Diabetes Mellitus (dsyn),CAUSES,"Kidney Failure, Chronic (dsyn)",8.08e-09,36.79,7,20,0,9.45,9.0
Fibrosis (patf),COEXISTS_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),8.07e-09,36.05,7,52,0,7.94,9.0
Fibrosis (patf),COEXISTS_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,Hospitalized Patients (humn),5.67e-07,34.93,7,15,0,10.27,1.0
Fibrosis (patf),COEXISTS_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.58e-08,34.45,7,21,0,9.33,1.0
Fibrosis (patf),COEXISTS_WITH,Diabetes Mellitus (dsyn),CAUSES,End stage renal failure (dsyn),8.07e-09,35.74,7,51,0,7.96,9.0
Fibrosis (patf),COEXISTS_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,Survivors (humn),8.42e-08,38.04,7,12,0,11.08,1.0
Fibrosis (patf),COEXISTS_WITH,Diabetes Mellitus (dsyn),CAUSES,Kidney Failure (dsyn),8.11e-09,40.39,7,15,0,10.27,9.0
Fibrosis (patf),COEXISTS_WITH,Diabetes Mellitus (dsyn),CAUSES,Cessation of life (orgf),8.07e-09,37.64,7,43,0,8.14,9.0
Fibrosis (patf),COEXISTS_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),1.28e-08,37.89,7,14,0,10.5,9.0
Fibrosis (patf),COEXISTS_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),8.07e-09,36.05,7,26,0,8.88,9.0
Fibrosis (patf),COEXISTS_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,General Population (humn),8.17e-09,35.24,7,22,0,9.23,1.0
Fibrosis (patf),COEXISTS_WITH,Diabetes Mellitus (dsyn),ISA,Metabolic Diseases (dsyn),1.63e-06,32.42,7,43,0,8.14,5.0
Fibrosis (patf),COEXISTS_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),8.07e-09,34.88,7,44,0,8.11,1.0
Physical assessment (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.16e-09,21.19,13,18,0,22.39,6.0
Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,7.67,31,20,0,32.9,1.0
Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,4.86,31,65,0,45.78,1.0
Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,7.18,31,16,0,24.26,1.0
Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,7.44,31,13,0,18.45,1.0
Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,8.42,31,16,0,24.26,1.0
Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,13.82,31,8,0,10.06,1.0
Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,7.3,31,23,0,40.06,1.0
Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,8.2,31,22,0,37.61,1.0
Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,8.12,31,13,0,18.45,1.0
Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,10.12,31,15,0,22.26,1.0
Insulin Resistance (patf),PROCESS_OF,Asians (popg),ISA,Population Group (humn),2.22e-09,27.24,8,29,0,10.21,1.0
Insulin Resistance (patf),PROCESS_OF,Asians (popg),ISA,Ethnic group (popg),2.19e-09,25.83,8,124,0,8.52,1.0
Testosterone (phsu),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),3.83e-09,24.76,8,33,0,9.94,1.0
Testosterone (phsu),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,25.3,8,16,0,12.0,9.0
Testosterone (phsu),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.58e-09,25.1,8,71,0,8.9,5.0
Testosterone (phsu),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.58e-09,38.95,8,35,0,9.83,21.0
Testosterone (phsu),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.58e-09,25.03,8,110,0,8.58,21.0
Testosterone (phsu),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),4.93e-09,24.37,8,37,0,9.73,1.0
Heart failure (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,10.9,24,18,0,31.5,1.0
Depressive Symptoms (sosy),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),6.01e-09,9.94,15,18,0,27.5,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,19.37,23,9,0,12.52,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.69e-20,18.43,23,194,0,25.73,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,17.16,23,17,0,29.57,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.93e-19,18.43,23,29,0,41.24,11.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,20.61,23,14,0,22.52,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,16.42,23,12,0,18.26,5.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.7e-20,15.24,23,48,0,34.02,11.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.68e-19,18.63,23,29,0,41.24,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.69e-20,15.67,23,98,0,28.4,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,14.34,23,24,0,45.04,9.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,20.75,23,10,0,14.35,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,13.11,23,37,0,37.3,7.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,14.91,23,20,0,37.39,9.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.69e-20,16.56,23,94,0,28.63,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,22.35,23,8,0,10.78,9.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,19.23,23,19,0,34.7,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,16.38,23,21,0,40.17,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,21.56,23,12,0,18.26,9.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,29.28,23,10,0,14.35,21.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,21.86,23,10,0,14.35,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,16.18,23,21,0,40.17,21.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,17.79,23,21,0,40.17,9.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.03e-17,15.92,23,32,0,39.53,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,23.28,23,10,0,14.35,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.69e-20,22.25,23,39,0,36.56,9.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.69e-20,26.22,23,44,0,35.02,11.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.69e-20,19.1,22,112,1,26.32,9.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,16.63,23,11,0,16.26,11.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,16.35,23,11,0,16.26,9.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,16.81,23,12,0,18.26,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,14.71,23,25,0,44.16,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.69e-20,20.38,23,87,0,29.08,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,15.37,23,33,0,39.03,9.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.69e-20,18.11,23,41,0,35.9,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,18.27,23,21,0,40.17,1.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,15.94,23,21,0,40.17,9.0
Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.69e-20,16.89,23,1021,0,23.52,11.0
Acanthosis Nigricans (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.76e-08,29.52,8,16,0,12.0,9.0
Acanthosis Nigricans (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.41e-07,34.69,8,9,0,15.11,9.0
Acanthosis Nigricans (dsyn),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.19e-07,27.07,8,31,0,10.06,9.0
Insulin (horm),TREATS,Participant (humn),USES,Medicare (rnlw),1.16e-09,27.48,18,18,0,36.0,4.0
Isoprostanes (bacs),PREDISPOSES,Oxidative Stress (comd),PROCESS_OF,Drosophila melanogaster (invt),4.91e-06,11.42,11,12,0,21.08,1.0
Isoprostanes (bacs),PREDISPOSES,Oxidative Stress (comd),COEXISTS_WITH,Critical Illness (dsyn),2.64e-06,15.2,11,9,0,16.36,9.0
Exercise (dora),CAUSES,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,29.12,27,12,0,17.33,1.0
Exercise (dora),CAUSES,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,26.49,27,24,0,45.33,5.0
Intervention regimes (hlca),TREATS,Diabetes Mellitus (dsyn),COEXISTS_WITH,Heart failure (dsyn),4.6e-07,19.93,9,15,0,14.4,4.0
Intervention regimes (hlca),TREATS,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.6e-07,22.4,9,15,0,14.4,4.0
Intervention regimes (hlca),TREATS,Diabetes Mellitus (dsyn),CAUSES,"Kidney Failure, Chronic (dsyn)",4.6e-07,13.9,9,20,0,13.05,4.0
Intervention regimes (hlca),TREATS,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.6e-07,13.16,9,52,0,10.56,4.0
Intervention regimes (hlca),TREATS,Diabetes Mellitus (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.02e-06,12.04,9,15,0,14.4,1.0
Intervention regimes (hlca),TREATS,Diabetes Mellitus (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",4.68e-07,11.56,9,21,0,12.86,1.0
Intervention regimes (hlca),TREATS,Diabetes Mellitus (dsyn),CAUSES,End stage renal failure (dsyn),4.6e-07,12.84,9,51,0,10.59,4.0
Intervention regimes (hlca),TREATS,Diabetes Mellitus (dsyn),PROCESS_OF,Survivors (humn),5.36e-07,15.15,9,12,0,15.75,1.0
Intervention regimes (hlca),TREATS,Diabetes Mellitus (dsyn),CAUSES,Kidney Failure (dsyn),4.6e-07,17.5,9,15,0,14.4,4.0
Intervention regimes (hlca),TREATS,Diabetes Mellitus (dsyn),CAUSES,Cessation of life (orgf),4.6e-07,14.75,9,43,0,10.88,4.0
Intervention regimes (hlca),TREATS,Diabetes Mellitus (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),4.65e-07,15.0,9,14,0,14.79,4.0
Intervention regimes (hlca),TREATS,Diabetes Mellitus (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),4.6e-07,13.16,9,26,0,12.12,4.0
Intervention regimes (hlca),TREATS,Diabetes Mellitus (dsyn),PROCESS_OF,General Population (humn),4.6e-07,12.35,9,22,0,12.68,1.0
Intervention regimes (hlca),TREATS,Diabetes Mellitus (dsyn),ISA,Metabolic Diseases (dsyn),2.09e-06,9.53,9,43,0,10.88,4.0
Intervention regimes (hlca),TREATS,Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),4.6e-07,11.99,9,44,0,10.84,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,23.15,58,9,0,10.4,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.59e-58,22.21,57,193,1,73.83,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,20.93,58,17,0,21.98,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,22.2,58,29,0,43.5,11.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,24.38,58,14,0,17.38,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,20.19,58,12,0,14.48,5.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),9.81e-23,19.01,58,48,0,87.72,11.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.51e-19,22.4,58,29,0,43.5,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.74e-50,19.45,58,98,0,92.33,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,18.11,58,24,0,33.93,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,24.52,58,10,0,11.72,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,16.88,58,37,0,60.6,7.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,18.68,58,20,0,26.9,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),6.68e-54,20.34,58,94,0,93.79,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,26.13,58,8,0,9.1,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,23.0,58,19,0,25.22,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,20.16,58,21,0,28.6,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,25.33,58,12,0,14.48,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,33.05,58,10,0,11.72,21.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,25.64,58,10,0,11.72,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,19.96,58,21,0,28.6,21.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,21.56,58,21,0,28.6,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,19.69,58,32,0,49.66,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,27.05,58,10,0,11.72,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.28e-31,26.02,58,39,0,65.22,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.34e-39,30.0,58,44,0,77.38,11.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.59e-58,22.87,58,113,0,87.77,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,20.4,58,11,0,13.09,11.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,20.12,58,11,0,13.09,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,20.59,58,12,0,14.48,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,18.48,58,25,0,35.78,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.59e-58,24.15,58,87,0,96.67,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,19.14,58,33,0,51.78,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),9.09e-27,21.88,58,41,0,69.98,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,22.05,58,21,0,28.6,1.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,19.71,58,21,0,28.6,9.0
Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.59e-58,20.66,58,1021,0,61.29,11.0
Gender (orga),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,41.29,9,16,0,14.06,8.0
Gender (orga),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),7e-12,51.5,9,26,0,12.12,8.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,29.29,13,20,0,21.45,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,26.48,13,65,0,15.6,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,28.8,13,16,0,23.56,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,29.06,13,13,0,26.0,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,30.04,13,16,0,23.56,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,35.45,13,8,0,12.92,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,28.92,13,23,0,20.35,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,29.82,13,22,0,20.68,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,29.75,13,13,0,26.0,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,31.74,13,15,0,24.27,1.0
altretamine/cisplatin/cyclophosphamide protocol (topp),TREATS,Age (orga),ASSOCIATED_WITH,Acute myocardial infarction (dsyn),4.75e-08,48.96,6,13,0,8.77,4.0
altretamine/cisplatin/cyclophosphamide protocol (topp),TREATS,Age (orga),ASSOCIATED_WITH,Pneumonia (dsyn),5.63e-07,47.76,6,11,0,9.27,4.0
altretamine/cisplatin/cyclophosphamide protocol (topp),TREATS,Age (orga),ASSOCIATED_WITH,Heart failure (dsyn),4.16e-08,49.35,6,20,0,7.8,4.0
altretamine/cisplatin/cyclophosphamide protocol (topp),TREATS,Age (orga),ASSOCIATED_WITH,Cerebrovascular accident (dsyn),4.16e-08,45.56,6,31,0,7.16,4.0
altretamine/cisplatin/cyclophosphamide protocol (topp),TREATS,Age (orga),ASSOCIATED_WITH,Myocardial Infarction (dsyn),2.18e-07,45.45,6,15,0,8.4,4.0
Lipids (lipd),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.06e-08,12.5,11,16,0,18.56,8.0
Lipids (lipd),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.54e-07,17.67,11,9,0,16.36,8.0
Lipids (lipd),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.32e-07,10.06,11,31,0,14.9,8.0
Physical activity (dora),TREATS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,26.56,10,16,0,16.25,4.0
Physical activity (dora),TREATS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,31.73,10,9,0,17.1,4.0
Physical activity (dora),TREATS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,24.11,10,31,0,13.23,4.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,49.62,44,9,0,10.84,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.5e-60,48.67,44,194,0,53.98,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,47.4,44,17,0,23.57,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,48.67,44,29,0,48.11,11.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,50.85,44,14,0,18.45,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,46.66,44,12,0,15.27,5.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),9.81e-23,45.48,44,48,0,84.33,11.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.51e-19,48.87,44,29,0,48.11,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.74e-50,45.91,44,98,0,63.76,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,44.58,44,24,0,37.09,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,50.99,44,10,0,12.27,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,43.35,44,37,0,68.11,7.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,45.15,44,20,0,29.09,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),6.68e-54,46.8,44,94,0,64.6,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,52.59,44,8,0,9.45,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,49.47,44,19,0,27.2,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,46.62,43,20,1,29.3,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,51.8,44,12,0,15.27,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,59.52,44,10,0,12.27,21.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,52.11,44,10,0,12.27,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,46.42,44,21,0,31.02,21.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,48.03,44,21,0,31.02,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,46.16,44,32,0,55.27,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,53.52,44,10,0,12.27,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.28e-31,52.49,44,39,0,73.57,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.34e-39,56.46,44,44,0,88.0,11.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.5e-60,49.34,44,113,0,61.13,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,46.87,44,11,0,13.75,11.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,46.59,44,11,0,13.75,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,47.05,44,12,0,15.27,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,44.95,44,25,0,39.2,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.5e-60,50.62,44,87,0,66.25,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,45.61,44,33,0,57.75,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),9.09e-27,48.35,44,41,0,79.2,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,48.52,44,21,0,31.02,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,46.18,44,21,0,31.02,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),3.5e-60,47.13,43,1020,1,44.81,11.0
Myocardial Infarction (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.57e-07,7.66,16,20,0,28.8,1.0
Myocardial Infarction (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.58e-07,4.84,16,65,0,19.94,1.0
Myocardial Infarction (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),5.31e-07,7.17,16,16,0,32.0,1.0
Myocardial Infarction (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.25e-06,7.42,16,13,0,23.56,1.0
Myocardial Infarction (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.68e-07,8.4,16,16,0,32.0,1.0
Myocardial Infarction (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.63e-06,13.81,16,8,0,12.0,1.0
Myocardial Infarction (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.56e-07,7.29,16,23,0,27.13,1.0
Myocardial Infarction (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.56e-07,8.18,16,22,0,27.64,1.0
Myocardial Infarction (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),1.04e-06,8.11,16,13,0,23.56,1.0
Myocardial Infarction (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.57e-07,10.11,16,15,0,29.06,1.0
Vitamin D Deficiency (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.17e-09,18.56,12,18,0,20.0,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,Critically ill children (podg),3.47e-06,37.73,8,8,0,16.0,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.33e-09,33.58,8,15,0,12.27,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),2.14e-09,32.28,8,18,0,11.56,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),9.87e-10,31.19,8,61,0,9.05,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,Surgical Patients (podg),1.04e-09,31.23,8,24,0,10.67,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,Cancer Patient (podg),9.79e-09,29.68,8,30,0,10.13,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,inpatient (humn),9.88e-10,31.12,8,28,0,10.29,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),CAUSES,Cessation of life (orgf),9.87e-10,33.04,8,28,0,10.29,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,cohort (humn),1.21e-09,34.3,8,16,0,12.0,1.0
Screening procedure (hlca),TREATS,Sleep Apnea Syndromes (dsyn),COEXISTS_WITH,Heart failure (dsyn),1.25e-06,18.16,9,10,0,17.1,4.0
Body Weight decreased (fndg),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,29.68,9,16,0,14.06,9.0
Body Weight decreased (fndg),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),8.76e-11,39.89,9,26,0,12.12,9.0
Dementia (mobd),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.19e-09,7.36,32,18,0,28.12,1.0
Gastrectomy (topp),TREATS,cohort (humn),USES,Medicare (rnlw),1.64e-07,34.32,6,20,0,7.8,4.0
Gastrectomy (topp),TREATS,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.65e-07,31.51,6,65,0,6.55,2.0
Gastrectomy (topp),TREATS,cohort (humn),USES,Treats (clas),5.38e-07,33.83,6,16,0,8.25,4.0
Gastrectomy (topp),TREATS,cohort (humn),LOCATION_OF,Calcium (bacs),4.26e-06,34.09,6,13,0,8.77,2.0
Gastrectomy (topp),TREATS,cohort (humn),USES,Classification (clas),1.75e-07,35.07,6,16,0,8.25,4.0
Gastrectomy (topp),TREATS,cohort (humn),LOCATION_OF,Sodium (elii),3.63e-06,40.48,6,8,0,10.5,2.0
Gastrectomy (topp),TREATS,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.63e-07,33.95,6,23,0,7.57,2.0
Gastrectomy (topp),TREATS,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.63e-07,34.85,6,22,0,7.64,2.0
Gastrectomy (topp),TREATS,cohort (humn),USES,Tissue Microarray (resd),1.05e-06,34.78,6,13,0,8.77,4.0
Gastrectomy (topp),TREATS,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.64e-07,36.77,6,15,0,8.4,2.0
dietary intervention (topp),TREATS,Malnutrition (dsyn),PROCESS_OF,Critically ill children (podg),3.8e-06,21.47,8,8,0,16.0,1.0
dietary intervention (topp),TREATS,Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.36e-07,17.32,8,15,0,12.27,4.0
dietary intervention (topp),TREATS,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),3.34e-07,16.02,8,18,0,11.56,1.0
dietary intervention (topp),TREATS,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),3.32e-07,14.93,8,61,0,9.05,1.0
dietary intervention (topp),TREATS,Malnutrition (dsyn),PROCESS_OF,Surgical Patients (podg),3.32e-07,14.97,8,24,0,10.67,1.0
dietary intervention (topp),TREATS,Malnutrition (dsyn),PROCESS_OF,Cancer Patient (podg),3.41e-07,13.42,8,30,0,10.13,1.0
dietary intervention (topp),TREATS,Malnutrition (dsyn),PROCESS_OF,inpatient (humn),3.32e-07,14.86,8,28,0,10.29,1.0
dietary intervention (topp),TREATS,Malnutrition (dsyn),CAUSES,Cessation of life (orgf),3.32e-07,16.78,8,28,0,10.29,4.0
dietary intervention (topp),TREATS,Malnutrition (dsyn),PROCESS_OF,cohort (humn),3.33e-07,18.04,8,16,0,12.0,1.0
Feeding behaviors (inbe),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,41.87,15,20,0,26.25,1.0
Feeding behaviors (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,39.06,15,65,0,18.46,1.0
Feeding behaviors (inbe),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,41.38,15,16,0,29.06,1.0
Feeding behaviors (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,41.63,15,13,0,24.27,1.0
Feeding behaviors (inbe),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,42.62,15,16,0,29.06,1.0
Feeding behaviors (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,48.02,15,8,0,12.27,1.0
Feeding behaviors (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,41.5,15,23,0,24.78,1.0
Feeding behaviors (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,42.39,15,22,0,25.23,1.0
Feeding behaviors (inbe),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,42.32,15,13,0,24.27,1.0
Feeding behaviors (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,44.32,15,15,0,30.0,1.0
Gastric banding (topp),PRECEDES,Gastric Bypass (topp),TREATS,Body Weight decreased (fndg),2.94e-06,50.87,5,14,0,6.79,4.0
Gastric banding (topp),PRECEDES,Gastric Bypass (topp),TREATS,"Obesity, Morbid (dsyn)",5.58e-07,49.74,5,48,0,5.52,4.0
Triglycerides (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.09e-07,34.55,6,16,0,8.25,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.1e-06,39.72,6,9,0,10.0,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),2.8e-07,32.1,6,31,0,7.16,8.0
candesartan (phsu),TREATS,Hypertensive (fndg),PROCESS_OF,Participant (humn),3.78e-06,12.35,7,53,0,7.92,1.0
Prostatectomy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),2.38e-06,6.9,14,78,0,16.51,1.0
Prostatectomy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),2.47e-06,6.03,14,22,0,22.91,1.0
Prostatectomy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),2.38e-06,13.13,14,12,0,22.29,1.0
Prostatectomy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),2.42e-06,7.0,14,18,0,24.89,1.0
Prostatectomy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (humn),2.38e-06,5.0,14,67,0,16.93,1.0
Prostatectomy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),2.38e-06,6.98,14,21,0,23.33,1.0
Prostatectomy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),2.38e-06,6.48,14,35,0,19.6,1.0
Polycystic Ovary Syndrome (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,28.42,15,18,0,27.5,1.0
Metformin (phsu),TREATS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,19.79,37,16,0,22.92,4.0
Metformin (phsu),TREATS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,24.96,37,9,0,11.19,4.0
Metformin (phsu),TREATS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,17.35,37,31,0,56.97,4.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,18.43,13,9,0,15.23,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.29e-11,17.49,13,194,0,13.87,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.69e-10,16.21,13,17,0,22.94,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),3.29e-11,17.48,13,29,0,18.83,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2.32e-10,19.66,13,14,0,25.07,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,15.47,13,12,0,23.08,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),3.29e-11,14.29,13,48,0,16.52,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),3.29e-11,17.68,13,29,0,18.83,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.29e-11,14.73,13,98,0,14.72,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.36e-09,13.39,13,24,0,20.04,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,19.8,13,10,0,17.69,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.22e-08,12.16,13,37,0,17.57,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.77e-09,13.96,13,20,0,21.45,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),3.29e-11,15.62,13,94,0,14.8,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,21.41,13,8,0,12.92,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.32e-11,18.28,13,19,0,21.89,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),4.49e-11,15.44,13,21,0,21.05,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.81e-09,20.62,13,12,0,23.08,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.67e-09,28.33,13,10,0,17.69,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,20.92,13,10,0,17.69,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),5.54e-11,15.24,13,21,0,21.05,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),3.32e-11,16.85,13,21,0,21.05,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.29e-11,14.97,13,32,0,18.28,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,22.33,13,10,0,17.69,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),3.29e-11,21.3,13,39,0,17.33,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),3.29e-11,25.28,13,44,0,16.84,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.29e-11,18.15,13,113,0,14.5,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,15.68,13,11,0,20.31,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,15.41,13,11,0,20.31,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,15.87,13,12,0,23.08,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.51e-10,13.76,13,25,0,19.76,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.29e-11,19.44,13,87,0,14.94,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),3.29e-11,14.43,13,33,0,18.12,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.29e-11,17.16,13,41,0,17.12,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),3.3e-11,17.33,13,21,0,21.05,1.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",8.29e-11,15.0,13,21,0,21.05,5.0
"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),3.29e-11,15.94,13,1021,0,13.17,5.0
Employed (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.18e-09,14.03,14,18,0,24.89,1.0
Intervention regimes (hlca),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular morbidity (dsyn),4.23e-08,15.36,12,23,0,18.26,7.0
Intervention regimes (hlca),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cerebrovascular accident (dsyn),2.74e-07,9.4,12,18,0,20.0,7.0
Intervention regimes (hlca),AFFECTS,Systemic arterial pressure (fndg),PROCESS_OF,General Population (humn),1.4e-06,8.05,12,27,0,17.33,1.0
Intervention regimes (hlca),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),4.23e-08,9.03,12,32,0,16.5,7.0
Intervention regimes (hlca),AFFECTS,Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),4.23e-08,8.46,12,39,0,15.69,1.0
Intervention regimes (hlca),AFFECTS,Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),7.6e-07,7.6,12,41,0,15.51,1.0
Intervention regimes (hlca),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular event (fndg),4.24e-08,9.34,12,27,0,17.33,7.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,64.05,83,9,0,9.98,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.36e-122,63.11,83,194,0,118.51,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,61.83,83,17,0,20.48,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,63.1,83,29,0,39.13,11.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,65.28,83,14,0,16.36,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,61.09,83,12,0,13.73,5.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),9.81e-23,59.91,83,48,0,75.76,11.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.51e-19,63.3,83,29,0,39.13,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.74e-50,60.35,83,98,0,153.3,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,59.01,83,24,0,30.94,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,65.42,83,10,0,11.2,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,57.78,83,37,0,53.49,7.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,59.58,83,20,0,24.82,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),6.68e-54,61.24,82,93,1,154.3,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,67.03,83,8,0,8.77,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,63.9,83,19,0,23.35,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,61.06,83,21,0,26.31,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,66.24,83,12,0,13.73,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,73.95,83,10,0,11.2,21.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,66.54,83,10,0,11.2,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,60.86,83,21,0,26.31,21.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,62.47,83,21,0,26.31,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,60.59,83,32,0,44.34,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,67.95,83,10,0,11.2,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.28e-31,66.92,83,39,0,57.33,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.34e-39,70.9,83,44,0,67.33,11.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.12e-79,63.77,83,113,0,143.96,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,61.3,83,11,0,12.46,11.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,61.03,83,11,0,12.46,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,61.49,83,12,0,13.73,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,59.38,83,25,0,32.53,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.68e-65,65.06,83,87,0,162.18,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,60.04,83,33,0,46.12,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),9.09e-27,62.78,83,41,0,61.25,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,62.95,83,21,0,26.31,1.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,60.61,83,21,0,26.31,9.0
Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),3.36e-122,61.56,83,1021,0,89.75,11.0
Pancreas (bpoc),LOCATION_OF,Graft loss (patf),MANIFESTATION_OF,Cessation of life (orgf),8.63e-08,16.88,10,18,0,15.56,2.0
Pancreas (bpoc),LOCATION_OF,Graft loss (patf),PROCESS_OF,"Recipient, Transplant (podg)",1.68e-06,13.03,10,12,0,18.33,1.0
Pancreas (bpoc),LOCATION_OF,Graft loss (patf),PROCESS_OF,"Recipient, Transplant (podg)",8.63e-08,13.98,10,55,0,11.82,1.0
Triglycerides (bacs),COEXISTS_WITH,C-reactive protein (aapp),ASSOCIATED_WITH,Ischemic stroke (dsyn),4.18e-06,34.43,7,11,0,11.45,8.0
Triglycerides (bacs),COEXISTS_WITH,C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),1.13e-08,31.66,7,34,0,8.44,9.0
Triglycerides (bacs),COEXISTS_WITH,C-reactive protein (aapp),PREDISPOSES,Septicemia (dsyn),1.1e-08,36.02,7,20,0,9.45,9.0
Triglycerides (bacs),COEXISTS_WITH,C-reactive protein (aapp),ISA,Albumins (aapp),1.1e-08,33.26,7,30,0,8.63,5.0
Triglycerides (bacs),COEXISTS_WITH,C-reactive protein (aapp),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),1.35e-07,33.77,7,15,0,10.27,8.0
Triglycerides (bacs),COEXISTS_WITH,C-reactive protein (aapp),ISA,Acute-Phase Proteins (aapp),1.1e-08,30.84,7,77,0,7.64,5.0
Triglycerides (bacs),COEXISTS_WITH,C-reactive protein (aapp),compared_with,procalcitonin (aapp),2.92e-08,34.07,7,16,0,10.06,9.0
Triglycerides (bacs),COEXISTS_WITH,C-reactive protein (aapp),PREDISPOSES,Myocardial Infarction (dsyn),2.07e-06,33.11,7,14,0,10.5,9.0
Medical center (hcro),LOCATION_OF,Prospective Studies (qnco),ISA,Techniques (ftcn),5.28e-09,6.67,16,911,1,16.28,2.0
Medical center (hcro),LOCATION_OF,Prospective Studies (qnco),ISA,contextual factors (ftcn),1.31e-06,6.14,17,26,0,28.12,2.0
Smoking (inbe),ISA,Behavior (inbe),PROCESS_OF,network (popg),2.21e-06,5.15,19,4,0,4.84,1.0
Fibrosis (patf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),7.39e-09,9.13,15,20,0,26.25,1.0
Fibrosis (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),8.93e-09,6.31,15,65,0,18.46,1.0
Fibrosis (patf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.82e-07,8.63,15,16,0,29.06,1.0
Fibrosis (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.1e-06,8.89,15,13,0,24.27,1.0
Fibrosis (patf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.86e-08,9.87,15,16,0,29.06,1.0
Fibrosis (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.48e-06,15.28,15,8,0,12.27,1.0
Fibrosis (patf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),6.57e-09,8.75,15,23,0,24.78,1.0
Fibrosis (patf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),6.41e-09,9.65,15,22,0,25.23,1.0
Fibrosis (patf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.91e-07,9.58,15,13,0,24.27,1.0
Fibrosis (patf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),7.94e-09,11.57,15,15,0,30.0,1.0
Dyslipidemias (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),1.24e-06,13.77,8,77,0,8.83,1.0
Dyslipidemias (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),1.25e-06,14.11,8,16,0,12.0,1.0
Dyslipidemias (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Young adult (aggp),5.32e-06,13.56,8,12,0,13.33,1.0
Dyslipidemias (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Middle Aged (aggp),1.24e-06,13.9,8,19,0,11.37,1.0
Dyslipidemias (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.24e-06,12.68,8,22,0,10.91,21.0
Dyslipidemias (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Outpatients (podg),1.3e-06,11.69,8,24,0,10.67,1.0
Dyslipidemias (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,General Population (humn),1.24e-06,13.4,8,42,0,9.52,1.0
Dyslipidemias (dsyn),PREDISPOSES,Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),1.24e-06,14.65,8,102,0,8.63,5.0
Dyslipidemias (dsyn),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Heart failure (dsyn),1.57e-06,14.24,8,13,0,12.92,11.0
Dyslipidemias (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),1.24e-06,13.98,8,83,0,8.77,1.0
Dyslipidemias (dsyn),PREDISPOSES,Coronary heart disease (dsyn),ISA,Death (finding) (fndg),1.24e-06,16.57,8,250,0,8.26,5.0
Dyslipidemias (dsyn),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),1.24e-06,13.74,8,194,0,8.33,11.0
Triglycerides (bacs),ISA,Lipids (lipd),PART_OF,Stratum corneum (tisu),7.96e-07,4.36,56,2,0,2.07,3.0
alpha-Fetoproteins (aapp),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.13e-06,30.62,5,23,0,6.09,8.0
alpha-Fetoproteins (aapp),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),4.13e-06,30.06,5,57,0,5.44,8.0
alpha-Fetoproteins (aapp),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.42e-06,38.53,5,9,0,7.78,8.0
Increase in blood pressure (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.56e-08,31.94,7,20,0,9.45,1.0
Increase in blood pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.72e-08,29.13,7,65,0,7.75,1.0
Increase in blood pressure (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.9e-07,31.45,7,16,0,10.06,1.0
Increase in blood pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.11e-06,31.7,7,13,0,10.77,1.0
Increase in blood pressure (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),2.69e-08,32.69,7,16,0,10.06,1.0
Increase in blood pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.48e-06,38.09,7,8,0,13.12,1.0
Increase in blood pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.48e-08,31.57,7,23,0,9.13,1.0
Increase in blood pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.47e-08,32.46,7,22,0,9.23,1.0
Increase in blood pressure (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.99e-07,32.39,7,13,0,10.77,1.0
Increase in blood pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.62e-08,34.39,7,15,0,10.27,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),3.09e-06,16.19,9,9,0,18.0,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),5.03e-07,15.25,9,194,0,9.42,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),5.04e-07,13.97,9,17,0,13.76,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),5.03e-07,15.24,9,29,0,11.79,11.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),5.03e-07,17.42,9,14,0,14.79,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.57e-06,13.23,9,12,0,15.75,5.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),5.03e-07,12.05,9,48,0,10.69,11.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),5.03e-07,15.44,9,29,0,11.79,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),5.03e-07,12.49,9,98,0,9.83,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),5.06e-07,11.15,9,24,0,12.38,9.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),6.79e-07,17.56,9,10,0,17.1,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),5.15e-07,9.92,9,37,0,11.19,7.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),5.1e-07,11.72,9,20,0,13.05,9.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),5.03e-07,13.38,9,94,0,9.86,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.85e-06,19.17,9,8,0,15.11,9.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),5.03e-07,16.04,9,19,0,13.26,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),5.03e-07,13.2,9,21,0,12.86,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),5.06e-07,18.38,9,12,0,15.75,9.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),5.06e-07,26.09,9,10,0,17.1,21.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),5.85e-07,18.68,9,10,0,17.1,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),5.03e-07,13.0,9,21,0,12.86,21.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),5.03e-07,14.61,9,21,0,12.86,9.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),5.03e-07,12.73,9,32,0,11.53,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),5.39e-07,20.09,9,10,0,17.1,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),5.03e-07,19.06,9,39,0,11.08,9.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),5.03e-07,23.04,9,44,0,10.84,11.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.03e-07,15.91,9,113,0,9.72,9.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),3.25e-06,13.44,9,11,0,16.36,11.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.68e-06,13.16,9,11,0,16.36,9.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),1.06e-06,13.63,9,12,0,15.75,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),5.03e-07,11.52,9,25,0,12.24,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",5.03e-07,17.19,9,87,0,9.93,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),5.03e-07,12.18,9,33,0,11.45,9.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),5.03e-07,14.92,9,41,0,10.98,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),5.03e-07,15.09,9,21,0,12.86,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5.03e-07,12.75,9,21,0,12.86,9.0
Hypertriglyceridemia (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),5.03e-07,13.7,9,1021,0,9.08,11.0
Pregnancy (orgf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,14.34,18,18,0,36.0,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),2.65e-06,34.62,5,18,0,6.39,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),2.35e-06,37.06,5,77,0,5.32,8.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),2.35e-06,35.13,5,33,0,5.76,5.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),2.35e-06,36.14,5,18,0,6.39,8.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),2.35e-06,39.39,5,15,0,6.67,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",2.35e-06,37.12,5,41,0,5.61,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),2.35e-06,35.66,5,30,0,5.83,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),2.35e-06,35.31,5,35,0,5.71,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),2.35e-06,39.68,5,27,0,5.93,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),6.3e-06,34.41,5,16,0,6.56,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),2.35e-06,37.1,5,22,0,6.14,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),2.37e-06,35.35,5,18,0,6.39,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),2.35e-06,39.22,5,19,0,6.32,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),2.45e-06,38.2,5,12,0,7.08,7.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),2.53e-06,43.91,5,9,0,7.78,8.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),2.35e-06,34.79,5,97,0,5.26,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),2.35e-06,35.8,5,68,0,5.37,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),2.35e-06,48.81,5,27,0,5.93,8.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),3.24e-06,38.95,5,10,0,7.5,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),2.35e-06,42.7,5,20,0,6.25,8.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.35e-06,39.79,5,19,0,6.32,8.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),2.35e-06,36.04,5,93,0,5.27,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),2.38e-06,35.94,5,16,0,6.56,5.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),2.83e-06,34.73,5,17,0,6.47,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),3.01e-06,39.27,5,10,0,7.5,8.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),2.35e-06,34.83,5,22,0,6.14,1.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),2.35e-06,36.65,5,24,0,6.04,8.0
Body Composition (orga),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),5.03e-06,37.87,5,10,0,7.5,8.0
Fatty Liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.71e-10,25.98,10,33,0,13.03,1.0
Fatty Liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,26.52,10,16,0,16.25,9.0
Fatty Liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.29e-11,26.33,10,71,0,11.41,5.0
Fatty Liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.29e-11,40.17,10,35,0,12.86,9.0
Fatty Liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.29e-11,26.25,10,110,0,10.91,9.0
Fatty Liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.37e-09,25.59,10,37,0,12.7,1.0
Hyperglycemia (dsyn),ISA,Diabetes Mellitus (dsyn),COEXISTS_WITH,Heart failure (dsyn),1.45e-06,16.66,11,15,0,19.07,5.0
Hyperglycemia (dsyn),ISA,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.45e-06,19.13,11,15,0,19.07,5.0
Hyperglycemia (dsyn),ISA,Diabetes Mellitus (dsyn),CAUSES,"Kidney Failure, Chronic (dsyn)",1.45e-06,10.63,11,20,0,17.05,5.0
Hyperglycemia (dsyn),ISA,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.45e-06,9.89,11,52,0,13.33,5.0
Hyperglycemia (dsyn),ISA,Diabetes Mellitus (dsyn),PROCESS_OF,Hospitalized Patients (humn),2.01e-06,8.77,11,15,0,19.07,1.0
Hyperglycemia (dsyn),ISA,Diabetes Mellitus (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.46e-06,8.29,11,21,0,16.76,1.0
Hyperglycemia (dsyn),ISA,Diabetes Mellitus (dsyn),CAUSES,End stage renal failure (dsyn),1.45e-06,9.57,11,51,0,13.37,5.0
Hyperglycemia (dsyn),ISA,Diabetes Mellitus (dsyn),PROCESS_OF,Survivors (humn),1.53e-06,11.88,11,12,0,21.08,1.0
Hyperglycemia (dsyn),ISA,Diabetes Mellitus (dsyn),CAUSES,Kidney Failure (dsyn),1.45e-06,14.23,11,15,0,19.07,5.0
Hyperglycemia (dsyn),ISA,Diabetes Mellitus (dsyn),CAUSES,Cessation of life (orgf),1.45e-06,11.47,11,43,0,13.81,5.0
Hyperglycemia (dsyn),ISA,Diabetes Mellitus (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),1.46e-06,11.73,11,14,0,19.64,5.0
Hyperglycemia (dsyn),ISA,Diabetes Mellitus (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),1.45e-06,9.89,11,26,0,15.65,5.0
Hyperglycemia (dsyn),ISA,Diabetes Mellitus (dsyn),PROCESS_OF,General Population (humn),1.45e-06,9.08,11,22,0,16.5,1.0
Hyperglycemia (dsyn),ISA,Diabetes Mellitus (dsyn),ISA,Metabolic Diseases (dsyn),3.08e-06,6.26,11,43,0,13.81,5.0
Hyperglycemia (dsyn),ISA,Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),1.45e-06,8.72,11,44,0,13.75,1.0
Cessation of life (orgf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,11.25,21,18,0,33.43,1.0
Fatty degeneration (patf),PROCESS_OF,Donor person (humn),LOCATION_OF,Antithymoglobulin (phsu),1.24e-06,21.85,7,17,0,9.88,1.0
Fatty degeneration (patf),PROCESS_OF,Donor person (humn),LOCATION_OF,Cyclophosphamide (opco),4.74e-06,20.29,7,9,0,12.44,1.0
"Hypertrophy, Left Ventricular (patf)",PROCESS_OF,African American (popg),ISA,Ethnic group (popg),8.67e-09,21.83,8,98,0,8.65,1.0
"Hypertrophy, Left Ventricular (patf)",PROCESS_OF,African American (popg),ISA,Racial group (popg),8.67e-09,22.77,8,324,0,8.2,1.0
Insulin (horm),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),7.05e-07,16.3,7,33,0,8.48,1.0
Insulin (horm),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),5.14e-06,16.84,7,16,0,10.06,4.0
Insulin (horm),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),7.04e-07,16.64,7,71,0,7.69,4.0
Insulin (horm),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),7.04e-07,30.49,7,35,0,8.4,4.0
Insulin (horm),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),7.04e-07,16.57,7,110,0,7.45,4.0
Insulin (horm),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),7.06e-07,15.91,7,37,0,8.32,1.0
"Endometriosis, site unspecified (dsyn)",PROCESS_OF,cohort (humn),USES,Medicare (rnlw),8.2e-07,17.68,7,20,0,9.45,1.0
"Endometriosis, site unspecified (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),8.21e-07,14.87,7,65,0,7.75,1.0
"Endometriosis, site unspecified (dsyn)",PROCESS_OF,cohort (humn),USES,Treats (clas),1.19e-06,17.19,7,16,0,10.06,1.0
"Endometriosis, site unspecified (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.91e-06,17.45,7,13,0,10.77,1.0
"Endometriosis, site unspecified (dsyn)",PROCESS_OF,cohort (humn),USES,Classification (clas),8.31e-07,18.43,7,16,0,10.06,1.0
"Endometriosis, site unspecified (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),4.29e-06,23.83,7,8,0,13.12,1.0
"Endometriosis, site unspecified (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),8.19e-07,17.31,7,23,0,9.13,1.0
"Endometriosis, site unspecified (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),8.19e-07,18.21,7,22,0,9.23,1.0
"Endometriosis, site unspecified (dsyn)",PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),1.7e-06,18.13,7,13,0,10.77,1.0
"Endometriosis, site unspecified (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),8.2e-07,20.13,7,15,0,10.27,1.0
Body mass index (clna),PREDISPOSES,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),8.01e-26,67.61,23,62,0,31.53,21.0
Body mass index (clna),PREDISPOSES,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.03e-14,78.2,23,17,0,29.57,21.0
Body mass index (clna),PREDISPOSES,Dyslipidemias (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.17e-11,69.9,23,19,0,34.7,9.0
Malnutrition (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,25.7,12,20,0,19.2,1.0
Malnutrition (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,22.89,12,65,0,14.22,1.0
Malnutrition (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,25.21,12,16,0,21.0,1.0
Malnutrition (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,25.46,12,13,0,23.08,1.0
Malnutrition (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,26.44,12,16,0,21.0,1.0
Malnutrition (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,31.85,12,8,0,13.33,1.0
Malnutrition (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,25.33,12,23,0,18.26,1.0
Malnutrition (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.54e-11,26.22,12,22,0,18.55,1.0
Malnutrition (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,26.15,12,13,0,23.08,1.0
Malnutrition (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,28.15,12,15,0,21.6,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.51e-11,23.23,11,22,0,16.5,9.0
Insulin Resistance (patf),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.48e-10,22.65,11,17,0,18.12,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.29e-08,18.72,11,27,0,15.48,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.38e-08,21.68,11,15,0,19.07,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.62e-10,19.88,11,24,0,16.04,9.0
Insulin Resistance (patf),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),2.51e-11,19.5,11,34,0,14.56,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),2.51e-11,20.92,11,40,0,14.03,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.24e-09,27.65,11,12,0,21.08,9.0
Body mass index (clna),PREDISPOSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,58.44,16,16,0,32.0,21.0
Body mass index (clna),PREDISPOSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.84e-22,68.66,16,26,0,25.85,21.0
Laparoscopic adjustable gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Gastric Adenocarcinoma (neop),6.31e-14,55.46,10,64,0,11.56,4.0
Laparoscopic adjustable gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Malignant neoplasm of stomach (neop),6.31e-14,52.32,10,578,0,10.17,4.0
Laparoscopic adjustable gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Advanced cancer (neop),6.33e-14,55.02,10,24,0,14.17,4.0
Laparoscopic adjustable gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Adenocarcinoma (neop),6.31e-14,53.52,10,30,0,13.33,4.0
Laparoscopic adjustable gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,"Obesity, Morbid (dsyn)",6.31e-14,51.2,10,80,0,11.25,4.0
Laparoscopic adjustable gastric banding (topp),PRECEDES,Gastrectomy (topp),USES,Sleeves (medd),6.31e-14,48.27,6,529,4,6.07,6.0
Laparoscopic adjustable gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Body Weight decreased (fndg),6.84e-14,51.49,10,30,0,13.33,4.0
Laparoscopic adjustable gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Stomach Carcinoma (neop),6.31e-14,52.21,10,49,0,12.04,4.0
Laparoscopic adjustable gastric banding (topp),PRECEDES,Gastrectomy (topp),ADMINISTERED_TO,Surgeon (humn),2e-09,54.58,10,14,0,17.14,15.0
Laparoscopic adjustable gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Malignant neoplasm of stomach stage III (neop),2.07e-06,53.83,10,10,0,20.0,4.0
Laparoscopic adjustable gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Early gastric cancer (neop),6.31e-14,50.76,10,71,0,11.41,4.0
Adiponectin (aapp),ASSOCIATED_WITH,Anorexia Nervosa (mobd),ISA,Mental disorders (mobd),6.56e-11,47.51,8,46,0,9.39,5.0
Schizophrenia (mobd),PROCESS_OF,inpatient (humn),USES,Medicare (rnlw),7.54e-16,7.76,38,32,0,58.95,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,22.15,39,18,0,26.31,1.0
Body mass index (clna),PREDISPOSES,Depressive disorder (mobd),PROCESS_OF,CARDIAC PATIENT (podg),4.09e-07,58.25,12,13,0,23.08,1.0
Body mass index (clna),PREDISPOSES,Depressive disorder (mobd),AFFECTS,Cessation of life (orgf),1.58e-06,60.2,12,10,0,18.33,7.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PROCESS_OF,General Population (humn),1.2e-06,23.59,6,18,0,8.0,1.0
Visceral Fat (tisu),LOCATION_OF,Biopsy (diap),DIAGNOSES,melanoma (neop),1.41e-17,37.2,14,45,0,18.36,2.0
Visceral Fat (tisu),LOCATION_OF,Biopsy (diap),ISA,Diagnosis (hlca),4.06e-10,35.0,14,161,0,15.22,2.0
Visceral Fat (tisu),LOCATION_OF,Biopsy (diap),ISA,Procedures (hlca),4.84e-07,35.12,14,81,0,16.42,2.0
Anorexia Nervosa (mobd),PROCESS_OF,inpatient (humn),USES,Medicare (rnlw),9.02e-17,25.73,50,32,0,52.48,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,21.04,12,9,0,15.75,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.39e-11,20.1,12,194,0,12.74,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.6e-10,18.82,12,17,0,20.47,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.39e-11,20.09,12,29,0,16.97,11.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2.23e-10,22.27,12,14,0,22.29,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,18.08,12,12,0,24.0,5.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),2.39e-11,16.9,12,48,0,15.0,11.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.39e-11,20.29,12,29,0,16.97,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.39e-11,17.34,12,98,0,13.47,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.35e-09,16.0,12,24,0,18.0,9.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,22.41,12,10,0,18.33,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.22e-08,14.77,12,37,0,15.89,7.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.76e-09,16.57,12,20,0,19.2,9.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.39e-11,18.23,12,94,0,13.53,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,24.02,12,8,0,13.33,9.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),2.42e-11,20.89,12,19,0,19.58,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),3.6e-11,18.05,12,21,0,18.86,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.8e-09,23.23,12,12,0,24.0,9.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.66e-09,30.94,12,10,0,18.33,21.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,23.53,12,10,0,18.33,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),4.64e-11,17.85,12,21,0,18.86,21.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.42e-11,19.46,12,21,0,18.86,9.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.39e-11,17.58,12,32,0,16.5,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,24.94,12,10,0,18.33,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.39e-11,23.91,12,39,0,15.69,9.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),2.39e-11,27.89,12,44,0,15.27,11.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.39e-11,20.76,12,113,0,13.27,9.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,18.29,12,11,0,21.08,11.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,18.02,12,11,0,21.08,9.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,18.48,12,12,0,24.0,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.42e-10,16.37,12,25,0,17.76,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.39e-11,22.05,12,87,0,13.66,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),2.39e-11,17.04,12,33,0,16.36,9.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.39e-11,19.77,12,41,0,15.51,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),2.4e-11,19.94,12,21,0,18.86,1.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",7.39e-11,17.61,12,21,0,18.86,9.0
Psoriasis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.39e-11,18.55,12,1021,0,12.14,11.0
Atherosclerosis (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,16.97,18,18,0,36.0,1.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),PROCESS_OF,Outpatients (podg),6.97e-06,78.3,4,17,0,4.94,1.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),ISA,Cardiovascular Diseases (dsyn),4.02e-06,80.7,4,25,0,4.64,5.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),PREDISPOSES,Cerebrovascular accident (dsyn),4.02e-06,79.86,4,184,0,4.09,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),PREDISPOSES,Ischemic stroke (dsyn),4.02e-06,78.06,4,28,0,4.57,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),COMPLICATES,Heart failure (dsyn),5.9e-06,83.99,4,9,0,5.78,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),ISA,cardiac arrhythmia (patf),4.02e-06,80.35,4,326,0,4.05,5.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),PROCESS_OF,Hospitalized Patients (humn),4.03e-06,78.84,4,21,0,4.76,1.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),PREDISPOSES,Heart failure (dsyn),4.02e-06,82.45,4,26,0,4.62,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),COEXISTS_WITH,Acute myocardial infarction (dsyn),5.83e-06,79.72,4,13,0,5.23,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),PROCESS_OF,Participant (humn),4.02e-06,78.74,4,56,0,4.29,1.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),PROCESS_OF,Surgical Patients (podg),4.02e-06,81.98,4,17,0,4.94,1.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),COEXISTS_WITH,Cerebrovascular accident (dsyn),4.02e-06,79.46,4,36,0,4.44,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),ISA,Atrial arrhythmia (patf),7.15e-06,78.49,4,16,0,5.0,5.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),COEXISTS_WITH,Acute coronary syndrome (dsyn),5.22e-06,82.67,4,10,0,5.6,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),PROCESS_OF,General Population (humn),4.09e-06,80.71,4,14,0,5.14,1.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),ISA,Heart Diseases (dsyn),4.16e-06,78.1,4,22,0,4.73,5.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),COEXISTS_WITH,Heart failure (dsyn),4.02e-06,82.05,4,68,0,4.24,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),OCCURS_IN,General Population (humn),7.43e-06,80.67,4,11,0,5.45,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),PROCESS_OF,General Population (humn),4.02e-06,80.71,4,53,0,4.3,1.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),COEXISTS_WITH,Sinus rhythm (fndg),8.88e-06,79.78,4,12,0,5.33,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),CAUSES,Cerebrovascular accident (dsyn),4.02e-06,78.06,4,29,0,4.55,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),CAUSES,Cardiovascular morbidity (dsyn),4.02e-06,89.68,4,15,0,5.07,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),PREDISPOSES,Cardiovascular morbidity (dsyn),4.22e-06,93.47,4,8,0,6.0,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),CAUSES,Heart failure (dsyn),4.02e-06,82.9,4,19,0,4.84,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),CAUSES,Cessation of life (orgf),4.02e-06,85.75,4,16,0,5.0,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),COEXISTS_WITH,Hypertrophic Cardiomyopathy (dsyn),4.37e-06,79.49,4,15,0,5.07,7.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),PROCESS_OF,Population Group (humn),5.13e-06,81.46,4,11,0,5.45,1.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),PROCESS_OF,Survivors (humn),5.13e-06,81.46,4,11,0,5.45,1.0
Body mass index procedure (diap),AFFECTS,Atrial Fibrillation (patf),PROCESS_OF,cohort (humn),4.02e-06,79.16,4,68,0,4.24,1.0
Esophagogastroduodenoscopy (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.43e-06,23.7,6,18,0,8.0,6.0
Trochanter (bpoc),PART_OF,Femur (bpoc),LOCATION_OF,Head (blor),2.64e-06,3.69,14,6,0,8.57,2.0
Trochanter (bpoc),PART_OF,Femur (bpoc),LOCATION_OF,Neck (blor),1.64e-06,3.97,14,393,0,14.5,2.0
Trochanter (bpoc),PART_OF,Femur (bpoc),LOCATION_OF,Slipped Epiphyses (dsyn),9.73e-07,3.6,14,1,0,1.07,2.0
Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),6.41e-12,10.99,15,98,0,17.3,1.0
Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),ISA,Racial group (popg),6.41e-12,11.93,15,324,0,15.69,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.17e-09,8.29,20,20,0,40.0,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.71e-09,5.47,20,65,0,26.15,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),USES,Treats (clas),3.76e-07,7.79,20,16,0,28.8,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,8.05,20,13,0,21.45,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),USES,Classification (clas),1.24e-08,9.03,20,16,0,28.8,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,14.44,20,8,0,11.2,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),3.48e-10,7.91,20,23,0,37.39,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.87e-10,8.81,20,22,0,38.18,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,8.74,20,13,0,21.45,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.71e-09,10.73,20,15,0,26.25,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),2.58e-11,11.44,16,77,0,19.32,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),1.01e-08,11.79,16,16,0,32.0,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Young adult (aggp),4.08e-06,11.23,16,12,0,21.0,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Middle Aged (aggp),4.6e-10,11.57,16,19,0,29.47,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary heart disease (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.41e-09,10.36,16,22,0,27.64,21.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Outpatients (podg),5.76e-08,9.36,16,24,0,26.67,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,General Population (humn),2.58e-11,11.07,16,42,0,22.1,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),2.58e-11,12.32,16,102,0,18.51,5.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Heart failure (dsyn),3.34e-07,11.91,16,13,0,23.56,11.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),2.58e-11,11.66,16,83,0,19.08,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary heart disease (dsyn),ISA,Death (finding) (fndg),2.58e-11,14.24,16,250,0,17.02,5.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),2.58e-11,11.42,16,194,0,17.32,11.0
Leptin|LEP (aapp),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,39.04,17,16,0,31.06,9.0
Leptin|LEP (aapp),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,44.21,17,9,0,13.76,9.0
Leptin|LEP (aapp),PREDISPOSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,36.59,17,31,0,26.32,21.0
Continuous Positive Airway Pressure (topp),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular morbidity (dsyn),4.84e-10,24.3,10,23,0,14.35,4.0
Continuous Positive Airway Pressure (topp),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cerebrovascular accident (dsyn),2.32e-07,18.33,10,18,0,15.56,4.0
Continuous Positive Airway Pressure (topp),TREATS,Systemic arterial pressure (fndg),PROCESS_OF,General Population (humn),1.36e-06,16.98,10,27,0,13.7,1.0
Continuous Positive Airway Pressure (topp),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),4.93e-10,17.96,10,32,0,13.12,4.0
Continuous Positive Airway Pressure (topp),TREATS,Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),4.96e-10,17.39,10,39,0,12.56,1.0
Continuous Positive Airway Pressure (topp),TREATS,Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),7.19e-07,16.53,10,41,0,12.44,1.0
Continuous Positive Airway Pressure (topp),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular event (fndg),5.63e-10,18.27,10,27,0,13.7,4.0
Hypogonadism (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.71e-06,38.44,5,20,0,6.25,1.0
Hypogonadism (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.71e-06,35.63,5,65,0,5.38,1.0
Hypogonadism (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),2.08e-06,37.95,5,16,0,6.56,1.0
Hypogonadism (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),5.8e-06,38.2,5,13,0,6.92,1.0
Hypogonadism (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.72e-06,39.18,5,16,0,6.56,1.0
Hypogonadism (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),5.17e-06,44.59,5,8,0,8.12,1.0
Hypogonadism (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.7e-06,38.07,5,23,0,6.09,1.0
Hypogonadism (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.7e-06,38.96,5,22,0,6.14,1.0
Hypogonadism (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),2.59e-06,38.89,5,13,0,6.92,1.0
Hypogonadism (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.71e-06,40.89,5,15,0,6.67,1.0
Hyperinsulinism (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",8.83e-07,11.91,9,16,0,14.06,9.0
Hyperinsulinism (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.78e-06,17.08,9,9,0,18.0,9.0
Hyperinsulinism (dsyn),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),9.54e-07,9.46,9,31,0,11.61,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),4.16e-06,20.19,6,15,0,8.4,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),4.18e-06,22.54,6,12,0,9.0,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),4.14e-06,20.84,6,15,0,8.4,5.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),4.13e-06,20.08,6,28,0,7.29,5.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),4.13e-06,18.24,6,28,0,7.29,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),4.13e-06,21.04,6,66,0,6.55,5.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),4.13e-06,18.89,6,47,0,6.77,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),4.13e-06,18.17,6,27,0,7.33,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),5.03e-06,22.6,6,10,0,9.6,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),4.14e-06,23.17,6,13,0,8.77,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",4.13e-06,18.59,6,26,0,7.38,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),4.27e-06,18.23,6,19,0,7.89,5.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),4.24e-06,19.59,6,15,0,8.4,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (humn),4.13e-06,18.52,6,23,0,7.57,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),7.26e-06,18.13,6,16,0,8.25,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),6.27e-06,19.27,6,13,0,8.77,5.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),6.48e-06,17.98,6,17,0,8.12,5.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),4.13e-06,18.62,6,51,0,6.71,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),4.13e-06,19.12,6,145,0,6.25,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),4.13e-06,19.97,6,39,0,6.92,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),7.55e-06,19.59,6,12,0,9.0,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.9e-06,18.75,6,14,0,8.57,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.8e-06,22.92,6,10,0,9.6,9.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,Scanning (diap),USES,Calcium (bacs),3.02e-06,18.27,6,32,0,7.12,6.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),3.22e-08,16.46,9,20,0,13.05,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Disability NOS (patf),1.38e-08,19.61,9,36,0,11.25,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Respiration Disorders (dsyn),1.38e-08,16.24,9,59,0,10.37,5.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Respiratory physiology (ortf),3.44e-08,15.9,9,23,0,12.52,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Acute respiratory failure (dsyn),3.67e-07,18.9,9,12,0,15.75,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),1.38e-08,16.61,9,72,0,10.12,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Lung diseases (dsyn),1.38e-08,16.08,9,73,0,10.11,5.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.38e-08,17.41,9,50,0,10.62,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospital admission (hlca),1.72e-08,19.2,9,15,0,14.4,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Cessation of life (orgf),1.38e-08,19.13,9,184,0,9.44,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Outpatients (podg),3.25e-08,14.67,8,42,1,9.52,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,General Population (humn),1.38e-08,16.64,9,27,0,12.0,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Diagnosis (hlca),1.84e-07,20.68,9,11,0,16.36,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospitalization (hlca),1.38e-08,18.82,9,31,0,11.61,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Participant (humn),1.38e-08,15.97,9,70,0,10.16,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),COEXISTS_WITH,Smoker (fndg),2.53e-07,15.15,9,27,0,12.0,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Chronic Disease (dsyn),1.38e-08,17.12,9,46,0,10.76,5.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Malignant neoplasm of lung (neop),1.02e-07,16.84,9,17,0,13.76,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Pneumonia (dsyn),4.59e-07,18.75,9,12,0,15.75,8.0
Adipose tissue (tisu),LOCATION_OF,Biopsy (diap),DIAGNOSES,melanoma (neop),9.23e-18,15.49,61,45,0,78.2,2.0
Adipose tissue (tisu),LOCATION_OF,Biopsy (diap),ISA,Diagnosis (hlca),4.06e-10,13.3,61,161,0,84.11,2.0
Adipose tissue (tisu),LOCATION_OF,Biopsy (diap),ISA,Procedures (hlca),4.84e-07,13.42,61,81,0,106.94,2.0
Caloric Restriction (topp),TREATS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.15e-06,21.78,6,16,0,8.25,4.0
Caloric Restriction (topp),TREATS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),3.05e-06,26.95,6,9,0,10.0,4.0
Caloric Restriction (topp),TREATS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),2.23e-06,19.33,6,31,0,7.16,4.0
Gastric Bypass (topp),TREATS,Age (orga),ASSOCIATED_WITH,Acute myocardial infarction (dsyn),6.22e-09,66.5,7,13,0,10.77,4.0
Gastric Bypass (topp),TREATS,Age (orga),ASSOCIATED_WITH,Pneumonia (dsyn),5.22e-07,65.3,7,11,0,11.45,4.0
Gastric Bypass (topp),TREATS,Age (orga),ASSOCIATED_WITH,Heart failure (dsyn),3.38e-10,66.88,7,20,0,9.45,4.0
Gastric Bypass (topp),TREATS,Age (orga),ASSOCIATED_WITH,Cerebrovascular accident (dsyn),3.38e-10,63.09,7,31,0,8.58,4.0
Gastric Bypass (topp),TREATS,Age (orga),ASSOCIATED_WITH,Myocardial Infarction (dsyn),1.76e-07,62.98,7,15,0,10.27,4.0
Federal Government (orgt),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),5.9e-07,53.67,5,13,0,6.92,2.0
Federal Government (orgt),LOCATION_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),5.9e-07,56.6,5,11,0,7.27,2.0
Federal Government (orgt),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),5.58e-07,57.8,5,13,0,6.92,2.0
Federal Government (orgt),LOCATION_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),5.58e-07,53.09,5,27,0,5.93,2.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),1.84e-08,8.75,21,20,0,39.05,1.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Disability NOS (patf),6.22e-13,11.9,21,36,0,33.25,4.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),ISA,Respiration Disorders (dsyn),6.22e-13,8.54,21,59,0,28.47,4.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Respiratory physiology (ortf),2.06e-08,8.19,21,23,0,40.17,1.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Acute respiratory failure (dsyn),3.54e-07,11.19,21,12,0,18.86,4.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),6.22e-13,8.91,21,72,0,27.12,1.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),ISA,Lung diseases (dsyn),6.22e-13,8.37,21,73,0,27.04,4.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Hospitalized Patients (humn),6.22e-13,9.7,21,50,0,29.82,1.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospital admission (hlca),3.35e-09,11.49,21,15,0,25.71,4.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Cessation of life (orgf),6.22e-13,11.42,21,184,0,23.4,4.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Outpatients (podg),1.87e-08,6.96,20,42,1,29.52,1.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,General Population (humn),8.2e-12,8.93,21,27,0,37.33,1.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Diagnosis (hlca),1.7e-07,12.97,21,11,0,16.76,4.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospitalization (hlca),6.22e-13,11.11,21,31,0,35.23,4.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Participant (humn),6.22e-13,8.27,21,70,0,27.3,1.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),COEXISTS_WITH,Smoker (fndg),2.39e-07,7.44,21,27,0,37.33,4.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),ISA,Chronic Disease (dsyn),6.22e-13,9.41,21,46,0,30.59,4.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Malignant neoplasm of lung (neop),8.79e-08,9.13,21,17,0,30.76,4.0
Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Pneumonia (dsyn),4.46e-07,11.04,21,12,0,18.86,4.0
Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),6.55e-09,9.63,13,25,0,19.76,1.0
Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,Participant (humn),4.81e-08,8.18,13,50,0,16.38,1.0
Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,cohort (humn),3.37e-09,10.16,13,65,0,15.6,1.0
Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,Population Group (humn),1.11e-06,12.77,13,11,0,20.31,1.0
abnormal glucose tolerance test (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,21.7,67,18,0,22.84,1.0
Body mass index procedure (diap),CAUSES,End stage renal failure (dsyn),ISA,Kidney Diseases (dsyn),2.18e-07,66.92,5,24,0,6.04,5.0
Body mass index procedure (diap),CAUSES,End stage renal failure (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.18e-07,67.9,5,22,0,6.14,1.0
Body mass index procedure (diap),CAUSES,End stage renal failure (dsyn),PROCESS_OF,Participant (humn),2.18e-07,68.89,5,29,0,5.86,1.0
Body mass index procedure (diap),CAUSES,End stage renal failure (dsyn),ISA,Kidney Failure (dsyn),3.43e-07,70.81,5,11,0,7.27,5.0
Body mass index procedure (diap),CAUSES,End stage renal failure (dsyn),PROCESS_OF,African American (popg),2.18e-07,65.47,5,35,0,5.71,1.0
Body mass index procedure (diap),CAUSES,End stage renal failure (dsyn),PREDISPOSES,Kidney Failure (dsyn),5.08e-07,74.46,5,9,0,7.78,11.0
Body mass index procedure (diap),CAUSES,End stage renal failure (dsyn),PROCESS_OF,General Population (humn),2.21e-07,67.82,5,17,0,6.47,1.0
Body mass index procedure (diap),CAUSES,End stage renal failure (dsyn),PROCESS_OF,Survivors (humn),2.18e-07,74.14,5,15,0,6.67,1.0
Body mass index procedure (diap),CAUSES,End stage renal failure (dsyn),ISA,"Kidney Failure, Chronic (dsyn)",2.18e-07,68.5,5,58,0,5.43,5.0
Body mass index procedure (diap),CAUSES,End stage renal failure (dsyn),CAUSES,Cessation of life (orgf),2.18e-07,70.39,5,20,0,6.25,11.0
Body mass index procedure (diap),CAUSES,End stage renal failure (dsyn),PROCESS_OF,cohort (humn),2.18e-07,70.41,5,71,0,5.35,1.0
Body mass index procedure (diap),CAUSES,End stage renal failure (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.8e-06,69.81,5,10,0,7.5,11.0
Body mass index procedure (diap),CAUSES,End stage renal failure (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.18e-07,68.21,5,21,0,6.19,1.0
Leptin|LEP (aapp),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),2.49e-11,6.28,17,5,0,6.47,3.0
Depressive Symptoms (sosy),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,9.4,41,18,0,25.9,1.0
Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),3.98e-19,38.75,16,25,0,26.24,1.0
Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),5.88e-09,36.55,16,13,0,23.56,1.0
Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),1.09e-19,41.01,16,32,0,24.0,1.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,17.49,19,33,0,29.94,1.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,18.03,19,16,0,29.47,9.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),5.35e-19,17.84,19,71,0,24.08,5.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),5.35e-19,31.68,19,35,0,29.31,9.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.35e-19,17.76,19,110,0,22.28,9.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,17.1,19,37,0,28.76,1.0
Anemia (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.12e-06,11.5,9,18,0,13.5,1.0
Upper Extremity (bpoc),LOCATION_OF,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular morbidity (dsyn),6.45e-10,13.31,19,23,0,34.7,2.0
Upper Extremity (bpoc),LOCATION_OF,Systemic arterial pressure (fndg),PREDISPOSES,Cerebrovascular accident (dsyn),2.33e-07,7.35,19,18,0,35.05,2.0
Upper Extremity (bpoc),LOCATION_OF,Systemic arterial pressure (fndg),PROCESS_OF,General Population (humn),1.36e-06,6.0,19,27,0,32.37,1.0
Upper Extremity (bpoc),LOCATION_OF,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),6.53e-10,6.98,19,32,0,30.28,2.0
Upper Extremity (bpoc),LOCATION_OF,Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),6.56e-10,6.4,19,39,0,28.26,1.0
Upper Extremity (bpoc),LOCATION_OF,Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),7.19e-07,5.55,19,41,0,27.8,1.0
Upper Extremity (bpoc),LOCATION_OF,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular event (fndg),7.24e-10,7.29,19,27,0,32.37,2.0
colonoscopy (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),4.43e-09,12.78,12,18,0,20.0,6.0
Antipsychotic Agents (phsu),TREATS,Schizophrenia (mobd),PROCESS_OF,Outpatients (podg),5.69e-08,1.75,57,12,0,14.53,1.0
Gastrectomy (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,44.4,65,12,0,14.22,1.0
Gastrectomy (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,41.77,65,24,0,32.86,4.0
Leptin|LEP (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,"Energy, Physics (npop)",8.92e-10,6.72,23,78,1,29.78,1.0
Leptin|LEP (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,Oxidation-Reduction (npop),3.42e-06,6.68,24,29,0,43.86,1.0
Assessment procedure (hlca),USES,Insulin (horm),TREATS,Hospitalized Patients (humn),2.75e-06,23.52,13,11,0,20.31,4.0
Assessment procedure (hlca),USES,Insulin (horm),TREATS,Hyperglycemia (dsyn),6.78e-14,21.31,13,57,0,15.96,4.0
Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.07e-09,11.44,14,18,0,24.89,1.0
Assessment procedure (hlca),PREVENTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",8.75e-08,45.53,6,16,0,8.25,9.0
Assessment procedure (hlca),PREVENTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.81e-07,50.7,6,9,0,10.0,9.0
Assessment procedure (hlca),PREVENTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.59e-07,43.08,6,31,0,7.16,21.0
Behavior Therapy (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,26.98,35,12,0,16.11,1.0
Behavior Therapy (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,24.34,35,24,0,40.46,4.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,29.33,18,9,0,13.5,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.19e-20,28.39,18,194,0,19.67,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,27.11,18,17,0,33.06,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),3.08e-19,28.38,18,29,0,29.17,11.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,30.56,18,14,0,24.89,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,26.37,18,12,0,20.0,5.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),3.2e-20,25.19,18,48,0,24.75,11.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.83e-19,28.58,18,29,0,29.17,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.19e-20,25.63,18,98,0,21.31,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,24.29,18,24,0,31.5,9.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,30.7,18,10,0,15.56,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,23.06,18,37,0,26.76,7.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,24.86,18,20,0,34.2,9.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),3.19e-20,26.52,18,94,0,21.45,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,32.31,18,8,0,11.56,9.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,29.18,18,19,0,35.05,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,26.34,18,21,0,33.43,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,31.52,18,12,0,20.0,9.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,39.23,18,10,0,15.56,21.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,31.82,18,10,0,15.56,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,26.14,18,21,0,33.43,21.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,27.75,18,21,0,33.43,9.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.03e-17,25.87,18,32,0,28.12,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,33.23,18,10,0,15.56,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),3.19e-20,32.2,18,39,0,26.31,9.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),3.19e-20,36.18,18,44,0,25.36,11.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.19e-20,29.05,18,113,0,20.87,9.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,26.58,18,11,0,17.72,11.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,26.3,18,11,0,17.72,9.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,26.77,18,12,0,20.0,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,24.66,18,25,0,30.96,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.19e-20,30.33,18,87,0,21.72,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,25.32,18,33,0,27.82,9.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.19e-20,28.06,18,41,0,25.9,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,28.23,18,21,0,33.43,1.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,25.89,18,21,0,33.43,9.0
Physical activity (dora),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),3.19e-20,26.84,18,1021,0,18.32,11.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,25.7,12,20,0,19.2,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,22.89,12,65,0,14.22,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,25.21,12,16,0,21.0,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,25.46,12,13,0,23.08,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,26.44,12,16,0,21.0,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,31.85,12,8,0,13.33,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,25.33,12,23,0,18.26,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.54e-11,26.22,12,22,0,18.55,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,26.15,12,13,0,23.08,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,28.15,12,15,0,21.6,1.0
High density lipoprotein decreased (fndg),ISA,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.53e-07,21.54,7,62,0,7.79,5.0
High density lipoprotein decreased (fndg),ISA,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.53e-07,32.13,7,17,0,9.88,5.0
High density lipoprotein decreased (fndg),ISA,Dyslipidemias (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.53e-07,23.82,7,19,0,9.58,5.0
C-reactive protein (aapp),PART_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,21.38,16,18,0,30.22,3.0
Intervention regimes (hlca),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,21.31,20,16,0,28.8,4.0
Intervention regimes (hlca),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),3.61e-21,31.53,20,26,0,35.38,4.0
Death (finding) (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,12.2,20,18,0,34.2,1.0
Body mass index (clna),PREDISPOSES,Liver diseases (dsyn),AFFECTS,American (popg),3.57e-07,56.27,5,39,0,5.64,7.0
Body mass index (clna),PREDISPOSES,Liver diseases (dsyn),PROCESS_OF,cohort (humn),3.56e-07,59.35,5,23,0,6.09,1.0
Body mass index (clna),PREDISPOSES,Liver diseases (dsyn),CAUSES,Cessation of life (orgf),3.56e-07,60.92,5,67,0,5.37,11.0
Body mass index (clna),PREDISPOSES,Liver diseases (dsyn),PROCESS_OF,Pregnant Women (popg),3.79e-07,59.76,5,14,0,6.79,1.0
Body mass index (clna),PREDISPOSES,Liver diseases (dsyn),PROCESS_OF,Hepatitis C virus (virs),3.86e-06,56.9,5,16,0,6.56,1.0
Adiponectin (aapp),INTERACTS_WITH,Lipids (lipd),PART_OF,Stratum corneum (tisu),7.96e-07,15.13,10,2,0,2.4,3.0
insulin sensitivity (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),3.83e-09,24.76,8,33,0,9.94,1.0
insulin sensitivity (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,25.3,8,16,0,12.0,9.0
insulin sensitivity (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.58e-09,25.1,8,71,0,8.9,5.0
insulin sensitivity (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.58e-09,38.95,8,35,0,9.83,9.0
insulin sensitivity (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.58e-09,25.03,8,110,0,8.58,9.0
insulin sensitivity (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),4.93e-09,24.37,8,37,0,9.73,1.0
Procedures (hlca),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,41.69,46,12,0,15.13,1.0
Procedures (hlca),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,39.06,46,24,0,36.52,4.0
Academic Medical Centers (hcro),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),3.64e-08,81.97,6,13,0,8.77,2.0
Academic Medical Centers (hcro),LOCATION_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),3.62e-08,84.9,6,11,0,9.27,2.0
Academic Medical Centers (hcro),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),4e-09,86.1,6,13,0,8.77,2.0
Academic Medical Centers (hcro),LOCATION_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),3.66e-09,81.39,6,27,0,7.33,2.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,valganciclovir (phsu),1.31e-06,4.15,38,29,0,51.13,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Septicemia (dsyn),2.63e-08,7.46,38,15,0,20.92,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Cytomegalovirus Infections (dsyn),1.51e-06,6.24,38,14,0,19.16,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Carcinoma of the Large Intestine (neop),4.09e-06,6.26,38,13,0,17.45,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Ciprofloxacin (phsu),1.16e-08,4.73,38,28,0,48.63,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Cerebrovascular accident (dsyn),9.6e-11,6.27,38,23,0,36.92,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),PREVENTS,Delirium (mobd),3.52e-07,10.94,38,10,0,12.63,16.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,atorvastatin (phsu),2.07e-06,9.03,38,10,0,12.63,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Haloperidol (phsu),2.75e-06,7.72,38,11,0,14.18,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),PREDISPOSES,Thromboembolism (patf),2.07e-07,5.42,38,19,0,28.5,16.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Clinicians (humn),4.08e-06,6.77,38,12,0,15.79,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Proton Pump Inhibitors (phsu),2.33e-12,6.06,38,30,0,53.68,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Magnesium Sulfate (phsu),1.6e-09,5.87,38,22,0,34.74,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Neutropenia (dsyn),2.16e-12,7.19,38,33,0,61.66,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Fluconazole (phsu),2.16e-12,6.23,38,139,0,48.39,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),PREVENTS,Thromboembolism (patf),2.16e-12,6.16,38,38,0,76.0,16.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Postpartum Hemorrhage (patf),1.88e-06,10.89,38,9,0,11.13,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Pre-Eclampsia (dsyn),2.53e-06,6.47,38,13,0,17.45,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,"Heparin, Low-Molecular-Weight (carb)",7.61e-07,5.79,38,16,0,22.74,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Acute graft-versus-host disease (patf),1.31e-06,7.39,38,12,0,15.79,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Methotrexate (orch),2.16e-12,6.94,38,105,0,51.75,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Trimethoprim-Sulfamethoxazole Combination (phsu),6.34e-12,6.05,38,27,0,46.18,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Amiodarone (phsu),2.33e-07,5.39,38,19,0,28.5,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Antifungal Agents (phsu),4.23e-11,6.22,38,24,0,39.16,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Pancreatitis (dsyn),5.12e-10,7.51,38,18,0,26.53,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),ADMINISTERED_TO,"Recipient, Transplant (podg)",4.79e-06,6.2,38,13,0,17.45,15.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,"Recipient, Transplant (podg)",2.16e-12,6.37,38,53,0,65.25,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Methotrexate (orch),2.02e-10,11.7,38,14,0,19.16,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,palivizumab (phsu),1.14e-11,4.35,38,46,0,69.39,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Critical Illness (dsyn),2.16e-12,8.3,38,29,0,51.13,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),PREVENTS,Atrial Fibrillation (patf),8.34e-10,8.49,38,16,0,22.74,16.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Mycoses (dsyn),2.16e-12,7.53,38,33,0,61.66,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),METHOD_OF,Vaccination (topp),2.8e-09,5.75,38,22,0,34.74,16.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Hematologic Neoplasms (neop),5.29e-11,8.48,38,18,0,26.53,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Adrenergic beta-Antagonists (phsu),3.11e-10,5.33,38,27,0,46.18,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Antibiotics (antb),2.16e-12,3.96,38,106,0,51.62,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Aspirin (phsu),2.16e-12,4.5,38,57,0,63.33,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Lamivudine (phsu),5.32e-12,4.71,38,40,0,74.1,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,voriconazole (phsu),2.16e-12,7.01,38,39,0,75.03,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),PREVENTS,Febrile neutropenia (dsyn),1.21e-07,12.37,38,10,0,12.63,16.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Adrenal Cortex Hormones (phsu),1.04e-11,4.88,38,36,0,70.11,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Heart failure (dsyn),2.47e-12,7.81,38,23,0,36.92,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Pneumonia (dsyn),1.34e-09,5.7,38,23,0,36.92,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,posaconazole (phsu),2.16e-12,5.51,38,47,0,68.72,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Ganciclovir (phsu),2.16e-12,4.61,38,54,0,64.74,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),PREVENTS,Mycoses (dsyn),7.91e-12,8.82,38,19,0,28.5,16.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Cyclosporine (phsu),2.16e-12,5.51,38,74,0,57.51,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Thromboembolism (patf),2.16e-12,4.98,38,68,0,59.24,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Vaccines (phsu),3.03e-12,3.96,38,66,0,59.88,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,"Kidney Failure, Chronic (dsyn)",1.76e-07,6.65,38,15,0,20.92,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Graft-vs-Host Disease (dsyn),2.16e-12,7.23,38,33,0,61.66,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,mycophenolate mofetil (orch),2.16e-12,8.37,38,47,0,68.72,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Neuraminidase inhibitor (phsu),9.34e-07,6.43,38,14,0,19.16,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,"Infant, Premature (humn)",2.16e-12,7.36,38,30,0,53.68,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,"amphotericin b, liposomal (antb)",1.96e-10,7.39,38,19,0,28.5,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Itraconazole (phsu),2.16e-12,6.31,38,39,0,75.03,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,defibrotide (phsu),8.7e-07,8.55,38,11,0,14.18,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,"ASPERGILLOSIS, INVASIVE (dsyn)",8.18e-08,12.96,38,10,0,12.63,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Levofloxacin (phsu),1.98e-07,5.24,38,20,0,30.53,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Atrial Fibrillation (patf),2.16e-12,5.06,38,54,0,64.74,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Malaria (dsyn),6.14e-10,4.54,38,35,0,67.24,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),PREVENTS,Ventilator-associated lung injury (inpo),3.47e-06,12.65,38,8,0,9.68,16.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Antiviral Agents (phsu),6.41e-11,5.44,38,28,0,48.63,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Antithymoglobulin (phsu),2.23e-12,7.48,38,25,0,41.45,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Fluoroquinolones (phsu),2.16e-12,6.39,38,47,0,68.72,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Delirium (mobd),3.08e-09,7.3,38,17,0,24.61,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Enoxaparin (carb),1.07e-06,4.22,38,28,0,48.63,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,"Heparin, Low-Molecular-Weight (carb)",2.16e-12,4.17,38,95,0,53.2,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Medical Patients (podg),4e-06,5.58,38,15,0,20.92,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Hemorrhage (fndg),1.32e-10,4.91,38,32,0,58.95,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,"Leukemia, Myelocytic, Acute (neop)",6.98e-08,8.37,38,13,0,17.45,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Hydroxymethylglutaryl-CoA Reductase Inhibitors (phsu),2.53e-12,6.52,38,27,0,46.18,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Cardiovascular Diseases (dsyn),4.54e-12,5.96,38,28,0,48.63,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Microbicides (phsu),2.16e-12,3.49,38,193,0,45.48,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Anticoagulants (phsu),7.16e-09,4.43,38,33,0,61.66,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Vitamin supplementation (phsu),1.06e-06,6.86,38,13,0,17.45,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,sulfadoxine-pyrimethamine (phsu),1.33e-08,4.32,38,34,0,64.42,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Trimethoprim-Sulfamethoxazole Combination (phsu),2.16e-12,5.09,38,195,0,45.41,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Cyclophosphamide (opco),8.56e-10,7.83,38,17,0,24.61,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Tacrolimus (phsu),2.16e-12,8.61,38,51,0,66.31,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,mycophenolate mofetil (orch),1.31e-06,7.39,38,12,0,15.79,6.0
Polysomnography (diap),CAUSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),1.93e-06,22.42,6,16,0,8.25,11.0
Polysomnography (diap),CAUSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.43e-06,32.64,6,26,0,7.38,11.0
Cesarean section (finding) (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.42e-06,16.42,7,20,0,9.45,1.0
Cesarean section (finding) (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.42e-06,13.61,7,65,0,7.75,1.0
Cesarean section (finding) (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),1.8e-06,15.93,7,16,0,10.06,1.0
Cesarean section (finding) (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),5.52e-06,16.19,7,13,0,10.77,1.0
Cesarean section (finding) (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.43e-06,17.17,7,16,0,10.06,1.0
Cesarean section (finding) (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),4.89e-06,22.57,7,8,0,13.12,1.0
Cesarean section (finding) (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.42e-06,16.05,7,23,0,9.13,1.0
Cesarean section (finding) (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.42e-06,16.95,7,22,0,9.23,1.0
Cesarean section (finding) (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),2.31e-06,16.87,7,13,0,10.77,1.0
Cesarean section (finding) (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.42e-06,18.87,7,15,0,10.27,1.0
Pharyngoplasty (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,25.12,14,16,0,26.25,4.0
Pharyngoplasty (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),7.98e-16,35.33,14,26,0,21.54,4.0
Left ventricular mass (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),8.76e-09,18.99,9,18,0,13.5,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,28.35,22,9,0,12.68,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.29e-24,27.41,22,194,0,24.49,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,26.13,22,17,0,30.14,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,27.4,21,28,1,36.75,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,29.59,22,14,0,22.91,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,25.39,22,12,0,18.55,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1e-22,24.21,22,48,0,32.08,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.51e-19,27.6,22,29,0,38.69,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.29e-24,24.65,22,98,0,26.94,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,23.31,22,24,0,42.17,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,29.73,22,10,0,14.55,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,22.08,22,37,0,35.08,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,23.89,22,20,0,38.18,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.29e-24,25.54,22,94,0,27.15,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,31.33,22,8,0,10.91,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,28.2,22,19,0,35.41,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,25.36,22,21,0,41.05,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,30.54,22,12,0,18.55,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,38.26,22,10,0,14.55,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,30.84,22,10,0,14.55,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,25.16,22,21,0,41.05,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,26.77,22,21,0,41.05,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,24.9,22,32,0,37.12,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,32.25,22,10,0,14.55,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.29e-24,31.22,22,39,0,34.41,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),2.29e-24,35.2,22,44,0,33.0,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.29e-24,28.08,22,113,0,26.28,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,25.6,22,11,0,16.5,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,25.33,22,11,0,16.5,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,25.79,22,12,0,18.55,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,23.68,22,25,0,41.36,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.29e-24,29.36,22,87,0,27.56,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,24.35,22,33,0,36.67,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.3e-24,27.08,22,41,0,33.8,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,27.25,22,21,0,41.05,1.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,24.92,22,21,0,41.05,4.0
Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.29e-24,25.86,22,1021,0,22.47,4.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),1.69e-09,15.64,10,33,0,13.03,1.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,16.18,10,16,0,16.25,9.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.43e-09,15.98,10,71,0,11.41,5.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.43e-09,29.83,10,35,0,12.86,9.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.43e-09,15.91,10,110,0,10.91,9.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),2.78e-09,15.25,10,37,0,12.7,1.0
Laparoscopic adjustable gastric banding (topp),compared_with,Gastrectomy (topp),TREATS,Gastric Adenocarcinoma (neop),3.18e-12,50.74,9,64,0,10.27,4.0
Laparoscopic adjustable gastric banding (topp),compared_with,Gastrectomy (topp),TREATS,Malignant neoplasm of stomach (neop),3.18e-12,47.6,9,578,0,9.14,4.0
Laparoscopic adjustable gastric banding (topp),compared_with,Gastrectomy (topp),TREATS,Advanced cancer (neop),3.18e-12,50.31,9,24,0,12.38,4.0
Laparoscopic adjustable gastric banding (topp),compared_with,Gastrectomy (topp),TREATS,Adenocarcinoma (neop),3.18e-12,48.8,9,30,0,11.7,4.0
Laparoscopic adjustable gastric banding (topp),compared_with,Gastrectomy (topp),TREATS,"Obesity, Morbid (dsyn)",3.18e-12,46.48,9,80,0,10.01,4.0
Laparoscopic adjustable gastric banding (topp),compared_with,Gastrectomy (topp),USES,Sleeves (medd),3.18e-12,43.56,8,532,1,8.12,6.0
Laparoscopic adjustable gastric banding (topp),compared_with,Gastrectomy (topp),TREATS,Body Weight decreased (fndg),3.19e-12,46.77,9,30,0,11.7,4.0
Laparoscopic adjustable gastric banding (topp),compared_with,Gastrectomy (topp),TREATS,Stomach Carcinoma (neop),3.18e-12,47.49,9,49,0,10.65,4.0
Laparoscopic adjustable gastric banding (topp),compared_with,Gastrectomy (topp),ADMINISTERED_TO,Surgeon (humn),2.01e-09,49.86,9,14,0,14.79,15.0
Laparoscopic adjustable gastric banding (topp),compared_with,Gastrectomy (topp),TREATS,Malignant neoplasm of stomach stage III (neop),2.07e-06,49.12,9,10,0,17.1,4.0
Laparoscopic adjustable gastric banding (topp),compared_with,Gastrectomy (topp),TREATS,Early gastric cancer (neop),3.18e-12,46.04,9,71,0,10.14,4.0
Metabolic syndrome (dsyn),NEG_PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,36.06,12,18,0,20.0,6.0
Assessment procedure (hlca),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.19e-06,24.01,7,12,0,11.08,1.0
Assessment procedure (hlca),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),1.95e-07,21.38,7,24,0,9.04,4.0
Bariatric Surgery (topp),TREATS,Male gender (orga),ISA,Gender (orga),1.51e-06,39.47,5,33,0,5.76,4.0
cohort (humn),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Ischemic stroke (dsyn),4.17e-06,20.17,22,11,0,16.5,2.0
cohort (humn),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),3.01e-10,17.4,22,34,0,36.24,2.0
cohort (humn),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Septicemia (dsyn),8.33e-13,21.76,22,20,0,38.18,2.0
cohort (humn),LOCATION_OF,C-reactive protein (aapp),ISA,Albumins (aapp),4.89e-14,19.01,22,30,0,38.13,2.0
cohort (humn),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),1.24e-07,19.52,22,15,0,25.23,2.0
cohort (humn),LOCATION_OF,C-reactive protein (aapp),ISA,Acute-Phase Proteins (aapp),1.55e-13,16.59,22,77,0,28.29,2.0
cohort (humn),LOCATION_OF,C-reactive protein (aapp),compared_with,procalcitonin (aapp),1.82e-08,19.82,22,16,0,27.64,2.0
cohort (humn),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Myocardial Infarction (dsyn),2.06e-06,18.86,22,14,0,22.91,2.0
Supplementation (topp),TREATS,Well adult (fndg),PROCESS_OF,Voluntary Workers (humn),1.35e-06,7.19,9,15,0,14.4,1.0
Control Groups (humn),LOCATION_OF,Cholesterol (bacs),PART_OF,Membrane (celc),5.97e-09,7.53,12,5,0,7.08,2.0
Billroth I Procedure (topp),TREATS,Malignant neoplasm of stomach (neop),PROCESS_OF,cohort (humn),3.86e-17,10.3,42,31,0,53.88,1.0
Billroth I Procedure (topp),TREATS,Malignant neoplasm of stomach (neop),ISA,Malignant disease (dsyn),3.28e-08,11.73,42,13,0,17.02,4.0
Metabolic syndrome (dsyn),PROCESS_OF,student (prog),USES,Grade (clas),1.31e-09,26.29,8,7,0,13.12,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Well adult (fndg),PROCESS_OF,Voluntary Workers (humn),9.1e-11,37.85,12,15,0,21.6,1.0
Intervention regimes (hlca),TREATS,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),3.92e-06,14.4,11,25,0,15.84,2.0
Intervention regimes (hlca),TREATS,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),3.93e-06,12.2,11,13,0,20.31,2.0
Intervention regimes (hlca),TREATS,Survivors (humn),LOCATION_OF,procalcitonin (aapp),3.92e-06,16.65,11,32,0,14.78,2.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.79e-10,21.34,37,23,0,37.3,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),1.67e-22,20.79,37,57,0,61.02,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,29.25,37,9,0,11.19,9.0
Fatty Liver (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),6.04e-08,12.14,10,23,0,14.35,9.0
Fatty Liver (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),6.01e-08,11.59,10,57,0,11.75,9.0
Fatty Liver (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),3.51e-07,20.06,10,9,0,17.1,9.0
Transaminases (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Hilum (bpoc),1.87e-06,5.15,14,56,0,17.5,2.0
Transaminases (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Neoplasm Metastasis (neop),1.87e-06,6.4,14,48,0,18.08,2.0
Transaminases (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Tumor Burden (diap),1.87e-06,8.28,14,28,0,21.0,2.0
Transaminases (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Primary Neoplasm (neop),1.87e-06,5.73,14,35,0,19.6,2.0
Transaminases (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Toxic effect (inpo),1.87e-06,4.77,14,145,0,15.35,2.0
Transaminases (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Decompensation (fndg),1.87e-06,7.27,14,224,0,14.88,2.0
Transaminases (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Hydrothorax (dsyn),1.87e-06,5.09,14,61,0,17.21,2.0
Transaminases (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Medical Imaging (diap),1.87e-06,3.43,14,3,0,3.64,2.0
Transaminases (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Hepatic Veno-Occlusive Disease (dsyn),2.28e-06,6.29,14,19,0,24.32,2.0
Smoking (inbe),AFFECTS,Alcohol consumption (inbe),PROCESS_OF,cohort (humn),1.39e-07,9.87,12,25,0,17.76,1.0
Smoking (inbe),AFFECTS,Alcohol consumption (inbe),ISA,Behavior (inbe),1.29e-08,7.77,12,50,0,14.88,5.0
Question of pregnancy (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,13.11,17,20,0,31.45,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,10.3,17,65,0,21.45,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,12.62,17,16,0,31.06,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,12.87,17,13,0,22.94,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,13.86,17,16,0,31.06,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,19.26,17,8,0,11.76,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,12.74,17,23,0,29.57,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.54e-11,13.63,17,22,0,30.14,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,13.56,17,13,0,22.94,1.0
Question of pregnancy (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,15.56,17,15,0,28.24,1.0
Eating Disorders (mobd),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,18.1,26,18,0,30.46,1.0
Laparoscopic radical nephrectomy (topp),TREATS,Renal Cell Carcinoma (neop),PROCESS_OF,cohort (humn),7.53e-07,9.17,12,15,0,21.6,1.0
Hepatic (blor),LOCATION_OF,Ultrasonography (diap),DIAGNOSES,"Aortic Aneurysm, Abdominal (dsyn)",9.38e-10,9.19,17,23,0,29.57,2.0
Hepatic (blor),LOCATION_OF,Ultrasonography (diap),ISA,Medical Imaging (diap),2.76e-06,4.93,17,25,0,28.56,2.0
Hepatic (blor),LOCATION_OF,Ultrasonography (diap),METHOD_OF,Early Diagnosis (diap),4.43e-06,6.37,17,30,0,26.63,2.0
Open approach (topp),TREATS,Malignant tumor of colon (neop),PROCESS_OF,Survivors (humn),3.5e-06,11.74,8,16,0,12.0,1.0
Open approach (topp),TREATS,Malignant tumor of colon (neop),PROCESS_OF,cohort (humn),2.02e-06,13.84,8,16,0,12.0,1.0
Vitamin D (phsu),PREDISPOSES,Fracture (inpo),PROCESS_OF,Geriatric Patients (humn),2.51e-07,13.1,10,15,0,16.67,1.0
Insulin Resistance (patf),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,25.04,24,33,0,41.45,1.0
Insulin Resistance (patf),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,25.58,24,16,0,26.67,9.0
Insulin Resistance (patf),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.34e-25,25.38,24,71,0,32.11,5.0
Insulin Resistance (patf),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.4e-27,39.23,24,35,0,40.46,21.0
Insulin Resistance (patf),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.4e-27,25.31,24,110,0,29.24,21.0
Insulin Resistance (patf),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,24.65,24,37,0,39.57,1.0
Hypertension induced by pregnancy (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.56e-08,31.94,7,20,0,9.45,1.0
Hypertension induced by pregnancy (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.72e-08,29.13,7,65,0,7.75,1.0
Hypertension induced by pregnancy (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.9e-07,31.45,7,16,0,10.06,1.0
Hypertension induced by pregnancy (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.11e-06,31.7,7,13,0,10.77,1.0
Hypertension induced by pregnancy (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),2.69e-08,32.69,7,16,0,10.06,1.0
Hypertension induced by pregnancy (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.48e-06,38.09,7,8,0,13.12,1.0
Hypertension induced by pregnancy (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.48e-08,31.57,7,23,0,9.13,1.0
Hypertension induced by pregnancy (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.47e-08,32.46,7,22,0,9.23,1.0
Hypertension induced by pregnancy (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.99e-07,32.39,7,13,0,10.77,1.0
Hypertension induced by pregnancy (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.62e-08,34.39,7,15,0,10.27,1.0
Entire lumbar spine (blor),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),2.51e-07,69.39,5,13,0,6.92,2.0
Entire lumbar spine (blor),LOCATION_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),2.5e-07,72.32,5,11,0,7.27,2.0
Entire lumbar spine (blor),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),2.18e-07,73.53,5,13,0,6.92,2.0
Entire lumbar spine (blor),LOCATION_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),2.18e-07,68.81,5,27,0,5.93,2.0
Gout (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.87e-08,16.75,9,18,0,13.5,1.0
Albuminuria (fndg),ISA,Kidney Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.03e-06,24.76,8,8,0,16.0,5.0
Albuminuria (fndg),ISA,Kidney Diseases (dsyn),AFFECTS,Systemic arterial pressure (fndg),1.67e-06,12.57,8,21,0,11.05,5.0
Albuminuria (fndg),ISA,Kidney Diseases (dsyn),CAUSES,"Kidney Failure, Acute (dsyn)",1.67e-06,13.02,8,23,0,10.78,5.0
Albuminuria (fndg),ISA,Kidney Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.64e-06,10.68,8,27,0,10.37,1.0
Albuminuria (fndg),ISA,Kidney Diseases (dsyn),CAUSES,End stage renal failure (dsyn),1.69e-06,11.73,8,22,0,10.91,5.0
Albuminuria (fndg),ISA,Kidney Diseases (dsyn),PROCESS_OF,cohort (humn),1.67e-06,12.38,8,22,0,10.91,1.0
Albuminuria (fndg),ISA,Kidney Diseases (dsyn),CAUSES,Cessation of life (orgf),1.67e-06,14.99,8,35,0,9.83,5.0
Body mass index procedure (diap),METHOD_OF,Coronary angiography (diap),DIAGNOSES,Adverse event (fndg),6.63e-07,74.91,8,10,0,14.4,16.0
Body mass index procedure (diap),METHOD_OF,Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),5.88e-12,68.99,8,88,0,8.73,16.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.9e-06,47.07,5,12,0,7.08,1.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),9.07e-07,44.44,5,24,0,6.04,4.0
Low Back Pain (sosy),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.3e-09,9.5,17,18,0,33.06,1.0
Selenoprotein P (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.02e-07,58.27,5,16,0,6.56,8.0
Selenoprotein P (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.3e-06,63.44,5,9,0,7.78,8.0
Selenoprotein P (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),4.74e-07,55.82,5,31,0,5.81,8.0
Magnetic Resonance Spectroscopy (diap),METHOD_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Glioblastoma (neop),3.76e-08,17.8,11,18,0,17.72,16.0
Magnetic Resonance Spectroscopy (diap),METHOD_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Congenital diaphragmatic hernia (cgab),2.51e-07,23.07,11,10,0,19.09,16.0
Osteopenia (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),9.51e-07,25.42,6,18,0,8.0,1.0
sex (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),6.81e-09,68.35,6,23,0,7.57,8.0
sex (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),6.53e-09,67.79,6,57,0,6.63,8.0
sex (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.97e-07,76.26,6,9,0,10.0,8.0
Bone structure of ischium (bpoc),PART_OF,cohort (humn),USES,Medicare (rnlw),1e-09,20.31,12,20,0,19.2,3.0
Bone structure of ischium (bpoc),PART_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,17.5,12,65,0,14.22,2.0
Bone structure of ischium (bpoc),PART_OF,cohort (humn),USES,Treats (clas),3.75e-07,19.82,12,16,0,21.0,3.0
Bone structure of ischium (bpoc),PART_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,20.07,12,13,0,23.08,2.0
Bone structure of ischium (bpoc),PART_OF,cohort (humn),USES,Classification (clas),1.22e-08,21.05,12,16,0,21.0,3.0
Bone structure of ischium (bpoc),PART_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,26.46,12,8,0,13.33,2.0
Bone structure of ischium (bpoc),PART_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.79e-10,19.94,12,23,0,18.26,2.0
Bone structure of ischium (bpoc),PART_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.78e-11,20.83,12,22,0,18.55,2.0
Bone structure of ischium (bpoc),PART_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,20.76,12,13,0,23.08,3.0
Bone structure of ischium (bpoc),PART_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.55e-09,22.76,12,15,0,21.6,2.0
Glomerular Filtration Rate (ortf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,14.59,50,18,0,24.48,1.0
Dopamine (nsba),PART_OF,Extracellular (celc),LOCATION_OF,Vesicle (acab),2.86e-08,0.23,1,57,0,1.02,2.0
Dopamine (nsba),PART_OF,Extracellular (celc),LOCATION_OF,Polysaccharides (carb),2.86e-08,0.04,1,3,0,1.33,2.0
Cardiovascular Diseases (dsyn),NEG_PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.46e-09,31.09,8,18,0,11.56,6.0
Body mass index (clna),PREDISPOSES,Anemia (dsyn),COEXISTS_WITH,Critical Illness (dsyn),8.85e-08,42.03,6,14,0,8.57,9.0
Body mass index (clna),PREDISPOSES,Anemia (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),8.58e-08,43.6,6,19,0,7.89,9.0
Body mass index (clna),PREDISPOSES,Anemia (dsyn),PROCESS_OF,cohort (humn),8.58e-08,41.14,6,48,0,6.75,1.0
Body mass index (clna),PREDISPOSES,Anemia (dsyn),PROCESS_OF,Hospitalized Patients (humn),8.58e-08,40.18,6,22,0,7.64,1.0
Body mass index (clna),PREDISPOSES,Anemia (dsyn),CAUSES,Cessation of life (orgf),2.92e-06,39.43,6,12,0,9.0,11.0
Body mass index (clna),PREDISPOSES,Anemia (dsyn),PROCESS_OF,cohort (humn),2.17e-07,41.38,6,12,0,9.0,1.0
Body mass index (clna),PREDISPOSES,Anemia (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.09e-07,37.65,6,23,0,7.57,1.0
Body mass index (clna),PREDISPOSES,Anemia (dsyn),PROCESS_OF,Surgical Patients (podg),8.58e-08,41.26,6,20,0,7.8,1.0
Body mass index (clna),PREDISPOSES,Anemia (dsyn),PROCESS_OF,General Population (humn),4.48e-06,40.83,6,10,0,9.6,1.0
Body mass index (clna),PREDISPOSES,Anemia (dsyn),PROCESS_OF,Participant (humn),9.63e-08,38.36,5,19,1,6.32,1.0
Body mass index (clna),PREDISPOSES,Anemia (dsyn),PROCESS_OF,Pregnant Women (popg),4.55e-07,38.19,6,17,0,8.12,1.0
Body mass index (clna),PREDISPOSES,Anemia (dsyn),PROCESS_OF,Cancer Patient (podg),9.31e-08,36.59,6,40,0,6.9,1.0
Body mass index (clna),PREDISPOSES,Anemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.86e-07,41.66,6,11,0,9.27,21.0
Body mass index (clna),PREDISPOSES,Anemia (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",8.58e-08,37.57,6,52,0,6.69,9.0
Body mass index (clna),PREDISPOSES,Anemia (dsyn),COEXISTS_WITH,Heart failure (dsyn),8.58e-08,42.1,6,63,0,6.57,9.0
Exercise (dora),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.02e-07,22.96,9,16,0,14.06,4.0
Exercise (dora),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),7.42e-10,33.18,9,26,0,12.12,4.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Participant (humn),7.04e-07,15.43,7,84,0,7.58,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Hyperglycemia (dsyn),1.06e-06,22.48,7,10,0,11.9,21.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Atrial Fibrillation (patf),7.27e-07,26.76,7,10,0,11.9,11.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Human Age Group (aggp),7.06e-07,18.53,7,18,0,9.72,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Population Group (humn),4.12e-06,19.11,7,11,0,11.45,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Vascular Diseases (dsyn),7.04e-07,17.45,7,38,0,8.29,5.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Cessation of life (orgf),7.04e-07,18.11,7,449,0,7.11,11.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Black race (popg),7.04e-07,18.14,7,24,0,9.04,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),7.04e-07,20.63,7,34,0,8.44,21.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Neurologist (humn),7.04e-07,16.5,7,31,0,8.58,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),7.05e-07,18.34,7,19,0,9.58,21.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Survivors (humn),7.04e-07,14.85,7,330,0,7.15,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.23e-06,20.5,7,11,0,11.45,9.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Deglutition Disorders (dsyn),1.32e-06,16.3,7,22,0,9.23,21.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Depressive disorder (mobd),7.06e-07,15.72,7,41,0,8.2,21.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,Myocardial Infarction (dsyn),7.29e-07,20.59,7,13,0,10.77,9.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Young adult (aggp),7.05e-07,15.62,7,48,0,8.02,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,inpatient (humn),5.4e-06,15.66,7,27,0,8.81,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,VICTIM (humn),9.53e-07,15.49,7,38,0,8.29,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),OCCURS_IN,cohort (humn),7.05e-07,20.16,7,16,0,10.06,21.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Disability NOS (patf),7.04e-07,16.56,7,163,0,7.3,11.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,General Population (humn),7.04e-07,17.55,7,44,0,8.11,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),AFFECTS,Systemic arterial pressure (fndg),7.04e-07,17.73,7,27,0,8.81,7.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Heart failure (dsyn),7.04e-07,26.51,7,14,0,10.5,21.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Octogenarians (aggp),7.04e-07,26.76,7,15,0,10.27,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Control Groups (humn),1.95e-06,16.57,7,19,0,9.58,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Disability NOS (patf),7.04e-07,17.04,7,47,0,8.04,21.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),AFFECTS,Cessation of life (orgf),1.15e-06,19.59,7,12,0,11.08,7.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Hospitalization (hlca),7.04e-07,22.54,7,24,0,9.04,11.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,Diabetic (fndg),7.04e-07,18.22,7,23,0,9.13,9.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Pneumonia (dsyn),1.4e-06,19.3,7,12,0,11.08,21.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Ethnic group (popg),7.07e-07,19.44,7,16,0,10.06,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),7.04e-07,18.12,7,155,0,7.32,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Teams (humn),7.04e-07,16.54,7,42,0,8.17,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Thrombosis (patf),7.04e-07,18.46,7,21,0,9.33,5.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Cerebrovascular Disorders (patf),7.04e-07,17.04,7,41,0,8.2,5.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Hospitalized Patients (humn),7.04e-07,18.42,7,64,0,7.77,1.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),7.04e-07,17.78,7,129,0,7.38,9.0
Cardiovascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),7.04e-07,18.21,7,39,0,8.26,1.0
trait (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),7.43e-08,16.44,8,33,0,9.94,1.0
trait (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.51e-06,16.98,8,16,0,12.0,8.0
trait (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),7.4e-08,16.78,8,71,0,8.9,5.0
trait (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),7.4e-08,30.63,8,35,0,9.83,8.0
trait (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),7.4e-08,16.71,8,110,0,8.58,8.0
trait (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),7.54e-08,16.05,8,37,0,9.73,1.0
Pregnancy (orgf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.34e-07,17.68,8,18,0,11.56,1.0
Respiratory physiology (ortf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,15.99,19,20,0,37.05,1.0
Respiratory physiology (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,13.17,19,65,0,24.55,1.0
Respiratory physiology (ortf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,15.5,19,16,0,29.47,1.0
Respiratory physiology (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,15.75,19,13,0,21.89,1.0
Respiratory physiology (ortf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,16.73,19,16,0,29.47,1.0
Respiratory physiology (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,22.14,19,8,0,11.37,1.0
Respiratory physiology (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,15.62,19,23,0,34.7,1.0
Respiratory physiology (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,16.51,19,22,0,35.41,1.0
Respiratory physiology (ortf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,16.44,19,13,0,21.89,1.0
Respiratory physiology (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,18.44,19,15,0,26.84,1.0
LDL Cholesterol Lipoproteins (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),7.43e-10,22.98,9,33,0,11.45,1.0
LDL Cholesterol Lipoproteins (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,23.52,9,16,0,14.06,8.0
LDL Cholesterol Lipoproteins (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),4.84e-10,23.32,9,71,0,10.14,5.0
LDL Cholesterol Lipoproteins (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.84e-10,37.17,9,35,0,11.31,8.0
LDL Cholesterol Lipoproteins (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.84e-10,23.25,9,110,0,9.74,8.0
LDL Cholesterol Lipoproteins (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.84e-09,22.59,9,37,0,11.19,1.0
Bariatric Surgery (topp),TREATS,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.11e-06,21.08,6,23,0,7.57,4.0
Bariatric Surgery (topp),TREATS,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),2.11e-06,20.53,6,57,0,6.63,4.0
Bariatric Surgery (topp),TREATS,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.4e-06,28.99,6,9,0,10.0,4.0
Leptin|LEP (aapp),COEXISTS_WITH,C-reactive protein (aapp),ASSOCIATED_WITH,Ischemic stroke (dsyn),4.17e-06,55.39,8,11,0,13.82,8.0
Leptin|LEP (aapp),COEXISTS_WITH,C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),3.29e-10,52.62,8,34,0,9.88,9.0
Leptin|LEP (aapp),COEXISTS_WITH,C-reactive protein (aapp),PREDISPOSES,Septicemia (dsyn),2.83e-11,56.98,8,20,0,11.2,9.0
Leptin|LEP (aapp),COEXISTS_WITH,C-reactive protein (aapp),ISA,Albumins (aapp),2.75e-11,54.22,8,30,0,10.13,5.0
Leptin|LEP (aapp),COEXISTS_WITH,C-reactive protein (aapp),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),1.24e-07,54.74,8,15,0,12.27,8.0
Leptin|LEP (aapp),COEXISTS_WITH,C-reactive protein (aapp),ISA,Acute-Phase Proteins (aapp),2.76e-11,51.81,8,77,0,8.83,5.0
Leptin|LEP (aapp),COEXISTS_WITH,C-reactive protein (aapp),compared_with,procalcitonin (aapp),1.82e-08,55.03,8,16,0,12.0,9.0
Leptin|LEP (aapp),COEXISTS_WITH,C-reactive protein (aapp),PREDISPOSES,Myocardial Infarction (dsyn),2.06e-06,54.07,8,14,0,12.57,9.0
Receptor Gene (gngm),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.48e-07,23.93,7,16,0,10.06,8.0
Receptor Gene (gngm),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.04e-06,29.1,7,9,0,12.44,8.0
Receptor Gene (gngm),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),2.2e-07,21.48,7,31,0,8.58,8.0
Waist circumference (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),1.13e-21,44.02,16,136,0,17.88,1.0
Waist circumference (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),1.13e-21,43.15,16,188,0,17.36,1.0
Waist circumference (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Population Group (humn),2.53e-06,44.04,16,20,0,28.8,1.0
Laparoscopic adjustable gastric banding (topp),METHOD_OF,Bariatric Surgery (topp),TREATS,"Obesity, Morbid (dsyn)",3.56e-07,56.68,5,94,0,5.27,4.0
Laparoscopic adjustable gastric banding (topp),METHOD_OF,Bariatric Surgery (topp),TREATS,Body Weight decreased (fndg),3.56e-07,56.61,5,47,0,5.53,4.0
Increase in blood pressure (fndg),PROCESS_OF,student (prog),USES,Grade (clas),3.33e-16,41.21,12,7,0,11.08,1.0
Vitamin D (phsu),TREATS,cohort (humn),USES,Medicare (rnlw),5.04e-07,12.23,9,20,0,13.05,4.0
Vitamin D (phsu),TREATS,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),5.06e-07,9.41,9,65,0,10.25,2.0
Vitamin D (phsu),TREATS,cohort (humn),USES,Treats (clas),8.79e-07,11.73,9,16,0,14.06,4.0
Vitamin D (phsu),TREATS,cohort (humn),LOCATION_OF,Calcium (bacs),4.6e-06,11.99,9,13,0,15.23,2.0
Vitamin D (phsu),TREATS,cohort (humn),USES,Classification (clas),5.15e-07,12.97,9,16,0,14.06,4.0
Vitamin D (phsu),TREATS,cohort (humn),LOCATION_OF,Sodium (elii),3.97e-06,18.38,9,8,0,15.11,2.0
Vitamin D (phsu),TREATS,cohort (humn),LOCATION_OF,C-reactive protein (aapp),5.03e-07,11.85,9,23,0,12.52,2.0
Vitamin D (phsu),TREATS,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),5.03e-07,12.75,9,22,0,12.68,2.0
Vitamin D (phsu),TREATS,cohort (humn),USES,Tissue Microarray (resd),1.39e-06,12.68,9,13,0,15.23,4.0
Vitamin D (phsu),TREATS,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),5.05e-07,14.67,9,15,0,14.4,2.0
Aortic valve replacement NOS (topp),USES,Prosthesis (medd),TREATS,Aortic Valve Stenosis (dsyn),1.32e-09,10.33,18,15,3,27.5,4.0
Aortic valve replacement NOS (topp),USES,Prosthesis (medd),USES,Valves (mnob),2.31e-07,8.1,21,14,0,23.33,6.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,15.45,18,18,0,36.0,1.0
Head (blor),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),4.05e-06,81.96,4,13,0,5.23,2.0
Head (blor),LOCATION_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),4.05e-06,84.89,4,11,0,5.45,2.0
Head (blor),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),4.02e-06,86.1,4,13,0,5.23,2.0
Head (blor),LOCATION_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),4.02e-06,81.39,4,27,0,4.59,2.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of stomach (neop),PROCESS_OF,cohort (humn),3.38e-10,63.77,7,31,0,8.58,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of stomach (neop),ISA,Malignant disease (dsyn),3.31e-08,65.2,7,13,0,10.77,5.0
Procedures (hlca),METHOD_OF,Bariatric Surgery (topp),TREATS,"Obesity, Morbid (dsyn)",3.72e-07,27.93,6,94,0,6.38,4.0
Procedures (hlca),METHOD_OF,Bariatric Surgery (topp),TREATS,Body Weight decreased (fndg),3.72e-07,27.86,6,47,0,6.77,4.0
Physical activity (dora),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular morbidity (dsyn),4.23e-17,26.16,20,23,0,37.39,4.0
Physical activity (dora),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cerebrovascular accident (dsyn),2.32e-07,20.2,20,18,0,34.2,4.0
Physical activity (dora),TREATS,Systemic arterial pressure (fndg),PROCESS_OF,General Population (humn),1.36e-06,18.85,20,27,0,34.81,1.0
Physical activity (dora),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),8.77e-12,19.83,20,32,0,32.5,4.0
Physical activity (dora),TREATS,Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),1.15e-11,19.25,20,39,0,30.26,1.0
Physical activity (dora),TREATS,Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),7.18e-07,18.4,20,41,0,29.76,1.0
Physical activity (dora),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular event (fndg),7.9e-11,20.14,20,27,0,34.81,4.0
Influenza (dsyn),ISA,Virus Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.11e-06,3.84,3,47,0,3.19,1.0
Influenza (dsyn),ISA,Virus Diseases (dsyn),PROCESS_OF,Shrimp (invt),1.11e-06,4.27,3,40,0,3.23,1.0
Influenza (dsyn),ISA,Virus Diseases (dsyn),PROCESS_OF,Larva (invt),1.98e-06,5.33,3,12,0,3.75,1.0
Influenza (dsyn),ISA,Virus Diseases (dsyn),PROCESS_OF,Litopenaeus vannamei (invt),1.14e-06,8.06,3,12,0,3.75,1.0
Influenza (dsyn),ISA,Virus Diseases (dsyn),CAUSES,Liver diseases (dsyn),1.29e-06,4.35,3,15,0,3.6,5.0
Influenza (dsyn),ISA,Virus Diseases (dsyn),CAUSES,Cessation of life (orgf),1.12e-06,3.38,3,24,0,3.38,5.0
Body mass index procedure (diap),AFFECTS,Pancreatic Fistula (anab),AFFECTS,Gastric Emptying (ortf),6.52e-08,108.48,4,21,1,4.76,7.0
Gout (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),2.67e-06,15.14,7,20,0,9.45,1.0
Gout (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.67e-06,12.33,7,65,0,7.75,1.0
Gout (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.05e-06,14.65,7,16,0,10.06,1.0
Gout (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),6.77e-06,14.91,7,13,0,10.77,1.0
Gout (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),2.68e-06,15.89,7,16,0,10.06,1.0
Gout (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),6.14e-06,21.3,7,8,0,13.12,1.0
Gout (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.67e-06,14.77,7,23,0,9.13,1.0
Gout (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),2.67e-06,15.67,7,22,0,9.23,1.0
Gout (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),3.56e-06,15.6,7,13,0,10.77,1.0
Gout (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.67e-06,17.59,7,15,0,10.27,1.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Glioblastoma (neop),3.75e-08,25.57,11,18,0,17.72,16.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Congenital diaphragmatic hernia (cgab),2.51e-07,30.85,11,10,0,19.09,16.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Pre-Eclampsia (dsyn),AFFECTS,Pathogenesis (patf),1.9e-06,18.75,8,25,0,10.56,7.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Pre-Eclampsia (dsyn),PROCESS_OF,Pregnant Women (popg),2.3e-08,17.97,8,105,0,8.61,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Pre-Eclampsia (dsyn),AFFECTS,Pregnancy (orgf),5.93e-08,19.82,8,21,0,11.05,7.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Pre-Eclampsia (dsyn),ISA,Hypertension induced by pregnancy (dsyn),5.96e-08,18.8,8,31,0,10.06,5.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Pre-Eclampsia (dsyn),PROCESS_OF,Pregnant Women (popg),2.78e-08,19.0,8,31,0,10.06,1.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Pre-Eclampsia (dsyn),ISA,Pregnancy Complications (dsyn),2.3e-08,19.42,8,46,0,9.39,5.0
"Diabetes, Gestational (dsyn)",PREDISPOSES,Pre-Eclampsia (dsyn),CAUSES,"Morbidity, perinatal (patf)",3.49e-06,27.06,8,8,0,16.0,11.0
Adiponectin (aapp),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.79e-10,24.1,13,23,0,20.35,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),1.91e-14,23.55,13,57,0,15.96,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,32.02,13,9,0,15.23,8.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Residual Tumor (neop),1.02e-06,12.57,9,15,0,14.4,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Anastomosis (acab),2.64e-07,12.79,9,30,0,11.7,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,"[M]Squamous cell carcinoma, metastatic NOS (neop)",2.64e-07,11.26,9,52,0,10.56,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Rhabdomyosarcoma (neop),1.03e-06,11.08,9,23,0,12.52,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Malignant Squamous Cell Neoplasm (neop),2.64e-07,10.9,9,52,0,10.56,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Adenoid Cystic Carcinoma (neop),2.64e-07,12.85,9,28,0,11.89,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Fracture with displacement (inpo),2.64e-07,11.36,9,32,0,11.53,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),2.64e-07,10.34,9,526,0,9.15,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,sarcoma (neop),2.64e-07,11.41,9,54,0,10.5,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Secondary malignant neoplasm of lymph node (neop),2.64e-07,10.75,9,58,0,10.4,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,"[X]Malignant melanoma of skin, unspecified (neop)",2.67e-07,11.35,9,28,0,11.89,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Squamous cell carcinoma of skin (neop),2.64e-07,13.35,9,43,0,10.88,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,melanoma (neop),2.64e-07,11.54,9,85,0,9.95,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Merkel cell carcinoma (neop),2.64e-07,12.65,9,27,0,12.0,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Neoplasm Metastasis (neop),2.11e-06,10.88,9,24,0,12.38,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Necrotizing fasciitis (dsyn),2.64e-07,13.67,9,35,0,11.31,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Wounds and Injuries (inpo),4.25e-07,10.22,9,47,0,10.72,2.0
Dietary intake (orgf),PROCESS_OF,student (prog),USES,Grade (clas),4.59e-08,15.14,8,7,0,13.12,1.0
Polysomnography (diap),DIAGNOSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,18.41,106,16,0,18.42,18.0
Polysomnography (diap),DIAGNOSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.39e-22,28.62,106,26,0,32.38,18.0
alpha-Actin (aapp),PART_OF,Smooth muscle (tissue) (tisu),PART_OF,Aorta (bpoc),4.56e-09,0.12,11,4,0,5.45,3.0
alpha-Actin (aapp),PART_OF,Smooth muscle (tissue) (tisu),PART_OF,Bronchial (bpoc),8.42e-07,0.13,11,4,0,5.45,3.0
alpha-Actin (aapp),PART_OF,Smooth muscle (tissue) (tisu),LOCATION_OF,Cell Culture Techniques (lbpr),3.99e-23,0.12,11,10,0,19.09,2.0
Underweight (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,50.41,32,18,0,28.12,1.0
Overweight (sosy),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,40.13,10,33,0,13.03,1.0
Overweight (sosy),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,40.67,10,16,0,16.25,9.0
Overweight (sosy),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.29e-13,40.48,10,71,0,11.41,5.0
Overweight (sosy),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.29e-13,54.32,10,35,0,12.86,21.0
Overweight (sosy),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.29e-13,40.4,10,110,0,10.91,21.0
Overweight (sosy),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,39.74,10,37,0,12.7,1.0
Subcutaneous Fat (tisu),LOCATION_OF,Biopsy (diap),DIAGNOSES,melanoma (neop),9.23e-18,17.29,74,45,0,72.36,2.0
Subcutaneous Fat (tisu),LOCATION_OF,Biopsy (diap),ISA,Diagnosis (hlca),4.06e-10,15.1,74,161,0,108.01,2.0
Subcutaneous Fat (tisu),LOCATION_OF,Biopsy (diap),ISA,Procedures (hlca),4.84e-07,15.22,74,81,0,141.6,2.0
Oral Glucose Tolerance Test (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.16e-09,29.66,73,18,0,22.44,6.0
Triglycerides (bacs),INHIBITS,Cholesterol (bacs),PART_OF,Membrane (celc),3.95e-06,6.16,9,5,0,7.78,3.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),2.63e-08,17.06,13,15,0,24.27,21.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),4.29e-08,19.42,13,12,0,23.08,1.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),6.96e-09,17.71,13,15,0,24.27,5.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),6.62e-12,16.96,13,28,0,19.04,5.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),4.4e-11,15.12,13,28,0,19.04,1.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),6.62e-12,17.91,13,66,0,15.56,5.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),6.62e-12,15.76,13,47,0,16.6,1.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),1.55e-10,15.04,13,27,0,19.26,9.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),8.95e-07,19.47,13,10,0,17.69,9.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),4.27e-09,20.04,13,13,0,26.0,9.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.89e-11,15.46,13,26,0,19.5,1.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),1.43e-07,15.1,13,19,0,21.89,5.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),1.03e-07,16.47,13,15,0,24.27,1.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (humn),8.97e-10,15.39,13,23,0,20.35,1.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),3.12e-06,15.0,13,16,0,23.56,1.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),2.14e-06,16.14,13,13,0,26.0,5.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),2.35e-06,14.85,13,17,0,22.94,5.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),6.62e-12,15.5,13,51,0,16.31,1.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),6.62e-12,15.99,13,145,0,14.17,11.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),6.62e-12,16.84,13,39,0,17.33,11.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.42e-06,16.47,13,12,0,23.08,1.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.76e-06,15.62,13,14,0,25.07,9.0
Triglycerides (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.63e-07,19.79,13,10,0,17.69,9.0
research organization (orgt),LOCATION_OF,Clinical Trials (resa),USES,Stents (medd),1.72e-07,12.32,10,78,0,11.28,2.0
research organization (orgt),LOCATION_OF,Clinical Trials (resa),USES,Probes (medd),2.1e-07,7.54,10,5,0,7.5,2.0
research organization (orgt),LOCATION_OF,Clinical Trials (resa),USES,Metal stent (medd),1.72e-07,14.68,10,34,0,12.94,2.0
research organization (orgt),LOCATION_OF,Clinical Trials (resa),USES,Treatment Protocols (resa),1.72e-07,10.91,10,147,0,10.68,2.0
research organization (orgt),LOCATION_OF,Clinical Trials (resa),USES,Drug eluting stent (medd),1.72e-07,13.13,10,38,0,12.63,2.0
research organization (orgt),LOCATION_OF,Clinical Trials (resa),USES,"Defibrillators, Implantable (medd)",1.72e-07,15.48,10,40,0,12.5,2.0
research organization (orgt),LOCATION_OF,Clinical Trials (resa),USES,"Stents, Vascular, Coronary (medd)",1.78e-07,15.28,10,13,0,17.69,2.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Survivors (humn),6.06e-08,41.51,6,34,0,7.06,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Fibrosis (patf),6.09e-08,41.89,6,21,0,7.71,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Septicemia (dsyn),6.06e-08,45.25,6,38,0,6.95,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Critical Illness (dsyn),6.06e-08,40.82,6,35,0,7.03,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,cohort (humn),6.06e-08,39.75,6,49,0,6.73,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Pneumonia (dsyn),6.06e-08,45.11,6,25,0,7.44,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Acute heart failure (dsyn),1.4e-06,46.74,6,9,0,10.0,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Surgical Patients (podg),1.15e-07,41.66,6,17,0,8.12,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),6.09e-08,40.09,6,33,0,7.09,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,End stage renal failure (dsyn),6.06e-08,43.62,6,18,0,8.0,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Pancreatitis (dsyn),3.04e-06,41.77,6,13,0,8.77,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Pulmonary Embolism (dsyn),5.36e-07,42.08,6,14,0,8.57,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Aortic Valve Stenosis (dsyn),5.38e-07,41.65,6,15,0,8.4,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Coronary heart disease (dsyn),6.94e-08,41.08,6,21,0,7.71,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Frailty (fndg),1.94e-06,46.26,6,9,0,10.0,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),USES,Brain natriuretic peptide (aapp),6.71e-08,42.88,6,16,0,8.25,5.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Chronic heart failure (dsyn),6.26e-08,42.36,6,18,0,8.0,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Heart failure (dsyn),6.06e-08,41.67,6,67,0,6.54,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,CARDIAC EVENT (dsyn),3.53e-06,48.02,6,8,0,10.5,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,Acute coronary syndrome (dsyn),6.13e-08,41.97,6,20,0,7.8,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),TREATS,End stage liver disease (dsyn),6.06e-08,50.49,6,17,0,8.12,4.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),METHOD_OF,Transplantation (topp),6.15e-08,40.32,6,29,0,7.24,5.0
Nutrition Assessment (diap),ISA,Assessment procedure (hlca),METHOD_OF,Percutaneous coronary intervention (topp),3.53e-06,48.02,6,8,0,10.5,5.0
Asymptomatic (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),9.44e-08,7.99,18,18,0,36.0,1.0
Carotid Arteries (bpoc),LOCATION_OF,Senile Plaques (acab),LOCATION_OF,Psoriasis (dsyn),3.11e-06,3.62,13,13,0,26.0,2.0
Metformin (phsu),INHIBITS,Insulin (horm),TREATS,Hospitalized Patients (humn),2.82e-06,19.39,8,11,0,13.82,4.0
Metformin (phsu),INHIBITS,Insulin (horm),TREATS,Hyperglycemia (dsyn),7.4e-08,17.18,8,57,0,9.12,4.0
Muscle strength (ortf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),5.52e-09,25.7,8,20,0,11.2,1.0
Muscle strength (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),7.06e-09,22.89,8,65,0,8.98,1.0
Muscle strength (ortf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.8e-07,25.21,8,16,0,12.0,1.0
Muscle strength (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.1e-06,25.46,8,13,0,12.92,1.0
Muscle strength (ortf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.68e-08,26.44,8,16,0,12.0,1.0
Muscle strength (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,31.85,8,8,0,16.0,1.0
Muscle strength (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),4.7e-09,25.33,8,23,0,10.78,1.0
Muscle strength (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),4.53e-09,26.22,8,22,0,10.91,1.0
Muscle strength (ortf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.89e-07,26.15,8,13,0,12.92,1.0
Muscle strength (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),6.06e-09,28.15,8,15,0,12.27,1.0
Coronary artery calcification (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,24.7,15,18,0,27.5,1.0
Intervention regimes (hlca),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.16e-09,8.9,50,18,0,24.48,6.0
"Osteoarthritis, Knee (dsyn)",PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.18e-09,13.87,14,18,0,24.89,1.0
Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.17e-09,14.27,14,18,0,24.89,1.0
Intervention regimes (hlca),USES,Metformin (phsu),TREATS,Pancreatic carcinoma (neop),4.73e-06,15.91,12,9,0,15.75,4.0
Intervention regimes (hlca),USES,Metformin (phsu),TREATS,Heart failure (dsyn),1.52e-08,14.69,12,14,0,22.29,4.0
Intervention regimes (hlca),USES,Metformin (phsu),CAUSES,"Acidosis, Lactic (dsyn)",1.57e-09,14.2,12,22,0,18.55,6.0
Intervention regimes (hlca),USES,Metformin (phsu),TREATS,Diabetic (fndg),1.73e-09,10.38,12,45,0,15.2,4.0
Intervention regimes (hlca),USES,Metformin (phsu),ISA,Antidiabetics (phsu),6.98e-08,10.05,12,44,0,15.27,5.0
Intervention regimes (hlca),USES,Metformin (phsu),TREATS,Malignant neoplasm of prostate (neop),2.07e-08,15.43,12,13,0,23.08,4.0
Metabolic syndrome (dsyn),AFFECTS,Participant (humn),USES,Medicare (rnlw),4.13e-06,31.79,5,18,0,6.39,6.0
Hyperglycemia (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,26.4,20,18,0,34.2,1.0
Testosterone (phsu),TREATS,Participant (humn),USES,Medicare (rnlw),2.11e-06,22.25,6,18,0,8.0,4.0
Overweight (sosy),PROCESS_OF,Households (humn),LOCATION_OF,Ephrin Receptor EphB1 (aapp),1.03e-06,32.36,19,17,0,32.21,1.0
Systolic blood pressure (ortf),AFFECTS,Age (orga),ASSOCIATED_WITH,Acute myocardial infarction (dsyn),5.88e-09,26.29,24,13,0,20.04,7.0
Systolic blood pressure (ortf),AFFECTS,Age (orga),ASSOCIATED_WITH,Pneumonia (dsyn),5.21e-07,25.09,24,11,0,16.04,7.0
Systolic blood pressure (ortf),AFFECTS,Age (orga),ASSOCIATED_WITH,Heart failure (dsyn),4.15e-14,26.67,24,20,0,36.67,7.0
Systolic blood pressure (ortf),AFFECTS,Age (orga),ASSOCIATED_WITH,Cerebrovascular accident (dsyn),1.12e-15,22.88,24,31,0,42.58,7.0
Systolic blood pressure (ortf),AFFECTS,Age (orga),ASSOCIATED_WITH,Myocardial Infarction (dsyn),1.76e-07,22.77,24,15,0,24.38,7.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),2.63e-08,17.96,15,15,0,30.0,8.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),4.29e-08,20.32,15,12,0,21.6,1.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),6.96e-09,18.61,15,15,0,30.0,5.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),4.16e-14,17.86,15,28,0,23.04,5.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),3.74e-11,16.01,15,28,0,23.04,1.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),3.9e-14,18.81,15,66,0,18.41,5.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),3.9e-14,16.66,15,47,0,19.79,1.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),1.49e-10,15.94,15,27,0,23.33,8.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),8.95e-07,20.37,15,10,0,16.67,8.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),4.26e-09,20.94,15,13,0,24.27,8.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.23e-11,16.36,15,26,0,23.65,1.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),1.43e-07,16.0,15,19,0,26.84,5.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),1.03e-07,17.37,15,15,0,30.0,1.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (humn),8.9e-10,16.29,15,23,0,24.78,1.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),3.12e-06,15.9,15,16,0,29.06,1.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),2.14e-06,17.04,15,13,0,24.27,5.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),2.35e-06,15.75,15,17,0,28.24,5.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.9e-14,16.4,15,51,0,19.41,1.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),3.9e-14,16.89,15,145,0,16.55,8.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),3.9e-14,17.74,15,39,0,20.77,8.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.42e-06,17.37,15,12,0,21.6,1.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.76e-06,16.52,15,14,0,27.07,8.0
Age (orga),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.63e-07,20.69,15,10,0,16.67,8.0
Intervention regimes (hlca),TREATS,Infertility (dsyn),PROCESS_OF,Couples (humn),2.28e-06,6.67,9,16,0,14.06,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,31.32,10,16,0,16.25,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,36.49,10,9,0,17.1,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,28.87,10,31,0,13.23,8.0
Palatopharyngoplasty (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,12.25,44,16,0,21.82,4.0
Palatopharyngoplasty (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.39e-22,22.46,44,26,0,41.36,4.0
"Diabetes, Gestational (dsyn)",PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,19.83,21,20,0,39.05,1.0
"Diabetes, Gestational (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,17.02,21,65,0,27.78,1.0
"Diabetes, Gestational (dsyn)",PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,19.34,21,16,0,28.19,1.0
"Diabetes, Gestational (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,19.59,21,13,0,21.05,1.0
"Diabetes, Gestational (dsyn)",PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,20.57,21,16,0,28.19,1.0
"Diabetes, Gestational (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,25.98,21,8,0,11.05,1.0
"Diabetes, Gestational (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,19.46,21,23,0,40.17,1.0
"Diabetes, Gestational (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,20.35,21,22,0,41.05,1.0
"Diabetes, Gestational (dsyn)",PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,20.28,21,13,0,21.05,1.0
"Diabetes, Gestational (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,22.28,21,15,0,25.71,1.0
Hospitals (hcro),LOCATION_OF,colonoscopy (diap),DIAGNOSES,Carcinoma of the Large Intestine (neop),7.95e-07,7.93,12,54,0,14.67,2.0
Hospitals (hcro),LOCATION_OF,colonoscopy (diap),AFFECTS,Carcinoma of the Large Intestine (neop),7.97e-07,13.24,12,13,0,23.08,2.0
Bariatric Surgery (topp),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),4.06e-10,26.65,9,33,0,11.45,1.0
Bariatric Surgery (topp),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,27.2,9,16,0,14.06,4.0
Bariatric Surgery (topp),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.47e-10,27.0,9,71,0,10.14,4.0
Bariatric Surgery (topp),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.47e-10,40.84,9,35,0,11.31,4.0
Bariatric Surgery (topp),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.47e-10,26.93,9,110,0,9.74,4.0
Bariatric Surgery (topp),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.5e-09,26.26,9,37,0,11.19,1.0
pioglitazone (orch),compared_with,Metformin (phsu),TREATS,Pancreatic carcinoma (neop),4.73e-06,18.8,10,9,0,17.1,4.0
pioglitazone (orch),compared_with,Metformin (phsu),TREATS,Heart failure (dsyn),1.85e-08,17.58,10,14,0,17.14,4.0
pioglitazone (orch),compared_with,Metformin (phsu),CAUSES,"Acidosis, Lactic (dsyn)",4.89e-09,17.09,10,22,0,14.55,11.0
pioglitazone (orch),compared_with,Metformin (phsu),TREATS,Diabetic (fndg),5.04e-09,13.28,10,45,0,12.22,4.0
pioglitazone (orch),compared_with,Metformin (phsu),ISA,Antidiabetics (phsu),7.31e-08,12.94,10,44,0,12.27,5.0
pioglitazone (orch),compared_with,Metformin (phsu),TREATS,Malignant neoplasm of prostate (neop),2.4e-08,18.32,10,13,0,17.69,4.0
Insulin (horm),TREATS,cohort (humn),USES,Medicare (rnlw),9.97e-10,25.04,18,20,0,34.2,4.0
Insulin (horm),TREATS,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,22.22,18,65,0,22.98,2.0
Insulin (horm),TREATS,cohort (humn),USES,Treats (clas),3.75e-07,24.55,18,16,0,30.22,4.0
Insulin (horm),TREATS,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,24.8,18,13,0,22.39,2.0
Insulin (horm),TREATS,cohort (humn),USES,Classification (clas),1.22e-08,25.78,18,16,0,30.22,4.0
Insulin (horm),TREATS,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,31.19,18,8,0,11.56,2.0
Insulin (horm),TREATS,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,24.66,18,23,0,32.09,2.0
Insulin (horm),TREATS,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,25.56,18,22,0,32.73,2.0
Insulin (horm),TREATS,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,25.49,18,13,0,22.39,4.0
Insulin (horm),TREATS,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,27.49,18,15,0,27.5,2.0
Menopause (phsf),AFFECTS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),8.37e-07,44.32,5,33,0,5.76,1.0
Menopause (phsf),AFFECTS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),5.27e-06,44.86,5,16,0,6.56,7.0
Menopause (phsf),AFFECTS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),8.37e-07,44.67,5,71,0,5.35,5.0
Menopause (phsf),AFFECTS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),8.37e-07,58.51,5,35,0,5.71,7.0
Menopause (phsf),AFFECTS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),8.37e-07,44.59,5,110,0,5.23,7.0
Menopause (phsf),AFFECTS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),8.38e-07,43.93,5,37,0,5.68,1.0
Fasting (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.01e-09,28.48,10,20,0,15.0,1.0
Fasting (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.55e-09,25.67,10,65,0,11.54,1.0
Fasting (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,27.99,10,16,0,16.25,1.0
Fasting (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,28.25,10,13,0,17.69,1.0
Fasting (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,29.23,10,16,0,16.25,1.0
Fasting (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,34.63,10,8,0,14.4,1.0
Fasting (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.87e-10,28.11,10,23,0,14.35,1.0
Fasting (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),2.53e-11,29.0,10,22,0,14.55,1.0
Fasting (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,28.93,10,13,0,17.69,1.0
Fasting (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.55e-09,30.93,10,15,0,16.67,1.0
Adiponectin (aapp),CAUSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.79e-08,21.34,9,16,0,14.06,9.0
Adiponectin (aapp),CAUSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.41e-07,26.51,9,9,0,18.0,9.0
Adiponectin (aapp),CAUSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.19e-07,18.9,9,31,0,11.61,11.0
poor health (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.17e-09,16.11,13,18,0,22.39,1.0
Walking (dora),ISA,Performance (inbe),PROCESS_OF,cohort (humn),4.84e-16,5.87,39,150,0,49.14,1.0
Walking (dora),ISA,Performance (inbe),PROCESS_OF,athlete (humn),5.53e-11,3.1,39,5,0,5.64,1.0
Walking (dora),ISA,Performance (inbe),PROCESS_OF,student (prog),4.84e-16,3.08,39,4,0,4.41,1.0
Walking (dora),ISA,Performance (inbe),PROCESS_OF,Surgeon (humn),1.11e-06,4.96,39,27,0,45.69,1.0
Walking (dora),ISA,Performance (inbe),PREDISPOSES,Septicemia (dsyn),2.59e-06,11.15,39,9,0,11.08,5.0
Adiponectin (aapp),COEXISTS_WITH,Insulin (horm),TREATS,Hospitalized Patients (humn),2.75e-06,29.5,8,11,0,13.82,4.0
Adiponectin (aapp),COEXISTS_WITH,Insulin (horm),TREATS,Hyperglycemia (dsyn),2.19e-09,27.29,8,57,0,9.12,4.0
Overweight (sosy),PREDISPOSES,Dementia (mobd),PROCESS_OF,cohort (humn),4.2e-09,54.7,14,38,0,19.16,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,17.31,15,9,0,14.4,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.85e-12,16.36,15,194,0,16.16,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.39e-10,15.09,15,17,0,28.24,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.85e-12,16.36,15,29,0,22.76,11.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2.02e-10,18.54,15,14,0,27.07,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,14.35,15,12,0,21.6,5.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),2.85e-12,13.17,15,48,0,19.69,11.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.85e-12,16.56,15,29,0,22.76,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.85e-12,13.6,15,98,0,17.3,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,12.27,15,24,0,24.38,9.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,18.68,15,10,0,16.67,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,11.04,15,37,0,21.08,7.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.74e-09,12.84,15,20,0,26.25,9.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.85e-12,14.49,15,94,0,17.39,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,20.28,15,8,0,12.27,9.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.17e-12,17.16,15,19,0,26.84,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.49e-11,14.31,15,21,0,25.71,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,19.49,15,12,0,21.6,9.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.64e-09,27.21,15,10,0,16.67,21.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,19.8,15,10,0,16.67,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.54e-11,14.11,15,21,0,25.71,21.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),3.12e-12,15.72,15,21,0,25.71,9.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.85e-12,13.85,15,32,0,22.03,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,21.21,15,10,0,16.67,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.85e-12,20.18,15,39,0,20.77,9.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),2.85e-12,24.15,15,44,0,20.11,11.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.85e-12,17.03,15,113,0,16.99,9.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,14.56,15,11,0,19.07,11.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,14.28,15,11,0,19.07,9.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,14.74,15,12,0,21.6,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.21e-10,12.64,15,25,0,24.0,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.85e-12,18.31,15,87,0,17.59,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),2.86e-12,13.3,15,33,0,21.82,9.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.85e-12,16.04,15,41,0,20.49,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),2.94e-12,16.21,15,21,0,25.71,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5.28e-11,13.87,15,21,0,25.71,9.0
Endothelial dysfunction (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.85e-12,14.82,15,1021,0,15.22,11.0
Tonsillectomy (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,12.64,16,16,0,32.0,4.0
Tonsillectomy (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),5.27e-13,22.85,16,26,0,25.85,4.0
Screening procedure (hlca),TREATS,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),8.63e-12,15.0,13,62,0,15.73,4.0
Screening procedure (hlca),TREATS,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),8.64e-12,25.59,13,17,0,22.94,4.0
Screening procedure (hlca),TREATS,Dyslipidemias (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.03e-11,17.29,13,19,0,21.89,4.0
Procedures (hlca),AFFECTS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.07e-06,38.16,7,12,0,11.08,1.0
Procedures (hlca),AFFECTS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.61e-08,35.53,7,24,0,9.04,5.0
Dual-Energy X-Ray Absorptiometry (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.16e-09,32.28,28,18,0,29.57,6.0
arterial stiffness (phsf),PROCESS_OF,CAROTID (bpoc),LOCATION_OF,Ultrasonography (diap),6.97e-07,10.55,19,68,0,24.31,1.0
arterial stiffness (phsf),PROCESS_OF,CAROTID (bpoc),LOCATION_OF,Restenosis (acab),3.24e-10,12.06,19,30,0,31.03,1.0
Cerebrovascular accident (dsyn),PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),1.45e-06,9.38,9,136,0,9.6,1.0
Cerebrovascular accident (dsyn),PROCESS_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),1.45e-06,8.52,9,188,0,9.43,1.0
Cerebrovascular accident (dsyn),PROCESS_OF,Caucasoid Race (popg),ISA,Population Group (humn),3.99e-06,9.4,9,20,0,13.05,1.0
Birth (orgf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,9.39,790,20,0,20.51,1.0
Birth (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,6.57,790,65,0,70.35,1.0
Birth (orgf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,8.9,790,16,0,16.32,1.0
Birth (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,9.15,790,13,0,13.21,1.0
Birth (orgf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,10.13,790,16,0,16.32,1.0
Birth (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,15.54,790,8,0,8.08,1.0
Birth (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,9.02,790,23,0,23.67,1.0
Birth (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,9.91,790,22,0,22.61,1.0
Birth (orgf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,9.84,790,13,0,13.21,1.0
Birth (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,11.84,790,15,0,15.28,1.0
LDL Cholesterol Lipoproteins (bacs),ISA,Cholesterol (bacs),PART_OF,Membrane (celc),6.5e-15,8.47,22,5,0,6.14,3.0
Intervention regimes (hlca),USES,Losartan (orch),compared_with,Atenolol (orch),2.21e-18,12.24,24,44,0,37.09,6.0
Intervention regimes (hlca),USES,Losartan (orch),compared_with,Captopril (aapp),2.12e-10,13.54,24,18,0,31.5,6.0
Total mesorectal excision (topp),TREATS,Cancer of Rectum (neop),PROCESS_OF,cohort (humn),3.24e-08,8.26,38,15,0,20.92,1.0
Ultrasound examination (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.24e-06,17.42,7,18,0,9.72,6.0
Scanning (diap),METHOD_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),3.31e-08,65.2,7,13,0,10.77,16.0
Scanning (diap),METHOD_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),3.29e-08,68.13,7,11,0,11.45,7.0
Scanning (diap),METHOD_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),6.8e-10,69.33,7,13,0,10.77,16.0
Scanning (diap),METHOD_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),3.38e-10,64.62,7,27,0,8.81,5.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.67e-06,14.82,7,25,0,8.96,21.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.67e-06,18.72,7,15,0,10.27,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),2.67e-06,24.1,7,24,0,9.04,11.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),2.67e-06,14.74,7,46,0,8.07,11.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Atherosclerosis (dsyn),PROCESS_OF,General Population (humn),2.67e-06,14.3,7,24,0,9.04,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),2.67e-06,16.15,7,18,0,9.72,11.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),2.67e-06,12.88,7,73,0,7.67,5.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),2.76e-06,13.47,7,24,0,9.04,11.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",2.67e-06,14.79,7,41,0,8.2,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),2.67e-06,15.57,7,19,0,9.58,11.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.67e-06,16.45,7,26,0,8.88,9.0
Metabolic syndrome (dsyn),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),2.89e-19,28.66,22,25,0,41.36,1.0
Metabolic syndrome (dsyn),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),5.88e-09,26.46,22,13,0,20.68,1.0
Metabolic syndrome (dsyn),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),1.04e-23,30.92,22,32,0,37.12,1.0
tomography (diap),DIAGNOSES,Well adult (fndg),PROCESS_OF,Voluntary Workers (humn),2.1e-09,40.75,7,15,0,10.27,1.0
Cholesterol levels raised (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),8.4e-08,25.15,7,18,0,9.72,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.23e-08,11.29,11,25,0,15.84,21.0
Endothelial dysfunction (dsyn),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),3.26e-08,15.2,11,15,0,19.07,9.0
Endothelial dysfunction (dsyn),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),3.23e-08,20.58,11,24,0,16.04,11.0
Endothelial dysfunction (dsyn),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),3.23e-08,11.21,11,46,0,13.63,11.0
Endothelial dysfunction (dsyn),PREDISPOSES,Atherosclerosis (dsyn),PROCESS_OF,General Population (humn),3.3e-08,10.78,11,24,0,16.04,1.0
Endothelial dysfunction (dsyn),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),3.28e-08,12.62,11,18,0,17.72,11.0
Endothelial dysfunction (dsyn),PREDISPOSES,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),3.23e-08,9.35,11,73,0,12.66,5.0
Endothelial dysfunction (dsyn),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),1.26e-07,9.95,11,24,0,16.04,11.0
Endothelial dysfunction (dsyn),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",3.23e-08,11.26,11,41,0,13.95,9.0
Endothelial dysfunction (dsyn),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),3.31e-08,12.04,11,19,0,17.37,11.0
Endothelial dysfunction (dsyn),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.23e-08,12.92,11,26,0,15.65,9.0
Atherosclerosis (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,17.8,21,20,0,39.05,1.0
Atherosclerosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,14.99,21,65,0,27.78,1.0
Atherosclerosis (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,17.31,21,16,0,28.19,1.0
Atherosclerosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,17.56,21,13,0,21.05,1.0
Atherosclerosis (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,18.55,21,16,0,28.19,1.0
Atherosclerosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,23.95,21,8,0,11.05,1.0
Atherosclerosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,17.43,21,23,0,40.17,1.0
Atherosclerosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,18.32,21,22,0,41.05,1.0
Atherosclerosis (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,18.25,21,13,0,21.05,1.0
Atherosclerosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,20.25,21,15,0,25.71,1.0
Fitness (dora),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular morbidity (dsyn),3.01e-06,25.37,6,23,0,7.57,4.0
Fitness (dora),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cerebrovascular accident (dsyn),3.24e-06,19.41,6,18,0,8.0,4.0
Fitness (dora),TREATS,Systemic arterial pressure (fndg),PROCESS_OF,General Population (humn),4.37e-06,18.06,6,27,0,7.33,1.0
Fitness (dora),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),3.01e-06,19.04,6,32,0,7.12,4.0
Fitness (dora),TREATS,Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),3.01e-06,18.47,6,39,0,6.92,1.0
Fitness (dora),TREATS,Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),3.73e-06,17.61,6,41,0,6.88,1.0
Fitness (dora),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular event (fndg),3.01e-06,19.35,6,27,0,7.33,4.0
Echocardiography (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.16e-09,14.49,22,18,0,32.73,6.0
Age (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,31.08,38,33,0,61.66,1.0
Age (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,31.62,38,16,0,22.74,8.0
Age (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.33e-25,31.42,38,71,0,58.34,5.0
Age (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.96e-32,45.27,38,35,0,67.24,8.0
Age (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.09e-38,31.35,38,110,0,51.13,8.0
Age (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,30.69,38,37,0,73.03,1.0
Mid upper arm circumference (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Critically ill children (podg),7.49e-06,85.75,4,8,0,6.0,1.0
Mid upper arm circumference (fndg),PREDISPOSES,Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.02e-06,81.6,4,15,0,5.07,9.0
Mid upper arm circumference (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),4.02e-06,80.3,4,18,0,4.89,1.0
Mid upper arm circumference (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),4.02e-06,79.21,4,61,0,4.26,1.0
Mid upper arm circumference (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Surgical Patients (podg),4.02e-06,79.25,4,24,0,4.67,1.0
Mid upper arm circumference (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Cancer Patient (podg),4.03e-06,77.7,4,30,0,4.53,1.0
Mid upper arm circumference (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,inpatient (humn),4.02e-06,79.14,4,28,0,4.57,1.0
Mid upper arm circumference (fndg),PREDISPOSES,Malnutrition (dsyn),CAUSES,Cessation of life (orgf),4.02e-06,81.06,4,28,0,4.57,11.0
Mid upper arm circumference (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,cohort (humn),4.02e-06,82.32,4,16,0,5.0,1.0
Eating Disorders (mobd),PROCESS_OF,student (prog),USES,Grade (clas),5.8e-12,12.16,13,7,0,10.77,1.0
Slinging procedure (topp),TREATS,"Urinary Incontinence, Stress (dsyn)",PROCESS_OF,Urodynamics (ortf),2.43e-06,2.39,19,1,0,1.05,1.0
Adipose tissue (tisu),LOCATION_OF,"TNF protein, human|TNF (aapp)",PART_OF,Recombinants (orgm),5.58e-10,6.1,16,2,0,2.25,2.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,Participant (humn),3.4e-10,8.71,14,84,0,16.33,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PRECEDES,Hyperglycemia (dsyn),3.52e-07,15.76,14,10,0,17.14,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),CAUSES,Atrial Fibrillation (patf),2.27e-08,20.05,14,10,0,17.14,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,Human Age Group (aggp),2.41e-09,11.82,14,18,0,24.89,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,Population Group (humn),3.41e-06,12.4,14,11,0,19.64,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),ISA,Vascular Diseases (dsyn),3.4e-10,10.73,14,38,0,19.16,5.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),CAUSES,Cessation of life (orgf),3.4e-10,11.39,14,449,0,14.44,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,Black race (popg),3.47e-10,11.42,14,24,0,22.17,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),3.4e-10,13.92,14,34,0,19.76,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,Neurologist (humn),5.26e-10,9.78,14,31,0,20.32,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),3.4e-10,11.75,14,140,0,15.4,5.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),1.46e-09,11.63,14,19,0,24.32,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,Survivors (humn),3.4e-10,8.14,14,330,0,14.59,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.22e-07,13.79,14,11,0,19.64,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PRECEDES,Deglutition Disorders (dsyn),6.17e-07,9.59,14,22,0,22.91,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PRECEDES,Depressive disorder (mobd),2.09e-09,9.01,14,41,0,18.78,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),COEXISTS_WITH,Myocardial Infarction (dsyn),2.54e-08,13.88,14,13,0,25.07,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,Young adult (aggp),6.18e-10,8.91,14,48,0,18.08,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,inpatient (humn),4.69e-06,8.95,14,27,0,21.26,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,VICTIM (humn),2.49e-07,8.77,14,38,0,19.16,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),OCCURS_IN,cohort (humn),9.84e-10,13.45,14,16,0,26.25,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),CAUSES,Disability NOS (patf),3.4e-10,9.85,14,163,0,15.2,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,General Population (humn),3.4e-10,10.84,14,44,0,18.45,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),AFFECTS,Systemic arterial pressure (fndg),3.42e-10,11.02,14,27,0,21.26,7.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PREDISPOSES,Heart failure (dsyn),3.51e-10,19.79,14,14,0,28.0,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,Octogenarians (aggp),3.41e-10,20.05,14,15,0,27.07,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,Control Groups (humn),1.24e-06,9.86,14,19,0,24.32,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PRECEDES,Disability NOS (patf),3.4e-10,10.32,14,47,0,18.17,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),AFFECTS,Cessation of life (orgf),4.46e-07,12.87,14,12,0,22.29,7.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),CAUSES,Hospitalization (hlca),3.4e-10,15.83,14,24,0,22.17,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),COEXISTS_WITH,Diabetic (fndg),3.57e-10,11.5,14,23,0,22.52,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PRECEDES,Pneumonia (dsyn),6.95e-07,12.59,14,12,0,22.29,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,Ethnic group (popg),3.08e-09,12.73,14,16,0,26.25,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),3.4e-10,11.4,14,155,0,15.26,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,Teams (humn),3.4e-10,9.82,14,42,0,18.67,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.06e-09,11.36,14,19,0,24.32,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),ISA,Thrombosis (patf),4.13e-10,11.74,14,21,0,23.33,5.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),ISA,Cerebrovascular Disorders (patf),3.4e-10,10.33,14,41,0,18.78,5.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,Hospitalized Patients (humn),3.4e-10,11.71,14,64,0,17.06,1.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),3.4e-10,11.07,14,129,0,15.52,9.0
racial differences (fndg),COEXISTS_WITH,Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),3.4e-10,11.5,14,39,0,19.03,1.0
One (qnco),ISA,Measurement (ftcn),ISA,Techniques (ftcn),1.14e-09,1.71,51,116,0,73.42,5.0
One (qnco),ISA,Measurement (ftcn),ISA,Health (idcn),1.14e-09,3.47,51,94,0,78.67,5.0
Moderate Exercise (dora),ISA,Exercise (dora),TREATS,Heart failure (dsyn),2.1e-06,13.68,7,39,0,8.26,4.0
Moderate Exercise (dora),ISA,Exercise (dora),TREATS,Coronary heart disease (dsyn),2.12e-06,14.36,7,23,0,9.13,4.0
Physical activity (dora),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,21.63,13,33,0,18.12,1.0
Physical activity (dora),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,22.18,13,16,0,23.56,9.0
Physical activity (dora),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.66e-14,21.98,13,71,0,15.38,5.0
Physical activity (dora),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.66e-14,35.82,13,35,0,17.83,21.0
Physical activity (dora),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.66e-14,21.91,13,110,0,14.54,21.0
Physical activity (dora),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,21.24,13,37,0,17.57,1.0
Body Weight decreased (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,29.58,98,18,0,21.31,1.0
Health center (hcro),LOCATION_OF,Clinical Trials (resa),USES,Stents (medd),4.78e-06,10.8,9,78,0,10.04,2.0
Health center (hcro),LOCATION_OF,Clinical Trials (resa),USES,Probes (medd),4.82e-06,6.03,9,5,0,7.78,2.0
Health center (hcro),LOCATION_OF,Clinical Trials (resa),USES,Metal stent (medd),4.78e-06,13.16,9,34,0,11.38,2.0
Health center (hcro),LOCATION_OF,Clinical Trials (resa),USES,Treatment Protocols (resa),4.78e-06,9.4,9,147,0,9.55,2.0
Health center (hcro),LOCATION_OF,Clinical Trials (resa),USES,Drug eluting stent (medd),4.78e-06,11.61,9,38,0,11.13,2.0
Health center (hcro),LOCATION_OF,Clinical Trials (resa),USES,"Defibrillators, Implantable (medd)",4.78e-06,13.96,9,40,0,11.03,2.0
Health center (hcro),LOCATION_OF,Clinical Trials (resa),USES,"Stents, Vascular, Coronary (medd)",4.79e-06,13.76,9,13,0,15.23,2.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,21.64,16,20,0,28.8,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,18.82,16,65,0,19.94,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,21.15,16,16,0,32.0,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,21.4,16,13,0,23.56,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,22.38,16,16,0,32.0,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,27.79,16,8,0,12.0,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,21.26,16,23,0,27.13,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,22.16,16,22,0,27.64,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,22.09,16,13,0,23.56,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,24.09,16,15,0,29.06,1.0
Oxidative Stress (comd),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),1.2e-07,34.69,6,98,0,6.37,1.0
Oxidative Stress (comd),PROCESS_OF,African American (popg),ISA,Racial group (popg),1.2e-07,35.63,6,324,0,6.11,1.0
Depressive disorder (mobd),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),3.54e-09,7.08,30,18,0,28.8,1.0
Metabolic syndrome (dsyn),OCCURS_IN,cohort (humn),USES,Medicare (rnlw),9.97e-10,30.12,21,20,0,39.05,6.0
Metabolic syndrome (dsyn),OCCURS_IN,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,27.31,21,65,0,27.78,2.0
Metabolic syndrome (dsyn),OCCURS_IN,cohort (humn),USES,Treats (clas),3.75e-07,29.63,21,16,0,28.19,6.0
Metabolic syndrome (dsyn),OCCURS_IN,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,29.88,21,13,0,21.05,2.0
Metabolic syndrome (dsyn),OCCURS_IN,cohort (humn),USES,Classification (clas),1.22e-08,30.86,21,16,0,28.19,6.0
Metabolic syndrome (dsyn),OCCURS_IN,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,36.27,21,8,0,11.05,2.0
Metabolic syndrome (dsyn),OCCURS_IN,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,29.75,21,23,0,40.17,2.0
Metabolic syndrome (dsyn),OCCURS_IN,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,30.64,21,22,0,41.05,2.0
Metabolic syndrome (dsyn),OCCURS_IN,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,30.57,21,13,0,21.05,6.0
Metabolic syndrome (dsyn),OCCURS_IN,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,32.57,21,15,0,25.71,2.0
Birth Weight (orga),ISA,Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),1.38e-09,53.86,66,22,0,29.33,5.0
Application procedure (hlca),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),1.43e-06,21.26,6,33,0,7.09,1.0
Application procedure (hlca),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),5.86e-06,21.81,6,16,0,8.25,4.0
Application procedure (hlca),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.43e-06,21.61,6,71,0,6.51,4.0
Application procedure (hlca),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.43e-06,35.45,6,35,0,7.03,4.0
Application procedure (hlca),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.43e-06,21.54,6,110,0,6.33,4.0
Application procedure (hlca),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.43e-06,20.87,6,37,0,6.97,1.0
X-Ray Computed Tomography (diap),METHOD_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),3.89e-07,60.4,5,13,0,6.92,16.0
X-Ray Computed Tomography (diap),METHOD_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),3.89e-07,63.33,5,11,0,7.27,7.0
X-Ray Computed Tomography (diap),METHOD_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),3.57e-07,64.54,5,13,0,6.92,16.0
X-Ray Computed Tomography (diap),METHOD_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),3.56e-07,59.83,5,27,0,5.93,5.0
insulin sensitivity (patf),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.16e-08,25.18,8,16,0,12.0,7.0
insulin sensitivity (patf),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.45e-07,30.35,8,9,0,15.11,7.0
insulin sensitivity (patf),AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.23e-07,22.74,8,31,0,10.06,7.0
GLUCOSE TOLERANCE (phsf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,27.37,40,18,0,26.1,1.0
"Diabetes, Gestational (dsyn)",PROCESS_OF,Hispanics (humn),ISA,Ethnic group (popg),1.46e-08,29.87,7,226,0,7.22,1.0
Waist circumference (fndg),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.81e-10,48.94,9,23,0,12.52,9.0
Waist circumference (fndg),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),2.08e-12,48.39,9,57,0,10.42,9.0
Waist circumference (fndg),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,56.85,9,9,0,18.0,9.0
Gastric Bypass (topp),ISA,Bariatric Surgery (topp),TREATS,"Obesity, Morbid (dsyn)",1.89e-26,29.13,21,93,1,25.74,4.0
Gastric Bypass (topp),ISA,Bariatric Surgery (topp),TREATS,Body Weight decreased (fndg),2e-16,29.06,22,47,0,32.3,4.0
Hip Fractures (inpo),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),3.19e-07,13.44,9,18,0,13.5,1.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.2e-14,68.04,17,22,0,30.14,9.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.23e-10,67.47,17,17,0,34.0,1.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.29e-08,63.54,17,27,0,27.7,1.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.38e-08,66.49,17,15,0,28.24,1.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.37e-10,64.69,17,24,0,29.04,9.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),8.91e-14,64.31,17,34,0,25.5,1.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),5.21e-21,65.74,17,40,0,24.22,1.0
Waist circumference (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.22e-09,72.47,17,12,0,20.47,9.0
Low Birth Weights (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),4.13e-06,29.35,5,33,0,5.76,1.0
Low Birth Weights (fndg),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),8.56e-06,29.89,5,16,0,6.56,9.0
Low Birth Weights (fndg),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),4.13e-06,29.69,5,71,0,5.35,5.0
Low Birth Weights (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.13e-06,43.54,5,35,0,5.71,21.0
Low Birth Weights (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.13e-06,29.62,5,110,0,5.23,21.0
Low Birth Weights (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),4.13e-06,28.96,5,37,0,5.68,1.0
Lower Extremity (blor),LOCATION_OF,Ankle brachial index (diap),DIAGNOSES,Peripheral Vascular Diseases (dsyn),6.21e-07,9.07,10,42,0,12.38,2.0
"Fatty Acids, Nonesterified (lipd)",ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.62e-08,12.9,13,16,0,23.56,8.0
"Fatty Acids, Nonesterified (lipd)",ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,18.06,13,9,0,15.23,8.0
"Fatty Acids, Nonesterified (lipd)",ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.18e-07,10.45,13,31,0,18.45,8.0
Kidney Calculi (patf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),4.82e-07,28.67,6,18,0,8.0,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.66e-06,12.22,15,9,0,14.4,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),6.73e-08,11.28,15,194,0,16.16,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),6.77e-08,10.0,15,17,0,28.24,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),6.73e-08,11.27,15,29,0,22.76,11.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),6.75e-08,13.45,15,14,0,27.07,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.13e-06,9.26,15,12,0,21.6,5.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),6.73e-08,8.08,15,48,0,19.69,11.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),6.73e-08,11.47,15,29,0,22.76,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),6.73e-08,8.52,15,98,0,17.3,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),6.97e-08,7.18,15,24,0,24.38,9.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),2.43e-07,13.59,15,10,0,16.67,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),7.95e-08,5.95,15,37,0,21.08,7.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),7.41e-08,7.75,15,20,0,26.25,9.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),6.73e-08,9.41,15,94,0,17.39,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.41e-06,15.2,15,8,0,12.27,9.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),6.73e-08,12.07,15,19,0,26.84,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),6.73e-08,9.23,15,21,0,25.71,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),7.01e-08,14.41,15,12,0,21.6,9.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),7e-08,22.12,15,10,0,16.67,21.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),1.49e-07,14.71,15,10,0,16.67,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),6.73e-08,9.03,15,21,0,25.71,21.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),6.73e-08,10.64,15,21,0,25.71,9.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),6.73e-08,8.76,15,32,0,22.03,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),1.03e-07,16.12,15,10,0,16.67,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),6.73e-08,15.09,15,39,0,20.77,9.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),6.73e-08,19.07,15,44,0,20.11,11.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.73e-08,11.94,15,113,0,16.99,9.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.82e-06,9.47,15,11,0,19.07,11.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.24e-06,9.2,15,11,0,19.07,9.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),6.27e-07,9.66,15,12,0,21.6,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),6.74e-08,7.55,15,25,0,24.0,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",6.73e-08,13.23,15,87,0,17.59,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.73e-08,8.21,15,33,0,21.82,9.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),6.73e-08,10.95,15,41,0,20.49,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),6.73e-08,11.12,15,21,0,25.71,1.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",6.74e-08,8.79,15,21,0,25.71,9.0
Hyperhomocysteinemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),6.73e-08,9.73,15,1021,0,15.22,11.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,18.71,17,9,0,13.76,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),8.55e-15,17.76,17,194,0,18.49,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,16.49,17,17,0,34.0,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),8.55e-15,17.76,17,29,0,26.97,11.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,19.94,17,14,0,25.53,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,15.75,17,12,0,20.47,5.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),8.55e-15,14.57,17,48,0,23.02,11.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),8.55e-15,17.96,17,29,0,26.97,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),8.55e-15,15.0,17,98,0,19.95,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,13.67,17,24,0,29.04,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,20.08,17,10,0,15.88,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,12.44,17,37,0,24.81,7.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,14.24,17,20,0,31.45,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),8.55e-15,15.89,17,94,0,20.07,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,21.68,17,8,0,11.76,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.22e-13,18.56,17,19,0,32.21,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,15.71,17,21,0,30.76,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,20.89,17,12,0,20.47,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,28.61,17,10,0,15.88,21.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,21.2,17,10,0,15.88,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,15.51,17,21,0,30.76,21.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.78e-13,17.12,17,21,0,30.76,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),8.64e-15,15.25,17,32,0,26.03,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,22.61,17,10,0,15.88,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),8.55e-15,21.58,17,39,0,24.41,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),8.55e-15,25.55,17,44,0,23.57,11.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",8.55e-15,18.43,17,113,0,19.56,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,15.96,17,11,0,18.12,11.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,15.68,17,11,0,18.12,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,16.14,17,12,0,20.47,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,14.04,17,25,0,28.56,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",8.55e-15,19.71,17,87,0,20.32,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),9.16e-15,14.7,17,33,0,25.76,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),8.55e-15,17.44,17,41,0,24.05,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),9.73e-14,17.61,17,21,0,30.76,1.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,15.27,17,21,0,30.76,9.0
Triglycerides (bacs),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),8.55e-15,16.22,17,1021,0,17.28,11.0
Exercise (dora),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,21.1,37,12,0,15.89,1.0
Exercise (dora),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,18.47,37,24,0,39.57,4.0
Well adult (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),3.38e-08,20.03,8,20,0,11.2,1.0
Well adult (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.54e-08,17.21,8,65,0,8.98,1.0
Well adult (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),4.08e-07,19.53,8,16,0,12.0,1.0
Well adult (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.13e-06,19.79,8,13,0,12.92,1.0
Well adult (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),4.51e-08,20.77,8,16,0,12.0,1.0
Well adult (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.5e-06,26.18,8,8,0,16.0,1.0
Well adult (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),3.3e-08,19.65,8,23,0,10.78,1.0
Well adult (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),3.28e-08,20.55,8,22,0,10.91,1.0
Well adult (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),9.17e-07,20.48,8,13,0,12.92,1.0
Well adult (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),3.44e-08,22.48,8,15,0,12.27,1.0
Central obesity (acab),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,37.57,11,16,0,18.56,9.0
Central obesity (acab),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,42.74,11,9,0,16.36,9.0
Central obesity (acab),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,35.12,11,31,0,14.9,9.0
C-reactive protein (aapp),PREDISPOSES,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.95e-11,16.9,13,25,0,19.76,21.0
C-reactive protein (aapp),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.77e-10,20.8,13,15,0,24.27,9.0
C-reactive protein (aapp),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),2.47e-12,26.18,13,24,0,20.04,11.0
C-reactive protein (aapp),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),2.47e-12,16.81,13,46,0,16.67,11.0
C-reactive protein (aapp),PREDISPOSES,Atherosclerosis (dsyn),PROCESS_OF,General Population (humn),6.46e-10,16.38,13,24,0,20.04,1.0
C-reactive protein (aapp),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),5.12e-10,18.23,13,18,0,22.39,11.0
C-reactive protein (aapp),PREDISPOSES,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),2.47e-12,14.96,13,73,0,15.32,5.0
C-reactive protein (aapp),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),9.39e-08,15.55,13,24,0,20.04,11.0
C-reactive protein (aapp),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",2.47e-12,16.87,13,41,0,17.12,9.0
C-reactive protein (aapp),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),7.77e-10,17.64,13,19,0,21.89,11.0
C-reactive protein (aapp),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.47e-12,18.52,13,26,0,19.5,9.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,American (popg),1.72e-11,59.1,13,17,0,22.94,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),AFFECTS,Depressed mood (fndg),1.53e-06,63.64,13,8,0,12.92,7.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Octogenarians (aggp),1.88e-06,60.16,13,9,0,15.23,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),CAUSES,Myocardial Infarction (dsyn),4.26e-09,59.71,13,13,0,26.0,11.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),CAUSES,follow-up (hlca),1.7e-07,57.99,13,12,0,23.08,11.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),CAUSES,"Death, Sudden (patf)",4.01e-14,60.88,13,19,0,21.89,11.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),CAUSES,Cessation of life (orgf),1.73e-18,57.75,13,251,0,13.67,11.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,High Risk Populations (popg),1.21e-07,61.64,13,10,0,17.69,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),1.82e-18,59.77,13,28,0,19.04,21.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,General Population (humn),1.73e-18,60.31,13,67,0,15.52,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Hospital specialist (humn),1.97e-10,56.25,13,20,0,21.45,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,General Population (humn),1.51e-13,61.17,13,18,0,22.39,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.34e-06,60.64,13,9,0,15.23,9.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,African American (popg),1.73e-18,57.36,13,49,0,16.45,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.74e-08,58.84,13,12,0,23.08,9.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Human Age Group (aggp),4.63e-08,60.64,13,11,0,20.31,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),1.73e-18,58.93,13,32,0,18.28,9.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Caucasoid Race (popg),3.09e-16,59.09,13,24,0,20.04,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),CAUSES,Cardiac Death (patf),5.29e-18,61.24,13,24,0,20.04,11.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,inpatient (humn),1.73e-18,57.58,13,37,0,17.57,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Physical findings (sosy),4.17e-06,56.71,13,11,0,20.31,9.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Veterans (popg),5.48e-09,57.51,13,15,0,24.27,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),1.73e-18,56.83,13,154,0,14.1,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),AFFECTS,Pathogenesis (patf),1.3e-07,54.44,13,21,0,21.05,7.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Participant (humn),1.73e-18,56.69,13,84,0,15.01,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),CAUSES,Hospital Readmissions (hlca),6.72e-12,64.9,13,14,0,25.07,11.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.73e-18,59.14,13,256,0,13.66,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),ISA,Cardiovascular Diseases (dsyn),1.73e-18,56.39,13,106,0,14.59,5.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),2.29e-07,58.97,13,11,0,20.31,21.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),CAUSES,Hospitalization (hlca),1.73e-18,60.46,13,249,0,13.68,11.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.73e-18,59.31,13,55,0,16.07,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Survivors (humn),1.73e-18,59.25,13,33,0,18.12,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),CAUSES,"Death, Sudden, Cardiac (patf)",5.1e-10,61.81,13,13,0,26.0,11.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),CAUSES,Diagnosis (hlca),5.45e-08,57.79,13,13,0,26.0,11.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),1.73e-18,58.01,13,34,0,17.97,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Population Group (humn),3.84e-13,61.84,13,17,0,22.94,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Participant (humn),4.59e-15,57.56,13,25,0,19.76,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),ISA,Heart Diseases (dsyn),1.73e-18,56.01,13,42,0,17.02,5.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),COMPLICATES,Acute myocardial infarction (dsyn),1.73e-18,58.57,13,42,0,17.02,21.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Sinus rhythm (fndg),2.01e-18,58.3,13,30,0,18.63,9.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),AFFECTS,Atrial Fibrillation (patf),2.91e-07,63.21,13,9,0,15.23,7.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),CAUSES,Hospital admission (hlca),1.73e-18,60.31,13,40,0,17.23,11.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Western society (popg),1.34e-06,60.64,13,9,0,15.23,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Anemia (dsyn),4.86e-07,59.82,13,10,0,17.69,9.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,cohort (humn),1.73e-18,59.57,12,118,1,13.22,1.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),COMPLICATES,Myocardial Infarction (dsyn),3.96e-12,57.64,13,20,0,21.45,21.0
Body mass index (clna),PREDISPOSES,Heart failure (dsyn),AFFECTS,Systemic arterial pressure (fndg),6.96e-09,57.38,13,15,0,24.27,7.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular event (fndg),PROCESS_OF,"Recipient, Transplant (podg)",6.06e-08,46.74,6,33,0,7.09,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular event (fndg),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.06e-08,44.55,6,28,0,7.29,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular event (fndg),PROCESS_OF,Survivors (humn),6.17e-08,44.48,6,15,0,8.4,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular event (fndg),PROCESS_OF,High Risk Populations (popg),6.06e-08,46.74,6,20,0,7.8,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular event (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),7.97e-08,44.62,6,13,0,8.77,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular event (fndg),PROCESS_OF,cohort (humn),6.06e-08,45.44,6,101,0,6.36,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular event (fndg),PROCESS_OF,General Population (humn),6.06e-08,46.14,6,91,0,6.4,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular event (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),9.59e-08,49.74,6,10,0,9.6,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular event (fndg),PROCESS_OF,Participant (humn),6.06e-08,44.91,6,69,0,6.52,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular event (fndg),COEXISTS_WITH,Acute coronary syndrome (dsyn),3.52e-06,43.94,6,10,0,9.6,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular event (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",7.07e-08,48.74,6,11,0,9.27,9.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular event (fndg),PROCESS_OF,Control Groups (humn),9.59e-08,43.33,6,14,0,8.57,1.0
Waist circumference (fndg),PREDISPOSES,Cardiovascular event (fndg),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),6.12e-08,44.84,6,15,0,8.4,9.0
Physical activity (dora),TREATS,Well adult (fndg),PROCESS_OF,Voluntary Workers (humn),9.1e-11,14.9,19,15,0,26.84,1.0
Insulin Resistance (patf),PROCESS_OF,South Asian (popg),ISA,Ethnic group (popg),4.43e-13,22.42,12,49,0,14.94,1.0
Depressed mood (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),5.07e-07,8.65,14,18,0,24.89,1.0
Metabolic Diseases (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.21e-08,26.63,7,23,0,9.13,9.0
Metabolic Diseases (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),4.19e-08,26.08,7,57,0,7.86,9.0
Metabolic Diseases (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),3.32e-07,34.54,7,9,0,12.44,9.0
Metabolic (ftcn),ISA,Risk (qlco),ISA,Probability (qnco),1.77e-08,28.42,11,42,0,13.88,5.0
Metabolic (ftcn),ISA,Risk (qlco),ISA,contextual factors (ftcn),2.89e-13,28.91,11,104,0,12.16,5.0
Metabolic (ftcn),ISA,Risk (qlco),ISA,Socioeconomic Factors (grpa),3.11e-07,28.91,11,26,0,15.65,5.0
Metabolic (ftcn),ISA,Risk (qlco),ISA,Techniques (ftcn),2.89e-13,28.74,11,143,0,11.85,5.0
Insulin Resistance (patf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,25.8,15,18,0,27.5,1.0
FAVOR (phsu),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular morbidity (dsyn),7.04e-07,23.11,7,23,0,9.13,7.0
FAVOR (phsu),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cerebrovascular accident (dsyn),9.36e-07,17.14,7,18,0,9.72,7.0
FAVOR (phsu),AFFECTS,Systemic arterial pressure (fndg),PROCESS_OF,General Population (humn),2.06e-06,15.79,7,27,0,8.81,1.0
FAVOR (phsu),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),7.04e-07,16.77,7,32,0,8.53,7.0
FAVOR (phsu),AFFECTS,Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),7.04e-07,16.2,7,39,0,8.26,1.0
FAVOR (phsu),AFFECTS,Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),1.42e-06,15.34,7,41,0,8.2,1.0
FAVOR (phsu),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular event (fndg),7.04e-07,17.08,7,27,0,8.81,7.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.55e-09,56.96,7,20,0,9.45,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.09e-09,54.15,7,65,0,7.75,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.76e-07,56.47,7,16,0,10.06,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,56.73,7,13,0,10.77,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.28e-08,57.71,7,16,0,10.06,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,63.11,7,8,0,13.12,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),7.3e-10,56.59,7,23,0,9.13,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),5.68e-10,57.49,7,22,0,9.23,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,57.41,7,13,0,10.77,1.0
Body Fat Distribution (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.1e-09,59.41,7,15,0,10.27,1.0
Management procedure (hlca),TREATS,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.37e-06,13.89,7,62,0,7.79,4.0
Management procedure (hlca),TREATS,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.37e-06,24.48,7,17,0,9.88,4.0
Management procedure (hlca),TREATS,Dyslipidemias (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.37e-06,16.17,7,19,0,9.58,4.0
Application procedure (hlca),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.19e-06,24.01,7,12,0,11.08,1.0
Application procedure (hlca),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),1.95e-07,21.38,7,24,0,9.04,4.0
Systemic arterial pressure (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),1.35e-18,13.47,21,136,0,24.24,1.0
Systemic arterial pressure (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),1.35e-18,12.6,21,188,0,23.35,1.0
Systemic arterial pressure (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Population Group (humn),2.53e-06,13.48,21,20,0,39.05,1.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),1.97e-08,47.42,7,20,0,9.45,1.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Disability NOS (patf),1.34e-09,50.57,7,36,0,8.36,9.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Respiration Disorders (dsyn),1.34e-09,47.2,7,59,0,7.83,5.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Respiratory physiology (ortf),2.19e-08,46.86,7,23,0,9.13,1.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Acute respiratory failure (dsyn),3.55e-07,49.86,7,12,0,11.08,9.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),1.34e-09,47.57,7,72,0,7.68,1.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Lung diseases (dsyn),1.34e-09,47.04,7,73,0,7.67,5.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.34e-09,48.37,7,50,0,7.98,1.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospital admission (hlca),4.69e-09,50.16,7,15,0,10.27,9.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Cessation of life (orgf),1.34e-09,50.09,7,184,0,7.27,9.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Outpatients (podg),2e-08,45.63,7,43,0,8.14,1.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,General Population (humn),1.35e-09,47.6,7,27,0,8.81,1.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Diagnosis (hlca),1.72e-07,51.64,7,11,0,11.45,9.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospitalization (hlca),1.34e-09,49.78,7,31,0,8.58,9.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Participant (humn),1.34e-09,46.93,7,70,0,7.7,1.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),COEXISTS_WITH,Smoker (fndg),2.4e-07,46.11,7,27,0,8.81,9.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Chronic Disease (dsyn),1.34e-09,48.08,7,46,0,8.07,5.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Malignant neoplasm of lung (neop),8.92e-08,47.8,7,17,0,9.88,9.0
Fat-free mass (fndg),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Pneumonia (dsyn),4.47e-07,49.71,7,12,0,11.08,9.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,American (popg),6.4e-09,8.92,50,17,0,22.78,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),AFFECTS,Depressed mood (fndg),1.54e-06,13.46,50,8,0,9.28,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,Octogenarians (aggp),1.88e-06,9.98,50,9,0,10.62,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),CAUSES,Myocardial Infarction (dsyn),1.06e-08,9.52,50,13,0,16.38,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),CAUSES,follow-up (hlca),1.77e-07,7.81,50,12,0,14.88,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),CAUSES,"Death, Sudden (patf)",6.39e-09,10.7,50,19,0,26.22,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),CAUSES,Cessation of life (orgf),6.39e-09,7.57,50,251,0,59.96,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,High Risk Populations (popg),1.28e-07,11.46,50,10,0,12.0,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),6.39e-09,9.58,50,28,0,43.68,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,General Population (humn),6.39e-09,10.13,50,67,0,87.31,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,Hospital specialist (humn),6.58e-09,6.07,50,20,0,28.0,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,General Population (humn),6.39e-09,10.99,50,18,0,24.48,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.34e-06,10.46,50,9,0,10.62,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,African American (popg),6.39e-09,7.18,50,49,0,97.02,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.38e-08,8.65,50,12,0,14.88,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,Human Age Group (aggp),5.26e-08,10.46,50,11,0,13.42,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),6.39e-09,8.75,50,32,0,52.48,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,Caucasoid Race (popg),6.39e-09,8.9,50,24,0,35.52,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),CAUSES,Cardiac Death (patf),6.39e-09,11.06,50,24,0,35.52,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,inpatient (humn),6.39e-09,7.4,50,37,0,64.38,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),COEXISTS_WITH,Physical findings (sosy),4.18e-06,6.53,50,11,0,13.42,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,Veterans (popg),1.19e-08,7.32,50,15,0,19.5,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),6.39e-09,6.65,49,153,1,64.69,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),AFFECTS,Pathogenesis (patf),1.36e-07,4.25,50,21,0,29.82,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,Participant (humn),6.39e-09,6.51,50,84,0,79.76,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),CAUSES,Hospital Readmissions (hlca),6.39e-09,14.72,50,14,0,17.92,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),6.39e-09,8.96,50,256,0,59.77,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),ISA,Cardiovascular Diseases (dsyn),6.39e-09,6.21,49,105,1,71.87,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),2.35e-07,8.79,50,11,0,13.42,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),6.39e-09,9.13,50,55,0,95.45,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,Survivors (humn),6.39e-09,9.07,50,33,0,54.78,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),CAUSES,"Death, Sudden, Cardiac (patf)",6.9e-09,11.63,50,13,0,16.38,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),CAUSES,Diagnosis (hlca),6.09e-08,7.61,50,13,0,16.38,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),6.39e-09,7.83,49,33,1,55.22,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,Population Group (humn),6.39e-09,11.66,50,17,0,22.78,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,Participant (humn),6.39e-09,7.38,50,25,0,37.5,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),ISA,Heart Diseases (dsyn),6.39e-09,5.82,50,42,0,77.28,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),COMPLICATES,Acute myocardial infarction (dsyn),6.39e-09,8.39,50,42,0,77.28,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),COEXISTS_WITH,Sinus rhythm (fndg),6.39e-09,8.12,50,30,0,48.0,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),AFFECTS,Atrial Fibrillation (patf),2.97e-07,13.03,50,9,0,10.62,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),CAUSES,Hospital admission (hlca),6.39e-09,10.13,50,40,0,72.0,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,Western society (popg),1.34e-06,10.46,50,9,0,10.62,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),COEXISTS_WITH,Anemia (dsyn),4.92e-07,9.64,50,10,0,12.0,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),PROCESS_OF,cohort (humn),6.39e-09,9.39,49,118,1,69.35,1.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),COMPLICATES,Myocardial Infarction (dsyn),6.39e-09,7.45,50,20,0,28.0,4.0
Hospitalization (hlca),TREATS,Heart failure (dsyn),AFFECTS,Systemic arterial pressure (fndg),1.33e-08,7.2,49,14,1,18.0,4.0
Weight Gain (fndg),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),2.63e-11,31.57,10,25,0,14.0,1.0
Weight Gain (fndg),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),5.91e-09,29.36,10,13,0,17.69,1.0
Weight Gain (fndg),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),2.63e-11,33.82,10,32,0,13.12,1.0
Bariatric Surgery (topp),TREATS,Participant (humn),USES,Medicare (rnlw),2.89e-07,31.47,6,18,0,8.0,4.0
Cardiopulmonary (blor),LOCATION_OF,Exercise stress test (diap),DIAGNOSES,Heart failure (dsyn),1.82e-08,8.21,227,15,1,15.99,2.0
Cardiopulmonary (blor),LOCATION_OF,Exercise stress test (diap),USES,Treadmill (medd),1.28e-15,4.75,228,119,0,181.11,2.0
Age (orga),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,45.14,27,16,0,25.48,8.0
Age (orga),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.39e-22,55.36,26,25,1,49.04,8.0
Gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Gastric Adenocarcinoma (neop),1.58e-08,26.05,8,64,0,9.0,4.0
Gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Malignant neoplasm of stomach (neop),1.58e-08,22.91,8,578,0,8.11,4.0
Gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Advanced cancer (neop),1.58e-08,25.61,8,24,0,10.67,4.0
Gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Adenocarcinoma (neop),1.58e-08,24.11,8,30,0,10.13,4.0
Gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,"Obesity, Morbid (dsyn)",1.58e-08,21.79,7,79,1,7.62,4.0
Gastric banding (topp),PRECEDES,Gastrectomy (topp),USES,Sleeves (medd),1.58e-08,18.86,3,528,5,3.02,6.0
Gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Body Weight decreased (fndg),1.58e-08,22.08,8,30,0,10.13,4.0
Gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Stomach Carcinoma (neop),1.58e-08,22.8,8,49,0,9.31,4.0
Gastric banding (topp),PRECEDES,Gastrectomy (topp),ADMINISTERED_TO,Surgeon (humn),1.78e-08,25.17,7,13,1,10.77,15.0
Gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Malignant neoplasm of stomach stage III (neop),2.09e-06,24.43,8,10,0,14.4,4.0
Gastric banding (topp),PRECEDES,Gastrectomy (topp),TREATS,Early gastric cancer (neop),1.58e-08,21.35,8,71,0,8.9,4.0
resistin|RETN (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),4.82e-07,26.23,6,33,0,7.09,1.0
resistin|RETN (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.91e-06,26.77,6,16,0,8.25,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),4.81e-07,26.57,6,71,0,6.51,5.0
resistin|RETN (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.81e-07,40.42,6,35,0,7.03,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.81e-07,26.5,6,110,0,6.33,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),4.83e-07,25.84,6,37,0,6.97,1.0
Myocardial Infarction (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.18e-07,30.69,6,33,0,7.09,1.0
Myocardial Infarction (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.65e-06,31.24,6,16,0,8.25,9.0
Myocardial Infarction (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),2.18e-07,31.04,6,71,0,6.51,5.0
Myocardial Infarction (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.18e-07,44.89,6,35,0,7.03,9.0
Myocardial Infarction (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.18e-07,30.97,6,110,0,6.33,9.0
Myocardial Infarction (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),2.19e-07,30.31,6,37,0,6.97,1.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),7.89e-07,30.19,6,16,0,8.25,9.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),2.88e-07,40.4,6,26,0,7.38,9.0
Systolic blood pressure (ortf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,19.61,54,18,0,24.0,1.0
Sex Characteristics (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.4e-10,24.5,10,22,0,14.55,8.0
Sex Characteristics (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),2.62e-10,23.93,10,17,0,15.88,1.0
Sex Characteristics (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.3e-08,19.99,10,27,0,13.7,1.0
Sex Characteristics (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.39e-08,22.95,10,15,0,16.67,1.0
Sex Characteristics (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),2.76e-10,21.15,10,24,0,14.17,8.0
Sex Characteristics (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.4e-10,20.77,10,34,0,12.94,1.0
Sex Characteristics (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),1.39e-10,22.2,10,40,0,12.5,1.0
Sex Characteristics (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.36e-09,28.92,10,12,0,18.33,8.0
Testosterone (phsu),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,25.33,10,16,0,16.25,8.0
Testosterone (phsu),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,30.5,10,9,0,17.1,8.0
Testosterone (phsu),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,22.88,10,31,0,13.23,8.0
Walking (dora),ISA,Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),1.72e-08,12.9,41,18,0,25.9,4.0
Walking (dora),ISA,Physical activity (dora),TREATS,Survivors (humn),4.06e-12,11.54,41,36,0,67.61,4.0
Walking (dora),ISA,Physical activity (dora),TREATS,General Population (humn),4.11e-11,13.04,41,23,0,35.9,4.0
Walking (dora),ISA,Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),1.66e-07,10.83,41,31,0,54.44,4.0
Walking (dora),ISA,Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),6.41e-10,13.57,41,19,0,27.8,5.0
Walking (dora),ISA,Physical activity (dora),TREATS,"Kidney Failure, Chronic (dsyn)",6.74e-07,15.33,41,11,0,13.95,4.0
Blood glucose normal (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.02e-07,16.91,8,18,0,11.56,1.0
Participant (humn),LOCATION_OF,Interleukin-6 (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),1.07e-06,19.82,8,10,0,14.4,2.0
Participant (humn),LOCATION_OF,Interleukin-6 (aapp),ASSOCIATED_WITH,Septicemia (dsyn),3.68e-06,15.58,8,15,0,12.27,2.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.6e-06,18.3,10,9,0,17.1,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.27e-08,17.36,10,194,0,10.52,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),1.31e-08,16.09,10,17,0,15.88,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.27e-08,17.35,10,29,0,13.45,11.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.29e-08,19.54,10,14,0,17.14,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.08e-06,15.34,10,12,0,18.33,5.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.27e-08,14.16,10,48,0,12.08,11.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.27e-08,17.55,10,29,0,13.45,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.27e-08,14.6,10,98,0,11.02,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),1.51e-08,13.26,10,24,0,14.17,9.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.89e-07,19.68,10,10,0,20.0,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),2.49e-08,12.03,10,37,0,12.7,7.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.95e-08,13.84,10,20,0,15.0,9.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.27e-08,15.49,10,94,0,11.06,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.36e-06,21.28,10,8,0,14.4,9.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),1.27e-08,18.15,10,19,0,15.26,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.28e-08,15.31,10,21,0,14.76,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),1.55e-08,20.49,10,12,0,18.33,9.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.54e-08,28.21,10,10,0,20.0,21.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),9.45e-08,20.79,10,10,0,20.0,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.28e-08,15.11,10,21,0,14.76,21.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.27e-08,16.72,10,21,0,14.76,9.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.27e-08,14.85,10,32,0,13.12,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),4.8e-08,22.2,10,10,0,20.0,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.27e-08,21.17,10,39,0,12.56,9.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.27e-08,25.15,10,44,0,12.27,11.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.27e-08,18.03,10,113,0,10.88,9.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.76e-06,15.55,10,11,0,19.09,11.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.19e-06,15.28,10,11,0,19.09,9.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.72e-07,15.74,10,12,0,18.33,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.29e-08,13.63,10,25,0,14.0,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.27e-08,19.31,10,87,0,11.15,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.27e-08,14.3,10,33,0,13.03,9.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.27e-08,17.03,10,41,0,12.44,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.27e-08,17.2,10,21,0,14.76,1.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",1.28e-08,14.87,10,21,0,14.76,9.0
Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.27e-08,15.81,10,1021,0,10.1,11.0
Premature Birth (patf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),3.07e-07,9.99,11,20,0,17.05,1.0
Premature Birth (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.09e-07,7.17,11,65,0,12.86,1.0
Premature Birth (patf),PROCESS_OF,cohort (humn),USES,Treats (clas),6.82e-07,9.49,11,16,0,18.56,1.0
Premature Birth (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.4e-06,9.75,11,13,0,20.31,1.0
Premature Birth (patf),PROCESS_OF,cohort (humn),USES,Classification (clas),3.19e-07,10.73,11,16,0,18.56,1.0
Premature Birth (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.78e-06,16.14,11,8,0,13.82,1.0
Premature Birth (patf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),3.07e-07,9.61,11,23,0,16.26,1.0
Premature Birth (patf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),3.06e-07,10.51,11,22,0,16.5,1.0
Premature Birth (patf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),1.19e-06,10.44,11,13,0,20.31,1.0
Premature Birth (patf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),3.08e-07,12.43,11,15,0,19.07,1.0
"Fibrosis, Liver (dsyn)",PROCESS_OF,cohort (humn),USES,Medicare (rnlw),4.61e-07,12.32,9,20,0,13.05,1.0
"Fibrosis, Liver (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),4.63e-07,9.51,9,65,0,10.25,1.0
"Fibrosis, Liver (dsyn)",PROCESS_OF,cohort (humn),USES,Treats (clas),8.36e-07,11.83,9,16,0,14.06,1.0
"Fibrosis, Liver (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.55e-06,12.08,9,13,0,15.23,1.0
"Fibrosis, Liver (dsyn)",PROCESS_OF,cohort (humn),USES,Classification (clas),4.72e-07,13.07,9,16,0,14.06,1.0
"Fibrosis, Liver (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.93e-06,18.47,9,8,0,15.11,1.0
"Fibrosis, Liver (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),4.6e-07,11.95,9,23,0,12.52,1.0
"Fibrosis, Liver (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),4.6e-07,12.84,9,22,0,12.68,1.0
"Fibrosis, Liver (dsyn)",PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),1.34e-06,12.77,9,13,0,15.23,1.0
"Fibrosis, Liver (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),4.62e-07,14.77,9,15,0,14.4,1.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),7.38e-09,38.08,7,25,0,8.96,1.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,Participant (humn),4.89e-08,36.63,7,50,0,7.98,1.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,cohort (humn),4.2e-09,38.61,7,65,0,7.75,1.0
Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,Population Group (humn),1.11e-06,41.22,7,11,0,11.45,1.0
Metabolic syndrome (dsyn),PROCESS_OF,South Asian (popg),ISA,Ethnic group (popg),6.7e-13,21.63,12,49,0,14.94,1.0
Physical activity (dora),ISA,Behavior (inbe),PROCESS_OF,network (popg),2.21e-06,12.01,115,4,0,4.14,1.0
Feeding behaviors (inbe),PROCESS_OF,student (prog),USES,Grade (clas),3.26e-20,21.61,18,7,0,9.72,1.0
Health education - diet (topp),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),3.18e-07,20.85,7,18,0,9.72,6.0
Vitamin D (phsu),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,33.52,17,16,0,31.06,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,38.69,17,9,0,13.76,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,31.08,17,31,0,26.32,8.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),2.33e-07,5.24,34,78,0,48.82,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),3.27e-07,4.36,34,22,0,36.24,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),2.37e-07,11.47,34,12,0,16.24,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),2.76e-07,5.33,34,18,0,27.53,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (humn),2.33e-07,3.33,33,66,1,49.5,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),2.35e-07,5.31,34,21,0,33.97,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),2.33e-07,4.81,34,35,0,67.03,1.0
Sarcopenia (fndg),PREDISPOSES,Prognosis bad (fndg),COEXISTS_WITH,Anemia (dsyn),5.68e-09,42.86,7,14,0,10.5,9.0
Sarcopenia (fndg),PREDISPOSES,Prognosis bad (fndg),COEXISTS_WITH,Acute myocardial infarction (dsyn),8.99e-07,42.72,7,10,0,11.9,9.0
Sarcopenia (fndg),PREDISPOSES,Prognosis bad (fndg),COEXISTS_WITH,Chronic heart failure (dsyn),3.08e-07,42.29,7,11,0,11.45,9.0
Sarcopenia (fndg),PREDISPOSES,Prognosis bad (fndg),COEXISTS_WITH,"Hypertension, Pulmonary (dsyn)",7.78e-09,42.22,7,14,0,10.5,9.0
Sarcopenia (fndg),PREDISPOSES,Prognosis bad (fndg),PROCESS_OF,cohort (humn),4.2e-09,41.89,7,40,0,8.22,1.0
Sarcopenia (fndg),PREDISPOSES,Prognosis bad (fndg),PROCESS_OF,Cancer Patient (podg),4.2e-09,38.95,7,45,0,8.09,1.0
Sarcopenia (fndg),PREDISPOSES,Prognosis bad (fndg),PROCESS_OF,Hospitalized Patients (humn),4.44e-07,46.02,7,9,0,12.44,1.0
Sarcopenia (fndg),PREDISPOSES,Prognosis bad (fndg),COEXISTS_WITH,Heart failure (dsyn),4.2e-09,43.11,7,39,0,8.26,9.0
Overweight (sosy),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,41.84,262,18,0,19.24,1.0
Diabetes Mellitus (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),1.18e-06,22.08,6,33,0,7.09,1.0
Diabetes Mellitus (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),5.61e-06,22.63,6,16,0,8.25,9.0
Diabetes Mellitus (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.18e-06,22.43,6,71,0,6.51,5.0
Diabetes Mellitus (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.18e-06,36.27,6,35,0,7.03,9.0
Diabetes Mellitus (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.18e-06,22.36,6,110,0,6.33,9.0
Diabetes Mellitus (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.18e-06,21.69,6,37,0,6.97,1.0
orlistat (phsu),CAUSES,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,26.11,10,12,0,18.33,1.0
orlistat (phsu),CAUSES,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,23.48,10,24,0,14.17,5.0
Chronic Kidney Insufficiency (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.56e-08,12.28,11,20,0,17.05,1.0
Chronic Kidney Insufficiency (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.72e-08,9.46,11,65,0,12.86,1.0
Chronic Kidney Insufficiency (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.9e-07,11.79,11,16,0,18.56,1.0
Chronic Kidney Insufficiency (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.11e-06,12.04,11,13,0,20.31,1.0
Chronic Kidney Insufficiency (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),2.69e-08,13.02,11,16,0,18.56,1.0
Chronic Kidney Insufficiency (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.48e-06,18.43,11,8,0,13.82,1.0
Chronic Kidney Insufficiency (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.48e-08,11.9,11,23,0,16.26,1.0
Chronic Kidney Insufficiency (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.47e-08,12.8,11,22,0,16.5,1.0
Chronic Kidney Insufficiency (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.99e-07,12.73,11,13,0,20.31,1.0
Chronic Kidney Insufficiency (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.62e-08,14.73,11,15,0,19.07,1.0
Upper Extremity (bpoc),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),3.29e-08,81.97,7,13,0,10.77,2.0
Upper Extremity (bpoc),LOCATION_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),3.27e-08,84.9,7,11,0,11.45,2.0
Upper Extremity (bpoc),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),4.51e-10,86.1,7,13,0,10.77,2.0
Upper Extremity (bpoc),LOCATION_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),1.09e-10,81.39,7,27,0,8.81,2.0
tomography (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),3.98e-09,21.01,9,18,0,13.5,6.0
Underweight (fndg),PROCESS_OF,student (prog),USES,Grade (clas),7.35e-21,28.99,28,7,0,8.75,1.0
Cardiovascular Diseases (dsyn),PROCESS_OF,South Asian (popg),ISA,Ethnic group (popg),4.08e-08,14.47,9,49,0,10.65,1.0
Magnetic Resonance Imaging (diap),METHOD_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),3.28e-08,76.16,12,13,0,23.08,16.0
Magnetic Resonance Imaging (diap),METHOD_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),3.25e-08,79.09,12,11,0,21.08,7.0
Magnetic Resonance Imaging (diap),METHOD_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),3.42e-10,80.3,12,13,0,23.08,16.0
Magnetic Resonance Imaging (diap),METHOD_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),2.79e-16,75.59,12,27,0,17.33,5.0
Questionnaires (inpr),ISA,Measurement (ftcn),ISA,Techniques (ftcn),1.93e-08,2.23,30,116,0,37.76,5.0
Questionnaires (inpr),ISA,Measurement (ftcn),ISA,Health (idcn),1.93e-08,3.99,30,94,0,39.57,5.0
Total excision of stomach NOS (topp),TREATS,Malignant neoplasm of stomach (neop),PROCESS_OF,cohort (humn),6.25e-13,8.05,32,31,0,61.03,1.0
Total excision of stomach NOS (topp),TREATS,Malignant neoplasm of stomach (neop),ISA,Malignant disease (dsyn),3.28e-08,9.48,32,13,0,18.28,4.0
Supplementation (topp),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.21e-07,16.69,8,16,0,12.0,7.0
Supplementation (topp),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.11e-06,21.85,8,9,0,15.11,7.0
Supplementation (topp),AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),2.92e-07,14.24,8,31,0,10.06,7.0
CA2 (gngm),PART_OF,Protoplasm (celc),LOCATION_OF,Compartments (bsoj),8.75e-27,0.1,2,23,0,2.17,2.0
Leptin|LEP (aapp),TREATS,"Infant, Premature (humn)",LOCATION_OF,"Ductus Arteriosus, Patent (cgab)",2.18e-07,30.91,6,50,0,6.72,2.0
Leptin|LEP (aapp),TREATS,"Infant, Premature (humn)",LOCATION_OF,Nitric Oxide (inch),2.18e-07,32.75,6,23,0,7.57,2.0
Peripheral Vascular Diseases (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),6.13e-09,13.26,11,20,0,17.05,1.0
Peripheral Vascular Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),7.68e-09,10.45,11,65,0,12.86,1.0
Peripheral Vascular Diseases (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.81e-07,12.77,11,16,0,18.56,1.0
Peripheral Vascular Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.1e-06,13.02,11,13,0,20.31,1.0
Peripheral Vascular Diseases (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.74e-08,14.01,11,16,0,18.56,1.0
Peripheral Vascular Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.48e-06,19.41,11,8,0,13.82,1.0
Peripheral Vascular Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),5.31e-09,12.89,11,23,0,16.26,1.0
Peripheral Vascular Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),5.15e-09,13.78,11,22,0,16.5,1.0
Peripheral Vascular Diseases (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.9e-07,13.71,11,13,0,20.31,1.0
Peripheral Vascular Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),6.68e-09,15.71,11,15,0,19.07,1.0
Non-alcoholic fatty liver (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,23.74,20,20,0,40.0,1.0
Non-alcoholic fatty liver (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,20.93,20,65,0,26.15,1.0
Non-alcoholic fatty liver (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,23.25,20,16,0,28.8,1.0
Non-alcoholic fatty liver (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,23.5,20,13,0,21.45,1.0
Non-alcoholic fatty liver (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,24.49,20,16,0,28.8,1.0
Non-alcoholic fatty liver (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,29.89,20,8,0,11.2,1.0
Non-alcoholic fatty liver (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,23.37,20,23,0,37.39,1.0
Non-alcoholic fatty liver (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,24.26,20,22,0,38.18,1.0
Non-alcoholic fatty liver (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,24.19,20,13,0,21.45,1.0
Non-alcoholic fatty liver (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,26.19,20,15,0,26.25,1.0
Urinary Incontinence (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),5.32e-08,15.79,9,18,0,13.5,1.0
homocysteine (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.65e-08,57.19,7,16,0,10.06,8.0
homocysteine (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,62.36,7,9,0,12.44,8.0
homocysteine (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.18e-07,54.74,7,31,0,8.58,8.0
Clomiphene Citrate (phsu),TREATS,Infertility (dsyn),PROCESS_OF,Couples (humn),2.28e-06,6.67,9,16,0,14.06,1.0
Dietary intake (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Survivors (humn),1.11e-08,17.18,17,15,0,28.24,1.0
Dietary intake (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,"Twins, Dizygotic (humn)",4.53e-15,13.65,17,60,0,21.82,1.0
Dietary intake (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Monoamniotic twins (podg),4.11e-12,14.52,17,33,0,25.76,1.0
Dietary intake (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Singleton (humn),2.13e-15,13.17,17,357,0,17.81,1.0
Roux-en-Y Gastric Bypass (topp),ISA,Bariatric Surgery (topp),TREATS,"Obesity, Morbid (dsyn)",1.86e-25,22.96,21,92,2,25.79,4.0
Roux-en-Y Gastric Bypass (topp),ISA,Bariatric Surgery (topp),TREATS,Body Weight decreased (fndg),2e-16,22.89,23,47,0,34.26,4.0
Common carotid artery (bpoc),LOCATION_OF,Ultrasonography (diap),DIAGNOSES,"Aortic Aneurysm, Abdominal (dsyn)",2.14e-11,18.39,12,23,0,18.26,2.0
Common carotid artery (bpoc),LOCATION_OF,Ultrasonography (diap),ISA,Medical Imaging (diap),2.76e-06,14.13,12,25,0,17.76,2.0
Common carotid artery (bpoc),LOCATION_OF,Ultrasonography (diap),METHOD_OF,Early Diagnosis (diap),4.43e-06,15.56,12,30,0,16.8,2.0
"Stenosis, unspecified (patf)",PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.52e-06,21.61,6,18,0,8.0,1.0
Abdomen (blor),LOCATION_OF,Ultrasonography (diap),DIAGNOSES,"Aortic Aneurysm, Abdominal (dsyn)",9.95e-12,6.53,171,23,0,26.09,2.0
Abdomen (blor),LOCATION_OF,Ultrasonography (diap),ISA,Medical Imaging (diap),2.76e-06,2.27,171,25,0,28.65,2.0
Abdomen (blor),LOCATION_OF,Ultrasonography (diap),METHOD_OF,Early Diagnosis (diap),4.43e-06,3.71,171,30,0,35.26,2.0
Assessment procedure (hlca),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,18.21,20,16,0,28.8,4.0
Assessment procedure (hlca),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),8.89e-20,28.42,20,26,0,35.38,4.0
Knee (blor),LOCATION_OF,Misalignment (anab),PART_OF,Dysplasia (neop),4.08e-06,13.53,22,12,0,18.55,2.0
olanzapine (orch),TREATS,Schizophrenia (mobd),PROCESS_OF,Outpatients (podg),3.74e-06,6.3,9,12,0,15.75,1.0
Spirometry (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.38e-07,11.22,11,18,0,17.72,6.0
Leptin (aapp),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.19e-06,33.39,5,16,0,6.56,9.0
Leptin (aapp),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),4.08e-06,38.56,5,9,0,7.78,9.0
Leptin (aapp),PREDISPOSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),3.26e-06,30.94,5,31,0,5.81,21.0
Body mass index procedure (diap),DIAGNOSES,Hypertensive (fndg),PROCESS_OF,Participant (humn),1.5e-13,49.78,19,53,0,25.81,1.0
Polycystic Ovary Syndrome (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,29.3,29,20,0,33.79,1.0
Polycystic Ovary Syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,26.48,29,65,0,41.94,1.0
Polycystic Ovary Syndrome (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,28.8,29,16,0,24.83,1.0
Polycystic Ovary Syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,29.06,29,13,0,18.83,1.0
Polycystic Ovary Syndrome (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,30.04,29,16,0,24.83,1.0
Polycystic Ovary Syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,35.45,29,8,0,10.21,1.0
Polycystic Ovary Syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,28.92,29,23,0,41.24,1.0
Polycystic Ovary Syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,29.82,29,22,0,38.69,1.0
Polycystic Ovary Syndrome (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,29.75,29,13,0,18.83,1.0
Polycystic Ovary Syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,31.75,29,15,0,22.76,1.0
Gastroesophageal reflux disease (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.85e-09,18.0,9,20,0,13.05,1.0
Gastroesophageal reflux disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.14e-08,15.18,9,65,0,10.25,1.0
Gastroesophageal reflux disease (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.84e-07,17.51,9,16,0,14.06,1.0
Gastroesophageal reflux disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.1e-06,17.76,9,13,0,15.23,1.0
Gastroesophageal reflux disease (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),2.11e-08,18.74,9,16,0,14.06,1.0
Gastroesophageal reflux disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.48e-06,24.15,9,8,0,15.11,1.0
Gastroesophageal reflux disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),9.03e-09,17.63,9,23,0,12.52,1.0
Gastroesophageal reflux disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),8.86e-09,18.52,9,22,0,12.68,1.0
Gastroesophageal reflux disease (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.93e-07,18.45,9,13,0,15.23,1.0
Gastroesophageal reflux disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.04e-08,20.45,9,15,0,14.4,1.0
Smoking (inbe),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),3.73e-10,27.55,9,33,0,11.45,1.0
Smoking (inbe),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,28.09,9,16,0,14.06,9.0
Smoking (inbe),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.14e-10,27.9,9,71,0,10.14,5.0
Smoking (inbe),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.14e-10,41.74,9,35,0,11.31,21.0
Smoking (inbe),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.14e-10,27.82,9,110,0,9.74,21.0
Smoking (inbe),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.47e-09,27.16,8,36,1,9.78,1.0
Tertiary referral hospital (hcro),LOCATION_OF,Prospective Studies (qnco),ISA,Techniques (ftcn),1.86e-06,4.77,20,912,0,20.44,2.0
Tertiary referral hospital (hcro),LOCATION_OF,Prospective Studies (qnco),ISA,contextual factors (ftcn),3.16e-06,4.24,20,26,0,35.38,2.0
Body mass index procedure (diap),DIAGNOSES,Well adult (fndg),PROCESS_OF,Voluntary Workers (humn),9.1e-11,69.29,11,15,0,19.07,1.0
Bariatric Surgery (topp),TREATS,Female (orga),ISA,Gender (orga),3.84e-06,42.7,11,51,0,13.37,4.0
Physical activity (dora),TREATS,Hispanics (humn),ISA,Ethnic group (popg),1.07e-08,20.94,8,226,0,8.28,4.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.64e-11,29.82,10,22,0,14.55,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.39e-10,29.25,10,17,0,15.88,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.29e-08,25.31,10,27,0,13.7,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.38e-08,28.27,10,15,0,16.67,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.53e-10,26.47,10,24,0,14.17,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.65e-11,26.09,10,34,0,12.94,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),1.64e-11,27.52,10,40,0,12.5,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.23e-09,34.24,10,12,0,18.33,8.0
Well adolescent (fndg),PROCESS_OF,Koreans (ethnic group) (popg),ISA,Population Group (humn),4.13e-06,30.23,5,22,0,6.14,1.0
Kidney Diseases (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.02e-06,14.27,8,18,0,11.56,1.0
Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,17.28,12,16,0,21.0,9.0
Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.33e-11,27.49,12,26,0,17.54,9.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),8.64e-08,13.58,10,15,0,16.67,21.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),1.03e-07,15.93,10,12,0,18.33,1.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),6.71e-08,14.23,10,15,0,16.67,5.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),6.01e-08,13.47,10,28,0,13.57,5.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),6.02e-08,11.63,10,28,0,13.57,1.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),6.01e-08,14.42,10,66,0,11.52,5.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),6.01e-08,12.27,10,47,0,12.13,1.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),6.03e-08,11.56,10,27,0,13.7,9.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),9.55e-07,15.98,10,10,0,20.0,9.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),6.44e-08,16.55,10,13,0,17.69,9.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",6.02e-08,11.97,10,26,0,13.85,1.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),2.03e-07,11.62,10,19,0,15.26,5.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),1.63e-07,12.98,10,15,0,16.67,1.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (humn),6.1e-08,11.9,10,23,0,14.35,1.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),3.18e-06,11.51,10,16,0,16.25,1.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),2.2e-06,12.66,10,13,0,17.69,5.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),2.41e-06,11.37,10,17,0,15.88,5.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),6.01e-08,12.01,10,51,0,11.96,1.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),6.01e-08,12.5,10,145,0,10.69,11.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),6.01e-08,13.36,10,39,0,12.56,11.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.48e-06,12.98,10,12,0,18.33,1.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.82e-06,12.13,10,14,0,17.14,9.0
LDL Cholesterol Lipoproteins (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",7.23e-07,16.31,10,10,0,20.0,9.0
Birth (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Survivors (humn),1.11e-08,9.68,25,15,0,24.0,1.0
Birth (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,"Twins, Dizygotic (humn)",4.32e-13,6.15,25,60,0,35.42,1.0
Birth (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Monoamniotic twins (podg),4.54e-12,7.02,25,33,0,43.94,1.0
Birth (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Singleton (humn),4.3e-13,5.67,25,357,0,26.75,1.0
Adiponectin (aapp),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,34.86,40,16,0,22.4,9.0
Adiponectin (aapp),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,40.03,40,9,0,11.03,9.0
Adiponectin (aapp),PREDISPOSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,32.41,40,31,0,55.02,21.0
follow-up (hlca),TREATS,cohort (humn),USES,Medicare (rnlw),9.97e-10,7.5,51,20,0,27.84,4.0
follow-up (hlca),TREATS,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,4.68,51,65,0,91.02,2.0
follow-up (hlca),TREATS,cohort (humn),USES,Treats (clas),3.75e-07,7.01,51,16,0,21.02,4.0
follow-up (hlca),TREATS,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,7.26,51,13,0,16.31,2.0
follow-up (hlca),TREATS,cohort (humn),USES,Classification (clas),1.22e-08,8.24,51,16,0,21.02,4.0
follow-up (hlca),TREATS,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,13.65,51,8,0,9.25,2.0
follow-up (hlca),TREATS,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,7.12,51,23,0,33.37,2.0
follow-up (hlca),TREATS,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,8.02,51,22,0,31.49,2.0
follow-up (hlca),TREATS,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,7.95,51,13,0,16.31,4.0
follow-up (hlca),TREATS,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,9.95,51,15,0,19.41,2.0
Malnutrition (dsyn),PROCESS_OF,inpatient (humn),USES,Medicare (rnlw),9.02e-17,21.72,31,32,0,61.03,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),8.32e-08,23.98,7,23,0,9.13,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),8.29e-08,23.43,7,57,0,7.86,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),3.73e-07,31.89,7,9,0,12.44,8.0
Cardiovascular Diseases (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.15e-08,15.63,10,16,0,16.25,9.0
Cardiovascular Diseases (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.44e-07,20.8,10,9,0,17.1,9.0
Normal blood pressure (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,18.11,51,18,0,24.35,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),2.13e-12,18.82,12,98,0,13.47,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,African American (popg),ISA,Racial group (popg),2.13e-12,19.76,12,324,0,12.44,1.0
Insulin Resistance (patf),OCCURS_IN,cohort (humn),USES,Medicare (rnlw),1.21e-06,41.87,5,20,0,6.25,6.0
Insulin Resistance (patf),OCCURS_IN,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.21e-06,39.06,5,65,0,5.38,2.0
Insulin Resistance (patf),OCCURS_IN,cohort (humn),USES,Treats (clas),1.59e-06,41.38,5,16,0,6.56,6.0
Insulin Resistance (patf),OCCURS_IN,cohort (humn),LOCATION_OF,Calcium (bacs),5.31e-06,41.63,5,13,0,6.92,2.0
Insulin Resistance (patf),OCCURS_IN,cohort (humn),USES,Classification (clas),1.22e-06,42.61,5,16,0,6.56,6.0
Insulin Resistance (patf),OCCURS_IN,cohort (humn),LOCATION_OF,Sodium (elii),4.68e-06,48.02,5,8,0,8.12,2.0
Insulin Resistance (patf),OCCURS_IN,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.21e-06,41.5,5,23,0,6.09,2.0
Insulin Resistance (patf),OCCURS_IN,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.21e-06,42.39,5,22,0,6.14,2.0
Insulin Resistance (patf),OCCURS_IN,cohort (humn),USES,Tissue Microarray (resd),2.1e-06,42.32,5,13,0,6.92,6.0
Insulin Resistance (patf),OCCURS_IN,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.21e-06,44.32,5,15,0,6.67,2.0
Total cholesterol (strd),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),1.21e-06,40.13,5,33,0,5.76,1.0
Total cholesterol (strd),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),5.64e-06,40.67,5,16,0,6.56,8.0
Total cholesterol (strd),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.21e-06,40.48,5,71,0,5.35,5.0
Total cholesterol (strd),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.21e-06,54.32,5,35,0,5.71,8.0
Total cholesterol (strd),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.21e-06,40.4,5,110,0,5.23,8.0
Total cholesterol (strd),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.21e-06,39.74,5,37,0,5.68,1.0
Gamma-glutamyl transferase (aapp),PREDISPOSES,Oxidative Stress (comd),PROCESS_OF,Drosophila melanogaster (invt),4.86e-06,24.01,12,12,0,24.0,1.0
Gamma-glutamyl transferase (aapp),PREDISPOSES,Oxidative Stress (comd),COEXISTS_WITH,Critical Illness (dsyn),2.59e-06,27.79,12,9,0,15.75,9.0
Waist circumference (fndg),PREDISPOSES,Systolic blood pressure (ortf),PROCESS_OF,cohort (humn),5.21e-06,37.56,5,15,0,6.67,1.0
Waist circumference (fndg),PREDISPOSES,Systolic blood pressure (ortf),PROCESS_OF,Survivors (humn),1.71e-06,43.31,5,13,0,6.92,1.0
Glomerular Filtration Rate (ortf),COEXISTS_WITH,Systolic blood pressure (ortf),PROCESS_OF,cohort (humn),5.24e-06,21.37,6,15,0,8.4,1.0
Glomerular Filtration Rate (ortf),COEXISTS_WITH,Systolic blood pressure (ortf),PROCESS_OF,Survivors (humn),1.74e-06,27.11,6,13,0,8.77,1.0
Waist circumference (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),COEXISTS_WITH,Heart failure (dsyn),2.02e-11,66.63,8,15,0,12.27,9.0
Waist circumference (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.75e-11,69.1,8,15,0,12.27,9.0
Waist circumference (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),CAUSES,"Kidney Failure, Chronic (dsyn)",2.51e-11,60.6,8,20,0,11.2,9.0
Waist circumference (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.7e-11,59.86,8,52,0,9.23,9.0
Waist circumference (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,Hospitalized Patients (humn),5.59e-07,58.74,8,15,0,12.27,1.0
Waist circumference (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",7.72e-09,58.26,8,21,0,11.05,1.0
Waist circumference (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),CAUSES,End stage renal failure (dsyn),1.7e-11,59.54,8,51,0,9.25,9.0
Waist circumference (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,Survivors (humn),7.62e-08,61.85,8,12,0,13.33,1.0
Waist circumference (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),CAUSES,Kidney Failure (dsyn),5.33e-11,64.2,8,15,0,12.27,9.0
Waist circumference (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),CAUSES,Cessation of life (orgf),1.7e-11,61.44,8,43,0,9.49,9.0
Waist circumference (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),4.74e-09,61.7,8,14,0,12.57,9.0
Waist circumference (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),1.7e-11,59.86,8,26,0,10.46,9.0
Waist circumference (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,General Population (humn),1.12e-10,59.05,8,22,0,10.91,1.0
Waist circumference (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),ISA,Metabolic Diseases (dsyn),1.63e-06,56.23,8,43,0,9.49,5.0
Waist circumference (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),1.7e-11,58.69,8,44,0,9.45,1.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Non-ischemic cardiomyopathy (dsyn),4.22e-06,11.41,14,9,0,14.79,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,Bone Screws (medd),7.2e-07,3.74,14,4,0,5.14,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),PRECEDES,Revascularization - action (topp),7.2e-07,7.88,14,30,0,20.53,16.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,"Ventricular Dysfunction, Left (patf)",7.2e-07,13.98,14,16,0,26.25,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,Ventricular assist device (medd),7.2e-07,8.72,14,171,0,15.15,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,Biventricular assist device (medd),7.23e-07,9.13,14,16,0,26.25,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),PRECEDES,Aortic valve replacement NOS (topp),3.41e-06,10.13,14,10,0,17.14,16.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),compared_with,Coronary Artery Bypass Surgery (topp),7.21e-07,13.06,14,13,0,25.07,16.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,"Stents, Vascular, Coronary (medd)",7.2e-07,5.55,14,128,0,15.53,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Aortic Valve Stenosis (dsyn),7.2e-07,10.96,14,456,0,14.43,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Coronary Arteriosclerosis (dsyn),7.2e-07,6.8,14,38,0,19.16,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,Drug eluting stent (medd),7.2e-07,7.16,14,457,0,14.43,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),METHOD_OF,Primary Prevention (topp),7.2e-07,11.83,14,56,0,17.5,16.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,CRT-D (medd),7.2e-07,8.84,14,24,0,22.17,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,Peritoneal dialysis catheter (medd),7.2e-07,6.24,14,33,0,19.94,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,Catheter valve (medd),7.2e-07,8.49,14,29,0,20.76,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,Stent/Grafts (medd),7.2e-07,7.35,14,96,0,16.04,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Mitral Valve Insufficiency (dsyn),7.2e-07,9.08,14,26,0,21.54,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,Intra-aortic balloon pump device (medd),7.2e-07,8.93,14,25,0,21.84,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),PRECEDES,Heart Transplantation (topp),1.12e-06,10.52,14,11,0,19.64,16.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,cohort (humn),7.2e-07,9.7,14,36,0,19.44,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,"Shock, Cardiogenic (patf)",7.38e-07,8.42,14,16,0,26.25,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,"Defibrillators, Implantable (medd)",7.2e-07,7.66,14,404,0,14.49,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Acute myocardial infarction (dsyn),7.2e-07,7.82,14,38,0,19.16,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),compared_with,Medical therapy (topp),7.2e-07,12.7,14,17,0,25.53,16.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Myocardial Infarction (dsyn),7.2e-07,9.79,14,44,0,18.45,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,Defibrillators (medd),7.2e-07,7.7,14,114,0,15.72,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),METHOD_OF,Secondary prevention (topp),7.2e-07,13.7,14,15,0,27.07,16.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,"Tubes, Gastrostomy, Percutaneous Endoscopic (medd)",7.95e-07,6.98,14,19,0,24.32,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Atrial Fibrillation (patf),7.2e-07,8.0,14,28,0,21.0,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Restenosis (acab),7.4e-07,6.17,14,26,0,21.54,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),compared_with,Aortic valve replacement NOS (topp),7.2e-07,10.86,14,82,0,16.39,16.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,aortic balloon pump (medd),7.2e-07,10.29,14,74,0,16.65,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,Prosthesis (medd),7.2e-07,6.46,14,80,0,16.45,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,PACEMAKER PERMANENT (medd),7.2e-07,6.93,14,315,0,14.62,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Ejection fraction (fndg),7.2e-07,12.01,14,18,0,24.89,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,Metal stent (medd),7.2e-07,7.06,14,94,0,16.09,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,"Kidney Failure, Chronic (dsyn)",7.2e-07,13.45,14,13,0,25.07,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Coronary Stenosis (dsyn),7.97e-07,7.87,14,16,0,26.25,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Multi vessel coronary artery disease (dsyn),7.2e-07,15.7,14,18,0,24.89,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Coronary heart disease (dsyn),8.24e-07,8.74,14,14,0,28.0,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,Left ventricular assist device (medd),7.2e-07,7.61,14,349,0,14.56,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Acute coronary syndrome (dsyn),7.2e-07,8.2,14,23,0,22.52,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,Stents (medd),7.2e-07,5.42,14,839,0,14.23,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Octogenarians (aggp),7.66e-07,12.7,14,11,0,19.64,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,Diethylstilbestrol (phsu),7.2e-07,7.55,14,37,0,19.3,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Heart failure (dsyn),7.2e-07,9.86,14,88,0,16.23,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,STEMI (dsyn),7.2e-07,10.11,14,26,0,21.54,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Diabetic (fndg),7.2e-07,7.3,14,25,0,21.84,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Left main coronary artery disease (dsyn),7.2e-07,12.55,14,30,0,20.53,4.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),METHOD_OF,Aortic valve replacement NOS (topp),7.2e-07,10.24,14,24,0,22.17,16.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),PRECEDES,Antiplatelet therapy (topp),7.2e-07,9.0,14,73,0,16.68,16.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),USES,Right ventricular assist device (medd),7.33e-07,9.84,14,14,0,28.0,6.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),PRECEDES,Cardiac resynchronisation therapy (topp),7.89e-07,9.7,14,13,0,25.07,16.0
Polymerase Chain Reaction (lbpr),METHOD_OF,Implantation procedure (topp),TREATS,Aortic valve disorder (dsyn),3.41e-06,10.13,14,10,0,17.14,4.0
Fitness (dora),TREATS,Participant (humn),USES,Medicare (rnlw),7.52e-08,18.88,8,18,0,11.56,4.0
Metabolic syndrome (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,23.02,46,18,0,25.04,1.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Medical Imaging (diap),USES,Transmission Electron Microscopes (medd),1.1e-06,7.26,16,9,0,14.06,5.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Medical Imaging (diap),USES,"Microscopes, Electron, Scanning (medd)",1.39e-11,7.16,16,2,0,2.25,5.0
Thromboembolism (patf),PREDISPOSES,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.18e-06,23.5,6,25,0,7.44,21.0
Thromboembolism (patf),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.18e-06,27.4,6,15,0,8.4,9.0
Thromboembolism (patf),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),1.18e-06,32.78,6,24,0,7.5,11.0
Thromboembolism (patf),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),1.18e-06,23.42,6,46,0,6.78,11.0
Thromboembolism (patf),PREDISPOSES,Atherosclerosis (dsyn),PROCESS_OF,General Population (humn),1.18e-06,22.99,6,24,0,7.5,1.0
Thromboembolism (patf),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),1.18e-06,24.83,6,18,0,8.0,11.0
Thromboembolism (patf),PREDISPOSES,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),1.18e-06,21.56,6,73,0,6.49,5.0
Thromboembolism (patf),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),1.27e-06,22.16,6,24,0,7.5,11.0
Thromboembolism (patf),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",1.18e-06,23.47,6,41,0,6.88,9.0
Thromboembolism (patf),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),1.18e-06,24.25,6,19,0,7.89,11.0
Thromboembolism (patf),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.18e-06,25.13,6,26,0,7.38,9.0
Insulin Resistance (patf),PREDISPOSES,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.69e-10,27.09,9,23,0,12.52,21.0
Insulin Resistance (patf),PREDISPOSES,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),1.89e-10,26.53,9,57,0,10.42,11.0
Insulin Resistance (patf),PREDISPOSES,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,35.0,9,9,0,18.0,9.0
Hospitals (hcro),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),3.28e-08,68.85,38,13,0,17.45,2.0
Hospitals (hcro),LOCATION_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),3.25e-08,71.78,38,11,0,14.18,2.0
Hospitals (hcro),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),3.42e-10,72.99,38,13,0,17.45,2.0
Hospitals (hcro),LOCATION_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),2.75e-16,68.28,38,27,0,46.18,2.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,17.49,25,9,0,12.24,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.44e-20,16.55,25,194,0,28.22,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,15.27,25,17,0,28.56,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.91e-19,16.54,25,29,0,46.55,11.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,18.72,25,14,0,21.84,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,14.53,25,12,0,17.76,5.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.45e-20,13.35,25,48,0,38.02,11.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.65e-19,16.74,25,29,0,46.55,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.44e-20,13.79,24,97,1,29.94,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,12.45,25,24,0,47.04,9.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,18.86,25,10,0,14.0,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,11.22,25,37,0,41.89,7.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,13.02,25,20,0,36.0,9.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.44e-20,14.68,25,94,0,31.65,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,20.47,25,8,0,10.56,9.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,17.34,25,19,0,33.44,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,14.5,25,21,0,38.64,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,19.68,25,12,0,17.76,9.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,27.39,25,10,0,14.0,21.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,19.98,25,10,0,14.0,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,14.3,25,21,0,38.64,21.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,15.91,25,21,0,38.64,9.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.03e-17,14.03,25,32,0,44.53,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,21.39,25,10,0,14.0,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.44e-20,20.36,25,39,0,41.03,9.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.44e-20,24.34,25,44,0,39.2,11.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.44e-20,17.21,25,113,0,30.53,9.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,14.74,25,11,0,15.84,11.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,14.47,25,11,0,15.84,9.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,14.93,25,12,0,17.76,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,12.82,25,25,0,50.0,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.44e-20,18.5,25,87,0,32.18,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,13.49,25,33,0,43.94,9.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.44e-20,16.22,25,41,0,40.24,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,16.39,25,21,0,38.64,1.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,14.06,25,21,0,38.64,9.0
Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.44e-20,15.0,24,1020,1,24.56,11.0
Triglycerides (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,24.37,23,33,0,39.03,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,24.91,23,16,0,27.13,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.69e-25,24.72,23,71,0,30.45,5.0
Triglycerides (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.64e-26,38.56,23,35,0,38.11,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.64e-26,24.64,23,110,0,27.81,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,23.98,23,37,0,37.3,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),5.04e-08,17.22,9,15,0,14.4,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),6.7e-08,19.58,9,12,0,15.75,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),3.11e-08,17.88,9,15,0,14.4,5.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),2.41e-08,17.12,9,28,0,11.89,5.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),2.42e-08,15.28,9,28,0,11.89,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),2.41e-08,18.07,9,66,0,10.23,5.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),2.41e-08,15.92,9,47,0,10.72,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),2.43e-08,15.21,9,27,0,12.0,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),9.19e-07,19.63,9,10,0,17.1,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),2.84e-08,20.2,9,13,0,15.23,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.41e-08,15.62,9,26,0,12.12,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),1.67e-07,15.27,9,19,0,13.26,5.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),1.27e-07,16.63,9,15,0,14.4,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (humn),2.5e-08,15.55,9,23,0,12.52,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),3.15e-06,15.16,9,16,0,14.06,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),2.16e-06,16.31,9,13,0,15.23,5.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),2.38e-06,15.02,9,17,0,13.76,5.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),2.41e-08,15.66,9,51,0,10.59,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),2.41e-08,16.15,9,145,0,9.56,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),2.41e-08,17.01,9,39,0,11.08,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.44e-06,16.63,9,12,0,15.75,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.79e-06,15.78,9,14,0,14.79,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.87e-07,19.96,9,10,0,17.1,8.0
Bariatric Surgery (topp),TREATS,Age (orga),ASSOCIATED_WITH,Acute myocardial infarction (dsyn),5.91e-09,58.11,8,13,0,12.92,4.0
Bariatric Surgery (topp),TREATS,Age (orga),ASSOCIATED_WITH,Pneumonia (dsyn),5.21e-07,56.91,8,11,0,13.82,4.0
Bariatric Surgery (topp),TREATS,Age (orga),ASSOCIATED_WITH,Heart failure (dsyn),2.75e-11,58.49,8,20,0,11.2,4.0
Bariatric Surgery (topp),TREATS,Age (orga),ASSOCIATED_WITH,Cerebrovascular accident (dsyn),2.74e-11,54.7,8,31,0,10.06,4.0
Bariatric Surgery (topp),TREATS,Age (orga),ASSOCIATED_WITH,Myocardial Infarction (dsyn),1.76e-07,54.6,8,15,0,12.27,4.0
Anorexia Nervosa (mobd),ISA,Mental disorders (mobd),PROCESS_OF,cohort (humn),1.91e-06,16.43,35,20,0,31.43,1.0
Diabetes Mellitus (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,18.24,19,18,0,35.05,1.0
Screening procedure (hlca),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,21.44,27,33,0,49.09,1.0
Screening procedure (hlca),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,21.98,27,16,0,25.48,4.0
Screening procedure (hlca),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.33e-25,21.79,27,71,0,37.27,4.0
Screening procedure (hlca),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.35e-29,35.63,27,35,0,47.83,4.0
Screening procedure (hlca),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.34e-29,21.71,27,110,0,33.63,4.0
Screening procedure (hlca),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,21.05,27,37,0,46.7,1.0
Dyslipidemias (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,22.77,24,18,0,31.5,1.0
Procedures (hlca),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),3.87e-06,14.12,7,16,0,10.06,4.0
Procedures (hlca),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),3.37e-06,24.34,7,26,0,8.88,4.0
Glucose Intolerance (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,33.89,9,16,0,14.06,9.0
Glucose Intolerance (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,39.06,9,9,0,18.0,9.0
Glucose Intolerance (dsyn),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,31.45,9,31,0,11.61,9.0
"Hypertrophy, Left Ventricular (patf)",PROCESS_OF,cohort (humn),USES,Medicare (rnlw),2.06e-09,17.86,10,20,0,15.0,1.0
"Hypertrophy, Left Ventricular (patf)",PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.61e-09,15.04,10,65,0,11.54,1.0
"Hypertrophy, Left Ventricular (patf)",PROCESS_OF,cohort (humn),USES,Treats (clas),3.77e-07,17.37,10,16,0,16.25,1.0
"Hypertrophy, Left Ventricular (patf)",PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.1e-06,17.62,10,13,0,17.69,1.0
"Hypertrophy, Left Ventricular (patf)",PROCESS_OF,cohort (humn),USES,Classification (clas),1.33e-08,18.6,10,16,0,16.25,1.0
"Hypertrophy, Left Ventricular (patf)",PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,24.01,10,8,0,14.4,1.0
"Hypertrophy, Left Ventricular (patf)",PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.24e-09,17.49,10,23,0,14.35,1.0
"Hypertrophy, Left Ventricular (patf)",PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.08e-09,18.38,10,22,0,14.55,1.0
"Hypertrophy, Left Ventricular (patf)",PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.86e-07,18.31,10,13,0,17.69,1.0
"Hypertrophy, Left Ventricular (patf)",PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.61e-09,20.31,10,15,0,16.67,1.0
Testosterone (phsu),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,21.51,19,33,0,29.94,1.0
Testosterone (phsu),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,22.06,19,16,0,29.47,8.0
Testosterone (phsu),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.24e-20,21.86,19,71,0,24.08,5.0
Testosterone (phsu),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.24e-20,35.71,19,35,0,29.31,8.0
Testosterone (phsu),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.24e-20,21.79,19,110,0,22.28,8.0
Testosterone (phsu),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,21.13,19,37,0,28.76,1.0
Physicians (humn),DIAGNOSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),7.89e-07,30.19,6,16,0,8.25,18.0
Physicians (humn),DIAGNOSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),2.88e-07,40.4,6,26,0,7.38,18.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),2.63e-08,19.8,15,15,0,30.0,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),4.29e-08,22.15,15,12,0,21.6,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),6.96e-09,20.45,15,15,0,30.0,5.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),9.69e-15,19.69,15,28,0,23.04,5.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),3.74e-11,17.85,15,28,0,23.04,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),7.14e-15,20.64,15,66,0,18.41,5.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),7.14e-15,18.5,15,47,0,19.79,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),1.49e-10,17.78,15,27,0,23.33,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),8.95e-07,22.2,15,10,0,16.67,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),4.26e-09,22.77,15,13,0,24.27,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.23e-11,18.2,15,26,0,23.65,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),1.43e-07,17.84,15,19,0,26.84,5.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),1.03e-07,19.2,15,15,0,30.0,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (humn),8.9e-10,18.12,15,23,0,24.78,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),3.12e-06,17.73,15,16,0,29.06,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),2.14e-06,18.88,15,13,0,24.27,5.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),2.35e-06,17.59,15,17,0,28.24,5.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),7.14e-15,18.23,15,51,0,19.41,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),7.14e-15,18.73,15,145,0,16.55,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),7.14e-15,19.58,15,39,0,20.77,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.42e-06,19.2,15,12,0,21.6,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.76e-06,18.35,15,14,0,27.07,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.63e-07,22.53,15,10,0,16.67,8.0
Eicosapentaenoic Acid (bacs),ISA,"Fatty Acids, Omega-3 (phsu)",TREATS,Cardiovascular Diseases (dsyn),5.45e-06,8.82,17,10,0,15.88,4.0
Blood specimen (bdsu),LOCATION_OF,Insulin (horm),TREATS,Hospitalized Patients (humn),2.75e-06,21.92,18,11,0,17.72,2.0
Blood specimen (bdsu),LOCATION_OF,Insulin (horm),TREATS,Hyperglycemia (dsyn),1.29e-18,19.71,18,57,0,23.68,2.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.6e-06,37.45,7,9,0,12.44,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.1e-08,36.51,7,194,0,7.25,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),1.13e-08,35.23,7,17,0,9.88,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.1e-08,36.5,7,29,0,8.69,11.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.12e-08,38.68,7,14,0,10.5,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.07e-06,34.49,7,12,0,11.08,5.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.1e-08,33.31,7,48,0,8.02,11.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.1e-08,36.7,7,29,0,8.69,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.1e-08,33.75,7,98,0,7.5,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),1.33e-08,32.41,7,24,0,9.04,9.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.87e-07,38.82,7,10,0,11.9,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),2.32e-08,31.18,7,37,0,8.32,7.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.77e-08,32.98,7,20,0,9.45,9.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.1e-08,34.64,7,94,0,7.52,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.35e-06,40.43,7,8,0,13.12,9.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),1.1e-08,37.3,7,19,0,9.58,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.1e-08,34.46,7,21,0,9.33,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),1.38e-08,39.64,7,12,0,11.08,9.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.36e-08,47.35,7,10,0,11.9,21.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),9.28e-08,39.94,7,10,0,11.9,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.1e-08,34.26,7,21,0,9.33,21.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.1e-08,35.87,7,21,0,9.33,9.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.1e-08,33.99,7,32,0,8.53,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),4.63e-08,41.35,7,10,0,11.9,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.1e-08,40.32,7,39,0,8.26,9.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.1e-08,44.3,7,44,0,8.11,11.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.1e-08,37.17,7,113,0,7.43,9.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.76e-06,34.7,7,11,0,11.45,11.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.18e-06,34.43,7,11,0,11.45,9.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.7e-07,34.89,7,12,0,11.08,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.11e-08,32.78,7,25,0,8.96,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.1e-08,38.46,7,87,0,7.56,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.1e-08,33.45,7,33,0,8.48,9.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.1e-08,36.18,7,41,0,8.2,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.1e-08,36.35,7,21,0,9.33,1.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",1.11e-08,34.02,7,21,0,9.33,9.0
Body Weight decreased (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.1e-08,34.96,7,1021,0,7.05,11.0
Degenerative polyarthritis (dsyn),CAUSES,Disability NOS (patf),PROCESS_OF,cohort (humn),2.59e-07,5.25,17,30,0,26.63,1.0
Degenerative polyarthritis (dsyn),CAUSES,Disability NOS (patf),CAUSES,Cessation of life (orgf),2.18e-07,6.17,17,58,0,21.98,11.0
Degenerative polyarthritis (dsyn),CAUSES,Disability NOS (patf),PROCESS_OF,Survivors (humn),2.18e-07,7.97,17,133,0,19.17,1.0
Degenerative polyarthritis (dsyn),CAUSES,Disability NOS (patf),COEXISTS_WITH,Vegetative State (dsyn),2.94e-07,10.15,17,12,0,20.47,9.0
Degenerative polyarthritis (dsyn),CAUSES,Disability NOS (patf),PROCESS_OF,Survivors (humn),2.18e-07,8.04,17,27,0,27.7,1.0
Degenerative polyarthritis (dsyn),CAUSES,Disability NOS (patf),PROCESS_OF,neurodevelopment (ortf),2.18e-07,5.4,17,117,0,19.47,1.0
Degenerative polyarthritis (dsyn),CAUSES,Disability NOS (patf),COEXISTS_WITH,Cerebrovascular accident (dsyn),5.52e-07,8.26,17,13,0,22.94,9.0
follow-up (hlca),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular morbidity (dsyn),2.29e-11,18.23,14,23,0,22.52,4.0
follow-up (hlca),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cerebrovascular accident (dsyn),2.32e-07,12.27,14,18,0,24.89,4.0
follow-up (hlca),TREATS,Systemic arterial pressure (fndg),PROCESS_OF,General Population (humn),1.36e-06,10.92,14,27,0,21.26,1.0
follow-up (hlca),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),3.16e-11,11.9,14,32,0,20.12,4.0
follow-up (hlca),TREATS,Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),3.44e-11,11.33,14,39,0,19.03,1.0
follow-up (hlca),TREATS,Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),7.18e-07,10.47,14,41,0,18.78,1.0
follow-up (hlca),TREATS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular event (fndg),1.02e-10,12.21,14,27,0,21.26,4.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),2.67e-07,20.65,7,20,0,9.45,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.69e-07,17.83,7,65,0,7.75,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),6.42e-07,20.15,7,16,0,10.06,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.36e-06,20.41,7,13,0,10.77,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),2.78e-07,21.39,7,16,0,10.06,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.74e-06,26.8,7,8,0,13.12,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.66e-07,20.27,7,23,0,9.13,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),2.66e-07,21.17,7,22,0,9.23,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),1.15e-06,21.1,7,13,0,10.77,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.68e-07,23.1,7,15,0,10.27,1.0
Roux-en-Y Gastric Bypass (topp),METHOD_OF,Bariatric Surgery (topp),TREATS,"Obesity, Morbid (dsyn)",4.28e-11,49.22,8,94,0,8.68,4.0
Roux-en-Y Gastric Bypass (topp),METHOD_OF,Bariatric Surgery (topp),TREATS,Body Weight decreased (fndg),4.28e-11,49.14,8,47,0,9.36,4.0
Continuous Positive Airway Pressure (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,12.03,164,16,0,17.56,4.0
Continuous Positive Airway Pressure (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.39e-22,22.25,164,26,0,30.12,4.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),COEXISTS_WITH,Cessation of life (orgf),1.33e-07,19.41,12,10,0,18.33,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),DIAGNOSES,Kidney Diseases (dsyn),1.19e-07,8.76,12,109,0,13.32,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),ISA,Renal function (ortf),1.19e-07,8.05,12,90,0,13.6,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),PROCESS_OF,Survivors (humn),1.85e-07,14.17,12,11,0,21.08,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),PROCESS_OF,Participant (humn),1.19e-07,8.72,12,68,0,14.12,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),PROCESS_OF,Renal function (ortf),1.62e-07,8.14,12,24,0,18.0,1.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),PROCESS_OF,cohort (humn),1.19e-07,8.86,12,38,0,15.79,1.0
Fatty Liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),CAUSES,Cessation of life (orgf),1.21e-06,47.83,5,23,0,6.09,11.0
Body mass index procedure (diap),AFFECTS,Systolic blood pressure (ortf),PROCESS_OF,cohort (humn),3.5e-06,56.59,53,15,0,19.25,1.0
Body mass index procedure (diap),AFFECTS,Systolic blood pressure (ortf),PROCESS_OF,Survivors (humn),1.56e-09,62.34,53,13,0,16.19,1.0
Physical activity (dora),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,33.66,34,12,0,16.24,1.0
Physical activity (dora),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,31.03,34,24,0,40.94,4.0
Screening procedure (hlca),TREATS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.6e-08,32.66,9,16,0,14.06,4.0
Screening procedure (hlca),TREATS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,37.83,9,9,0,18.0,4.0
Screening procedure (hlca),TREATS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,30.22,9,31,0,11.61,4.0
Left ventricular mass (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.35e-06,33.84,5,33,0,5.76,1.0
Left ventricular mass (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),6.78e-06,34.38,5,16,0,6.56,9.0
Left ventricular mass (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),2.35e-06,34.19,5,71,0,5.35,5.0
Left ventricular mass (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.35e-06,48.03,5,35,0,5.71,9.0
Left ventricular mass (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.35e-06,34.11,5,110,0,5.23,9.0
Left ventricular mass (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),2.35e-06,33.45,5,37,0,5.68,1.0
Waist circumference (fndg),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),5.04e-13,58.95,9,98,0,9.83,1.0
Waist circumference (fndg),PROCESS_OF,African American (popg),ISA,Racial group (popg),5.04e-13,59.89,9,324,0,9.25,1.0
Respiration (phsf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),5.04e-07,12.92,9,18,0,13.5,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),2.99e-07,66.07,15,18,0,27.5,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),3.07e-22,68.5,15,77,0,17.92,18.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),8.22e-15,66.58,15,33,0,21.82,5.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),1.72e-09,67.59,15,18,0,27.5,18.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),2e-10,70.83,15,15,0,30.0,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",3.1e-22,68.57,15,41,0,20.49,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),9.02e-15,67.11,15,30,0,22.5,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),3.05e-16,66.76,15,35,0,21.43,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),3.59e-19,71.13,15,27,0,23.33,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),3.96e-06,65.86,15,16,0,29.06,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),6.32e-13,68.55,15,22,0,25.23,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),2.02e-08,66.79,15,18,0,27.5,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),4.32e-13,70.66,15,19,0,26.84,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),1e-07,69.64,15,12,0,21.6,7.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),1.87e-07,75.36,15,9,0,14.4,11.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),3.07e-22,66.24,15,97,0,17.32,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),3.07e-22,67.25,15,68,0,18.31,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),3.07e-22,80.25,15,27,0,23.33,18.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),8.95e-07,70.39,15,10,0,16.67,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),4.38e-16,74.14,15,20,0,26.25,9.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),1.62e-13,71.23,15,19,0,26.84,9.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),3.07e-22,67.49,14,92,1,16.13,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),3.21e-08,67.39,15,16,0,29.06,5.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),4.83e-07,66.18,15,17,0,28.24,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),6.63e-07,70.72,15,10,0,16.67,18.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),2.8e-09,66.27,15,22,0,25.23,1.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),1.87e-13,68.1,15,24,0,24.38,11.0
Body mass index procedure (diap),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),2.69e-06,69.32,15,10,0,16.67,9.0
Degenerative polyarthritis (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,14.79,24,20,0,36.67,1.0
Degenerative polyarthritis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,11.98,24,65,0,32.86,1.0
Degenerative polyarthritis (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,14.3,24,16,0,26.67,1.0
Degenerative polyarthritis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,14.56,24,13,0,20.04,1.0
Degenerative polyarthritis (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,15.54,24,16,0,26.67,1.0
Degenerative polyarthritis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,20.94,24,8,0,10.67,1.0
Degenerative polyarthritis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,14.42,24,23,0,45.04,1.0
Degenerative polyarthritis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,15.32,24,22,0,42.17,1.0
Degenerative polyarthritis (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,15.24,24,13,0,20.04,1.0
Degenerative polyarthritis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,17.24,24,15,0,24.38,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Anorexia Nervosa (mobd),ISA,Mental disorders (mobd),2.03e-21,30.01,18,46,0,25.04,5.0
Screening procedure (hlca),TREATS,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.33e-08,21.96,8,23,0,10.78,4.0
Screening procedure (hlca),TREATS,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),1.3e-08,21.4,8,57,0,9.12,4.0
Screening procedure (hlca),TREATS,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),3.04e-07,29.87,8,9,0,15.11,4.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.71e-06,40.44,6,9,0,10.0,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.2e-07,39.5,6,194,0,6.19,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),1.2e-07,38.23,6,17,0,8.12,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.2e-07,39.5,6,29,0,7.24,11.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.2e-07,41.68,6,14,0,8.57,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.18e-06,37.49,6,12,0,9.0,5.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.2e-07,36.31,6,48,0,6.75,11.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.2e-07,39.7,6,29,0,7.24,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.2e-07,36.74,6,98,0,6.37,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),1.22e-07,35.41,6,24,0,7.5,9.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),2.96e-07,41.82,6,10,0,9.6,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.32e-07,34.18,6,37,0,6.97,7.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.26e-07,35.98,6,20,0,7.8,9.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.2e-07,37.63,6,94,0,6.38,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.46e-06,43.42,6,8,0,10.5,9.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),1.2e-07,40.3,6,19,0,7.89,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-07,37.45,6,21,0,7.71,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),1.22e-07,42.63,6,12,0,9.0,9.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.22e-07,50.35,6,10,0,9.6,21.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),2.01e-07,42.93,6,10,0,9.6,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.2e-07,37.25,6,21,0,7.71,21.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.2e-07,38.86,6,21,0,7.71,9.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.2e-07,36.99,6,32,0,7.12,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),1.55e-07,44.35,6,10,0,9.6,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.2e-07,43.32,6,39,0,6.92,9.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.2e-07,47.29,6,44,0,6.82,11.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.2e-07,40.17,6,113,0,6.32,9.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.87e-06,37.69,6,11,0,9.27,11.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.29e-06,37.42,6,11,0,9.27,9.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),6.79e-07,37.88,6,12,0,9.0,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.2e-07,35.78,6,25,0,7.44,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.2e-07,41.45,6,87,0,6.41,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.2e-07,36.44,6,33,0,7.09,9.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.2e-07,39.18,6,41,0,6.88,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.2e-07,39.34,6,21,0,7.71,1.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",1.2e-07,37.01,6,21,0,7.71,9.0
Thickened (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.2e-07,37.96,6,1021,0,6.04,11.0
GLUCOSE TOLERANCE (phsf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),4.13e-06,19.23,6,20,0,7.8,1.0
GLUCOSE TOLERANCE (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),4.13e-06,16.42,6,65,0,6.55,1.0
GLUCOSE TOLERANCE (phsf),PROCESS_OF,cohort (humn),USES,Treats (clas),4.51e-06,18.74,6,16,0,8.25,1.0
GLUCOSE TOLERANCE (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),8.23e-06,18.99,6,13,0,8.77,1.0
GLUCOSE TOLERANCE (phsf),PROCESS_OF,cohort (humn),USES,Classification (clas),4.14e-06,19.98,6,16,0,8.25,1.0
GLUCOSE TOLERANCE (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),7.6e-06,25.38,6,8,0,10.5,1.0
GLUCOSE TOLERANCE (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),4.13e-06,18.86,6,23,0,7.57,1.0
GLUCOSE TOLERANCE (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),4.13e-06,19.75,6,22,0,7.64,1.0
GLUCOSE TOLERANCE (phsf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),5.02e-06,19.68,6,13,0,8.77,1.0
GLUCOSE TOLERANCE (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),4.13e-06,21.68,6,15,0,8.4,1.0
"Leukemia, Lymphocytic, Acute, L1 (neop)",PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),4.64e-09,17.68,12,25,0,17.76,1.0
"Leukemia, Lymphocytic, Acute, L1 (neop)",PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),1.05e-08,15.48,11,12,1,21.08,1.0
"Leukemia, Lymphocytic, Acute, L1 (neop)",PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),4.64e-09,19.94,12,32,0,16.5,1.0
PROTEIN INTAKE (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),3.73e-07,29.99,6,18,0,8.0,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,21.94,22,9,0,12.68,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.78e-21,21.0,22,194,0,24.49,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,19.72,22,17,0,30.14,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.79e-19,20.99,22,29,0,38.69,11.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,23.17,22,14,0,22.91,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,18.98,22,12,0,18.55,5.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),2.87e-21,17.8,22,48,0,32.08,11.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.53e-19,21.19,22,29,0,38.69,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.78e-21,18.24,22,98,0,26.94,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,16.9,22,24,0,42.17,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,23.31,22,10,0,14.55,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,15.67,22,37,0,35.08,7.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,17.47,22,20,0,38.18,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.78e-21,19.13,22,94,0,27.15,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,24.92,22,8,0,10.91,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,21.79,22,19,0,35.41,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,18.95,22,21,0,41.05,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,24.13,22,12,0,18.55,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,31.84,22,10,0,14.55,21.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,24.43,22,10,0,14.55,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,18.75,22,21,0,41.05,21.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,20.36,22,21,0,41.05,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,18.48,22,32,0,37.12,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,25.84,22,10,0,14.55,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.78e-21,24.81,22,39,0,34.41,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),2.78e-21,28.79,22,44,0,33.0,11.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.78e-21,21.66,22,113,0,26.28,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,19.19,22,11,0,16.5,11.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,18.92,22,11,0,16.5,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,19.38,22,12,0,18.55,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,17.27,22,25,0,41.36,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.78e-21,22.95,22,87,0,27.56,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,17.93,22,33,0,36.67,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.78e-21,20.67,22,41,0,33.8,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,20.84,22,21,0,41.05,1.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,18.5,22,21,0,41.05,9.0
"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.78e-21,19.45,22,1021,0,22.47,11.0
Scanning (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),6.28e-08,8.98,15,18,0,27.5,6.0
GLUCOSE TOLERANCE (phsf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Survivors (humn),1.11e-08,15.57,16,15,0,29.06,1.0
GLUCOSE TOLERANCE (phsf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,"Twins, Dizygotic (humn)",1.31e-13,12.05,16,60,0,20.27,1.0
GLUCOSE TOLERANCE (phsf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Monoamniotic twins (podg),4.24e-12,12.92,16,33,0,23.76,1.0
GLUCOSE TOLERANCE (phsf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Singleton (humn),1.29e-13,11.57,16,357,0,16.72,1.0
Adipose tissue (tisu),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,14.81,18,16,0,30.22,7.0
Adipose tissue (tisu),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,19.98,18,9,0,13.5,7.0
Adipose tissue (tisu),AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,12.37,18,31,0,28.45,7.0
Hypertriglyceridemia (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),1.24e-06,14.97,7,33,0,8.48,1.0
Hypertriglyceridemia (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),5.67e-06,15.52,7,16,0,10.06,9.0
Hypertriglyceridemia (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.24e-06,15.32,7,71,0,7.69,5.0
Hypertriglyceridemia (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.24e-06,29.16,7,35,0,8.4,9.0
Hypertriglyceridemia (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.24e-06,15.25,7,110,0,7.45,9.0
Hypertriglyceridemia (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.24e-06,14.58,7,37,0,8.32,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.71e-11,18.91,15,25,0,24.0,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.74e-10,22.81,15,15,0,30.0,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),5.11e-15,28.19,15,24,0,24.38,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),5.11e-15,18.82,15,46,0,19.89,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),PROCESS_OF,General Population (humn),6.44e-10,18.39,15,24,0,24.38,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),5.09e-10,20.24,15,18,0,27.5,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),5.13e-15,16.97,15,73,0,18.08,5.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),9.39e-08,17.56,15,24,0,24.38,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",5.11e-15,18.88,15,41,0,20.49,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),7.75e-10,19.66,15,19,0,26.84,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.1e-14,20.54,15,26,0,23.65,8.0
Depressive Symptoms (sosy),INTERACTS_WITH,Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),1.38e-09,89.78,8,22,0,10.91,10.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Participant (humn),3.03e-09,11.18,11,84,0,12.44,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Hyperglycemia (dsyn),3.55e-07,18.23,11,10,0,19.09,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Atrial Fibrillation (patf),2.54e-08,22.52,11,10,0,19.09,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Human Age Group (aggp),5.11e-09,14.28,11,18,0,17.72,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Population Group (humn),3.42e-06,14.87,10,10,1,20.0,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Vascular Diseases (dsyn),3.03e-09,13.2,11,38,0,14.18,5.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Cessation of life (orgf),3.03e-09,13.86,11,449,0,11.27,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Black race (popg),3.04e-09,13.89,11,24,0,16.04,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),3.03e-09,16.38,11,34,0,14.56,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Neurologist (humn),3.22e-09,12.25,11,31,0,14.9,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),3.03e-09,14.21,11,140,0,11.86,5.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),4.15e-09,14.1,11,19,0,17.37,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Survivors (humn),3.03e-09,10.6,11,330,0,11.37,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.24e-07,16.26,11,11,0,22.0,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Deglutition Disorders (dsyn),6.2e-07,12.05,11,22,0,16.5,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Depressive disorder (mobd),4.78e-09,11.48,11,41,0,13.95,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,Myocardial Infarction (dsyn),2.81e-08,16.34,11,13,0,20.31,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Young adult (aggp),3.31e-09,11.37,11,48,0,13.52,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,inpatient (humn),4.7e-06,11.41,11,27,0,15.48,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,VICTIM (humn),2.52e-07,11.24,11,38,0,14.18,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),OCCURS_IN,cohort (humn),3.68e-09,15.92,11,16,0,18.56,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Disability NOS (patf),3.03e-09,12.31,11,163,0,11.74,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,General Population (humn),3.03e-09,13.3,11,44,0,13.75,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),AFFECTS,Systemic arterial pressure (fndg),3.03e-09,13.48,11,27,0,15.48,7.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Heart failure (dsyn),3.04e-09,22.26,11,14,0,19.64,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Octogenarians (aggp),3.03e-09,22.52,11,15,0,19.07,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Control Groups (humn),1.25e-06,12.33,11,19,0,17.37,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Disability NOS (patf),3.03e-09,12.79,11,47,0,13.57,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),AFFECTS,Cessation of life (orgf),4.49e-07,15.34,11,12,0,21.08,7.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Hospitalization (hlca),3.03e-09,18.3,11,24,0,16.04,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,Diabetic (fndg),3.05e-09,13.97,11,23,0,16.26,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Pneumonia (dsyn),6.98e-07,15.05,11,12,0,21.08,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Ethnic group (popg),5.77e-09,15.19,11,16,0,18.56,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),3.03e-09,13.87,11,155,0,11.78,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Teams (humn),3.03e-09,12.29,11,42,0,13.88,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.75e-09,13.83,11,19,0,17.37,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Thrombosis (patf),3.11e-09,14.21,11,21,0,16.76,5.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Cerebrovascular Disorders (patf),3.03e-09,12.79,11,41,0,13.95,5.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Hospitalized Patients (humn),3.03e-09,14.17,11,64,0,12.89,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),3.03e-09,13.53,11,129,0,11.94,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),3.03e-09,13.96,11,39,0,14.1,1.0
Alanine Transaminase (aapp),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.79e-10,53.98,14,23,0,22.52,8.0
Alanine Transaminase (aapp),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),8.49e-20,53.42,14,57,0,17.44,8.0
Alanine Transaminase (aapp),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,61.89,14,9,0,14.79,8.0
Interleukin-6 (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.5e-08,21.61,7,15,1,10.27,8.0
Interleukin-6 (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.58e-07,26.78,8,9,0,15.11,8.0
Interleukin-6 (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.37e-07,19.17,8,31,0,10.06,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),3.15e-07,20.93,8,18,0,11.56,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.58e-08,23.37,8,77,0,8.83,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),1.58e-08,21.45,8,33,0,9.94,5.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),1.75e-08,22.45,8,18,0,11.56,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),1.6e-08,25.7,8,15,0,12.27,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",1.58e-08,23.44,8,41,0,9.56,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),1.58e-08,21.98,8,30,0,10.13,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),1.58e-08,21.62,8,35,0,9.83,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),1.58e-08,26.0,8,27,0,10.37,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),3.97e-06,20.73,8,16,0,12.0,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),1.58e-08,23.42,8,22,0,10.91,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),3.6e-08,21.66,8,18,0,11.56,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),1.58e-08,25.53,8,19,0,11.37,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),1.16e-07,24.51,8,12,0,13.33,7.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),2.03e-07,30.22,8,9,0,15.11,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),1.58e-08,21.1,8,97,0,8.66,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),1.58e-08,22.11,8,68,0,8.94,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.58e-08,35.12,8,27,0,10.37,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),9.11e-07,25.26,8,10,0,14.4,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),1.58e-08,29.01,8,20,0,11.2,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),1.58e-08,26.1,8,19,0,11.37,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),1.58e-08,22.36,8,93,0,8.69,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),4.79e-08,22.26,8,16,0,12.0,5.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),4.99e-07,21.05,8,17,0,11.76,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),6.79e-07,25.59,8,10,0,14.4,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),1.86e-08,21.14,8,22,0,10.91,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),1.58e-08,22.96,8,24,0,10.67,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),2.7e-06,24.19,8,10,0,14.4,8.0
Fatty Acids (bacs),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),1.87e-09,6.27,14,5,0,6.79,3.0
C-reactive protein (aapp),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),2.93e-26,24.1,24,77,0,31.48,1.0
C-reactive protein (aapp),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),1e-08,24.44,24,16,0,26.67,1.0
C-reactive protein (aapp),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Young adult (aggp),4.08e-06,23.89,24,12,0,18.0,1.0
C-reactive protein (aapp),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Middle Aged (aggp),4.35e-10,24.23,24,19,0,34.04,1.0
C-reactive protein (aapp),PREDISPOSES,Coronary heart disease (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.38e-09,23.01,24,22,0,42.17,21.0
C-reactive protein (aapp),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Outpatients (podg),5.76e-08,22.02,24,24,0,48.0,1.0
C-reactive protein (aapp),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,General Population (humn),7.97e-21,23.73,24,42,0,37.71,1.0
C-reactive protein (aapp),PREDISPOSES,Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),2.93e-26,24.98,24,102,0,29.65,5.0
C-reactive protein (aapp),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Heart failure (dsyn),3.34e-07,24.57,24,13,0,20.04,11.0
C-reactive protein (aapp),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),2.93e-26,24.31,24,83,0,30.94,1.0
C-reactive protein (aapp),PREDISPOSES,Coronary heart disease (dsyn),ISA,Death (finding) (fndg),2.93e-26,26.89,24,250,0,26.3,5.0
C-reactive protein (aapp),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),2.93e-26,24.07,24,194,0,26.97,11.0
Abdomen (blor),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),3.29e-08,44.23,8,13,0,12.92,2.0
Abdomen (blor),LOCATION_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),3.27e-08,47.16,8,11,0,13.82,2.0
Abdomen (blor),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),4.84e-10,48.37,8,13,0,12.92,2.0
Abdomen (blor),LOCATION_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),1.42e-10,43.66,8,27,0,10.37,2.0
Vitamin D (phsu),TREATS,Vitamin D Deficiency (dsyn),PROCESS_OF,General Population (humn),4.07e-06,11.55,8,18,0,11.56,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),5.58e-07,50.76,5,78,0,5.32,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),6.52e-07,49.88,5,22,0,6.14,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),5.62e-07,56.99,5,12,0,7.08,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),6.01e-07,50.85,5,18,0,6.39,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (humn),5.58e-07,48.85,5,67,0,5.37,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),5.6e-07,50.84,5,21,0,6.19,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),5.58e-07,50.33,5,35,0,5.71,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),1.44e-11,27.3,11,25,0,15.84,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),5.89e-09,25.1,10,12,1,18.33,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),1.44e-11,29.55,11,32,0,14.78,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.32e-07,15.0,8,25,0,10.56,21.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),3.33e-07,18.9,8,15,0,12.27,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),3.32e-07,24.28,8,24,0,10.67,11.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),3.32e-07,14.91,8,46,0,9.39,11.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Atherosclerosis (dsyn),PROCESS_OF,General Population (humn),3.33e-07,14.48,8,24,0,10.67,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),3.33e-07,16.32,8,18,0,11.56,11.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),3.32e-07,13.06,8,73,0,8.88,5.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),4.26e-07,13.65,8,24,0,10.67,11.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",3.32e-07,14.97,8,41,0,9.56,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),3.33e-07,15.74,8,19,0,11.37,11.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.32e-07,16.62,8,26,0,10.46,9.0
Gamma-glutamyl transferase (aapp),PREDISPOSES,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.58e-07,50.83,5,23,0,6.09,21.0
Gamma-glutamyl transferase (aapp),PREDISPOSES,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),5.58e-07,50.27,5,57,0,5.44,11.0
Gamma-glutamyl transferase (aapp),PREDISPOSES,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),8.48e-07,58.74,5,9,0,7.78,9.0
Body Weight Changes (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,28.92,15,18,0,27.5,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,26.9,60,20,0,26.67,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,24.08,60,65,0,115.38,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,26.41,60,16,0,20.27,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,26.66,60,13,0,15.82,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,27.64,60,16,0,20.27,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,33.05,60,8,0,9.07,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,26.52,60,23,0,31.82,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,27.42,60,22,0,30.07,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,27.35,60,13,0,15.82,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,29.35,60,15,0,18.75,1.0
Physical activity (dora),TREATS,cohort (humn),USES,Medicare (rnlw),9.97e-10,17.11,33,20,0,32.12,4.0
Physical activity (dora),TREATS,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,14.3,33,65,0,49.75,2.0
Physical activity (dora),TREATS,cohort (humn),USES,Treats (clas),3.75e-07,16.62,33,16,0,23.76,4.0
Physical activity (dora),TREATS,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,16.87,33,13,0,18.12,2.0
Physical activity (dora),TREATS,cohort (humn),USES,Classification (clas),1.22e-08,17.86,33,16,0,23.76,4.0
Physical activity (dora),TREATS,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,23.26,33,8,0,9.94,2.0
Physical activity (dora),TREATS,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,16.74,33,23,0,39.03,2.0
Physical activity (dora),TREATS,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,17.63,33,22,0,36.67,2.0
Physical activity (dora),TREATS,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,17.56,33,13,0,18.12,4.0
Physical activity (dora),TREATS,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,19.56,33,15,0,21.82,2.0
Body mass index (clna),PREDISPOSES,Chronic Disease (dsyn),CAUSES,Cessation of life (orgf),1.34e-09,49.65,7,66,0,7.74,11.0
Body mass index (clna),PREDISPOSES,Chronic Disease (dsyn),PROCESS_OF,cohort (humn),2.81e-07,47.76,7,16,0,10.06,1.0
Body mass index (clna),PREDISPOSES,Chronic Disease (dsyn),CAUSES,Disability NOS (patf),4.85e-06,46.57,7,18,0,9.72,11.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,10.14,29,20,0,33.79,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,7.32,29,65,0,41.94,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,9.64,29,16,0,24.83,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,9.9,29,13,0,18.83,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,10.88,29,16,0,24.83,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,16.29,29,8,0,10.21,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,9.76,29,23,0,41.24,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,10.66,29,22,0,38.69,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,10.59,29,13,0,18.83,1.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,12.58,29,15,0,22.76,1.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),3.1e-06,6.16,16,20,0,28.8,1.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Disability NOS (patf),3.08e-06,9.31,16,36,0,23.11,4.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),ISA,Respiration Disorders (dsyn),3.08e-06,5.94,16,59,0,20.34,4.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Respiratory physiology (ortf),3.1e-06,5.6,16,23,0,27.13,1.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Acute respiratory failure (dsyn),3.43e-06,8.6,16,12,0,21.0,4.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),3.08e-06,6.32,16,72,0,19.56,1.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),ISA,Lung diseases (dsyn),3.08e-06,5.78,16,73,0,19.51,4.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Hospitalized Patients (humn),3.08e-06,7.11,16,50,0,21.12,1.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospital admission (hlca),3.08e-06,8.9,16,15,0,29.06,4.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Cessation of life (orgf),3.08e-06,8.83,16,184,0,17.39,4.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Outpatients (podg),3.1e-06,4.37,15,42,1,20.36,1.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,General Population (humn),3.08e-06,6.34,16,27,0,25.48,1.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Diagnosis (hlca),3.25e-06,10.38,16,11,0,18.56,4.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Participant (humn),3.08e-06,5.67,16,70,0,19.66,1.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),COEXISTS_WITH,Smoker (fndg),3.32e-06,4.85,16,27,0,25.48,4.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),ISA,Chronic Disease (dsyn),3.08e-06,6.82,16,46,0,21.57,4.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Malignant neoplasm of lung (neop),3.17e-06,6.54,16,17,0,31.06,4.0
Hospitalization (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Pneumonia (dsyn),3.53e-06,8.45,16,12,0,21.0,4.0
Gastrectomy (topp),TREATS,Diabetes Mellitus (dsyn),COEXISTS_WITH,Heart failure (dsyn),2.35e-06,43.19,5,15,0,6.67,4.0
Gastrectomy (topp),TREATS,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.35e-06,45.66,5,15,0,6.67,4.0
Gastrectomy (topp),TREATS,Diabetes Mellitus (dsyn),CAUSES,"Kidney Failure, Chronic (dsyn)",2.35e-06,37.16,5,20,0,6.25,4.0
Gastrectomy (topp),TREATS,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.35e-06,36.42,5,52,0,5.48,4.0
Gastrectomy (topp),TREATS,Diabetes Mellitus (dsyn),PROCESS_OF,Hospitalized Patients (humn),2.9e-06,35.3,5,15,0,6.67,1.0
Gastrectomy (topp),TREATS,Diabetes Mellitus (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.35e-06,34.82,5,21,0,6.19,1.0
Gastrectomy (topp),TREATS,Diabetes Mellitus (dsyn),CAUSES,End stage renal failure (dsyn),2.35e-06,36.1,5,51,0,5.49,4.0
Gastrectomy (topp),TREATS,Diabetes Mellitus (dsyn),PROCESS_OF,Survivors (humn),2.42e-06,38.41,5,12,0,7.08,1.0
Gastrectomy (topp),TREATS,Diabetes Mellitus (dsyn),CAUSES,Kidney Failure (dsyn),2.35e-06,40.76,5,15,0,6.67,4.0
Gastrectomy (topp),TREATS,Diabetes Mellitus (dsyn),CAUSES,Cessation of life (orgf),2.35e-06,38.01,5,43,0,5.58,4.0
Gastrectomy (topp),TREATS,Diabetes Mellitus (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),2.35e-06,38.26,5,14,0,6.79,4.0
Gastrectomy (topp),TREATS,Diabetes Mellitus (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),2.35e-06,36.42,5,26,0,5.96,4.0
Gastrectomy (topp),TREATS,Diabetes Mellitus (dsyn),PROCESS_OF,General Population (humn),2.35e-06,35.61,5,22,0,6.14,1.0
Gastrectomy (topp),TREATS,Diabetes Mellitus (dsyn),ISA,Metabolic Diseases (dsyn),3.97e-06,32.79,5,43,0,5.58,4.0
Gastrectomy (topp),TREATS,Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),2.35e-06,35.25,5,44,0,5.57,1.0
Fitness (dora),TREATS,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.46e-08,34.75,7,22,0,9.23,4.0
Fitness (dora),TREATS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.48e-08,34.18,7,17,0,9.88,1.0
Fitness (dora),TREATS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),2.75e-08,30.25,7,27,0,8.81,1.0
Fitness (dora),TREATS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),2.85e-08,33.2,7,15,0,10.27,1.0
Fitness (dora),TREATS,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.48e-08,31.4,7,24,0,9.04,4.0
Fitness (dora),TREATS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.46e-08,31.02,7,34,0,8.44,1.0
Fitness (dora),TREATS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),1.46e-08,32.45,7,40,0,8.22,1.0
Fitness (dora),TREATS,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.59e-08,39.18,7,12,0,11.08,4.0
Dyslipidemias (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.91e-09,18.11,10,20,0,15.0,1.0
Dyslipidemias (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.45e-09,15.3,10,65,0,11.54,1.0
Dyslipidemias (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.76e-07,17.62,10,16,0,16.25,1.0
Dyslipidemias (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.1e-06,17.88,10,13,0,17.69,1.0
Dyslipidemias (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.32e-08,18.86,10,16,0,16.25,1.0
Dyslipidemias (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,24.27,10,8,0,14.4,1.0
Dyslipidemias (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.09e-09,17.74,10,23,0,14.35,1.0
Dyslipidemias (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),9.31e-10,18.64,10,22,0,14.55,1.0
Dyslipidemias (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,18.57,10,13,0,17.69,1.0
Dyslipidemias (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.46e-09,20.56,10,15,0,16.67,1.0
Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Gastric Adenocarcinoma (neop),1.7e-18,31.51,16,64,0,20.0,4.0
Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Malignant neoplasm of stomach (neop),1.7e-18,28.37,16,578,0,16.44,4.0
Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Advanced cancer (neop),1.22e-16,31.08,16,24,0,26.67,4.0
Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Adenocarcinoma (neop),2.54e-18,29.58,16,30,0,24.53,4.0
Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,"Obesity, Morbid (dsyn)",1.7e-18,27.26,15,79,1,17.85,4.0
Gastric Bypass (topp),compared_with,Gastrectomy (topp),USES,Sleeves (medd),1.7e-18,24.33,12,529,4,12.27,6.0
Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Body Weight decreased (fndg),5.28e-15,27.54,16,30,0,24.53,4.0
Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Stomach Carcinoma (neop),1.7e-18,28.26,16,49,0,21.22,4.0
Gastric Bypass (topp),compared_with,Gastrectomy (topp),ADMINISTERED_TO,Surgeon (humn),2e-09,30.64,16,14,0,26.25,15.0
Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Malignant neoplasm of stomach stage III (neop),2.07e-06,29.89,16,10,0,16.25,4.0
Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Early gastric cancer (neop),1.7e-18,26.81,16,71,0,19.61,4.0
Malignant Childhood Neoplasm (neop),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),3.31e-18,11.94,70,25,0,33.93,1.0
Malignant Childhood Neoplasm (neop),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),5.88e-09,9.74,70,13,0,15.41,1.0
Malignant Childhood Neoplasm (neop),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),3.02e-18,14.2,70,32,0,46.63,1.0
Abdominal obesity (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,28.6,17,18,0,33.06,1.0
body mass (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Critically ill children (podg),7.49e-06,85.75,4,8,0,6.0,1.0
body mass (fndg),PREDISPOSES,Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.02e-06,81.6,4,15,0,5.07,9.0
body mass (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),4.02e-06,80.3,4,18,0,4.89,1.0
body mass (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),4.02e-06,79.21,4,61,0,4.26,1.0
body mass (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Surgical Patients (podg),4.02e-06,79.25,4,24,0,4.67,1.0
body mass (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Cancer Patient (podg),4.03e-06,77.7,4,30,0,4.53,1.0
body mass (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,inpatient (humn),4.02e-06,79.14,4,28,0,4.57,1.0
body mass (fndg),PREDISPOSES,Malnutrition (dsyn),CAUSES,Cessation of life (orgf),4.02e-06,81.06,4,28,0,4.57,11.0
body mass (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,cohort (humn),4.02e-06,82.32,4,16,0,5.0,1.0
Cardiovascular event (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.13e-09,9.58,17,20,0,31.45,1.0
Cardiovascular event (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.67e-09,6.76,17,65,0,21.45,1.0
Cardiovascular event (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.76e-07,9.08,17,16,0,31.06,1.0
Cardiovascular event (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,9.34,17,13,0,22.94,1.0
Cardiovascular event (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.24e-08,10.32,17,16,0,31.06,1.0
Cardiovascular event (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,15.73,17,8,0,11.76,1.0
Cardiovascular event (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),3.09e-10,9.2,17,23,0,29.57,1.0
Cardiovascular event (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.48e-10,10.1,17,22,0,30.14,1.0
Cardiovascular event (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,10.03,17,13,0,22.94,1.0
Cardiovascular event (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.68e-09,12.02,17,15,0,28.24,1.0
Exercise (dora),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,14.57,15,33,0,21.82,1.0
Exercise (dora),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,15.11,15,16,0,29.06,4.0
Exercise (dora),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),7.91e-14,14.92,15,71,0,18.17,4.0
Exercise (dora),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),7.91e-14,28.76,15,35,0,21.43,4.0
Exercise (dora),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),7.91e-14,14.84,15,110,0,17.05,4.0
Exercise (dora),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,14.18,15,37,0,21.08,1.0
Foot pain (sosy),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),4.13e-06,31.79,5,18,0,6.39,1.0
End stage renal failure (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.98e-10,11.69,17,20,0,31.45,1.0
End stage renal failure (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,8.87,17,65,0,21.45,1.0
End stage renal failure (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,11.19,17,16,0,31.06,1.0
End stage renal failure (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,11.45,17,13,0,22.94,1.0
End stage renal failure (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,12.43,17,16,0,31.06,1.0
End stage renal failure (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,17.84,17,8,0,11.76,1.0
End stage renal failure (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.78e-10,11.31,17,23,0,29.57,1.0
End stage renal failure (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.65e-11,12.21,17,22,0,30.14,1.0
End stage renal failure (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,12.14,17,13,0,22.94,1.0
End stage renal failure (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,14.13,17,15,0,28.24,1.0
Body mass index procedure (diap),AFFECTS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.18e-07,65.28,5,33,0,5.76,1.0
Body mass index procedure (diap),AFFECTS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.65e-06,65.83,5,16,0,6.56,7.0
Body mass index procedure (diap),AFFECTS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),2.18e-07,65.63,5,71,0,5.35,5.0
Body mass index procedure (diap),AFFECTS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.18e-07,79.47,5,35,0,5.71,7.0
Body mass index procedure (diap),AFFECTS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.18e-07,65.56,5,110,0,5.23,7.0
Body mass index procedure (diap),AFFECTS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),2.19e-07,64.89,5,37,0,5.68,1.0
Myocardial Infarction (dsyn),ISA,Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),2.28e-13,9.86,22,77,0,28.29,1.0
Myocardial Infarction (dsyn),ISA,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),1e-08,10.21,22,16,0,27.64,1.0
Myocardial Infarction (dsyn),ISA,Coronary heart disease (dsyn),PROCESS_OF,Young adult (aggp),4.08e-06,9.65,22,12,0,18.55,1.0
Myocardial Infarction (dsyn),ISA,Coronary heart disease (dsyn),PROCESS_OF,Middle Aged (aggp),4.35e-10,9.99,21,18,1,33.43,1.0
Myocardial Infarction (dsyn),ISA,Coronary heart disease (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.38e-09,8.77,22,22,0,44.0,5.0
Myocardial Infarction (dsyn),ISA,Coronary heart disease (dsyn),PROCESS_OF,Outpatients (podg),5.76e-08,7.78,22,24,0,42.17,1.0
Myocardial Infarction (dsyn),ISA,Coronary heart disease (dsyn),PROCESS_OF,General Population (humn),2.28e-13,9.49,22,42,0,33.52,1.0
Myocardial Infarction (dsyn),ISA,Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),2.28e-13,10.74,22,102,0,26.75,5.0
Myocardial Infarction (dsyn),ISA,Coronary heart disease (dsyn),CAUSES,Heart failure (dsyn),3.34e-07,10.33,22,13,0,20.68,5.0
Myocardial Infarction (dsyn),ISA,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),2.28e-13,10.08,22,83,0,27.83,1.0
Myocardial Infarction (dsyn),ISA,Coronary heart disease (dsyn),ISA,Death (finding) (fndg),2.28e-13,12.66,22,250,0,23.94,5.0
Myocardial Infarction (dsyn),ISA,Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),2.28e-13,9.84,22,194,0,24.49,5.0
Body mass index procedure (diap),DIAGNOSES,Infertility (dsyn),PROCESS_OF,Couples (humn),1.95e-10,66.1,7,16,0,10.06,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of lung (neop),PROCESS_OF,Workers (humn),3.6e-07,70.52,6,12,0,9.0,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of lung (neop),PROCESS_OF,Workers (humn),6.53e-09,68.29,6,99,0,6.36,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of lung (neop),PROCESS_OF,Miner (general) (humn),1.13e-06,66.66,6,26,0,7.38,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of lung (neop),PROCESS_OF,High Risk Populations (popg),2.06e-06,68.45,6,14,0,8.57,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of lung (neop),ISA,Respiration Disorders (dsyn),6.53e-09,71.11,6,25,0,7.44,5.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of lung (neop),PROCESS_OF,Males (popg),9.45e-07,74.22,6,9,0,10.0,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of lung (neop),PROCESS_OF,Octogenarians (aggp),6.53e-09,72.9,6,26,0,7.38,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of lung (neop),PROCESS_OF,Participant (humn),6.53e-09,68.93,6,25,0,7.44,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of lung (neop),PROCESS_OF,Human Age Group (aggp),3.58e-07,73.26,6,10,0,9.6,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of lung (neop),PROCESS_OF,General Population (humn),2.35e-08,68.99,6,17,0,8.12,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of lung (neop),PROCESS_OF,cohort (humn),6.53e-09,70.66,6,97,0,6.37,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of lung (neop),PROCESS_OF,cohort (humn),8.53e-09,71.11,6,15,0,8.4,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of lung (neop),ISA,Malignant disease (dsyn),7.39e-07,69.36,6,13,0,8.77,5.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of lung (neop),PROCESS_OF,Survivors (humn),8.39e-09,67.02,6,31,0,7.16,1.0
Body mass index (clna),PREDISPOSES,Malignant neoplasm of lung (neop),PROCESS_OF,African American (popg),2.71e-06,68.02,6,15,0,8.4,1.0
Electrocardiogram (diap),DIAGNOSES,"Hypertrophy, Left Ventricular (patf)",PREDISPOSES,Cerebrovascular accident (dsyn),3.41e-06,9.13,21,11,0,16.76,18.0
Electrocardiogram (diap),DIAGNOSES,"Hypertrophy, Left Ventricular (patf)",PROCESS_OF,cohort (humn),2.77e-07,8.5,21,14,0,23.33,1.0
Electrocardiogram (diap),DIAGNOSES,"Hypertrophy, Left Ventricular (patf)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.42e-10,15.81,21,70,0,27.3,18.0
Electrocardiogram (diap),DIAGNOSES,"Hypertrophy, Left Ventricular (patf)",ISA,Cardiovascular Diseases (dsyn),6.25e-07,7.14,21,17,0,30.76,5.0
Electrocardiogram (diap),DIAGNOSES,"Hypertrophy, Left Ventricular (patf)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.45e-09,9.15,21,16,0,28.19,9.0
Electrocardiogram (diap),DIAGNOSES,"Hypertrophy, Left Ventricular (patf)",ISA,Heart failure (dsyn),7.55e-08,7.74,21,17,0,30.76,5.0
insulin secretion (celf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),2.11e-06,21.55,6,20,0,7.8,1.0
insulin secretion (celf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.11e-06,18.74,6,65,0,6.55,1.0
insulin secretion (celf),PROCESS_OF,cohort (humn),USES,Treats (clas),2.48e-06,21.06,6,16,0,8.25,1.0
insulin secretion (celf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),6.2e-06,21.32,6,13,0,8.77,1.0
insulin secretion (celf),PROCESS_OF,cohort (humn),USES,Classification (clas),2.12e-06,22.3,6,16,0,8.25,1.0
insulin secretion (celf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),5.58e-06,27.7,6,8,0,10.5,1.0
insulin secretion (celf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.11e-06,21.18,6,23,0,7.57,1.0
insulin secretion (celf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),2.11e-06,22.08,6,22,0,7.64,1.0
insulin secretion (celf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),2.99e-06,22.0,6,13,0,8.77,1.0
insulin secretion (celf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.11e-06,24.0,6,15,0,8.4,1.0
Leptin|LEP (aapp),TREATS,Parkinson Disease (dsyn),ISA,Neurodegenerative Disorders (dsyn),4.02e-06,75.62,4,34,0,4.47,4.0
Fracture (inpo),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,11.22,24,20,0,36.67,1.0
Fracture (inpo),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,8.4,24,65,0,32.86,1.0
Fracture (inpo),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,10.72,24,16,0,26.67,1.0
Fracture (inpo),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,10.98,24,13,0,20.04,1.0
Fracture (inpo),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,11.96,24,16,0,26.67,1.0
Fracture (inpo),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,17.37,24,8,0,10.67,1.0
Fracture (inpo),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,10.84,24,23,0,45.04,1.0
Fracture (inpo),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,11.74,24,22,0,42.17,1.0
Fracture (inpo),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,11.67,24,13,0,20.04,1.0
Fracture (inpo),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,13.66,24,15,0,24.38,1.0
Diabetes Mellitus (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,16.34,50,18,0,24.48,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,30.43,62,20,0,26.45,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,27.62,62,65,0,121.14,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,29.94,62,16,0,20.13,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,30.19,62,13,0,15.73,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,31.18,62,16,0,20.13,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,36.58,62,8,0,9.03,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,30.06,62,23,0,31.53,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,30.95,62,22,0,29.81,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,30.88,62,13,0,15.73,1.0
Insulin Resistance (patf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,32.88,62,15,0,18.63,1.0
Body mass index (clna),PREDISPOSES,Pre-Eclampsia (dsyn),AFFECTS,Pathogenesis (patf),1.87e-06,44.43,9,25,0,12.24,7.0
Body mass index (clna),PREDISPOSES,Pre-Eclampsia (dsyn),PROCESS_OF,Pregnant Women (popg),4.59e-12,43.65,9,105,0,9.77,1.0
Body mass index (clna),PREDISPOSES,Pre-Eclampsia (dsyn),AFFECTS,Pregnancy (orgf),3.63e-08,45.5,9,21,0,12.86,7.0
Body mass index (clna),PREDISPOSES,Pre-Eclampsia (dsyn),ISA,Hypertension induced by pregnancy (dsyn),3.66e-08,44.48,9,31,0,11.61,5.0
Body mass index (clna),PREDISPOSES,Pre-Eclampsia (dsyn),PROCESS_OF,Pregnant Women (popg),4.89e-09,44.68,9,31,0,11.61,1.0
Body mass index (clna),PREDISPOSES,Pre-Eclampsia (dsyn),ISA,Pregnancy Complications (dsyn),3.18e-12,45.1,9,46,0,10.76,5.0
Body mass index (clna),PREDISPOSES,Pre-Eclampsia (dsyn),CAUSES,"Morbidity, perinatal (patf)",3.47e-06,52.74,9,8,0,15.11,11.0
Lipoproteins (aapp),ISA,Lipids (lipd),PART_OF,Stratum corneum (tisu),7.96e-07,3.82,37,2,0,2.11,3.0
Bariatric Surgery (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,31.36,14,16,0,26.25,4.0
Bariatric Surgery (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),4.53e-17,41.57,14,26,0,21.54,4.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.64e-06,23.2,8,9,0,15.11,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),4.59e-08,22.25,8,194,0,8.33,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),4.63e-08,20.98,8,17,0,11.76,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),4.59e-08,22.25,8,29,0,10.21,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),4.61e-08,24.43,8,14,0,12.57,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.11e-06,20.24,8,12,0,13.33,5.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),4.59e-08,19.06,8,48,0,9.33,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),4.59e-08,22.45,8,29,0,10.21,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),4.59e-08,19.49,8,98,0,8.65,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),2.22e-07,24.57,8,10,0,14.4,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),5.81e-08,16.93,8,37,0,9.73,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),5.27e-08,18.73,8,20,0,11.2,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),4.59e-08,20.38,8,94,0,8.68,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.39e-06,26.17,8,8,0,16.0,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),4.59e-08,23.05,8,19,0,11.37,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),4.6e-08,20.2,8,21,0,11.05,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),4.87e-08,25.38,8,12,0,13.33,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.86e-08,33.1,8,10,0,14.4,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),1.28e-07,25.69,8,10,0,14.4,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),4.6e-08,20.0,8,21,0,11.05,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),4.59e-08,21.61,8,21,0,11.05,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),4.59e-08,19.74,8,32,0,10.0,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),8.13e-08,27.1,8,10,0,14.4,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),4.59e-08,26.07,8,39,0,9.64,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),4.59e-08,30.04,8,44,0,9.45,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,22.92,8,113,0,8.57,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.8e-06,20.45,8,11,0,13.82,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.22e-06,20.17,8,11,0,13.82,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),6.05e-07,20.63,8,12,0,13.33,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),4.61e-08,18.53,8,25,0,10.56,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",4.59e-08,24.2,8,87,0,8.74,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),4.59e-08,19.19,8,33,0,9.94,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),4.59e-08,21.93,8,41,0,9.56,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),4.59e-08,22.1,8,21,0,11.05,1.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",4.6e-08,19.76,8,21,0,11.05,7.0
Metabolic syndrome (dsyn),AFFECTS,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),4.59e-08,20.71,8,1021,0,8.06,7.0
Cognitive Therapy (topp),TREATS,Anorexia Nervosa (mobd),ISA,Mental disorders (mobd),4.29e-19,17.74,20,46,0,28.7,4.0
European origin (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),1.02e-06,11.82,8,136,0,8.47,1.0
European origin (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),1.02e-06,10.95,8,188,0,8.34,1.0
European origin (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Population Group (humn),3.55e-06,11.83,8,20,0,11.2,1.0
Sedentary (fndg),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),2.66e-07,26.51,7,25,0,8.96,1.0
Sedentary (fndg),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),2.72e-07,24.31,7,13,0,10.77,1.0
Sedentary (fndg),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),2.66e-07,28.77,7,32,0,8.53,1.0
Polysomnography (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.16e-09,25.76,56,18,0,23.79,6.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.69e-06,13.06,13,9,0,15.23,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),9.8e-08,12.12,13,194,0,13.87,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),9.83e-08,10.84,13,17,0,22.94,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),9.8e-08,12.11,13,29,0,18.83,11.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),9.82e-08,14.29,13,14,0,25.07,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.16e-06,10.1,13,12,0,23.08,5.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),9.8e-08,8.92,13,48,0,16.52,11.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),9.8e-08,12.31,13,29,0,18.83,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.8e-08,9.36,13,98,0,14.72,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),1e-07,8.02,13,24,0,20.04,9.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),2.74e-07,14.43,13,10,0,17.69,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.1e-07,6.79,13,37,0,17.57,7.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.05e-07,8.59,13,20,0,21.45,9.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),9.8e-08,10.25,13,94,0,14.8,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.44e-06,16.04,13,8,0,12.92,9.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),9.8e-08,12.91,13,19,0,21.89,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),9.8e-08,10.07,13,21,0,21.05,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),1.01e-07,15.24,13,12,0,23.08,9.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.01e-07,22.96,13,10,0,17.69,21.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),1.8e-07,15.55,13,10,0,17.69,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),9.8e-08,9.87,13,21,0,21.05,21.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),9.8e-08,11.47,13,21,0,21.05,9.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.8e-08,9.6,13,32,0,18.28,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),1.33e-07,16.96,13,10,0,17.69,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),9.8e-08,15.93,13,39,0,17.33,9.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),9.8e-08,19.91,13,44,0,16.84,11.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",9.8e-08,12.78,13,113,0,14.5,9.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.85e-06,10.31,13,11,0,20.31,11.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.27e-06,10.03,13,11,0,20.31,9.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),6.57e-07,10.5,13,12,0,23.08,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),9.81e-08,8.39,13,25,0,19.76,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",9.8e-08,14.06,13,87,0,14.94,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),9.8e-08,9.05,13,33,0,18.12,9.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),9.8e-08,11.79,13,41,0,17.12,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),9.8e-08,11.96,13,21,0,21.05,1.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",9.8e-08,9.62,13,21,0,21.05,9.0
Lipoproteins (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),9.8e-08,10.57,13,1021,0,13.17,11.0
Married (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.28e-09,12.66,14,18,0,24.89,1.0
Behavior (inbe),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.11e-09,9.65,17,20,0,31.45,1.0
Behavior (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.65e-09,6.83,17,65,0,21.45,1.0
Behavior (inbe),PROCESS_OF,cohort (humn),USES,Treats (clas),3.76e-07,9.15,17,16,0,31.06,1.0
Behavior (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,9.41,17,13,0,22.94,1.0
Behavior (inbe),PROCESS_OF,cohort (humn),USES,Classification (clas),1.24e-08,10.39,17,16,0,31.06,1.0
Behavior (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,15.8,17,8,0,11.76,1.0
Behavior (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.87e-10,9.27,17,23,0,29.57,1.0
Behavior (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.26e-10,10.17,17,22,0,30.14,1.0
Behavior (inbe),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,10.1,17,13,0,22.94,1.0
Behavior (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.65e-09,12.09,17,15,0,28.24,1.0
Bariatric Surgery (topp),AFFECTS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,50.0,8,16,0,12.0,7.0
Bariatric Surgery (topp),AFFECTS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),4.28e-11,60.21,8,26,0,10.46,7.0
Walking (dora),ISA,Behavior (inbe),PROCESS_OF,network (popg),2.65e-06,2.46,21,4,0,4.76,1.0
Assessment procedure (hlca),TREATS,cohort (humn),USES,Medicare (rnlw),6.08e-07,7.08,17,20,0,31.45,4.0
Assessment procedure (hlca),TREATS,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),6.1e-07,4.26,17,65,0,21.45,2.0
Assessment procedure (hlca),TREATS,cohort (humn),USES,Treats (clas),9.82e-07,6.58,17,16,0,31.06,4.0
Assessment procedure (hlca),TREATS,cohort (humn),LOCATION_OF,Calcium (bacs),4.7e-06,6.84,17,13,0,22.94,2.0
Assessment procedure (hlca),TREATS,cohort (humn),USES,Classification (clas),6.19e-07,7.82,17,16,0,31.06,4.0
Assessment procedure (hlca),TREATS,cohort (humn),LOCATION_OF,Sodium (elii),4.08e-06,13.23,17,8,0,11.76,2.0
Assessment procedure (hlca),TREATS,cohort (humn),LOCATION_OF,C-reactive protein (aapp),6.07e-07,6.7,17,23,0,29.57,2.0
Assessment procedure (hlca),TREATS,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),6.07e-07,7.6,17,22,0,30.14,2.0
Assessment procedure (hlca),TREATS,cohort (humn),USES,Tissue Microarray (resd),1.49e-06,7.53,17,13,0,22.94,4.0
Assessment procedure (hlca),TREATS,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),6.09e-07,9.52,17,15,0,28.24,2.0
Body mass index procedure (diap),ISA,Procedures (hlca),METHOD_OF,Aortic valve replacement NOS (topp),1.18e-13,77.31,14,21,0,23.33,5.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,Atrial Fibrillation (patf),1.51e-13,73.48,14,35,0,19.6,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,End stage liver disease (dsyn),3.96e-08,75.35,14,15,0,27.07,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,Congenital heart disease (dsyn),1.06e-06,75.58,14,12,0,22.29,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,cohort (humn),2.78e-07,73.25,14,20,0,23.8,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,Heart failure (dsyn),1.34e-09,74.82,14,19,0,24.32,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,Aortic Valve Stenosis (dsyn),3.29e-21,77.88,14,43,0,18.56,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,Octogenarians (aggp),1.17e-07,83.94,14,9,0,14.79,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),ADMINISTERED_TO,Surgeon (humn),1.89e-14,72.3,14,61,0,17.21,5.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,Coronary Arteriosclerosis (dsyn),2.58e-10,74.36,14,22,0,22.91,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,"Pancreatitis, Chronic (dsyn)",4.17e-14,74.58,14,29,0,20.76,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,Need for isolation (fndg),1.82e-14,70.46,14,2,0,2.29,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,Diabetic (fndg),3.68e-06,73.99,14,14,0,28.0,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,Aortic valve disorder (dsyn),6.65e-14,76.93,14,22,0,22.91,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,Septicemia (dsyn),1.58e-06,77.36,14,10,0,17.14,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,Hypoplastic Left Heart Syndrome (dsyn),3.29e-21,77.37,14,72,0,16.72,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,Rectal Prolapse (dsyn),5.87e-07,73.26,14,19,0,24.32,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,Dissection of aorta (dsyn),4.09e-07,75.42,14,13,0,25.07,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,Hemorrhage (fndg),1.9e-10,72.66,14,36,0,19.44,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,Body Weight decreased (fndg),3.66e-09,74.23,14,20,0,23.8,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),TREATS,"Obesity, Morbid (dsyn)",1.61e-17,73.89,13,40,1,17.23,4.0
Body mass index procedure (diap),ISA,Procedures (hlca),METHOD_OF,Coronary Artery Bypass Surgery (topp),3.09e-09,78.8,14,13,0,25.07,5.0
Myocardial Ischemia (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),3.44e-06,10.37,9,20,0,13.05,1.0
Myocardial Ischemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.44e-06,7.56,9,65,0,10.25,1.0
Myocardial Ischemia (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.82e-06,9.88,9,16,0,14.06,1.0
Myocardial Ischemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),7.54e-06,10.13,9,13,0,15.23,1.0
Myocardial Ischemia (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),3.45e-06,11.11,9,16,0,14.06,1.0
Myocardial Ischemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),6.91e-06,16.52,9,8,0,15.11,1.0
Myocardial Ischemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),3.44e-06,10.0,9,23,0,12.52,1.0
Myocardial Ischemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),3.44e-06,10.89,9,22,0,12.68,1.0
Myocardial Ischemia (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),4.33e-06,10.82,9,13,0,15.23,1.0
Myocardial Ischemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),3.44e-06,12.82,9,15,0,14.4,1.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Uterus - Cervix (MMHCC) (tisu),4.33e-09,1.27,7,79,0,7.62,2.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Mucous Membrane (tisu),2.72e-08,2.75,7,24,0,9.04,2.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Buccal mucosa (bpoc),8.44e-07,2.33,7,23,0,9.13,2.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Tongue (bpoc),1.7e-09,1.89,7,311,0,7.16,2.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Entire oropharynx (bpoc),1.7e-09,4.09,7,45,0,8.09,2.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Vulva (bpoc),3.08e-07,1.27,7,61,0,7.8,2.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Entire hypopharynx (bpoc),1.7e-09,3.5,7,50,0,7.98,2.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),COEXISTS_WITH,Adenocarcinoma (neop),8.35e-08,2.38,7,26,0,8.88,2.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Tonsil (bpoc),1.7e-09,2.85,7,35,0,8.4,2.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Thoracic esophagus (bpoc),1.7e-09,4.73,7,65,0,7.75,2.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Esophagus (bpoc),1.7e-09,2.28,7,293,0,7.17,2.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Larynx (bpoc),1.7e-09,1.9,7,179,0,7.27,2.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Anus (bpoc),2.83e-07,1.83,7,33,0,8.48,2.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PROCESS_OF,cohort (humn),1.16e-08,4.58,7,17,0,9.88,1.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Entire temporal bone (bpoc),1.91e-09,3.24,7,26,0,8.88,2.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,penis (bpoc),1.7e-09,1.91,7,69,0,7.71,2.0
Head (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Anal canal (bpoc),1.7e-09,2.64,7,44,0,8.11,2.0
Physical activity (dora),PREVENTS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),1.93e-08,19.65,8,33,0,9.94,1.0
Physical activity (dora),PREVENTS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.45e-06,20.19,8,16,0,12.0,9.0
Physical activity (dora),PREVENTS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.91e-08,19.99,8,71,0,8.9,5.0
Physical activity (dora),PREVENTS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.91e-08,33.84,8,35,0,9.83,21.0
Physical activity (dora),PREVENTS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.91e-08,19.92,8,110,0,8.58,21.0
Physical activity (dora),PREVENTS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),2.04e-08,19.26,8,37,0,9.73,1.0
Insulin Resistance (patf),PREDISPOSES,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.71e-11,18.56,17,25,0,28.56,21.0
Insulin Resistance (patf),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.74e-10,22.46,17,15,0,28.24,9.0
Insulin Resistance (patf),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),7.26e-17,27.84,17,24,0,29.04,11.0
Insulin Resistance (patf),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),7.26e-17,18.48,17,46,0,23.28,11.0
Insulin Resistance (patf),PREDISPOSES,Atherosclerosis (dsyn),PROCESS_OF,General Population (humn),6.44e-10,18.05,17,24,0,29.04,1.0
Insulin Resistance (patf),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),5.09e-10,19.89,17,18,0,33.06,11.0
Insulin Resistance (patf),PREDISPOSES,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),9.37e-17,16.62,17,73,0,20.96,5.0
Insulin Resistance (patf),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),9.39e-08,17.22,17,24,0,29.04,11.0
Insulin Resistance (patf),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",7.35e-17,18.53,17,41,0,24.05,9.0
Insulin Resistance (patf),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),7.75e-10,19.31,17,19,0,32.21,11.0
Insulin Resistance (patf),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.95e-15,20.19,17,26,0,28.12,9.0
Entire lumbar spine (blor),LOCATION_OF,Scanning (diap),USES,Calcium (bacs),1.02e-08,10.69,14,32,0,20.12,2.0
Hypertensive (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,15.53,68,18,0,22.76,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,20.68,11,9,0,16.36,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.65e-10,19.74,11,194,0,11.62,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),6.01e-10,18.46,11,17,0,18.12,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.65e-10,19.73,11,29,0,15.17,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),4.64e-10,21.91,11,14,0,19.64,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,17.72,11,12,0,21.08,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),2.65e-10,16.54,11,48,0,13.52,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.65e-10,19.93,11,29,0,15.17,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.65e-10,16.98,11,98,0,12.23,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.59e-09,15.64,11,24,0,16.04,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,22.06,11,10,0,19.09,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.24e-08,14.41,11,37,0,14.27,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),7e-09,16.22,11,20,0,17.05,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.65e-10,17.87,11,94,0,12.29,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,23.66,11,8,0,13.82,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),2.65e-10,20.53,11,19,0,17.37,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),2.77e-10,17.69,11,21,0,16.76,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),3.04e-09,22.87,11,12,0,21.08,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.9e-09,30.59,11,10,0,19.09,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.21e-08,23.17,11,10,0,19.09,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.87e-10,17.49,11,21,0,16.76,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.65e-10,19.1,11,21,0,16.76,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.65e-10,17.22,11,32,0,14.78,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.56e-08,24.58,11,10,0,19.09,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.65e-10,23.55,11,39,0,14.1,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),2.65e-10,27.53,11,44,0,13.75,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.65e-10,20.4,11,113,0,12.07,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,17.93,11,11,0,22.0,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,17.66,11,11,0,22.0,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.6e-07,18.12,11,12,0,21.08,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),3.82e-10,16.01,11,25,0,15.84,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.65e-10,21.69,11,87,0,12.39,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),2.65e-10,16.68,11,33,0,14.67,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.65e-10,19.41,11,41,0,13.95,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),2.65e-10,19.58,11,21,0,16.76,1.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",3.15e-10,17.25,11,21,0,16.76,5.0
Increase in blood pressure (fndg),ISA,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.65e-10,18.19,11,1021,0,11.12,5.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),4.64e-06,8.4,10,20,0,15.0,1.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Disability NOS (patf),4.62e-06,11.55,10,36,0,12.78,4.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),ISA,Respiration Disorders (dsyn),4.62e-06,8.18,10,59,0,11.69,4.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Respiratory physiology (ortf),4.65e-06,7.83,10,23,0,14.35,1.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Acute respiratory failure (dsyn),4.98e-06,10.84,10,12,0,18.33,4.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),4.62e-06,8.55,10,72,0,11.39,1.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),ISA,Lung diseases (dsyn),4.62e-06,8.01,10,73,0,11.37,4.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Hospitalized Patients (humn),4.62e-06,9.35,10,50,0,12.0,1.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospital admission (hlca),4.63e-06,11.14,10,15,0,16.67,4.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Cessation of life (orgf),4.62e-06,11.07,10,184,0,10.54,4.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Outpatients (podg),4.64e-06,6.61,10,43,0,12.33,1.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,General Population (humn),4.63e-06,8.57,10,27,0,13.7,1.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Diagnosis (hlca),4.8e-06,12.62,10,11,0,19.09,4.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospitalization (hlca),4.62e-06,10.75,10,31,0,13.23,4.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Participant (humn),4.62e-06,7.91,10,70,0,11.43,1.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),COEXISTS_WITH,Smoker (fndg),4.86e-06,7.08,10,27,0,13.7,4.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),ISA,Chronic Disease (dsyn),4.62e-06,9.06,10,46,0,12.17,4.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Malignant neoplasm of lung (neop),4.71e-06,8.78,10,17,0,15.88,4.0
Rehabilitation therapy (topp),TREATS,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Pneumonia (dsyn),5.07e-06,10.68,10,12,0,18.33,4.0
Insulin Resistance (patf),AFFECTS,Pregnancy (orgf),PROCESS_OF,Survivors (humn),6.19e-07,28.15,6,15,0,8.4,1.0
Insulin Resistance (patf),AFFECTS,Pregnancy (orgf),PROCESS_OF,"Twins, Dizygotic (humn)",6.08e-07,24.63,6,60,0,6.6,1.0
Insulin Resistance (patf),AFFECTS,Pregnancy (orgf),PROCESS_OF,Monoamniotic twins (podg),6.08e-07,25.5,6,33,0,7.09,1.0
Insulin Resistance (patf),AFFECTS,Pregnancy (orgf),PROCESS_OF,Singleton (humn),6.08e-07,24.14,6,357,0,6.1,1.0
Insulin Resistance (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,15.31,71,33,0,48.34,1.0
Insulin Resistance (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,15.85,71,16,0,19.61,9.0
Insulin Resistance (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.33e-25,15.66,71,71,0,142.0,5.0
Insulin Resistance (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.96e-32,29.5,71,35,0,52.25,9.0
Insulin Resistance (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.09e-38,15.58,71,110,0,116.83,9.0
Insulin Resistance (patf),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,14.92,71,37,0,56.28,1.0
Vitamin D (phsu),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.29e-07,24.68,7,16,0,10.06,7.0
Vitamin D (phsu),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.02e-06,29.85,7,9,0,12.44,7.0
Vitamin D (phsu),AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),2e-07,22.24,7,31,0,8.58,7.0
Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.08e-09,8.19,21,20,0,39.05,1.0
Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.62e-09,5.38,21,65,0,27.78,1.0
Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),USES,Treats (clas),3.76e-07,7.7,21,16,0,28.19,1.0
Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,7.95,21,13,0,21.05,1.0
Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),USES,Classification (clas),1.23e-08,8.94,21,16,0,28.19,1.0
Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,14.34,21,8,0,11.05,1.0
Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.55e-10,7.82,21,23,0,40.17,1.0
Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),9.39e-11,8.71,21,22,0,41.05,1.0
Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,8.64,21,13,0,21.05,1.0
Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.62e-09,10.64,21,15,0,25.71,1.0
Metformin (phsu),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.16e-09,36.48,13,18,0,22.39,6.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,American (popg),8.29e-08,17.76,9,17,0,13.76,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),AFFECTS,Depressed mood (fndg),1.62e-06,22.3,9,8,0,15.11,7.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Octogenarians (aggp),1.96e-06,18.82,9,9,0,18.0,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),CAUSES,Myocardial Infarction (dsyn),8.72e-08,18.36,9,13,0,15.23,11.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),CAUSES,follow-up (hlca),2.53e-07,16.65,9,12,0,15.75,11.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),CAUSES,"Death, Sudden (patf)",8.29e-08,19.54,9,19,0,13.26,11.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),CAUSES,Cessation of life (orgf),8.29e-08,16.41,9,251,0,9.32,11.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,High Risk Populations (popg),2.04e-07,20.29,9,10,0,17.1,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),8.29e-08,18.42,9,28,0,11.89,21.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,General Population (humn),8.29e-08,18.97,9,67,0,10.21,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Hospital specialist (humn),8.31e-08,14.91,9,20,0,13.05,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,General Population (humn),8.29e-08,19.82,9,18,0,13.5,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.42e-06,19.29,9,9,0,18.0,9.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,African American (popg),8.29e-08,16.02,9,49,0,10.65,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.4e-07,17.49,9,12,0,15.75,9.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Human Age Group (aggp),1.29e-07,19.29,9,11,0,16.36,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),8.29e-08,17.59,9,32,0,11.53,9.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Caucasoid Race (popg),8.29e-08,17.74,9,24,0,12.38,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),CAUSES,Cardiac Death (patf),8.29e-08,19.89,9,24,0,12.38,11.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,inpatient (humn),8.29e-08,16.24,9,37,0,11.19,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Physical findings (sosy),4.26e-06,15.37,9,11,0,16.36,9.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Veterans (popg),8.84e-08,16.16,9,15,0,14.4,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),8.29e-08,15.48,9,154,0,9.53,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),AFFECTS,Pathogenesis (patf),2.13e-07,13.09,9,21,0,12.86,7.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Participant (humn),8.29e-08,15.35,9,84,0,9.96,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),CAUSES,Hospital Readmissions (hlca),8.29e-08,23.56,9,14,0,14.79,11.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),8.29e-08,17.8,8,255,1,8.25,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),ISA,Cardiovascular Diseases (dsyn),8.29e-08,15.05,9,106,0,9.76,5.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),3.12e-07,17.63,9,11,0,16.36,21.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),CAUSES,Hospitalization (hlca),8.29e-08,19.12,9,249,0,9.33,11.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),8.29e-08,17.97,8,54,1,9.19,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Survivors (humn),8.29e-08,17.91,9,33,0,11.45,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),CAUSES,"Death, Sudden, Cardiac (patf)",8.34e-08,20.47,9,13,0,15.23,11.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),CAUSES,Diagnosis (hlca),1.37e-07,16.45,9,13,0,15.23,11.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),8.29e-08,16.67,9,34,0,11.38,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Population Group (humn),8.29e-08,20.5,9,17,0,13.76,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Participant (humn),8.29e-08,16.21,9,25,0,12.24,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),ISA,Heart Diseases (dsyn),8.29e-08,14.66,9,42,0,10.93,5.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),COMPLICATES,Acute myocardial infarction (dsyn),8.29e-08,17.23,9,42,0,10.93,21.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Sinus rhythm (fndg),8.29e-08,16.96,9,30,0,11.7,9.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),AFFECTS,Atrial Fibrillation (patf),3.73e-07,21.87,9,9,0,18.0,7.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),CAUSES,Hospital admission (hlca),8.29e-08,18.97,9,40,0,11.03,11.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Western society (popg),1.42e-06,19.29,9,9,0,18.0,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Anemia (dsyn),5.69e-07,18.48,9,10,0,17.1,9.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,cohort (humn),8.29e-08,18.23,9,119,0,9.68,1.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),COMPLICATES,Myocardial Infarction (dsyn),8.29e-08,16.29,9,20,0,13.05,21.0
N-terminal pro-B-type natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),AFFECTS,Systemic arterial pressure (fndg),8.98e-08,16.04,9,15,0,14.4,7.0
Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,9.89,29,18,0,29.17,1.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Cancer of Rectum (neop),PROCESS_OF,cohort (humn),3.24e-08,9.98,26,15,0,23.65,1.0
Endothelial dysfunction (dsyn),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.02e-07,17.8,10,16,0,16.25,9.0
Endothelial dysfunction (dsyn),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),7.86e-10,28.01,10,26,0,13.85,9.0
resistin|RETN (aapp),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.66e-07,36.71,6,16,0,8.25,7.0
resistin|RETN (aapp),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.06e-06,41.87,6,9,0,10.0,7.0
resistin|RETN (aapp),AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),2.37e-07,34.26,6,31,0,7.16,7.0
Fatty degeneration (patf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),2.23e-07,21.18,7,20,0,9.45,1.0
Fatty degeneration (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.24e-07,18.36,7,65,0,7.75,1.0
Fatty degeneration (patf),PROCESS_OF,cohort (humn),USES,Treats (clas),5.97e-07,20.69,7,16,0,10.06,1.0
Fatty degeneration (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.32e-06,20.94,7,13,0,10.77,1.0
Fatty degeneration (patf),PROCESS_OF,cohort (humn),USES,Classification (clas),2.34e-07,21.92,7,16,0,10.06,1.0
Fatty degeneration (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.69e-06,27.33,7,8,0,13.12,1.0
Fatty degeneration (patf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.22e-07,20.81,7,23,0,9.13,1.0
Fatty degeneration (patf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),2.22e-07,21.7,7,22,0,9.23,1.0
Fatty degeneration (patf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),1.11e-06,21.63,7,13,0,10.77,1.0
Fatty degeneration (patf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.23e-07,23.63,7,15,0,10.27,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,24.73,13,9,0,15.23,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.77e-13,23.79,13,194,0,13.87,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,22.52,13,17,0,22.94,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.77e-13,23.78,13,29,0,18.83,11.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2e-10,25.97,13,14,0,25.07,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,21.77,13,12,0,23.08,5.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.77e-13,20.59,13,48,0,16.52,11.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.77e-13,23.98,13,29,0,18.83,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.77e-13,21.03,13,98,0,14.72,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,19.69,13,24,0,20.04,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,26.11,13,10,0,17.69,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,18.46,13,37,0,17.57,7.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,20.27,13,20,0,21.45,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.77e-13,21.92,13,94,0,14.8,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,27.71,13,8,0,12.92,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),4.9e-13,24.59,13,19,0,21.89,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.22e-11,21.74,13,21,0,21.05,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,26.92,13,12,0,23.08,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,34.64,13,10,0,17.69,21.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,27.22,13,10,0,17.69,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.27e-11,21.54,13,21,0,21.05,21.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),4.47e-13,23.15,13,21,0,21.05,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.77e-13,21.28,13,32,0,18.28,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,28.63,13,10,0,17.69,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.77e-13,27.6,13,39,0,17.33,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.77e-13,31.58,13,44,0,16.84,11.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.77e-13,24.46,13,113,0,14.5,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,21.98,13,11,0,20.31,11.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,21.71,13,11,0,20.31,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,22.17,13,12,0,23.08,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,20.06,13,25,0,19.76,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.77e-13,25.74,13,87,0,14.94,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.78e-13,20.73,13,33,0,18.12,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.77e-13,23.46,13,41,0,17.12,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),2.66e-13,23.63,13,21,0,21.05,1.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5.02e-11,21.3,13,21,0,21.05,9.0
Adiponectin (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.77e-13,22.24,13,1021,0,13.17,11.0
"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,14.67,68,18,0,22.76,1.0
Exercise (dora),ISA,Behavior (inbe),PROCESS_OF,network (popg),2.21e-06,4.91,133,4,0,4.12,1.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Uterus - Cervix (MMHCC) (tisu),3.8e-09,1.26,6,79,0,6.46,2.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Mucous Membrane (tisu),2.67e-08,2.74,6,24,0,7.5,2.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Buccal mucosa (bpoc),8.43e-07,2.32,6,23,0,7.57,2.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Tongue (bpoc),1.17e-09,1.88,6,311,0,6.12,2.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Entire oropharynx (bpoc),1.17e-09,4.08,6,45,0,6.8,2.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Vulva (bpoc),3.08e-07,1.27,6,61,0,6.59,2.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Entire hypopharynx (bpoc),1.17e-09,3.5,6,50,0,6.72,2.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),COEXISTS_WITH,Adenocarcinoma (neop),8.29e-08,2.37,6,26,0,7.38,2.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Tonsil (bpoc),1.17e-09,2.84,6,35,0,7.03,2.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Thoracic esophagus (bpoc),1.17e-09,4.72,6,65,0,6.55,2.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Esophagus (bpoc),1.17e-09,2.27,6,293,0,6.12,2.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Larynx (bpoc),1.17e-09,1.9,6,179,0,6.2,2.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Anus (bpoc),2.83e-07,1.82,6,33,0,7.09,2.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PROCESS_OF,cohort (humn),1.11e-08,4.57,6,17,0,8.12,1.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Entire temporal bone (bpoc),1.38e-09,3.24,6,26,0,7.38,2.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,penis (bpoc),1.17e-09,1.9,6,69,0,6.52,2.0
Neck (blor),LOCATION_OF,Squamous cell carcinoma (neop),PART_OF,Anal canal (bpoc),1.17e-09,2.63,6,44,0,6.82,2.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Sleep Apnea Syndromes (dsyn),COEXISTS_WITH,Heart failure (dsyn),2.14e-06,20.41,7,10,0,11.9,5.0
Hip Fractures (inpo),ISA,Fracture (inpo),PROCESS_OF,Geriatric Patients (humn),2.1e-07,10.54,20,15,0,26.25,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,African American (popg),ISA,Ethnic group (popg),5.21e-08,13.31,9,98,0,9.83,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,African American (popg),ISA,Racial group (popg),5.21e-08,14.25,9,324,0,9.25,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,Vascular calcification (patf),5.98e-10,36.98,9,17,0,13.76,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",9.04e-10,33.48,9,12,0,15.75,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),PROCESS_OF,General Population (humn),5.98e-10,32.94,9,36,0,11.25,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),5.98e-10,35.21,9,22,0,12.68,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",6.51e-07,30.11,9,9,0,18.0,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,"Hypertrophy, Left Ventricular (patf)",2.34e-06,31.06,9,8,0,15.11,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,Atherosclerosis (dsyn),1.14e-09,36.48,9,11,0,16.36,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.98e-10,35.73,9,28,0,11.89,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,Peripheral Vascular Diseases (dsyn),5.98e-10,37.98,9,17,0,13.76,9.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,14.92,17,20,0,31.45,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,12.11,17,65,0,21.45,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,14.43,17,16,0,31.06,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,14.68,17,13,0,22.94,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,15.66,17,16,0,31.06,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,21.07,17,8,0,11.76,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,14.55,17,23,0,29.57,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,15.44,17,22,0,30.14,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,15.37,17,13,0,22.94,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,17.37,17,15,0,28.24,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),1e-09,21.8,9,33,0,11.45,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,22.35,9,16,0,14.06,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),7.42e-10,22.15,9,71,0,10.14,5.0
Vitamin D (phsu),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),7.42e-10,35.99,9,35,0,11.31,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),7.42e-10,22.07,9,110,0,9.74,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),2.1e-09,21.41,9,37,0,11.19,1.0
Bone structure of ischium (bpoc),LOCATION_OF,Scanning (diap),USES,Calcium (bacs),1.02e-08,14.4,15,32,0,22.03,2.0
Body Weight Changes (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,33.35,24,20,0,36.67,1.0
Body Weight Changes (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,30.54,24,65,0,32.86,1.0
Body Weight Changes (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,32.86,24,16,0,26.67,1.0
Body Weight Changes (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,33.12,24,13,0,20.04,1.0
Body Weight Changes (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,34.1,24,16,0,26.67,1.0
Body Weight Changes (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,39.5,24,8,0,10.67,1.0
Body Weight Changes (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,32.98,24,23,0,45.04,1.0
Body Weight Changes (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,33.88,24,22,0,42.17,1.0
Body Weight Changes (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,33.8,24,13,0,20.04,1.0
Body Weight Changes (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,35.8,24,15,0,24.38,1.0
Blood Pressure (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Survivors (humn),1.11e-08,14.25,22,15,0,25.23,1.0
Blood Pressure (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,"Twins, Dizygotic (humn)",2.42e-15,10.73,22,60,0,30.07,1.0
Blood Pressure (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Monoamniotic twins (podg),4.11e-12,11.6,22,33,0,36.67,1.0
Blood Pressure (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Singleton (humn),1.55e-17,10.24,22,357,0,23.36,1.0
Oxidative Stress (comd),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.04e-07,15.73,10,16,0,16.25,9.0
Oxidative Stress (comd),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),2.89e-09,25.94,10,26,0,13.85,9.0
Body mass index (clna),PREDISPOSES,Diabetes Mellitus (dsyn),COEXISTS_WITH,Heart failure (dsyn),3.21e-12,72.12,24,15,0,24.38,9.0
Body mass index (clna),PREDISPOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.71e-13,74.59,24,15,0,24.38,21.0
Body mass index (clna),PREDISPOSES,Diabetes Mellitus (dsyn),CAUSES,"Kidney Failure, Chronic (dsyn)",8.14e-12,66.09,24,20,0,36.67,11.0
Body mass index (clna),PREDISPOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.41e-28,65.36,24,52,0,35.08,21.0
Body mass index (clna),PREDISPOSES,Diabetes Mellitus (dsyn),PROCESS_OF,Hospitalized Patients (humn),5.59e-07,64.23,24,15,0,24.38,1.0
Body mass index (clna),PREDISPOSES,Diabetes Mellitus (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",7.7e-09,63.75,24,21,0,39.38,1.0
Body mass index (clna),PREDISPOSES,Diabetes Mellitus (dsyn),CAUSES,End stage renal failure (dsyn),6.7e-27,65.04,24,51,0,35.29,11.0
Body mass index (clna),PREDISPOSES,Diabetes Mellitus (dsyn),PROCESS_OF,Survivors (humn),7.61e-08,67.35,24,12,0,18.0,1.0
Body mass index (clna),PREDISPOSES,Diabetes Mellitus (dsyn),CAUSES,Kidney Failure (dsyn),3.63e-11,69.69,24,15,0,24.38,11.0
Body mass index (clna),PREDISPOSES,Diabetes Mellitus (dsyn),CAUSES,Cessation of life (orgf),1.64e-27,66.94,24,43,0,37.4,11.0
Body mass index (clna),PREDISPOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),4.72e-09,67.19,24,14,0,22.17,21.0
Body mass index (clna),PREDISPOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),3.35e-14,65.36,24,26,0,46.15,21.0
Body mass index (clna),PREDISPOSES,Diabetes Mellitus (dsyn),PROCESS_OF,General Population (humn),9.45e-11,64.55,24,22,0,42.17,1.0
Body mass index (clna),PREDISPOSES,Diabetes Mellitus (dsyn),ISA,Metabolic Diseases (dsyn),1.63e-06,61.73,24,43,0,37.4,5.0
Body mass index (clna),PREDISPOSES,Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),3.07e-20,64.19,24,44,0,37.09,1.0
FNDC5 (gngm),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.68e-08,52.39,7,16,0,10.06,8.0
FNDC5 (gngm),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.4e-07,57.56,7,9,0,12.44,8.0
FNDC5 (gngm),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.18e-07,49.94,7,31,0,8.58,8.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,American (popg),1.72e-11,82.94,22,17,0,30.14,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),AFFECTS,Depressed mood (fndg),1.53e-06,87.47,22,8,0,10.91,7.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,Octogenarians (aggp),1.88e-06,84.0,22,9,0,12.68,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),CAUSES,Myocardial Infarction (dsyn),4.26e-09,83.54,22,13,0,20.68,11.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),CAUSES,follow-up (hlca),1.7e-07,81.82,22,12,0,18.55,11.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),CAUSES,"Death, Sudden (patf)",4.01e-14,84.72,22,19,0,35.41,11.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),CAUSES,Cessation of life (orgf),5.38e-34,81.59,22,251,0,23.93,11.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,High Risk Populations (popg),1.21e-07,85.47,22,10,0,14.55,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),9.03e-20,83.6,22,28,0,39.29,18.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,General Population (humn),5.38e-34,84.15,20,65,2,26.15,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,Hospital specialist (humn),1.97e-10,80.09,22,20,0,38.18,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,General Population (humn),1.51e-13,85.0,22,18,0,32.73,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.34e-06,84.47,22,9,0,12.68,9.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,African American (popg),3.42e-29,81.2,22,49,0,31.88,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.74e-08,82.67,22,12,0,18.55,9.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,Human Age Group (aggp),4.63e-08,84.47,22,11,0,16.5,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),1.64e-21,82.76,22,32,0,37.12,9.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,Caucasoid Race (popg),3.07e-16,82.92,22,24,0,42.17,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),CAUSES,Cardiac Death (patf),3.56e-18,85.07,22,24,0,42.17,11.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,inpatient (humn),1.92e-22,81.42,22,37,0,35.08,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),COEXISTS_WITH,Physical findings (sosy),4.17e-06,80.55,22,11,0,16.5,9.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,Veterans (popg),5.48e-09,81.34,22,15,0,25.23,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),5.38e-34,80.66,21,153,1,23.88,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),AFFECTS,Pathogenesis (patf),1.3e-07,78.27,22,21,0,41.05,7.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,Participant (humn),5.38e-34,80.53,21,83,1,26.31,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),CAUSES,Hospital Readmissions (hlca),6.72e-12,88.74,22,14,0,22.91,11.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),5.38e-34,82.98,21,255,1,22.73,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),ISA,Cardiovascular Diseases (dsyn),5.38e-34,80.23,22,106,0,26.57,5.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),2.29e-07,82.81,22,11,0,16.5,18.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),CAUSES,Hospitalization (hlca),5.38e-34,84.3,22,249,0,23.94,11.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),5.38e-34,83.15,22,55,0,30.8,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,Survivors (humn),1.16e-22,83.09,22,33,0,36.67,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),CAUSES,"Death, Sudden, Cardiac (patf)",5.1e-10,85.65,22,13,0,20.68,11.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),CAUSES,Diagnosis (hlca),5.45e-08,81.63,22,13,0,20.68,11.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),2.22e-21,81.85,22,34,0,36.24,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,Population Group (humn),3.84e-13,85.67,22,17,0,30.14,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,Participant (humn),4.59e-15,81.39,22,25,0,41.36,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),ISA,Heart Diseases (dsyn),3.18e-21,79.84,22,42,0,33.52,5.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),COMPLICATES,Acute myocardial infarction (dsyn),1.23e-27,82.41,22,42,0,33.52,18.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),COEXISTS_WITH,Sinus rhythm (fndg),2.83e-19,82.14,22,30,0,38.13,9.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),AFFECTS,Atrial Fibrillation (patf),2.91e-07,87.05,22,9,0,12.68,7.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),CAUSES,Hospital admission (hlca),3.31e-29,84.15,22,40,0,34.1,11.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,Western society (popg),1.34e-06,84.47,22,9,0,12.68,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),COEXISTS_WITH,Anemia (dsyn),4.86e-07,83.65,22,10,0,14.55,9.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),PROCESS_OF,cohort (humn),5.38e-34,83.41,21,118,1,24.74,1.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),COMPLICATES,Myocardial Infarction (dsyn),3.96e-12,81.47,22,20,0,38.18,18.0
Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),AFFECTS,Systemic arterial pressure (fndg),6.96e-09,81.22,22,15,0,25.23,7.0
Very low energy diet (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.07e-06,21.71,9,12,0,15.75,1.0
Very low energy diet (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.26e-08,19.08,9,24,0,12.38,4.0
"Leukemia, Lymphocytic, Acute (neop)",PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),2.89e-19,17.79,33,25,0,43.94,1.0
"Leukemia, Lymphocytic, Acute (neop)",PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),5.88e-09,15.59,32,12,1,16.5,1.0
"Leukemia, Lymphocytic, Acute (neop)",PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),7.83e-25,20.04,33,32,0,63.03,1.0
Metabolic syndrome (dsyn),OCCURS_IN,Participant (humn),USES,Medicare (rnlw),1.18e-06,24.52,6,18,0,8.0,6.0
Diabetic (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,15.96,94,18,0,21.45,1.0
Mean blood pressure (fndg),PREDISPOSES,Pre-Eclampsia (dsyn),AFFECTS,Pathogenesis (patf),3.5e-06,13.99,7,25,0,8.96,7.0
Mean blood pressure (fndg),PREDISPOSES,Pre-Eclampsia (dsyn),PROCESS_OF,Pregnant Women (popg),1.63e-06,13.21,7,105,0,7.47,1.0
Mean blood pressure (fndg),PREDISPOSES,Pre-Eclampsia (dsyn),AFFECTS,Pregnancy (orgf),1.66e-06,15.06,7,21,0,9.33,7.0
Mean blood pressure (fndg),PREDISPOSES,Pre-Eclampsia (dsyn),ISA,Hypertension induced by pregnancy (dsyn),1.66e-06,14.04,7,31,0,8.58,5.0
Mean blood pressure (fndg),PREDISPOSES,Pre-Eclampsia (dsyn),PROCESS_OF,Pregnant Women (popg),1.63e-06,14.24,7,31,0,8.58,1.0
Mean blood pressure (fndg),PREDISPOSES,Pre-Eclampsia (dsyn),ISA,Pregnancy Complications (dsyn),1.63e-06,14.65,7,46,0,8.07,5.0
Mean blood pressure (fndg),PREDISPOSES,Pre-Eclampsia (dsyn),CAUSES,"Morbidity, perinatal (patf)",5.1e-06,22.3,7,8,0,13.12,11.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,student (prog),USES,Grade (clas),5.89e-12,26.07,10,7,0,11.9,1.0
Overweight (sosy),INTERACTS_WITH,Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),1.38e-09,70.78,49,22,0,31.88,10.0
Microalbuminuria (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.29e-09,15.75,12,18,0,20.0,1.0
Systemic arterial pressure (fndg),PROCESS_OF,Asians (popg),ISA,Population Group (humn),4.1e-10,24.31,9,29,0,11.79,1.0
Systemic arterial pressure (fndg),PROCESS_OF,Asians (popg),ISA,Ethnic group (popg),3.87e-10,22.91,9,124,0,9.65,1.0
macrophage (cell),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),6.4e-09,2.73,24,5,0,6.04,3.0
Epithelial Cells (cell),PART_OF,Intestines (bpoc),LOCATION_OF,Spontaneous perforation (acab),8.08e-13,2.11,1,47,0,1.02,2.0
Epithelial Cells (cell),PART_OF,Intestines (bpoc),LOCATION_OF,Gangrene (dsyn),2.29e-19,4.63,1,37,0,1.03,2.0
Epithelial Cells (cell),PART_OF,Intestines (bpoc),LOCATION_OF,Necrosis (patf),7.41e-29,3.51,1,104,0,1.01,2.0
Epithelial Cells (cell),PART_OF,Intestines (bpoc),LOCATION_OF,Reperfusion Injury (inpo),1.5e-17,1.48,1,103,0,1.01,2.0
Epithelial Cells (cell),PART_OF,Intestines (bpoc),LOCATION_OF,Anastomosis (acab),2.38e-09,1.68,1,45,0,1.02,2.0
Dyslipidemias (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.6e-10,9.22,18,33,0,27.82,1.0
Dyslipidemias (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,9.77,18,16,0,30.22,9.0
Dyslipidemias (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.03e-12,9.57,18,71,0,22.56,5.0
Dyslipidemias (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.03e-12,23.41,18,35,0,27.26,9.0
Dyslipidemias (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.03e-12,9.5,18,110,0,20.95,9.0
Dyslipidemias (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.36e-09,8.83,18,37,0,26.76,1.0
intensive care unit (hcro),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),3.28e-08,75.41,21,13,0,21.05,2.0
intensive care unit (hcro),LOCATION_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),3.25e-08,78.34,21,11,0,16.76,2.0
intensive care unit (hcro),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),3.42e-10,79.55,21,13,0,21.05,2.0
intensive care unit (hcro),LOCATION_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),2.75e-16,74.84,21,27,0,37.33,2.0
End stage renal failure (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),6.53e-07,12.64,9,18,0,13.5,1.0
Leptin|LEP (aapp),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular morbidity (dsyn),6.57e-17,48.45,13,23,0,20.35,7.0
Leptin|LEP (aapp),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cerebrovascular accident (dsyn),2.32e-07,42.48,13,18,0,22.39,7.0
Leptin|LEP (aapp),AFFECTS,Systemic arterial pressure (fndg),PROCESS_OF,General Population (humn),1.36e-06,41.13,13,27,0,19.26,1.0
Leptin|LEP (aapp),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),8.77e-12,42.11,13,32,0,18.28,7.0
Leptin|LEP (aapp),AFFECTS,Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),1.15e-11,41.54,13,39,0,17.33,1.0
Leptin|LEP (aapp),AFFECTS,Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),7.18e-07,40.68,13,41,0,17.12,1.0
Leptin|LEP (aapp),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular event (fndg),7.9e-11,42.42,13,27,0,19.26,7.0
adiposity (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.8e-10,41.4,10,23,0,14.35,8.0
adiposity (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),3.29e-13,40.84,10,57,0,11.75,8.0
adiposity (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,49.31,10,9,0,17.1,8.0
Leptin|LEP (aapp),AUGMENTS,Pregnancy (orgf),PROCESS_OF,Survivors (humn),3.4e-08,22.28,8,15,0,12.27,1.0
Leptin|LEP (aapp),AUGMENTS,Pregnancy (orgf),PROCESS_OF,"Twins, Dizygotic (humn)",2.3e-08,18.76,8,60,0,9.07,1.0
Leptin|LEP (aapp),AUGMENTS,Pregnancy (orgf),PROCESS_OF,Monoamniotic twins (podg),2.3e-08,19.63,8,33,0,9.94,1.0
Leptin|LEP (aapp),AUGMENTS,Pregnancy (orgf),PROCESS_OF,Singleton (humn),2.3e-08,18.27,8,357,0,8.18,1.0
arterial stiffness (phsf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.24e-06,16.72,7,20,0,9.45,1.0
arterial stiffness (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.24e-06,13.9,7,65,0,7.75,1.0
arterial stiffness (phsf),PROCESS_OF,cohort (humn),USES,Treats (clas),1.61e-06,16.22,7,16,0,10.06,1.0
arterial stiffness (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),5.33e-06,16.48,7,13,0,10.77,1.0
arterial stiffness (phsf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.25e-06,17.46,7,16,0,10.06,1.0
arterial stiffness (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),4.71e-06,22.87,7,8,0,13.12,1.0
arterial stiffness (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.24e-06,16.34,7,23,0,9.13,1.0
arterial stiffness (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.24e-06,17.24,7,22,0,9.23,1.0
arterial stiffness (phsf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),2.12e-06,17.17,7,13,0,10.77,1.0
arterial stiffness (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.24e-06,19.17,7,15,0,10.27,1.0
Eating Disorders (mobd),PROCESS_OF,inpatient (humn),USES,Medicare (rnlw),2.27e-13,15.86,15,32,0,22.03,1.0
ghrelin (aapp),AFFECTS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,26.37,9,12,0,15.75,1.0
ghrelin (aapp),AFFECTS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.07e-08,23.74,9,24,0,12.38,5.0
Wound complication (inpo),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),2.89e-07,30.77,6,20,0,7.8,1.0
Wound complication (inpo),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.9e-07,27.96,6,65,0,6.55,1.0
Wound complication (inpo),PROCESS_OF,cohort (humn),USES,Treats (clas),6.63e-07,30.28,6,16,0,8.25,1.0
Wound complication (inpo),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.38e-06,30.54,6,13,0,8.77,1.0
Wound complication (inpo),PROCESS_OF,cohort (humn),USES,Classification (clas),3e-07,31.52,6,16,0,8.25,1.0
Wound complication (inpo),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.76e-06,36.92,6,8,0,10.5,1.0
Wound complication (inpo),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.88e-07,30.4,6,23,0,7.57,1.0
Wound complication (inpo),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),2.88e-07,31.29,6,22,0,7.64,1.0
Wound complication (inpo),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),1.17e-06,31.22,6,13,0,8.77,1.0
Wound complication (inpo),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.89e-07,33.22,6,15,0,8.4,1.0
Tumor Necrosis Factor-alpha (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,28.78,11,16,0,18.56,8.0
Tumor Necrosis Factor-alpha (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,33.95,11,9,0,16.36,8.0
Tumor Necrosis Factor-alpha (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,26.33,11,31,0,14.9,8.0
ORALIT (phsu),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),1.6e-09,20.27,9,33,0,11.45,1.0
ORALIT (phsu),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,20.81,9,16,0,14.06,4.0
ORALIT (phsu),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.34e-09,20.62,9,71,0,10.14,4.0
ORALIT (phsu),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.34e-09,34.46,9,35,0,11.31,4.0
ORALIT (phsu),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.34e-09,20.54,9,110,0,9.74,4.0
ORALIT (phsu),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),2.7e-09,19.88,9,37,0,11.19,1.0
Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),PROCESS_OF,Octogenarians (aggp),3.25e-08,81.31,20,11,0,17.05,1.0
Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),PROCESS_OF,Surgical Patients (podg),1.31e-21,78.78,20,33,0,32.12,1.0
Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),CAUSES,Cessation of life (orgf),4.17e-06,76.95,20,11,0,17.05,7.0
Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),PROCESS_OF,"Recipient, Transplant (podg)",2.69e-06,78.31,20,10,0,15.0,1.0
Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),PROCESS_OF,cohort (humn),3.72e-19,78.46,20,30,0,33.33,1.0
Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),PROCESS_OF,Control Groups (humn),2.79e-07,75.62,20,16,0,28.8,1.0
arterial stiffness (phsf),COEXISTS_WITH,Aging (orgf),PROCESS_OF,Population Group (humn),1.18e-06,24.64,6,138,0,6.26,1.0
arterial stiffness (phsf),COEXISTS_WITH,Aging (orgf),PROCESS_OF,cohort (humn),1.18e-06,22.22,6,47,0,6.77,1.0
arterial stiffness (phsf),COEXISTS_WITH,Aging (orgf),PROCESS_OF,Actuary (humn),1.18e-06,26.23,6,20,0,7.8,1.0
"Fibrosis, Liver (dsyn)",COEXISTS_WITH,"Hepatitis C, Chronic (dsyn)",ISA,Virus Diseases (dsyn),2.67e-06,6.19,10,301,0,10.33,5.0
"Fibrosis, Liver (dsyn)",COEXISTS_WITH,"Hepatitis C, Chronic (dsyn)",CAUSES,Liver diseases (dsyn),2.67e-06,10.67,10,18,0,15.56,9.0
Maternal Nutrition (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Survivors (humn),1.36e-06,12.59,9,15,0,14.4,1.0
Maternal Nutrition (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,"Twins, Dizygotic (humn)",1.35e-06,9.06,9,60,0,10.35,1.0
Maternal Nutrition (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Monoamniotic twins (podg),1.35e-06,9.93,9,33,0,11.45,1.0
Maternal Nutrition (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Singleton (humn),1.35e-06,8.58,9,357,0,9.23,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Asians (popg),ISA,Population Group (humn),2.88e-07,29.72,6,29,0,7.24,1.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Asians (popg),ISA,Ethnic group (popg),2.88e-07,28.32,6,124,0,6.29,1.0
Physical activity (dora),CAUSES,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,23.55,10,12,0,18.33,1.0
Physical activity (dora),CAUSES,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.04e-08,20.92,10,24,0,14.17,5.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),3.75e-07,13.84,8,25,0,10.56,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,Participant (humn),4.17e-07,12.39,8,50,0,9.28,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,cohort (humn),3.72e-07,14.37,8,65,0,8.98,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,Population Group (humn),1.48e-06,16.98,8,11,0,13.82,1.0
Age related macular degeneration (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.17e-09,10.74,18,18,0,36.0,1.0
Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",ISA,Autoimmune Diseases (dsyn),6.84e-07,5.68,12,133,0,13.08,5.0
Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",PROCESS_OF,cohort (humn),6.85e-07,6.64,12,39,0,15.69,1.0
Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",CAUSES,Cessation of life (orgf),6.84e-07,12.6,12,19,0,19.58,9.0
Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),6.84e-07,11.06,12,26,0,17.54,1.0
Insulin Resistance (patf),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PROCESS_OF,General Population (humn),4.56e-08,29.06,7,18,0,9.72,1.0
Overweight (sosy),PROCESS_OF,Donor person (humn),LOCATION_OF,Antithymoglobulin (phsu),4.2e-09,44.49,7,17,0,9.88,1.0
Overweight (sosy),PROCESS_OF,Donor person (humn),LOCATION_OF,Cyclophosphamide (opco),3.51e-06,42.93,7,9,0,12.44,1.0
CAROTID (bpoc),LOCATION_OF,Ultrasonography (diap),DIAGNOSES,"Aortic Aneurysm, Abdominal (dsyn)",9.95e-12,9.26,70,23,0,30.56,2.0
CAROTID (bpoc),LOCATION_OF,Ultrasonography (diap),ISA,Medical Imaging (diap),2.76e-06,5.0,70,25,0,33.93,2.0
CAROTID (bpoc),LOCATION_OF,Ultrasonography (diap),METHOD_OF,Early Diagnosis (diap),4.43e-06,6.44,70,30,0,42.86,2.0
Intervention regimes (hlca),TREATS,cohort (humn),USES,Medicare (rnlw),4.07e-06,7.99,12,20,0,19.2,4.0
Intervention regimes (hlca),TREATS,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),4.07e-06,5.18,12,65,0,14.22,2.0
Intervention regimes (hlca),TREATS,cohort (humn),USES,Treats (clas),4.45e-06,7.5,12,16,0,21.0,4.0
Intervention regimes (hlca),TREATS,cohort (humn),LOCATION_OF,Calcium (bacs),8.17e-06,7.76,12,13,0,23.08,2.0
Intervention regimes (hlca),TREATS,cohort (humn),USES,Classification (clas),4.08e-06,8.74,12,16,0,21.0,4.0
Intervention regimes (hlca),TREATS,cohort (humn),LOCATION_OF,Sodium (elii),7.54e-06,14.14,12,8,0,13.33,2.0
Intervention regimes (hlca),TREATS,cohort (humn),LOCATION_OF,C-reactive protein (aapp),4.07e-06,7.62,12,23,0,18.26,2.0
Intervention regimes (hlca),TREATS,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),4.07e-06,8.51,12,22,0,18.55,2.0
Intervention regimes (hlca),TREATS,cohort (humn),USES,Tissue Microarray (resd),4.96e-06,8.44,12,13,0,23.08,4.0
Intervention regimes (hlca),TREATS,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),4.07e-06,10.44,12,15,0,21.6,2.0
"Hospitals, University (mnob)",LOCATION_OF,Prospective Studies (qnco),ISA,Techniques (ftcn),6.78e-12,8.53,18,912,0,18.36,2.0
"Hospitals, University (mnob)",LOCATION_OF,Prospective Studies (qnco),ISA,contextual factors (ftcn),1.3e-06,8.0,18,26,0,30.46,2.0
hair (bpoc),LOCATION_OF,Hydrocortisone (phsu),TREATS,Septic Shock (patf),1.29e-08,15.3,13,15,0,24.27,2.0
hair (bpoc),LOCATION_OF,Hydrocortisone (phsu),ASSOCIATED_WITH,Septic Shock (patf),5.53e-08,12.31,13,13,0,26.0,2.0
hair (bpoc),LOCATION_OF,Hydrocortisone (phsu),TREATS,Septicemia (dsyn),1.29e-08,16.27,13,16,0,23.56,2.0
hair (bpoc),LOCATION_OF,Hydrocortisone (phsu),TREATS,Septic Shock (patf),1.3e-08,16.07,13,14,0,25.07,2.0
Body mass index (clna),PREDISPOSES,End stage renal failure (dsyn),ISA,Kidney Diseases (dsyn),1.77e-11,52.87,11,24,0,16.04,5.0
Body mass index (clna),PREDISPOSES,End stage renal failure (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),4.6e-12,53.85,11,22,0,16.5,1.0
Body mass index (clna),PREDISPOSES,End stage renal failure (dsyn),PROCESS_OF,Participant (humn),1.91e-15,54.83,11,29,0,15.17,1.0
Body mass index (clna),PREDISPOSES,End stage renal failure (dsyn),ISA,Kidney Failure (dsyn),1.25e-07,56.75,11,11,0,22.0,5.0
Body mass index (clna),PREDISPOSES,End stage renal failure (dsyn),PROCESS_OF,African American (popg),9.61e-12,51.41,11,35,0,14.46,1.0
Body mass index (clna),PREDISPOSES,End stage renal failure (dsyn),PREDISPOSES,Kidney Failure (dsyn),2.91e-07,60.41,11,9,0,16.36,21.0
Body mass index (clna),PREDISPOSES,End stage renal failure (dsyn),PROCESS_OF,General Population (humn),3.08e-09,53.77,11,17,0,18.12,1.0
Body mass index (clna),PREDISPOSES,End stage renal failure (dsyn),PROCESS_OF,Survivors (humn),4.97e-12,60.09,11,15,0,19.07,1.0
Body mass index (clna),PREDISPOSES,End stage renal failure (dsyn),ISA,"Kidney Failure, Chronic (dsyn)",1.9e-15,54.45,11,58,0,13.09,5.0
Body mass index (clna),PREDISPOSES,End stage renal failure (dsyn),CAUSES,Cessation of life (orgf),1.49e-13,56.33,11,20,0,17.05,11.0
Body mass index (clna),PREDISPOSES,End stage renal failure (dsyn),PROCESS_OF,cohort (humn),1.9e-15,56.35,11,71,0,12.7,1.0
Body mass index (clna),PREDISPOSES,End stage renal failure (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.58e-06,55.76,11,10,0,19.09,21.0
Body mass index (clna),PREDISPOSES,End stage renal failure (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",6.33e-12,54.16,11,21,0,16.76,1.0
Body Weight decreased (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),3.83e-13,28.32,11,136,0,11.89,1.0
Body Weight decreased (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),3.83e-13,27.45,11,188,0,11.64,1.0
Body Weight decreased (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Population Group (humn),2.53e-06,28.34,11,20,0,17.05,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),2.99e-07,10.95,24,18,0,31.5,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),4.5e-18,13.39,24,77,0,31.48,18.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),8.22e-15,11.46,24,33,0,41.45,5.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),1.72e-09,12.47,24,18,0,31.5,18.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),2e-10,15.72,24,15,0,24.38,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",4.5e-18,13.45,24,41,0,38.05,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),9.03e-15,11.99,24,30,0,43.2,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),4.85e-18,16.01,24,27,0,45.33,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),3.96e-06,10.74,24,16,0,26.67,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),6.32e-13,13.43,24,22,0,42.17,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),2.02e-08,11.68,24,18,0,31.5,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),4.32e-13,15.55,24,19,0,34.04,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),1e-07,14.53,24,12,0,18.0,7.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),1.87e-07,20.24,24,9,0,12.38,11.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),4.5e-18,11.12,24,97,0,29.94,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),4.5e-18,12.13,24,68,0,32.47,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),4.5e-18,25.14,24,27,0,45.33,18.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),8.95e-07,15.28,24,10,0,14.17,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),4.42e-16,19.03,24,20,0,36.67,9.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),1.62e-13,16.12,24,19,0,34.04,9.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),4.5e-18,12.38,24,93,0,30.19,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),3.21e-08,12.28,24,16,0,26.67,5.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),4.83e-07,11.07,24,17,0,29.04,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),6.63e-07,15.6,24,10,0,14.17,18.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),2.8e-09,11.16,24,22,0,42.17,1.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),1.87e-13,12.98,24,24,0,48.0,11.0
Glomerular Filtration Rate (ortf),DIAGNOSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),2.69e-06,14.21,24,10,0,14.17,9.0
Overweight (sosy),PREDISPOSES,Pre-Eclampsia (dsyn),AFFECTS,Pathogenesis (patf),1.87e-06,50.01,14,25,0,21.84,7.0
Overweight (sosy),PREDISPOSES,Pre-Eclampsia (dsyn),PROCESS_OF,Pregnant Women (popg),1.41e-12,49.23,14,105,0,15.87,1.0
Overweight (sosy),PREDISPOSES,Pre-Eclampsia (dsyn),AFFECTS,Pregnancy (orgf),3.63e-08,51.07,14,21,0,23.33,7.0
Overweight (sosy),PREDISPOSES,Pre-Eclampsia (dsyn),ISA,Hypertension induced by pregnancy (dsyn),3.66e-08,50.05,14,31,0,20.32,5.0
Overweight (sosy),PREDISPOSES,Pre-Eclampsia (dsyn),PROCESS_OF,Pregnant Women (popg),4.89e-09,50.26,14,31,0,20.32,1.0
Overweight (sosy),PREDISPOSES,Pre-Eclampsia (dsyn),ISA,Pregnancy Complications (dsyn),9.2e-16,50.67,14,46,0,18.26,5.0
Overweight (sosy),PREDISPOSES,Pre-Eclampsia (dsyn),CAUSES,"Morbidity, perinatal (patf)",3.47e-06,58.31,14,8,0,12.57,11.0
topiramate (orch),CAUSES,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,30.3,11,12,0,21.08,1.0
topiramate (orch),CAUSES,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,27.67,11,24,0,16.04,5.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,42.12,20,33,0,32.12,1.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,42.66,20,16,0,28.8,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.4e-25,42.46,20,71,0,25.63,5.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),7.53e-27,56.31,20,35,0,31.43,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),7.53e-27,42.39,20,110,0,23.64,9.0
Systemic arterial pressure (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,41.73,20,37,0,30.81,1.0
orlistat (phsu),AFFECTS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,42.88,8,12,0,13.33,1.0
orlistat (phsu),AFFECTS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.04e-08,40.24,8,24,0,10.67,5.0
Testosterone (phsu),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),3.14e-06,31.42,5,33,0,5.76,1.0
Testosterone (phsu),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),7.57e-06,31.96,5,16,0,6.56,4.0
Testosterone (phsu),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.14e-06,31.77,5,71,0,5.35,4.0
Testosterone (phsu),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.14e-06,45.61,5,35,0,5.71,4.0
Testosterone (phsu),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.14e-06,31.69,5,110,0,5.23,4.0
Testosterone (phsu),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),3.14e-06,31.03,5,37,0,5.68,1.0
Metabolic syndrome (dsyn),AFFECTS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.07e-06,36.22,7,12,0,11.08,1.0
Metabolic syndrome (dsyn),AFFECTS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.83e-08,33.59,7,24,0,9.04,5.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),2.48e-09,7.77,20,20,0,40.0,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),4.02e-09,4.95,20,65,0,26.15,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.77e-07,7.28,20,16,0,28.8,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.1e-06,7.53,20,13,0,21.45,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.37e-08,8.51,20,16,0,28.8,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,13.92,20,8,0,11.2,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.66e-09,7.39,20,23,0,37.39,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.5e-09,8.29,20,22,0,38.18,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.86e-07,8.22,20,13,0,21.45,1.0
AUSTRALIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),3.02e-09,10.22,20,15,0,26.25,1.0
Weight Gain (fndg),PROCESS_OF,inpatient (humn),USES,Medicare (rnlw),8.58e-08,39.48,6,32,0,7.12,1.0
Periodontitis (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.3e-09,13.84,13,18,0,22.39,1.0
Participant (humn),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Ischemic stroke (dsyn),4.17e-06,27.28,25,11,0,15.84,2.0
Participant (humn),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),3.01e-10,24.51,25,34,0,43.38,2.0
Participant (humn),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Septicemia (dsyn),8.33e-13,28.87,25,20,0,36.0,2.0
Participant (humn),LOCATION_OF,C-reactive protein (aapp),ISA,Albumins (aapp),4.89e-14,26.11,25,30,0,45.83,2.0
Participant (humn),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),1.24e-07,26.63,25,15,0,24.0,2.0
Participant (humn),LOCATION_OF,C-reactive protein (aapp),ISA,Acute-Phase Proteins (aapp),1.55e-13,23.69,25,77,0,33.12,2.0
Participant (humn),LOCATION_OF,C-reactive protein (aapp),compared_with,procalcitonin (aapp),1.82e-08,26.92,25,16,0,26.24,2.0
Participant (humn),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Myocardial Infarction (dsyn),2.06e-06,25.96,25,14,0,21.84,2.0
Energy Metabolism (phsf),PROCESS_OF,Chamber (bpoc),LOCATION_OF,Pathological Dilatation (patf),5.34e-08,14.9,17,25,0,28.56,1.0
Nasal Continuous Positive Airway Pressure (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,8.73,24,16,0,26.67,4.0
Nasal Continuous Positive Airway Pressure (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.83e-14,18.95,24,26,0,46.15,4.0
"Diabetes, Gestational (dsyn)",PROCESS_OF,South Asian (popg),ISA,Ethnic group (popg),3.14e-06,32.18,5,49,0,5.51,1.0
Radical cystectomy (topp),TREATS,Malignant neoplasm of urinary bladder (neop),PART_OF,Urothelium (tisu),5.72e-11,4.87,37,79,0,54.33,3.0
Increase in blood pressure (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,21.61,14,18,0,24.89,1.0
Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,13.45,37,20,0,30.81,1.0
Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,10.63,37,65,0,58.06,1.0
Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,12.96,37,16,0,22.92,1.0
Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,13.21,37,13,0,17.57,1.0
Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,14.19,37,16,0,22.92,1.0
Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,19.6,37,8,0,9.73,1.0
Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,13.07,37,23,0,37.3,1.0
Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,13.97,37,22,0,35.08,1.0
Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,13.9,37,13,0,17.57,1.0
Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,15.9,37,15,0,21.08,1.0
Fibrosis (patf),COEXISTS_WITH,"Hepatitis C, Chronic (dsyn)",ISA,Virus Diseases (dsyn),3.69e-14,8.74,25,301,0,27.08,5.0
Fibrosis (patf),COEXISTS_WITH,"Hepatitis C, Chronic (dsyn)",CAUSES,Liver diseases (dsyn),3.31e-10,13.21,25,18,0,30.96,9.0
Sleep Apnea Syndromes (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),3.54e-06,20.45,6,18,0,8.0,1.0
Body Weight decreased (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,37.32,40,20,0,30.0,1.0
Body Weight decreased (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,34.5,40,65,0,64.62,1.0
Body Weight decreased (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,36.82,40,16,0,22.4,1.0
Body Weight decreased (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,37.08,40,13,0,17.23,1.0
Body Weight decreased (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,38.06,40,16,0,22.4,1.0
Body Weight decreased (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,43.47,40,8,0,9.6,1.0
Body Weight decreased (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,36.94,40,23,0,36.22,1.0
Body Weight decreased (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,37.84,40,22,0,34.1,1.0
Body Weight decreased (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,37.77,40,13,0,17.23,1.0
Body Weight decreased (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,39.76,40,15,0,20.62,1.0
Assessment procedure (hlca),TREATS,Participant (humn),USES,Medicare (rnlw),1.16e-09,11.27,61,18,0,23.31,4.0
Alcohol consumption (inbe),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),3.83e-09,24.76,8,33,0,9.94,1.0
Alcohol consumption (inbe),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,25.3,8,16,0,12.0,9.0
Alcohol consumption (inbe),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.58e-09,25.1,8,71,0,8.9,5.0
Alcohol consumption (inbe),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.58e-09,38.95,8,35,0,9.83,21.0
Alcohol consumption (inbe),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.58e-09,25.03,8,110,0,8.58,21.0
Alcohol consumption (inbe),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),4.93e-09,24.37,8,37,0,9.73,1.0
Malnutrition (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.19e-09,20.5,11,18,0,17.72,1.0
Usual body weight (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.88e-08,50.12,6,18,0,8.0,1.0
Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,11.19,26,18,0,30.46,1.0
Cardiovascular morbidity (dsyn),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,22.65,21,16,0,28.19,9.0
Malnutrition (dsyn),PROCESS_OF,Households (humn),LOCATION_OF,Ephrin Receptor EphB1 (aapp),1.04e-06,17.86,9,17,0,13.76,1.0
BRAZILIAN (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.07e-07,8.52,14,20,0,23.8,1.0
BRAZILIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.09e-07,5.71,14,65,0,17.02,1.0
BRAZILIAN (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),4.82e-07,8.03,14,16,0,26.25,1.0
BRAZILIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.2e-06,8.29,14,13,0,25.07,1.0
BRAZILIAN (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.18e-07,9.27,14,16,0,26.25,1.0
BRAZILIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.58e-06,14.67,14,8,0,12.57,1.0
BRAZILIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.06e-07,8.15,14,23,0,22.52,1.0
BRAZILIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.06e-07,9.04,14,22,0,22.91,1.0
BRAZILIAN (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),9.91e-07,8.97,14,13,0,25.07,1.0
BRAZILIAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.08e-07,10.97,14,15,0,27.07,1.0
Vitamin D (phsu),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),5.08e-06,80.61,4,12,0,5.33,1.0
Vitamin D (phsu),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),4.09e-06,77.97,4,24,0,4.67,4.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Malignant tumor of colon (neop),PROCESS_OF,Survivors (humn),1.48e-06,9.18,17,16,0,31.06,1.0
"Surgical Procedures, Laparoscopic (topp)",TREATS,Malignant tumor of colon (neop),PROCESS_OF,cohort (humn),4.3e-09,11.28,17,16,0,31.06,1.0
Systemic arterial pressure (fndg),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),7.83e-21,12.95,24,98,0,29.88,1.0
Systemic arterial pressure (fndg),PROCESS_OF,African American (popg),ISA,Racial group (popg),7.83e-21,13.88,24,324,0,25.78,1.0
Peritoneal Dialysis (topp),TREATS,End stage renal failure (dsyn),ISA,Kidney Diseases (dsyn),3.92e-06,6.75,16,24,0,26.67,4.0
Peritoneal Dialysis (topp),TREATS,End stage renal failure (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),3.92e-06,7.72,16,22,0,27.64,1.0
Peritoneal Dialysis (topp),TREATS,End stage renal failure (dsyn),PROCESS_OF,Participant (humn),3.92e-06,8.71,16,29,0,24.83,1.0
Peritoneal Dialysis (topp),TREATS,End stage renal failure (dsyn),ISA,Kidney Failure (dsyn),4.05e-06,10.63,16,11,0,18.56,4.0
Peritoneal Dialysis (topp),TREATS,End stage renal failure (dsyn),PROCESS_OF,African American (popg),3.92e-06,5.29,16,35,0,23.31,1.0
Peritoneal Dialysis (topp),TREATS,End stage renal failure (dsyn),PREDISPOSES,Kidney Failure (dsyn),4.21e-06,14.28,16,9,0,14.06,4.0
Peritoneal Dialysis (topp),TREATS,End stage renal failure (dsyn),PROCESS_OF,General Population (humn),3.93e-06,7.64,16,17,0,31.06,1.0
Peritoneal Dialysis (topp),TREATS,End stage renal failure (dsyn),PROCESS_OF,Survivors (humn),3.92e-06,13.96,16,15,0,29.06,1.0
Peritoneal Dialysis (topp),TREATS,End stage renal failure (dsyn),ISA,"Kidney Failure, Chronic (dsyn)",3.92e-06,8.32,16,58,0,20.41,4.0
Peritoneal Dialysis (topp),TREATS,End stage renal failure (dsyn),CAUSES,Cessation of life (orgf),3.92e-06,10.21,16,20,0,28.8,4.0
Peritoneal Dialysis (topp),TREATS,End stage renal failure (dsyn),PROCESS_OF,cohort (humn),3.92e-06,10.23,15,70,1,18.21,1.0
Peritoneal Dialysis (topp),TREATS,End stage renal failure (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.5e-06,9.63,16,10,0,16.25,4.0
Peritoneal Dialysis (topp),TREATS,End stage renal failure (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.92e-06,8.03,16,21,0,28.19,1.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Survivors (humn),1.59e-15,6.03,65,34,0,51.78,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Fibrosis (patf),3.08e-10,6.41,65,21,0,27.78,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Septicemia (dsyn),5e-20,9.77,65,38,0,60.22,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Critical Illness (dsyn),1.04e-13,5.34,65,35,0,53.85,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,cohort (humn),9.34e-13,4.27,65,49,0,85.94,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Pneumonia (dsyn),7.6e-17,9.63,65,25,0,34.62,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Acute heart failure (dsyn),1.34e-06,11.26,65,9,0,10.25,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Surgical Patients (podg),5.48e-08,6.18,65,17,0,21.45,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),3.74e-10,4.61,65,33,0,49.75,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,End stage renal failure (dsyn),8.3e-11,8.15,65,18,0,22.98,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Pancreatitis (dsyn),2.98e-06,6.29,65,13,0,15.6,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Pulmonary Embolism (dsyn),4.76e-07,6.6,65,14,0,17.02,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Aortic Valve Stenosis (dsyn),4.77e-07,6.17,65,15,0,18.46,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Coronary heart disease (dsyn),8.81e-09,5.6,65,21,0,27.78,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Frailty (fndg),1.88e-06,10.78,65,9,0,10.25,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),USES,Brain natriuretic peptide (aapp),6.59e-09,7.4,65,16,0,19.94,5.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Chronic heart failure (dsyn),2.07e-09,6.88,65,18,0,22.98,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Heart failure (dsyn),5e-20,6.2,65,67,0,128.06,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,CARDIAC EVENT (dsyn),3.47e-06,12.54,65,8,0,8.98,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,Acute coronary syndrome (dsyn),7.06e-10,6.49,65,20,0,26.15,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),TREATS,End stage liver disease (dsyn),2.79e-14,15.01,65,17,0,21.45,4.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),METHOD_OF,Transplantation (topp),9.45e-10,4.84,65,29,0,41.94,5.0
Ultrasonography (diap),ISA,Assessment procedure (hlca),METHOD_OF,Percutaneous coronary intervention (topp),3.47e-06,12.54,65,8,0,8.98,5.0
Heart failure (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,10.57,23,20,0,37.39,1.0
Heart failure (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,7.75,23,65,0,31.14,1.0
Heart failure (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,10.08,23,16,0,27.13,1.0
Heart failure (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,10.33,23,13,0,20.35,1.0
Heart failure (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,11.31,23,16,0,27.13,1.0
Heart failure (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,16.72,23,8,0,10.78,1.0
Heart failure (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,10.19,23,23,0,46.0,1.0
Heart failure (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,11.09,23,22,0,43.04,1.0
Heart failure (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,11.02,23,13,0,20.35,1.0
Heart failure (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,13.02,23,15,0,24.78,1.0
Insulin Resistance (patf),COEXISTS_WITH,Oxidative Stress (comd),PROCESS_OF,Drosophila melanogaster (invt),7.22e-06,15.56,7,12,0,11.08,1.0
Insulin Resistance (patf),COEXISTS_WITH,Oxidative Stress (comd),COEXISTS_WITH,Critical Illness (dsyn),4.96e-06,19.34,7,9,0,12.44,9.0
Overweight (sosy),PROCESS_OF,Hispanics (humn),ISA,Ethnic group (popg),1.72e-21,42.32,16,226,0,17.13,1.0
insulin sensitivity (patf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,40.77,10,18,0,15.56,1.0
Gastrectomy (topp),TREATS,Age (orga),ASSOCIATED_WITH,Acute myocardial infarction (dsyn),5.88e-09,56.86,13,13,0,26.0,4.0
Gastrectomy (topp),TREATS,Age (orga),ASSOCIATED_WITH,Pneumonia (dsyn),5.21e-07,55.66,13,11,0,20.31,4.0
Gastrectomy (topp),TREATS,Age (orga),ASSOCIATED_WITH,Heart failure (dsyn),4.15e-14,57.24,13,20,0,21.45,4.0
Gastrectomy (topp),TREATS,Age (orga),ASSOCIATED_WITH,Cerebrovascular accident (dsyn),1.12e-15,53.45,13,31,0,18.45,4.0
Gastrectomy (topp),TREATS,Age (orga),ASSOCIATED_WITH,Myocardial Infarction (dsyn),1.76e-07,53.34,13,15,0,24.27,4.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,27.92,23,33,0,39.03,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,28.47,23,16,0,27.13,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.35e-25,28.27,23,71,0,30.45,5.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.07e-27,42.11,23,35,0,38.11,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.07e-27,28.2,23,110,0,27.81,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,27.53,23,37,0,37.3,1.0
Cortisone (horm),INTERACTS_WITH,Hydrocortisone (phsu),TREATS,Septic Shock (patf),4.18e-07,14.96,11,15,0,19.07,4.0
Cortisone (horm),INTERACTS_WITH,Hydrocortisone (phsu),ASSOCIATED_WITH,Septic Shock (patf),4.6e-07,11.97,11,13,0,20.31,8.0
Cortisone (horm),INTERACTS_WITH,Hydrocortisone (phsu),TREATS,Septicemia (dsyn),4.18e-07,15.94,11,16,0,18.56,4.0
Cortisone (horm),INTERACTS_WITH,Hydrocortisone (phsu),TREATS,Septic Shock (patf),4.18e-07,15.73,11,14,0,19.64,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Atrial Fibrillation (patf),3.39e-07,11.33,18,21,0,33.43,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Primary Prevention (topp),1.5e-07,11.22,18,23,0,32.09,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,STEMI (dsyn),2.44e-14,15.94,18,47,0,24.89,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,General Population (humn),1.67e-08,11.44,18,24,0,31.5,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),PREVENTS,Premature Birth (patf),2.46e-14,13.66,18,30,0,28.8,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),PREVENTS,Death (finding) (fndg),2.44e-14,20.07,18,94,0,21.45,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,"Aortic Aneurysm, Abdominal (dsyn)",3.48e-14,17.71,18,20,0,34.2,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Hemorrhage (fndg),2.44e-14,12.82,18,65,0,22.98,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Pulmonary Embolism (dsyn),2.22e-08,14.57,18,14,0,24.89,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cerebrovascular accident (dsyn),6.7e-11,12.97,18,22,0,32.73,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Septicemia (dsyn),2.44e-14,16.4,18,41,0,25.9,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Malaria (dsyn),2.44e-14,11.88,18,56,0,23.79,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),PREVENTS,Stillbirth (patf),1.21e-08,17.35,18,12,0,20.0,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),2.44e-14,11.55,18,60,0,23.4,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Critical limb ischemia (patf),2.44e-14,15.57,18,40,0,26.1,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,"Shock, Cardiogenic (patf)",5.68e-10,17.11,18,14,0,24.89,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Cardiovascular Diseases (dsyn),3.39e-14,12.38,18,33,0,27.82,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Pneumonia (dsyn),9.32e-10,13.21,18,19,0,35.05,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Chronic heart failure (dsyn),2.79e-14,14.71,18,25,0,30.96,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),PREVENTS,"Death, Sudden, Cardiac (patf)",6.63e-07,16.54,18,10,0,15.56,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,high-risk group (humn),1.79e-11,12.13,18,27,0,30.0,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,"Pancreatitis, Acute Necrotizing (dsyn)",8.18e-14,16.71,18,20,0,34.2,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,"Stenosis, unspecified (patf)",8.57e-11,12.03,18,26,0,30.46,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Deglutition Disorders (dsyn),7.56e-07,12.46,18,15,0,27.5,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Depressed mood (fndg),1.87e-06,10.42,18,30,0,28.8,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,High Risk Populations (popg),3.35e-09,11.71,18,24,0,31.5,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Octogenarians (aggp),1.21e-07,18.71,18,10,0,15.56,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Acute myocardial infarction (dsyn),2.44e-14,13.54,18,104,0,21.12,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),USES,Losartan (orch),2.44e-14,13.91,18,65,0,22.98,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Peripheral Vascular Diseases (dsyn),2.44e-14,13.78,18,40,0,26.1,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Postpartum Hemorrhage (patf),6.54e-08,17.32,18,11,0,17.72,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Coronary Arteriosclerosis (dsyn),2.44e-14,13.0,18,60,0,23.4,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Anemia (dsyn),3.7e-07,12.07,18,17,0,33.06,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),PREVENTS,Adverse event (fndg),2.4e-07,12.5,18,16,0,30.22,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Ischemia (dsyn),5.71e-12,13.31,18,23,0,32.09,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Endoleak (patf),2.44e-14,16.32,18,30,0,28.8,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Carotid Stenosis (dsyn),1.76e-07,13.0,18,15,0,27.5,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Secondary prevention (topp),3.09e-06,12.0,18,15,0,27.5,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Malnutrition (dsyn),5.8e-09,12.38,18,20,0,34.2,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Systemic arterial pressure (fndg),1.25e-11,10.79,18,43,0,25.53,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Pre-Eclampsia (dsyn),1.09e-09,18.07,18,13,0,22.39,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,"Kidney Failure, Chronic (dsyn)",2.44e-14,13.59,18,52,0,24.23,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Myocardial Infarction (dsyn),2.44e-14,14.62,18,91,0,21.56,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Maternal Mortality (fndg),2.44e-14,25.0,18,19,0,35.05,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Mitral Valve Insufficiency (dsyn),6.68e-07,12.91,18,14,0,24.89,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Survivors (humn),2.27e-09,10.21,18,53,0,24.11,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,"Stroke, Acute (dsyn)",1.02e-06,12.36,18,15,0,27.5,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),PREVENTS,Perinatal death (fndg),3.05e-14,23.29,18,17,0,33.06,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,End stage renal failure (dsyn),1.27e-12,14.62,18,21,0,33.43,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Diabetic (fndg),2.61e-14,12.19,18,36,0,27.0,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),PREVENTS,Newborn death (patf),2.24e-08,21.57,18,10,0,15.56,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,"Hepatitis C, Chronic (dsyn)",6.5e-07,18.84,18,9,0,13.5,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),PREVENTS,Maternal Mortality (fndg),2.44e-14,24.2,18,80,0,22.05,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cardiovascular event (fndg),2.44e-14,14.93,18,28,0,29.57,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Death (finding) (fndg),6.44e-14,17.96,18,19,0,35.05,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Acute coronary syndrome (dsyn),2.44e-14,13.93,18,60,0,23.4,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Heart Arrest (patf),2.45e-14,14.94,18,27,0,30.0,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Disease Progression (patf),3.47e-07,12.74,18,15,0,27.5,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Critical Illness (dsyn),2.44e-14,13.96,18,42,0,25.71,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Diarrhea (sosy),2.07e-09,13.34,18,18,0,36.0,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Congestive heart failure (dsyn),6.68e-07,12.91,18,14,0,24.89,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),USES,Pravastatin (phsu),2.44e-14,15.91,18,30,0,28.8,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Septic Shock (patf),2.2e-09,17.38,18,13,0,22.39,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Control Groups (humn),3.03e-06,9.86,18,57,0,23.68,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Coronary heart disease (dsyn),2.44e-14,12.76,18,49,0,24.61,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),PREVENTS,Hemorrhage (fndg),2.4e-07,12.5,18,16,0,30.22,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Claudication (dsyn),1.76e-12,17.71,18,17,0,33.06,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,"Respiratory Distress Syndrome, Adult (dsyn)",8.54e-10,14.17,18,17,0,33.06,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Ischemic stroke (dsyn),4.76e-07,11.42,18,20,0,34.2,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),2.44e-14,10.53,18,123,0,20.63,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Upper gastrointestinal hemorrhage (dsyn),5.53e-14,19.51,18,18,0,36.0,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Revascularization - action (topp),2.48e-14,16.03,18,24,0,31.5,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),2.48e-14,12.68,18,34,0,27.53,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,cohort (humn),6.07e-14,11.62,18,38,0,26.53,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cardiovascular morbidity (dsyn),2.44e-14,23.61,18,24,0,31.5,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Aortic Valve Stenosis (dsyn),2.44e-14,14.78,18,28,0,29.57,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Heart failure (dsyn),2.44e-14,13.4,18,103,0,21.15,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),PREVENTS,Malaria (dsyn),1.19e-07,12.12,18,18,0,36.0,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),AFFECTS,Maternal Mortality (fndg),1.42e-12,24.46,18,14,0,24.89,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),ISA,Procedures (hlca),2.44e-14,10.66,18,125,0,20.59,5.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,Fetofetal Transfusion (dsyn),4.39e-07,19.51,18,9,0,13.5,4.0
Diet education (hlca),ISA,Intervention regimes (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",1.33e-11,12.37,18,26,0,30.46,4.0
Female Breast Carcinoma (neop),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),5.44e-10,16.91,14,25,0,21.84,1.0
Female Breast Carcinoma (neop),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),6.42e-09,14.71,14,13,0,25.07,1.0
Female Breast Carcinoma (neop),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),5.44e-10,19.17,14,32,0,20.12,1.0
Clozapine (phsu),TREATS,Schizophrenia (mobd),PROCESS_OF,Outpatients (podg),5.69e-08,2.56,35,12,0,16.11,1.0
Malignant neoplasm of endometrium (neop),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),3.64e-19,18.7,25,25,0,50.0,1.0
Malignant neoplasm of endometrium (neop),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),5.88e-09,16.5,25,13,0,19.76,1.0
Malignant neoplasm of endometrium (neop),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),7.5e-20,20.96,25,32,0,44.53,1.0
"Diabetes, Gestational (dsyn)",ISA,Diabetes Mellitus (dsyn),COEXISTS_WITH,Heart failure (dsyn),6.04e-07,26.02,7,15,0,10.27,5.0
"Diabetes, Gestational (dsyn)",ISA,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),6.04e-07,28.49,7,15,0,10.27,5.0
"Diabetes, Gestational (dsyn)",ISA,Diabetes Mellitus (dsyn),CAUSES,"Kidney Failure, Chronic (dsyn)",6.04e-07,19.99,7,20,0,9.45,5.0
"Diabetes, Gestational (dsyn)",ISA,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),6.04e-07,19.26,7,52,0,7.94,5.0
"Diabetes, Gestational (dsyn)",ISA,Diabetes Mellitus (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.16e-06,18.14,7,15,0,10.27,1.0
"Diabetes, Gestational (dsyn)",ISA,Diabetes Mellitus (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",6.12e-07,17.65,7,21,0,9.33,1.0
"Diabetes, Gestational (dsyn)",ISA,Diabetes Mellitus (dsyn),CAUSES,End stage renal failure (dsyn),6.04e-07,18.94,7,51,0,7.96,5.0
"Diabetes, Gestational (dsyn)",ISA,Diabetes Mellitus (dsyn),PROCESS_OF,Survivors (humn),6.81e-07,21.25,7,12,0,11.08,1.0
"Diabetes, Gestational (dsyn)",ISA,Diabetes Mellitus (dsyn),CAUSES,Kidney Failure (dsyn),6.04e-07,23.59,7,15,0,10.27,5.0
"Diabetes, Gestational (dsyn)",ISA,Diabetes Mellitus (dsyn),CAUSES,Cessation of life (orgf),6.04e-07,20.84,7,43,0,8.14,5.0
"Diabetes, Gestational (dsyn)",ISA,Diabetes Mellitus (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),6.09e-07,21.09,7,14,0,10.5,5.0
"Diabetes, Gestational (dsyn)",ISA,Diabetes Mellitus (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),6.04e-07,19.26,7,26,0,8.88,5.0
"Diabetes, Gestational (dsyn)",ISA,Diabetes Mellitus (dsyn),PROCESS_OF,General Population (humn),6.04e-07,18.45,7,22,0,9.23,1.0
"Diabetes, Gestational (dsyn)",ISA,Diabetes Mellitus (dsyn),ISA,Metabolic Diseases (dsyn),2.23e-06,15.63,7,43,0,8.14,5.0
"Diabetes, Gestational (dsyn)",ISA,Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),6.04e-07,18.09,7,44,0,8.11,1.0
Waist circumference (fndg),PREDISPOSES,Diabetes Mellitus (dsyn),COEXISTS_WITH,Heart failure (dsyn),2.02e-11,66.63,8,15,0,12.27,9.0
Waist circumference (fndg),PREDISPOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.75e-11,69.1,8,15,0,12.27,21.0
Waist circumference (fndg),PREDISPOSES,Diabetes Mellitus (dsyn),CAUSES,"Kidney Failure, Chronic (dsyn)",2.51e-11,60.6,8,20,0,11.2,11.0
Waist circumference (fndg),PREDISPOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.7e-11,59.86,8,52,0,9.23,21.0
Waist circumference (fndg),PREDISPOSES,Diabetes Mellitus (dsyn),PROCESS_OF,Hospitalized Patients (humn),5.59e-07,58.74,8,15,0,12.27,1.0
Waist circumference (fndg),PREDISPOSES,Diabetes Mellitus (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",7.72e-09,58.26,8,21,0,11.05,1.0
Waist circumference (fndg),PREDISPOSES,Diabetes Mellitus (dsyn),CAUSES,End stage renal failure (dsyn),1.7e-11,59.54,8,51,0,9.25,11.0
Waist circumference (fndg),PREDISPOSES,Diabetes Mellitus (dsyn),PROCESS_OF,Survivors (humn),7.62e-08,61.85,8,12,0,13.33,1.0
Waist circumference (fndg),PREDISPOSES,Diabetes Mellitus (dsyn),CAUSES,Kidney Failure (dsyn),5.33e-11,64.2,8,15,0,12.27,11.0
Waist circumference (fndg),PREDISPOSES,Diabetes Mellitus (dsyn),CAUSES,Cessation of life (orgf),1.7e-11,61.44,8,43,0,9.49,11.0
Waist circumference (fndg),PREDISPOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),4.74e-09,61.7,8,14,0,12.57,21.0
Waist circumference (fndg),PREDISPOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),1.7e-11,59.86,8,26,0,10.46,21.0
Waist circumference (fndg),PREDISPOSES,Diabetes Mellitus (dsyn),PROCESS_OF,General Population (humn),1.12e-10,59.05,8,22,0,10.91,1.0
Waist circumference (fndg),PREDISPOSES,Diabetes Mellitus (dsyn),ISA,Metabolic Diseases (dsyn),1.63e-06,56.23,8,43,0,9.49,5.0
Waist circumference (fndg),PREDISPOSES,Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),1.7e-11,58.69,8,44,0,9.45,1.0
Prostate (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,melanoma (neop),4.28e-13,4.21,127,45,0,60.94,2.0
Prostate (bpoc),LOCATION_OF,Biopsy (diap),ISA,Diagnosis (hlca),4.07e-10,2.02,127,161,0,227.18,2.0
Prostate (bpoc),LOCATION_OF,Biopsy (diap),ISA,Procedures (hlca),4.84e-07,2.14,127,81,0,132.66,2.0
Polycystic Ovary Syndrome (dsyn),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,40.0,17,16,0,31.06,7.0
Polycystic Ovary Syndrome (dsyn),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,45.17,17,9,0,13.76,7.0
Polycystic Ovary Syndrome (dsyn),AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,37.56,17,31,0,26.32,7.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,22.36,17,9,0,13.76,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.19e-16,21.42,17,194,0,18.49,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,20.14,17,17,0,34.0,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.19e-16,21.41,17,29,0,26.97,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,23.59,17,14,0,25.53,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,19.4,17,12,0,20.47,5.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.19e-16,18.22,17,48,0,23.02,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.19e-16,21.61,17,29,0,26.97,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.19e-16,18.66,17,98,0,19.95,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,17.32,17,24,0,29.04,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,23.73,17,10,0,15.88,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,16.09,17,37,0,24.81,7.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,17.89,17,20,0,31.45,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.19e-16,19.55,17,94,0,20.07,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,25.34,17,8,0,11.76,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,22.21,17,19,0,32.21,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,19.37,17,21,0,30.76,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,24.55,17,12,0,20.47,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,32.26,17,10,0,15.88,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,24.85,17,10,0,15.88,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,19.17,17,21,0,30.76,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.7e-13,20.78,17,21,0,30.76,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.09e-16,18.9,17,32,0,26.03,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,26.26,17,10,0,15.88,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.19e-16,25.23,17,39,0,24.41,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.19e-16,29.21,17,44,0,23.57,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.19e-16,22.08,17,113,0,19.56,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,19.61,17,11,0,18.12,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,19.33,17,11,0,18.12,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,19.8,17,12,0,20.47,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,17.69,17,25,0,28.56,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.19e-16,23.36,17,87,0,20.32,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),7.35e-16,18.35,17,33,0,25.76,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.19e-16,21.09,17,41,0,24.05,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.88e-14,21.26,17,21,0,30.76,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,18.92,17,21,0,30.76,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.19e-16,19.87,17,1021,0,17.28,8.0
Eating (orgf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.64e-09,19.93,10,18,0,15.56,1.0
Blood Pressure (orgf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,41.43,16,18,0,30.22,1.0
Carcinoma of the Large Intestine (neop),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.58e-09,12.16,13,18,0,22.39,1.0
Metformin (phsu),TREATS,Participant (humn),USES,Medicare (rnlw),2.11e-06,22.25,6,18,0,8.0,4.0
Total proctectomy (topp),TREATS,Cancer of Rectum (neop),PROCESS_OF,cohort (humn),1.45e-06,7.95,16,15,0,29.06,1.0
Coronary artery calcification (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),7.5e-08,18.18,8,20,0,11.2,1.0
Coronary artery calcification (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),7.66e-08,15.36,8,65,0,8.98,1.0
Coronary artery calcification (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),4.5e-07,17.69,8,16,0,12.0,1.0
Coronary artery calcification (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.17e-06,17.94,8,13,0,12.92,1.0
Coronary artery calcification (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),8.63e-08,18.92,8,16,0,12.0,1.0
Coronary artery calcification (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.54e-06,24.33,8,8,0,16.0,1.0
Coronary artery calcification (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),7.42e-08,17.81,8,23,0,10.78,1.0
Coronary artery calcification (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),7.4e-08,18.7,8,22,0,10.91,1.0
Coronary artery calcification (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),9.59e-07,18.63,8,13,0,12.92,1.0
Coronary artery calcification (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),7.56e-08,20.63,8,15,0,12.27,1.0
Body mass index (clna),PREDISPOSES,Dementia (mobd),PROCESS_OF,cohort (humn),4.2e-09,60.2,34,38,0,64.42,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,traveler (humn),4.72e-06,12.22,39,9,0,11.08,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),COEXISTS_WITH,Epilepsy (dsyn),3.59e-20,16.1,39,25,0,41.03,5.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Young adult (aggp),1.79e-22,13.6,39,52,0,68.25,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Cancer Patient (podg),3.84e-08,9.28,39,16,0,22.56,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Participant (humn),1.79e-22,17.32,39,142,0,49.71,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Females (humn),1.79e-22,17.13,39,30,0,53.08,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),COEXISTS_WITH,Pneumonia (dsyn),2.59e-06,12.95,39,9,0,11.08,5.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Black race (popg),1.8e-22,14.78,39,32,0,58.26,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,member (popg),2.77e-14,11.12,39,23,0,36.56,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Alaska Native (humn),1.22e-09,16.22,39,12,0,15.69,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Prisoners (humn),1.51e-13,14.38,39,18,0,26.31,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Pedestrian (humn),2.95e-22,10.91,39,37,0,72.1,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,high-risk group (humn),7.61e-08,11.82,39,12,0,15.69,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Youth (humn),7.74e-10,9.84,39,18,0,26.31,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),COEXISTS_WITH,Acquired Immunodeficiency Syndrome (dsyn),1.12e-16,17.27,39,20,0,30.26,5.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Workers (humn),3.25e-08,14.28,39,11,0,14.1,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Caucasoid Race (popg),1.82e-22,13.72,39,33,0,60.92,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Human Age Group (aggp),1.79e-22,15.05,39,68,0,61.37,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Girls (popg),5.97e-13,16.37,39,16,0,22.56,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),COEXISTS_WITH,Myocardial Infarction (dsyn),3.47e-06,15.14,39,8,0,9.64,5.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Hispanics (humn),2.95e-22,17.32,39,27,0,45.69,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,VICTIM (humn),3.62e-18,11.66,39,28,0,48.1,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Pregnant Women (popg),9.45e-12,13.85,39,16,0,22.56,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Households (humn),1.79e-22,15.1,39,33,0,60.92,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Aboriginals (humn),2.75e-06,10.2,39,11,0,14.1,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Population Group (humn),5.99e-20,18.66,39,23,0,36.56,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.85e-10,13.85,39,14,0,19.03,5.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,American (popg),4.09e-09,14.67,39,12,0,15.69,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Control Groups (humn),1.79e-22,11.62,39,129,0,50.79,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,nursing home resident (popg),4.19e-09,17.23,39,11,0,14.1,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),COEXISTS_WITH,Influenza (dsyn),2.1e-12,15.14,39,16,0,22.56,5.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),COEXISTS_WITH,Septicemia (dsyn),8.14e-09,11.31,39,14,0,19.03,5.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),ISA,Suicide (inpo),8.55e-09,13.85,39,12,0,15.69,5.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Survivors (humn),1.88e-06,13.38,39,9,0,11.08,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,sibling (humn),1.41e-07,10.42,39,13,0,17.33,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Surgical Patients (podg),1.73e-11,16.85,39,14,0,19.03,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,inpatient (humn),1.79e-22,13.49,39,118,0,51.89,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Hospitalized Patients (humn),3.12e-12,14.78,39,16,0,22.56,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Participant (humn),1.82e-22,15.19,39,31,0,55.64,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,"Recipient, Transplant (podg)",2.32e-08,12.85,39,12,0,15.69,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Males (popg),1.79e-22,13.3,39,53,0,67.7,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,cohort (humn),1.79e-22,15.27,39,373,0,43.08,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,athlete (humn),1.69e-08,13.16,39,12,0,15.69,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),NEG_PROCESS_OF,cohort (humn),4e-07,11.68,39,11,0,14.1,5.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Workers (humn),1.79e-22,11.87,39,71,0,60.42,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Passenger (humn),4.24e-08,11.18,39,13,0,17.33,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),COEXISTS_WITH,Tuberculosis (dsyn),1.76e-07,14.33,39,10,0,12.56,5.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,civilian (humn),4.09e-07,9.83,39,13,0,17.33,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,African American (popg),2.95e-22,17.32,39,27,0,45.69,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Offspring (humn),3.98e-07,9.27,39,14,0,19.03,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,General Population (humn),1.79e-22,14.46,39,71,0,60.42,1.0
Coronary heart disease (dsyn),ISA,Death (finding) (fndg),PROCESS_OF,Survivors (humn),2.48e-22,11.02,39,37,0,72.1,1.0
Physical function (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.61e-07,14.27,9,18,0,13.5,1.0
Relative Risk (qlco),ISA,Risk (qlco),ISA,Probability (qnco),1.77e-08,5.59,41,42,0,81.02,5.0
Relative Risk (qlco),ISA,Risk (qlco),ISA,contextual factors (ftcn),1.45e-20,6.08,41,104,0,57.16,5.0
Relative Risk (qlco),ISA,Risk (qlco),ISA,Socioeconomic Factors (grpa),3.11e-07,6.08,41,26,0,42.49,5.0
Relative Risk (qlco),ISA,Risk (qlco),ISA,Techniques (ftcn),1.45e-20,5.91,41,143,0,52.76,5.0
Metabolic syndrome (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),3.06e-18,18.15,19,77,0,23.69,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),1e-08,18.49,19,16,0,29.47,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Young adult (aggp),4.08e-06,17.94,19,12,0,19.58,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Middle Aged (aggp),4.35e-10,18.28,19,19,0,38.0,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.38e-09,17.06,19,22,0,35.41,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Outpatients (podg),5.76e-08,16.07,19,24,0,34.04,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,General Population (humn),3.06e-18,17.78,19,42,0,27.6,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),3.06e-18,19.03,19,102,0,22.54,5.0
Metabolic syndrome (dsyn),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Heart failure (dsyn),3.34e-07,18.62,19,13,0,21.89,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),3.06e-18,18.36,18,82,1,21.95,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Coronary heart disease (dsyn),ISA,Death (finding) (fndg),3.06e-18,20.95,19,250,0,20.44,5.0
Metabolic syndrome (dsyn),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),3.06e-18,18.12,19,194,0,20.86,11.0
Mastectomy (topp),compared_with,Reconstructive Surgical Procedures (topp),TREATS,Heart failure (dsyn),1.49e-06,19.71,7,11,0,11.45,4.0
Mastectomy (topp),compared_with,Reconstructive Surgical Procedures (topp),TREATS,Malignant neoplasm of stomach (neop),1.52e-06,16.49,7,16,0,10.06,4.0
Mastectomy (topp),compared_with,Reconstructive Surgical Procedures (topp),TREATS,Hypoplastic Left Heart Syndrome (dsyn),5.16e-06,17.29,7,12,0,11.08,4.0
Mastectomy (topp),compared_with,Reconstructive Surgical Procedures (topp),TREATS,Generalized ischemic myocardial dysfunction (dsyn),1.09e-06,21.31,7,22,0,9.23,4.0
Mastectomy (topp),compared_with,Reconstructive Surgical Procedures (topp),USES,"PATCH, PERICARDIAL (medd)",1.09e-06,16.59,7,21,0,9.33,6.0
Mastectomy (topp),compared_with,Reconstructive Surgical Procedures (topp),TREATS,sarcoma (neop),1.09e-06,16.67,7,21,0,9.33,4.0
Mastectomy (topp),compared_with,Reconstructive Surgical Procedures (topp),TREATS,Aneurysm (anab),1.1e-06,16.64,7,19,0,9.58,4.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,Vascular calcification (patf),3.28e-08,32.89,8,17,0,11.76,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",3.31e-08,29.39,8,12,0,13.33,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),PROCESS_OF,General Population (humn),3.28e-08,28.85,8,36,0,9.78,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),3.28e-08,31.12,8,22,0,10.91,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",3.28e-08,28.69,8,59,0,9.08,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",6.83e-07,26.02,8,9,0,15.11,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,"Hypertrophy, Left Ventricular (patf)",2.38e-06,26.97,8,8,0,16.0,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,Atherosclerosis (dsyn),3.34e-08,32.39,8,11,0,13.82,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.28e-08,31.64,8,28,0,10.29,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,Peripheral Vascular Diseases (dsyn),3.28e-08,33.9,8,17,0,11.76,9.0
Underweight (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),4.29e-08,27.11,7,20,0,9.45,1.0
Underweight (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),4.44e-08,24.29,7,65,0,7.75,1.0
Underweight (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),4.17e-07,26.61,7,16,0,10.06,1.0
Underweight (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.14e-06,26.87,7,13,0,10.77,1.0
Underweight (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),5.41e-08,27.85,7,16,0,10.06,1.0
Underweight (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.51e-06,33.26,7,8,0,13.12,1.0
Underweight (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),4.2e-08,26.73,7,23,0,9.13,1.0
Underweight (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),4.19e-08,27.63,7,22,0,9.23,1.0
Underweight (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),9.26e-07,27.56,7,13,0,10.77,1.0
Underweight (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),4.34e-08,29.56,7,15,0,10.27,1.0
Body mass index procedure (diap),DIAGNOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),7.06e-18,68.28,12,78,0,13.85,1.0
Body mass index procedure (diap),DIAGNOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),9.42e-08,67.4,12,22,0,18.55,1.0
Body mass index procedure (diap),DIAGNOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),4.09e-09,74.51,12,12,0,24.0,1.0
Body mass index procedure (diap),DIAGNOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),4.35e-08,68.37,12,18,0,20.0,1.0
Body mass index procedure (diap),DIAGNOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (humn),5.8e-14,66.37,12,67,0,14.15,1.0
Body mass index procedure (diap),DIAGNOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),2.1e-09,68.36,12,21,0,18.86,1.0
Body mass index procedure (diap),DIAGNOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),5.51e-14,67.85,12,35,0,16.11,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,24.07,11,9,0,16.36,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.98e-11,23.12,11,194,0,11.62,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.66e-10,21.85,11,17,0,18.12,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.98e-11,23.12,11,29,0,15.17,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2.29e-10,25.3,11,14,0,19.64,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,21.11,11,12,0,21.08,5.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),2.98e-11,19.93,11,48,0,13.52,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.98e-11,23.32,11,29,0,15.17,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.98e-11,20.37,11,98,0,12.23,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.36e-09,19.03,11,24,0,16.04,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,25.44,11,10,0,19.09,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.22e-08,17.8,11,37,0,14.27,7.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.76e-09,19.6,11,20,0,17.05,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.98e-11,21.25,11,94,0,12.29,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,27.05,11,8,0,13.82,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.01e-11,23.92,11,19,0,17.37,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),4.18e-11,21.07,11,21,0,16.76,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.81e-09,26.25,11,12,0,21.08,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.66e-09,33.97,11,10,0,19.09,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,26.56,11,10,0,19.09,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),5.23e-11,20.87,11,21,0,16.76,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),3.01e-11,22.48,11,21,0,16.76,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.98e-11,20.61,11,32,0,14.78,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,27.97,11,10,0,19.09,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.98e-11,26.94,11,39,0,14.1,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),2.98e-11,30.91,11,44,0,13.75,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.98e-11,23.79,11,113,0,12.07,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,21.32,11,11,0,22.0,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,21.04,11,11,0,22.0,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,21.5,11,12,0,21.08,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.48e-10,19.4,11,25,0,15.84,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.98e-11,25.07,11,87,0,12.39,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),2.98e-11,20.06,11,33,0,14.67,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.98e-11,22.8,11,41,0,13.95,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),2.99e-11,22.97,11,21,0,16.76,1.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",7.98e-11,20.63,11,21,0,16.76,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.98e-11,21.58,11,1021,0,11.12,8.0
Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,19.11,97,18,0,21.34,1.0
olanzapine (orch),TREATS,Anorexia Nervosa (mobd),ISA,Mental disorders (mobd),1.63e-06,16.39,6,45,1,6.8,4.0
Visceral Fat (tisu),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,26.8,11,16,0,18.56,7.0
Visceral Fat (tisu),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,31.97,11,9,0,16.36,7.0
Visceral Fat (tisu),AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,24.35,11,31,0,14.9,7.0
Triglycerides (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,23.86,39,16,0,22.56,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,29.03,39,9,0,11.08,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,21.41,39,31,0,55.64,8.0
Heart Diseases (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.37e-06,13.85,8,18,0,11.56,1.0
Kuwait (geoa),ISA,Country (geoa),ISA,United States (geoa),1.33e-07,11.32,9,46,0,10.76,5.0
Fatty degeneration (patf),PROCESS_OF,Hepatitis C virus (virs),PROCESS_OF,cohort (humn),3.13e-06,18.33,6,27,0,7.33,1.0
Fatty degeneration (patf),PROCESS_OF,Hepatitis C virus (virs),CAUSES,Fibrosis (patf),3.01e-06,18.95,6,39,0,6.92,1.0
Fatty degeneration (patf),PROCESS_OF,Hepatitis C virus (virs),PROCESS_OF,"Recipient, Transplant (podg)",3.01e-06,20.24,6,40,0,6.9,1.0
Fatty degeneration (patf),PROCESS_OF,Hepatitis C virus (virs),CAUSES,Liver diseases (dsyn),3.1e-06,18.11,6,31,0,7.16,1.0
Insulin (horm),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,25.69,13,16,0,23.56,9.0
Insulin (horm),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,30.86,13,9,0,15.23,9.0
Insulin (horm),PREDISPOSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,23.25,13,31,0,18.45,21.0
Age (orga),ASSOCIATED_WITH,Kidney Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.88e-06,32.78,6,8,0,10.5,8.0
Age (orga),ASSOCIATED_WITH,Kidney Diseases (dsyn),AFFECTS,Systemic arterial pressure (fndg),2.52e-06,20.59,6,21,0,7.71,7.0
Age (orga),ASSOCIATED_WITH,Kidney Diseases (dsyn),CAUSES,"Kidney Failure, Acute (dsyn)",2.52e-06,21.04,6,23,0,7.57,8.0
Age (orga),ASSOCIATED_WITH,Kidney Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.48e-06,18.7,6,27,0,7.33,1.0
Age (orga),ASSOCIATED_WITH,Kidney Diseases (dsyn),CAUSES,End stage renal failure (dsyn),2.54e-06,19.75,6,22,0,7.64,8.0
Age (orga),ASSOCIATED_WITH,Kidney Diseases (dsyn),PROCESS_OF,cohort (humn),2.52e-06,20.4,6,22,0,7.64,1.0
Age (orga),ASSOCIATED_WITH,Kidney Diseases (dsyn),CAUSES,Cessation of life (orgf),2.52e-06,23.01,6,35,0,7.03,8.0
Osteopenia (dsyn),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),4.13e-06,36.96,5,25,0,6.0,1.0
Osteopenia (dsyn),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),4.13e-06,34.75,5,13,0,6.92,1.0
Osteopenia (dsyn),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),4.13e-06,39.21,5,32,0,5.78,1.0
Malignant tumor of colon (neop),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),4.18e-09,19.33,11,25,0,15.84,1.0
Malignant tumor of colon (neop),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),1.01e-08,17.13,11,13,0,20.31,1.0
Malignant tumor of colon (neop),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),4.18e-09,21.59,11,32,0,14.78,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,21.19,17,9,0,13.76,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),4.03e-16,20.25,17,194,0,18.49,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,18.98,17,17,0,34.0,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),4.03e-16,20.25,17,29,0,26.97,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,22.43,17,14,0,25.53,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,18.24,17,12,0,20.47,5.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),4.03e-16,17.06,17,48,0,23.02,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),4.03e-16,20.45,17,29,0,26.97,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),4.03e-16,17.49,17,98,0,19.95,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,22.57,17,10,0,15.88,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,14.93,17,37,0,24.81,7.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,16.73,17,20,0,31.45,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),4.03e-16,18.38,17,94,0,20.07,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,24.17,17,8,0,11.76,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.14e-13,21.05,17,19,0,32.21,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,18.2,17,21,0,30.76,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,23.38,17,12,0,20.47,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,31.1,17,10,0,15.88,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,23.68,17,10,0,15.88,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,18.0,17,21,0,30.76,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.7e-13,19.61,17,21,0,30.76,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),4.93e-16,17.74,17,32,0,26.03,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,25.1,17,10,0,15.88,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),4.03e-16,24.07,17,39,0,24.41,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),4.03e-16,28.04,17,44,0,23.57,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.03e-16,20.92,17,113,0,19.56,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,18.44,17,11,0,18.12,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,18.17,17,11,0,18.12,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,18.63,17,12,0,20.47,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,16.53,17,25,0,28.56,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",4.03e-16,22.2,17,87,0,20.32,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.02e-15,17.19,17,33,0,25.76,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),4.03e-16,19.93,17,41,0,24.05,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.91e-14,20.09,17,21,0,30.76,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,17.76,17,21,0,30.76,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),4.03e-16,18.71,17,1021,0,17.28,9.0
Nephroureterectomy (topp),TREATS,"Carcinoma, Transitional Cell (neop)",PART_OF,Tract (bpoc),4.05e-06,4.24,20,249,3,21.61,3.0
Nephroureterectomy (topp),TREATS,"Carcinoma, Transitional Cell (neop)",PART_OF,Bladder (bpoc),4.05e-06,3.6,23,656,0,23.81,3.0
Nephroureterectomy (topp),TREATS,"Carcinoma, Transitional Cell (neop)",PART_OF,Ureter (bpoc),6.47e-06,3.42,22,34,1,36.24,3.0
Nephroureterectomy (topp),TREATS,"Carcinoma, Transitional Cell (neop)",PART_OF,Urothelium (tisu),4.05e-06,4.44,23,30,0,40.63,3.0
Nephroureterectomy (topp),TREATS,"Carcinoma, Transitional Cell (neop)",PART_OF,Urinary tract (bpoc),4.05e-06,4.34,22,38,1,34.74,3.0
Reconstructive Surgical Procedures (topp),TREATS,Malignant neoplasm of stomach (neop),PROCESS_OF,cohort (humn),3.5e-07,13.56,9,31,0,11.61,1.0
Reconstructive Surgical Procedures (topp),TREATS,Malignant neoplasm of stomach (neop),ISA,Malignant disease (dsyn),3.83e-07,14.99,9,13,0,15.23,4.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.6e-06,18.44,10,9,0,17.1,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.13e-08,17.5,10,194,0,10.52,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),1.17e-08,16.22,10,17,0,15.88,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.13e-08,17.49,10,29,0,13.45,11.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.15e-08,19.68,10,14,0,17.14,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.07e-06,15.48,10,12,0,18.33,5.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.13e-08,14.3,10,48,0,12.08,11.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.13e-08,17.69,10,29,0,13.45,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.13e-08,14.74,10,98,0,11.02,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),1.37e-08,13.4,10,24,0,14.17,9.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.87e-07,19.82,10,10,0,20.0,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),2.35e-08,12.17,10,37,0,12.7,7.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.81e-08,13.98,10,20,0,15.0,9.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.13e-08,15.63,10,94,0,11.06,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.35e-06,21.42,10,8,0,14.4,9.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),1.13e-08,18.29,10,19,0,15.26,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.13e-08,15.45,10,21,0,14.76,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),1.41e-08,20.63,10,12,0,18.33,9.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.4e-08,28.35,10,10,0,20.0,21.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),9.31e-08,20.93,10,10,0,20.0,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.14e-08,15.25,10,21,0,14.76,21.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.13e-08,16.86,10,21,0,14.76,9.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.13e-08,14.98,10,32,0,13.12,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),4.66e-08,22.34,10,10,0,20.0,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.13e-08,21.31,10,39,0,12.56,9.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.13e-08,25.29,10,44,0,12.27,11.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.13e-08,18.17,10,113,0,10.88,9.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.76e-06,15.69,10,11,0,19.09,11.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.18e-06,15.42,10,11,0,19.09,9.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.71e-07,15.88,10,12,0,18.33,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.15e-08,13.77,10,25,0,14.0,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.13e-08,19.45,10,87,0,11.15,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.13e-08,14.44,10,33,0,13.03,9.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.13e-08,17.17,10,41,0,12.44,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.13e-08,17.34,10,21,0,14.76,1.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",1.14e-08,15.01,10,21,0,14.76,9.0
Increase in blood pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.13e-08,15.95,10,1021,0,10.1,11.0
Body mass index (clna),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Octogenarians (aggp),6.5e-07,62.96,14,9,0,14.79,1.0
Body mass index (clna),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Surgical Patients (podg),1.22e-08,57.71,14,16,0,26.25,1.0
Body mass index (clna),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,General Population (humn),3.61e-16,57.44,14,31,0,20.32,1.0
Body mass index (clna),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),2.25e-13,56.86,14,28,0,21.0,1.0
Body mass index (clna),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,African American (popg),5.24e-20,59.36,14,53,0,17.7,1.0
Body mass index (clna),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Caucasoid Race (popg),1.24e-06,55.5,14,19,0,24.32,1.0
Body mass index (clna),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Participant (humn),8.62e-17,57.26,14,33,0,19.94,1.0
Body mass index (clna),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Long-Term Survivors (podg),8.54e-10,58.29,14,17,0,25.53,1.0
Body mass index (clna),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),5.24e-20,54.95,14,100,0,15.96,1.0
Body mass index (clna),PREDISPOSES,Carcinoma of the Large Intestine (neop),ISA,Common Neoplasm (neop),3.66e-09,56.62,14,20,0,23.8,5.0
Body mass index (clna),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,cohort (humn),6.77e-08,56.39,14,18,0,24.89,1.0
Body mass index (clna),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,cohort (humn),5.24e-20,56.63,14,63,0,17.11,1.0
Body mass index (clna),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Black race (popg),2.22e-08,58.69,14,14,0,28.0,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Diabetes Mellitus (dsyn),COEXISTS_WITH,Heart failure (dsyn),6.04e-07,26.02,7,15,0,10.27,9.0
Metabolic syndrome (dsyn),PREDISPOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),6.04e-07,28.49,7,15,0,10.27,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Diabetes Mellitus (dsyn),CAUSES,"Kidney Failure, Chronic (dsyn)",6.04e-07,19.99,7,20,0,9.45,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),6.04e-07,19.26,7,52,0,7.94,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Diabetes Mellitus (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.16e-06,18.14,7,15,0,10.27,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Diabetes Mellitus (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",6.12e-07,17.65,7,21,0,9.33,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Diabetes Mellitus (dsyn),CAUSES,End stage renal failure (dsyn),6.04e-07,18.94,7,51,0,7.96,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Diabetes Mellitus (dsyn),PROCESS_OF,Survivors (humn),6.81e-07,21.25,7,12,0,11.08,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Diabetes Mellitus (dsyn),CAUSES,Kidney Failure (dsyn),6.04e-07,23.59,7,15,0,10.27,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Diabetes Mellitus (dsyn),CAUSES,Cessation of life (orgf),6.04e-07,20.84,7,43,0,8.14,11.0
Metabolic syndrome (dsyn),PREDISPOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),6.09e-07,21.09,7,14,0,10.5,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),6.04e-07,19.26,7,26,0,8.88,21.0
Metabolic syndrome (dsyn),PREDISPOSES,Diabetes Mellitus (dsyn),PROCESS_OF,General Population (humn),6.04e-07,18.45,7,22,0,9.23,1.0
Metabolic syndrome (dsyn),PREDISPOSES,Diabetes Mellitus (dsyn),ISA,Metabolic Diseases (dsyn),2.23e-06,15.63,7,43,0,8.14,5.0
Metabolic syndrome (dsyn),PREDISPOSES,Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),6.04e-07,18.09,7,44,0,8.11,1.0
ghrelin (aapp),ASSOCIATED_WITH,Anorexia Nervosa (mobd),ISA,Mental disorders (mobd),1.44e-11,21.68,11,46,0,13.63,5.0
Cell physiology (celf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),2.69e-09,29.29,8,20,0,11.2,1.0
Cell physiology (celf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),4.23e-09,26.48,8,65,0,8.98,1.0
Cell physiology (celf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.77e-07,28.8,8,16,0,12.0,1.0
Cell physiology (celf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.1e-06,29.06,8,13,0,12.92,1.0
Cell physiology (celf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.39e-08,30.04,8,16,0,12.0,1.0
Cell physiology (celf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,35.44,8,8,0,16.0,1.0
Cell physiology (celf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.87e-09,28.92,8,23,0,10.78,1.0
Cell physiology (celf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.71e-09,29.82,8,22,0,10.91,1.0
Cell physiology (celf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.86e-07,29.74,8,13,0,12.92,1.0
Cell physiology (celf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),3.24e-09,31.74,8,15,0,12.27,1.0
High Density Lipoprotein Cholesterol (bacs),ISA,Cholesterol (bacs),PART_OF,Membrane (celc),6.47e-15,19.5,25,5,0,6.0,3.0
Urine ratio (lbpr),USES,Potassium (bacs),PART_OF,Extracellular (celc),4.13e-06,15.15,6,8,0,10.5,3.0
Urine ratio (lbpr),USES,Potassium (bacs),ASSOCIATED_WITH,Acute myocardial infarction (dsyn),8.21e-06,19.5,6,12,0,9.0,6.0
follow-up (hlca),AFFECTS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.54e-06,28.98,6,12,0,9.0,1.0
follow-up (hlca),AFFECTS,Body Weight decreased (fndg),ISA,Physical findings (sosy),5.52e-07,26.34,6,24,0,7.5,5.0
Subcutaneous Fat (tisu),PART_OF,Femur (bpoc),LOCATION_OF,Head (blor),1.67e-06,15.18,9,6,0,10.0,2.0
Subcutaneous Fat (tisu),PART_OF,Femur (bpoc),LOCATION_OF,Neck (blor),6.68e-07,15.47,9,393,0,9.21,2.0
Subcutaneous Fat (tisu),PART_OF,Femur (bpoc),LOCATION_OF,Slipped Epiphyses (dsyn),4.71e-09,15.1,9,1,0,1.11,2.0
Chronic Disease (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,11.93,17,18,0,33.06,1.0
Sedentary (fndg),PROCESS_OF,student (prog),USES,Grade (clas),3.86e-13,12.78,14,7,0,10.5,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),3.41e-07,44.34,6,18,0,8.0,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),4.16e-08,46.78,6,77,0,6.47,4.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),4.16e-08,44.85,6,33,0,7.09,4.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),4.33e-08,45.86,6,18,0,8.0,4.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),4.18e-08,49.11,6,15,0,8.4,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",4.16e-08,46.84,6,41,0,6.88,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),4.16e-08,45.38,6,30,0,7.2,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),4.16e-08,45.03,6,35,0,7.03,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),4.16e-08,49.4,6,27,0,7.33,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),4e-06,44.13,6,16,0,8.25,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),4.16e-08,46.82,6,22,0,7.64,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),6.18e-08,45.07,6,18,0,8.0,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),4.16e-08,48.94,6,19,0,7.89,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),1.42e-07,47.91,6,12,0,9.0,4.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),2.29e-07,53.63,6,9,0,10.0,4.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),4.16e-08,44.51,6,97,0,6.37,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),4.16e-08,45.52,6,68,0,6.53,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),4.16e-08,58.53,6,27,0,7.33,4.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),9.37e-07,48.66,6,10,0,9.6,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),4.16e-08,52.42,6,20,0,7.8,4.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.16e-08,49.51,6,19,0,7.89,4.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),4.16e-08,45.76,6,93,0,6.39,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),7.37e-08,45.66,6,16,0,8.25,4.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),5.24e-07,44.45,6,17,0,8.12,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),7.05e-07,48.99,6,10,0,9.6,4.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),4.44e-08,44.55,6,22,0,7.64,1.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),4.16e-08,46.37,6,24,0,7.5,4.0
Bariatric Surgery (topp),TREATS,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),2.73e-06,47.59,6,10,0,9.6,4.0
Overweight (sosy),PREDISPOSES,Chronic Disease (dsyn),CAUSES,Cessation of life (orgf),1.05e-14,33.93,12,66,0,14.18,11.0
Overweight (sosy),PREDISPOSES,Chronic Disease (dsyn),PROCESS_OF,cohort (humn),2.79e-07,32.04,12,16,0,21.0,1.0
Overweight (sosy),PREDISPOSES,Chronic Disease (dsyn),CAUSES,Disability NOS (patf),4.85e-06,30.85,12,18,0,20.0,11.0
Fatty degeneration (patf),COEXISTS_WITH,"Hepatitis C, Chronic (dsyn)",ISA,Virus Diseases (dsyn),3.69e-14,24.2,26,301,0,28.25,5.0
Fatty degeneration (patf),COEXISTS_WITH,"Hepatitis C, Chronic (dsyn)",CAUSES,Liver diseases (dsyn),3.31e-10,28.67,26,18,0,30.46,9.0
Diabetic (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),5.79e-19,15.51,20,136,0,22.94,1.0
Diabetic (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),5.79e-19,14.64,20,188,0,22.13,1.0
Diabetic (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Population Group (humn),2.53e-06,15.53,20,20,0,40.0,1.0
Fatty Liver (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,22.03,11,16,0,18.56,9.0
Fatty Liver (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,27.2,11,9,0,16.36,9.0
Fatty Liver (dsyn),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,19.58,11,31,0,14.9,9.0
olanzapine (orch),TREATS,Schizophrenia (mobd),PROCESS_OF,Outpatients (podg),5.69e-08,5.17,56,12,0,14.57,1.0
Waist circumference (fndg),PREDISPOSES,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.71e-11,66.7,10,25,0,14.0,21.0
Waist circumference (fndg),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.74e-10,70.6,10,15,0,16.67,9.0
Waist circumference (fndg),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),8.51e-15,75.98,10,24,0,14.17,11.0
Waist circumference (fndg),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),8.51e-15,66.62,10,46,0,12.17,11.0
Waist circumference (fndg),PREDISPOSES,Atherosclerosis (dsyn),PROCESS_OF,General Population (humn),6.44e-10,66.19,10,24,0,14.17,1.0
Waist circumference (fndg),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),5.09e-10,68.03,10,18,0,15.56,11.0
Waist circumference (fndg),PREDISPOSES,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),8.53e-15,64.76,10,73,0,11.37,5.0
Waist circumference (fndg),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),9.39e-08,65.36,10,24,0,14.17,11.0
Waist circumference (fndg),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",8.51e-15,66.67,10,41,0,12.44,9.0
Waist circumference (fndg),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),7.75e-10,67.45,10,19,0,15.26,11.0
Waist circumference (fndg),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.44e-14,68.33,10,26,0,13.85,9.0
Proteinuria (dsyn),PREDISPOSES,End stage renal failure (dsyn),ISA,Kidney Diseases (dsyn),4.18e-06,14.2,7,24,0,9.04,5.0
Proteinuria (dsyn),PREDISPOSES,End stage renal failure (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),4.18e-06,15.17,7,22,0,9.23,1.0
Proteinuria (dsyn),PREDISPOSES,End stage renal failure (dsyn),PROCESS_OF,Participant (humn),4.18e-06,16.16,7,29,0,8.69,1.0
Proteinuria (dsyn),PREDISPOSES,End stage renal failure (dsyn),ISA,Kidney Failure (dsyn),4.3e-06,18.08,7,11,0,11.45,5.0
Proteinuria (dsyn),PREDISPOSES,End stage renal failure (dsyn),PROCESS_OF,African American (popg),4.18e-06,12.74,7,35,0,8.4,1.0
Proteinuria (dsyn),PREDISPOSES,End stage renal failure (dsyn),PREDISPOSES,Kidney Failure (dsyn),4.47e-06,21.73,7,9,0,12.44,21.0
Proteinuria (dsyn),PREDISPOSES,End stage renal failure (dsyn),PROCESS_OF,General Population (humn),4.18e-06,15.1,7,17,0,9.88,1.0
Proteinuria (dsyn),PREDISPOSES,End stage renal failure (dsyn),PROCESS_OF,Survivors (humn),4.18e-06,21.41,7,15,0,10.27,1.0
Proteinuria (dsyn),PREDISPOSES,End stage renal failure (dsyn),ISA,"Kidney Failure, Chronic (dsyn)",4.18e-06,15.77,7,58,0,7.84,5.0
Proteinuria (dsyn),PREDISPOSES,End stage renal failure (dsyn),CAUSES,Cessation of life (orgf),4.18e-06,17.66,7,20,0,9.45,11.0
Proteinuria (dsyn),PREDISPOSES,End stage renal failure (dsyn),PROCESS_OF,cohort (humn),4.18e-06,17.68,7,71,0,7.69,1.0
Proteinuria (dsyn),PREDISPOSES,End stage renal failure (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.76e-06,17.08,7,10,0,11.9,21.0
Proteinuria (dsyn),PREDISPOSES,End stage renal failure (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",4.18e-06,15.48,7,21,0,9.33,1.0
"Hypertrophy, Left Ventricular (patf)",PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,Vascular calcification (patf),1.57e-09,25.55,12,17,0,20.47,9.0
"Hypertrophy, Left Ventricular (patf)",PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",1.87e-09,22.05,12,12,0,24.0,9.0
"Hypertrophy, Left Ventricular (patf)",PREDISPOSES,Cardiovascular morbidity (dsyn),PROCESS_OF,General Population (humn),1.57e-09,21.51,12,36,0,16.0,1.0
"Hypertrophy, Left Ventricular (patf)",PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),1.57e-09,23.78,12,22,0,18.55,9.0
"Hypertrophy, Left Ventricular (patf)",PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",1.57e-09,21.34,12,59,0,14.44,9.0
"Hypertrophy, Left Ventricular (patf)",PREDISPOSES,Cardiovascular morbidity (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",6.52e-07,18.67,12,9,0,15.75,1.0
"Hypertrophy, Left Ventricular (patf)",PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,Atherosclerosis (dsyn),2.11e-09,25.05,12,11,0,21.08,9.0
"Hypertrophy, Left Ventricular (patf)",PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.57e-09,24.3,12,28,0,17.14,9.0
"Hypertrophy, Left Ventricular (patf)",PREDISPOSES,Cardiovascular morbidity (dsyn),COEXISTS_WITH,Peripheral Vascular Diseases (dsyn),1.57e-09,26.55,12,17,0,20.47,9.0
Diagnosis (hlca),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,13.09,12,16,0,21.0,4.0
Diagnosis (hlca),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),5.21e-10,23.3,12,26,0,17.54,4.0
C-reactive protein (aapp),ASSOCIATED_WITH,Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),5.87e-08,15.4,9,77,0,10.05,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),6.87e-08,15.75,9,16,0,14.06,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Coronary heart disease (dsyn),PROCESS_OF,Young adult (aggp),4.14e-06,15.19,9,12,0,15.75,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Coronary heart disease (dsyn),PROCESS_OF,Middle Aged (aggp),5.91e-08,15.53,9,19,0,13.26,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Coronary heart disease (dsyn),PREDISPOSES,Atherosclerosis (dsyn),6e-08,14.32,9,22,0,12.68,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Coronary heart disease (dsyn),PROCESS_OF,Outpatients (podg),1.16e-07,13.32,9,24,0,12.38,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Coronary heart disease (dsyn),PROCESS_OF,General Population (humn),5.87e-08,15.03,9,42,0,10.93,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),5.87e-08,16.28,9,102,0,9.79,5.0
C-reactive protein (aapp),ASSOCIATED_WITH,Coronary heart disease (dsyn),CAUSES,Heart failure (dsyn),3.93e-07,15.87,9,13,0,15.23,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),5.87e-08,15.62,9,83,0,9.98,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Coronary heart disease (dsyn),ISA,Death (finding) (fndg),5.87e-08,18.2,9,250,0,9.32,5.0
C-reactive protein (aapp),ASSOCIATED_WITH,Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),5.87e-08,15.38,9,194,0,9.42,8.0
Age (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.73e-06,11.56,8,25,0,10.56,8.0
Age (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),3.73e-06,15.46,8,15,0,12.27,8.0
Age (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),3.73e-06,20.84,8,24,0,10.67,8.0
Age (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),3.73e-06,11.47,8,46,0,9.39,8.0
Age (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),PROCESS_OF,General Population (humn),3.73e-06,11.04,8,24,0,10.67,1.0
Age (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),3.73e-06,12.88,8,18,0,11.56,8.0
Age (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),3.73e-06,9.62,8,73,0,8.88,5.0
Age (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),3.82e-06,10.21,8,24,0,10.67,8.0
Age (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",3.73e-06,11.53,8,41,0,9.56,8.0
Age (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),3.73e-06,12.3,8,19,0,11.37,8.0
Age (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.73e-06,13.18,8,26,0,10.46,8.0
Adipose tissue (tisu),PART_OF,Entire trunk (bpoc),LOCATION_OF,Hemorrhage (fndg),1.72e-07,31.51,8,12,0,13.33,2.0
Adipose tissue (tisu),PART_OF,Entire trunk (bpoc),PART_OF,Elephants (mamm),1.69e-09,29.82,8,140,0,8.46,3.0
Adipose tissue (tisu),PART_OF,Entire trunk (bpoc),PART_OF,Aorta (bpoc),3.73e-09,27.23,8,35,0,9.83,3.0
Extensor (blor),LOCATION_OF,Endurance (fndg),PROCESS_OF,athlete (humn),2.25e-06,5.61,10,22,0,14.55,1.0
"Osteoarthritis, Knee (dsyn)",PROCESS_OF,African American (popg),ISA,Ethnic group (popg),1.43e-06,21.22,6,98,0,6.37,1.0
"Osteoarthritis, Knee (dsyn)",PROCESS_OF,African American (popg),ISA,Racial group (popg),1.43e-06,22.16,6,324,0,6.11,1.0
Sex Hormone-Binding Globulin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,32.58,12,33,0,16.36,1.0
Sex Hormone-Binding Globulin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,33.13,12,16,0,21.0,8.0
Sex Hormone-Binding Globulin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),5.72e-15,32.93,12,71,0,14.03,5.0
Sex Hormone-Binding Globulin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),5.72e-15,46.77,12,35,0,16.11,8.0
Sex Hormone-Binding Globulin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.72e-15,32.86,12,110,0,13.31,8.0
Sex Hormone-Binding Globulin (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,32.19,12,37,0,15.89,1.0
Free testosterone (horm),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.6e-08,47.49,8,16,0,12.0,8.0
Free testosterone (horm),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,52.66,8,9,0,15.11,8.0
Free testosterone (horm),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,45.04,8,31,0,10.06,8.0
Overweight (sosy),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,53.56,108,20,0,23.7,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,50.74,108,65,0,104.12,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,53.07,108,16,0,18.37,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,53.32,108,13,0,14.56,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,54.3,108,16,0,18.37,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,59.71,108,8,0,8.59,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,53.19,108,23,0,27.9,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,54.08,108,22,0,26.48,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,54.01,108,13,0,14.56,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,56.01,108,15,0,17.08,1.0
Insulin Resistance (patf),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),5.31e-08,32.01,7,25,0,8.96,1.0
Insulin Resistance (patf),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),5.9e-08,29.81,7,13,0,10.77,1.0
Insulin Resistance (patf),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),5.31e-08,34.27,7,32,0,8.53,1.0
Pregnancy (orgf),ASSOCIATED_WITH,Pre-Eclampsia (dsyn),AFFECTS,Pathogenesis (patf),1.87e-06,5.98,21,25,0,38.64,7.0
Pregnancy (orgf),ASSOCIATED_WITH,Pre-Eclampsia (dsyn),PROCESS_OF,Pregnant Women (popg),1.03e-10,5.2,21,105,0,25.2,1.0
Pregnancy (orgf),ASSOCIATED_WITH,Pre-Eclampsia (dsyn),ISA,Hypertension induced by pregnancy (dsyn),3.67e-08,6.02,21,31,0,35.23,5.0
Pregnancy (orgf),ASSOCIATED_WITH,Pre-Eclampsia (dsyn),PROCESS_OF,Pregnant Women (popg),4.99e-09,6.23,21,31,0,35.23,1.0
Pregnancy (orgf),ASSOCIATED_WITH,Pre-Eclampsia (dsyn),ISA,Pregnancy Complications (dsyn),1.02e-10,6.64,21,46,0,30.59,5.0
Pregnancy (orgf),ASSOCIATED_WITH,Pre-Eclampsia (dsyn),CAUSES,"Morbidity, perinatal (patf)",3.47e-06,14.28,21,8,0,11.05,8.0
Universities (orgt),LOCATION_OF,Prospective Studies (qnco),ISA,Techniques (ftcn),1.08e-12,6.99,23,912,0,23.58,2.0
Universities (orgt),LOCATION_OF,Prospective Studies (qnco),ISA,contextual factors (ftcn),1.3e-06,6.46,23,26,0,43.35,2.0
Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,15.19,55,18,0,23.89,1.0
Excessive weight loss (fndg),ISA,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,49.74,26,12,0,17.54,1.0
Excessive weight loss (fndg),ISA,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,47.11,26,24,0,46.15,5.0
Radical prostatectomy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),1.49e-34,5.96,113,77,1,129.47,1.0
Radical prostatectomy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),9.42e-08,5.08,114,22,0,26.25,1.0
Radical prostatectomy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),4.09e-09,12.19,114,12,0,13.26,1.0
Radical prostatectomy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),4.35e-08,6.05,114,18,0,20.84,1.0
Radical prostatectomy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (humn),5.8e-14,4.06,114,67,0,106.38,1.0
Radical prostatectomy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),2.1e-09,6.04,114,21,0,24.87,1.0
Radical prostatectomy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),5.51e-14,5.53,114,35,0,45.75,1.0
insulin sensitivity (patf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,33.77,23,18,0,32.09,1.0
abnormal glucose tolerance test (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,26.26,17,20,0,31.45,1.0
abnormal glucose tolerance test (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,23.44,17,65,0,21.45,1.0
abnormal glucose tolerance test (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,25.77,17,16,0,31.06,1.0
abnormal glucose tolerance test (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,26.02,17,13,0,22.94,1.0
abnormal glucose tolerance test (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,27.0,17,16,0,31.06,1.0
abnormal glucose tolerance test (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,32.41,17,8,0,11.76,1.0
abnormal glucose tolerance test (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,25.88,17,23,0,29.57,1.0
abnormal glucose tolerance test (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,26.78,17,22,0,30.14,1.0
abnormal glucose tolerance test (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,26.71,17,13,0,22.94,1.0
abnormal glucose tolerance test (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,28.71,17,15,0,28.24,1.0
Habits (inbe),PROCESS_OF,student (prog),USES,Grade (clas),1.42e-07,5.5,12,7,0,11.08,1.0
ghrelin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,35.44,14,16,0,26.25,8.0
ghrelin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,40.61,14,9,0,14.79,8.0
ghrelin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,32.99,14,31,0,20.32,8.0
Insulin (horm),TREATS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,29.92,87,16,0,18.94,4.0
Insulin (horm),TREATS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,35.09,87,9,0,9.93,4.0
Insulin (horm),TREATS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,27.47,87,31,0,42.05,4.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,27.34,13,9,0,15.23,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.66e-14,26.4,13,194,0,13.87,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,25.12,13,17,0,22.94,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),3.66e-14,26.39,13,29,0,18.83,11.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,28.57,13,14,0,25.07,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,24.38,13,12,0,23.08,5.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),3.66e-14,23.2,13,48,0,16.52,11.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),3.66e-14,26.59,13,29,0,18.83,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.66e-14,23.64,13,98,0,14.72,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,22.3,13,24,0,20.04,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,28.71,13,10,0,17.69,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,21.07,13,37,0,17.57,7.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,22.87,13,20,0,21.45,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),3.66e-14,24.53,13,94,0,14.8,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,30.32,13,8,0,12.92,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.5e-13,27.19,13,19,0,21.89,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.21e-11,24.35,13,21,0,21.05,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,29.53,13,12,0,23.08,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,37.24,13,10,0,17.69,21.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,29.83,13,10,0,17.69,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.26e-11,24.15,13,21,0,21.05,21.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),3.06e-13,25.76,13,21,0,21.05,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.67e-14,23.88,13,32,0,18.28,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,31.24,13,10,0,17.69,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),3.66e-14,30.21,13,39,0,17.33,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),3.66e-14,34.19,13,44,0,16.84,11.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.66e-14,27.06,13,113,0,14.5,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,24.59,13,11,0,20.31,11.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,24.32,13,11,0,20.31,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,24.78,13,12,0,23.08,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,22.67,13,25,0,19.76,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.66e-14,28.35,13,87,0,14.94,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),3.72e-14,23.33,13,33,0,18.12,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.66e-14,26.07,13,41,0,17.12,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.25e-13,26.24,13,21,0,21.05,1.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,23.91,13,21,0,21.05,9.0
Abdominal obesity (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),3.66e-14,24.85,13,1021,0,13.17,11.0
Supplementation (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.12e-06,27.16,7,12,0,11.08,1.0
Supplementation (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),1.23e-07,24.52,7,24,0,9.04,4.0
"Blood Pressure Monitoring, Ambulatory (diap)",ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.16e-09,19.93,15,18,0,27.5,6.0
Assessment procedure (hlca),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.17e-09,9.29,21,18,0,33.43,6.0
Mean blood pressure (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),7.05e-07,18.74,7,18,0,9.72,1.0
Albumins (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,Critically ill children (podg),3.63e-06,40.48,6,8,0,10.5,1.0
Albumins (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.66e-07,36.32,6,15,0,8.4,8.0
Albumins (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.64e-07,35.02,6,18,0,8.0,1.0
Albumins (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.63e-07,33.93,6,61,0,6.59,1.0
Albumins (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,Surgical Patients (podg),1.63e-07,33.98,6,24,0,7.5,1.0
Albumins (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,Cancer Patient (podg),1.72e-07,32.43,6,30,0,7.2,1.0
Albumins (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,inpatient (humn),1.63e-07,33.87,6,28,0,7.29,1.0
Albumins (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),CAUSES,Cessation of life (orgf),1.63e-07,35.79,6,28,0,7.29,8.0
Albumins (aapp),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,cohort (humn),1.63e-07,37.05,6,16,0,8.25,1.0
Nutritional status (orga),ASSOCIATED_WITH,Cystic Fibrosis (dsyn),ISA,Hereditary Diseases (dsyn),8.21e-13,19.92,12,79,0,13.82,5.0
Nutritional status (orga),ASSOCIATED_WITH,Cystic Fibrosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",5.78e-07,21.63,12,16,0,21.0,1.0
Leptin (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,"Energy, Physics (npop)",3.82e-07,8.63,9,79,0,10.03,1.0
Leptin (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,Oxidation-Reduction (npop),3.8e-06,8.59,9,29,0,11.79,1.0
Insulin Resistance (patf),COEXISTS_WITH,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.9e-06,11.37,8,62,0,9.03,9.0
Insulin Resistance (patf),COEXISTS_WITH,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.9e-06,21.96,8,17,0,11.76,9.0
Insulin Resistance (patf),COEXISTS_WITH,Dyslipidemias (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.9e-06,13.66,8,19,0,11.37,9.0
Non-alcoholic fatty liver (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,27.64,42,18,0,25.71,1.0
Form of muscle (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,34.57,13,18,0,22.39,1.0
Adiponectin (aapp),PART_OF,Adipose tissue (tisu),PART_OF,Epididymis (bpoc),5.63e-12,7.29,23,5,0,6.09,3.0
"TNF protein, human|TNF (aapp)",ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,21.07,29,16,0,24.83,8.0
"TNF protein, human|TNF (aapp)",ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,26.24,29,9,0,11.79,8.0
"TNF protein, human|TNF (aapp)",ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,18.63,29,31,0,56.13,8.0
Dietary intake (orgf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,17.18,14,20,0,23.8,1.0
Dietary intake (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,14.37,14,65,0,17.02,1.0
Dietary intake (orgf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,16.69,14,16,0,26.25,1.0
Dietary intake (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,16.95,14,13,0,25.07,1.0
Dietary intake (orgf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,17.93,14,16,0,26.25,1.0
Dietary intake (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,23.33,14,8,0,12.57,1.0
Dietary intake (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,16.81,14,23,0,22.52,1.0
Dietary intake (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.56e-11,17.7,14,22,0,22.91,1.0
Dietary intake (orgf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,17.63,14,13,0,25.07,1.0
Dietary intake (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,19.63,14,15,0,27.07,1.0
risk factors (qnco),ISA,Risk (qlco),ISA,Probability (qnco),1.77e-08,9.06,154,42,0,53.45,5.0
risk factors (qnco),ISA,Risk (qlco),ISA,contextual factors (ftcn),8.59e-29,9.55,154,104,0,174.23,5.0
risk factors (qnco),ISA,Risk (qlco),ISA,Socioeconomic Factors (grpa),3.11e-07,9.55,154,26,0,30.39,5.0
risk factors (qnco),ISA,Risk (qlco),ISA,Techniques (ftcn),4.07e-36,9.38,154,143,0,275.79,5.0
"Obesity, Morbid (dsyn)",PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,42.57,15,18,0,27.5,1.0
Running (dora),ISA,Performance (inbe),PROCESS_OF,cohort (humn),3.05e-21,5.33,62,150,0,87.63,1.0
Running (dora),ISA,Performance (inbe),PROCESS_OF,athlete (humn),5.53e-11,2.56,62,5,0,5.4,1.0
Running (dora),ISA,Performance (inbe),PROCESS_OF,student (prog),3.51e-20,2.53,62,4,0,4.26,1.0
Running (dora),ISA,Performance (inbe),PROCESS_OF,Surgeon (humn),1.11e-06,4.42,62,27,0,38.76,1.0
Running (dora),ISA,Performance (inbe),PREDISPOSES,Septicemia (dsyn),2.59e-06,10.61,62,9,0,10.31,5.0
"Obesity, Morbid (dsyn)",PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,53.19,13,20,0,21.45,1.0
"Obesity, Morbid (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,50.38,13,65,0,15.6,1.0
"Obesity, Morbid (dsyn)",PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,52.7,13,16,0,23.56,1.0
"Obesity, Morbid (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,52.95,13,13,0,26.0,1.0
"Obesity, Morbid (dsyn)",PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,53.94,13,16,0,23.56,1.0
"Obesity, Morbid (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,59.34,13,8,0,12.92,1.0
"Obesity, Morbid (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,52.82,13,23,0,20.35,1.0
"Obesity, Morbid (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,53.71,13,22,0,20.68,1.0
"Obesity, Morbid (dsyn)",PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,53.64,13,13,0,26.0,1.0
"Obesity, Morbid (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,55.64,13,15,0,24.27,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,31.69,25,9,0,12.24,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),4.15e-29,30.74,25,194,0,28.22,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,29.47,25,17,0,28.56,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,30.74,25,29,0,46.55,11.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,32.92,25,14,0,21.84,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,28.73,25,12,0,17.76,5.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),9.81e-23,27.55,25,48,0,38.02,11.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.51e-19,30.94,25,29,0,46.55,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),4.15e-29,27.99,25,98,0,31.38,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,26.65,25,24,0,47.04,9.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,33.06,25,10,0,14.0,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,25.42,25,37,0,41.89,7.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,27.22,25,20,0,36.0,9.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),4.15e-29,28.87,25,94,0,31.65,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,34.67,25,8,0,10.56,9.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,31.54,25,19,0,33.44,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,28.69,25,21,0,38.64,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,33.87,25,12,0,17.76,9.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,41.59,25,10,0,14.0,21.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,34.18,25,10,0,14.0,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,28.5,25,21,0,38.64,21.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,30.1,25,21,0,38.64,9.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,28.23,25,32,0,44.53,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,35.59,25,10,0,14.0,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),4.17e-29,34.56,25,39,0,41.03,9.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),4.15e-29,38.53,25,44,0,39.2,11.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.15e-29,31.41,25,113,0,30.53,9.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,28.94,25,11,0,15.84,11.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,28.66,25,11,0,15.84,9.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,29.13,25,12,0,17.76,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,27.02,25,25,0,50.0,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",4.15e-29,32.69,25,87,0,32.18,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,27.68,25,33,0,43.94,9.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),9.13e-27,30.42,25,41,0,40.24,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,30.59,25,21,0,38.64,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,28.25,25,21,0,38.64,9.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),4.15e-29,29.2,25,1021,0,25.61,11.0
Entire proximal femur (blor),LOCATION_OF,Scanning (diap),USES,Calcium (bacs),1.38e-08,24.46,8,32,0,10.0,2.0
Fracture (inpo),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.23e-09,12.0,15,18,0,27.5,1.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,"Myeloid Leukemia, Chronic (neop)",1.74e-08,7.83,15,26,0,23.65,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Liver Failure (patf),1.72e-08,7.98,15,71,0,18.17,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Alcoholic Liver Diseases (dsyn),1.72e-08,8.67,15,52,0,19.33,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Secondary malignant neoplasm of liver (neop),1.72e-08,8.75,15,32,0,22.03,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,End stage liver disease (dsyn),1.72e-08,9.16,15,272,0,15.83,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,"Hepatitis, Autoimmune (dsyn)",7.45e-08,7.96,15,19,0,26.84,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Hodgkin Disease (neop),1.6e-06,11.53,15,10,0,16.67,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),PRECEDES,Prophylactic treatment (topp),1.72e-08,7.69,15,74,0,18.04,22.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Primary biliary cirrhosis (dsyn),1.81e-08,6.88,15,33,0,21.82,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Amyloidosis (dsyn),3.51e-07,9.69,15,13,0,24.27,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Aneurysm (anab),5.42e-07,7.45,15,19,0,26.84,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Portal vein thrombosis (dsyn),1.72e-08,10.05,15,23,0,24.78,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Decompensated cirrhosis (dsyn),1.54e-06,8.94,15,13,0,24.27,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Congenital heart disease (dsyn),1.72e-08,11.27,15,20,0,26.25,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),PRECEDES,Therapeutic immunosuppression (topp),2.94e-07,7.26,15,21,0,25.71,22.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Hepatoblastoma (neop),1.72e-08,11.62,15,23,0,24.78,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Myeloproliferative disease (neop),3.49e-06,14.89,15,8,0,12.27,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Hilar Cholangiocarcinoma (neop),1.72e-08,11.18,15,23,0,24.78,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),CAUSES,Liver diseases (dsyn),4.23e-08,11.29,15,13,0,24.27,11.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),PRECEDES,Renal Replacement Therapy (topp),1.74e-08,12.79,15,15,0,30.0,22.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Dysmyelopoietic Syndromes (neop),1.72e-08,11.91,15,54,0,19.17,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Polycystic liver disease (cgab),1.86e-08,9.88,15,17,0,28.24,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Acute leukemia (neop),1.72e-08,9.56,15,38,0,20.92,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),USES,Ventricular assist device (medd),1.75e-08,11.46,15,16,0,29.06,6.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Sickle Cell Anemia (dsyn),5.56e-08,9.03,15,16,0,29.06,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Hepatitis C (dsyn),1.72e-08,8.73,15,36,0,21.25,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Prognosis bad (fndg),1.8e-08,14.36,15,13,0,24.27,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Cystic Fibrosis (dsyn),1.72e-08,9.44,15,25,0,24.0,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,HIV Seropositivity (fndg),1.89e-08,10.36,15,16,0,29.06,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Transplanted organ and tissue status (fndg),1.72e-08,9.66,15,25,0,24.0,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),PRECEDES,Heart Transplantation (topp),7.56e-08,8.2,15,18,0,27.5,22.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,"Leukemia, Lymphocytic, Acute (neop)",1.72e-08,12.02,15,49,0,19.59,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Primary carcinoma of the liver cells (neop),1.72e-08,9.45,15,734,0,15.31,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),PREDISPOSES,Graft loss (patf),1.54e-06,8.94,15,13,0,24.27,21.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Hematologic Neoplasms (neop),1.72e-08,10.86,15,89,0,17.53,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),USES,Left ventricular assist device (medd),1.75e-08,11.46,15,16,0,29.06,6.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),PRECEDES,Dialysis procedure (topp),1.72e-08,7.94,15,35,0,21.43,22.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),USES,Cyclophosphamide (opco),1.72e-08,9.96,15,33,0,21.82,6.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,anemia; profound (dsyn),7.56e-08,8.2,15,18,0,27.5,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),PRECEDES,Antiviral prophylaxis (topp),3.49e-06,14.89,15,8,0,12.27,22.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Liver diseases (dsyn),1.72e-08,7.77,15,87,0,17.59,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Cholangiocarcinoma (neop),1.72e-08,8.65,15,40,0,20.62,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),PRECEDES,Repeat Surgery (topp),2.23e-06,10.1,15,11,0,19.07,22.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),PRECEDES,retransplantation (topp),1.72e-08,11.46,15,32,0,22.03,22.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Multiple Myeloma (neop),1.72e-08,9.96,15,25,0,24.0,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Liver Cirrhosis (dsyn),1.72e-08,7.48,15,31,0,22.26,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Age (orga),1.72e-08,9.06,15,24,0,24.38,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,End stage renal failure (dsyn),1.72e-08,7.82,15,40,0,20.62,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),AFFECTS,leukemia (neop),1.73e-08,15.11,15,14,0,27.07,7.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Hepatoma recurrent (neop),2.09e-08,9.04,15,18,0,27.5,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,"Leukemia, Myelocytic, Acute (neop)",1.72e-08,12.69,15,115,0,16.96,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),PRECEDES,Lung Transplantation (topp),1.74e-08,11.63,15,16,0,29.06,22.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),ISA,Reconstructive Surgical Procedures (topp),4.39e-07,6.15,15,38,0,20.92,5.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Hepatorenal Syndrome (dsyn),1.26e-07,8.66,15,16,0,29.06,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Hepatopulmonary Syndrome (dsyn),1.72e-08,8.72,15,27,0,23.33,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Myelofibrosis (neop),1.75e-08,15.75,15,13,0,24.27,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Acute alcoholic liver disease (dsyn),9.56e-07,14.14,15,9,0,14.4,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Primary sclerosing cholangitis (dsyn),1.72e-08,7.34,15,53,0,19.25,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Neuroendocrine Tumors (neop),2.38e-08,9.75,15,16,0,29.06,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,"Aortic Aneurysm, Abdominal (dsyn)",1.72e-08,8.26,15,27,0,23.33,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),compared_with,Dialysis procedure (topp),1.72e-08,10.16,15,21,0,25.71,17.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Diabetic (fndg),1.72e-08,8.32,15,31,0,22.26,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,cohort (humn),1.72e-08,12.28,15,58,0,18.88,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Coronary Arteriosclerosis (dsyn),1.72e-08,9.1,15,25,0,24.0,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,"Hypertension, Pulmonary (dsyn)",2.37e-06,9.3,15,12,0,21.6,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,"Hepatitis, Alcoholic (dsyn)",2.18e-08,9.38,15,17,0,28.24,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),AFFECTS,Graft Survival (ortf),1.76e-08,7.82,15,25,0,24.0,7.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),PRECEDES,Hematopoietic Stem Cell Transplantation (topp),1.72e-08,10.94,15,25,0,24.0,22.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Donor person (humn),1.72e-08,9.1,15,32,0,22.03,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Biliary Atresia (dsyn),1.72e-08,10.02,15,37,0,21.08,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),USES,Aortic Stents (medd),1.72e-08,9.24,15,26,0,23.65,6.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Hepatitis B (dsyn),4.49e-08,7.54,15,22,0,25.23,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Fibrosis (patf),1.72e-08,8.4,15,134,0,16.68,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Biliary Atresia (dsyn),1.72e-08,8.11,15,47,0,19.79,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,"Recipient, Transplant (podg)",1.72e-08,8.06,15,59,0,18.81,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),METHOD_OF,Revascularization - action (topp),1.73e-08,9.1,15,22,0,25.23,16.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,"Liver Cirrhosis, Alcoholic (dsyn)",1.72e-08,7.65,15,33,0,21.82,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Heart failure (dsyn),1.72e-08,8.4,15,35,0,21.43,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,"Liver Failure, Acute (dsyn)",1.72e-08,8.26,15,224,0,16.0,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),PRECEDES,Treatment Protocols (resa),1.72e-08,9.22,15,51,0,19.41,22.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Abnormal renal function (patf),2.46e-07,11.94,15,11,0,19.07,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),USES,Stents (medd),1.72e-08,9.0,15,240,0,15.94,6.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Left main coronary artery disease (dsyn),6.2e-07,19.01,15,8,0,12.27,4.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),PRECEDES,Stem cell transplant (topp),1.72e-08,13.28,15,27,0,23.33,22.0
Kidney Transplantation (topp),PRECEDES,Transplantation (topp),TREATS,Chronic liver disease NOS (dsyn),1.72e-08,8.88,15,29,0,22.76,4.0
Life Style (socb),ISA,Behavior (inbe),PROCESS_OF,network (popg),2.21e-06,11.63,355,4,0,4.05,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,33.2,11,16,0,18.56,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.19e-13,43.42,11,26,0,15.65,8.0
Gastrectomy (topp),compared_with,Roux-en-Y Gastric Bypass (topp),TREATS,"Obesity, Morbid (dsyn)",2.12e-18,31.93,32,53,1,51.32,4.0
olanzapine (orch),ISA,Atypical antipsychotic (phsu),TREATS,Dementia (mobd),1.12e-06,9.25,16,17,0,31.06,4.0
Prescription of prophylactic anticoagulant (topp),USES,Enoxaparin (carb),ISA,"Heparin, Low-Molecular-Weight (carb)",1.02e-06,11.48,8,82,0,8.78,5.0
Prescription of prophylactic anticoagulant (topp),USES,Enoxaparin (carb),higher_than,"Heparin, Low-Molecular-Weight (carb)",1.02e-06,14.32,8,19,0,11.37,6.0
Prescription of prophylactic anticoagulant (topp),USES,Enoxaparin (carb),PREVENTS,Thromboembolism (patf),1.02e-06,12.85,8,38,0,9.68,6.0
Prescription of prophylactic anticoagulant (topp),USES,Enoxaparin (carb),compared_with,"Heparin, Low-Molecular-Weight (carb)",1.02e-06,12.61,8,65,0,8.98,6.0
Metabolic syndrome (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.2e-14,36.6,22,22,0,44.0,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.23e-10,36.03,22,17,0,30.14,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.29e-08,32.09,22,27,0,39.93,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.38e-08,35.05,22,15,0,25.23,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.37e-10,33.25,22,24,0,42.17,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),8.91e-14,32.87,22,34,0,36.24,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),5.21e-21,34.3,22,40,0,34.1,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.22e-09,41.02,22,12,0,18.55,9.0
Impaired cognition (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.31e-07,6.6,32,18,0,28.12,1.0
Snoring (sosy),PREDISPOSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,41.29,12,16,0,21.0,21.0
Snoring (sosy),PREDISPOSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),7.24e-16,51.5,12,26,0,17.54,21.0
"Amino Acids, Branched-Chain (aapp)",ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.7e-08,22.72,9,16,0,14.06,8.0
"Amino Acids, Branched-Chain (aapp)",ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.4e-07,27.89,9,9,0,18.0,8.0
"Amino Acids, Branched-Chain (aapp)",ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.19e-07,20.27,9,31,0,11.61,8.0
Body mass index procedure (diap),DIAGNOSES,Diabetes Mellitus (dsyn),COEXISTS_WITH,Heart failure (dsyn),1.99e-10,77.77,7,15,0,10.27,9.0
Body mass index procedure (diap),DIAGNOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.96e-10,80.25,7,15,0,10.27,18.0
Body mass index procedure (diap),DIAGNOSES,Diabetes Mellitus (dsyn),CAUSES,"Kidney Failure, Chronic (dsyn)",2.04e-10,71.75,7,20,0,9.45,11.0
Body mass index procedure (diap),DIAGNOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.95e-10,71.01,7,52,0,7.94,18.0
Body mass index procedure (diap),DIAGNOSES,Diabetes Mellitus (dsyn),PROCESS_OF,Hospitalized Patients (humn),5.59e-07,69.89,7,15,0,10.27,1.0
Body mass index procedure (diap),DIAGNOSES,Diabetes Mellitus (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",7.89e-09,69.41,7,21,0,9.33,1.0
Body mass index procedure (diap),DIAGNOSES,Diabetes Mellitus (dsyn),CAUSES,End stage renal failure (dsyn),1.95e-10,70.69,7,51,0,7.96,11.0
Body mass index procedure (diap),DIAGNOSES,Diabetes Mellitus (dsyn),PROCESS_OF,Survivors (humn),7.63e-08,73.0,7,12,0,11.08,1.0
Body mass index procedure (diap),DIAGNOSES,Diabetes Mellitus (dsyn),CAUSES,Kidney Failure (dsyn),2.32e-10,75.34,7,15,0,10.27,11.0
Body mass index procedure (diap),DIAGNOSES,Diabetes Mellitus (dsyn),CAUSES,Cessation of life (orgf),1.95e-10,72.59,7,43,0,8.14,11.0
Body mass index procedure (diap),DIAGNOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),4.92e-09,72.84,7,14,0,10.5,18.0
Body mass index procedure (diap),DIAGNOSES,Diabetes Mellitus (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),1.95e-10,71.01,7,26,0,8.88,18.0
Body mass index procedure (diap),DIAGNOSES,Diabetes Mellitus (dsyn),PROCESS_OF,General Population (humn),2.9e-10,70.2,7,22,0,9.23,1.0
Body mass index procedure (diap),DIAGNOSES,Diabetes Mellitus (dsyn),ISA,Metabolic Diseases (dsyn),1.63e-06,67.38,7,43,0,8.14,5.0
Body mass index procedure (diap),DIAGNOSES,Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),1.95e-10,69.84,7,44,0,8.11,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,14.53,16,9,0,14.06,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),5.8e-11,13.58,16,194,0,17.32,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.94e-10,12.31,16,17,0,31.06,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),5.8e-11,13.58,16,29,0,24.83,11.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2.57e-10,15.76,16,14,0,26.25,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,11.57,16,12,0,21.0,5.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),5.8e-11,10.39,16,48,0,21.33,11.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),5.8e-11,13.78,16,29,0,24.83,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),5.8e-11,10.82,16,98,0,18.61,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.38e-09,9.49,16,24,0,26.67,9.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,15.9,16,10,0,16.25,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.22e-08,8.26,16,37,0,22.92,7.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),5.8e-11,11.71,16,94,0,18.72,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,17.5,16,8,0,12.0,9.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),5.83e-11,14.38,16,19,0,29.47,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),7e-11,11.53,16,21,0,28.19,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.83e-09,16.71,16,12,0,21.0,9.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.69e-09,24.43,16,10,0,16.25,21.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,17.02,16,10,0,16.25,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),8.05e-11,11.33,16,21,0,28.19,21.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),5.82e-11,12.94,16,21,0,28.19,9.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),5.8e-11,11.07,16,32,0,24.0,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.54e-08,18.43,16,10,0,16.25,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),5.8e-11,17.4,16,39,0,22.56,9.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),5.8e-11,21.37,16,44,0,21.82,11.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.8e-11,14.25,16,113,0,18.27,9.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,11.78,16,11,0,18.56,11.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,11.5,16,11,0,18.56,9.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,11.96,16,12,0,21.0,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.76e-10,9.86,16,25,0,26.24,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",5.8e-11,15.53,16,87,0,18.94,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),5.8e-11,10.52,16,33,0,23.76,9.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),5.8e-11,13.26,16,41,0,22.24,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),5.8e-11,13.43,16,21,0,28.19,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",1.08e-10,11.09,16,21,0,28.19,9.0
Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),5.8e-11,12.04,16,1021,0,16.25,11.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,22.08,10,9,0,17.1,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),9.16e-10,21.14,10,194,0,10.52,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),1.25e-09,19.86,10,17,0,15.88,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),9.16e-10,21.13,10,29,0,13.45,11.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.12e-09,23.31,10,14,0,17.14,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,19.12,10,12,0,18.33,5.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),9.16e-10,17.94,10,48,0,12.08,11.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),9.16e-10,21.33,10,29,0,13.45,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.16e-10,18.38,10,98,0,11.02,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),3.24e-09,17.04,10,24,0,14.17,9.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.77e-07,23.45,10,10,0,20.0,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.31e-08,15.81,10,37,0,12.7,7.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),7.65e-09,17.61,10,20,0,15.0,9.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),9.16e-10,19.27,10,94,0,11.06,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,25.06,10,8,0,14.4,9.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),9.16e-10,21.93,10,19,0,15.26,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),9.28e-10,19.09,10,21,0,14.76,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),3.69e-09,24.27,10,12,0,18.33,9.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.55e-09,31.98,10,10,0,20.0,21.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.27e-08,24.57,10,10,0,20.0,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),9.38e-10,18.89,10,21,0,14.76,21.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),9.16e-10,20.5,10,21,0,14.76,9.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.16e-10,18.62,10,32,0,13.12,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.62e-08,25.98,10,10,0,20.0,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),9.16e-10,24.95,10,39,0,12.56,9.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),9.16e-10,28.93,10,44,0,12.27,11.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",9.16e-10,21.8,10,113,0,10.88,9.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,19.33,10,11,0,19.09,11.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,19.05,10,11,0,19.09,9.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.6e-07,19.52,10,12,0,18.33,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.03e-09,17.41,10,25,0,14.0,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",9.16e-10,23.08,10,87,0,11.15,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),9.16e-10,18.07,10,33,0,13.03,9.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),9.16e-10,20.81,10,41,0,12.44,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),9.16e-10,20.98,10,21,0,14.76,1.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",9.66e-10,18.64,10,21,0,14.76,9.0
Total cholesterol (strd),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),9.16e-10,19.59,10,1021,0,10.1,11.0
Performance (inbe),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.18e-06,6.59,28,18,0,29.57,1.0
Early endosome (celc),PART_OF,Upper Extremity (bpoc),LOCATION_OF,Death (finding) (fndg),8.24e-12,14.35,17,95,0,20.04,2.0
Early endosome (celc),PART_OF,Upper Extremity (bpoc),LOCATION_OF,Serious Adverse Event (fndg),3.34e-07,11.7,17,13,0,22.94,2.0
Early endosome (celc),PART_OF,Upper Extremity (bpoc),LOCATION_OF,Upper arm (blor),8.24e-12,8.93,17,51,0,22.67,2.0
Early endosome (celc),PART_OF,Upper Extremity (bpoc),LOCATION_OF,Diarrhea (sosy),2.74e-10,12.02,17,18,0,33.06,2.0
Early endosome (celc),PART_OF,Upper Extremity (bpoc),LOCATION_OF,Hemorrhage (fndg),1.29e-06,10.55,17,14,0,25.53,2.0
Early endosome (celc),PART_OF,Upper Extremity (bpoc),LOCATION_OF,partial response (fndg),6.68e-07,10.81,17,14,0,25.53,2.0
Early endosome (celc),PART_OF,Upper Extremity (bpoc),LOCATION_OF,Disability NOS (patf),8.24e-12,6.68,17,10,0,15.88,2.0
Early endosome (celc),PART_OF,Upper Extremity (bpoc),LOCATION_OF,Ischemia (dsyn),5.28e-10,8.25,17,50,0,22.78,2.0
Early endosome (celc),PART_OF,Upper Extremity (bpoc),LOCATION_OF,Adverse event (fndg),8.24e-12,10.12,17,44,0,23.57,2.0
Early endosome (celc),PART_OF,Upper Extremity (bpoc),LOCATION_OF,Toxic effect (inpo),8.24e-12,12.0,17,111,0,19.6,2.0
Weight Gain (fndg),PREDISPOSES,Pre-Eclampsia (dsyn),AFFECTS,Pathogenesis (patf),4.22e-06,33.43,5,25,0,6.0,7.0
Weight Gain (fndg),PREDISPOSES,Pre-Eclampsia (dsyn),PROCESS_OF,Pregnant Women (popg),2.35e-06,32.65,5,105,0,5.24,1.0
Weight Gain (fndg),PREDISPOSES,Pre-Eclampsia (dsyn),AFFECTS,Pregnancy (orgf),2.38e-06,34.49,5,21,0,6.19,7.0
Weight Gain (fndg),PREDISPOSES,Pre-Eclampsia (dsyn),ISA,Hypertension induced by pregnancy (dsyn),2.38e-06,33.47,5,31,0,5.81,5.0
Weight Gain (fndg),PREDISPOSES,Pre-Eclampsia (dsyn),PROCESS_OF,Pregnant Women (popg),2.35e-06,33.68,5,31,0,5.81,1.0
Weight Gain (fndg),PREDISPOSES,Pre-Eclampsia (dsyn),ISA,Pregnancy Complications (dsyn),2.35e-06,34.09,5,46,0,5.54,5.0
Weight Gain (fndg),PREDISPOSES,Pre-Eclampsia (dsyn),CAUSES,"Morbidity, perinatal (patf)",5.82e-06,41.73,5,8,0,8.12,11.0
Participant (humn),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),2.15e-06,18.61,7,11,0,11.45,2.0
Participant (humn),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),1.63e-06,12.86,7,194,0,7.25,2.0
Participant (humn),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),1.63e-06,12.09,7,75,0,7.65,2.0
Participant (humn),LOCATION_OF,Calcium (bacs),PART_OF,Cytosol (celc),1.63e-06,12.1,7,23,0,9.13,2.0
Participant (humn),LOCATION_OF,Calcium (bacs),PREDISPOSES,Atherosclerosis (dsyn),2.18e-06,17.55,7,12,0,11.08,2.0
Participant (humn),LOCATION_OF,Calcium (bacs),PART_OF,Extracellular (celc),1.63e-06,12.05,7,19,0,9.58,2.0
Metabolic Diseases (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,36.84,13,20,0,21.45,1.0
Metabolic Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,34.03,13,65,0,15.6,1.0
Metabolic Diseases (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,36.35,13,16,0,23.56,1.0
Metabolic Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,36.6,13,13,0,26.0,1.0
Metabolic Diseases (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,37.59,13,16,0,23.56,1.0
Metabolic Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,42.99,13,8,0,12.92,1.0
Metabolic Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,36.47,13,23,0,20.35,1.0
Metabolic Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,37.36,13,22,0,20.68,1.0
Metabolic Diseases (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,37.29,13,13,0,26.0,1.0
Metabolic Diseases (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,39.29,13,15,0,24.27,1.0
Ferritin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,38.95,11,16,0,18.56,8.0
Ferritin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,44.12,11,9,0,16.36,8.0
Ferritin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,36.51,11,31,0,14.9,8.0
Diet (food),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Octogenarians (aggp),6.96e-07,21.26,9,9,0,18.0,1.0
Diet (food),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Surgical Patients (podg),5.82e-08,16.02,9,16,0,14.06,1.0
Diet (food),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,General Population (humn),4.59e-08,15.75,9,31,0,11.61,1.0
Diet (food),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),4.59e-08,15.17,9,28,0,11.89,1.0
Diet (food),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,African American (popg),4.59e-08,17.67,9,53,0,10.53,1.0
Diet (food),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Caucasoid Race (popg),1.29e-06,13.81,9,19,0,13.26,1.0
Diet (food),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Participant (humn),4.59e-08,15.57,9,33,0,11.45,1.0
Diet (food),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Long-Term Survivors (podg),4.68e-08,16.6,9,17,0,13.76,1.0
Diet (food),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),4.59e-08,13.26,8,99,1,8.65,1.0
Diet (food),PREDISPOSES,Carcinoma of the Large Intestine (neop),ISA,Common Neoplasm (neop),4.96e-08,14.93,9,20,0,13.05,5.0
Diet (food),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,cohort (humn),1.14e-07,14.7,9,18,0,13.5,1.0
Diet (food),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,cohort (humn),4.59e-08,14.94,9,63,0,10.29,1.0
Diet (food),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Black race (popg),6.81e-08,17.0,9,14,0,14.79,1.0
Diabetic (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,12.89,40,20,0,30.0,1.0
Diabetic (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,10.07,40,65,0,64.62,1.0
Diabetic (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,12.4,40,16,0,22.4,1.0
Diabetic (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,12.65,40,13,0,17.23,1.0
Diabetic (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,13.63,40,16,0,22.4,1.0
Diabetic (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,19.04,40,8,0,9.6,1.0
Diabetic (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,12.52,40,23,0,36.22,1.0
Diabetic (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,13.41,40,22,0,34.1,1.0
Diabetic (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,13.34,40,13,0,17.23,1.0
Diabetic (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,15.34,40,15,0,20.62,1.0
Dietary intake (orgf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.4e-09,27.48,9,18,0,13.5,1.0
Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,16.31,26,33,0,46.48,1.0
Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.13e-25,30.5,26,35,0,45.31,9.0
Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,15.92,26,37,0,44.27,1.0
Atherosclerosis (dsyn),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.02e-07,20.97,9,16,0,14.06,9.0
Atherosclerosis (dsyn),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.63e-09,31.19,9,26,0,12.12,9.0
Roux-en-Y Gastric Bypass (topp),TREATS,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),1.13e-08,33.94,7,25,0,8.96,1.0
Roux-en-Y Gastric Bypass (topp),TREATS,Diabetic (fndg),PROCESS_OF,Participant (humn),5.28e-08,32.48,7,50,0,7.98,1.0
Roux-en-Y Gastric Bypass (topp),TREATS,Diabetic (fndg),PROCESS_OF,cohort (humn),8.07e-09,34.47,7,65,0,7.75,1.0
Roux-en-Y Gastric Bypass (topp),TREATS,Diabetic (fndg),PROCESS_OF,Population Group (humn),1.11e-06,37.08,7,11,0,11.45,1.0
tomography (diap),DIAGNOSES,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),6.08e-08,41.4,6,23,0,7.57,18.0
tomography (diap),DIAGNOSES,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),6.06e-08,40.84,6,57,0,6.63,11.0
tomography (diap),DIAGNOSES,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),3.51e-07,49.31,6,9,0,10.0,9.0
Cardiovascular Diseases (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),4.41e-07,18.2,7,57,0,7.86,9.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Caucasoid Race (popg),6.39e-09,9.44,15,19,0,26.84,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Tuberculosis (dsyn),4.03e-09,7.17,15,42,0,20.36,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Thromboembolism (patf),2.59e-09,10.14,15,22,0,25.23,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Critical Illness (dsyn),2.74e-08,8.93,15,19,0,26.84,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,HIV Seropositivity (fndg),1.41e-07,9.01,15,17,0,28.24,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,inpatient (humn),1.03e-06,8.46,15,17,0,28.24,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Pulmonary Embolism (dsyn),2.58e-09,9.05,15,27,0,23.33,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Congestive heart failure (dsyn),1.31e-06,10.39,15,12,0,21.6,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Malaria (dsyn),1.93e-08,8.1,15,24,0,24.38,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Survivors (humn),2.58e-09,11.9,15,37,0,21.08,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Prognosis bad (fndg),4.61e-09,10.47,15,17,0,28.24,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),ADMINISTERED_TO,cohort (humn),1.52e-06,9.24,15,14,0,27.07,5.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Bacterial Endocarditis (dsyn),3.79e-08,10.97,15,14,0,27.07,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Human Age Group (aggp),1.22e-07,9.05,15,17,0,28.24,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Death (finding) (fndg),2.58e-09,15.91,15,24,0,24.38,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Heart failure (dsyn),2.58e-09,9.8,15,50,0,19.5,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Septic Shock (patf),1.88e-06,13.89,15,9,0,14.4,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),USES,Brain natriuretic peptide (aapp),2.58e-09,9.47,15,31,0,22.26,5.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Hamman-Rich syndrome (dsyn),2.65e-09,12.02,15,17,0,28.24,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Acute coronary syndrome (dsyn),2.66e-08,9.56,15,17,0,28.24,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Pneumonia (dsyn),2.58e-09,8.81,15,31,0,22.26,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Dissection of aorta (dsyn),3.06e-07,12.44,15,11,0,19.07,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Acute myocardial infarction (dsyn),2.58e-09,10.36,15,23,0,24.78,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Myocardial Infarction (dsyn),3.98e-06,7.96,15,18,0,27.5,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,cohort (humn),2.58e-09,9.72,15,131,0,16.72,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),TREATS,Septicemia (dsyn),2.58e-09,11.57,15,40,0,20.62,4.0
Polysomnography (diap),ISA,Diagnosis (hlca),METHOD_OF,Transplantation (topp),2.58e-09,10.54,15,29,0,22.76,5.0
Sex Characteristics (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),4.13e-06,17.49,6,33,0,7.09,1.0
Sex Characteristics (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),8.56e-06,18.03,6,16,0,8.25,8.0
Sex Characteristics (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),4.13e-06,17.84,6,71,0,6.51,5.0
Sex Characteristics (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.13e-06,31.68,6,35,0,7.03,8.0
Sex Characteristics (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.13e-06,17.76,6,110,0,6.33,8.0
Sex Characteristics (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),4.13e-06,17.1,6,37,0,6.97,1.0
Respiration (phsf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Survivors (humn),1.81e-08,16.45,10,15,0,16.67,1.0
Respiration (phsf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,"Twins, Dizygotic (humn)",7.06e-09,12.93,10,60,0,11.67,1.0
Respiration (phsf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Monoamniotic twins (podg),7.06e-09,13.79,10,33,0,13.03,1.0
Respiration (phsf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Singleton (humn),7.06e-09,12.44,10,357,0,10.28,1.0
Excessive daytime somnolence (sosy),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,17.93,12,16,0,21.0,8.0
Excessive daytime somnolence (sosy),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),8.39e-12,28.15,12,26,0,17.54,8.0
Sleep Apnea Syndromes (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,28.81,17,20,0,31.45,1.0
Sleep Apnea Syndromes (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,26.0,17,65,0,21.45,1.0
Sleep Apnea Syndromes (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,28.32,17,16,0,31.06,1.0
Sleep Apnea Syndromes (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,28.57,17,13,0,22.94,1.0
Sleep Apnea Syndromes (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,29.56,17,16,0,31.06,1.0
Sleep Apnea Syndromes (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,34.96,17,8,0,11.76,1.0
Sleep Apnea Syndromes (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,28.44,17,23,0,29.57,1.0
Sleep Apnea Syndromes (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,29.33,17,22,0,30.14,1.0
Sleep Apnea Syndromes (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,29.26,17,13,0,22.94,1.0
Sleep Apnea Syndromes (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,31.26,17,15,0,28.24,1.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,American (popg),1.74e-06,25.58,6,17,0,8.12,1.0
Fitness (dora),TREATS,Heart failure (dsyn),AFFECTS,Depressed mood (fndg),3.27e-06,30.12,6,8,0,10.5,4.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,Octogenarians (aggp),3.62e-06,26.64,6,9,0,10.0,1.0
Fitness (dora),TREATS,Heart failure (dsyn),CAUSES,Myocardial Infarction (dsyn),1.74e-06,26.18,6,13,0,8.77,4.0
Fitness (dora),TREATS,Heart failure (dsyn),CAUSES,follow-up (hlca),1.91e-06,24.47,6,12,0,9.0,4.0
Fitness (dora),TREATS,Heart failure (dsyn),CAUSES,"Death, Sudden (patf)",1.74e-06,27.36,6,19,0,7.89,4.0
Fitness (dora),TREATS,Heart failure (dsyn),CAUSES,Cessation of life (orgf),1.74e-06,24.23,6,251,0,6.14,4.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,High Risk Populations (popg),1.86e-06,28.12,6,10,0,9.6,1.0
Fitness (dora),TREATS,Heart failure (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),1.74e-06,26.24,6,28,0,7.29,4.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,General Population (humn),1.74e-06,26.79,6,67,0,6.54,1.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,Hospital specialist (humn),1.74e-06,22.73,6,20,0,7.8,1.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,General Population (humn),1.74e-06,27.64,6,18,0,8.0,1.0
Fitness (dora),TREATS,Heart failure (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),3.08e-06,27.11,6,9,0,10.0,4.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,African American (popg),1.74e-06,23.84,6,49,0,6.73,1.0
Fitness (dora),TREATS,Heart failure (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.8e-06,25.31,6,12,0,9.0,4.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,Human Age Group (aggp),1.79e-06,27.11,6,11,0,9.27,1.0
Fitness (dora),TREATS,Heart failure (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),1.74e-06,25.41,6,32,0,7.12,4.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,Caucasoid Race (popg),1.74e-06,25.56,6,24,0,7.5,1.0
Fitness (dora),TREATS,Heart failure (dsyn),CAUSES,Cardiac Death (patf),1.74e-06,27.72,6,24,0,7.5,4.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,inpatient (humn),1.74e-06,24.06,6,37,0,6.97,1.0
Fitness (dora),TREATS,Heart failure (dsyn),COEXISTS_WITH,Physical findings (sosy),5.91e-06,23.19,6,11,0,9.27,4.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,Veterans (popg),1.75e-06,23.98,6,15,0,8.4,1.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),1.74e-06,23.31,6,154,0,6.23,1.0
Fitness (dora),TREATS,Heart failure (dsyn),AFFECTS,Pathogenesis (patf),1.87e-06,20.91,6,21,0,7.71,4.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,Participant (humn),1.74e-06,23.17,6,84,0,6.43,1.0
Fitness (dora),TREATS,Heart failure (dsyn),CAUSES,Hospital Readmissions (hlca),1.74e-06,31.38,6,14,0,8.57,4.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.74e-06,25.62,6,256,0,6.14,1.0
Fitness (dora),TREATS,Heart failure (dsyn),ISA,Cardiovascular Diseases (dsyn),1.74e-06,22.87,6,106,0,6.34,4.0
Fitness (dora),TREATS,Heart failure (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),1.97e-06,25.45,6,11,0,9.27,4.0
Fitness (dora),TREATS,Heart failure (dsyn),CAUSES,Hospitalization (hlca),1.74e-06,26.94,6,249,0,6.14,4.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.74e-06,25.79,6,55,0,6.65,1.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,Survivors (humn),1.74e-06,25.73,6,33,0,7.09,1.0
Fitness (dora),TREATS,Heart failure (dsyn),CAUSES,"Death, Sudden, Cardiac (patf)",1.74e-06,28.29,6,13,0,8.77,4.0
Fitness (dora),TREATS,Heart failure (dsyn),CAUSES,Diagnosis (hlca),1.79e-06,24.27,6,13,0,8.77,4.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),1.74e-06,24.49,6,34,0,7.06,1.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,Population Group (humn),1.74e-06,28.32,6,17,0,8.12,1.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,Participant (humn),1.74e-06,24.03,6,25,0,7.44,1.0
Fitness (dora),TREATS,Heart failure (dsyn),ISA,Heart Diseases (dsyn),1.74e-06,22.48,6,42,0,6.86,4.0
Fitness (dora),TREATS,Heart failure (dsyn),COMPLICATES,Acute myocardial infarction (dsyn),1.74e-06,25.05,6,42,0,6.86,4.0
Fitness (dora),TREATS,Heart failure (dsyn),COEXISTS_WITH,Sinus rhythm (fndg),1.74e-06,24.78,6,30,0,7.2,4.0
Fitness (dora),TREATS,Heart failure (dsyn),AFFECTS,Atrial Fibrillation (patf),2.03e-06,29.69,6,9,0,10.0,4.0
Fitness (dora),TREATS,Heart failure (dsyn),CAUSES,Hospital admission (hlca),1.74e-06,26.79,6,40,0,6.9,4.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,Western society (popg),3.08e-06,27.11,6,9,0,10.0,1.0
Fitness (dora),TREATS,Heart failure (dsyn),COEXISTS_WITH,Anemia (dsyn),2.23e-06,26.3,6,10,0,9.6,4.0
Fitness (dora),TREATS,Heart failure (dsyn),PROCESS_OF,cohort (humn),1.74e-06,26.05,6,119,0,6.3,1.0
Fitness (dora),TREATS,Heart failure (dsyn),COMPLICATES,Myocardial Infarction (dsyn),1.74e-06,24.11,6,20,0,7.8,4.0
Fitness (dora),TREATS,Heart failure (dsyn),AFFECTS,Systemic arterial pressure (fndg),1.75e-06,23.86,6,15,0,8.4,4.0
Obese build (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.69e-10,27.09,9,23,0,12.52,8.0
Obese build (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),1.89e-10,26.53,9,57,0,10.42,8.0
Obese build (orga),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,35.0,9,9,0,18.0,8.0
Adiponectin (aapp),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,47.95,10,16,0,16.25,8.0
Adiponectin (aapp),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),9.82e-14,58.16,10,26,0,13.85,8.0
"ATPase, Aminophospholipid Transporter-Like, Class I, Type 8A, Member 2|ATP8A2 (aapp)",PART_OF,Protoplasm (celc),LOCATION_OF,Compartments (bsoj),6.24e-07,0.11,1,23,0,1.04,2.0
Non-alcoholic fatty liver (dsyn),CAUSES,Liver diseases (dsyn),AFFECTS,American (popg),4.68e-12,13.6,18,39,0,26.31,7.0
Non-alcoholic fatty liver (dsyn),CAUSES,Liver diseases (dsyn),PROCESS_OF,cohort (humn),3.12e-13,16.68,18,23,0,32.09,1.0
Non-alcoholic fatty liver (dsyn),CAUSES,Liver diseases (dsyn),CAUSES,Cessation of life (orgf),4.84e-16,18.24,18,67,0,22.84,11.0
Non-alcoholic fatty liver (dsyn),CAUSES,Liver diseases (dsyn),PROCESS_OF,Pregnant Women (popg),2.22e-08,17.09,18,14,0,24.89,1.0
Non-alcoholic fatty liver (dsyn),CAUSES,Liver diseases (dsyn),PROCESS_OF,Hepatitis C virus (virs),3.5e-06,14.23,18,16,0,30.22,1.0
Waist-Hip Ratio (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),1.14e-09,50.42,7,33,0,8.48,1.0
Waist-Hip Ratio (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,50.96,7,16,0,10.06,8.0
Waist-Hip Ratio (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),8.79e-10,50.77,7,71,0,7.69,5.0
Waist-Hip Ratio (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),8.79e-10,64.61,7,35,0,8.4,8.0
Waist-Hip Ratio (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),8.79e-10,50.69,7,110,0,7.45,8.0
Waist-Hip Ratio (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),2.23e-09,50.03,7,37,0,8.32,1.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Aneurysm (anab),7.74e-14,1.99,3,55,0,3.16,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Anastomosis (acab),6.48e-10,1.96,3,40,0,3.23,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Thrombus (dsyn),3.19e-08,1.96,3,33,0,3.27,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Wounds and Injuries (inpo),1.57e-07,2.96,3,20,0,3.45,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,"Aneurysm, Infected (dsyn)",5.57e-10,2.16,3,36,0,3.25,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Atresia (cgab),7.48e-17,2.36,3,60,0,3.15,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Root abscess (dsyn),8.7e-09,2.14,3,32,0,3.28,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Adverse event (fndg),3.19e-12,7.57,3,18,0,3.5,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Bacterial Endocarditis (dsyn),9.34e-07,4.09,3,14,0,3.64,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Acute chest syndrome (dsyn),8.7e-07,6.22,3,11,0,3.82,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,"Aneurysm, Mycotic (dsyn)",1.39e-16,2.35,3,56,0,3.16,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Prosthetic valve (medd),8.76e-10,1.98,3,39,0,3.23,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,H/O: surgery NOS (fndg),7.13e-17,10.37,3,27,0,3.33,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Traumatic Rupture (inpo),7.13e-17,2.42,3,75,0,3.12,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Neck (blor),7.13e-17,3.66,3,63,0,3.14,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Cuffs (medd),4.15e-15,7.05,3,23,0,3.39,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Traumatic chest injury NOS (inpo),7.13e-17,6.97,3,47,0,3.19,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Thoracic Diseases (dsyn),7.13e-17,4.38,3,155,0,3.06,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Prosthesis (medd),7.13e-17,2.05,3,110,0,3.08,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Short neck (fndg),9.08e-08,8.28,3,11,0,3.82,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Penetrating ulcer (patf),7.13e-17,3.28,3,54,0,3.17,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Contraction (patf),8.7e-09,0.13,3,9,0,4.0,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,CHEST PATHOLOGY (dsyn),7.13e-17,6.67,3,66,0,3.14,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Prosthetic valve endocarditis (dsyn),7.18e-17,4.03,3,40,0,3.23,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Pseudoaneurysm (anab),7.13e-17,2.65,3,80,0,3.11,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Hypertrophy (patf),1.12e-10,2.14,3,39,0,3.23,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Dissection of aorta (dsyn),1.7e-07,6.38,3,12,0,3.75,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,"Trauma, chest (inpo)",2.79e-07,6.03,3,12,0,3.75,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Intramural hematoma (patf),1.64e-16,2.37,3,55,0,3.16,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Thoracic Injuries (inpo),7.13e-17,3.77,3,57,0,3.16,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Coarctation (anab),1.31e-13,0.92,3,241,0,3.04,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Bioprosthesis device (medd),7.13e-17,4.39,3,63,0,3.14,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Stiffness (sosy),7.13e-17,1.45,3,261,0,3.03,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Nonpenetrating Wounds (inpo),7.13e-17,3.75,3,86,0,3.1,2.0
Endothelial Cells (cell),PART_OF,Aorta (bpoc),LOCATION_OF,Ulcer (patf),7.13e-17,4.92,3,53,0,3.17,2.0
"AFRICAN, SOUTH (popg)",ISA,African American (popg),ISA,Ethnic group (popg),3.02e-06,8.7,9,98,0,9.83,5.0
"AFRICAN, SOUTH (popg)",ISA,African American (popg),ISA,Racial group (popg),3.02e-06,9.64,9,324,0,9.25,5.0
Systolic blood pressure (ortf),PROCESS_OF,Black race (popg),ISA,Ethnic group (popg),5.91e-07,17.6,7,23,0,9.13,1.0
Systolic blood pressure (ortf),PROCESS_OF,Black race (popg),ISA,Racial group (popg),4.41e-07,19.54,7,41,0,8.2,1.0
Diet (food),AFFECTS,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.41e-08,21.68,8,22,0,10.91,7.0
Diet (food),AFFECTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),5.42e-08,21.1,8,17,0,11.76,1.0
Diet (food),AFFECTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),6.7e-08,17.17,8,27,0,10.37,1.0
Diet (food),AFFECTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),6.79e-08,20.13,8,15,0,12.27,1.0
Diet (food),AFFECTS,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),5.42e-08,18.33,8,24,0,10.67,7.0
Diet (food),AFFECTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),5.41e-08,17.95,8,34,0,9.88,1.0
Diet (food),AFFECTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),5.41e-08,19.37,8,40,0,9.6,1.0
Diet (food),AFFECTS,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),5.53e-08,26.1,8,12,0,13.33,7.0
Entire radius (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Pulmonary Embolism (dsyn),1.47e-06,8.04,10,29,0,13.45,2.0
Entire radius (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Secondary malignant neoplasm of liver (neop),2.18e-06,7.79,10,26,0,13.85,2.0
Entire radius (bpoc),LOCATION_OF,tomography (diap),ISA,Medical Imaging (diap),3.73e-06,6.13,10,318,0,10.31,2.0
Entire radius (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Malignant neoplasm of lung (neop),1.46e-06,11.27,10,129,0,10.78,2.0
Entire radius (bpoc),LOCATION_OF,tomography (diap),ISA,Diagnosis (hlca),1.46e-06,6.9,10,112,0,10.89,2.0
Entire radius (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Solid tumor (neop),1.47e-06,9.02,10,21,0,14.76,2.0
Exercise (dora),ISA,Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),1.72e-08,9.54,26,18,0,30.46,4.0
Exercise (dora),ISA,Physical activity (dora),TREATS,Survivors (humn),4.06e-12,8.18,26,36,0,44.78,4.0
Exercise (dora),ISA,Physical activity (dora),TREATS,General Population (humn),4.11e-11,9.69,26,23,0,43.35,4.0
Exercise (dora),ISA,Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),1.66e-07,7.48,26,31,0,47.81,4.0
Exercise (dora),ISA,Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),6.41e-10,10.21,26,19,0,32.88,5.0
Exercise (dora),ISA,Physical activity (dora),TREATS,"Kidney Failure, Chronic (dsyn)",6.74e-07,11.98,26,11,0,15.65,4.0
Age (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.03e-07,26.51,7,22,0,9.23,8.0
Age (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.03e-07,25.94,7,17,0,9.88,1.0
Age (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.15e-07,22.01,7,27,0,8.81,1.0
Age (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.16e-07,24.97,7,15,0,10.27,1.0
Age (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.03e-07,23.17,7,24,0,9.04,8.0
Age (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.03e-07,22.79,7,34,0,8.44,1.0
Age (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),1.03e-07,24.21,7,40,0,8.22,1.0
Age (orga),ASSOCIATED_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.04e-07,30.94,7,12,0,11.08,8.0
Normal blood pressure (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),4.42e-07,19.23,7,20,0,9.45,1.0
Normal blood pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),4.44e-07,16.42,7,65,0,7.75,1.0
Normal blood pressure (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),8.17e-07,18.74,7,16,0,10.06,1.0
Normal blood pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.54e-06,18.99,7,13,0,10.77,1.0
Normal blood pressure (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),4.53e-07,19.98,7,16,0,10.06,1.0
Normal blood pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.91e-06,25.38,7,8,0,13.12,1.0
Normal blood pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),4.41e-07,18.86,7,23,0,9.13,1.0
Normal blood pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),4.41e-07,19.75,7,22,0,9.23,1.0
Normal blood pressure (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),1.33e-06,19.68,7,13,0,10.77,1.0
Normal blood pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),4.43e-07,21.68,7,15,0,10.27,1.0
Screening procedure (hlca),TREATS,Malnutrition (dsyn),PROCESS_OF,Critically ill children (podg),3.47e-06,23.64,23,8,0,10.78,1.0
Screening procedure (hlca),TREATS,Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.35e-09,19.49,23,15,0,24.78,4.0
Screening procedure (hlca),TREATS,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.16e-09,18.19,23,18,0,32.09,1.0
Screening procedure (hlca),TREATS,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),6.03e-22,17.1,23,61,0,31.67,1.0
Screening procedure (hlca),TREATS,Malnutrition (dsyn),PROCESS_OF,Surgical Patients (podg),5.5e-11,17.14,23,24,0,45.04,1.0
Screening procedure (hlca),TREATS,Malnutrition (dsyn),PROCESS_OF,Cancer Patient (podg),8.8e-09,15.59,23,30,0,40.63,1.0
Screening procedure (hlca),TREATS,Malnutrition (dsyn),PROCESS_OF,inpatient (humn),1.52e-12,17.03,23,28,0,41.89,1.0
Screening procedure (hlca),TREATS,Malnutrition (dsyn),CAUSES,Cessation of life (orgf),2.24e-16,18.95,23,28,0,41.89,4.0
Screening procedure (hlca),TREATS,Malnutrition (dsyn),PROCESS_OF,cohort (humn),2.22e-10,20.21,23,16,0,27.13,1.0
Alcohol consumption (inbe),AFFECTS,Smoking (inbe),PROCESS_OF,Males (popg),7.06e-07,8.7,11,35,0,14.46,1.0
Alcohol consumption (inbe),AFFECTS,Smoking (inbe),PROCESS_OF,cohort (humn),5.25e-08,9.92,11,54,0,13.24,1.0
Alcohol consumption (inbe),AFFECTS,Smoking (inbe),PROCESS_OF,Survivors (humn),5.92e-08,11.73,11,17,0,18.12,1.0
Alcohol consumption (inbe),AFFECTS,Smoking (inbe),PREDISPOSES,Malignant neoplasm of lung (neop),5.3e-08,9.43,11,33,0,14.67,7.0
Alcohol consumption (inbe),AFFECTS,Smoking (inbe),PREDISPOSES,Cardiovascular Diseases (dsyn),7.27e-08,11.35,11,17,0,18.12,7.0
Alcohol consumption (inbe),AFFECTS,Smoking (inbe),ISA,Habits (inbe),5.25e-08,8.0,11,609,0,11.2,5.0
Alcohol consumption (inbe),AFFECTS,Smoking (inbe),PREDISPOSES,Chronic Obstructive Airway Disease (dsyn),5.26e-08,10.51,11,25,0,15.84,7.0
Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,19.68,63,20,0,26.35,1.0
Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,16.87,63,65,0,124.06,1.0
Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,19.19,63,16,0,20.06,1.0
Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,19.44,63,13,0,15.68,1.0
Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,20.42,63,16,0,20.06,1.0
Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,25.83,63,8,0,9.02,1.0
Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,19.31,63,23,0,31.4,1.0
Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,20.2,63,22,0,29.68,1.0
Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,20.13,63,13,0,15.68,1.0
Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,22.13,63,15,0,18.57,1.0
Adiponectin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.81e-08,28.51,8,16,0,12.0,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.41e-07,33.68,8,9,0,15.11,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.2e-07,26.07,8,31,0,10.06,8.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Participant (humn),5.58e-07,48.69,5,84,0,5.3,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Hyperglycemia (dsyn),9.09e-07,55.74,5,10,0,7.5,21.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Atrial Fibrillation (patf),5.8e-07,60.03,5,10,0,7.5,11.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Human Age Group (aggp),5.6e-07,51.79,5,18,0,6.39,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Population Group (humn),3.97e-06,52.38,5,11,0,7.27,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Vascular Diseases (dsyn),5.58e-07,50.71,5,38,0,5.66,5.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Cessation of life (orgf),5.58e-07,51.37,5,449,0,5.06,11.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Black race (popg),5.58e-07,51.4,5,24,0,6.04,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),5.58e-07,53.89,5,34,0,5.74,21.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Neurologist (humn),5.58e-07,49.76,5,31,0,5.81,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),5.58e-07,51.72,5,140,0,5.18,5.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),5.59e-07,51.61,5,19,0,6.32,21.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Survivors (humn),5.58e-07,48.11,5,330,0,5.08,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.08e-06,53.77,5,11,0,7.27,9.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Deglutition Disorders (dsyn),1.17e-06,49.57,5,22,0,6.14,21.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Depressive disorder (mobd),5.59e-07,48.99,5,41,0,5.61,21.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,Myocardial Infarction (dsyn),5.83e-07,53.85,5,13,0,6.92,9.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Young adult (aggp),5.58e-07,48.88,5,48,0,5.52,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,inpatient (humn),5.25e-06,48.93,5,27,0,5.93,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,VICTIM (humn),8.07e-07,48.75,5,38,0,5.66,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),OCCURS_IN,cohort (humn),5.58e-07,53.43,5,16,0,6.56,21.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Disability NOS (patf),5.58e-07,49.82,5,163,0,5.15,11.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,General Population (humn),5.58e-07,50.82,5,44,0,5.57,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),AFFECTS,Systemic arterial pressure (fndg),5.58e-07,50.99,5,27,0,5.93,7.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Heart failure (dsyn),5.58e-07,59.77,5,14,0,6.79,21.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Octogenarians (aggp),5.58e-07,60.03,5,15,0,6.67,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Control Groups (humn),1.8e-06,49.84,5,19,0,6.32,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Disability NOS (patf),5.58e-07,50.3,5,47,0,5.53,21.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),AFFECTS,Cessation of life (orgf),1e-06,52.85,5,12,0,7.08,7.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Hospitalization (hlca),5.58e-07,55.81,5,24,0,6.04,11.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,Diabetic (fndg),5.58e-07,51.48,5,23,0,6.09,9.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Pneumonia (dsyn),1.25e-06,52.57,5,12,0,7.08,21.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Ethnic group (popg),5.6e-07,52.7,5,16,0,6.56,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),5.58e-07,51.38,5,155,0,5.16,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Teams (humn),5.58e-07,49.8,5,42,0,5.6,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.6e-07,51.34,5,19,0,6.32,21.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Thrombosis (patf),5.58e-07,51.72,5,21,0,6.19,5.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Cerebrovascular Disorders (patf),5.58e-07,50.31,5,41,0,5.61,5.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Hospitalized Patients (humn),5.58e-07,51.68,5,64,0,5.39,1.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),5.58e-07,51.04,5,129,0,5.19,9.0
Overweight (sosy),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),5.58e-07,51.47,5,39,0,5.64,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,42.69,11,9,0,16.36,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.19e-14,41.75,11,194,0,11.62,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,40.48,11,17,0,18.12,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),3.19e-14,41.74,11,29,0,15.17,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,43.93,11,14,0,19.64,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,39.73,11,12,0,21.08,5.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),3.19e-14,38.55,11,48,0,13.52,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),3.19e-14,41.94,11,29,0,15.17,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.19e-14,38.99,11,98,0,12.23,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,37.65,11,24,0,16.04,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,44.07,11,10,0,19.09,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,36.42,11,37,0,14.27,7.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,38.23,11,20,0,17.05,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),3.19e-14,39.88,11,94,0,12.29,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,45.67,11,8,0,13.82,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.45e-13,42.55,11,19,0,17.37,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.21e-11,39.7,11,21,0,16.76,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,44.88,11,12,0,21.08,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,52.6,11,10,0,19.09,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,45.18,11,10,0,19.09,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,39.5,11,21,0,16.76,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),3.01e-13,41.11,11,21,0,16.76,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.2e-14,39.24,11,32,0,14.78,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,46.59,11,10,0,19.09,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),3.19e-14,45.56,11,39,0,14.1,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),3.19e-14,49.54,11,44,0,13.75,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.19e-14,42.42,11,113,0,12.07,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,39.94,11,11,0,22.0,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,39.67,11,11,0,22.0,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,40.13,11,12,0,21.08,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,38.02,11,25,0,15.84,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.19e-14,43.7,11,87,0,12.39,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),3.26e-14,38.69,11,33,0,14.67,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.19e-14,41.42,11,41,0,13.95,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.21e-13,41.59,11,21,0,16.76,1.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,39.26,11,21,0,16.76,8.0
adiposity (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),3.19e-14,40.2,11,1021,0,11.12,8.0
Laparoscopic adjustable gastric banding (topp),compared_with,Roux-en-Y Gastric Bypass (topp),TREATS,"Obesity, Morbid (dsyn)",1.32e-12,34.07,10,54,0,11.85,4.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,13.07,22,9,0,12.68,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),6.03e-13,12.13,22,194,0,24.49,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,10.86,22,17,0,30.14,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),6.03e-13,12.12,22,29,0,38.69,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2e-10,14.31,22,14,0,22.91,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,10.12,22,12,0,18.55,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),6.03e-13,8.94,22,48,0,32.08,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),6.03e-13,12.33,22,29,0,38.69,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),6.03e-13,9.37,22,98,0,26.94,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,8.04,22,24,0,42.17,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,14.45,22,10,0,14.55,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,6.81,22,37,0,35.08,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,8.61,22,20,0,38.18,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),6.03e-13,10.26,22,94,0,27.15,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),9.17e-13,12.93,22,19,0,35.41,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.26e-11,10.08,22,21,0,41.05,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,15.26,22,12,0,18.55,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.64e-09,22.98,22,10,0,14.55,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,15.56,22,10,0,14.55,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.31e-11,9.88,22,21,0,41.05,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),8.73e-13,11.49,22,21,0,41.05,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),6.04e-13,9.62,22,32,0,37.12,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,16.98,22,10,0,14.55,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),6.03e-13,15.94,22,39,0,34.41,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),6.03e-13,19.92,22,44,0,33.0,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.03e-13,12.8,22,113,0,26.28,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,10.32,22,11,0,16.5,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,10.05,22,11,0,16.5,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,10.51,22,12,0,18.55,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,8.41,22,25,0,41.36,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",6.03e-13,14.08,22,87,0,27.56,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.04e-13,9.07,22,33,0,36.67,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),6.03e-13,11.81,22,41,0,33.8,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),6.92e-13,11.97,22,21,0,41.05,1.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5.06e-11,9.64,22,21,0,41.05,5.0
Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),6.03e-13,10.59,22,1021,0,22.47,5.0
Overweight (sosy),PROCESS_OF,student (prog),USES,Grade (clas),7.35e-21,35.49,153,7,0,7.32,1.0
Fatty Liver (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,26.06,18,18,0,36.0,1.0
body mass (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,38.44,15,20,0,26.25,1.0
body mass (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,35.63,15,65,0,18.46,1.0
body mass (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,37.95,15,16,0,29.06,1.0
body mass (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,38.2,15,13,0,24.27,1.0
body mass (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,39.19,15,16,0,29.06,1.0
body mass (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,44.59,15,8,0,12.27,1.0
body mass (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,38.07,15,23,0,24.78,1.0
body mass (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,38.96,15,22,0,25.23,1.0
body mass (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,38.89,15,13,0,24.27,1.0
body mass (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,40.89,15,15,0,30.0,1.0
Insulin (horm),TREATS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,35.96,18,16,0,30.22,4.0
Insulin (horm),TREATS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,41.12,18,9,0,13.5,4.0
Insulin (horm),TREATS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,33.51,18,31,0,28.45,4.0
High Density Lipoprotein Cholesterol (bacs),ISA,Cholesterol (bacs),PART_OF,Membrane (celc),6.47e-15,15.15,138,5,0,5.18,3.0
Intervention regimes (hlca),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,28.25,122,11,1,11.99,1.0
Intervention regimes (hlca),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,25.62,123,24,0,28.68,4.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),2.63e-08,51.54,8,15,0,12.27,21.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),4.29e-08,53.89,8,12,0,13.33,1.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),7e-09,52.19,8,15,0,12.27,5.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),4.28e-11,51.43,8,28,0,10.29,5.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),8.02e-11,49.59,8,28,0,10.29,1.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),4.28e-11,52.38,8,66,0,8.97,5.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),4.28e-11,50.23,8,47,0,9.36,1.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),1.91e-10,49.52,8,27,0,10.37,9.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),8.95e-07,53.94,8,10,0,14.4,9.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),4.31e-09,54.51,8,13,0,12.92,9.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",7.51e-11,49.93,8,26,0,10.46,1.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),1.43e-07,49.58,8,19,0,11.37,5.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),1.03e-07,50.94,8,15,0,12.27,1.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (humn),9.33e-10,49.86,8,23,0,10.78,1.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),3.12e-06,49.47,8,16,0,12.0,1.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),2.14e-06,50.62,8,13,0,12.92,5.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),2.35e-06,49.33,8,17,0,11.76,5.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),4.28e-11,49.97,8,51,0,9.25,1.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),4.28e-11,50.46,8,145,0,8.44,11.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),4.28e-11,51.32,8,39,0,9.64,11.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.42e-06,50.94,8,12,0,13.33,1.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.76e-06,50.09,8,14,0,12.57,9.0
Body mass index (clna),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.63e-07,54.27,8,10,0,14.4,9.0
Overweight (sosy),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),6.75e-13,38.92,10,77,0,11.3,1.0
Overweight (sosy),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),1e-08,39.27,10,16,0,16.25,1.0
Overweight (sosy),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Young adult (aggp),4.08e-06,38.71,10,12,0,18.33,1.0
Overweight (sosy),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Middle Aged (aggp),4.35e-10,39.05,10,19,0,15.26,1.0
Overweight (sosy),PREDISPOSES,Coronary heart disease (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.38e-09,37.84,10,22,0,14.55,21.0
Overweight (sosy),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Outpatients (podg),5.76e-08,36.84,10,24,0,14.17,1.0
Overweight (sosy),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,General Population (humn),6.75e-13,38.55,10,42,0,12.38,1.0
Overweight (sosy),PREDISPOSES,Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),6.75e-13,39.8,10,102,0,10.98,5.0
Overweight (sosy),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Heart failure (dsyn),3.34e-07,39.39,10,13,0,17.69,11.0
Overweight (sosy),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),6.75e-13,39.14,10,83,0,11.2,1.0
Overweight (sosy),PREDISPOSES,Coronary heart disease (dsyn),ISA,Death (finding) (fndg),6.75e-13,41.72,10,250,0,10.4,5.0
Overweight (sosy),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),6.75e-13,38.9,10,194,0,10.52,11.0
Entire tibia (bpoc),LOCATION_OF,High Resolution Computed Tomography (diap),DIAGNOSES,Hamman-Rich syndrome (dsyn),1.76e-07,22.42,18,13,0,22.39,2.0
Triglycerides (bacs),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,30.07,11,33,0,14.67,1.0
Triglycerides (bacs),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,30.61,11,16,0,18.56,9.0
Triglycerides (bacs),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),2.16e-13,30.41,11,71,0,12.7,5.0
Triglycerides (bacs),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.16e-13,44.26,11,35,0,14.46,21.0
Triglycerides (bacs),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.16e-13,30.34,11,110,0,12.1,21.0
Triglycerides (bacs),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,29.68,11,37,0,14.27,1.0
"Hepatitis C, Chronic (dsyn)",ISA,Virus Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",7.14e-17,5.1,113,47,0,66.55,1.0
"Hepatitis C, Chronic (dsyn)",ISA,Virus Diseases (dsyn),PROCESS_OF,Shrimp (invt),7.15e-17,5.54,113,40,0,54.16,1.0
"Hepatitis C, Chronic (dsyn)",ISA,Virus Diseases (dsyn),PROCESS_OF,Larva (invt),8.65e-07,6.6,113,12,0,13.27,1.0
"Hepatitis C, Chronic (dsyn)",ISA,Virus Diseases (dsyn),PROCESS_OF,Litopenaeus vannamei (invt),2.32e-08,9.33,113,12,0,13.27,1.0
"Hepatitis C, Chronic (dsyn)",ISA,Virus Diseases (dsyn),CAUSES,Liver diseases (dsyn),1.76e-07,5.61,113,15,0,16.99,5.0
"Hepatitis C, Chronic (dsyn)",ISA,Virus Diseases (dsyn),CAUSES,Cessation of life (orgf),5.63e-10,4.65,113,24,0,29.1,5.0
Abdominal obesity (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.1e-09,44.39,8,20,0,11.2,1.0
Abdominal obesity (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.64e-09,41.57,8,65,0,8.98,1.0
Abdominal obesity (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.76e-07,43.89,8,16,0,12.0,1.0
Abdominal obesity (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,44.15,8,13,0,12.92,1.0
Abdominal obesity (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.23e-08,45.13,8,16,0,12.0,1.0
Abdominal obesity (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,50.54,8,8,0,16.0,1.0
Abdominal obesity (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.75e-10,44.01,8,23,0,10.78,1.0
Abdominal obesity (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.13e-10,44.91,8,22,0,10.91,1.0
Abdominal obesity (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,44.84,8,13,0,12.92,1.0
Abdominal obesity (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.64e-09,46.84,8,15,0,12.27,1.0
Sarcopenia (fndg),PREDISPOSES,Frailty (fndg),PROCESS_OF,cohort (humn),7.42e-10,36.33,8,32,0,10.0,1.0
Sarcopenia (fndg),PREDISPOSES,Frailty (fndg),PROCESS_OF,inpatient (humn),3.47e-06,39.04,8,8,0,16.0,1.0
Sarcopenia (fndg),PREDISPOSES,Frailty (fndg),PROCESS_OF,Participant (humn),7.42e-10,33.76,8,27,0,10.37,1.0
Sarcopenia (fndg),PREDISPOSES,Frailty (fndg),PROCESS_OF,Surgical Patients (podg),7.59e-10,38.75,8,15,0,12.27,1.0
Sarcopenia (fndg),PREDISPOSES,Frailty (fndg),PROCESS_OF,Hospitalized Patients (humn),1.71e-07,36.37,8,11,0,13.82,1.0
Sarcopenia (fndg),PREDISPOSES,Frailty (fndg),PROCESS_OF,Population Group (humn),6.62e-09,36.55,8,13,0,12.92,1.0
Well adult (fndg),PROCESS_OF,Koreans (ethnic group) (popg),ISA,Population Group (humn),4.79e-09,18.27,29,22,0,38.69,1.0
Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),CAUSES,Cessation of life (orgf),3.47e-11,14.68,20,23,0,37.39,11.0
Physical function (fndg),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),1.32e-12,21.49,14,25,0,21.84,1.0
Physical function (fndg),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),5.88e-09,19.29,14,13,0,25.07,1.0
Physical function (fndg),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),1.32e-12,23.74,14,32,0,20.12,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,American (popg),1.93e-11,52.75,9,17,0,13.76,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),AFFECTS,Depressed mood (fndg),1.53e-06,57.28,9,8,0,15.11,7.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,Octogenarians (aggp),1.88e-06,53.81,9,9,0,18.0,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),CAUSES,Myocardial Infarction (dsyn),4.26e-09,53.35,9,13,0,15.23,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),CAUSES,follow-up (hlca),1.7e-07,51.63,9,12,0,15.75,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),CAUSES,"Death, Sudden (patf)",2.12e-12,54.53,9,19,0,13.26,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),CAUSES,Cessation of life (orgf),2.08e-12,51.4,9,251,0,9.32,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,High Risk Populations (popg),1.21e-07,55.28,9,10,0,17.1,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),2.08e-12,53.41,9,28,0,11.89,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,General Population (humn),2.08e-12,53.96,9,67,0,10.21,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,Hospital specialist (humn),1.99e-10,49.9,9,20,0,13.05,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,General Population (humn),2.23e-12,54.81,9,18,0,13.5,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.34e-06,54.28,9,9,0,18.0,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,African American (popg),2.08e-12,51.01,9,49,0,10.65,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.74e-08,52.48,9,12,0,15.75,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,Human Age Group (aggp),4.63e-08,54.28,9,11,0,16.36,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),2.08e-12,52.57,9,32,0,11.53,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,Caucasoid Race (popg),2.08e-12,52.73,9,24,0,12.38,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),CAUSES,Cardiac Death (patf),2.08e-12,54.88,9,24,0,12.38,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,inpatient (humn),2.08e-12,51.23,9,37,0,11.19,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),COEXISTS_WITH,Physical findings (sosy),4.17e-06,50.36,9,11,0,16.36,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,Veterans (popg),5.48e-09,51.15,9,15,0,14.4,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),2.08e-12,50.47,9,154,0,9.53,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),AFFECTS,Pathogenesis (patf),1.3e-07,48.08,9,21,0,12.86,7.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,Participant (humn),2.08e-12,50.34,9,84,0,9.96,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),CAUSES,Hospital Readmissions (hlca),8.81e-12,58.55,9,14,0,14.79,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),2.08e-12,52.79,9,256,0,9.32,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),ISA,Cardiovascular Diseases (dsyn),2.08e-12,50.04,9,106,0,9.76,5.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),2.29e-07,52.61,9,11,0,16.36,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),CAUSES,Hospitalization (hlca),2.08e-12,54.11,9,249,0,9.33,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),2.08e-12,52.96,9,55,0,10.47,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,Survivors (humn),2.08e-12,52.9,9,33,0,11.45,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),CAUSES,"Death, Sudden, Cardiac (patf)",5.12e-10,55.46,9,13,0,15.23,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),CAUSES,Diagnosis (hlca),5.45e-08,51.44,9,13,0,15.23,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),2.08e-12,51.66,9,34,0,11.38,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,Population Group (humn),2.47e-12,55.48,9,17,0,13.76,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,Participant (humn),2.09e-12,51.2,9,25,0,12.24,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),ISA,Heart Diseases (dsyn),2.08e-12,49.65,9,42,0,10.93,5.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),COMPLICATES,Acute myocardial infarction (dsyn),2.08e-12,52.22,9,42,0,10.93,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),COEXISTS_WITH,Sinus rhythm (fndg),2.08e-12,51.95,9,30,0,11.7,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),AFFECTS,Atrial Fibrillation (patf),2.91e-07,56.85,9,9,0,18.0,7.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),CAUSES,Hospital admission (hlca),2.08e-12,53.96,9,40,0,11.03,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,Western society (popg),1.34e-06,54.28,9,9,0,18.0,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),COEXISTS_WITH,Anemia (dsyn),4.86e-07,53.46,9,10,0,17.1,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),PROCESS_OF,cohort (humn),2.08e-12,53.22,8,118,1,8.54,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),COMPLICATES,Myocardial Infarction (dsyn),6.04e-12,51.28,9,20,0,13.05,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Heart failure (dsyn),AFFECTS,Systemic arterial pressure (fndg),6.96e-09,51.03,9,15,0,14.4,7.0
DMD|BEST1 (gngm),PREDISPOSES,Fracture (inpo),PROCESS_OF,Geriatric Patients (humn),3.03e-06,8.78,11,15,0,19.07,1.0
Public school (orgt),LOCATION_OF,Clinical Trials (resa),USES,Stents (medd),3.28e-08,20.73,8,78,0,8.82,2.0
Public school (orgt),LOCATION_OF,Clinical Trials (resa),USES,Probes (medd),7.03e-08,15.96,8,5,0,8.12,2.0
Public school (orgt),LOCATION_OF,Clinical Trials (resa),USES,Metal stent (medd),3.28e-08,23.09,8,34,0,9.88,2.0
Public school (orgt),LOCATION_OF,Clinical Trials (resa),USES,Treatment Protocols (resa),3.28e-08,19.33,8,147,0,8.44,2.0
Public school (orgt),LOCATION_OF,Clinical Trials (resa),USES,Drug eluting stent (medd),3.28e-08,21.54,8,38,0,9.68,2.0
Public school (orgt),LOCATION_OF,Clinical Trials (resa),USES,"Defibrillators, Implantable (medd)",3.28e-08,23.89,8,40,0,9.6,2.0
Public school (orgt),LOCATION_OF,Clinical Trials (resa),USES,"Stents, Vascular, Coronary (medd)",3.87e-08,23.69,8,13,0,12.92,2.0
Testosterone (phsu),TREATS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.19e-06,33.39,5,16,0,6.56,4.0
Testosterone (phsu),TREATS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),4.08e-06,38.56,5,9,0,7.78,4.0
Testosterone (phsu),TREATS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),3.26e-06,30.94,5,31,0,5.81,4.0
Oral Glucose Tolerance Test (diap),DIAGNOSES,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),3.42e-06,10.71,8,25,0,10.56,1.0
Oral Glucose Tolerance Test (diap),DIAGNOSES,Diabetic (fndg),PROCESS_OF,Participant (humn),3.47e-06,9.25,8,50,0,9.28,1.0
Oral Glucose Tolerance Test (diap),DIAGNOSES,Diabetic (fndg),PROCESS_OF,cohort (humn),3.42e-06,11.23,8,65,0,8.98,1.0
Oral Glucose Tolerance Test (diap),DIAGNOSES,Diabetic (fndg),PROCESS_OF,Population Group (humn),4.53e-06,13.84,8,11,0,13.82,1.0
ghrelin (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,"Energy, Physics (npop)",8.92e-10,9.9,22,79,0,28.13,1.0
ghrelin (aapp),AFFECTS,Homeostasis (orgf),PROCESS_OF,Oxidation-Reduction (npop),3.42e-06,9.86,22,29,0,38.69,1.0
Fatty degeneration (patf),COEXISTS_WITH,Fibrosis (patf),CAUSES,Cessation of life (orgf),6.7e-13,23.05,12,34,0,16.24,9.0
Fatty degeneration (patf),COEXISTS_WITH,Fibrosis (patf),PROCESS_OF,Hepatitis C virus (virs),6.7e-13,21.76,12,89,0,13.62,1.0
Fatty degeneration (patf),COEXISTS_WITH,Fibrosis (patf),PREDISPOSES,Primary carcinoma of the liver cells (neop),6.86e-13,21.23,12,41,0,15.51,9.0
Fatty degeneration (patf),COEXISTS_WITH,Fibrosis (patf),PROCESS_OF,Hospitalized Patients (humn),6.7e-13,25.05,12,50,0,14.88,1.0
Fatty degeneration (patf),COEXISTS_WITH,Fibrosis (patf),PROCESS_OF,Hospitalized Patients (humn),1.88e-12,27.76,12,17,0,20.47,1.0
Fatty degeneration (patf),COEXISTS_WITH,Fibrosis (patf),PROCESS_OF,cohort (humn),6.84e-13,21.5,12,38,0,15.79,1.0
Fatty degeneration (patf),COEXISTS_WITH,Fibrosis (patf),COEXISTS_WITH,Primary carcinoma of the liver cells (neop),1.78e-10,20.92,12,33,0,16.36,9.0
Systolic blood pressure (ortf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,17.78,15,20,0,26.25,1.0
Systolic blood pressure (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,14.96,15,65,0,18.46,1.0
Systolic blood pressure (ortf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,17.29,15,16,0,29.06,1.0
Systolic blood pressure (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,17.54,15,13,0,24.27,1.0
Systolic blood pressure (ortf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,18.52,15,16,0,29.06,1.0
Systolic blood pressure (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,23.93,15,8,0,12.27,1.0
Systolic blood pressure (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,17.4,15,23,0,24.78,1.0
Systolic blood pressure (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,18.3,15,22,0,25.23,1.0
Systolic blood pressure (ortf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,18.23,15,13,0,24.27,1.0
Systolic blood pressure (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,20.23,15,15,0,30.0,1.0
Metabolic syndrome (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,22.67,186,18,0,19.74,1.0
Weight Gain (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Octogenarians (aggp),8.68e-07,73.01,5,9,0,7.78,1.0
Weight Gain (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Surgical Patients (podg),2.3e-07,67.77,5,16,0,6.56,1.0
Weight Gain (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,General Population (humn),2.18e-07,67.5,5,31,0,5.81,1.0
Weight Gain (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),2.18e-07,66.92,5,28,0,5.89,1.0
Weight Gain (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,African American (popg),2.18e-07,69.42,5,53,0,5.47,1.0
Weight Gain (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Caucasoid Race (popg),1.46e-06,65.56,5,19,0,6.32,1.0
Weight Gain (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Participant (humn),2.18e-07,67.32,5,33,0,5.76,1.0
Weight Gain (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Long-Term Survivors (podg),2.19e-07,68.35,5,17,0,6.47,1.0
Weight Gain (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),2.18e-07,65.01,5,100,0,5.25,1.0
Weight Gain (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),ISA,Common Neoplasm (neop),2.22e-07,66.68,5,20,0,6.25,5.0
Weight Gain (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,cohort (humn),2.86e-07,66.45,5,18,0,6.39,1.0
Weight Gain (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,cohort (humn),2.18e-07,66.69,5,63,0,5.4,1.0
Weight Gain (fndg),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Black race (popg),2.4e-07,68.75,5,14,0,6.79,1.0
Body mass index (clna),PREDISPOSES,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.79e-10,61.89,27,23,0,42.59,21.0
Body mass index (clna),PREDISPOSES,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),1.67e-22,61.33,27,57,0,39.79,11.0
Body mass index (clna),PREDISPOSES,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,69.8,27,9,0,12.0,9.0
Vitamin D Deficiency (dsyn),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),2.52e-06,19.12,6,98,0,6.37,1.0
Vitamin D Deficiency (dsyn),PROCESS_OF,African American (popg),ISA,Racial group (popg),2.52e-06,20.06,6,324,0,6.11,1.0
Supplementation (topp),USES,"Fatty Acids, Omega-3 (phsu)",TREATS,Cardiovascular Diseases (dsyn),4.39e-06,8.87,25,10,0,14.0,4.0
Body mass index (clna),PREDISPOSES,Pancreatic carcinoma (neop),PROCESS_OF,cohort (humn),1.73e-16,58.65,11,28,1,15.32,1.0
Metformin (phsu),TREATS,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),3.19e-09,10.24,43,25,0,39.53,1.0
Metformin (phsu),TREATS,Diabetic (fndg),PROCESS_OF,Participant (humn),4.47e-08,8.79,43,50,0,79.98,1.0
Metformin (phsu),TREATS,Diabetic (fndg),PROCESS_OF,cohort (humn),1.59e-27,10.77,43,65,0,71.45,1.0
Metformin (phsu),TREATS,Diabetic (fndg),PROCESS_OF,Population Group (humn),1.11e-06,13.38,43,11,0,13.81,1.0
Body Weight decreased (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Critically ill children (podg),3.47e-06,40.48,8,8,0,16.0,1.0
Body Weight decreased (fndg),PREDISPOSES,Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.9e-09,36.32,8,15,0,12.27,9.0
Body Weight decreased (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.71e-09,35.02,8,18,0,11.56,1.0
Body Weight decreased (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),5.5e-10,33.93,8,61,0,9.05,1.0
Body Weight decreased (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Surgical Patients (podg),6.05e-10,33.98,8,24,0,10.67,1.0
Body Weight decreased (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Cancer Patient (podg),9.35e-09,32.43,8,30,0,10.13,1.0
Body Weight decreased (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,inpatient (humn),5.51e-10,33.87,8,28,0,10.29,1.0
Body Weight decreased (fndg),PREDISPOSES,Malnutrition (dsyn),CAUSES,Cessation of life (orgf),5.5e-10,35.79,8,28,0,10.29,11.0
Body Weight decreased (fndg),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,cohort (humn),7.71e-10,37.05,8,16,0,12.0,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,13.31,34,9,0,11.38,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.73e-20,12.37,34,194,0,39.96,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,11.09,34,17,0,25.5,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.94e-19,12.36,34,29,0,53.74,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,14.54,34,14,0,19.76,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,10.35,34,12,0,16.24,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.74e-20,9.17,34,48,0,58.08,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.68e-19,12.56,34,29,0,53.74,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.73e-20,9.61,33,97,1,44.23,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,8.27,34,24,0,40.94,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,14.68,34,10,0,12.94,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,7.04,34,37,0,65.24,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,8.84,34,20,0,31.76,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.73e-20,10.5,34,94,0,46.3,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,16.29,34,8,0,9.88,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,13.16,34,19,0,29.62,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,10.32,34,21,0,33.97,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,15.5,34,12,0,16.24,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,23.21,34,10,0,12.94,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,15.8,34,10,0,12.94,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,10.12,34,21,0,33.97,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,11.73,34,21,0,33.97,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.03e-17,9.85,34,32,0,62.12,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,17.21,34,10,0,12.94,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.73e-20,16.18,34,39,0,63.64,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.73e-20,20.16,34,44,0,60.27,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.73e-20,13.03,34,113,0,44.23,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,10.28,34,11,0,14.56,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,10.75,34,12,0,16.24,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,8.64,34,25,0,43.38,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.73e-20,14.31,34,87,0,47.29,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,9.3,34,33,0,65.03,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.73e-20,12.04,34,41,0,62.2,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,12.21,34,21,0,33.97,1.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,9.87,34,21,0,33.97,5.0
Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.73e-20,10.82,32,1019,2,33.0,5.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Survivors (humn),1.18e-06,23.47,6,34,0,7.06,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Fibrosis (patf),1.18e-06,23.84,6,21,0,7.71,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Septicemia (dsyn),1.18e-06,27.21,6,38,0,6.95,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Critical Illness (dsyn),1.18e-06,22.78,6,35,0,7.03,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,cohort (humn),1.18e-06,21.71,6,49,0,6.73,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Pneumonia (dsyn),1.18e-06,27.07,6,25,0,7.44,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Acute heart failure (dsyn),2.52e-06,28.69,6,9,0,10.0,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Surgical Patients (podg),1.23e-06,23.61,6,17,0,8.12,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),1.18e-06,22.04,6,33,0,7.09,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,End stage renal failure (dsyn),1.18e-06,25.58,6,18,0,8.0,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Pancreatitis (dsyn),4.16e-06,23.72,6,13,0,8.77,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Pulmonary Embolism (dsyn),1.66e-06,24.03,6,14,0,8.57,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Aortic Valve Stenosis (dsyn),1.66e-06,23.6,6,15,0,8.4,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Coronary heart disease (dsyn),1.19e-06,23.03,6,21,0,7.71,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Frailty (fndg),3.06e-06,28.22,6,9,0,10.0,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),USES,Brain natriuretic peptide (aapp),1.19e-06,24.83,6,16,0,8.25,5.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Chronic heart failure (dsyn),1.18e-06,24.32,6,18,0,8.0,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Heart failure (dsyn),1.18e-06,23.63,6,67,0,6.54,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,CARDIAC EVENT (dsyn),4.65e-06,29.98,6,8,0,10.5,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,Acute coronary syndrome (dsyn),1.18e-06,23.92,6,20,0,7.8,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),TREATS,End stage liver disease (dsyn),1.18e-06,32.44,6,17,0,8.12,4.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),METHOD_OF,Transplantation (topp),1.18e-06,22.27,6,29,0,7.24,5.0
Oral Glucose Tolerance Test (diap),ISA,Assessment procedure (hlca),METHOD_OF,Percutaneous coronary intervention (topp),4.65e-06,29.98,6,8,0,10.5,5.0
Microalbuminuria (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),7.16e-07,8.19,11,25,0,15.84,1.0
Microalbuminuria (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,Participant (humn),7.58e-07,6.73,11,50,0,13.42,1.0
Microalbuminuria (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,cohort (humn),7.13e-07,8.71,11,65,0,12.86,1.0
Microalbuminuria (dsyn),COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,Population Group (humn),1.82e-06,11.32,11,11,0,22.0,1.0
General Population (humn),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Ischemic stroke (dsyn),4.17e-06,24.84,11,11,0,22.0,2.0
General Population (humn),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),3.05e-10,22.08,11,34,0,14.56,2.0
General Population (humn),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Septicemia (dsyn),5.18e-12,26.43,11,20,0,17.05,2.0
General Population (humn),LOCATION_OF,C-reactive protein (aapp),ISA,Albumins (aapp),4.39e-12,23.68,11,30,0,15.03,2.0
General Population (humn),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),1.24e-07,24.19,11,15,0,19.07,2.0
General Population (humn),LOCATION_OF,C-reactive protein (aapp),ISA,Acute-Phase Proteins (aapp),4.5e-12,21.26,11,77,0,12.57,2.0
General Population (humn),LOCATION_OF,C-reactive protein (aapp),compared_with,procalcitonin (aapp),1.82e-08,24.49,11,16,0,18.56,2.0
General Population (humn),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Myocardial Infarction (dsyn),2.06e-06,23.53,11,14,0,19.64,2.0
Gastrectomy (topp),TREATS,Participant (humn),USES,Medicare (rnlw),5.59e-07,52.0,5,18,0,6.39,4.0
Operation on nose (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.04e-07,15.73,10,16,0,16.25,4.0
Operation on nose (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),2.89e-09,25.94,10,26,0,13.85,4.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,36.66,14,9,0,14.79,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.37e-17,35.72,14,194,0,15.01,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,34.44,14,17,0,25.53,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),3.4e-17,35.71,14,29,0,20.76,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,37.89,14,14,0,28.0,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,33.7,14,12,0,22.29,5.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),3.37e-17,32.52,14,48,0,18.08,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),3.39e-17,35.91,14,29,0,20.76,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.37e-17,32.96,14,98,0,16.0,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,31.62,14,24,0,22.17,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,38.03,14,10,0,17.14,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,30.39,14,37,0,19.3,7.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,32.19,14,20,0,23.8,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),3.37e-17,33.84,14,94,0,16.09,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,39.64,14,8,0,12.57,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,36.51,14,19,0,24.32,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,33.67,14,21,0,23.33,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,38.84,14,12,0,22.29,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,46.56,14,10,0,17.14,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,39.15,14,10,0,17.14,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,33.47,14,21,0,23.33,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,35.07,14,21,0,23.33,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.24e-16,33.2,14,32,0,20.12,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,40.56,14,10,0,17.14,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),3.37e-17,39.53,14,39,0,19.03,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),3.37e-17,43.51,14,44,0,18.45,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.37e-17,36.38,14,113,0,15.73,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,33.91,14,11,0,19.64,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,33.63,14,11,0,19.64,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,34.1,14,12,0,22.29,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,31.99,14,25,0,21.84,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.37e-17,37.66,14,87,0,16.25,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.49e-16,32.65,14,33,0,19.94,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.37e-17,35.39,14,41,0,18.78,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,35.56,14,21,0,23.33,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,33.22,14,21,0,23.33,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),3.37e-17,34.17,13,1020,1,13.17,8.0
Muscle strength (ortf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,19.68,12,18,0,20.0,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),2.99e-07,18.49,14,18,0,24.89,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),4.3e-14,20.93,14,77,0,16.55,4.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),5.12e-14,19.0,14,33,0,19.94,4.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),1.72e-09,20.01,14,18,0,24.89,4.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),2e-10,23.26,14,15,0,27.07,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",4.3e-14,20.99,14,41,0,18.78,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),5.2e-14,19.53,14,30,0,20.53,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),4.33e-14,19.18,14,35,0,19.6,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),4.3e-14,23.55,14,27,0,21.26,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),3.96e-06,18.28,14,16,0,26.25,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),6.75e-13,20.97,14,22,0,22.91,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),2.02e-08,19.22,14,18,0,24.89,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),4.75e-13,23.09,14,19,0,24.32,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),1e-07,22.06,14,12,0,22.29,4.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),1.87e-07,27.78,14,9,0,14.79,4.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),4.3e-14,18.66,14,97,0,16.02,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),4.3e-14,19.67,14,68,0,16.88,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),4.3e-14,32.68,14,27,0,21.26,4.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),8.95e-07,22.82,14,10,0,17.14,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),4.34e-14,26.57,14,20,0,23.8,4.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.05e-13,23.66,14,19,0,24.32,4.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),4.3e-14,19.91,14,93,0,16.11,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),3.21e-08,19.81,14,16,0,26.25,4.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),4.83e-07,18.6,14,17,0,25.53,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),6.63e-07,23.14,14,10,0,17.14,4.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),2.8e-09,18.7,14,22,0,22.91,1.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),2.3e-13,20.52,14,24,0,22.17,4.0
Leptin|LEP (aapp),TREATS,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),2.69e-06,21.74,14,10,0,17.14,4.0
C-reactive protein (aapp),ASSOCIATED_WITH,Schizophrenia (mobd),PROCESS_OF,Outpatients (podg),8.24e-07,21.68,5,11,1,7.27,1.0
Renal function (ortf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.4e-07,10.23,10,20,0,15.0,1.0
Renal function (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),9.41e-07,7.41,10,65,0,11.54,1.0
Renal function (ortf),PROCESS_OF,cohort (humn),USES,Treats (clas),1.31e-06,9.73,10,16,0,16.25,1.0
Renal function (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),5.03e-06,9.99,10,13,0,17.69,1.0
Renal function (ortf),PROCESS_OF,cohort (humn),USES,Classification (clas),9.51e-07,10.97,10,16,0,16.25,1.0
Renal function (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),4.41e-06,16.38,10,8,0,14.4,1.0
Renal function (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),9.39e-07,9.85,10,23,0,14.35,1.0
Renal function (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),9.39e-07,10.75,10,22,0,14.55,1.0
Renal function (ortf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),1.82e-06,10.68,10,13,0,17.69,1.0
Renal function (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),9.4e-07,12.67,10,15,0,16.67,1.0
Antihypertensive Agents (phsu),TREATS,Hypertensive (fndg),PROCESS_OF,Participant (humn),5.92e-07,5.75,13,52,1,16.25,1.0
Gastrectomy (topp),TREATS,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),3.19e-09,33.05,10,25,0,14.0,1.0
Gastrectomy (topp),TREATS,Diabetic (fndg),PROCESS_OF,Participant (humn),4.47e-08,31.6,10,50,0,12.0,1.0
Gastrectomy (topp),TREATS,Diabetic (fndg),PROCESS_OF,cohort (humn),1.82e-12,33.58,10,65,0,11.54,1.0
Gastrectomy (topp),TREATS,Diabetic (fndg),PROCESS_OF,Population Group (humn),1.11e-06,36.19,10,11,0,19.09,1.0
Hypercapnia (sosy),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),9.42e-07,18.65,7,16,0,10.06,8.0
Hypercapnia (sosy),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),4.41e-07,28.86,7,26,0,8.88,8.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),1.92e-06,15.18,7,18,0,9.72,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.63e-06,17.62,7,77,0,7.64,9.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),1.63e-06,15.7,7,33,0,8.48,5.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),1.63e-06,16.7,7,18,0,9.72,9.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),1.63e-06,19.95,7,15,0,10.27,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",1.63e-06,17.69,7,41,0,8.2,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),1.63e-06,16.23,7,30,0,8.63,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),1.63e-06,15.87,7,35,0,8.4,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),1.63e-06,20.25,7,27,0,8.81,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),5.58e-06,14.98,7,16,0,10.06,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),1.63e-06,17.67,7,22,0,9.23,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),1.65e-06,15.91,7,18,0,9.72,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),1.63e-06,19.78,7,19,0,9.58,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),1.73e-06,18.76,7,12,0,11.08,7.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),1.81e-06,24.47,7,9,0,12.44,9.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),1.63e-06,15.35,7,97,0,7.51,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),1.63e-06,16.36,7,68,0,7.72,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.63e-06,29.37,7,27,0,8.81,9.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),2.52e-06,19.51,7,10,0,11.9,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),1.63e-06,23.26,7,20,0,9.45,9.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),1.63e-06,20.35,7,19,0,9.58,9.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),1.63e-06,16.61,7,93,0,7.53,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),1.66e-06,16.51,7,16,0,10.06,5.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),2.11e-06,15.3,7,17,0,9.88,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),2.29e-06,19.83,7,10,0,11.9,9.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),1.63e-06,15.39,7,22,0,9.23,1.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),1.63e-06,17.21,7,24,0,9.04,9.0
Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),4.31e-06,18.44,7,10,0,11.9,9.0
Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),3.37e-06,12.96,7,33,0,8.48,1.0
Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),7.8e-06,13.5,7,16,0,10.06,8.0
Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.37e-06,13.31,7,71,0,7.69,5.0
Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.37e-06,27.15,7,35,0,8.4,8.0
Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.37e-06,13.23,7,110,0,7.45,8.0
Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),3.37e-06,12.57,7,37,0,8.32,1.0
insulin sensitivity (patf),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),3.75e-15,21.22,14,98,0,16.0,1.0
insulin sensitivity (patf),PROCESS_OF,African American (popg),ISA,Racial group (popg),3.75e-15,22.16,14,324,0,14.6,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,17.27,13,9,0,15.23,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.21e-10,16.33,13,194,0,13.87,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),4.57e-10,15.06,12,16,1,21.0,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.21e-10,16.32,13,29,0,18.83,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),3.2e-10,18.51,13,14,0,25.07,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,14.31,13,12,0,23.08,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.21e-10,13.13,13,48,0,16.52,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.21e-10,16.52,13,29,0,18.83,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.21e-10,13.57,12,97,1,13.48,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.45e-09,12.23,13,24,0,20.04,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,18.65,13,10,0,17.69,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.23e-08,11.0,13,37,0,17.57,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.85e-09,12.81,13,20,0,21.45,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.21e-10,14.46,13,94,0,14.8,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,20.25,13,8,0,12.92,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),1.21e-10,17.13,12,18,1,20.0,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.33e-10,14.28,13,21,0,21.05,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.9e-09,19.46,13,12,0,23.08,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.76e-09,27.18,13,10,0,17.69,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.19e-08,19.76,13,10,0,17.69,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.43e-10,14.08,13,21,0,21.05,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.21e-10,15.69,13,21,0,21.05,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.21e-10,13.82,12,31,1,16.65,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.54e-08,21.17,13,10,0,17.69,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.21e-10,20.14,13,39,0,17.33,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.21e-10,24.12,12,43,1,15.35,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.21e-10,17.0,13,113,0,14.5,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,14.52,13,11,0,20.31,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,14.25,13,11,0,20.31,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,14.71,13,12,0,23.08,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),2.39e-10,12.61,13,25,0,19.76,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.21e-10,18.28,13,87,0,14.94,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.21e-10,13.27,13,33,0,18.12,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.21e-10,16.01,13,41,0,17.12,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.21e-10,16.17,13,21,0,21.05,1.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",1.71e-10,13.84,13,21,0,21.05,4.0
Assessment procedure (hlca),TREATS,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.21e-10,14.78,13,1021,0,13.17,4.0
Age (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),COEXISTS_WITH,Heart failure (dsyn),3.21e-12,31.07,21,15,0,25.71,8.0
Age (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.71e-13,33.54,21,15,0,25.71,8.0
Age (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),CAUSES,"Kidney Failure, Chronic (dsyn)",8.14e-12,25.04,21,20,0,39.05,8.0
Age (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),6.87e-23,24.31,21,52,0,29.48,8.0
Age (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,Hospitalized Patients (humn),5.59e-07,23.19,21,15,0,25.71,1.0
Age (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",7.7e-09,22.7,21,21,0,42.0,1.0
Age (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),CAUSES,End stage renal failure (dsyn),6.88e-23,23.99,21,51,0,29.65,8.0
Age (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,Survivors (humn),7.61e-08,26.3,21,12,0,18.86,1.0
Age (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),CAUSES,Kidney Failure (dsyn),3.63e-11,28.64,21,15,0,25.71,8.0
Age (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),CAUSES,Cessation of life (orgf),6.87e-23,25.89,20,42,1,29.52,8.0
Age (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),4.72e-09,26.14,21,14,0,23.33,8.0
Age (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),3.35e-14,24.31,21,26,0,37.96,8.0
Age (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,General Population (humn),9.45e-11,23.5,21,22,0,41.05,1.0
Age (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),ISA,Metabolic Diseases (dsyn),1.63e-06,20.68,21,43,0,31.26,5.0
Age (orga),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),3.07e-20,23.14,21,44,0,31.02,1.0
Procedures (hlca),TREATS,"Urinary Incontinence, Stress (dsyn)",PROCESS_OF,Urodynamics (ortf),2.75e-07,3.3,30,1,0,1.03,1.0
Open approach (topp),TREATS,Cancer of Rectum (neop),PROCESS_OF,cohort (humn),3.51e-08,11.91,13,15,0,24.27,1.0
Insulin (horm),TREATS,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),3.19e-09,6.13,37,25,0,41.89,1.0
Insulin (horm),TREATS,Diabetic (fndg),PROCESS_OF,Participant (humn),4.47e-08,4.67,37,50,0,64.38,1.0
Insulin (horm),TREATS,Diabetic (fndg),PROCESS_OF,cohort (humn),4.21e-16,6.66,37,65,0,58.06,1.0
Insulin (horm),TREATS,Diabetic (fndg),PROCESS_OF,Population Group (humn),1.11e-06,9.26,37,11,0,14.27,1.0
Two (qnco),ISA,Measurement (ftcn),ISA,Techniques (ftcn),1.57e-19,2.18,73,116,0,118.94,5.0
Two (qnco),ISA,Measurement (ftcn),ISA,Health (idcn),1.57e-19,3.94,73,94,0,129.69,5.0
"Osteoarthritis, Knee (dsyn)",PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,17.01,55,18,0,23.89,1.0
Body mass index procedure (diap),AFFECTS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),1.24e-07,79.05,5,78,0,5.32,1.0
Body mass index procedure (diap),AFFECTS,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),2.18e-07,78.18,5,22,0,6.14,1.0
Body mass index procedure (diap),AFFECTS,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),1.28e-07,85.28,5,12,0,7.08,1.0
Body mass index procedure (diap),AFFECTS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (humn),1.68e-07,79.15,5,18,0,6.39,1.0
Body mass index procedure (diap),AFFECTS,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (humn),1.24e-07,77.15,5,67,0,5.37,1.0
Body mass index procedure (diap),AFFECTS,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),1.26e-07,79.13,5,21,0,6.19,1.0
Body mass index procedure (diap),AFFECTS,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),1.24e-07,78.63,5,35,0,5.71,1.0
Hospitals (hcro),LOCATION_OF,Prospective Studies (qnco),ISA,Techniques (ftcn),7.54e-16,4.38,63,912,0,67.35,2.0
Hospitals (hcro),LOCATION_OF,Prospective Studies (qnco),ISA,contextual factors (ftcn),1.3e-06,3.84,63,26,0,36.73,2.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.96e-06,33.26,6,9,0,10.0,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.72e-07,32.31,6,194,0,6.19,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.72e-07,31.04,6,17,0,8.12,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),3.72e-07,32.31,6,29,0,7.24,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),3.72e-07,34.49,6,14,0,8.57,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.44e-06,30.3,6,12,0,9.0,5.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),3.72e-07,29.12,6,48,0,6.75,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),3.72e-07,32.51,6,29,0,7.24,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.72e-07,29.56,6,98,0,6.37,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),3.74e-07,28.22,6,24,0,7.5,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),5.48e-07,34.63,6,10,0,9.6,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),3.84e-07,26.99,6,37,0,6.97,7.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),3.79e-07,28.79,6,20,0,7.8,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),3.72e-07,30.44,6,94,0,6.38,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.71e-06,36.24,6,8,0,10.5,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.72e-07,33.11,6,19,0,7.89,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),3.72e-07,30.26,6,21,0,7.71,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),3.75e-07,35.44,6,12,0,9.0,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.75e-07,43.16,6,10,0,9.6,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),4.54e-07,35.75,6,10,0,9.6,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),3.72e-07,30.07,6,21,0,7.71,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),3.72e-07,31.67,6,21,0,7.71,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.72e-07,29.8,6,32,0,7.12,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),4.07e-07,37.16,6,10,0,9.6,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),3.72e-07,36.13,6,39,0,6.92,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),3.72e-07,40.1,6,44,0,6.82,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.72e-07,32.98,6,113,0,6.32,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),3.12e-06,30.51,6,11,0,9.27,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.55e-06,30.23,6,11,0,9.27,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),9.32e-07,30.7,6,12,0,9.0,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),3.72e-07,28.59,6,25,0,7.44,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.72e-07,34.26,6,87,0,6.41,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),3.72e-07,29.25,6,33,0,7.09,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.72e-07,31.99,6,41,0,6.88,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),3.72e-07,32.16,6,21,0,7.71,1.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",3.72e-07,29.82,6,21,0,7.71,8.0
Overweight (sosy),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),3.72e-07,30.77,6,1021,0,6.04,8.0
Intervention regimes (hlca),TREATS,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.21e-06,12.05,8,23,0,10.78,4.0
Intervention regimes (hlca),TREATS,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),2.21e-06,11.5,8,57,0,9.12,4.0
Intervention regimes (hlca),TREATS,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.5e-06,19.96,8,9,0,15.11,4.0
Abdomen (blor),LOCATION_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Glioblastoma (neop),3.75e-08,6.8,46,18,0,25.04,2.0
Abdomen (blor),LOCATION_OF,Magnetic Resonance Imaging (diap),DIAGNOSES,Congenital diaphragmatic hernia (cgab),2.51e-07,12.08,46,10,0,12.17,2.0
Waist circumference (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,42.59,89,18,0,21.64,1.0
Fibrosis (patf),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.79e-10,17.01,32,23,0,39.53,9.0
Fibrosis (patf),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),1.67e-22,16.45,32,57,0,49.96,9.0
Fibrosis (patf),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,24.92,32,9,0,11.53,9.0
Fitness (dora),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),4.41e-07,17.49,7,33,0,8.48,1.0
Fitness (dora),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.87e-06,18.03,7,16,0,10.06,9.0
Fitness (dora),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),4.41e-07,17.84,7,71,0,7.69,5.0
Fitness (dora),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.41e-07,31.68,7,35,0,8.4,21.0
Fitness (dora),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.41e-07,17.76,7,110,0,7.45,21.0
Fitness (dora),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),4.43e-07,17.1,7,37,0,8.32,1.0
Umbilicus (Anatomy) (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Pulmonary Embolism (dsyn),1.25e-08,34.05,8,29,0,10.21,2.0
Umbilicus (Anatomy) (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Secondary malignant neoplasm of liver (neop),7.23e-07,33.8,8,26,0,10.46,2.0
Umbilicus (Anatomy) (bpoc),LOCATION_OF,tomography (diap),ISA,Medical Imaging (diap),2.27e-06,32.15,8,318,0,8.2,2.0
Umbilicus (Anatomy) (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Malignant neoplasm of lung (neop),4.01e-10,37.28,8,129,0,8.5,2.0
Umbilicus (Anatomy) (bpoc),LOCATION_OF,tomography (diap),ISA,Diagnosis (hlca),4.06e-10,32.92,8,112,0,8.57,2.0
Umbilicus (Anatomy) (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Solid tumor (neop),1.36e-08,35.03,8,21,0,11.05,2.0
Metabolic syndrome (dsyn),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,20.97,11,16,0,18.56,7.0
Metabolic syndrome (dsyn),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,26.14,11,9,0,16.36,7.0
Metabolic syndrome (dsyn),AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,18.52,11,31,0,14.9,7.0
Knee (blor),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),3.28e-08,64.55,10,13,0,17.69,2.0
Knee (blor),LOCATION_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),3.25e-08,67.48,10,11,0,19.09,2.0
Knee (blor),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),3.42e-10,68.69,10,13,0,17.69,2.0
Knee (blor),LOCATION_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),1.5e-14,63.98,10,27,0,13.7,2.0
Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.29e-07,24.68,7,16,0,10.06,8.0
Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.02e-06,29.85,7,9,0,12.44,8.0
Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),2e-07,22.24,7,31,0,8.58,8.0
Waist circumference (fndg),PROCESS_OF,Hispanics (humn),ISA,Ethnic group (popg),5.88e-12,69.15,8,226,0,8.28,1.0
Insulin Resistance (patf),ASSOCIATED_WITH,Insulin (horm),TREATS,Hospitalized Patients (humn),2.75e-06,20.65,15,11,0,19.07,4.0
Insulin Resistance (patf),ASSOCIATED_WITH,Insulin (horm),TREATS,Hyperglycemia (dsyn),4.34e-15,18.44,15,57,0,18.95,4.0
Fatty degeneration (patf),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.04e-09,15.46,10,23,0,14.35,9.0
Fatty degeneration (patf),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),3.76e-09,14.9,10,57,0,11.75,9.0
Fatty degeneration (patf),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.94e-07,23.37,10,9,0,17.1,9.0
Neck (blor),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),3.28e-08,71.91,13,13,0,26.0,2.0
Neck (blor),LOCATION_OF,Body mass index procedure (diap),AFFECTS,Postoperative Complications (patf),3.25e-08,74.84,13,11,0,20.31,2.0
Neck (blor),LOCATION_OF,Body mass index procedure (diap),DIAGNOSES,Heart failure (dsyn),3.42e-10,76.04,13,13,0,26.0,2.0
Neck (blor),LOCATION_OF,Body mass index procedure (diap),ISA,Diagnosis (hlca),2.75e-16,71.33,13,27,0,19.26,2.0
Coronary artery calcification (dsyn),PREDISPOSES,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.76e-08,20.13,8,25,0,10.56,21.0
Coronary artery calcification (dsyn),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.78e-08,24.03,8,15,0,12.27,9.0
Coronary artery calcification (dsyn),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),2.76e-08,29.41,8,24,0,10.67,11.0
Coronary artery calcification (dsyn),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),2.76e-08,20.05,8,46,0,9.39,11.0
Coronary artery calcification (dsyn),PREDISPOSES,Atherosclerosis (dsyn),PROCESS_OF,General Population (humn),2.82e-08,19.62,8,24,0,10.67,1.0
Coronary artery calcification (dsyn),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),2.81e-08,21.46,8,18,0,11.56,11.0
Coronary artery calcification (dsyn),PREDISPOSES,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),2.76e-08,18.19,8,73,0,8.88,5.0
Coronary artery calcification (dsyn),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),1.21e-07,18.79,8,24,0,10.67,11.0
Coronary artery calcification (dsyn),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",2.76e-08,20.1,8,41,0,9.56,9.0
Coronary artery calcification (dsyn),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),2.83e-08,20.88,8,19,0,11.37,11.0
Coronary artery calcification (dsyn),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.76e-08,21.76,8,26,0,10.46,9.0
Assessment procedure (hlca),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,23.11,14,33,0,19.94,1.0
Assessment procedure (hlca),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,23.66,14,16,0,26.25,4.0
Assessment procedure (hlca),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.26e-15,23.46,14,71,0,16.76,4.0
Assessment procedure (hlca),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.26e-15,37.3,14,35,0,19.6,4.0
Assessment procedure (hlca),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.26e-15,23.39,14,110,0,15.78,4.0
Assessment procedure (hlca),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,22.72,14,37,0,19.3,1.0
cohort (humn),LOCATION_OF,Lipids (lipd),PART_OF,Stratum corneum (tisu),7.96e-07,15.13,11,2,0,2.36,2.0
Hyperuricemia (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,22.95,12,18,0,20.0,1.0
Middle school (orgt),LOCATION_OF,Clinical Trials (resa),USES,Stents (medd),3.14e-06,33.87,5,78,0,5.32,2.0
Middle school (orgt),LOCATION_OF,Clinical Trials (resa),USES,Probes (medd),3.18e-06,29.09,5,5,0,10.0,2.0
Middle school (orgt),LOCATION_OF,Clinical Trials (resa),USES,Metal stent (medd),3.14e-06,36.23,5,34,0,5.74,2.0
Middle school (orgt),LOCATION_OF,Clinical Trials (resa),USES,Treatment Protocols (resa),3.14e-06,32.46,5,147,0,5.17,2.0
Middle school (orgt),LOCATION_OF,Clinical Trials (resa),USES,Drug eluting stent (medd),3.14e-06,34.68,5,38,0,5.66,2.0
Middle school (orgt),LOCATION_OF,Clinical Trials (resa),USES,"Defibrillators, Implantable (medd)",3.14e-06,37.03,5,40,0,5.62,2.0
Middle school (orgt),LOCATION_OF,Clinical Trials (resa),USES,"Stents, Vascular, Coronary (medd)",3.15e-06,36.83,5,13,0,6.92,2.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,43.28,10,16,0,16.25,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),2.23e-13,53.49,10,26,0,13.85,8.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Atrial Fibrillation (patf),5.57e-07,65.51,5,21,0,6.19,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),METHOD_OF,Primary Prevention (topp),3.68e-07,65.4,5,23,0,6.09,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,STEMI (dsyn),2.18e-07,70.12,5,47,0,5.53,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,General Population (humn),2.35e-07,65.62,5,24,0,6.04,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),PREVENTS,Premature Birth (patf),2.18e-07,67.84,5,30,0,5.83,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),PREVENTS,Death (finding) (fndg),2.18e-07,74.25,5,94,0,5.27,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,"Aortic Aneurysm, Abdominal (dsyn)",2.18e-07,71.89,5,20,0,6.25,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Hemorrhage (fndg),2.18e-07,66.99,5,65,0,5.38,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Pulmonary Embolism (dsyn),2.4e-07,68.75,5,14,0,6.79,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),PREVENTS,Cerebrovascular accident (dsyn),2.18e-07,67.15,5,22,0,6.14,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Septicemia (dsyn),2.18e-07,70.58,5,41,0,5.61,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Malaria (dsyn),2.18e-07,66.06,5,56,0,5.45,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),PREVENTS,Stillbirth (patf),2.3e-07,71.53,5,12,0,7.08,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),2.18e-07,65.73,5,60,0,5.42,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Critical limb ischemia (patf),2.18e-07,69.75,5,40,0,5.62,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,"Shock, Cardiogenic (patf)",2.18e-07,71.29,5,14,0,6.79,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Cardiovascular Diseases (dsyn),2.18e-07,66.55,5,33,0,5.76,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Pneumonia (dsyn),2.19e-07,67.39,5,19,0,6.32,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Chronic heart failure (dsyn),2.18e-07,68.89,5,25,0,6.0,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),PREVENTS,"Death, Sudden, Cardiac (patf)",8.81e-07,70.71,5,10,0,7.5,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,high-risk group (humn),2.18e-07,66.31,5,27,0,5.93,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,"Pancreatitis, Acute Necrotizing (dsyn)",2.18e-07,70.89,5,20,0,6.25,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,"Stenosis, unspecified (patf)",2.18e-07,66.21,5,26,0,5.96,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Deglutition Disorders (dsyn),9.74e-07,66.64,5,15,0,6.67,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Depressed mood (fndg),2.09e-06,64.59,5,30,0,5.83,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,High Risk Populations (popg),2.21e-07,65.89,5,24,0,6.04,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Octogenarians (aggp),3.39e-07,72.89,5,10,0,7.5,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Acute myocardial infarction (dsyn),2.18e-07,67.71,5,104,0,5.24,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),USES,Losartan (orch),2.18e-07,68.09,5,65,0,5.38,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Peripheral Vascular Diseases (dsyn),2.18e-07,67.96,5,40,0,5.62,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Postpartum Hemorrhage (patf),2.83e-07,71.5,5,11,0,7.27,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Coronary Arteriosclerosis (dsyn),2.18e-07,67.17,5,60,0,5.42,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Anemia (dsyn),5.88e-07,66.25,5,17,0,6.47,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),PREVENTS,Adverse event (fndg),4.58e-07,66.68,5,16,0,6.56,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Ischemia (dsyn),2.18e-07,67.49,5,23,0,6.09,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Endoleak (patf),2.18e-07,70.49,5,30,0,5.83,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Carotid Stenosis (dsyn),3.94e-07,67.17,5,15,0,6.67,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),METHOD_OF,Secondary prevention (topp),3.31e-06,66.18,5,15,0,6.67,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Malnutrition (dsyn),2.24e-07,66.56,5,20,0,6.25,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Systemic arterial pressure (fndg),2.18e-07,64.97,5,43,0,5.58,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Pre-Eclampsia (dsyn),2.19e-07,72.25,5,13,0,6.92,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,"Kidney Failure, Chronic (dsyn)",2.18e-07,67.76,5,52,0,5.48,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Myocardial Infarction (dsyn),2.18e-07,68.8,5,91,0,5.27,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Maternal Mortality (fndg),2.18e-07,79.18,5,19,0,6.32,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Mitral Valve Insufficiency (dsyn),8.86e-07,67.09,5,14,0,6.79,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Survivors (humn),2.2e-07,64.38,5,53,0,5.47,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,"Stroke, Acute (dsyn)",1.23e-06,66.54,5,15,0,6.67,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),PREVENTS,Perinatal death (fndg),2.18e-07,77.46,5,17,0,6.47,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,End stage renal failure (dsyn),2.18e-07,68.79,5,21,0,6.19,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Diabetic (fndg),2.18e-07,66.37,5,36,0,5.69,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),PREVENTS,Newborn death (patf),2.4e-07,75.75,5,10,0,7.5,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,"Hepatitis C, Chronic (dsyn)",8.68e-07,73.01,5,9,0,7.78,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),PREVENTS,Maternal Mortality (fndg),2.18e-07,78.38,5,80,0,5.31,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),PREVENTS,Cardiovascular event (fndg),2.18e-07,69.11,5,28,0,5.89,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Death (finding) (fndg),2.18e-07,72.13,5,19,0,6.32,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Acute coronary syndrome (dsyn),2.18e-07,68.11,5,60,0,5.42,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Heart Arrest (patf),2.18e-07,69.12,5,27,0,5.93,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Disease Progression (patf),5.65e-07,66.92,5,15,0,6.67,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Critical Illness (dsyn),2.18e-07,68.14,5,42,0,5.6,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Diarrhea (sosy),2.2e-07,67.52,5,18,0,6.39,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Congestive heart failure (dsyn),8.86e-07,67.09,5,14,0,6.79,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),USES,Pravastatin (phsu),2.18e-07,70.09,5,30,0,5.83,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Septic Shock (patf),2.2e-07,71.56,5,13,0,6.92,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Control Groups (humn),3.25e-06,64.04,5,57,0,5.44,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Coronary heart disease (dsyn),2.18e-07,66.93,5,49,0,5.51,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),PREVENTS,Hemorrhage (fndg),4.58e-07,66.68,5,16,0,6.56,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Claudication (dsyn),2.18e-07,71.89,5,17,0,6.47,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,"Respiratory Distress Syndrome, Adult (dsyn)",2.19e-07,68.35,5,17,0,6.47,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Ischemic stroke (dsyn),6.94e-07,65.59,5,20,0,6.25,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),2.18e-07,64.71,5,123,0,5.2,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Upper gastrointestinal hemorrhage (dsyn),2.18e-07,73.69,5,18,0,6.39,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),METHOD_OF,Revascularization - action (topp),2.18e-07,70.21,5,24,0,6.04,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),2.18e-07,66.86,5,34,0,5.74,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,cohort (humn),2.18e-07,65.8,5,38,0,5.66,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),PREVENTS,Cardiovascular morbidity (dsyn),2.18e-07,77.79,5,24,0,6.04,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Aortic Valve Stenosis (dsyn),2.18e-07,68.96,5,28,0,5.89,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Heart failure (dsyn),2.18e-07,67.58,5,103,0,5.24,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),PREVENTS,Malaria (dsyn),3.37e-07,66.3,5,18,0,6.39,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),AFFECTS,Maternal Mortality (fndg),2.18e-07,78.64,5,14,0,6.79,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),ISA,Procedures (hlca),2.18e-07,64.84,5,125,0,5.2,5.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,Fetofetal Transfusion (dsyn),6.57e-07,73.69,5,9,0,7.78,4.0
Body mass index procedure (diap),ISA,Intervention regimes (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",2.18e-07,66.54,5,26,0,5.96,4.0
Continuous Positive Airway Pressure (topp),TREATS,Sleep Apnea Syndromes (dsyn),COEXISTS_WITH,Heart failure (dsyn),1.2e-06,13.24,22,10,0,14.55,4.0
Eating Disorders (mobd),ISA,Mental disorders (mobd),PROCESS_OF,cohort (humn),5.13e-06,8.74,9,20,0,13.05,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),CAUSES,Cessation of life (orgf),9.05e-14,82.89,9,331,0,9.24,11.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Hospitalized Patients (humn),9.05e-14,81.09,9,244,0,9.33,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Control Groups (humn),1.57e-06,78.97,9,15,0,14.4,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Pneumocystis (fngs),9.05e-14,77.01,9,212,0,9.38,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Human Age Group (aggp),2.38e-13,82.97,9,20,0,13.05,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Acinetobacter baumannii (bact),4.27e-10,81.24,9,17,0,13.76,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Outpatients (podg),9.68e-14,78.91,9,35,0,11.31,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Respiratory syncytial virus (virs),4.96e-06,77.33,9,25,0,12.24,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),COEXISTS_WITH,"Respiratory Distress Syndrome, Adult (dsyn)",1.44e-08,82.56,9,13,0,15.23,9.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),CAUSES,Septicemia (dsyn),9.05e-14,82.79,9,37,0,11.19,11.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),COEXISTS_WITH,Immunocompromised Host (fndg),9.05e-14,78.67,9,64,0,10.27,9.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),ISA,Respiratory Tract Infections (dsyn),3.2e-13,78.81,9,32,0,11.53,5.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Streptococcus pneumoniae (bact),2.01e-09,78.73,9,23,0,12.52,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,cohort (humn),9.05e-14,82.69,9,55,0,10.47,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),CAUSES,Bacteremia (dsyn),7.79e-12,82.51,9,18,0,13.5,11.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,General Population (humn),3.73e-10,82.97,9,15,0,14.4,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),CAUSES,Respiratory Failure (dsyn),2.25e-13,80.41,9,25,0,12.24,11.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",9.05e-14,78.67,9,52,0,10.56,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),CAUSES,"Infections, Hospital (dsyn)",4.29e-08,82.92,9,12,0,15.75,11.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Pseudomonas aeruginosa (bact),9.05e-14,78.66,9,86,0,9.94,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),ISA,Respiration Disorders (dsyn),9.12e-14,80.2,9,30,0,11.7,5.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Pneumocystis jiroveci (fngs),9.05e-14,78.22,9,152,0,9.53,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Staphylococcus aureus (bact),2.74e-13,79.77,9,27,0,12.0,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Cancer Patient (podg),2.77e-07,80.05,9,14,0,14.79,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),CAUSES,Acute respiratory failure (dsyn),2.87e-13,81.06,9,23,0,12.52,11.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Cytomegalovirus (virs),4.25e-06,76.82,9,40,0,11.03,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,nursing home resident (popg),9.05e-14,82.67,9,44,0,10.84,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),CAUSES,"Respiratory Distress Syndrome, Adult (dsyn)",6.28e-13,80.38,9,24,0,12.38,11.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),CAUSES,Hospitalization (hlca),9.05e-14,81.9,9,79,0,10.03,11.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Hospitalized Patients (humn),9.05e-14,84.66,9,48,0,10.69,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Participant (humn),1.77e-06,79.28,9,14,0,14.79,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,Survivors (humn),6.27e-11,85.97,9,14,0,14.79,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,inpatient (humn),1.67e-10,82.49,9,16,0,14.06,1.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),CAUSES,Hospital admission (hlca),3.42e-09,80.9,9,16,0,14.06,11.0
Body mass index (clna),PREDISPOSES,Pneumonia (dsyn),PROCESS_OF,inpatient (humn),9.05e-14,80.78,9,72,0,10.12,1.0
Pre-Eclampsia (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.03e-09,14.58,13,20,0,21.45,1.0
Pre-Eclampsia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.57e-09,11.76,13,65,0,15.6,1.0
Pre-Eclampsia (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.76e-07,14.08,13,16,0,23.56,1.0
Pre-Eclampsia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,14.34,13,13,0,26.0,1.0
Pre-Eclampsia (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.23e-08,15.32,13,16,0,23.56,1.0
Pre-Eclampsia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,20.73,13,8,0,12.92,1.0
Pre-Eclampsia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.06e-10,14.2,13,23,0,20.35,1.0
Pre-Eclampsia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),4.46e-11,15.1,13,22,0,20.68,1.0
Pre-Eclampsia (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,15.03,13,13,0,26.0,1.0
Pre-Eclampsia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.57e-09,17.02,13,15,0,24.27,1.0
Hypothyroidism (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),4.13e-06,19.93,6,18,0,8.0,1.0
Ankle brachial index (diap),DIAGNOSES,Peripheral Vascular Diseases (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),2.09e-06,10.94,16,10,0,16.25,18.0
Ankle brachial index (diap),DIAGNOSES,Peripheral Vascular Diseases (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.32e-08,12.71,16,15,0,29.06,18.0
Ankle brachial index (diap),DIAGNOSES,Peripheral Vascular Diseases (dsyn),ISA,Vascular Diseases (dsyn),1.31e-08,10.62,16,18,0,30.22,5.0
Ankle brachial index (diap),DIAGNOSES,Peripheral Vascular Diseases (dsyn),PROCESS_OF,General Population (humn),9.75e-08,9.41,16,14,0,26.25,1.0
Ankle brachial index (diap),DIAGNOSES,Peripheral Vascular Diseases (dsyn),ISA,Cardiovascular Diseases (dsyn),1.31e-08,9.09,16,30,0,24.53,5.0
Ankle brachial index (diap),DIAGNOSES,Peripheral Vascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.31e-08,9.41,16,26,0,25.85,1.0
Ankle brachial index (diap),DIAGNOSES,Peripheral Vascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.37e-08,10.53,16,16,0,32.0,18.0
Ankle brachial index (diap),DIAGNOSES,Peripheral Vascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.31e-08,6.92,16,34,0,23.53,1.0
Baseline weight (orga),ISA,Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),1.38e-09,55.42,11,22,0,16.5,5.0
Vitamin D (phsu),TREATS,Well adult (fndg),PROCESS_OF,Voluntary Workers (humn),5.19e-07,14.79,7,15,0,10.27,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,21.47,46,16,0,21.57,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,26.64,46,9,0,10.76,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,19.02,46,31,0,51.89,9.0
Degenerative polyarthritis (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,13.46,33,18,0,27.82,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,African American (popg),ISA,Ethnic group (popg),8.79e-10,50.38,7,98,0,7.5,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,African American (popg),ISA,Racial group (popg),8.79e-10,51.31,7,324,0,7.15,1.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),2.19e-07,15.47,8,20,0,11.2,1.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Disability NOS (patf),2e-07,18.62,8,36,0,9.78,9.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Respiration Disorders (dsyn),2e-07,15.26,8,59,0,9.08,5.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Respiratory physiology (ortf),2.21e-07,14.91,8,23,0,10.78,1.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Acute respiratory failure (dsyn),5.54e-07,17.91,8,12,0,13.33,9.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),2e-07,15.63,8,72,0,8.89,1.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Lung diseases (dsyn),2e-07,15.09,8,73,0,8.88,5.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Hospitalized Patients (humn),2e-07,16.42,8,50,0,9.28,1.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospital admission (hlca),2.04e-07,18.21,8,15,0,12.27,9.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Cessation of life (orgf),2e-07,18.14,8,184,0,8.35,9.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Outpatients (podg),2.19e-07,13.68,8,43,0,9.49,1.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,General Population (humn),2e-07,15.65,8,27,0,10.37,1.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Diagnosis (hlca),3.71e-07,19.69,8,11,0,13.82,9.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospitalization (hlca),2e-07,17.83,8,31,0,10.06,9.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Participant (humn),2e-07,14.99,8,70,0,8.91,1.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),COEXISTS_WITH,Smoker (fndg),4.39e-07,14.16,8,27,0,10.37,9.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Chronic Disease (dsyn),2e-07,16.13,8,46,0,9.39,5.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Malignant neoplasm of lung (neop),2.88e-07,15.85,8,17,0,11.76,9.0
Osteoporosis (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Pneumonia (dsyn),6.46e-07,17.76,8,12,0,13.33,9.0
Retinal Diseases (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.65e-06,13.0,8,18,0,11.56,1.0
Physical activity (dora),TREATS,AUSTRALIAN (fndg),PROCESS_OF,Population Group (humn),3.72e-06,19.03,8,14,0,12.57,1.0
Physical activity (dora),TREATS,AUSTRALIAN (fndg),PROCESS_OF,cohort (humn),3.91e-08,17.51,8,47,0,9.36,1.0
Physical activity (dora),TREATS,AUSTRALIAN (fndg),PROCESS_OF,Aboriginals (humn),3.46e-06,16.6,8,60,0,9.07,1.0
Physical activity (dora),TREATS,AUSTRALIAN (fndg),PROCESS_OF,Coroners (humn),8.05e-08,31.69,8,9,0,15.11,1.0
Physical activity (dora),TREATS,AUSTRALIAN (fndg),PROCESS_OF,General Population (humn),8.57e-08,17.68,8,28,0,10.29,1.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,37.69,34,16,0,23.53,8.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,42.86,34,9,0,11.38,8.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,35.24,34,31,0,59.26,8.0
Respiratory physiology (ortf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),9.2e-07,14.42,8,18,0,11.56,1.0
Alcohol consumption (inbe),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),2.73e-08,13.94,10,77,0,11.3,1.0
Alcohol consumption (inbe),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),3.73e-08,14.28,10,16,0,16.25,1.0
Alcohol consumption (inbe),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Young adult (aggp),4.1e-06,13.73,10,12,0,18.33,1.0
Alcohol consumption (inbe),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Middle Aged (aggp),2.77e-08,14.07,10,19,0,15.26,1.0
Alcohol consumption (inbe),PREDISPOSES,Coronary heart disease (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.86e-08,12.85,10,22,0,14.55,21.0
Alcohol consumption (inbe),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Outpatients (podg),8.49e-08,11.86,10,24,0,14.17,1.0
Alcohol consumption (inbe),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,General Population (humn),2.73e-08,13.57,10,42,0,12.38,1.0
Alcohol consumption (inbe),PREDISPOSES,Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),2.73e-08,14.82,10,102,0,10.98,5.0
Alcohol consumption (inbe),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Heart failure (dsyn),3.61e-07,14.41,10,13,0,17.69,11.0
Alcohol consumption (inbe),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),2.73e-08,14.15,10,83,0,11.2,1.0
Alcohol consumption (inbe),PREDISPOSES,Coronary heart disease (dsyn),ISA,Death (finding) (fndg),2.73e-08,16.74,10,250,0,10.4,5.0
Alcohol consumption (inbe),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),2.73e-08,13.91,10,194,0,10.52,11.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,13.61,35,20,0,31.43,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,10.79,35,65,0,53.85,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,13.12,35,16,0,23.31,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,13.37,35,13,0,17.83,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,14.35,35,16,0,23.31,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,19.76,35,8,0,9.83,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,13.23,35,23,0,38.11,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,14.13,35,22,0,35.83,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,14.06,35,13,0,17.83,1.0
Pregnancy (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,16.06,35,15,0,21.43,1.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,tomography (diap),DIAGNOSES,Pulmonary Embolism (dsyn),1.55e-08,11.82,11,29,0,15.17,16.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,tomography (diap),DIAGNOSES,Secondary malignant neoplasm of liver (neop),7.26e-07,11.57,11,26,0,15.65,16.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,tomography (diap),ISA,Medical Imaging (diap),2.27e-06,9.91,11,318,0,11.38,5.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,tomography (diap),DIAGNOSES,Malignant neoplasm of lung (neop),3.37e-09,15.05,11,129,0,11.94,16.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,tomography (diap),ISA,Diagnosis (hlca),3.38e-09,10.68,11,112,0,12.08,5.0
Dual-Energy X-Ray Absorptiometry (diap),METHOD_OF,tomography (diap),DIAGNOSES,Solid tumor (neop),1.66e-08,12.8,11,21,0,16.76,16.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),3e-07,15.39,11,18,0,17.72,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),3.49e-10,17.82,11,77,0,12.57,21.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),3.49e-10,15.9,11,33,0,14.67,5.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),2.06e-09,16.91,11,18,0,17.72,21.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),5.49e-10,20.15,11,15,0,19.07,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",3.49e-10,17.89,11,41,0,13.95,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),3.49e-10,16.43,11,30,0,15.03,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),3.49e-10,16.07,11,35,0,14.46,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),3.49e-10,20.45,11,27,0,15.48,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),3.96e-06,15.18,11,16,0,18.56,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),3.5e-10,17.87,11,22,0,16.5,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),2.06e-08,16.11,11,18,0,17.72,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),3.49e-10,19.98,11,19,0,17.37,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),1.01e-07,18.96,11,12,0,21.08,7.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),1.87e-07,24.67,11,9,0,16.36,11.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),3.49e-10,15.55,11,97,0,12.25,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),3.49e-10,16.57,11,68,0,12.78,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),3.49e-10,29.57,11,27,0,15.48,21.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),8.95e-07,19.71,11,10,0,19.09,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),3.49e-10,23.46,11,20,0,17.05,9.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),3.49e-10,20.55,11,19,0,17.37,9.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),3.49e-10,16.81,11,93,0,12.3,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),3.25e-08,16.71,11,16,0,18.56,5.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),4.83e-07,15.5,11,17,0,18.12,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),6.64e-07,20.04,11,10,0,19.09,21.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),3.15e-09,15.59,11,22,0,16.5,1.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),3.49e-10,17.41,11,24,0,16.04,11.0
Metabolic syndrome (dsyn),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),2.69e-06,18.64,11,10,0,19.09,9.0
homocysteine (aapp),PREDISPOSES,Vascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.06e-06,8.8,11,22,0,16.5,11.0
Laparoscopic adjustable gastric banding (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,52.73,29,12,0,16.97,1.0
Laparoscopic adjustable gastric banding (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,50.09,29,24,0,43.86,4.0
Community Health Centers (hcro),LOCATION_OF,Clinical Trials (resa),USES,Stents (medd),3.72e-07,15.82,8,78,0,8.82,2.0
Community Health Centers (hcro),LOCATION_OF,Clinical Trials (resa),USES,Probes (medd),4.1e-07,11.05,8,5,0,8.12,2.0
Community Health Centers (hcro),LOCATION_OF,Clinical Trials (resa),USES,Metal stent (medd),3.72e-07,18.18,8,34,0,9.88,2.0
Community Health Centers (hcro),LOCATION_OF,Clinical Trials (resa),USES,Treatment Protocols (resa),3.72e-07,14.41,8,147,0,8.44,2.0
Community Health Centers (hcro),LOCATION_OF,Clinical Trials (resa),USES,Drug eluting stent (medd),3.72e-07,16.63,8,38,0,9.68,2.0
Community Health Centers (hcro),LOCATION_OF,Clinical Trials (resa),USES,"Defibrillators, Implantable (medd)",3.72e-07,18.98,8,40,0,9.6,2.0
Community Health Centers (hcro),LOCATION_OF,Clinical Trials (resa),USES,"Stents, Vascular, Coronary (medd)",3.78e-07,18.78,8,13,0,12.92,2.0
Extraction (topp),USES,Insulin (horm),TREATS,Hospitalized Patients (humn),2.75e-06,8.93,21,11,0,16.76,4.0
Extraction (topp),USES,Insulin (horm),TREATS,Hyperglycemia (dsyn),6.5e-10,6.72,21,57,0,28.74,4.0
"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,25.1,51,18,0,24.35,1.0
Buffers (bacs),PART_OF,network (popg),USES,regulatory (rnlw),5.87e-08,10.94,9,119,0,9.68,3.0
Buffers (bacs),PART_OF,network (popg),USES,Sensors (medd),5.87e-08,10.81,9,6,0,10.0,3.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,34.32,11,33,0,14.67,1.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,34.87,11,16,0,18.56,9.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),6.31e-14,34.67,11,71,0,12.7,5.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),6.31e-14,48.51,11,35,0,14.46,21.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),6.31e-14,34.6,11,110,0,12.1,21.0
Polycystic Ovary Syndrome (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,33.93,11,37,0,14.27,1.0
Well adult (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),1.35e-06,9.46,9,136,0,9.6,1.0
Well adult (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),1.35e-06,8.59,9,188,0,9.43,1.0
Well adult (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Population Group (humn),3.88e-06,9.48,9,20,0,13.05,1.0
Entire uterosacral ligament (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,melanoma (neop),4.19e-08,26.08,7,45,0,8.09,2.0
Entire uterosacral ligament (bpoc),LOCATION_OF,Biopsy (diap),ISA,Diagnosis (hlca),4.23e-08,23.89,7,161,0,7.3,2.0
Entire uterosacral ligament (bpoc),LOCATION_OF,Biopsy (diap),ISA,Procedures (hlca),5.26e-07,24.01,7,81,0,7.6,2.0
Uric Acid (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.12e-07,25.5,7,16,0,10.06,8.0
Uric Acid (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.01e-06,30.66,7,9,0,12.44,8.0
Uric Acid (bacs),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.84e-07,23.05,7,31,0,8.58,8.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),2.19e-07,32.44,6,20,0,7.8,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.2e-07,29.62,6,65,0,6.55,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),USES,Treats (clas),5.93e-07,31.95,6,16,0,8.25,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.31e-06,32.2,6,13,0,8.77,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),USES,Classification (clas),2.3e-07,33.18,6,16,0,8.25,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.69e-06,38.59,6,8,0,10.5,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.18e-07,32.06,6,23,0,7.57,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),2.18e-07,32.96,6,22,0,7.64,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),1.1e-06,32.89,6,13,0,8.77,1.0
insulin sensitivity (patf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.19e-07,34.89,6,15,0,8.4,1.0
alpha-Fetoproteins (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),3.14e-06,31.42,5,33,0,5.76,1.0
alpha-Fetoproteins (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),7.57e-06,31.96,5,16,0,6.56,8.0
alpha-Fetoproteins (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.14e-06,31.77,5,71,0,5.35,5.0
alpha-Fetoproteins (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.14e-06,45.61,5,35,0,5.71,8.0
alpha-Fetoproteins (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.14e-06,31.69,5,110,0,5.23,8.0
alpha-Fetoproteins (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),3.14e-06,31.03,5,37,0,5.68,1.0
Roux-en-Y Gastric Bypass (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,29.4,27,12,0,17.33,1.0
Roux-en-Y Gastric Bypass (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,26.77,27,24,0,45.33,4.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),6.75e-09,16.85,9,33,0,11.45,1.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.44e-06,17.39,9,16,0,14.06,8.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),6.49e-09,17.19,9,71,0,10.14,5.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),6.49e-09,31.04,9,35,0,11.31,8.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),6.49e-09,17.12,9,110,0,9.74,8.0
High Density Lipoprotein Cholesterol (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),7.85e-09,16.46,9,37,0,11.19,1.0
Ratio (inpr),ISA,Measurement (ftcn),ISA,Techniques (ftcn),1.58e-12,2.72,36,116,0,47.17,5.0
Ratio (inpr),ISA,Measurement (ftcn),ISA,Health (idcn),1.58e-12,4.48,36,94,0,49.79,5.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),5.27e-07,15.02,8,18,0,11.56,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),2.27e-07,17.45,8,77,0,8.83,8.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),2.27e-07,15.53,8,33,0,9.94,5.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),2.29e-07,16.54,8,18,0,11.56,8.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),2.28e-07,19.78,8,15,0,12.27,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",2.27e-07,17.52,8,41,0,9.56,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),2.27e-07,16.06,8,30,0,10.13,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),2.27e-07,15.7,8,35,0,9.83,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),2.27e-07,20.08,8,27,0,10.37,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),4.18e-06,14.81,8,16,0,12.0,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),2.27e-07,17.5,8,22,0,10.91,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),2.48e-07,15.74,8,18,0,11.56,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),2.27e-07,19.61,8,19,0,11.37,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),3.28e-07,18.59,8,12,0,13.33,7.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),4.14e-07,24.3,8,9,0,15.11,8.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),2.27e-07,15.18,8,97,0,8.66,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),2.27e-07,16.2,8,68,0,8.94,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),2.27e-07,29.2,8,27,0,10.37,8.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),1.12e-06,19.34,8,10,0,14.4,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),2.27e-07,23.09,8,20,0,11.2,8.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.27e-07,20.18,8,19,0,11.37,8.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),2.27e-07,16.44,8,93,0,8.69,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),2.59e-07,16.34,8,16,0,12.0,5.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),7.1e-07,15.13,8,17,0,11.76,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),8.91e-07,19.67,8,10,0,14.4,8.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),2.3e-07,15.22,8,22,0,10.91,1.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),2.27e-07,17.04,8,24,0,10.67,8.0
Uric Acid (bacs),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),2.92e-06,18.27,8,10,0,14.4,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),6.67e-11,32.11,9,25,0,12.24,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),3.24e-10,36.02,9,15,0,14.4,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),4.97e-11,41.4,9,24,0,12.38,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),4.97e-11,32.03,9,46,0,10.76,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),PROCESS_OF,General Population (humn),6.94e-10,31.6,9,24,0,12.38,1.0
resistin|RETN (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),5.59e-10,33.44,9,18,0,13.5,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),4.97e-11,30.17,9,73,0,10.11,5.0
resistin|RETN (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),9.39e-08,30.77,9,24,0,12.38,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",4.97e-11,32.09,9,41,0,10.98,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),8.24e-10,32.86,9,19,0,13.26,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.97e-11,33.74,9,26,0,12.12,8.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),2.99e-07,58.06,8,18,0,11.56,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.7e-11,60.5,8,77,0,8.83,8.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),1.7e-11,58.57,8,33,0,9.94,5.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),1.73e-09,59.58,8,18,0,11.56,8.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),2.17e-10,62.83,8,15,0,12.27,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",1.7e-11,60.56,8,41,0,9.56,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),1.7e-11,59.1,8,30,0,10.13,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),1.7e-11,58.75,8,35,0,9.83,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),1.7e-11,63.12,8,27,0,10.37,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),3.96e-06,57.85,8,16,0,12.0,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),1.76e-11,60.54,8,22,0,10.91,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),2.02e-08,58.79,8,18,0,11.56,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),1.74e-11,62.66,8,19,0,11.37,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),1.01e-07,61.64,8,12,0,13.33,7.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),1.87e-07,67.35,8,9,0,15.11,8.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),1.7e-11,58.23,8,97,0,8.66,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),1.7e-11,59.24,8,68,0,8.94,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.7e-11,72.25,8,27,0,10.37,8.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),8.95e-07,62.39,8,10,0,14.4,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),1.7e-11,66.14,8,20,0,11.2,8.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),1.72e-11,63.23,8,19,0,11.37,8.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),1.7e-11,59.48,8,93,0,8.69,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),3.21e-08,59.38,8,16,0,12.0,5.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),4.83e-07,58.17,8,17,0,11.76,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),6.63e-07,62.71,8,10,0,14.4,8.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),2.81e-09,58.27,8,22,0,10.91,1.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),1.72e-11,60.09,8,24,0,10.67,8.0
Overweight (sosy),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),2.69e-06,61.31,8,10,0,14.4,8.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,American (popg),1.05e-10,33.59,9,17,0,13.76,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),AFFECTS,Depressed mood (fndg),1.53e-06,38.13,9,8,0,15.11,7.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Octogenarians (aggp),1.88e-06,34.65,9,9,0,18.0,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),CAUSES,Myocardial Infarction (dsyn),4.35e-09,34.19,9,13,0,15.23,11.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),CAUSES,follow-up (hlca),1.7e-07,32.48,9,12,0,15.75,11.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),CAUSES,"Death, Sudden (patf)",8.76e-11,35.37,9,19,0,13.26,11.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),CAUSES,Cessation of life (orgf),8.76e-11,32.24,9,251,0,9.32,11.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,High Risk Populations (popg),1.21e-07,36.13,9,10,0,17.1,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),8.76e-11,34.25,9,28,0,11.89,21.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,General Population (humn),8.76e-11,34.8,9,67,0,10.21,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Hospital specialist (humn),2.85e-10,30.74,9,20,0,13.05,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,General Population (humn),8.78e-11,35.66,9,18,0,13.5,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.34e-06,35.13,9,9,0,18.0,9.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,African American (popg),8.76e-11,31.85,9,49,0,10.65,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.75e-08,33.33,9,12,0,15.75,9.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Human Age Group (aggp),4.63e-08,35.13,9,11,0,16.36,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),8.76e-11,33.42,9,32,0,11.53,9.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Caucasoid Race (popg),8.76e-11,33.57,9,24,0,12.38,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),CAUSES,Cardiac Death (patf),8.76e-11,35.73,9,24,0,12.38,11.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,inpatient (humn),8.76e-11,32.07,9,37,0,11.19,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Physical findings (sosy),4.17e-06,31.2,9,11,0,16.36,9.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Veterans (popg),5.57e-09,31.99,9,15,0,14.4,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),8.76e-11,31.32,9,154,0,9.53,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),AFFECTS,Pathogenesis (patf),1.3e-07,28.92,9,21,0,12.86,7.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Participant (humn),8.76e-11,31.18,9,84,0,9.96,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),CAUSES,Hospital Readmissions (hlca),9.43e-11,39.39,9,14,0,14.79,11.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),8.76e-11,33.63,9,256,0,9.32,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),ISA,Cardiovascular Diseases (dsyn),8.76e-11,30.88,9,106,0,9.76,5.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),2.29e-07,33.46,9,11,0,16.36,21.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),CAUSES,Hospitalization (hlca),8.76e-11,34.95,9,249,0,9.33,11.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),8.76e-11,33.8,9,55,0,10.47,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Survivors (humn),8.76e-11,33.74,9,33,0,11.45,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),CAUSES,"Death, Sudden, Cardiac (patf)",5.97e-10,36.3,9,13,0,15.23,11.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),CAUSES,Diagnosis (hlca),5.46e-08,32.28,9,13,0,15.23,11.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),8.76e-11,32.5,9,34,0,11.38,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Population Group (humn),8.8e-11,36.33,9,17,0,13.76,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Participant (humn),8.76e-11,32.05,9,25,0,12.24,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),ISA,Heart Diseases (dsyn),8.76e-11,30.49,9,42,0,10.93,5.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),COMPLICATES,Acute myocardial infarction (dsyn),8.76e-11,33.06,9,42,0,10.93,21.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Sinus rhythm (fndg),8.76e-11,32.79,9,30,0,11.7,9.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),AFFECTS,Atrial Fibrillation (patf),2.91e-07,37.7,9,9,0,18.0,7.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),CAUSES,Hospital admission (hlca),8.76e-11,34.8,9,40,0,11.03,11.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Western society (popg),1.34e-06,35.13,9,9,0,18.0,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Anemia (dsyn),4.86e-07,34.31,9,10,0,17.1,9.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,cohort (humn),8.76e-11,34.06,9,119,0,9.68,1.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),COMPLICATES,Myocardial Infarction (dsyn),9.16e-11,32.12,9,20,0,13.05,21.0
Physical activity (dora),PREDISPOSES,Heart failure (dsyn),AFFECTS,Systemic arterial pressure (fndg),7.04e-09,31.87,9,15,0,14.4,7.0
Triglycerides (bacs),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.79e-10,31.96,12,23,0,18.26,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),1.05e-14,31.41,12,57,0,14.53,8.0
Triglycerides (bacs),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,39.88,12,9,0,15.75,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,34.42,45,16,0,21.69,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,39.59,45,9,0,10.8,8.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,31.98,45,31,0,52.36,8.0
Uric Acid (bacs),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",8.83e-07,46.29,5,16,0,6.56,9.0
Uric Acid (bacs),PREDISPOSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.78e-06,51.46,5,9,0,7.78,9.0
Uric Acid (bacs),PREDISPOSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),9.54e-07,43.84,5,31,0,5.81,21.0
Alcohol consumption (inbe),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.9e-09,9.97,15,20,0,26.25,1.0
Alcohol consumption (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.45e-09,7.16,15,65,0,18.46,1.0
Alcohol consumption (inbe),PROCESS_OF,cohort (humn),USES,Treats (clas),3.76e-07,9.48,15,16,0,29.06,1.0
Alcohol consumption (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.1e-06,9.74,15,13,0,24.27,1.0
Alcohol consumption (inbe),PROCESS_OF,cohort (humn),USES,Classification (clas),1.31e-08,10.72,15,16,0,29.06,1.0
Alcohol consumption (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,16.13,15,8,0,12.27,1.0
Alcohol consumption (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.08e-09,9.6,15,23,0,24.78,1.0
Alcohol consumption (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),9.22e-10,10.5,15,22,0,25.23,1.0
Alcohol consumption (inbe),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,10.43,15,13,0,24.27,1.0
Alcohol consumption (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.45e-09,12.42,15,15,0,30.0,1.0
Apnea (patf),PREDISPOSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),2.21e-06,37.86,5,16,0,6.56,21.0
Apnea (patf),PREDISPOSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.7e-06,48.07,5,26,0,5.96,21.0
Insulin Resistance (patf),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.79e-10,16.02,45,23,0,34.76,9.0
Insulin Resistance (patf),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),1.67e-22,15.46,45,57,0,80.53,9.0
Insulin Resistance (patf),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,23.93,45,9,0,10.8,9.0
Behavior (inbe),PREDISPOSES,Chronic Disease (dsyn),CAUSES,Cessation of life (orgf),3.17e-07,21.64,7,66,0,7.74,11.0
Behavior (inbe),PREDISPOSES,Chronic Disease (dsyn),PROCESS_OF,cohort (humn),5.96e-07,19.75,7,16,0,10.06,1.0
Behavior (inbe),PREDISPOSES,Chronic Disease (dsyn),CAUSES,Disability NOS (patf),5.17e-06,18.56,7,18,0,9.72,11.0
Sarcopenia (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,46.59,18,20,0,34.2,1.0
Sarcopenia (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,43.77,18,65,0,22.98,1.0
Sarcopenia (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,46.1,18,16,0,30.22,1.0
Sarcopenia (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,46.35,18,13,0,22.39,1.0
Sarcopenia (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,47.33,18,16,0,30.22,1.0
Sarcopenia (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,52.74,18,8,0,11.56,1.0
Sarcopenia (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,46.22,18,23,0,32.09,1.0
Sarcopenia (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,47.11,18,22,0,32.73,1.0
Sarcopenia (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,47.04,18,13,0,22.39,1.0
Sarcopenia (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,49.04,18,15,0,27.5,1.0
Intervention regimes (hlca),TREATS,Physical function (fndg),PROCESS_OF,Survivors (humn),2.17e-06,11.68,16,15,1,29.06,1.0
Participant (humn),LOCATION_OF,Lipids (lipd),PART_OF,Stratum corneum (tisu),9.49e-07,18.26,7,2,0,2.57,2.0
Sleep (orgf),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),2.62e-06,10.22,9,16,0,14.06,8.0
Sleep (orgf),ASSOCIATED_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),2.12e-06,20.43,9,26,0,12.12,8.0
Fat-free mass (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.05e-08,31.25,7,18,0,9.72,1.0
Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.34e-08,25.68,7,23,0,9.13,8.0
Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),5.31e-08,25.12,7,57,0,7.86,8.0
Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),3.44e-07,33.59,7,9,0,12.44,8.0
Diabetes Mellitus (dsyn),PREDISPOSES,Primary carcinoma of the liver cells (neop),ISA,Common Neoplasm (neop),2.54e-09,15.73,10,28,0,13.57,5.0
Diabetes Mellitus (dsyn),PREDISPOSES,Primary carcinoma of the liver cells (neop),ISA,Liver and Intrahepatic Biliary Tract Carcinoma (neop),2.53e-09,15.71,10,68,0,11.47,5.0
Diabetes Mellitus (dsyn),PREDISPOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,Hispanics (humn),4.88e-08,21.38,10,11,0,19.09,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,cohort (humn),2.53e-09,18.1,10,85,0,11.18,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,"Recipient, Transplant (podg)",2.53e-09,18.37,10,25,0,14.0,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Primary carcinoma of the liver cells (neop),ISA,Chronic liver disease NOS (dsyn),4.99e-06,15.28,10,16,0,16.25,5.0
Diabetes Mellitus (dsyn),PREDISPOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,Hepatitis C virus (virs),7.03e-08,15.93,10,18,0,15.56,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Primary carcinoma of the liver cells (neop),ISA,Liver neoplasms (neop),1.52e-08,14.92,10,26,0,13.85,5.0
Diabetes Mellitus (dsyn),PREDISPOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,African American (popg),6.79e-08,20.98,10,11,0,19.09,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,cohort (humn),2.53e-09,16.71,10,26,0,13.85,1.0
Diabetes Mellitus (dsyn),PREDISPOSES,Primary carcinoma of the liver cells (neop),COEXISTS_WITH,Fibrosis (patf),2.53e-09,15.13,10,69,0,11.45,9.0
Excessive weight gain (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.35e-09,70.87,7,18,0,9.72,1.0
Plasma specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Ischemic stroke (dsyn),4.25e-06,19.12,8,11,0,13.82,2.0
Plasma specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),7.43e-08,16.35,8,34,0,9.88,2.0
Plasma specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Septicemia (dsyn),7.4e-08,20.71,8,20,0,11.2,2.0
Plasma specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),ISA,Albumins (aapp),7.4e-08,17.95,8,30,0,10.13,2.0
Plasma specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),1.98e-07,18.47,8,15,0,12.27,2.0
Plasma specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),ISA,Acute-Phase Proteins (aapp),7.4e-08,15.54,8,77,0,8.83,2.0
Plasma specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),compared_with,procalcitonin (aapp),9.22e-08,18.76,8,16,0,12.0,2.0
Plasma specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Myocardial Infarction (dsyn),2.13e-06,17.8,8,14,0,12.57,2.0
resistin|RETN (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,20.93,27,16,0,25.48,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,26.1,27,9,0,12.0,8.0
resistin|RETN (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,18.49,27,31,0,50.52,8.0
Insulin (horm),COEXISTS_WITH,C-reactive protein (aapp),ASSOCIATED_WITH,Ischemic stroke (dsyn),4.17e-06,51.52,8,11,0,13.82,8.0
Insulin (horm),COEXISTS_WITH,C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),3.44e-10,48.75,8,34,0,9.88,9.0
Insulin (horm),COEXISTS_WITH,C-reactive protein (aapp),PREDISPOSES,Septicemia (dsyn),4.36e-11,53.11,8,20,0,11.2,9.0
Insulin (horm),COEXISTS_WITH,C-reactive protein (aapp),ISA,Albumins (aapp),4.28e-11,50.35,8,30,0,10.13,5.0
Insulin (horm),COEXISTS_WITH,C-reactive protein (aapp),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),1.24e-07,50.87,8,15,0,12.27,8.0
Insulin (horm),COEXISTS_WITH,C-reactive protein (aapp),ISA,Acute-Phase Proteins (aapp),4.29e-11,47.94,8,77,0,8.83,5.0
Insulin (horm),COEXISTS_WITH,C-reactive protein (aapp),compared_with,procalcitonin (aapp),1.82e-08,51.16,8,16,0,12.0,9.0
Insulin (horm),COEXISTS_WITH,C-reactive protein (aapp),PREDISPOSES,Myocardial Infarction (dsyn),2.06e-06,50.2,8,14,0,12.57,9.0
Interleukin-6 (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),8.31e-08,22.71,7,33,0,8.48,1.0
Interleukin-6 (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.51e-06,23.26,7,16,0,10.06,8.0
Interleukin-6 (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),8.29e-08,23.06,7,71,0,7.69,5.0
Interleukin-6 (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),8.29e-08,36.9,7,35,0,8.4,8.0
Interleukin-6 (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),8.29e-08,22.99,7,110,0,7.45,8.0
Interleukin-6 (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),8.42e-08,22.32,7,37,0,8.32,1.0
"Schools, Secondary (orgt)",LOCATION_OF,Clinical Trials (resa),USES,Stents (medd),5.32e-07,15.25,8,78,0,8.82,2.0
"Schools, Secondary (orgt)",LOCATION_OF,Clinical Trials (resa),USES,Probes (medd),5.7e-07,10.48,8,5,0,8.12,2.0
"Schools, Secondary (orgt)",LOCATION_OF,Clinical Trials (resa),USES,Metal stent (medd),5.32e-07,17.61,8,34,0,9.88,2.0
"Schools, Secondary (orgt)",LOCATION_OF,Clinical Trials (resa),USES,Treatment Protocols (resa),5.32e-07,13.85,8,147,0,8.44,2.0
"Schools, Secondary (orgt)",LOCATION_OF,Clinical Trials (resa),USES,Drug eluting stent (medd),5.32e-07,16.06,8,38,0,9.68,2.0
"Schools, Secondary (orgt)",LOCATION_OF,Clinical Trials (resa),USES,"Defibrillators, Implantable (medd)",5.32e-07,18.41,8,40,0,9.6,2.0
"Schools, Secondary (orgt)",LOCATION_OF,Clinical Trials (resa),USES,"Stents, Vascular, Coronary (medd)",5.38e-07,18.21,8,13,0,12.92,2.0
Insulin|INS (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.06e-07,12.84,10,16,0,16.25,8.0
Insulin|INS (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.99e-07,18.01,10,9,0,17.1,8.0
Insulin|INS (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.78e-07,10.4,10,31,0,13.23,8.0
C-reactive protein (aapp),PREDISPOSES,Oxidative Stress (comd),PROCESS_OF,Drosophila melanogaster (invt),5.3e-06,19.41,7,12,0,11.08,1.0
C-reactive protein (aapp),PREDISPOSES,Oxidative Stress (comd),COEXISTS_WITH,Critical Illness (dsyn),3.03e-06,23.2,7,9,0,12.44,9.0
Exercise (dora),PREVENTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular morbidity (dsyn),1.92e-08,17.11,11,23,0,16.26,21.0
Exercise (dora),PREVENTS,Systemic arterial pressure (fndg),PREDISPOSES,Cerebrovascular accident (dsyn),2.51e-07,11.15,11,18,0,17.72,21.0
Exercise (dora),PREVENTS,Systemic arterial pressure (fndg),PROCESS_OF,General Population (humn),1.38e-06,9.8,11,27,0,15.48,1.0
Exercise (dora),PREVENTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),1.92e-08,10.77,11,32,0,14.78,21.0
Exercise (dora),PREVENTS,Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),1.92e-08,10.2,11,39,0,14.1,1.0
Exercise (dora),PREVENTS,Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),7.37e-07,9.35,11,41,0,13.95,1.0
Exercise (dora),PREVENTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular event (fndg),1.93e-08,11.08,11,27,0,15.48,21.0
Body mass index procedure (diap),CAUSES,Infertility (dsyn),PROCESS_OF,Couples (humn),5.1e-26,75.54,17,16,0,31.06,1.0
Weight Gain (fndg),PREDISPOSES,Chronic Disease (dsyn),CAUSES,Cessation of life (orgf),2.35e-06,37.08,5,66,0,5.38,11.0
Weight Gain (fndg),PREDISPOSES,Chronic Disease (dsyn),PROCESS_OF,cohort (humn),2.63e-06,35.18,5,16,0,6.56,1.0
Weight Gain (fndg),PREDISPOSES,Chronic Disease (dsyn),CAUSES,Disability NOS (patf),7.2e-06,33.99,5,18,0,6.39,11.0
Intervention regimes (hlca),AFFECTS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,30.51,41,11,1,13.95,1.0
Intervention regimes (hlca),AFFECTS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,27.87,42,24,0,37.71,5.0
Insulin Resistance (patf),AFFECTS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,27.55,18,33,0,27.82,1.0
Insulin Resistance (patf),AFFECTS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,28.1,18,16,0,30.22,7.0
Insulin Resistance (patf),AFFECTS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),2.62e-21,27.9,18,71,0,22.56,5.0
Insulin Resistance (patf),AFFECTS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.62e-21,41.74,18,35,0,27.26,7.0
Insulin Resistance (patf),AFFECTS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.62e-21,27.83,18,110,0,20.95,7.0
Insulin Resistance (patf),AFFECTS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,27.16,18,37,0,26.76,1.0
Aggressive cancer (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Cancer Diagnosis (diap),5.49e-13,9.44,18,179,0,19.81,2.0
Aggressive cancer (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Localized Malignant Neoplasm (neop),1.25e-11,10.3,18,29,0,29.17,2.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),2.99e-07,18.04,13,18,0,22.39,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),6.05e-13,20.48,13,77,0,15.19,9.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),6.13e-13,18.56,13,33,0,18.12,5.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),1.72e-09,19.56,13,18,0,22.39,9.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),2.01e-10,22.81,13,15,0,24.27,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",6.05e-13,20.54,13,41,0,17.12,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),6.14e-13,19.09,13,30,0,18.63,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),6.05e-13,18.73,13,35,0,17.83,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),6.05e-13,23.11,13,27,0,19.26,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),3.96e-06,17.83,13,16,0,23.56,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),1.24e-12,20.52,13,22,0,20.68,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),2.02e-08,18.77,13,18,0,22.39,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),1.04e-12,22.64,13,19,0,21.89,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),1e-07,21.62,13,12,0,23.08,7.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),1.87e-07,27.33,13,9,0,15.23,9.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),6.05e-13,18.21,13,97,0,14.74,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),6.05e-13,19.22,13,68,0,15.49,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),6.05e-13,32.23,13,27,0,19.26,9.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),8.95e-07,22.37,13,10,0,17.69,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),6.06e-13,26.12,13,20,0,21.45,9.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),7.67e-13,23.21,13,19,0,21.89,9.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),6.05e-13,19.47,13,93,0,14.82,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),3.21e-08,19.37,13,16,0,23.56,5.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),4.83e-07,18.16,13,17,0,22.94,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),6.63e-07,22.69,13,10,0,17.69,9.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),2.8e-09,18.25,13,22,0,20.68,1.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),7.92e-13,20.07,13,24,0,20.04,9.0
Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),2.69e-06,21.3,13,10,0,17.69,9.0
"Fatty Acids, Nonesterified (lipd)",CAUSES,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.38e-06,8.7,12,16,0,21.0,9.0
"Fatty Acids, Nonesterified (lipd)",CAUSES,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),2.27e-06,13.87,12,9,0,15.75,9.0
"Fatty Acids, Nonesterified (lipd)",CAUSES,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.45e-06,6.25,12,31,0,16.65,11.0
Plication (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,42.88,8,12,0,13.33,1.0
Plication (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.04e-08,40.24,8,24,0,10.67,4.0
Carotid Arteries (bpoc),LOCATION_OF,Ultrasonography (diap),DIAGNOSES,"Aortic Aneurysm, Abdominal (dsyn)",9.95e-12,11.35,34,23,0,38.56,2.0
Carotid Arteries (bpoc),LOCATION_OF,Ultrasonography (diap),ISA,Medical Imaging (diap),2.76e-06,7.09,34,25,0,43.38,2.0
Carotid Arteries (bpoc),LOCATION_OF,Ultrasonography (diap),METHOD_OF,Early Diagnosis (diap),4.43e-06,8.53,34,30,0,56.47,2.0
Ambulatory Care Facilities (hcro),LOCATION_OF,Prospective Studies (qnco),ISA,Techniques (ftcn),2.12e-16,5.95,35,911,1,36.34,2.0
Ambulatory Care Facilities (hcro),LOCATION_OF,Prospective Studies (qnco),ISA,contextual factors (ftcn),1.3e-06,5.42,36,26,0,44.78,2.0
MEDITERRANEAN (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,15.12,16,20,0,28.8,1.0
MEDITERRANEAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,12.3,16,65,0,19.94,1.0
MEDITERRANEAN (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,14.62,16,16,0,32.0,1.0
MEDITERRANEAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,14.88,16,13,0,23.56,1.0
MEDITERRANEAN (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,15.86,16,16,0,32.0,1.0
MEDITERRANEAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,21.27,16,8,0,12.0,1.0
MEDITERRANEAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,14.74,16,23,0,27.13,1.0
MEDITERRANEAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,15.64,16,22,0,27.64,1.0
MEDITERRANEAN (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,15.57,16,13,0,23.56,1.0
MEDITERRANEAN (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,17.57,16,15,0,29.06,1.0
Left ventricular mass (fndg),PREDISPOSES,Cardiovascular event (fndg),PROCESS_OF,"Recipient, Transplant (podg)",1.74e-06,27.12,6,33,0,7.09,1.0
Left ventricular mass (fndg),PREDISPOSES,Cardiovascular event (fndg),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.74e-06,24.92,6,28,0,7.29,9.0
Left ventricular mass (fndg),PREDISPOSES,Cardiovascular event (fndg),PROCESS_OF,Survivors (humn),1.74e-06,24.86,6,15,0,8.4,1.0
Left ventricular mass (fndg),PREDISPOSES,Cardiovascular event (fndg),PROCESS_OF,High Risk Populations (popg),1.74e-06,27.12,6,20,0,7.8,1.0
Left ventricular mass (fndg),PREDISPOSES,Cardiovascular event (fndg),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.76e-06,25.0,6,13,0,8.77,9.0
Left ventricular mass (fndg),PREDISPOSES,Cardiovascular event (fndg),PROCESS_OF,cohort (humn),1.74e-06,25.82,6,101,0,6.36,1.0
Left ventricular mass (fndg),PREDISPOSES,Cardiovascular event (fndg),PROCESS_OF,General Population (humn),1.74e-06,26.52,6,91,0,6.4,1.0
Left ventricular mass (fndg),PREDISPOSES,Cardiovascular event (fndg),COEXISTS_WITH,Cardiovascular Diseases (dsyn),1.78e-06,30.12,6,10,0,9.6,9.0
Left ventricular mass (fndg),PREDISPOSES,Cardiovascular event (fndg),PROCESS_OF,Participant (humn),1.74e-06,25.29,6,69,0,6.52,1.0
Left ventricular mass (fndg),PREDISPOSES,Cardiovascular event (fndg),COEXISTS_WITH,Acute coronary syndrome (dsyn),5.2e-06,24.32,6,10,0,9.6,9.0
Left ventricular mass (fndg),PREDISPOSES,Cardiovascular event (fndg),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",1.75e-06,29.12,6,11,0,9.27,9.0
Left ventricular mass (fndg),PREDISPOSES,Cardiovascular event (fndg),PROCESS_OF,Control Groups (humn),1.78e-06,23.71,6,14,0,8.57,1.0
Left ventricular mass (fndg),PREDISPOSES,Cardiovascular event (fndg),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),1.74e-06,25.22,6,15,0,8.4,9.0
Veins (bpoc),PART_OF,Tail (bpoc),PART_OF,Pancreas (bpoc),8.39e-08,1.24,1,193,0,1.01,3.0
Antidiabetics (phsu),TREATS,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),2.29e-06,9.46,9,25,0,12.24,1.0
Antidiabetics (phsu),TREATS,Diabetic (fndg),PROCESS_OF,Participant (humn),2.33e-06,8.01,9,50,0,10.62,1.0
Antidiabetics (phsu),TREATS,Diabetic (fndg),PROCESS_OF,cohort (humn),2.28e-06,9.99,9,65,0,10.25,1.0
Antidiabetics (phsu),TREATS,Diabetic (fndg),PROCESS_OF,Population Group (humn),3.39e-06,12.6,9,11,0,16.36,1.0
Excretory function (phsf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,19.03,22,18,0,32.73,1.0
Obese build (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,25.75,13,33,0,18.12,1.0
Obese build (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,26.3,13,16,0,23.56,8.0
Obese build (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),4.63e-15,26.1,13,71,0,15.38,5.0
Obese build (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.63e-15,39.95,13,35,0,17.83,8.0
Obese build (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.63e-15,26.03,13,110,0,14.54,8.0
Obese build (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,25.37,13,37,0,17.57,1.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),3.19e-08,25.91,8,15,0,12.27,4.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),4.86e-08,28.27,8,12,0,13.33,1.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),1.26e-08,26.56,8,15,0,12.27,4.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),5.67e-09,25.81,8,28,0,10.29,4.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),5.7e-09,23.97,8,28,0,10.29,1.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),5.67e-09,26.76,8,66,0,8.97,4.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),5.67e-09,24.61,8,47,0,9.36,1.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),5.81e-09,23.89,8,27,0,10.37,4.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),9.01e-07,28.32,8,10,0,14.4,4.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),9.93e-09,28.89,8,13,0,12.92,4.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",5.7e-09,24.31,8,26,0,10.46,1.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),1.48e-07,23.96,8,19,0,11.37,4.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),1.09e-07,25.32,8,15,0,12.27,1.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (humn),6.56e-09,24.24,8,23,0,10.78,1.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),3.13e-06,23.85,8,16,0,12.0,1.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),2.15e-06,25.0,8,13,0,12.92,4.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),2.36e-06,23.71,8,17,0,11.76,4.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),5.67e-09,24.35,8,51,0,9.25,1.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),5.67e-09,24.84,8,145,0,8.44,4.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),5.67e-09,25.69,8,39,0,9.64,4.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.42e-06,25.32,8,12,0,13.33,1.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.77e-06,24.47,8,14,0,12.57,4.0
Leptin|LEP (aapp),TREATS,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.69e-07,28.65,8,10,0,14.4,4.0
Psoriasis (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),6.13e-09,35.41,7,33,0,8.48,1.0
Psoriasis (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.44e-06,35.96,7,16,0,10.06,9.0
Psoriasis (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),5.88e-09,35.76,7,71,0,7.69,5.0
Psoriasis (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),5.88e-09,49.6,7,35,0,8.4,9.0
Psoriasis (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.88e-09,35.69,7,110,0,7.45,9.0
Psoriasis (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),7.23e-09,35.02,7,37,0,8.32,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),4.01e-10,34.16,8,136,0,8.47,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),4.01e-10,33.29,8,188,0,8.34,1.0
"Sleep Apnea, Obstructive (dsyn)",PROCESS_OF,Caucasoid Race (popg),ISA,Population Group (humn),2.53e-06,34.18,8,20,0,11.2,1.0
Gastrectomy (topp),TREATS,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.1e-08,59.92,6,62,0,6.58,4.0
Gastrectomy (topp),TREATS,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.1e-08,70.51,6,17,0,8.12,4.0
Gastrectomy (topp),TREATS,Dyslipidemias (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.11e-08,62.21,6,19,0,7.89,4.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),1.21e-06,10.64,9,18,0,13.5,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),9.13e-07,13.08,9,77,0,10.05,8.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),9.13e-07,11.15,9,33,0,11.45,5.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),9.15e-07,12.16,9,18,0,13.5,8.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),9.13e-07,15.41,9,15,0,14.4,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",9.13e-07,13.14,9,41,0,10.98,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),9.13e-07,11.68,8,29,1,10.21,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),9.13e-07,11.33,9,35,0,11.31,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),9.13e-07,15.7,9,27,0,12.0,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),4.87e-06,10.43,9,16,0,14.06,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),9.13e-07,13.12,9,22,0,12.68,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),9.33e-07,11.37,9,18,0,13.5,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),9.13e-07,15.24,9,19,0,13.26,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),1.01e-06,14.22,9,12,0,15.75,7.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),1.1e-06,19.93,9,9,0,18.0,8.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),9.13e-07,10.81,7,95,2,7.52,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),9.13e-07,11.82,9,68,0,10.19,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),9.13e-07,24.83,9,27,0,12.0,8.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),1.81e-06,14.97,9,10,0,17.1,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),9.13e-07,18.72,9,20,0,13.05,8.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),9.13e-07,15.81,9,19,0,13.26,8.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),9.13e-07,12.06,9,93,0,9.87,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),9.45e-07,11.97,9,16,0,14.06,5.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),1.4e-06,10.76,9,17,0,13.76,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),1.58e-06,15.29,9,10,0,17.1,8.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),9.16e-07,10.85,9,22,0,12.68,1.0
Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),3.6e-06,13.89,9,10,0,17.1,8.0
Body Weight decreased (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),3.08e-09,25.62,8,33,0,9.94,1.0
Body Weight decreased (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,26.16,8,16,0,12.0,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),2.82e-09,25.96,8,71,0,8.9,5.0
Body Weight decreased (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.82e-09,39.81,8,35,0,9.83,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.82e-09,25.89,8,110,0,8.58,9.0
Body Weight decreased (fndg),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),4.18e-09,25.23,8,37,0,9.73,1.0
Body mass index procedure (diap),DIAGNOSES,Primary carcinoma of the liver cells (neop),ISA,Common Neoplasm (neop),1.19e-10,78.82,7,28,0,8.75,5.0
Body mass index procedure (diap),DIAGNOSES,Primary carcinoma of the liver cells (neop),ISA,Liver and Intrahepatic Biliary Tract Carcinoma (neop),1.09e-10,78.8,7,68,0,7.72,5.0
Body mass index procedure (diap),DIAGNOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,Hispanics (humn),4.64e-08,84.47,7,11,0,11.45,1.0
Body mass index procedure (diap),DIAGNOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,cohort (humn),1.09e-10,81.2,7,85,0,7.58,1.0
Body mass index procedure (diap),DIAGNOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,"Recipient, Transplant (podg)",1.09e-10,81.47,7,25,0,8.96,1.0
Body mass index procedure (diap),DIAGNOSES,Primary carcinoma of the liver cells (neop),ISA,Chronic liver disease NOS (dsyn),4.98e-06,78.37,7,16,0,10.06,5.0
Body mass index procedure (diap),DIAGNOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,Hepatitis C virus (virs),6.78e-08,79.03,7,18,0,9.72,1.0
Body mass index procedure (diap),DIAGNOSES,Primary carcinoma of the liver cells (neop),ISA,Liver neoplasms (neop),1.28e-08,78.01,7,26,0,8.88,5.0
Body mass index procedure (diap),DIAGNOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,African American (popg),6.55e-08,84.08,7,11,0,11.45,1.0
Body mass index procedure (diap),DIAGNOSES,Primary carcinoma of the liver cells (neop),PROCESS_OF,cohort (humn),1.09e-10,79.8,7,26,0,8.88,1.0
Body mass index procedure (diap),DIAGNOSES,Primary carcinoma of the liver cells (neop),COEXISTS_WITH,Fibrosis (patf),1.09e-10,78.22,7,69,0,7.71,9.0
Gastric banding (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,48.6,19,12,0,19.58,1.0
Gastric banding (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,45.96,19,24,0,34.04,4.0
Exercise (dora),TREATS,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.33e-08,21.96,8,23,0,10.78,4.0
Exercise (dora),TREATS,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),1.3e-08,21.4,8,57,0,9.12,4.0
Exercise (dora),TREATS,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),3.04e-07,29.87,8,9,0,15.11,4.0
Polycystic Ovary Syndrome (dsyn),CAUSES,Infertility (dsyn),PROCESS_OF,Couples (humn),3.11e-14,7.74,19,16,0,29.47,1.0
Glomerular Filtration Rate (ortf),AFFECTS,Age (orga),ASSOCIATED_WITH,Acute myocardial infarction (dsyn),1.6e-08,18.28,10,13,0,17.69,7.0
Glomerular Filtration Rate (ortf),AFFECTS,Age (orga),ASSOCIATED_WITH,Pneumonia (dsyn),5.32e-07,17.08,10,11,0,19.09,7.0
Glomerular Filtration Rate (ortf),AFFECTS,Age (orga),ASSOCIATED_WITH,Heart failure (dsyn),1.01e-08,18.67,10,20,0,15.0,7.0
Glomerular Filtration Rate (ortf),AFFECTS,Age (orga),ASSOCIATED_WITH,Cerebrovascular accident (dsyn),1.01e-08,14.88,10,31,0,13.23,7.0
Glomerular Filtration Rate (ortf),AFFECTS,Age (orga),ASSOCIATED_WITH,Myocardial Infarction (dsyn),1.86e-07,14.77,10,15,0,16.67,7.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),1.97e-08,29.65,8,20,0,11.2,1.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Disability NOS (patf),1.31e-09,32.8,8,36,0,9.78,9.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Respiration Disorders (dsyn),1.31e-09,29.43,8,59,0,9.08,5.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Respiratory physiology (ortf),2.19e-08,29.09,8,23,0,10.78,1.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Acute respiratory failure (dsyn),3.55e-07,32.09,8,12,0,13.33,9.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),1.31e-09,29.8,8,72,0,8.89,1.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Lung diseases (dsyn),1.31e-09,29.26,8,73,0,8.88,5.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.31e-09,30.6,8,50,0,9.28,1.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospital admission (hlca),4.65e-09,32.39,8,15,0,12.27,9.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Cessation of life (orgf),1.31e-09,32.32,8,184,0,8.35,9.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Outpatients (podg),2e-08,27.86,8,43,0,9.49,1.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,General Population (humn),1.31e-09,29.82,8,27,0,10.37,1.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Diagnosis (hlca),1.72e-07,33.87,8,11,0,13.82,9.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospitalization (hlca),1.31e-09,32.0,8,31,0,10.06,9.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Participant (humn),1.31e-09,29.16,8,70,0,8.91,1.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),COEXISTS_WITH,Smoker (fndg),2.4e-07,28.33,8,27,0,10.37,9.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Chronic Disease (dsyn),1.31e-09,30.31,8,46,0,9.39,5.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Malignant neoplasm of lung (neop),8.92e-08,30.03,8,17,0,11.76,9.0
Malnutrition (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Pneumonia (dsyn),4.47e-07,31.93,8,12,0,13.33,9.0
Magnetic Resonance Imaging (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.16e-09,9.19,34,18,0,27.53,6.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Males (popg),3.03e-30,14.84,180,38,0,46.02,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Surgical Patients (podg),1.3e-34,13.91,180,45,0,56.25,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Malnutrition (dsyn),1.68e-13,15.08,180,17,0,18.61,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),8.79e-16,10.15,180,26,0,29.76,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,"Infant, Premature (humn)",3.19e-12,11.69,180,18,0,19.8,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Animalia (anim),5.19e-14,6.2,180,53,0,68.61,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),COEXISTS_WITH,Glomerular Filtration Rate (ortf),1.85e-09,14.95,180,12,0,12.8,9.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Ischemic stroke (dsyn),5.21e-07,10.75,180,11,0,11.67,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Respiratory Distress Syndrome, Adult (dsyn)",6.5e-07,14.28,180,9,0,9.45,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Ischemia (dsyn),2.38e-06,7.85,180,14,0,15.09,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Apgar Score (orga),2.91e-07,15.72,180,9,0,9.45,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Proteinuria (dsyn),2.34e-06,15.23,180,8,0,8.36,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Survivors (humn),4.97e-15,11.77,180,22,0,24.69,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,African race (popg),1.4e-12,14.82,180,16,0,17.42,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,General Population (humn),5.23e-23,13.97,180,30,0,35.0,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Cancer Patient (podg),3.46e-10,8.59,180,20,0,22.22,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Surgical Patients (podg),5.44e-08,15.4,180,10,0,10.56,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,parent (humn),3.73e-12,9.23,180,22,0,24.69,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,member (popg),1.09e-12,10.7,180,20,0,22.22,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Rural Population (popg),1.87e-07,16.61,180,9,0,9.45,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Liver Failure, Acute (dsyn)",1.11e-06,10.15,180,11,0,11.67,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Japanese Population (popg),1.17e-07,17.65,180,9,0,9.45,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),6.29e-24,16.02,180,29,0,33.67,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Males (popg),1.08e-11,16.75,180,14,0,15.09,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Pulmonary arterial hypertension (dsyn),8.55e-09,13.15,180,12,0,12.8,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Human Age Group (aggp),1.53e-59,14.54,180,75,0,106.25,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",1.55e-36,13.65,179,47,1,59.34,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,American (popg),2.41e-13,10.15,180,22,0,24.69,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),2.74e-10,11.86,180,15,0,16.25,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,VICTIM (humn),5.66e-41,11.08,180,62,0,83.36,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,cohort (humn),5.5e-94,15.9,180,124,0,209.42,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Racial group (popg),8.33e-13,13.71,179,16,1,17.43,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Black race (popg),3.34e-29,12.35,180,41,0,50.34,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Physicians (humn),3.5e-06,7.15,180,16,0,17.42,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Myocardial Infarction (dsyn),1.01e-29,10.83,180,46,0,57.76,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Larva (invt),3.73e-11,7.62,180,26,0,29.76,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Participant (humn),5.5e-94,14.21,179,137,1,241.85,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Population Group (humn),1.41e-28,15.61,180,35,0,41.81,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Pregnant Women (popg),5.07e-11,10.26,180,18,0,19.8,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Survivors (humn),5.51e-94,12.22,180,135,0,236.25,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Long-Term Survivors (podg),7.61e-08,11.12,180,12,0,12.8,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,sex (orga),2.34e-06,15.23,180,8,0,8.36,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Pancreatitis (dsyn),2.56e-19,12.53,180,27,0,31.05,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Western society (popg),4.63e-08,7.33,180,20,0,22.22,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Primary carcinoma of the liver cells (neop),4.39e-07,14.95,180,9,0,9.45,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Black race (popg),6.03e-07,18.55,180,8,0,8.36,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Fishes (fish),1.16e-09,8.99,180,18,0,19.8,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,hypoglycemia (dsyn),8.95e-07,11.65,180,10,0,10.56,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Youth (humn),3.28e-09,7.71,180,21,0,23.45,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,"Infant, Premature (humn)",1.82e-42,11.13,180,64,0,86.76,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Middle Aged (aggp),2.71e-14,11.71,179,20,1,22.23,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,heart rate (orga),2.34e-06,15.23,180,8,0,8.36,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Renal function (ortf),3.25e-08,13.58,180,11,0,11.67,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Cardiomyopathies (dsyn),3.46e-06,10.36,180,10,0,10.56,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Sickle Cell Anemia (dsyn),7.61e-08,11.12,180,12,0,12.8,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Physical findings (sosy),4.05e-10,12.84,180,14,0,15.09,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Respiration Disorders (dsyn),1.53e-06,16.15,180,8,0,8.36,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Seizures (sosy),6.95e-07,9.55,180,12,0,12.8,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,"Recipient, Transplant (podg)",7.31e-94,12.34,179,130,1,224.41,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Donor person (humn),1.12e-12,7.88,180,28,0,32.36,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Septicemia (dsyn),1.4e-47,12.46,180,66,0,90.2,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,high-risk group (humn),5.04e-17,14.31,180,22,0,24.69,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Girls (popg),4.39e-06,10.15,180,10,0,10.56,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Heart failure (dsyn),1.69e-65,13.77,180,85,0,125.14,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,STEMI (dsyn),1.17e-07,17.65,180,9,0,9.45,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Human Age Group (aggp),9.29e-11,16.47,180,13,0,13.94,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),OCCURS_IN,year (tmco),2.69e-13,10.67,180,21,0,23.45,11.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Teens (popg),3.34e-07,9.24,180,13,0,13.94,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Vasculitis (dsyn),3.47e-06,14.44,180,8,0,8.36,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Veterans (popg),3.49e-20,14.33,180,26,0,29.76,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Females (humn),5.21e-18,13.54,180,24,0,27.2,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Hospitalized Patients (humn),2.45e-50,11.47,180,74,0,104.42,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Older Population (popg),2.78e-09,14.44,180,12,0,12.8,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Heart Diseases (dsyn),4.31e-12,11.51,180,18,0,19.8,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Boys (popg),1.11e-06,10.15,180,11,0,11.67,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Hypertension, Pulmonary (dsyn)",2.32e-08,12.15,180,12,0,12.8,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Infant, Very Low Birth Weight (dsyn)",2.31e-15,14.15,180,20,0,22.22,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,athlete (humn),4.88e-13,9.46,180,23,0,25.94,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,"Recipient, Transplant (podg)",4.01e-14,13.39,180,19,0,21.01,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,End stage renal failure (dsyn),2.91e-30,15.64,180,37,0,44.61,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Alaska Native (humn),4.86e-07,12.33,180,10,0,10.56,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Male gender (orga),1.85e-09,14.95,180,12,0,12.8,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Influenza (dsyn),2.29e-07,11.48,180,11,0,11.67,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Lupus Erythematosus, Systemic (dsyn)",5.91e-13,11.75,180,19,0,21.01,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Acquired Immunodeficiency Syndrome (dsyn),3.12e-13,9.6,180,23,0,25.94,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Prisoners (humn),2.78e-09,14.44,180,12,0,12.8,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Population Group (humn),1.05e-27,16.53,180,33,0,39.05,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),OCCURS_IN,month (tmco),1.62e-13,12.49,180,19,0,21.01,11.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Pulmonary Embolism (dsyn),2.31e-15,14.15,180,20,0,22.22,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Control Groups (humn),1.24e-48,11.58,178,69,2,95.75,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,cohort (humn),5.5e-94,16.35,180,625,0,231.84,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Felis catus (mamm),3.23e-08,7.92,180,18,0,19.8,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Workers (humn),9.94e-23,10.57,180,36,0,43.2,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,African American (popg),3.23e-32,12.85,180,44,0,54.76,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Hispanics (humn),1.77e-21,14.95,180,27,0,31.05,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,HIV Infections (dsyn),4.11e-10,9.38,180,18,0,19.8,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Glomerular Filtration Rate (ortf),4.97e-12,15.4,180,15,0,16.25,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,offender (popg),9.08e-08,12.4,180,11,0,11.67,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Participant (humn),2e-25,14.05,180,33,0,39.05,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Outpatients (podg),1.74e-12,13.15,180,17,0,18.61,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Liver diseases (dsyn),3.15e-13,13.15,180,18,0,19.8,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Peripheral Vascular Diseases (dsyn),1.87e-07,16.61,180,9,0,9.45,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Cancer Patient (podg),6.49e-42,8.32,180,85,0,125.14,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Myocardial Ischemia (dsyn),1.08e-08,11.46,180,13,0,13.94,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Epilepsy (dsyn),4.49e-43,12.11,180,61,0,81.67,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Racial group (popg),1.14e-11,14.54,180,15,0,16.25,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Research Personnel (humn),4.35e-10,8.9,180,19,0,21.01,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),1.59e-26,14.35,180,34,0,40.42,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,inpatient (humn),5.5e-94,14.52,180,152,0,280.36,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Metabolic syndrome (dsyn),6.03e-07,18.55,180,8,0,8.36,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,cohort (humn),4.17e-16,14.1,180,21,0,23.45,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Atrial Fibrillation (patf),7.58e-12,14.95,179,14,1,15.09,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Young adult (aggp),7.85e-53,9.77,180,89,0,133.01,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Households (humn),6.32e-19,13.73,180,25,0,28.47,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Caucasoid Race (popg),1.16e-29,12.19,180,42,0,51.8,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,General Population (humn),5.5e-94,14.42,179,157,1,294.7,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Cerebrovascular accident (dsyn),5.59e-40,11.72,180,58,0,76.69,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),COEXISTS_WITH,Pregnancy (orgf),2.47e-31,10.68,180,49,0,62.34,9.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Pneumonia (dsyn),3.69e-19,11.2,180,29,0,33.67,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Anemia (dsyn),2.8e-16,14.37,180,21,0,23.45,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Age (orga),5.5e-94,15.13,180,125,0,211.81,7.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Systemic Scleroderma (dsyn),6.63e-16,11.96,180,23,0,25.94,8.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Offspring (humn),9.48e-15,9.85,180,25,0,28.47,1.0
Gastrectomy (topp),TREATS,Female (orga),ISA,Gender (orga),3.84e-06,23.04,11,51,0,13.37,4.0
Assessment procedure (hlca),TREATS,Cystic Fibrosis (dsyn),ISA,Hereditary Diseases (dsyn),3.68e-06,7.98,9,79,0,10.03,4.0
Assessment procedure (hlca),TREATS,Cystic Fibrosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",4.26e-06,9.69,9,16,0,14.06,1.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Caucasoid Race (popg),3.81e-09,71.28,73,19,0,23.95,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Tuberculosis (dsyn),1.45e-09,69.0,73,42,0,66.16,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Thromboembolism (patf),1.03e-11,71.98,73,22,0,28.63,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Critical Illness (dsyn),2.48e-08,70.77,73,19,0,23.95,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,HIV Seropositivity (fndg),1.38e-07,70.85,73,17,0,20.96,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,inpatient (humn),1.03e-06,70.3,73,17,0,20.96,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Pulmonary Embolism (dsyn),4.18e-12,70.89,73,27,0,36.99,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Congestive heart failure (dsyn),1.31e-06,72.23,73,12,0,13.97,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Malaria (dsyn),1.67e-08,69.94,73,24,0,31.89,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Survivors (humn),1.4e-23,73.74,73,37,0,55.75,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Prognosis bad (fndg),2.03e-09,72.31,73,17,0,20.96,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),ADMINISTERED_TO,cohort (humn),1.51e-06,71.08,73,14,0,16.68,5.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Bacterial Endocarditis (dsyn),3.53e-08,72.81,73,14,0,16.68,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Human Age Group (aggp),1.19e-07,70.89,73,17,0,20.96,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Death (finding) (fndg),7.11e-19,77.75,73,24,0,31.89,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Heart failure (dsyn),1.53e-25,71.64,73,50,0,84.25,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Septic Shock (patf),1.88e-06,75.73,73,9,0,10.11,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),USES,Brain natriuretic peptide (aapp),5.52e-15,71.31,73,31,0,44.16,5.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Hamman-Rich syndrome (dsyn),7.25e-11,73.86,73,17,0,20.96,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Acute coronary syndrome (dsyn),2.4e-08,71.4,73,17,0,20.96,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Pneumonia (dsyn),3.14e-13,70.65,73,31,0,44.16,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Dissection of aorta (dsyn),3.03e-07,74.28,73,11,0,12.66,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Acute myocardial infarction (dsyn),1.42e-12,72.19,73,23,0,30.25,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Myocardial Infarction (dsyn),3.98e-06,69.8,73,18,0,22.44,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,cohort (humn),9.91e-67,71.56,73,131,0,113.68,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),TREATS,Septicemia (dsyn),7.64e-25,73.41,73,40,0,61.92,4.0
Body mass index procedure (diap),ISA,Diagnosis (hlca),METHOD_OF,Transplantation (topp),3.34e-16,72.37,73,29,0,40.52,5.0
Age (orga),ASSOCIATED_WITH,Anemia (dsyn),COEXISTS_WITH,Critical Illness (dsyn),9.47e-07,20.41,7,14,0,10.5,8.0
Age (orga),ASSOCIATED_WITH,Anemia (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),9.45e-07,21.98,7,19,0,9.58,8.0
Age (orga),ASSOCIATED_WITH,Anemia (dsyn),PROCESS_OF,cohort (humn),9.45e-07,19.52,7,48,0,8.02,1.0
Age (orga),ASSOCIATED_WITH,Anemia (dsyn),PROCESS_OF,Hospitalized Patients (humn),9.45e-07,18.56,7,22,0,9.23,1.0
Age (orga),ASSOCIATED_WITH,Anemia (dsyn),CAUSES,Cessation of life (orgf),3.78e-06,17.8,7,12,0,11.08,8.0
Age (orga),ASSOCIATED_WITH,Anemia (dsyn),PROCESS_OF,cohort (humn),1.08e-06,19.75,7,12,0,11.08,1.0
Age (orga),ASSOCIATED_WITH,Anemia (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",9.68e-07,16.02,7,23,0,9.13,1.0
Age (orga),ASSOCIATED_WITH,Anemia (dsyn),PROCESS_OF,Surgical Patients (podg),9.45e-07,19.64,7,20,0,9.45,1.0
Age (orga),ASSOCIATED_WITH,Anemia (dsyn),PROCESS_OF,General Population (humn),5.34e-06,19.21,7,10,0,11.9,1.0
Age (orga),ASSOCIATED_WITH,Anemia (dsyn),PROCESS_OF,Participant (humn),9.55e-07,16.74,7,20,0,9.45,1.0
Age (orga),ASSOCIATED_WITH,Anemia (dsyn),PROCESS_OF,Pregnant Women (popg),1.31e-06,16.57,7,17,0,9.88,1.0
Age (orga),ASSOCIATED_WITH,Anemia (dsyn),PROCESS_OF,Cancer Patient (podg),9.52e-07,14.97,7,40,0,8.22,1.0
Age (orga),ASSOCIATED_WITH,Anemia (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.34e-06,20.04,7,11,0,11.45,8.0
Age (orga),ASSOCIATED_WITH,Anemia (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",9.45e-07,15.94,7,52,0,7.94,8.0
Age (orga),ASSOCIATED_WITH,Anemia (dsyn),COEXISTS_WITH,Heart failure (dsyn),9.45e-07,20.48,7,63,0,7.78,8.0
Overweight (sosy),ASSOCIATED_WITH,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.76e-08,48.6,6,62,0,6.58,8.0
Overweight (sosy),ASSOCIATED_WITH,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.76e-08,59.19,6,17,0,8.12,8.0
Overweight (sosy),ASSOCIATED_WITH,Dyslipidemias (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.77e-08,50.89,6,19,0,7.89,8.0
Insulin Resistance (patf),AFFECTS,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.01e-06,19.84,6,23,0,7.57,7.0
Insulin Resistance (patf),AFFECTS,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),3.01e-06,19.28,6,57,0,6.63,7.0
Insulin Resistance (patf),AFFECTS,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),3.3e-06,27.75,6,9,0,10.0,7.0
Cartilage (tisu),PART_OF,Femur (bpoc),LOCATION_OF,Head (blor),1.67e-06,3.71,20,6,0,7.8,2.0
Cartilage (tisu),PART_OF,Femur (bpoc),LOCATION_OF,Neck (blor),6.65e-07,4.0,20,393,0,21.02,2.0
Cartilage (tisu),PART_OF,Femur (bpoc),LOCATION_OF,Slipped Epiphyses (dsyn),1.54e-09,3.63,20,1,0,1.05,2.0
calcification (patf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),6.45e-08,19.21,8,18,0,11.56,1.0
Atrial Fibrillation (patf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),3.54e-06,7.33,14,20,0,23.8,1.0
Atrial Fibrillation (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.54e-06,4.52,14,65,0,17.02,1.0
Atrial Fibrillation (patf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.91e-06,6.84,14,16,0,26.25,1.0
Atrial Fibrillation (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),7.63e-06,7.09,14,13,0,25.07,1.0
Atrial Fibrillation (patf),PROCESS_OF,cohort (humn),USES,Classification (clas),3.55e-06,8.08,14,16,0,26.25,1.0
Atrial Fibrillation (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),7.01e-06,13.48,14,8,0,12.57,1.0
Atrial Fibrillation (patf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),3.54e-06,6.96,14,23,0,22.52,1.0
Atrial Fibrillation (patf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),3.54e-06,7.85,14,22,0,22.91,1.0
Atrial Fibrillation (patf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),4.42e-06,7.78,14,13,0,25.07,1.0
Atrial Fibrillation (patf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),3.54e-06,9.78,14,15,0,27.07,1.0
Ultrasonography (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.67e-09,12.88,13,18,0,22.39,6.0
Entire radius (bpoc),LOCATION_OF,High Resolution Computed Tomography (diap),DIAGNOSES,Hamman-Rich syndrome (dsyn),1.76e-07,18.4,17,13,0,22.94,2.0
Thromboembolism (patf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.38e-07,10.53,11,20,0,17.05,1.0
Thromboembolism (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.4e-07,7.71,11,65,0,12.86,1.0
Thromboembolism (patf),PROCESS_OF,cohort (humn),USES,Treats (clas),5.13e-07,10.03,11,16,0,18.56,1.0
Thromboembolism (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.23e-06,10.29,11,13,0,20.31,1.0
Thromboembolism (patf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.49e-07,11.27,11,16,0,18.56,1.0
Thromboembolism (patf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.61e-06,16.68,11,8,0,13.82,1.0
Thromboembolism (patf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.37e-07,10.15,11,23,0,16.26,1.0
Thromboembolism (patf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.37e-07,11.05,11,22,0,16.5,1.0
Thromboembolism (patf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),1.02e-06,10.98,11,13,0,20.31,1.0
Thromboembolism (patf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.39e-07,12.97,11,15,0,19.07,1.0
Central obesity (acab),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,27.12,19,33,0,29.94,1.0
Central obesity (acab),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,27.66,19,16,0,29.47,9.0
Central obesity (acab),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),2.21e-22,27.47,19,71,0,24.08,5.0
Central obesity (acab),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.21e-22,41.31,19,35,0,29.31,9.0
Central obesity (acab),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.21e-22,27.39,19,110,0,22.28,9.0
Central obesity (acab),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,26.73,19,37,0,28.76,1.0
Microalbuminuria (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.6e-10,35.21,10,33,0,13.03,1.0
Microalbuminuria (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,35.75,10,16,0,16.25,9.0
Microalbuminuria (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),9.5e-13,35.55,10,71,0,11.41,5.0
Microalbuminuria (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),9.5e-13,49.4,10,35,0,12.86,9.0
Microalbuminuria (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),9.5e-13,35.48,10,110,0,10.91,9.0
Microalbuminuria (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.36e-09,34.82,10,37,0,12.7,1.0
C-reactive protein (aapp),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,34.54,23,33,0,39.03,1.0
C-reactive protein (aapp),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,35.08,23,16,0,27.13,9.0
C-reactive protein (aapp),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.33e-25,34.89,23,71,0,30.45,5.0
C-reactive protein (aapp),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.84e-29,48.73,23,35,0,38.11,21.0
C-reactive protein (aapp),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),2.84e-29,34.81,23,110,0,27.81,21.0
C-reactive protein (aapp),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,34.15,23,37,0,37.3,1.0
Bariatric Surgery (topp),compared_with,Medical therapy (topp),TREATS,Atrial Fibrillation (patf),6.54e-08,35.78,9,11,0,16.36,4.0
Bariatric Surgery (topp),compared_with,Medical therapy (topp),TREATS,Congestive heart failure (dsyn),7.85e-11,33.28,9,19,0,13.26,4.0
Bariatric Surgery (topp),compared_with,Medical therapy (topp),TREATS,Myocardial Ischemia (dsyn),7.87e-11,34.82,9,17,0,13.76,4.0
Bariatric Surgery (topp),compared_with,Medical therapy (topp),TREATS,Acute coronary syndrome (dsyn),1.02e-10,36.48,9,15,0,14.4,4.0
Bariatric Surgery (topp),compared_with,Medical therapy (topp),compared_with,Electric Countershock (topp),6.67e-11,38.69,9,16,0,14.06,17.0
Bariatric Surgery (topp),compared_with,Medical therapy (topp),TREATS,Heart failure (dsyn),6.61e-11,34.59,9,96,0,9.84,4.0
Bariatric Surgery (topp),compared_with,Medical therapy (topp),TREATS,Chronic heart failure (dsyn),9.57e-10,34.09,9,15,0,14.4,4.0
Bariatric Surgery (topp),compared_with,Medical therapy (topp),TREATS,Coronary Arteriosclerosis (dsyn),6.61e-11,33.21,9,54,0,10.5,4.0
Bariatric Surgery (topp),compared_with,Medical therapy (topp),USES,Angiotensin-Converting Enzyme Inhibitors (phsu),5.44e-08,38.42,9,10,0,17.1,6.0
Bariatric Surgery (topp),compared_with,Medical therapy (topp),USES,Adrenergic beta-Antagonists (phsu),7.53e-11,35.02,9,17,0,13.76,6.0
Bariatric Surgery (topp),compared_with,Medical therapy (topp),TREATS,"Ventricular Dysfunction, Left (patf)",6.63e-07,35.0,9,10,0,17.1,4.0
Bariatric Surgery (topp),compared_with,Medical therapy (topp),TREATS,Stable angina (dsyn),3.16e-09,35.53,9,13,0,15.23,4.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),2.64e-08,13.1,14,15,0,27.07,21.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),4.3e-08,15.46,14,12,0,22.29,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),7.05e-09,13.75,14,15,0,27.07,5.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),9.54e-11,13.0,14,28,0,21.0,5.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),1.33e-10,11.16,14,28,0,21.0,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),9.54e-11,13.95,14,66,0,16.97,5.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),9.54e-11,11.8,14,47,0,18.17,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),2.44e-10,11.08,14,27,0,21.26,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),8.95e-07,15.51,14,10,0,17.14,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),4.36e-09,16.08,14,13,0,25.07,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.28e-10,11.5,14,26,0,21.54,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),1.43e-07,11.14,14,19,0,24.32,5.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),1.03e-07,12.51,14,15,0,27.07,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (humn),9.86e-10,11.43,14,23,0,22.52,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),3.12e-06,11.04,14,16,0,26.25,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),2.14e-06,12.18,14,13,0,25.07,5.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),2.35e-06,10.89,14,17,0,25.53,5.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),9.54e-11,11.54,14,51,0,17.84,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),9.54e-11,12.03,14,145,0,15.35,11.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),9.54e-11,12.88,14,39,0,19.03,11.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.42e-06,12.51,14,12,0,22.29,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.76e-06,11.66,14,14,0,28.0,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.63e-07,15.83,14,10,0,17.14,9.0
Physical activity (dora),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Octogenarians (aggp),6.51e-07,28.49,9,9,0,18.0,1.0
Physical activity (dora),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Surgical Patients (podg),1.34e-08,23.24,9,16,0,14.06,1.0
Physical activity (dora),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,General Population (humn),1.11e-09,22.97,9,31,0,11.61,1.0
Physical activity (dora),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),1.11e-09,22.39,9,28,0,11.89,1.0
Physical activity (dora),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,African American (popg),1.11e-09,24.89,9,53,0,10.53,1.0
Physical activity (dora),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Caucasoid Race (popg),1.24e-06,21.03,9,19,0,13.26,1.0
Physical activity (dora),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Participant (humn),1.11e-09,22.79,9,33,0,11.45,1.0
Physical activity (dora),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Long-Term Survivors (podg),1.97e-09,23.82,9,17,0,13.76,1.0
Physical activity (dora),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),1.11e-09,20.48,8,99,1,8.65,1.0
Physical activity (dora),PREDISPOSES,Carcinoma of the Large Intestine (neop),ISA,Common Neoplasm (neop),4.77e-09,22.15,9,20,0,13.05,5.0
Physical activity (dora),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,cohort (humn),6.88e-08,21.92,9,18,0,13.5,1.0
Physical activity (dora),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,cohort (humn),1.11e-09,22.16,9,63,0,10.29,1.0
Physical activity (dora),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Black race (popg),2.33e-08,24.22,9,14,0,14.79,1.0
Non-alcoholic fatty liver (dsyn),ISA,Disease Progression (patf),PROCESS_OF,cohort (humn),1.12e-07,7.41,14,37,0,19.3,1.0
Non-alcoholic fatty liver (dsyn),ISA,Disease Progression (patf),PROCESS_OF,Cancer Patient (podg),4.51e-06,10.37,14,10,0,17.14,1.0
Non-alcoholic fatty liver (dsyn),ISA,Disease Progression (patf),PROCESS_OF,Hepatitis C virus (virs),1.25e-06,7.68,14,16,0,26.25,1.0
Non-alcoholic fatty liver (dsyn),ISA,Disease Progression (patf),CAUSES,Cessation of life (orgf),1.12e-07,13.37,14,44,0,18.45,5.0
Non-alcoholic fatty liver (dsyn),ISA,Disease Progression (patf),COEXISTS_WITH,Hamman-Rich syndrome (dsyn),1.12e-07,11.49,14,17,0,25.53,5.0
Hyperglycemia (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.6e-10,19.48,12,33,0,16.36,1.0
Hyperglycemia (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,20.03,12,16,0,21.0,9.0
Hyperglycemia (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.47e-12,19.83,12,71,0,14.03,5.0
Hyperglycemia (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.47e-12,33.67,12,35,0,16.11,9.0
Hyperglycemia (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.47e-12,19.76,12,110,0,13.31,9.0
Hyperglycemia (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.36e-09,19.09,12,37,0,15.89,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Depressive disorder (mobd),PROCESS_OF,CARDIAC PATIENT (podg),4.51e-07,27.95,7,13,0,10.77,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Depressive disorder (mobd),AFFECTS,Cessation of life (orgf),1.62e-06,29.89,7,10,0,11.9,7.0
Smoking (inbe),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,10.88,30,18,0,28.8,1.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Chronic heart failure (dsyn),2.81e-09,25.95,11,12,0,21.08,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Diabetic (fndg),3.66e-11,20.08,11,25,0,15.84,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Myocardial Infarction (dsyn),3.55e-11,22.63,11,29,0,15.17,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Cardiac Death (patf),4.68e-11,26.05,11,15,0,19.07,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),METHOD_OF,Revascularization - action (topp),4.22e-11,23.72,11,17,0,18.12,11.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,General Population (humn),3.34e-07,20.75,11,13,0,20.31,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Adverse event (fndg),4.76e-07,20.01,11,14,0,19.64,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Control Groups (humn),3.55e-11,17.94,11,84,0,12.44,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Sinus rhythm (fndg),6.67e-11,18.99,11,27,0,15.48,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Cerebrovascular accident (dsyn),3.6e-11,20.26,11,25,0,15.84,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Heart failure (dsyn),3.55e-11,24.28,11,78,0,12.55,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Acute myocardial infarction (dsyn),4.46e-07,21.35,11,12,0,21.08,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),METHOD_OF,Transplantation (topp),3.46e-06,21.87,11,10,0,19.09,11.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Ischemic stroke (dsyn),2.69e-06,22.09,11,10,0,19.09,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Acute heart failure (dsyn),6.03e-07,30.07,11,8,0,13.82,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Coronary Arteriosclerosis (dsyn),1.36e-08,21.81,11,14,0,19.64,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,cohort (humn),3.55e-11,20.87,11,331,0,11.37,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Participant (humn),3.55e-11,18.49,11,55,0,13.2,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),1.31e-06,20.69,11,12,0,21.08,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Atrial Fibrillation (patf),3.55e-11,21.74,11,27,0,15.48,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Survivors (humn),3.55e-11,22.9,11,43,0,13.81,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Survivors (humn),3.55e-11,23.68,11,270,0,11.45,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Ejection fraction (fndg),4.31e-09,21.67,11,15,0,19.07,4.0
Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),TREATS,Acute coronary syndrome (dsyn),7.22e-11,23.67,11,16,0,18.56,4.0
Glomerular Filtration Rate (ortf),PROCESS_OF,Renal function (ortf),PROCESS_OF,Survivors (humn),1.31e-06,12.12,11,27,0,15.48,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,Renal function (ortf),PROCESS_OF,cohort (humn),1.31e-06,8.31,11,23,0,16.26,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,Renal function (ortf),PROCESS_OF,"Recipient, Transplant (podg)",1.34e-06,6.6,11,41,0,13.95,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,Renal function (ortf),PROCESS_OF,Hospitalized Patients (humn),5.39e-06,9.38,11,12,0,21.08,1.0
Intervention regimes (hlca),PREVENTS,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.15e-10,24.92,10,22,0,14.55,9.0
Intervention regimes (hlca),PREVENTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),2.37e-10,24.35,10,17,0,15.88,1.0
Intervention regimes (hlca),PREVENTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.3e-08,20.41,10,27,0,13.7,1.0
Intervention regimes (hlca),PREVENTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.39e-08,23.37,10,15,0,16.67,1.0
Intervention regimes (hlca),PREVENTS,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),2.51e-10,21.57,10,24,0,14.17,21.0
Intervention regimes (hlca),PREVENTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.15e-10,21.19,10,34,0,12.94,1.0
Intervention regimes (hlca),PREVENTS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),1.15e-10,22.62,10,40,0,12.5,1.0
Intervention regimes (hlca),PREVENTS,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.33e-09,29.34,10,12,0,18.33,9.0
Encounter due to puberty (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),3.82e-09,27.36,8,20,0,11.2,1.0
Encounter due to puberty (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),5.36e-09,24.54,8,65,0,8.98,1.0
Encounter due to puberty (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.78e-07,26.87,8,16,0,12.0,1.0
Encounter due to puberty (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.1e-06,27.12,8,13,0,12.92,1.0
Encounter due to puberty (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.51e-08,28.1,8,16,0,12.0,1.0
Encounter due to puberty (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,33.51,8,8,0,16.0,1.0
Encounter due to puberty (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),3e-09,26.98,8,23,0,10.78,1.0
Encounter due to puberty (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),2.84e-09,27.88,8,22,0,10.91,1.0
Encounter due to puberty (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.87e-07,27.81,8,13,0,12.92,1.0
Encounter due to puberty (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),4.37e-09,29.81,8,15,0,12.27,1.0
Body mass index procedure (diap),DIAGNOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,65.28,10,33,0,13.03,1.0
Body mass index procedure (diap),DIAGNOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,65.83,10,16,0,16.25,9.0
Body mass index procedure (diap),DIAGNOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),8.51e-15,65.63,10,71,0,11.41,5.0
Body mass index procedure (diap),DIAGNOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),8.51e-15,79.47,10,35,0,12.86,18.0
Body mass index procedure (diap),DIAGNOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),8.51e-15,65.56,10,110,0,10.91,18.0
Body mass index procedure (diap),DIAGNOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,64.89,10,37,0,12.7,1.0
Medical exam (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),1.17e-09,22.88,11,18,0,17.72,6.0
liraglutide (gngm),CAUSES,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.08e-06,23.44,8,12,0,13.33,1.0
liraglutide (gngm),CAUSES,Body Weight decreased (fndg),ISA,Physical findings (sosy),8.33e-08,20.81,8,24,0,10.67,5.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,21.38,19,9,0,13.26,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),4.14e-18,20.44,19,194,0,20.86,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,19.16,19,17,0,32.21,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),4.41e-18,20.43,19,29,0,31.45,11.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,22.61,19,14,0,24.32,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,18.42,19,12,0,19.58,5.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),4.14e-18,17.24,19,48,0,26.52,11.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),4.29e-18,20.63,19,29,0,31.45,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),4.14e-18,17.68,19,98,0,22.68,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,16.34,19,24,0,34.04,9.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,22.75,19,10,0,15.26,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,15.11,19,37,0,28.76,7.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,16.91,19,20,0,37.05,9.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),4.14e-18,18.57,19,94,0,22.84,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,24.36,19,8,0,11.37,9.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,21.23,19,19,0,38.0,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,18.39,19,21,0,36.19,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,23.57,19,12,0,19.58,9.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,31.28,19,10,0,15.26,21.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,23.87,19,10,0,15.26,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,18.19,19,21,0,36.19,21.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,19.8,19,21,0,36.19,9.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.44e-17,17.92,19,32,0,30.28,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,25.28,19,10,0,15.26,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),4.14e-18,24.25,19,39,0,28.26,9.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),4.14e-18,28.23,19,44,0,27.2,11.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.14e-18,21.1,19,113,0,22.19,9.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,18.63,19,11,0,17.37,11.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,18.36,19,11,0,17.37,9.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,18.82,19,12,0,19.58,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,16.71,19,25,0,33.44,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",4.14e-18,22.39,19,87,0,23.15,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.2e-16,17.38,19,33,0,29.94,9.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),4.14e-18,20.11,19,41,0,27.8,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,20.28,19,21,0,36.19,1.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,17.95,19,21,0,36.19,9.0
Lipids (lipd),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),4.14e-18,18.89,19,1021,0,19.35,11.0
Assessment procedure (hlca),TREATS,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.1e-09,26.88,8,23,0,10.78,4.0
Assessment procedure (hlca),TREATS,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),2.82e-09,26.33,8,57,0,9.12,4.0
Assessment procedure (hlca),TREATS,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.93e-07,34.8,8,9,0,15.11,4.0
"Hospitals, University (mnob)",LOCATION_OF,Prospective Studies (qnco),ISA,Techniques (ftcn),2.32e-29,6.4,58,911,1,61.69,2.0
"Hospitals, University (mnob)",LOCATION_OF,Prospective Studies (qnco),ISA,contextual factors (ftcn),1.3e-06,5.86,59,26,0,37.46,2.0
Screening procedure (hlca),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,16.94,36,16,0,23.11,4.0
Screening procedure (hlca),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.39e-22,27.16,36,26,0,44.78,4.0
Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.28e-06,11.43,9,18,0,13.5,1.0
Insulin Resistance (patf),PROCESS_OF,Hispanics (humn),ISA,Ethnic group (popg),3.29e-11,23.03,10,226,0,10.44,1.0
Physical activity (dora),PREVENTS,Chronic Disease (dsyn),CAUSES,Cessation of life (orgf),1.59e-14,17.36,16,66,0,19.88,11.0
Physical activity (dora),PREVENTS,Chronic Disease (dsyn),PROCESS_OF,cohort (humn),2.79e-07,15.46,16,16,0,32.0,1.0
Physical activity (dora),PREVENTS,Chronic Disease (dsyn),CAUSES,Disability NOS (patf),4.85e-06,14.28,16,18,0,30.22,11.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,24.05,56,9,0,10.45,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.63e-57,23.11,56,194,0,72.16,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,21.84,56,17,0,22.16,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,23.1,55,28,1,42.25,11.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,25.29,56,14,0,17.5,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,21.1,56,12,0,14.57,5.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),9.81e-23,19.92,56,48,0,89.14,11.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.51e-19,23.31,56,29,0,44.02,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.74e-50,20.35,56,98,0,88.0,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,19.02,56,24,0,34.29,9.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,25.43,56,10,0,11.79,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,17.79,56,37,0,61.45,7.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,19.59,56,20,0,27.14,9.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),6.68e-54,21.24,56,94,0,89.36,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,27.03,56,8,0,9.14,9.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,23.91,56,19,0,25.45,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,21.06,56,21,0,28.88,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,26.24,56,12,0,14.57,9.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,33.96,56,10,0,11.79,21.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,26.54,56,10,0,11.79,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,20.86,56,21,0,28.88,21.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,22.47,56,21,0,28.88,9.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,20.6,56,32,0,50.29,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,27.96,56,10,0,11.79,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.28e-31,26.92,56,39,0,66.16,9.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.34e-39,30.9,56,44,0,78.57,11.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.63e-57,23.78,56,113,0,83.75,9.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,21.3,56,11,0,13.16,11.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,21.03,56,11,0,13.16,9.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,21.49,56,12,0,14.57,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,19.39,56,25,0,36.16,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.63e-57,25.06,56,87,0,92.05,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,20.05,56,33,0,52.45,9.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),9.09e-27,22.79,56,41,0,71.02,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,22.95,56,21,0,28.88,1.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,20.62,56,21,0,28.88,9.0
C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.63e-57,21.57,56,1021,0,59.07,11.0
Fatty Liver (dsyn),PROCESS_OF,Donor person (humn),LOCATION_OF,Antithymoglobulin (phsu),3.01e-06,25.45,6,17,0,8.12,1.0
Fatty Liver (dsyn),PROCESS_OF,Donor person (humn),LOCATION_OF,Cyclophosphamide (opco),6.51e-06,23.89,6,9,0,10.0,1.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.76e-11,60.41,9,25,0,12.24,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.75e-10,64.32,9,15,0,14.4,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),5.04e-13,69.69,9,24,0,12.38,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),5.04e-13,60.33,9,46,0,10.76,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),PROCESS_OF,General Population (humn),6.44e-10,59.9,9,24,0,12.38,1.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),5.1e-10,61.74,9,18,0,13.5,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),5.04e-13,58.47,9,73,0,10.11,5.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),9.39e-08,59.07,9,24,0,12.38,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",5.04e-13,60.38,9,41,0,10.98,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),7.75e-10,61.16,9,19,0,13.26,8.0
adiposity (orga),ASSOCIATED_WITH,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.09e-13,62.04,9,26,0,12.12,8.0
Atherosclerosis (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.88e-10,25.57,9,23,0,12.52,9.0
Atherosclerosis (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),3.09e-10,25.02,9,57,0,10.42,9.0
Atherosclerosis (dsyn),COEXISTS_WITH,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,33.49,9,9,0,18.0,9.0
Weight Gain (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,34.74,45,20,0,28.89,1.0
Weight Gain (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,31.92,45,65,0,76.15,1.0
Weight Gain (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,34.25,45,16,0,21.69,1.0
Weight Gain (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,34.5,45,13,0,16.76,1.0
Weight Gain (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,35.48,45,16,0,21.69,1.0
Weight Gain (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,40.89,45,8,0,9.42,1.0
Weight Gain (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,34.36,45,23,0,34.76,1.0
Weight Gain (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,35.26,45,22,0,32.76,1.0
Weight Gain (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,35.19,45,13,0,16.76,1.0
Weight Gain (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,37.19,45,15,0,20.0,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Participant (humn),8.85e-09,15.39,9,84,0,9.96,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Hyperglycemia (dsyn),3.61e-07,22.44,9,10,0,17.1,21.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Atrial Fibrillation (patf),3.12e-08,26.72,9,10,0,17.1,11.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Human Age Group (aggp),1.09e-08,18.49,9,18,0,13.5,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Population Group (humn),3.42e-06,19.07,9,11,0,16.36,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Vascular Diseases (dsyn),8.85e-09,17.41,9,38,0,11.13,5.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Cessation of life (orgf),8.85e-09,18.07,9,449,0,9.18,11.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Black race (popg),8.86e-09,18.1,9,24,0,12.38,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),8.85e-09,20.59,9,34,0,11.38,21.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Neurologist (humn),9.03e-09,16.46,9,31,0,11.61,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),8.85e-09,18.42,9,140,0,9.58,5.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),9.97e-09,18.3,9,19,0,13.26,21.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Survivors (humn),8.85e-09,14.81,9,330,0,9.25,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.3e-07,20.46,9,11,0,16.36,9.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Deglutition Disorders (dsyn),6.26e-07,16.26,9,22,0,12.68,21.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Depressive disorder (mobd),1.06e-08,15.68,9,41,0,10.98,21.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,Myocardial Infarction (dsyn),3.39e-08,20.55,9,13,0,15.23,9.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Young adult (aggp),9.13e-09,15.58,9,48,0,10.69,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,inpatient (humn),4.7e-06,15.62,9,27,0,12.0,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,VICTIM (humn),2.58e-07,15.44,9,38,0,11.13,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),OCCURS_IN,cohort (humn),9.49e-09,20.12,9,16,0,14.06,21.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Disability NOS (patf),8.85e-09,16.52,9,163,0,9.5,11.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,General Population (humn),8.85e-09,17.51,9,44,0,10.84,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),AFFECTS,Systemic arterial pressure (fndg),8.85e-09,17.69,9,27,0,12.0,7.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Heart failure (dsyn),8.86e-09,26.47,9,14,0,14.79,21.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Octogenarians (aggp),8.85e-09,26.72,9,15,0,14.4,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Control Groups (humn),1.25e-06,16.53,9,19,0,13.26,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Disability NOS (patf),8.85e-09,17.0,9,47,0,10.72,21.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),AFFECTS,Cessation of life (orgf),4.55e-07,19.55,9,12,0,15.75,7.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),CAUSES,Hospitalization (hlca),8.85e-09,22.5,9,24,0,12.38,11.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,Diabetic (fndg),8.87e-09,18.18,9,23,0,12.52,9.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PRECEDES,Pneumonia (dsyn),7.04e-07,19.26,9,12,0,15.75,21.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Ethnic group (popg),1.16e-08,19.4,9,16,0,14.06,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),8.85e-09,18.08,9,155,0,9.52,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Teams (humn),8.85e-09,16.5,9,42,0,10.93,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.16e-08,18.03,9,19,0,13.26,21.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Thrombosis (patf),8.92e-09,18.42,9,21,0,12.86,5.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),ISA,Cerebrovascular Disorders (patf),8.85e-09,17.0,9,41,0,10.98,5.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,Hospitalized Patients (humn),8.85e-09,18.38,9,64,0,10.27,1.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),8.85e-09,17.74,9,129,0,9.63,9.0
Alcohol consumption (inbe),PREDISPOSES,Cerebrovascular accident (dsyn),PROCESS_OF,cohort (humn),8.85e-09,18.17,9,39,0,11.08,1.0
Aortic valve replacement NOS (topp),TREATS,Aortic Valve Stenosis (dsyn),PROCESS_OF,Surgical Patients (podg),3.05e-06,9.58,34,42,1,61.52,1.0
Aortic valve replacement NOS (topp),TREATS,Aortic Valve Stenosis (dsyn),PROCESS_OF,Nonagenarians (aggp),3.24e-06,13.9,35,9,0,11.31,1.0
Aortic valve replacement NOS (topp),TREATS,Aortic Valve Stenosis (dsyn),PROCESS_OF,Octogenarians (aggp),3.05e-06,8.77,34,21,1,33.97,1.0
Aortic valve replacement NOS (topp),TREATS,Aortic Valve Stenosis (dsyn),ISA,Heart Valve Diseases (dsyn),3.05e-06,7.03,35,37,0,68.11,4.0
Ultrasound examination (diap),DIAGNOSES,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.57e-07,57.57,5,23,0,6.09,18.0
Ultrasound examination (diap),DIAGNOSES,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),3.56e-07,57.01,5,57,0,5.44,11.0
Ultrasound examination (diap),DIAGNOSES,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),6.47e-07,65.48,5,9,0,7.78,9.0
Waist circumference (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,44.11,63,33,0,50.29,1.0
Waist circumference (fndg),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,44.66,63,16,0,20.06,9.0
Waist circumference (fndg),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.33e-25,44.46,63,71,0,118.9,5.0
Waist circumference (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.96e-32,58.3,63,35,0,54.44,21.0
Waist circumference (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.09e-38,44.39,63,110,0,99.08,21.0
Waist circumference (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,43.72,63,37,0,58.73,1.0
endoscopy (diap),DIAGNOSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),1.45e-06,24.14,6,16,0,8.25,18.0
endoscopy (diap),DIAGNOSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),9.5e-07,34.35,6,26,0,7.38,18.0
Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,10.82,23,20,0,37.39,1.0
Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,8.0,23,65,0,31.14,1.0
Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,10.32,23,16,0,27.13,1.0
Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,10.58,23,13,0,20.35,1.0
Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,11.56,23,16,0,27.13,1.0
Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,16.97,23,8,0,10.78,1.0
Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,10.44,23,23,0,46.0,1.0
Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,11.34,23,22,0,43.04,1.0
Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,11.27,23,13,0,20.35,1.0
Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,13.26,23,15,0,24.78,1.0
Peripheral Vascular Diseases (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,13.99,28,18,0,29.57,1.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Atrial Fibrillation (patf),3.39e-07,7.11,77,21,0,26.73,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Primary Prevention (topp),1.5e-07,7.0,76,22,1,28.37,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,STEMI (dsyn),1.32e-31,11.72,77,47,0,75.69,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,General Population (humn),1.67e-08,7.22,77,24,0,31.48,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),PREVENTS,Premature Birth (patf),2.38e-16,9.44,77,30,0,41.69,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),PREVENTS,Death (finding) (fndg),2.65e-42,15.85,77,94,0,140.07,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,"Aortic Aneurysm, Abdominal (dsyn)",1.04e-14,13.49,77,20,0,25.19,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Hemorrhage (fndg),1.27e-31,8.6,77,65,0,119.87,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Pulmonary Embolism (dsyn),2.22e-08,10.35,77,14,0,16.55,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cerebrovascular accident (dsyn),6.7e-11,8.75,77,22,0,28.29,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Septicemia (dsyn),2.39e-28,12.18,77,41,0,62.83,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Malaria (dsyn),1.86e-22,7.66,77,56,0,96.73,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),PREVENTS,Stillbirth (patf),1.21e-08,13.13,77,12,0,13.87,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),5.82e-22,7.33,77,60,0,106.75,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Critical limb ischemia (patf),3.73e-26,11.35,77,40,0,60.78,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,"Shock, Cardiogenic (patf)",5.68e-10,12.89,77,14,0,16.55,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Cardiovascular Diseases (dsyn),9.55e-15,8.16,77,33,0,47.14,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Pneumonia (dsyn),9.32e-10,8.99,77,19,0,23.69,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Chronic heart failure (dsyn),3.58e-15,10.49,77,25,0,33.12,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),PREVENTS,"Death, Sudden, Cardiac (patf)",6.63e-07,12.32,77,10,0,11.3,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,high-risk group (humn),1.79e-11,7.91,77,27,0,36.47,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,"Pancreatitis, Acute Necrotizing (dsyn)",5.74e-14,12.49,77,20,0,25.19,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,"Stenosis, unspecified (patf)",8.57e-11,7.81,77,26,0,34.78,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Deglutition Disorders (dsyn),7.56e-07,8.24,77,15,0,17.92,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Depressed mood (fndg),1.87e-06,6.2,77,30,0,41.69,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,High Risk Populations (popg),3.35e-09,7.49,77,24,0,31.48,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Octogenarians (aggp),1.21e-07,14.49,77,10,0,11.3,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Acute myocardial infarction (dsyn),2.65e-42,9.32,77,104,0,134.01,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),USES,Losartan (orch),9.27e-37,9.69,77,65,0,119.87,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Peripheral Vascular Diseases (dsyn),3.57e-22,9.56,77,40,0,60.78,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Postpartum Hemorrhage (patf),6.54e-08,13.1,77,11,0,12.57,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Coronary Arteriosclerosis (dsyn),5.02e-30,8.78,77,60,0,106.75,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Anemia (dsyn),3.7e-07,7.85,77,17,0,20.75,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),PREVENTS,Adverse event (fndg),2.4e-07,8.28,77,16,0,19.32,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Ischemia (dsyn),5.68e-12,9.09,77,23,0,29.87,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Endoleak (patf),1.47e-20,12.1,77,30,0,41.69,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Carotid Stenosis (dsyn),1.76e-07,8.78,77,15,0,17.92,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Secondary prevention (topp),3.09e-06,7.78,77,15,0,17.92,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Malnutrition (dsyn),5.8e-09,8.16,77,20,0,25.19,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Systemic arterial pressure (fndg),1.25e-11,6.58,77,43,0,67.01,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Pre-Eclampsia (dsyn),1.09e-09,13.85,77,13,0,15.19,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,"Kidney Failure, Chronic (dsyn)",3.24e-28,9.37,77,52,0,87.12,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Myocardial Infarction (dsyn),2.65e-42,10.4,77,91,0,142.15,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Maternal Mortality (fndg),2.49e-17,20.78,77,19,0,23.69,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Mitral Valve Insufficiency (dsyn),6.68e-07,8.69,77,14,0,16.55,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Survivors (humn),2.27e-09,5.99,77,53,0,89.48,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,"Stroke, Acute (dsyn)",1.02e-06,8.14,77,15,0,17.92,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),PREVENTS,Perinatal death (fndg),6.1e-15,19.07,77,17,0,20.75,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,End stage renal failure (dsyn),1.25e-12,10.4,77,21,0,26.73,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Diabetic (fndg),1.71e-15,7.97,77,36,0,52.83,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),PREVENTS,Newborn death (patf),2.24e-08,17.35,77,10,0,11.3,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,"Hepatitis C, Chronic (dsyn)",6.5e-07,14.62,77,9,0,10.05,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),PREVENTS,Maternal Mortality (fndg),2.65e-42,19.98,77,80,0,151.11,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cardiovascular event (fndg),2.42e-17,10.71,77,28,0,38.18,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Death (finding) (fndg),4.01e-14,13.74,77,19,0,23.69,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Acute coronary syndrome (dsyn),5.74e-34,9.71,77,60,0,106.75,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Heart Arrest (patf),9.96e-17,10.72,77,27,0,36.47,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Disease Progression (patf),3.47e-07,8.52,77,15,0,17.92,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Critical Illness (dsyn),8.95e-24,9.74,77,42,0,64.91,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Diarrhea (sosy),2.07e-09,9.12,77,18,0,22.21,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Congestive heart failure (dsyn),6.68e-07,8.69,77,14,0,16.55,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),USES,Pravastatin (phsu),5.02e-20,11.69,77,30,0,41.69,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Septic Shock (patf),2.2e-09,13.16,77,13,0,15.19,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Control Groups (humn),3.03e-06,5.64,77,57,0,99.19,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Coronary heart disease (dsyn),1.52e-23,8.54,77,49,0,80.18,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),PREVENTS,Hemorrhage (fndg),2.4e-07,8.28,77,16,0,19.32,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Claudication (dsyn),1.74e-12,13.49,77,17,0,20.75,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,"Respiratory Distress Syndrome, Adult (dsyn)",8.54e-10,9.96,77,17,0,20.75,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Ischemic stroke (dsyn),4.76e-07,7.2,77,20,0,25.19,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),2.08e-28,6.31,77,123,0,125.2,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Upper gastrointestinal hemorrhage (dsyn),3.09e-14,15.29,77,18,0,22.21,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),METHOD_OF,Revascularization - action (topp),4.17e-16,11.81,77,24,0,31.48,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cardiovascular Diseases (dsyn),4.37e-16,8.46,77,34,0,49.01,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,cohort (humn),3.64e-14,7.4,77,38,0,56.75,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),PREVENTS,Cardiovascular morbidity (dsyn),2.26e-21,19.39,77,24,0,31.48,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Aortic Valve Stenosis (dsyn),4.06e-17,10.56,77,28,0,38.18,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Heart failure (dsyn),2.65e-42,9.18,77,103,0,134.56,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),PREVENTS,Malaria (dsyn),1.19e-07,7.9,77,18,0,22.21,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),AFFECTS,Maternal Mortality (fndg),1.4e-12,20.25,77,14,0,16.55,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),ISA,Procedures (hlca),2.32e-31,6.44,77,125,0,124.43,5.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,Fetofetal Transfusion (dsyn),4.39e-07,15.29,77,9,0,10.05,4.0
Health Promotion (hlca),ISA,Intervention regimes (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",1.33e-11,8.15,77,26,0,34.78,4.0
Insulin Resistance (patf),AFFECTS,cohort (humn),USES,Medicare (rnlw),1.71e-06,38.44,5,20,0,6.25,6.0
Insulin Resistance (patf),AFFECTS,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.71e-06,35.63,5,65,0,5.38,2.0
Insulin Resistance (patf),AFFECTS,cohort (humn),USES,Treats (clas),2.08e-06,37.95,5,16,0,6.56,6.0
Insulin Resistance (patf),AFFECTS,cohort (humn),LOCATION_OF,Calcium (bacs),5.8e-06,38.2,5,13,0,6.92,2.0
Insulin Resistance (patf),AFFECTS,cohort (humn),USES,Classification (clas),1.72e-06,39.18,5,16,0,6.56,6.0
Insulin Resistance (patf),AFFECTS,cohort (humn),LOCATION_OF,Sodium (elii),5.17e-06,44.59,5,8,0,8.12,2.0
Insulin Resistance (patf),AFFECTS,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.7e-06,38.07,5,23,0,6.09,2.0
Insulin Resistance (patf),AFFECTS,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.7e-06,38.96,5,22,0,6.14,2.0
Insulin Resistance (patf),AFFECTS,cohort (humn),USES,Tissue Microarray (resd),2.59e-06,38.89,5,13,0,6.92,6.0
Insulin Resistance (patf),AFFECTS,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.71e-06,40.89,5,15,0,6.67,2.0
Stimulation procedure (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,14.96,13,16,0,23.56,4.0
Stimulation procedure (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.11e-11,25.18,13,26,0,19.5,4.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,19.01,12,9,0,15.75,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.33e-10,18.07,12,194,0,12.74,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),4.69e-10,16.8,12,17,0,20.47,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.33e-10,18.06,12,29,0,16.97,11.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),3.32e-10,20.25,12,14,0,22.29,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,16.06,12,12,0,24.0,5.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.33e-10,14.88,12,48,0,15.0,11.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.33e-10,18.27,12,29,0,16.97,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.33e-10,15.31,12,98,0,13.47,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.46e-09,13.98,12,24,0,18.0,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,20.39,12,10,0,18.33,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.23e-08,12.75,12,37,0,15.89,7.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.87e-09,14.55,12,20,0,19.2,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.33e-10,16.2,12,94,0,13.53,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,21.99,12,8,0,13.33,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),1.33e-10,18.87,12,19,0,19.58,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.45e-10,16.02,12,21,0,18.86,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.91e-09,21.2,12,12,0,24.0,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.77e-09,28.92,12,10,0,18.33,21.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.19e-08,21.5,12,10,0,18.33,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.55e-10,15.82,12,21,0,18.86,21.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.33e-10,17.43,12,21,0,18.86,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.33e-10,15.56,12,32,0,16.5,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.54e-08,22.92,12,10,0,18.33,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.33e-10,21.88,12,39,0,15.69,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.33e-10,25.86,12,44,0,15.27,11.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.33e-10,18.74,12,113,0,13.27,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,16.26,12,11,0,21.08,11.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,15.99,12,11,0,21.08,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,16.45,12,12,0,24.0,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),2.5e-10,14.35,12,25,0,17.76,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.33e-10,20.02,12,87,0,13.66,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.33e-10,15.01,12,33,0,16.36,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.33e-10,17.75,12,41,0,15.51,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.33e-10,17.91,12,21,0,18.86,1.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",1.83e-10,15.58,12,21,0,18.86,9.0
"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.33e-10,16.53,12,1021,0,12.14,11.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),9.77e-07,7.19,23,15,0,24.78,18.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),9.93e-07,9.54,23,12,0,18.26,1.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),9.57e-07,7.84,23,15,0,24.78,5.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),9.5e-07,7.08,23,28,0,41.89,5.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),9.5e-07,5.24,23,28,0,41.89,1.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),9.5e-07,8.03,23,66,0,31.02,5.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),9.5e-07,5.88,23,47,0,34.26,1.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),9.5e-07,5.17,23,27,0,42.59,9.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),1.85e-06,9.59,23,10,0,14.35,9.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),9.54e-07,10.16,23,13,0,20.35,9.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",9.5e-07,5.58,23,26,0,43.35,1.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),1.09e-06,5.23,23,19,0,34.7,5.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),1.05e-06,6.59,23,15,0,24.78,1.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (humn),9.51e-07,5.51,23,23,0,46.0,1.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),4.07e-06,5.12,23,16,0,27.13,1.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),3.09e-06,6.27,23,13,0,20.35,5.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),3.3e-06,4.98,23,17,0,29.57,5.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),9.5e-07,5.62,23,51,0,33.37,1.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),9.5e-07,6.11,23,145,0,26.65,11.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),9.5e-07,6.97,23,39,0,36.56,11.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),4.37e-06,6.59,23,12,0,18.26,1.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),3.71e-06,5.74,23,14,0,22.52,9.0
Coronary angiography (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.61e-06,9.92,23,10,0,14.35,9.0
Nutritional Support (topp),TREATS,Malnutrition (dsyn),PROCESS_OF,Critically ill children (podg),3.51e-06,17.7,11,8,0,13.82,1.0
Nutritional Support (topp),TREATS,Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.84e-08,13.55,11,15,0,19.07,4.0
Nutritional Support (topp),TREATS,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),3.62e-08,12.25,11,18,0,17.72,1.0
Nutritional Support (topp),TREATS,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),3.5e-08,11.16,11,61,0,12.98,1.0
Nutritional Support (topp),TREATS,Malnutrition (dsyn),PROCESS_OF,Surgical Patients (podg),3.51e-08,11.2,11,24,0,16.04,1.0
Nutritional Support (topp),TREATS,Malnutrition (dsyn),PROCESS_OF,Cancer Patient (podg),4.39e-08,9.65,11,30,0,15.03,1.0
Nutritional Support (topp),TREATS,Malnutrition (dsyn),PROCESS_OF,inpatient (humn),3.51e-08,11.09,11,28,0,15.32,1.0
Nutritional Support (topp),TREATS,Malnutrition (dsyn),CAUSES,Cessation of life (orgf),3.5e-08,13.01,11,28,0,15.32,4.0
Nutritional Support (topp),TREATS,Malnutrition (dsyn),PROCESS_OF,cohort (humn),3.53e-08,14.27,11,16,0,18.56,1.0
Cessation of life (orgf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,7.33,39,20,0,30.26,1.0
Cessation of life (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,4.51,39,65,0,62.4,1.0
Cessation of life (orgf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,6.84,39,16,0,22.56,1.0
Cessation of life (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,7.09,39,13,0,17.33,1.0
Cessation of life (orgf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,8.07,39,16,0,22.56,1.0
Cessation of life (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,13.48,39,8,0,9.64,1.0
Cessation of life (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,6.95,39,23,0,36.56,1.0
Cessation of life (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,7.85,39,22,0,34.41,1.0
Cessation of life (orgf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,7.78,39,13,0,17.33,1.0
Cessation of life (orgf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,9.78,39,15,0,20.77,1.0
Body mass index (clna),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Critically ill children (podg),3.47e-06,76.33,28,8,0,10.29,1.0
Body mass index (clna),PREDISPOSES,Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.35e-09,72.18,28,15,0,23.04,9.0
Body mass index (clna),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.16e-09,70.88,28,18,0,29.57,1.0
Body mass index (clna),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),8.07e-28,69.79,28,61,0,40.85,1.0
Body mass index (clna),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Surgical Patients (podg),5.5e-11,69.83,28,24,0,44.57,1.0
Body mass index (clna),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,Cancer Patient (podg),8.8e-09,68.28,28,30,0,54.13,1.0
Body mass index (clna),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,inpatient (humn),1.52e-12,69.72,28,28,0,56.0,1.0
Body mass index (clna),PREDISPOSES,Malnutrition (dsyn),CAUSES,Cessation of life (orgf),2.24e-16,71.64,28,28,0,56.0,11.0
Body mass index (clna),PREDISPOSES,Malnutrition (dsyn),PROCESS_OF,cohort (humn),2.22e-10,72.9,28,16,0,25.14,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Males (popg),1.96e-14,13.97,33,38,0,61.66,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Surgical Patients (podg),1.96e-14,13.04,33,45,0,57.2,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Malnutrition (dsyn),1.87e-13,14.21,33,17,0,25.76,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Diabetes Mellitus (dsyn),2.05e-14,9.28,33,26,0,46.48,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,"Infant, Premature (humn)",3.21e-12,10.82,33,18,0,27.82,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Animalia (anim),7.14e-14,5.33,33,53,0,53.55,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),COEXISTS_WITH,Glomerular Filtration Rate (ortf),1.85e-09,14.08,33,12,0,16.36,9.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Ischemic stroke (dsyn),5.21e-07,9.88,33,11,0,14.67,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Respiratory Distress Syndrome, Adult (dsyn)",6.5e-07,13.41,33,9,0,11.45,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Ischemia (dsyn),2.38e-06,6.98,33,14,0,19.94,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Apgar Score (orga),2.91e-07,14.85,33,9,0,11.45,7.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Proteinuria (dsyn),2.34e-06,14.36,33,8,0,9.94,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Survivors (humn),2.46e-14,10.9,33,22,0,36.67,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,African race (popg),1.42e-12,13.95,33,16,0,23.76,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,General Population (humn),1.96e-14,13.1,33,30,0,57.27,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Cancer Patient (podg),3.46e-10,7.72,33,20,0,32.12,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Surgical Patients (podg),5.44e-08,14.53,33,10,0,13.03,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,parent (humn),3.75e-12,8.36,33,22,0,36.67,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,member (popg),1.11e-12,9.83,33,20,0,32.12,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Rural Population (popg),1.87e-07,15.74,33,9,0,11.45,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Liver Failure, Acute (dsyn)",1.11e-06,9.28,33,11,0,14.67,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Japanese Population (popg),1.17e-07,16.78,33,9,0,11.45,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),1.96e-14,15.15,33,29,0,54.48,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Males (popg),1.09e-11,15.88,33,14,0,19.94,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Pulmonary arterial hypertension (dsyn),8.55e-09,12.28,33,12,0,16.36,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Human Age Group (aggp),1.96e-14,13.67,33,75,0,47.52,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",1.96e-14,12.78,33,48,0,55.69,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,American (popg),2.6e-13,9.28,33,22,0,36.67,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Coronary Arteriosclerosis (dsyn),2.74e-10,10.99,33,15,0,21.82,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,VICTIM (humn),1.96e-14,10.21,32,61,1,48.79,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,cohort (humn),1.96e-14,15.03,33,124,0,41.78,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Racial group (popg),8.52e-13,12.84,33,17,0,25.76,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Black race (popg),1.96e-14,11.48,33,41,0,59.56,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Physicians (humn),3.5e-06,6.28,33,16,0,23.76,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Myocardial Infarction (dsyn),1.96e-14,9.96,33,46,0,56.67,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Larva (invt),3.73e-11,6.75,33,26,0,46.48,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Participant (humn),1.96e-14,13.34,32,137,1,39.47,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Population Group (humn),1.96e-14,14.74,33,35,0,64.11,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Pregnant Women (popg),5.08e-11,9.39,33,18,0,27.82,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Survivors (humn),1.96e-14,11.35,33,135,0,41.07,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Long-Term Survivors (podg),7.61e-08,10.25,33,12,0,16.36,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,sex (orga),2.34e-06,14.36,33,8,0,9.94,7.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Pancreatitis (dsyn),1.96e-14,11.66,33,27,0,49.09,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Western society (popg),4.63e-08,6.46,33,20,0,32.12,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Primary carcinoma of the liver cells (neop),4.39e-07,14.08,33,9,0,11.45,7.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Black race (popg),6.03e-07,17.68,33,8,0,9.94,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Fishes (fish),1.16e-09,8.12,33,18,0,27.82,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,hypoglycemia (dsyn),8.95e-07,10.78,33,10,0,13.03,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Youth (humn),3.28e-09,6.84,33,21,0,34.36,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,"Infant, Premature (humn)",1.96e-14,10.26,33,64,0,50.02,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Middle Aged (aggp),4.67e-14,10.84,33,21,0,34.36,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,heart rate (orga),2.34e-06,14.36,33,8,0,9.94,7.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Renal function (ortf),3.25e-08,12.71,33,11,0,14.67,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Cardiomyopathies (dsyn),3.46e-06,9.49,33,10,0,13.03,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Sickle Cell Anemia (dsyn),7.61e-08,10.25,33,12,0,16.36,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Physical findings (sosy),4.05e-10,11.97,33,14,0,19.94,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Respiration Disorders (dsyn),1.53e-06,15.28,33,8,0,9.94,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Seizures (sosy),6.95e-07,8.68,33,12,0,16.36,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,"Recipient, Transplant (podg)",1.96e-14,11.47,33,131,0,41.31,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Donor person (humn),1.14e-12,7.01,33,28,0,51.76,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Septicemia (dsyn),1.96e-14,11.59,33,66,0,49.5,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,high-risk group (humn),1.96e-14,13.44,33,22,0,36.67,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Girls (popg),4.39e-06,9.28,33,10,0,13.03,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Heart failure (dsyn),1.96e-14,12.9,33,85,0,45.81,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,STEMI (dsyn),1.17e-07,16.78,33,9,0,11.45,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Human Age Group (aggp),9.29e-11,15.6,33,13,0,18.12,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),OCCURS_IN,year (tmco),2.89e-13,9.8,33,21,0,34.36,11.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Teens (popg),3.34e-07,8.37,33,13,0,18.12,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Vasculitis (dsyn),3.47e-06,13.57,33,8,0,9.94,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Veterans (popg),1.96e-14,13.46,33,26,0,46.48,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Females (humn),1.96e-14,12.67,33,24,0,41.45,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Hospitalized Patients (humn),1.96e-14,10.6,33,74,0,47.72,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Older Population (popg),2.78e-09,13.57,33,12,0,16.36,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Heart Diseases (dsyn),4.33e-12,10.64,33,18,0,27.82,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Boys (popg),1.11e-06,9.28,33,11,0,14.67,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Hypertension, Pulmonary (dsyn)",2.32e-08,11.28,33,12,0,16.36,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Infant, Very Low Birth Weight (dsyn)",2.19e-14,13.28,33,20,0,32.12,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,athlete (humn),5.08e-13,8.59,33,23,0,39.03,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,"Recipient, Transplant (podg)",5.97e-14,12.52,33,19,0,29.94,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,End stage renal failure (dsyn),1.96e-14,14.77,33,37,0,62.43,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Alaska Native (humn),4.86e-07,11.46,33,10,0,13.03,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Male gender (orga),1.85e-09,14.08,33,12,0,16.36,7.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Influenza (dsyn),2.29e-07,10.61,33,11,0,14.67,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,"Lupus Erythematosus, Systemic (dsyn)",6.1e-13,10.88,33,19,0,29.94,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Acquired Immunodeficiency Syndrome (dsyn),3.31e-13,8.73,33,23,0,39.03,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Prisoners (humn),2.78e-09,13.57,33,12,0,16.36,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Population Group (humn),1.96e-14,15.66,33,33,0,66.0,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),OCCURS_IN,month (tmco),1.81e-13,11.62,33,19,0,29.94,11.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Pulmonary Embolism (dsyn),2.19e-14,13.28,33,20,0,32.12,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Control Groups (humn),1.96e-14,10.71,33,71,0,48.34,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,cohort (humn),1.96e-14,15.48,33,625,0,34.74,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),1.96e-14,11.25,33,31,0,60.12,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Felis catus (mamm),3.23e-08,7.05,33,18,0,27.82,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Workers (humn),1.96e-14,9.7,33,36,0,63.25,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,African American (popg),1.96e-14,11.98,33,44,0,57.75,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Hispanics (humn),1.96e-14,14.08,33,27,0,49.09,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,HIV Infections (dsyn),4.11e-10,8.51,33,18,0,27.82,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Glomerular Filtration Rate (ortf),4.99e-12,14.53,33,15,0,21.82,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,offender (popg),9.08e-08,11.53,33,11,0,14.67,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Participant (humn),1.96e-14,13.18,32,32,1,64.0,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Outpatients (podg),1.75e-12,12.28,33,17,0,25.76,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Liver diseases (dsyn),3.34e-13,12.28,33,18,0,27.82,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Peripheral Vascular Diseases (dsyn),1.87e-07,15.74,33,9,0,11.45,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Cancer Patient (podg),1.96e-14,7.45,33,85,0,45.81,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Myocardial Ischemia (dsyn),1.08e-08,10.59,33,13,0,18.12,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Epilepsy (dsyn),1.96e-14,11.24,33,61,0,50.85,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Racial group (popg),1.14e-11,13.67,33,15,0,21.82,7.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Research Personnel (humn),4.35e-10,8.03,33,19,0,29.94,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),1.96e-14,13.48,33,34,0,65.03,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,inpatient (humn),1.96e-14,13.65,33,152,0,40.16,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Metabolic syndrome (dsyn),6.03e-07,17.68,33,8,0,9.94,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,cohort (humn),2e-14,13.23,33,21,0,34.36,7.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Atrial Fibrillation (patf),7.6e-12,14.08,33,15,0,21.82,7.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Young adult (aggp),1.96e-14,8.9,33,89,0,45.24,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Households (humn),1.96e-14,12.86,33,25,0,43.94,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Caucasoid Race (popg),1.96e-14,11.32,33,42,0,58.93,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,General Population (humn),1.96e-14,13.55,33,158,0,39.89,1.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Cerebrovascular accident (dsyn),1.96e-14,10.85,33,58,0,51.78,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),COEXISTS_WITH,Pregnancy (orgf),1.96e-14,9.81,33,49,0,55.22,9.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Pneumonia (dsyn),1.96e-14,10.33,33,29,0,54.48,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Anemia (dsyn),1.99e-14,13.5,33,21,0,34.36,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),AFFECTS,Age (orga),1.96e-14,14.26,33,125,0,41.71,7.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),ASSOCIATED_WITH,Systemic Scleroderma (dsyn),2.02e-14,11.09,33,23,0,39.03,8.0
Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Offspring (humn),2.91e-14,8.98,33,25,0,43.94,1.0
Systolic blood pressure (ortf),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),5.98e-10,22.33,9,98,0,9.83,1.0
Systolic blood pressure (ortf),PROCESS_OF,African American (popg),ISA,Racial group (popg),5.98e-10,23.27,9,324,0,9.25,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),3.42e-06,17.84,8,9,0,15.11,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),8.27e-07,16.9,8,194,0,8.33,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),8.28e-07,15.62,8,17,0,11.76,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),8.27e-07,16.89,8,29,0,10.21,11.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),8.28e-07,19.07,8,14,0,12.57,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.89e-06,14.88,8,12,0,13.33,5.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),8.27e-07,13.7,8,48,0,9.33,11.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),8.27e-07,17.09,8,29,0,10.21,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),8.27e-07,14.14,8,98,0,8.65,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),8.3e-07,12.8,8,24,0,10.67,9.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1e-06,19.22,8,10,0,14.4,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),8.4e-07,11.57,8,37,0,9.73,7.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),8.34e-07,13.38,8,20,0,11.2,9.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),8.27e-07,15.03,8,94,0,8.68,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),3.17e-06,20.82,8,8,0,16.0,9.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),8.27e-07,17.69,8,19,0,11.37,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),8.27e-07,14.85,8,21,0,11.05,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),8.3e-07,20.03,8,12,0,13.33,9.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),8.3e-07,27.75,8,10,0,14.4,21.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),9.09e-07,20.33,8,10,0,14.4,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),8.28e-07,14.65,8,21,0,11.05,21.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),8.27e-07,16.26,8,21,0,11.05,9.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),8.27e-07,14.38,8,32,0,10.0,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),8.63e-07,21.74,8,10,0,14.4,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),8.27e-07,20.71,8,39,0,9.64,9.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),8.27e-07,24.69,8,44,0,9.45,11.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",8.27e-07,17.56,8,113,0,8.57,9.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),3.58e-06,15.09,8,11,0,13.82,11.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),5e-06,14.82,8,11,0,13.82,9.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),1.39e-06,15.28,8,12,0,13.33,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),8.28e-07,13.17,8,25,0,10.56,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",8.27e-07,18.85,8,87,0,8.74,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),8.27e-07,13.84,8,33,0,9.94,9.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),8.27e-07,16.57,8,41,0,9.56,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.27e-07,16.74,8,21,0,11.05,1.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",8.28e-07,14.41,8,21,0,11.05,9.0
Prophylactic treatment (topp),PREVENTS,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),8.27e-07,15.35,8,1021,0,8.06,11.0
Metabolic syndrome (dsyn),PROCESS_OF,Asians (popg),ISA,Population Group (humn),2.27e-11,32.12,15,29,0,22.76,1.0
Metabolic syndrome (dsyn),PROCESS_OF,Asians (popg),ISA,Ethnic group (popg),1.65e-18,30.71,15,124,0,16.81,1.0
Leptin|LEP (aapp),TREATS,Epilepsy (dsyn),CAUSES,Cessation of life (orgf),2.18e-07,35.98,6,55,0,6.65,4.0
Leptin|LEP (aapp),TREATS,Epilepsy (dsyn),PROCESS_OF,Survivors (humn),2.72e-07,34.46,6,13,0,8.77,1.0
Girls (popg),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Ischemic stroke (dsyn),4.18e-06,38.09,7,11,0,11.45,2.0
Girls (popg),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),6.18e-09,35.33,7,34,0,8.44,2.0
Girls (popg),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Septicemia (dsyn),5.88e-09,39.68,7,20,0,9.45,2.0
Girls (popg),LOCATION_OF,C-reactive protein (aapp),ISA,Albumins (aapp),5.88e-09,36.93,7,30,0,8.63,2.0
Girls (popg),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),1.3e-07,37.44,7,15,0,10.27,2.0
Girls (popg),LOCATION_OF,C-reactive protein (aapp),ISA,Acute-Phase Proteins (aapp),5.88e-09,34.51,7,77,0,7.64,2.0
Girls (popg),LOCATION_OF,C-reactive protein (aapp),compared_with,procalcitonin (aapp),2.4e-08,37.74,7,16,0,10.06,2.0
Girls (popg),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Myocardial Infarction (dsyn),2.06e-06,36.78,7,14,0,10.5,2.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,Hypertensive (fndg),PROCESS_OF,Participant (humn),6.04e-07,16.27,7,53,0,7.92,1.0
Clinic (hcro),LOCATION_OF,Prospective Studies (qnco),ISA,Techniques (ftcn),5.22e-11,8.3,17,912,0,17.32,2.0
Clinic (hcro),LOCATION_OF,Prospective Studies (qnco),ISA,contextual factors (ftcn),1.3e-06,7.76,17,26,0,28.12,2.0
Thinness (fndg),PROCESS_OF,student (prog),USES,Grade (clas),2.93e-09,37.78,7,7,0,14.0,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,American (popg),6.54e-09,72.15,6,17,0,8.12,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),AFFECTS,Depressed mood (fndg),1.54e-06,76.69,6,8,0,10.5,7.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Octogenarians (aggp),1.88e-06,73.21,6,9,0,10.0,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),CAUSES,Myocardial Infarction (dsyn),1.08e-08,72.75,6,13,0,8.77,11.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),CAUSES,follow-up (hlca),1.77e-07,71.04,6,12,0,9.0,11.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),CAUSES,"Death, Sudden (patf)",6.53e-09,73.93,6,19,0,7.89,11.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),CAUSES,Cessation of life (orgf),6.53e-09,70.8,6,251,0,6.14,11.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,High Risk Populations (popg),1.28e-07,74.69,6,10,0,9.6,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),6.53e-09,72.82,6,28,0,7.29,21.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,General Population (humn),6.53e-09,73.36,6,67,0,6.54,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Hospital specialist (humn),6.72e-09,69.3,6,20,0,7.8,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,General Population (humn),6.53e-09,74.22,6,18,0,8.0,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.34e-06,73.69,6,9,0,10.0,9.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,African American (popg),6.53e-09,70.41,6,49,0,6.73,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.39e-08,71.89,6,12,0,9.0,9.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Human Age Group (aggp),5.28e-08,73.69,6,11,0,9.27,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),6.53e-09,71.98,6,32,0,7.12,9.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Caucasoid Race (popg),6.53e-09,72.13,6,24,0,7.5,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),CAUSES,Cardiac Death (patf),6.53e-09,74.29,6,24,0,7.5,11.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,inpatient (humn),6.53e-09,70.63,6,37,0,6.97,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Physical findings (sosy),4.18e-06,69.76,6,11,0,9.27,9.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Veterans (popg),1.2e-08,70.55,6,15,0,8.4,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),6.53e-09,69.88,6,154,0,6.23,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),AFFECTS,Pathogenesis (patf),1.37e-07,67.48,6,21,0,7.71,7.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Participant (humn),6.53e-09,69.74,6,84,0,6.43,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),CAUSES,Hospital Readmissions (hlca),6.53e-09,77.95,6,14,0,8.57,11.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),6.53e-09,72.19,6,256,0,6.14,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),ISA,Cardiovascular Diseases (dsyn),6.53e-09,69.44,5,105,1,5.24,5.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),2.35e-07,72.02,6,11,0,9.27,21.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),CAUSES,Hospitalization (hlca),6.53e-09,73.51,6,249,0,6.14,11.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),6.53e-09,72.36,6,55,0,6.65,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Survivors (humn),6.53e-09,72.3,6,33,0,7.09,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),CAUSES,"Death, Sudden, Cardiac (patf)",7.04e-09,74.86,6,13,0,8.77,11.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),CAUSES,Diagnosis (hlca),6.1e-08,70.84,6,13,0,8.77,11.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),6.53e-09,71.06,6,34,0,7.06,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Population Group (humn),6.53e-09,74.89,6,17,0,8.12,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Participant (humn),6.53e-09,70.61,6,25,0,7.44,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),ISA,Heart Diseases (dsyn),6.53e-09,69.05,6,42,0,6.86,5.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),COMPLICATES,Acute myocardial infarction (dsyn),6.53e-09,71.62,6,42,0,6.86,21.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Sinus rhythm (fndg),6.53e-09,71.35,6,30,0,7.2,9.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),AFFECTS,Atrial Fibrillation (patf),2.97e-07,76.26,6,9,0,10.0,7.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),CAUSES,Hospital admission (hlca),6.53e-09,73.36,6,40,0,6.9,11.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,Western society (popg),1.34e-06,73.69,6,9,0,10.0,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),COEXISTS_WITH,Anemia (dsyn),4.92e-07,72.87,6,10,0,9.6,9.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),PROCESS_OF,cohort (humn),6.53e-09,72.62,6,119,0,6.3,1.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),COMPLICATES,Myocardial Infarction (dsyn),6.53e-09,70.69,6,20,0,7.8,21.0
Overweight (sosy),PREDISPOSES,Heart failure (dsyn),AFFECTS,Systemic arterial pressure (fndg),1.35e-08,70.43,6,15,0,8.4,7.0
adiposity (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,43.83,28,33,0,51.76,1.0
adiposity (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,44.38,28,16,0,25.14,8.0
adiposity (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.33e-25,44.18,28,71,0,39.04,5.0
adiposity (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.96e-32,58.02,28,35,0,50.4,8.0
adiposity (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),6.93e-38,44.11,28,110,0,35.13,8.0
adiposity (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,43.44,28,37,0,49.19,1.0
"Diet, Carbohydrate-Restricted (topp)",TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,22.96,17,12,0,20.47,1.0
"Diet, Carbohydrate-Restricted (topp)",TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,20.33,17,24,0,29.04,4.0
Gastric Bypass (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,41.77,33,12,0,16.36,1.0
Gastric Bypass (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,39.14,33,24,0,41.45,4.0
"Diabetes, Gestational (dsyn)",PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.19e-09,20.5,11,18,0,17.72,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,American (popg),6.22e-08,12.06,14,17,0,25.53,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),AFFECTS,Depressed mood (fndg),1.6e-06,16.6,14,8,0,12.57,7.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Octogenarians (aggp),1.94e-06,13.12,14,9,0,14.79,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,Myocardial Infarction (dsyn),6.65e-08,12.67,14,13,0,25.07,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,follow-up (hlca),2.32e-07,10.95,14,12,0,22.29,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,"Death, Sudden (patf)",6.22e-08,13.84,14,19,0,24.32,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,Cessation of life (orgf),6.22e-08,10.71,14,251,0,14.78,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,High Risk Populations (popg),1.83e-07,14.6,14,10,0,17.14,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),6.22e-08,12.73,14,28,0,21.0,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,General Population (humn),6.22e-08,13.27,14,67,0,16.93,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Hospital specialist (humn),6.24e-08,9.21,14,20,0,23.8,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,General Population (humn),6.22e-08,14.13,14,18,0,24.89,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.4e-06,13.6,14,9,0,14.79,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,African American (popg),6.22e-08,10.32,14,49,0,18.0,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.2e-07,11.8,14,12,0,22.29,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Human Age Group (aggp),1.08e-07,13.6,14,11,0,19.64,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),6.22e-08,11.89,14,32,0,20.12,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Caucasoid Race (popg),6.22e-08,12.05,14,24,0,22.17,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,Cardiac Death (patf),6.22e-08,14.2,14,24,0,22.17,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,inpatient (humn),6.22e-08,10.54,13,36,1,17.69,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),COEXISTS_WITH,Physical findings (sosy),4.24e-06,9.67,14,11,0,19.64,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Veterans (popg),6.77e-08,10.47,14,15,0,27.07,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),6.22e-08,9.79,13,153,1,14.1,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),AFFECTS,Pathogenesis (patf),1.92e-07,7.39,14,21,0,23.33,7.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Participant (humn),6.22e-08,9.65,14,84,0,16.33,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,Hospital Readmissions (hlca),6.22e-08,17.86,14,14,0,28.0,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),6.22e-08,12.1,14,256,0,14.77,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),ISA,Cardiovascular Diseases (dsyn),6.22e-08,9.35,14,106,0,15.85,5.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),2.91e-07,11.93,14,11,0,19.64,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,Hospitalization (hlca),6.22e-08,13.42,14,249,0,14.79,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),6.22e-08,12.27,14,55,0,17.56,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Survivors (humn),6.22e-08,12.21,14,33,0,19.94,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,"Death, Sudden, Cardiac (patf)",6.27e-08,14.77,14,13,0,25.07,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,Diagnosis (hlca),1.17e-07,10.75,14,13,0,25.07,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),6.22e-08,10.97,14,34,0,19.76,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Population Group (humn),6.22e-08,14.8,14,17,0,25.53,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Participant (humn),6.22e-08,10.52,14,25,0,21.84,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),ISA,Heart Diseases (dsyn),6.22e-08,8.97,14,42,0,18.67,5.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),COMPLICATES,Acute myocardial infarction (dsyn),6.22e-08,11.53,14,42,0,18.67,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),COEXISTS_WITH,Sinus rhythm (fndg),6.22e-08,11.26,14,30,0,20.53,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),AFFECTS,Atrial Fibrillation (patf),3.53e-07,16.17,14,9,0,14.79,7.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,Hospital admission (hlca),6.22e-08,13.27,14,40,0,18.9,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Western society (popg),1.4e-06,13.6,14,9,0,14.79,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),COEXISTS_WITH,Anemia (dsyn),5.48e-07,12.78,14,10,0,17.14,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,cohort (humn),6.22e-08,12.53,14,119,0,15.65,1.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),COMPLICATES,Myocardial Infarction (dsyn),6.22e-08,10.6,14,20,0,23.8,8.0
Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),AFFECTS,Systemic arterial pressure (fndg),6.92e-08,10.34,14,15,0,27.07,7.0
Glomerular Filtration Rate (ortf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.21e-06,8.51,12,20,0,19.2,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.22e-06,5.7,12,65,0,14.22,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,cohort (humn),USES,Treats (clas),1.59e-06,8.02,12,16,0,21.0,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),5.31e-06,8.28,12,13,0,23.08,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.23e-06,9.26,12,16,0,21.0,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),4.68e-06,14.66,12,8,0,13.33,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.21e-06,8.14,12,23,0,18.26,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.21e-06,9.04,12,22,0,18.55,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),2.1e-06,8.97,12,13,0,23.08,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.21e-06,10.96,12,15,0,21.6,1.0
Eating (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Survivors (humn),3.52e-08,17.64,9,15,0,14.4,1.0
Eating (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,"Twins, Dizygotic (humn)",2.41e-08,14.12,9,60,0,10.35,1.0
Eating (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Monoamniotic twins (podg),2.41e-08,14.99,9,33,0,11.45,1.0
Eating (orgf),COEXISTS_WITH,Pregnancy (orgf),PROCESS_OF,Singleton (humn),2.41e-08,13.63,9,357,0,9.23,1.0
Fibrosis (patf),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.6e-08,28.62,9,16,0,14.06,9.0
Fibrosis (patf),COEXISTS_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,33.79,9,9,0,18.0,9.0
Fibrosis (patf),COEXISTS_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.18e-07,26.17,9,31,0,11.61,9.0
Body mass index procedure (diap),ADMINISTERED_TO,Participant (humn),USES,Medicare (rnlw),4.02e-06,80.3,4,18,0,4.89,6.0
Bariatric Surgery (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,30.71,106,12,0,13.36,1.0
Bariatric Surgery (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,28.08,106,24,0,29.43,4.0
hypercholesterolemia (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.74e-06,22.25,6,20,0,7.8,1.0
hypercholesterolemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.74e-06,19.44,6,65,0,6.55,1.0
hypercholesterolemia (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),2.12e-06,21.76,6,16,0,8.25,1.0
hypercholesterolemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),5.83e-06,22.01,6,13,0,8.77,1.0
hypercholesterolemia (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.75e-06,22.99,6,16,0,8.25,1.0
hypercholesterolemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),5.21e-06,28.4,6,8,0,10.5,1.0
hypercholesterolemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.74e-06,21.88,6,23,0,7.57,1.0
hypercholesterolemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.74e-06,22.77,6,22,0,7.64,1.0
hypercholesterolemia (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),2.62e-06,22.7,6,13,0,8.77,1.0
hypercholesterolemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.74e-06,24.7,6,15,0,8.4,1.0
Body mass index procedure (diap),AFFECTS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,79.03,21,16,0,28.19,7.0
Body mass index procedure (diap),AFFECTS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.39e-22,89.24,21,26,0,37.96,7.0
Glomerular Filtration Rate (ortf),PROCESS_OF,Donor person (humn),LOCATION_OF,Antithymoglobulin (phsu),1.35e-06,16.35,9,17,0,13.76,1.0
Glomerular Filtration Rate (ortf),PROCESS_OF,Donor person (humn),LOCATION_OF,Cyclophosphamide (opco),4.85e-06,14.79,9,9,0,18.0,1.0
alpha-carotene (bacs),ISA,Carotenoids (bacs),ISA,Pigment (chvf),3.28e-07,6.71,11,4,0,5.45,5.0
Gastrectomy (topp),compared_with,Gastric Bypass (topp),TREATS,Body Weight decreased (fndg),2.38e-06,35.0,17,14,0,25.53,4.0
Gastrectomy (topp),compared_with,Gastric Bypass (topp),TREATS,"Obesity, Morbid (dsyn)",5.03e-16,33.86,17,48,0,23.02,4.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),2.63e-08,75.53,14,15,0,27.07,18.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),4.29e-08,77.89,14,12,0,22.29,1.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),6.96e-09,76.18,14,15,0,27.07,5.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),2.55e-15,75.43,14,28,0,21.0,5.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),3.74e-11,73.59,14,28,0,21.0,1.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),3.29e-21,76.38,14,66,0,16.97,5.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),4.69e-21,74.23,14,47,0,18.17,1.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),1.49e-10,73.51,14,27,0,21.26,9.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),8.95e-07,77.94,14,10,0,17.14,9.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),4.26e-09,78.51,14,13,0,25.07,9.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.23e-11,73.93,14,26,0,21.54,1.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),1.43e-07,73.57,14,19,0,24.32,5.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),1.03e-07,74.94,14,15,0,27.07,1.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (humn),8.9e-10,73.86,14,23,0,22.52,1.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),3.12e-06,73.47,14,16,0,26.25,1.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),2.14e-06,74.62,14,13,0,25.07,5.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),2.35e-06,73.32,14,17,0,25.53,5.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.6e-21,73.97,13,50,1,16.38,1.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),3.29e-21,74.46,14,145,0,15.35,11.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),7.48e-21,75.31,14,39,0,19.03,11.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.42e-06,74.94,14,12,0,22.29,1.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.76e-06,74.09,14,14,0,28.0,9.0
Body mass index procedure (diap),DIAGNOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.63e-07,78.26,14,10,0,17.14,9.0
Body mass index (clna),PREDISPOSES,Atherosclerosis (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.71e-11,72.1,19,25,0,33.44,21.0
Body mass index (clna),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.74e-10,76.0,19,15,0,26.84,9.0
Body mass index (clna),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular morbidity (dsyn),1.86e-20,81.38,19,24,0,34.04,11.0
Body mass index (clna),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cardiovascular Diseases (dsyn),7.39e-21,72.01,19,46,0,26.85,11.0
Body mass index (clna),PREDISPOSES,Atherosclerosis (dsyn),PROCESS_OF,General Population (humn),6.44e-10,71.58,19,24,0,34.04,1.0
Body mass index (clna),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Peripheral Vascular Diseases (dsyn),5.09e-10,73.43,19,18,0,35.05,11.0
Body mass index (clna),PREDISPOSES,Atherosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),2.11e-17,70.16,19,73,0,23.95,5.0
Body mass index (clna),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Cerebrovascular accident (dsyn),9.39e-08,70.75,19,24,0,34.04,11.0
Body mass index (clna),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Lupus Erythematosus, Systemic (dsyn)",9.04e-19,72.07,19,41,0,27.8,9.0
Body mass index (clna),PREDISPOSES,Atherosclerosis (dsyn),CAUSES,Coronary heart disease (dsyn),7.75e-10,72.84,19,19,0,38.0,11.0
Body mass index (clna),PREDISPOSES,Atherosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",5.88e-15,73.72,19,26,0,32.88,9.0
Vitamin D (phsu),ASSOCIATED_WITH,Vitamin D Deficiency (dsyn),PROCESS_OF,General Population (humn),2.02e-08,22.07,13,18,0,22.39,1.0
Bariatric Surgery (topp),TREATS,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),3.19e-09,30.48,15,25,0,24.0,1.0
Bariatric Surgery (topp),TREATS,Diabetic (fndg),PROCESS_OF,Participant (humn),4.47e-08,29.02,15,50,0,19.5,1.0
Bariatric Surgery (topp),TREATS,Diabetic (fndg),PROCESS_OF,cohort (humn),2.97e-18,31.0,15,65,0,18.46,1.0
Bariatric Surgery (topp),TREATS,Diabetic (fndg),PROCESS_OF,Population Group (humn),1.11e-06,33.61,15,11,0,19.07,1.0
Fatty Acid-Binding Proteins (aapp),PART_OF,Adipocytes (cell),PART_OF,Caucasoid Race (popg),2.49e-08,4.89,67,4,0,4.24,3.0
Fatty Acid-Binding Proteins (aapp),PART_OF,Adipocytes (cell),PART_OF,Stroma (bpoc),1.2e-08,4.92,67,7,0,7.73,3.0
Body mass index procedure (diap),DIAGNOSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,55.1,28,16,0,25.14,18.0
Body mass index procedure (diap),DIAGNOSES,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.39e-22,65.31,28,26,0,50.14,18.0
Gastroesophageal reflux disease (dsyn),ISA,Gastrointestinal Diseases (dsyn),CAUSES,Cessation of life (orgf),4.52e-06,16.69,8,9,0,15.11,5.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),PREDISPOSES,Heart failure (dsyn),3.98e-08,9.32,26,17,0,28.12,5.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),TREATS,Heart failure (dsyn),9.66e-12,11.51,26,19,0,32.88,4.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Acute decompensated heart failure (dsyn),7.75e-16,16.75,26,21,0,37.96,5.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),TREATS,Heart failure (dsyn),7.24e-16,9.79,26,101,0,32.69,4.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),ISA,Natriuretic Peptides (aapp),8.85e-07,8.21,26,18,0,30.46,5.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),TREATS,Septicemia (dsyn),2.32e-08,13.29,26,12,0,17.54,4.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Septic Shock (patf),5.44e-08,16.54,26,10,0,13.85,5.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),TREATS,Outpatients (podg),4.63e-08,14.29,26,11,0,15.65,4.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Chronic heart failure (dsyn),8.34e-13,11.96,26,20,0,35.38,5.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),TREATS,Heart failure (dsyn),8.91e-10,12.22,26,15,0,23.65,4.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),ASSOCIATED_WITH,Heart failure (dsyn),7.24e-16,10.85,26,71,0,35.52,5.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),TREATS,Congestive heart failure (dsyn),4.28e-11,8.92,26,25,0,49.04,4.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),TREATS,Acute decompensated heart failure (dsyn),5.44e-08,16.54,26,10,0,13.85,4.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),TREATS,Acute heart failure (dsyn),8.14e-09,11.75,26,14,0,21.54,4.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),TREATS,Chronic heart failure (dsyn),7.27e-16,11.29,26,30,0,48.53,4.0
Amino-terminal pro-brain natriuretic peptide (aapp),ISA,Brain natriuretic peptide (aapp),TREATS,Acute decompensated heart failure (dsyn),7.24e-16,13.82,26,36,0,44.78,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Survivors (humn),1.59e-15,17.16,25,34,0,43.38,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Fibrosis (patf),3.08e-10,17.54,25,21,0,38.64,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Septicemia (dsyn),7e-24,20.9,25,38,0,41.45,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Critical Illness (dsyn),1.04e-13,16.47,25,35,0,42.86,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,cohort (humn),9.34e-13,15.4,25,49,0,37.76,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Pneumonia (dsyn),7.6e-17,20.76,25,25,0,50.0,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Acute heart failure (dsyn),1.34e-06,22.39,25,9,0,12.24,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Surgical Patients (podg),5.48e-08,17.31,25,17,0,28.56,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),3.74e-10,15.74,25,33,0,43.94,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,End stage renal failure (dsyn),8.3e-11,19.27,25,18,0,30.96,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Pancreatitis (dsyn),2.98e-06,17.42,25,13,0,19.76,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Pulmonary Embolism (dsyn),4.76e-07,17.73,25,14,0,21.84,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Aortic Valve Stenosis (dsyn),4.77e-07,17.3,25,15,0,24.0,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Coronary heart disease (dsyn),8.81e-09,16.73,25,21,0,38.64,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Frailty (fndg),1.88e-06,21.91,25,9,0,12.24,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),USES,Brain natriuretic peptide (aapp),6.59e-09,18.53,25,16,0,26.24,5.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Chronic heart failure (dsyn),2.07e-09,18.01,25,18,0,30.96,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Heart failure (dsyn),6.94e-24,17.32,25,67,0,34.33,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,CARDIAC EVENT (dsyn),3.47e-06,23.67,25,8,0,10.56,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,Acute coronary syndrome (dsyn),7.06e-10,17.62,25,20,0,36.0,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,End stage liver disease (dsyn),2.79e-14,26.14,25,17,0,28.56,4.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),METHOD_OF,Transplantation (topp),9.45e-10,15.97,25,29,0,46.55,5.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),METHOD_OF,Percutaneous coronary intervention (topp),3.47e-06,23.67,25,8,0,10.56,5.0
Proinsulin (aapp),ISA,Insulin (horm),TREATS,Hospitalized Patients (humn),2.75e-06,15.31,12,11,0,21.08,4.0
Proinsulin (aapp),ISA,Insulin (horm),TREATS,Hyperglycemia (dsyn),3.38e-10,13.09,12,57,0,14.53,4.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.6e-06,18.88,10,9,0,17.1,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),7.98e-09,17.94,10,194,0,10.52,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),8.32e-09,16.67,10,17,0,15.88,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),7.98e-09,17.93,10,29,0,13.45,11.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),8.18e-09,20.12,10,14,0,17.14,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.07e-06,15.93,10,12,0,18.33,5.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),7.98e-09,14.75,10,48,0,12.08,11.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),7.98e-09,18.14,10,29,0,13.45,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),7.98e-09,15.18,10,98,0,11.02,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),1.03e-08,13.85,10,24,0,14.17,9.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.84e-07,20.26,10,10,0,20.0,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),2.01e-08,12.62,10,37,0,12.7,7.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.47e-08,14.42,10,20,0,15.0,9.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),7.98e-09,16.07,10,94,0,11.06,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.35e-06,21.86,10,8,0,14.4,9.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),7.98e-09,18.74,10,19,0,15.26,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),7.99e-09,15.89,10,21,0,14.76,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),1.08e-08,21.07,10,12,0,18.33,9.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.06e-08,28.79,10,10,0,20.0,21.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.98e-08,21.37,10,10,0,20.0,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),8e-09,15.69,10,21,0,14.76,21.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),7.98e-09,17.3,10,21,0,14.76,9.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),7.98e-09,15.43,10,32,0,13.12,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),4.33e-08,22.79,10,10,0,20.0,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),7.98e-09,21.75,10,39,0,12.56,9.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),7.98e-09,25.73,10,44,0,12.27,11.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",7.98e-09,18.61,10,113,0,10.88,9.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.76e-06,16.13,10,11,0,19.09,11.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.18e-06,15.86,10,11,0,19.09,9.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.67e-07,16.32,10,12,0,18.33,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),8.1e-09,14.22,10,25,0,14.0,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",7.98e-09,19.89,10,87,0,11.15,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),7.98e-09,14.88,10,33,0,13.03,9.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),7.98e-09,17.62,10,41,0,12.44,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),7.98e-09,17.78,10,21,0,14.76,1.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",8.03e-09,15.45,10,21,0,14.76,9.0
abnormal glucose tolerance test (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),7.98e-09,16.4,10,1021,0,10.1,11.0
Tonsillectomy and adenoidectomy (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,10.45,36,16,0,23.11,4.0
Tonsillectomy and adenoidectomy (topp),TREATS,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.39e-22,20.67,36,26,0,44.78,4.0
Diagnosis (hlca),TREATS,cohort (humn),USES,Medicare (rnlw),2.12e-06,6.65,18,20,0,34.2,4.0
Diagnosis (hlca),TREATS,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.12e-06,3.83,18,65,0,22.98,2.0
Diagnosis (hlca),TREATS,cohort (humn),USES,Treats (clas),2.5e-06,6.15,18,16,0,30.22,4.0
Diagnosis (hlca),TREATS,cohort (humn),LOCATION_OF,Calcium (bacs),6.22e-06,6.41,18,13,0,22.39,2.0
Diagnosis (hlca),TREATS,cohort (humn),USES,Classification (clas),2.13e-06,7.39,18,16,0,30.22,4.0
Diagnosis (hlca),TREATS,cohort (humn),LOCATION_OF,Sodium (elii),5.59e-06,12.8,18,8,0,11.56,2.0
Diagnosis (hlca),TREATS,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.12e-06,6.27,18,23,0,32.09,2.0
Diagnosis (hlca),TREATS,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),2.12e-06,7.17,18,22,0,32.73,2.0
Diagnosis (hlca),TREATS,cohort (humn),USES,Tissue Microarray (resd),3.01e-06,7.1,18,13,0,22.39,4.0
Diagnosis (hlca),TREATS,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.12e-06,9.09,18,15,0,27.5,2.0
Fitness (dora),TREATS,cohort (humn),USES,Medicare (rnlw),9.97e-10,24.46,14,20,0,23.8,4.0
Fitness (dora),TREATS,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,21.64,14,65,0,17.02,2.0
Fitness (dora),TREATS,cohort (humn),USES,Treats (clas),3.75e-07,23.96,14,16,0,26.25,4.0
Fitness (dora),TREATS,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,24.22,14,13,0,25.07,2.0
Fitness (dora),TREATS,cohort (humn),USES,Classification (clas),1.22e-08,25.2,14,16,0,26.25,4.0
Fitness (dora),TREATS,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,30.61,14,8,0,12.57,2.0
Fitness (dora),TREATS,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,24.08,14,23,0,22.52,2.0
Fitness (dora),TREATS,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,24.98,14,22,0,22.91,2.0
Fitness (dora),TREATS,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,24.91,14,13,0,25.07,4.0
Fitness (dora),TREATS,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,26.91,14,15,0,27.07,2.0
Body mass index procedure (diap),DIAGNOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Octogenarians (aggp),6.54e-07,85.59,6,9,0,10.0,1.0
Body mass index procedure (diap),DIAGNOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Surgical Patients (podg),1.59e-08,80.35,6,16,0,8.25,1.0
Body mass index procedure (diap),DIAGNOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,General Population (humn),3.66e-09,80.08,6,31,0,7.16,1.0
Body mass index procedure (diap),DIAGNOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),3.66e-09,79.5,6,28,0,7.29,1.0
Body mass index procedure (diap),DIAGNOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,African American (popg),3.66e-09,82.0,6,53,0,6.68,1.0
Body mass index procedure (diap),DIAGNOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Caucasoid Race (popg),1.25e-06,78.14,6,19,0,7.89,1.0
Body mass index procedure (diap),DIAGNOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Participant (humn),3.66e-09,79.9,6,33,0,7.09,1.0
Body mass index procedure (diap),DIAGNOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Long-Term Survivors (podg),4.51e-09,80.93,6,17,0,8.12,1.0
Body mass index procedure (diap),DIAGNOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),3.66e-09,77.59,6,100,0,6.36,1.0
Body mass index procedure (diap),DIAGNOSES,Carcinoma of the Large Intestine (neop),ISA,Common Neoplasm (neop),7.32e-09,79.25,6,20,0,7.8,5.0
Body mass index procedure (diap),DIAGNOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,cohort (humn),7.14e-08,79.02,6,18,0,8.0,1.0
Body mass index procedure (diap),DIAGNOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,cohort (humn),3.66e-09,79.27,6,63,0,6.57,1.0
Body mass index procedure (diap),DIAGNOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Black race (popg),2.58e-08,81.33,6,14,0,8.57,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.71e-06,17.95,9,9,0,18.0,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.16e-07,17.0,9,194,0,9.42,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),1.17e-07,15.73,9,17,0,13.76,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.16e-07,17.0,9,29,0,11.79,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.17e-07,19.18,9,14,0,14.79,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.18e-06,14.99,9,12,0,15.75,5.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.16e-07,13.81,9,48,0,10.69,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.16e-07,17.2,9,29,0,11.79,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.16e-07,14.24,9,98,0,9.83,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),1.19e-07,12.91,9,24,0,12.38,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),2.92e-07,19.32,9,10,0,17.1,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.29e-07,11.68,9,37,0,11.19,7.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.23e-07,13.48,9,20,0,13.05,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.16e-07,15.13,9,94,0,9.86,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.46e-06,20.92,9,8,0,15.11,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),1.16e-07,17.8,9,19,0,13.26,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.16e-07,14.95,9,21,0,12.86,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),1.19e-07,20.13,9,12,0,15.75,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.19e-07,27.85,9,10,0,17.1,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),1.98e-07,20.44,9,10,0,17.1,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.16e-07,14.75,9,21,0,12.86,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.16e-07,16.36,9,21,0,12.86,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.16e-07,14.49,9,32,0,11.53,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),1.52e-07,21.85,9,10,0,17.1,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.16e-07,20.82,9,39,0,11.08,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.16e-07,24.79,9,44,0,10.84,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.16e-07,17.67,9,113,0,9.72,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.87e-06,15.2,9,11,0,16.36,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.29e-06,14.92,9,11,0,16.36,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),6.76e-07,15.38,9,12,0,15.75,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.17e-07,13.28,9,25,0,12.24,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.16e-07,18.95,9,87,0,9.93,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.16e-07,13.94,9,33,0,11.45,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.16e-07,16.68,9,41,0,10.98,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.16e-07,16.85,9,21,0,12.86,1.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",1.16e-07,14.51,9,21,0,12.86,8.0
Age (orga),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.16e-07,15.46,9,1021,0,9.08,8.0
Gastrectomy (topp),compared_with,Laparoscopic adjustable gastric banding (topp),TREATS,"Obesity, Morbid (dsyn)",1.27e-08,28.38,10,28,0,13.57,4.0
Lipids (lipd),ASSOCIATED_WITH,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),4.81e-07,27.15,6,62,0,6.58,8.0
Lipids (lipd),ASSOCIATED_WITH,Dyslipidemias (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),4.81e-07,37.75,6,17,0,8.12,8.0
Lipids (lipd),ASSOCIATED_WITH,Dyslipidemias (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.81e-07,29.44,6,19,0,7.89,8.0
Diabetic (fndg),NEG_PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.88e-08,50.12,6,18,0,8.0,6.0
25-hydroxyvitamin D (strd),ISA,Vitamin D (phsu),ASSOCIATED_WITH,Carcinoma of the Large Intestine (neop),3.03e-07,15.5,24,11,0,16.04,5.0
25-hydroxyvitamin D (strd),ISA,Vitamin D (phsu),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),6.05e-11,13.04,24,21,0,39.38,5.0
25-hydroxyvitamin D (strd),ISA,Vitamin D (phsu),TREATS,Cardiovascular Diseases (dsyn),2.69e-06,14.86,24,10,0,14.17,4.0
25-hydroxyvitamin D (strd),ISA,Vitamin D (phsu),TREATS,"Hyperparathyroidism, Secondary (dsyn)",8.83e-09,12.58,24,18,0,31.5,4.0
25-hydroxyvitamin D (strd),ISA,Vitamin D (phsu),TREATS,Critical Illness (dsyn),9.08e-08,16.68,24,11,0,16.04,4.0
25-hydroxyvitamin D (strd),ISA,Vitamin D (phsu),TREATS,"Kidney Failure, Chronic (dsyn)",6.32e-12,12.7,24,24,0,48.0,4.0
25-hydroxyvitamin D (strd),ISA,Vitamin D (phsu),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",9.54e-14,12.63,24,28,0,44.57,5.0
CAROTID (bpoc),LOCATION_OF,Senile Plaques (acab),LOCATION_OF,Psoriasis (dsyn),9.39e-23,2.67,171,13,0,13.99,2.0
Meetings (hlca),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),6.08e-08,40.13,6,33,0,7.09,1.0
Meetings (hlca),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.49e-06,40.67,6,16,0,8.25,4.0
Meetings (hlca),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),6.06e-08,40.48,6,71,0,6.51,4.0
Meetings (hlca),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),6.06e-08,54.32,6,35,0,7.03,4.0
Meetings (hlca),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),6.06e-08,40.4,6,110,0,6.33,4.0
Meetings (hlca),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),6.19e-08,39.74,6,37,0,6.97,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),2.99e-07,36.19,14,18,0,24.89,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),6.82e-18,38.63,14,77,0,16.55,8.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),8.22e-15,36.71,14,33,0,19.94,5.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),1.72e-09,37.71,14,18,0,24.89,8.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),2e-10,40.96,14,15,0,27.07,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",6.82e-18,38.7,14,41,0,18.78,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),9.03e-15,37.24,14,30,0,20.53,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),3.11e-16,36.88,14,35,0,19.6,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),7.18e-18,41.26,14,27,0,21.26,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),3.96e-06,35.99,14,16,0,26.25,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),6.32e-13,38.68,14,22,0,22.91,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),2.02e-08,36.92,14,18,0,24.89,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),4.32e-13,40.79,14,19,0,24.32,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),1e-07,39.77,14,12,0,22.29,7.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),1.87e-07,45.48,14,9,0,14.79,8.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),6.82e-18,36.36,14,97,0,16.02,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),6.82e-18,37.37,14,68,0,16.88,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),6.82e-18,50.38,14,27,0,21.26,8.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),8.95e-07,40.52,14,10,0,17.14,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),4.45e-16,44.27,14,20,0,23.8,8.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),1.62e-13,41.36,14,19,0,24.32,8.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),6.82e-18,37.62,14,93,0,16.11,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),3.21e-08,37.52,14,16,0,26.25,5.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),4.83e-07,36.31,14,17,0,25.53,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),6.63e-07,40.85,14,10,0,17.14,8.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),2.8e-09,36.4,14,22,0,22.91,1.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),1.87e-13,38.22,14,24,0,22.17,8.0
Adiponectin (aapp),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),2.69e-06,39.45,14,10,0,17.14,8.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.85e-06,15.22,10,9,0,17.1,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.58e-07,14.28,10,194,0,10.52,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),2.58e-07,13.01,9,16,1,14.06,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.58e-07,14.27,10,29,0,13.45,11.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2.58e-07,16.46,10,14,0,17.14,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.32e-06,12.26,10,12,0,18.33,5.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),2.58e-07,11.08,10,48,0,12.08,11.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.58e-07,14.47,10,29,0,13.45,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.58e-07,11.52,10,98,0,11.02,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.6e-07,10.18,10,24,0,14.17,9.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),4.34e-07,16.6,10,10,0,20.0,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),2.7e-07,8.95,10,37,0,12.7,7.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.65e-07,10.76,10,20,0,15.0,9.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.58e-07,12.41,10,94,0,11.06,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.6e-06,18.2,10,8,0,14.4,9.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),2.58e-07,15.08,10,19,0,15.26,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),2.58e-07,12.23,10,21,0,14.76,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.61e-07,17.41,10,12,0,18.33,9.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.61e-07,25.13,10,10,0,20.0,21.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),3.4e-07,17.71,10,10,0,20.0,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.58e-07,12.03,10,21,0,14.76,21.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.58e-07,13.64,10,21,0,14.76,9.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.58e-07,11.77,10,32,0,13.12,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),2.93e-07,19.12,10,10,0,20.0,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.58e-07,18.09,10,39,0,12.56,9.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),2.58e-07,22.07,10,44,0,12.27,11.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.58e-07,14.95,10,113,0,10.88,9.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),3.01e-06,12.47,10,11,0,19.09,11.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.43e-06,12.2,10,11,0,19.09,9.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),8.17e-07,12.66,10,12,0,18.33,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),2.58e-07,10.56,10,25,0,14.0,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.58e-07,16.23,10,87,0,11.15,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),2.58e-07,11.22,10,33,0,13.03,9.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.58e-07,13.96,10,41,0,12.44,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),2.58e-07,14.12,10,21,0,14.76,1.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",2.58e-07,11.79,10,21,0,14.76,9.0
Diet (food),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.58e-07,12.73,10,1021,0,10.1,11.0
Academic Medical Centers (hcro),LOCATION_OF,Prospective Studies (qnco),ISA,Techniques (ftcn),1.3e-08,5.32,22,912,0,22.53,2.0
Academic Medical Centers (hcro),LOCATION_OF,Prospective Studies (qnco),ISA,contextual factors (ftcn),1.31e-06,4.79,22,26,0,40.62,2.0
Blood specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Ischemic stroke (dsyn),4.17e-06,19.77,22,11,0,16.5,2.0
Blood specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),3.01e-10,17.0,22,34,0,36.24,2.0
Blood specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Septicemia (dsyn),8.33e-13,21.36,22,20,0,38.18,2.0
Blood specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),ISA,Albumins (aapp),4.89e-14,18.61,22,30,0,38.13,2.0
Blood specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),1.24e-07,19.12,22,15,0,25.23,2.0
Blood specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),ISA,Acute-Phase Proteins (aapp),1.55e-13,16.19,22,77,0,28.29,2.0
Blood specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),compared_with,procalcitonin (aapp),1.82e-08,19.42,22,16,0,27.64,2.0
Blood specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Myocardial Infarction (dsyn),2.06e-06,18.46,22,14,0,22.91,2.0
Screening procedure (hlca),TREATS,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),1.92e-08,10.93,11,25,0,15.84,1.0
Screening procedure (hlca),TREATS,Diabetic (fndg),PROCESS_OF,Participant (humn),6.08e-08,9.47,11,50,0,13.42,1.0
Screening procedure (hlca),TREATS,Diabetic (fndg),PROCESS_OF,cohort (humn),1.61e-08,11.45,11,65,0,12.86,1.0
Screening procedure (hlca),TREATS,Diabetic (fndg),PROCESS_OF,Population Group (humn),1.12e-06,14.06,11,11,0,22.0,1.0
High Density Lipoprotein Cholesterol (bacs),ISA,Lipids (lipd),PART_OF,Stratum corneum (tisu),7.96e-07,13.1,18,2,0,2.22,3.0
Weight Gain (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,31.09,32,18,0,28.12,1.0
Biopsy (diap),DIAGNOSES,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),7.36e-10,15.52,11,23,0,16.26,18.0
Biopsy (diap),DIAGNOSES,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),4.56e-10,14.97,11,57,0,13.12,11.0
Biopsy (diap),DIAGNOSES,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.91e-07,23.44,11,9,0,16.36,9.0
Habits (inbe),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.9e-07,13.55,9,18,0,13.5,1.0
sex (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,40.13,11,33,0,14.67,1.0
sex (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,40.67,11,16,0,18.56,8.0
sex (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.54e-14,40.48,11,71,0,12.7,5.0
sex (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.54e-14,54.32,11,35,0,14.46,8.0
sex (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.54e-14,40.4,11,110,0,12.1,8.0
sex (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,39.74,11,37,0,14.27,1.0
Intervention regimes (hlca),TREATS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,25.22,21,16,0,28.19,4.0
Intervention regimes (hlca),TREATS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,30.39,21,9,0,12.86,4.0
Intervention regimes (hlca),TREATS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,22.77,21,31,0,35.23,4.0
Physical activity (dora),TREATS,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),2.89e-19,19.06,30,25,0,45.83,2.0
Physical activity (dora),TREATS,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),5.88e-09,16.86,30,13,0,18.63,2.0
Physical activity (dora),TREATS,Survivors (humn),LOCATION_OF,procalcitonin (aapp),2.78e-24,21.32,30,32,0,58.12,2.0
Stiffness (sosy),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,20.45,12,18,0,20.0,1.0
Triglycerides (bacs),PART_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,26.68,11,18,0,17.72,3.0
Gender (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,23.96,12,33,0,16.36,1.0
Gender (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,24.5,12,16,0,21.0,8.0
Gender (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.46e-13,24.31,12,71,0,14.03,5.0
Gender (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.46e-13,38.15,12,35,0,16.11,8.0
Gender (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.46e-13,24.23,12,110,0,13.31,8.0
Gender (orga),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,23.57,12,37,0,15.89,1.0
Overweight (sosy),ASSOCIATED_WITH,Chronic Disease (dsyn),CAUSES,Cessation of life (orgf),5.5e-10,35.82,8,66,0,8.97,8.0
Overweight (sosy),ASSOCIATED_WITH,Chronic Disease (dsyn),PROCESS_OF,cohort (humn),2.8e-07,33.93,8,16,0,12.0,1.0
Overweight (sosy),ASSOCIATED_WITH,Chronic Disease (dsyn),CAUSES,Disability NOS (patf),4.85e-06,32.74,8,18,0,11.56,8.0
Training (edac),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular morbidity (dsyn),4.53e-08,15.32,12,23,0,18.26,7.0
Training (edac),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cerebrovascular accident (dsyn),2.77e-07,9.36,12,18,0,20.0,7.0
Training (edac),AFFECTS,Systemic arterial pressure (fndg),PROCESS_OF,General Population (humn),1.41e-06,8.01,12,27,0,17.33,1.0
Training (edac),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),4.53e-08,8.99,12,32,0,16.5,7.0
Training (edac),AFFECTS,Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),4.53e-08,8.41,12,39,0,15.69,1.0
Training (edac),AFFECTS,Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),7.64e-07,7.56,12,41,0,15.51,1.0
Training (edac),AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular event (fndg),4.54e-08,9.3,12,27,0,17.33,7.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),1.84e-08,10.88,25,20,0,36.0,1.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Disability NOS (patf),1.81e-18,14.04,25,36,0,42.36,4.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),ISA,Respiration Disorders (dsyn),1.81e-18,10.67,25,59,0,35.59,4.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Respiratory physiology (ortf),2.06e-08,10.32,25,23,0,44.16,1.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Acute respiratory failure (dsyn),3.54e-07,13.33,25,12,0,17.76,4.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),1.81e-18,11.04,25,72,0,33.68,1.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),ISA,Lung diseases (dsyn),1.81e-18,10.5,25,73,0,33.56,4.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.81e-18,11.84,25,50,0,37.5,1.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospital admission (hlca),3.35e-09,13.63,25,15,0,24.0,4.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Cessation of life (orgf),1.81e-18,13.56,25,184,0,28.4,4.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Outpatients (podg),1.87e-08,9.1,23,41,2,35.9,1.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,General Population (humn),7.58e-12,11.06,25,27,0,48.15,1.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Diagnosis (hlca),1.7e-07,15.11,25,11,0,15.84,4.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospitalization (hlca),3.82e-18,13.24,25,31,0,45.16,4.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Participant (humn),1.81e-18,10.4,25,70,0,33.93,1.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),COEXISTS_WITH,Smoker (fndg),2.39e-07,9.57,25,27,0,48.15,4.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),ISA,Chronic Disease (dsyn),1.81e-18,11.55,25,46,0,38.59,4.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Malignant neoplasm of lung (neop),8.79e-08,11.27,25,17,0,28.56,4.0
Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Pneumonia (dsyn),4.46e-07,13.17,25,12,0,17.76,4.0
Body mass index procedure (diap),DIAGNOSES,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular morbidity (dsyn),4.23e-17,52.7,34,23,0,38.56,18.0
Body mass index procedure (diap),DIAGNOSES,Systemic arterial pressure (fndg),PREDISPOSES,Cerebrovascular accident (dsyn),2.32e-07,46.73,34,18,0,27.53,18.0
Body mass index procedure (diap),DIAGNOSES,Systemic arterial pressure (fndg),PROCESS_OF,General Population (humn),1.36e-06,45.39,34,27,0,48.44,1.0
Body mass index procedure (diap),DIAGNOSES,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),8.77e-12,46.36,34,32,0,62.12,18.0
Body mass index procedure (diap),DIAGNOSES,Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),1.15e-11,45.79,34,39,0,63.64,1.0
Body mass index procedure (diap),DIAGNOSES,Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),7.18e-07,44.93,34,41,0,62.2,1.0
Body mass index procedure (diap),DIAGNOSES,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular event (fndg),7.9e-11,46.67,34,27,0,48.44,18.0
Stimulation procedure (topp),USES,Insulin (horm),TREATS,Hospitalized Patients (humn),2.92e-06,6.64,52,11,0,13.33,4.0
Stimulation procedure (topp),USES,Insulin (horm),TREATS,Hyperglycemia (dsyn),1.7e-07,4.43,52,57,0,99.44,4.0
Hypertriglyceridemia (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),3.72e-07,27.55,6,33,0,7.09,1.0
Hypertriglyceridemia (fndg),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.8e-06,28.09,6,16,0,8.25,9.0
Hypertriglyceridemia (fndg),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.72e-07,27.9,6,71,0,6.51,5.0
Hypertriglyceridemia (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.72e-07,41.74,6,35,0,7.03,21.0
Hypertriglyceridemia (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.72e-07,27.82,6,110,0,6.33,21.0
Hypertriglyceridemia (fndg),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),3.73e-07,27.16,6,37,0,6.97,1.0
Hyperuricemia (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),1.2e-09,39.65,8,20,0,11.2,1.0
Hyperuricemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.74e-09,36.84,8,65,0,8.98,1.0
Hyperuricemia (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.76e-07,39.16,8,16,0,12.0,1.0
Hyperuricemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,39.41,8,13,0,12.92,1.0
Hyperuricemia (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.24e-08,40.4,8,16,0,12.0,1.0
Hyperuricemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,45.8,8,8,0,16.0,1.0
Hyperuricemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),3.81e-10,39.28,8,23,0,10.78,1.0
Hyperuricemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),2.19e-10,40.17,8,22,0,10.91,1.0
Hyperuricemia (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,40.1,8,13,0,12.92,1.0
Hyperuricemia (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.75e-09,42.1,8,15,0,12.27,1.0
Nutrition Assessment (diap),DIAGNOSES,Malnutrition (dsyn),PROCESS_OF,Critically ill children (podg),3.47e-06,33.07,16,8,0,12.0,1.0
Nutrition Assessment (diap),DIAGNOSES,Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.35e-09,28.92,16,15,0,29.06,9.0
Nutrition Assessment (diap),DIAGNOSES,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.16e-09,27.62,16,18,0,30.22,1.0
Nutrition Assessment (diap),DIAGNOSES,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),2.18e-18,26.53,15,60,1,18.75,1.0
Nutrition Assessment (diap),DIAGNOSES,Malnutrition (dsyn),PROCESS_OF,Surgical Patients (podg),5.5e-11,26.57,16,24,0,26.67,1.0
Nutrition Assessment (diap),DIAGNOSES,Malnutrition (dsyn),PROCESS_OF,Cancer Patient (podg),8.8e-09,25.02,16,30,0,24.53,1.0
Nutrition Assessment (diap),DIAGNOSES,Malnutrition (dsyn),PROCESS_OF,inpatient (humn),1.52e-12,26.46,16,28,0,25.14,1.0
Nutrition Assessment (diap),DIAGNOSES,Malnutrition (dsyn),CAUSES,Cessation of life (orgf),2.26e-16,28.38,16,28,0,25.14,11.0
Nutrition Assessment (diap),DIAGNOSES,Malnutrition (dsyn),PROCESS_OF,cohort (humn),2.22e-10,29.64,16,16,0,32.0,1.0
Assessment procedure (hlca),TREATS,Malnutrition (dsyn),PROCESS_OF,Critically ill children (podg),3.47e-06,30.15,10,8,0,14.4,1.0
Assessment procedure (hlca),TREATS,Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.4e-09,26.0,10,15,0,16.67,4.0
Assessment procedure (hlca),TREATS,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.21e-09,24.7,10,18,0,15.56,1.0
Assessment procedure (hlca),TREATS,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),5.09e-11,23.61,10,61,0,11.64,1.0
Assessment procedure (hlca),TREATS,Malnutrition (dsyn),PROCESS_OF,Surgical Patients (podg),1.06e-10,23.65,10,24,0,14.17,1.0
Assessment procedure (hlca),TREATS,Malnutrition (dsyn),PROCESS_OF,Cancer Patient (podg),8.85e-09,22.1,10,30,0,13.33,1.0
Assessment procedure (hlca),TREATS,Malnutrition (dsyn),PROCESS_OF,inpatient (humn),5.24e-11,23.54,10,28,0,13.57,1.0
Assessment procedure (hlca),TREATS,Malnutrition (dsyn),CAUSES,Cessation of life (orgf),5.09e-11,25.46,10,28,0,13.57,4.0
Assessment procedure (hlca),TREATS,Malnutrition (dsyn),PROCESS_OF,cohort (humn),2.72e-10,26.72,9,15,1,14.4,1.0
High Density Lipoprotein Cholesterol (bacs),COEXISTS_WITH,C-reactive protein (aapp),ASSOCIATED_WITH,Ischemic stroke (dsyn),4.17e-06,49.67,13,11,0,20.31,8.0
High Density Lipoprotein Cholesterol (bacs),COEXISTS_WITH,C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),3.01e-10,46.9,13,34,0,17.97,9.0
High Density Lipoprotein Cholesterol (bacs),COEXISTS_WITH,C-reactive protein (aapp),PREDISPOSES,Septicemia (dsyn),8.33e-13,51.26,13,20,0,21.45,9.0
High Density Lipoprotein Cholesterol (bacs),COEXISTS_WITH,C-reactive protein (aapp),ISA,Albumins (aapp),4.89e-14,48.51,13,30,0,18.63,5.0
High Density Lipoprotein Cholesterol (bacs),COEXISTS_WITH,C-reactive protein (aapp),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),1.24e-07,49.02,13,15,0,24.27,8.0
High Density Lipoprotein Cholesterol (bacs),COEXISTS_WITH,C-reactive protein (aapp),ISA,Acute-Phase Proteins (aapp),1.55e-13,46.09,13,77,0,15.19,5.0
High Density Lipoprotein Cholesterol (bacs),COEXISTS_WITH,C-reactive protein (aapp),compared_with,procalcitonin (aapp),1.82e-08,49.32,13,16,0,23.56,9.0
High Density Lipoprotein Cholesterol (bacs),COEXISTS_WITH,C-reactive protein (aapp),PREDISPOSES,Myocardial Infarction (dsyn),2.06e-06,48.36,13,14,0,25.07,9.0
Spinal Fractures (inpo),ISA,Fracture (inpo),PROCESS_OF,Geriatric Patients (humn),1.05e-06,8.77,12,15,0,21.6,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,American (popg),3.14e-06,36.49,5,17,0,6.47,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),AFFECTS,Depressed mood (fndg),4.67e-06,41.03,5,8,0,8.12,7.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Octogenarians (aggp),5.02e-06,37.55,5,9,0,7.78,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,Myocardial Infarction (dsyn),3.14e-06,37.1,5,13,0,6.92,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,follow-up (hlca),3.31e-06,35.38,5,12,0,7.08,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,"Death, Sudden (patf)",3.14e-06,38.27,5,19,0,6.32,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,Cessation of life (orgf),3.14e-06,35.14,5,251,0,5.1,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,High Risk Populations (popg),3.26e-06,39.03,5,10,0,7.5,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),3.14e-06,37.16,5,28,0,5.89,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,General Population (humn),3.14e-06,37.7,5,67,0,5.37,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Hospital specialist (humn),3.14e-06,33.64,5,20,0,6.25,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,General Population (humn),3.14e-06,38.56,5,18,0,6.39,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),4.48e-06,38.03,5,9,0,7.78,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,African American (popg),3.14e-06,34.75,5,49,0,5.51,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.2e-06,36.23,5,12,0,7.08,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Human Age Group (aggp),3.19e-06,38.03,5,11,0,7.27,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),COEXISTS_WITH,Atrial Fibrillation (patf),3.14e-06,36.32,5,32,0,5.78,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Caucasoid Race (popg),3.14e-06,36.48,5,24,0,6.04,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,Cardiac Death (patf),3.14e-06,38.63,5,24,0,6.04,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,inpatient (humn),3.14e-06,34.97,5,37,0,5.68,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),COEXISTS_WITH,Physical findings (sosy),7.31e-06,34.1,5,11,0,7.27,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Veterans (popg),3.15e-06,34.9,5,15,0,6.67,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),3.14e-06,34.22,4,153,1,4.1,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),AFFECTS,Pathogenesis (patf),3.27e-06,31.83,5,21,0,6.19,7.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Participant (humn),3.14e-06,34.08,5,84,0,5.3,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,Hospital Readmissions (hlca),3.14e-06,42.29,5,14,0,6.79,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),3.14e-06,36.53,5,256,0,5.1,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),ISA,Cardiovascular Diseases (dsyn),3.14e-06,33.78,5,106,0,5.24,5.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PREDISPOSES,Myocardial Infarction (dsyn),3.37e-06,36.36,5,11,0,7.27,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,Hospitalization (hlca),3.14e-06,37.85,5,249,0,5.1,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Hospitalized Patients (humn),3.14e-06,36.7,5,55,0,5.45,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Survivors (humn),3.14e-06,36.64,5,33,0,5.76,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,"Death, Sudden, Cardiac (patf)",3.14e-06,39.2,5,13,0,6.92,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,Diagnosis (hlca),3.2e-06,35.18,5,13,0,6.92,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Outpatients (podg),3.14e-06,35.4,5,34,0,5.74,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Population Group (humn),3.14e-06,39.23,5,17,0,6.47,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Participant (humn),3.14e-06,34.95,5,25,0,6.0,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),ISA,Heart Diseases (dsyn),3.14e-06,33.4,5,42,0,5.6,5.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),COMPLICATES,Acute myocardial infarction (dsyn),3.14e-06,35.96,5,42,0,5.6,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),COEXISTS_WITH,Sinus rhythm (fndg),3.14e-06,35.69,5,30,0,5.83,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),AFFECTS,Atrial Fibrillation (patf),3.43e-06,40.6,5,9,0,7.78,7.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),CAUSES,Hospital admission (hlca),3.14e-06,37.7,5,40,0,5.62,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,Western society (popg),4.48e-06,38.03,5,9,0,7.78,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),COEXISTS_WITH,Anemia (dsyn),3.63e-06,37.21,5,10,0,7.5,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),PROCESS_OF,cohort (humn),3.14e-06,36.96,5,119,0,5.21,1.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),COMPLICATES,Myocardial Infarction (dsyn),3.14e-06,35.03,5,20,0,6.25,8.0
Nutritional status (orga),ASSOCIATED_WITH,Heart failure (dsyn),AFFECTS,Systemic arterial pressure (fndg),3.15e-06,34.77,5,15,0,6.67,7.0
Apnea (patf),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),1.02e-06,18.23,7,16,0,10.06,9.0
Apnea (patf),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),5.19e-07,28.44,7,26,0,8.88,9.0
insulin sensitivity (patf),ASSOCIATED_WITH,Insulin (horm),TREATS,Hospitalized Patients (humn),2.8e-06,20.08,8,11,0,13.82,4.0
insulin sensitivity (patf),ASSOCIATED_WITH,Insulin (horm),TREATS,Hyperglycemia (dsyn),5.41e-08,17.86,8,57,0,9.12,4.0
Overweight (sosy),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,43.09,16,20,0,28.8,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,40.27,16,65,0,19.94,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,42.6,16,16,0,32.0,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,42.85,16,13,0,23.56,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,43.83,16,16,0,32.0,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,49.24,16,8,0,12.0,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,42.72,16,23,0,27.13,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,43.61,16,22,0,27.64,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,43.54,16,13,0,23.56,1.0
Overweight (sosy),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,45.54,16,15,0,29.06,1.0
Asleep (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),2.52e-06,21.61,6,18,0,8.0,1.0
"Diabetes Mellitus, Insulin-Dependent (dsyn)",PROCESS_OF,cohort (humn),USES,Medicare (rnlw),2.35e-07,8.7,13,20,0,21.45,1.0
"Diabetes Mellitus, Insulin-Dependent (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.36e-07,5.89,13,65,0,15.6,1.0
"Diabetes Mellitus, Insulin-Dependent (dsyn)",PROCESS_OF,cohort (humn),USES,Treats (clas),6.09e-07,8.21,13,16,0,23.56,1.0
"Diabetes Mellitus, Insulin-Dependent (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.33e-06,8.46,13,13,0,26.0,1.0
"Diabetes Mellitus, Insulin-Dependent (dsyn)",PROCESS_OF,cohort (humn),USES,Classification (clas),2.46e-07,9.45,13,16,0,23.56,1.0
"Diabetes Mellitus, Insulin-Dependent (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.7e-06,14.85,13,8,0,12.92,1.0
"Diabetes Mellitus, Insulin-Dependent (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),2.34e-07,8.33,13,23,0,20.35,1.0
"Diabetes Mellitus, Insulin-Dependent (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),2.34e-07,9.22,13,22,0,20.68,1.0
"Diabetes Mellitus, Insulin-Dependent (dsyn)",PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),1.12e-06,9.15,13,13,0,26.0,1.0
"Diabetes Mellitus, Insulin-Dependent (dsyn)",PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.35e-07,11.15,13,15,0,24.27,1.0
Hyperglycemia (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),1.2e-07,34.74,6,33,0,7.09,1.0
Hyperglycemia (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.55e-06,35.28,6,16,0,8.25,9.0
Hyperglycemia (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.2e-07,35.09,6,71,0,6.51,5.0
Hyperglycemia (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.2e-07,48.93,6,35,0,7.03,21.0
Hyperglycemia (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.2e-07,35.01,6,110,0,6.33,21.0
Hyperglycemia (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.21e-07,34.35,6,37,0,6.97,1.0
Glomerular Filtration Rate (ortf),ISA,Renal function (ortf),PROCESS_OF,Survivors (humn),2.06e-15,10.87,32,27,0,49.78,1.0
Glomerular Filtration Rate (ortf),ISA,Renal function (ortf),PROCESS_OF,cohort (humn),1.34e-09,7.06,32,23,0,39.53,1.0
Glomerular Filtration Rate (ortf),ISA,Renal function (ortf),PROCESS_OF,"Recipient, Transplant (podg)",3.5e-08,5.34,32,41,0,56.98,1.0
Glomerular Filtration Rate (ortf),ISA,Renal function (ortf),PROCESS_OF,Hospitalized Patients (humn),4.08e-06,8.13,32,12,0,16.5,1.0
Metabolic syndrome (dsyn),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,31.11,23,16,0,27.13,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.39e-22,41.32,22,25,1,41.36,9.0
Hypoxia (patf),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.04e-07,10.32,13,16,0,23.56,9.0
Hypoxia (patf),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),3.37e-09,20.54,13,26,0,19.5,9.0
Patient Selection (hlca),PREVENTS,Postoperative Complications (patf),PROCESS_OF,Octogenarians (aggp),8.69e-07,51.36,5,11,0,7.27,1.0
Patient Selection (hlca),PREVENTS,Postoperative Complications (patf),PROCESS_OF,Surgical Patients (podg),8.37e-07,48.83,5,33,0,5.76,1.0
Patient Selection (hlca),PREVENTS,Postoperative Complications (patf),CAUSES,Cessation of life (orgf),5.01e-06,47.0,5,11,0,7.27,11.0
Patient Selection (hlca),PREVENTS,Postoperative Complications (patf),PROCESS_OF,"Recipient, Transplant (podg)",3.52e-06,48.35,5,10,0,7.5,1.0
Patient Selection (hlca),PREVENTS,Postoperative Complications (patf),PROCESS_OF,cohort (humn),8.37e-07,48.51,5,30,0,5.83,1.0
Patient Selection (hlca),PREVENTS,Postoperative Complications (patf),PROCESS_OF,Control Groups (humn),1.12e-06,45.67,5,16,0,6.56,1.0
Operation on stomach (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,25.12,9,12,0,15.75,1.0
Operation on stomach (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.09e-08,22.49,9,24,0,12.38,4.0
High Density Lipoprotein Cholesterol (bacs),COEXISTS_WITH,Cholesterol (bacs),PART_OF,Membrane (celc),1.11e-11,11.45,13,5,0,6.92,3.0
Overweight (sosy),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),2.89e-19,50.1,17,25,0,28.56,1.0
Overweight (sosy),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),5.88e-09,47.9,17,13,0,22.94,1.0
Overweight (sosy),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),7.97e-23,52.35,17,32,0,26.03,1.0
Ultrasonography of abdomen (diap),DIAGNOSES,Non-alcoholic fatty liver (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.21e-09,41.4,7,23,0,9.13,18.0
Ultrasonography of abdomen (diap),DIAGNOSES,Non-alcoholic fatty liver (dsyn),CAUSES,Chronic liver disease NOS (dsyn),2.93e-09,40.84,7,57,0,7.86,11.0
Ultrasonography of abdomen (diap),DIAGNOSES,Non-alcoholic fatty liver (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.94e-07,49.31,7,9,0,12.44,9.0
"Sleep Apnea, Obstructive (dsyn)",AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular morbidity (dsyn),4.77e-06,16.66,8,23,0,10.78,7.0
"Sleep Apnea, Obstructive (dsyn)",AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cerebrovascular accident (dsyn),5e-06,10.69,8,18,0,11.56,7.0
"Sleep Apnea, Obstructive (dsyn)",AFFECTS,Systemic arterial pressure (fndg),PROCESS_OF,General Population (humn),6.13e-06,9.35,8,27,0,10.37,1.0
"Sleep Apnea, Obstructive (dsyn)",AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),4.77e-06,10.32,8,32,0,10.0,7.0
"Sleep Apnea, Obstructive (dsyn)",AFFECTS,Systemic arterial pressure (fndg),PROCESS_OF,cohort (humn),4.77e-06,9.75,8,39,0,9.64,1.0
"Sleep Apnea, Obstructive (dsyn)",AFFECTS,Systemic arterial pressure (fndg),PROCESS_OF,Participant (humn),5.49e-06,8.89,8,41,0,9.56,1.0
"Sleep Apnea, Obstructive (dsyn)",AFFECTS,Systemic arterial pressure (fndg),PREDISPOSES,Cardiovascular event (fndg),4.77e-06,10.63,8,27,0,10.37,7.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,15.07,30,9,0,11.7,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.54e-21,14.13,30,194,0,34.64,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,12.85,30,17,0,26.63,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.79e-19,14.12,30,29,0,57.03,11.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,16.3,30,14,0,20.53,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,12.11,30,12,0,16.8,5.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),2.64e-21,10.93,30,48,0,48.75,11.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.53e-19,14.32,30,29,0,57.03,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.54e-21,11.37,30,98,0,39.18,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,10.03,30,24,0,43.2,9.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,16.44,30,10,0,13.33,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,8.8,30,37,0,54.32,7.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,10.6,30,20,0,33.33,9.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.54e-21,12.26,30,94,0,39.57,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,18.05,30,8,0,10.13,9.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,14.92,30,19,0,31.03,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,12.08,30,21,0,35.7,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,17.26,30,12,0,16.8,9.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,24.97,30,10,0,13.33,21.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,17.56,30,10,0,13.33,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,11.88,30,21,0,35.7,21.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,13.49,30,21,0,35.7,9.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,11.61,30,32,0,58.12,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,18.97,30,10,0,13.33,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.54e-21,17.94,30,39,0,53.08,9.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),2.54e-21,21.92,30,44,0,50.45,11.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.54e-21,14.79,30,113,0,37.96,9.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,12.32,30,11,0,15.03,11.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,12.05,30,11,0,15.03,9.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,12.51,30,12,0,16.8,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,10.4,30,25,0,45.83,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.54e-21,16.08,30,87,0,40.34,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,11.07,30,33,0,57.27,9.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.54e-21,13.8,30,41,0,51.95,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,13.97,30,21,0,35.7,1.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,11.64,30,21,0,35.7,9.0
homocysteine (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.54e-21,12.58,30,1021,0,30.88,11.0
C-reactive protein (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,30.44,19,16,0,29.47,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,35.6,19,9,0,13.26,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,27.99,19,31,0,30.65,8.0
Pre-diabetic (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,26.4,12,18,0,20.0,1.0
company (orgt),LOCATION_OF,Prospective Studies (qnco),ISA,Techniques (ftcn),8.29e-08,22.81,7,912,0,7.05,2.0
company (orgt),LOCATION_OF,Prospective Studies (qnco),ISA,contextual factors (ftcn),1.38e-06,22.28,7,26,0,8.88,2.0
Androgens (horm),PART_OF,Ovaro- (bpoc),LOCATION_OF,Advanced cancer (neop),1.99e-12,10.34,24,22,0,42.17,2.0
Androgens (horm),PART_OF,Ovaro- (bpoc),LOCATION_OF,Cancer Diagnosis (diap),7.26e-12,7.85,24,33,0,41.45,2.0
Androgens (horm),PART_OF,Ovaro- (bpoc),LOCATION_OF,Diagnostic Neoplasm Staging (diap),1.52e-06,9.39,24,13,0,20.04,2.0
Body Weight (orga),ISA,Body mass index (clna),PREDISPOSES,Cardiovascular Diseases (dsyn),1.38e-09,58.88,485,22,0,23.0,5.0
Body mass index procedure (diap),USES,Calcium (bacs),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),5.28e-07,71.29,6,11,0,9.27,6.0
Body mass index procedure (diap),USES,Calcium (bacs),PART_OF,Coronary artery (bpoc),7.47e-09,65.54,5,193,1,5.13,3.0
Body mass index procedure (diap),USES,Calcium (bacs),PART_OF,Protoplasm (celc),6.53e-09,64.77,6,75,0,6.48,3.0
Body mass index procedure (diap),USES,Calcium (bacs),PART_OF,Cytosol (celc),6.53e-09,64.78,6,23,0,7.57,3.0
Body mass index procedure (diap),USES,Calcium (bacs),PREDISPOSES,Atherosclerosis (dsyn),5.66e-07,70.22,6,12,0,9.0,6.0
Body mass index procedure (diap),USES,Calcium (bacs),PART_OF,Extracellular (celc),6.53e-09,64.72,6,19,0,7.89,3.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),2.65e-06,34.62,5,18,0,6.39,1.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),2.35e-06,37.06,5,77,0,5.32,11.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),2.35e-06,35.13,5,33,0,5.76,5.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),2.35e-06,36.14,5,18,0,6.39,11.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),2.35e-06,39.39,5,15,0,6.67,1.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",2.35e-06,37.12,5,41,0,5.61,1.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),2.35e-06,35.66,5,30,0,5.83,1.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),2.35e-06,39.68,5,27,0,5.93,1.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),6.3e-06,34.41,5,16,0,6.56,1.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),2.35e-06,37.1,5,22,0,6.14,1.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),2.37e-06,35.35,5,18,0,6.39,1.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),2.35e-06,39.22,5,19,0,6.32,1.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),2.45e-06,38.2,5,12,0,7.08,7.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),2.53e-06,43.91,5,9,0,7.78,11.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),2.35e-06,34.79,5,97,0,5.26,1.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),2.35e-06,35.8,5,68,0,5.37,1.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),2.35e-06,48.81,5,27,0,5.93,11.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),3.24e-06,38.95,5,10,0,7.5,1.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),2.35e-06,42.7,5,20,0,6.25,9.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),2.35e-06,39.79,5,19,0,6.32,9.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),2.35e-06,36.04,5,93,0,5.27,1.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),2.38e-06,35.94,5,16,0,6.56,5.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),2.83e-06,34.73,5,17,0,6.47,1.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),3.01e-06,39.27,5,10,0,7.5,11.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),2.35e-06,34.83,5,22,0,6.14,1.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),2.35e-06,36.65,5,24,0,6.04,11.0
Glomerular Filtration Rate (ortf),CAUSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),5.03e-06,37.87,5,10,0,7.5,9.0
Lymphocyte (cell),PART_OF,Spleen (bpoc),LOCATION_OF,Nonpenetrating Wounds (inpo),1.52e-11,2.95,1,47,0,1.02,2.0
Lymphocyte (cell),PART_OF,Spleen (bpoc),LOCATION_OF,Infiltration (patf),1.99e-08,2.32,1,28,0,1.04,2.0
Lymphocyte (cell),PART_OF,Spleen (bpoc),PART_OF,Fishes (fish),3.75e-07,2.62,1,21,0,1.05,3.0
Intervention regimes (hlca),PREVENTS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,29.03,12,33,0,16.36,1.0
Intervention regimes (hlca),PREVENTS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,29.57,12,16,0,21.0,9.0
Intervention regimes (hlca),PREVENTS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.88e-14,29.38,12,71,0,14.03,5.0
Intervention regimes (hlca),PREVENTS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.88e-14,43.22,12,35,0,16.11,21.0
Intervention regimes (hlca),PREVENTS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.88e-14,29.3,12,110,0,13.31,21.0
Intervention regimes (hlca),PREVENTS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,28.64,12,37,0,15.89,1.0
Gamma-glutamyl transferase (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),5.92e-09,23.21,8,33,0,9.94,1.0
Gamma-glutamyl transferase (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.44e-06,23.76,8,16,0,12.0,8.0
Gamma-glutamyl transferase (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),5.67e-09,23.56,8,71,0,8.9,5.0
Gamma-glutamyl transferase (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),5.67e-09,37.4,8,35,0,9.83,8.0
Gamma-glutamyl transferase (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),5.67e-09,23.49,8,110,0,8.58,8.0
Gamma-glutamyl transferase (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),7.02e-09,22.82,8,37,0,9.73,1.0
Metabolic syndrome (dsyn),PROCESS_OF,Hispanics (humn),ISA,Ethnic group (popg),1.38e-12,24.51,11,226,0,11.54,1.0
Assessment procedure (hlca),METHOD_OF,Bariatric Surgery (topp),TREATS,"Obesity, Morbid (dsyn)",1.05e-14,42.31,11,94,0,12.29,4.0
Assessment procedure (hlca),METHOD_OF,Bariatric Surgery (topp),TREATS,Body Weight decreased (fndg),1.07e-14,42.23,11,47,0,13.57,4.0
Systolic blood pressure (ortf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,29.22,21,18,0,33.43,1.0
Cigarette Smoking (dora),ISA,Life Style (socb),ISA,Behavior (inbe),1.37e-06,10.25,8,160,0,8.4,5.0
Adiponectin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,27.24,102,15,1,17.21,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,32.41,103,9,0,9.79,8.0
Adiponectin (aapp),ASSOCIATED_WITH,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,24.79,103,31,0,40.33,8.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),3.19e-09,15.61,13,25,0,19.76,1.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,Participant (humn),4.47e-08,14.15,13,50,0,16.38,1.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,cohort (humn),3.29e-12,16.13,13,65,0,15.6,1.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,Diabetic (fndg),PROCESS_OF,Population Group (humn),1.11e-06,18.74,13,11,0,20.31,1.0
"Subcutaneous Fat, Abdominal (tisu)",LOCATION_OF,Biopsy (diap),DIAGNOSES,melanoma (neop),9.7e-18,24.15,17,45,0,23.42,2.0
"Subcutaneous Fat, Abdominal (tisu)",LOCATION_OF,Biopsy (diap),ISA,Diagnosis (hlca),4.06e-10,21.95,17,161,0,18.8,2.0
"Subcutaneous Fat, Abdominal (tisu)",LOCATION_OF,Biopsy (diap),ISA,Procedures (hlca),4.84e-07,22.07,17,81,0,20.57,2.0
Sarcopenia (fndg),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,38.51,29,18,0,29.17,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.73e-10,36.36,9,33,0,11.45,1.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,36.9,9,16,0,14.06,9.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.42e-11,36.7,9,71,0,10.14,5.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.42e-11,50.55,9,35,0,11.31,21.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.42e-11,36.63,9,110,0,9.74,21.0
High Density Lipoprotein Cholesterol (bacs),PREDISPOSES,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.37e-09,35.97,9,37,0,11.19,1.0
Uric Acid (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.6e-10,16.61,13,33,0,18.12,1.0
Uric Acid (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,17.16,13,16,0,23.56,8.0
Uric Acid (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),9.81e-13,16.96,13,71,0,15.38,5.0
Uric Acid (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),9.81e-13,30.8,13,35,0,17.83,8.0
Uric Acid (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),9.81e-13,16.89,13,110,0,14.54,8.0
Uric Acid (bacs),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.36e-09,16.23,13,37,0,17.57,1.0
Performance (inbe),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,7.53,43,20,0,29.3,1.0
Performance (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,4.72,43,65,0,71.45,1.0
Performance (inbe),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,7.04,43,16,0,21.95,1.0
Performance (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,7.3,43,13,0,16.93,1.0
Performance (inbe),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,8.28,43,16,0,21.95,1.0
Performance (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,13.68,43,8,0,9.49,1.0
Performance (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,7.16,43,23,0,35.3,1.0
Performance (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,8.06,43,22,0,33.26,1.0
Performance (inbe),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,7.99,43,13,0,16.93,1.0
Performance (inbe),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,9.98,43,15,0,20.23,1.0
Osteoporosis (dsyn),COEXISTS_WITH,Fracture (inpo),PROCESS_OF,Geriatric Patients (humn),1.59e-06,9.16,11,15,0,19.07,1.0
Magnetic Resonance Imaging (diap),METHOD_OF,Magnetic Resonance Spectroscopy (diap),USES,Mandibular right second molar prosthesis (medd),2.8e-07,13.37,9,3,0,4.0,6.0
Magnetic Resonance Imaging (diap),METHOD_OF,Magnetic Resonance Spectroscopy (diap),USES,Protons (elii),1.2e-08,13.43,9,35,0,11.31,6.0
pioglitazone (orch),TREATS,Diabetic (fndg),PROCESS_OF,Hospitalized Patients (humn),3.19e-09,15.35,22,25,0,41.36,1.0
pioglitazone (orch),TREATS,Diabetic (fndg),PROCESS_OF,Participant (humn),4.47e-08,13.89,22,50,0,31.68,1.0
pioglitazone (orch),TREATS,Diabetic (fndg),PROCESS_OF,cohort (humn),1.91e-20,15.88,22,65,0,29.45,1.0
pioglitazone (orch),TREATS,Diabetic (fndg),PROCESS_OF,Population Group (humn),1.11e-06,18.49,22,11,0,16.5,1.0
Menarche (orgf),AFFECTS,Age (orga),ASSOCIATED_WITH,Acute myocardial infarction (dsyn),2.72e-07,24.31,7,13,0,10.77,7.0
Menarche (orgf),AFFECTS,Age (orga),ASSOCIATED_WITH,Pneumonia (dsyn),7.88e-07,23.11,7,11,0,11.45,7.0
Menarche (orgf),AFFECTS,Age (orga),ASSOCIATED_WITH,Heart failure (dsyn),2.66e-07,24.69,7,20,0,9.45,7.0
Menarche (orgf),AFFECTS,Age (orga),ASSOCIATED_WITH,Cerebrovascular accident (dsyn),2.66e-07,20.9,7,31,0,8.58,7.0
Menarche (orgf),AFFECTS,Age (orga),ASSOCIATED_WITH,Myocardial Infarction (dsyn),4.42e-07,20.8,7,15,0,10.27,7.0
Fatty Liver (dsyn),ISA,Liver diseases (dsyn),AFFECTS,American (popg),1.76e-07,11.68,9,39,0,11.08,5.0
Fatty Liver (dsyn),ISA,Liver diseases (dsyn),PROCESS_OF,cohort (humn),1.76e-07,14.75,9,23,0,12.52,1.0
Fatty Liver (dsyn),ISA,Liver diseases (dsyn),CAUSES,Cessation of life (orgf),1.76e-07,16.32,9,67,0,10.21,5.0
Fatty Liver (dsyn),ISA,Liver diseases (dsyn),PROCESS_OF,Pregnant Women (popg),1.99e-07,15.17,9,14,0,14.79,1.0
Fatty Liver (dsyn),ISA,Liver diseases (dsyn),PROCESS_OF,Hepatitis C virus (virs),3.68e-06,12.31,9,16,0,14.06,1.0
Pathological Dilatation (patf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),9.46e-07,18.04,7,18,0,9.72,1.0
Overweight (sosy),CAUSES,Chronic Disease (dsyn),CAUSES,Cessation of life (orgf),3.56e-07,59.53,5,66,0,5.38,11.0
Overweight (sosy),CAUSES,Chronic Disease (dsyn),PROCESS_OF,cohort (humn),6.36e-07,57.64,5,16,0,6.56,1.0
Overweight (sosy),CAUSES,Chronic Disease (dsyn),CAUSES,Disability NOS (patf),5.21e-06,56.45,5,18,0,6.39,11.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),8.37e-07,16.94,7,20,0,9.45,1.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Disability NOS (patf),8.19e-07,20.09,7,36,0,8.36,8.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Respiration Disorders (dsyn),8.19e-07,16.73,7,59,0,7.83,5.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Respiratory physiology (ortf),8.4e-07,16.38,7,23,0,9.13,1.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Acute respiratory failure (dsyn),1.17e-06,19.39,7,12,0,11.08,8.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),8.19e-07,17.1,7,72,0,7.68,1.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Lung diseases (dsyn),8.19e-07,16.56,7,73,0,7.67,5.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Hospitalized Patients (humn),8.19e-07,17.89,7,50,0,7.98,1.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospital admission (hlca),8.22e-07,19.68,7,15,0,10.27,8.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Cessation of life (orgf),8.19e-07,19.61,7,184,0,7.27,8.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Outpatients (podg),8.38e-07,15.15,7,43,0,8.14,1.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,General Population (humn),8.19e-07,17.12,7,27,0,8.81,1.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Diagnosis (hlca),9.89e-07,21.16,7,11,0,11.45,8.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospitalization (hlca),8.19e-07,19.3,7,31,0,8.58,8.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Participant (humn),8.19e-07,16.46,7,70,0,7.7,1.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),COEXISTS_WITH,Smoker (fndg),1.06e-06,15.63,7,27,0,8.81,8.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),ISA,Chronic Disease (dsyn),8.19e-07,17.61,7,46,0,8.07,5.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Malignant neoplasm of lung (neop),9.07e-07,17.32,7,17,0,9.88,8.0
Sex Characteristics (orga),ASSOCIATED_WITH,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Pneumonia (dsyn),1.26e-06,19.23,7,12,0,11.08,8.0
Myocardial Infarction (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.16e-09,13.02,27,18,0,30.0,1.0
Nutritional status (orga),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,Critically ill children (podg),3.7e-06,22.13,8,8,0,16.0,1.0
Nutritional status (orga),ASSOCIATED_WITH,Malnutrition (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.31e-07,17.98,8,15,0,12.27,8.0
Nutritional status (orga),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),2.28e-07,16.68,8,18,0,11.56,1.0
Nutritional status (orga),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,Hospitalized Patients (humn),2.27e-07,15.59,8,61,0,9.05,1.0
Nutritional status (orga),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,Surgical Patients (podg),2.27e-07,15.63,8,24,0,10.67,1.0
Nutritional status (orga),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,Cancer Patient (podg),2.36e-07,14.08,8,30,0,10.13,1.0
Nutritional status (orga),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,inpatient (humn),2.27e-07,15.52,8,28,0,10.29,1.0
Nutritional status (orga),ASSOCIATED_WITH,Malnutrition (dsyn),CAUSES,Cessation of life (orgf),2.27e-07,17.44,8,28,0,10.29,8.0
Nutritional status (orga),ASSOCIATED_WITH,Malnutrition (dsyn),PROCESS_OF,cohort (humn),2.28e-07,18.7,8,16,0,12.0,1.0
Carcinoma (neop),PART_OF,Bladder (bpoc),LOCATION_OF,Contraction (patf),2.65e-08,0.1,8,1,0,1.12,2.0
Carcinoma (neop),PART_OF,Bladder (bpoc),LOCATION_OF,Cancer Diagnosis (diap),2.65e-08,2.73,8,33,0,9.94,2.0
Carcinoma (neop),PART_OF,Bladder (bpoc),LOCATION_OF,Neck (blor),2.65e-08,0.24,8,34,0,9.88,2.0
Carcinoma (neop),PART_OF,Bladder (bpoc),LOCATION_OF,Toxic effect (inpo),1.5e-07,2.19,8,28,0,10.29,2.0
Gastrectomy (topp),METHOD_OF,Bariatric Surgery (topp),TREATS,"Obesity, Morbid (dsyn)",2.04e-10,38.29,8,94,0,8.68,4.0
Gastrectomy (topp),METHOD_OF,Bariatric Surgery (topp),TREATS,Body Weight decreased (fndg),2.04e-10,38.22,8,47,0,9.36,4.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.62e-06,23.99,8,9,0,15.11,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.28e-08,23.05,8,194,0,8.33,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.32e-08,21.77,8,17,0,11.76,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),3.28e-08,23.04,8,29,0,10.21,11.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),3.3e-08,25.22,8,14,0,12.57,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.1e-06,21.03,8,12,0,13.33,5.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),3.28e-08,19.85,8,48,0,9.33,11.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),3.28e-08,23.24,8,29,0,10.21,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.28e-08,20.29,8,98,0,8.65,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),3.52e-08,18.95,8,24,0,10.67,9.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),2.09e-07,25.36,8,10,0,14.4,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),4.5e-08,17.72,8,37,0,9.73,7.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),3.96e-08,19.53,8,20,0,11.2,9.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),3.28e-08,21.18,8,94,0,8.68,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.38e-06,26.97,8,8,0,16.0,9.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.28e-08,23.84,8,19,0,11.37,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),3.28e-08,21.0,8,21,0,11.05,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),3.56e-08,26.18,8,12,0,13.33,9.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),3.55e-08,33.89,8,10,0,14.4,21.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),1.15e-07,26.48,8,10,0,14.4,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),3.28e-08,20.8,8,21,0,11.05,21.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),3.28e-08,22.41,8,21,0,11.05,9.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),3.28e-08,20.53,8,32,0,10.0,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),6.81e-08,27.89,8,10,0,14.4,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),3.28e-08,26.86,8,39,0,9.64,9.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),3.28e-08,30.84,8,44,0,9.45,11.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",3.28e-08,23.71,8,113,0,8.57,9.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.78e-06,21.24,8,11,0,13.82,11.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.21e-06,20.97,8,11,0,13.82,9.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.92e-07,21.43,8,12,0,13.33,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),3.29e-08,19.32,8,25,0,10.56,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.28e-08,25.0,8,87,0,8.74,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),3.28e-08,19.99,8,33,0,9.94,9.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),3.28e-08,22.72,8,41,0,9.56,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),3.28e-08,22.89,8,21,0,11.05,1.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",3.29e-08,20.56,8,21,0,11.05,9.0
Low Birth Weights (fndg),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),3.28e-08,21.5,8,1021,0,8.06,11.0
topiramate (orch),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,31.02,12,12,0,24.0,1.0
topiramate (orch),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,28.39,12,24,0,18.0,4.0
Body mass index procedure (diap),DIAGNOSES,Postoperative Complications (patf),PROCESS_OF,Octogenarians (aggp),1.57e-07,84.9,5,11,0,7.27,1.0
Body mass index procedure (diap),DIAGNOSES,Postoperative Complications (patf),PROCESS_OF,Surgical Patients (podg),1.24e-07,82.37,5,33,0,5.76,1.0
Body mass index procedure (diap),DIAGNOSES,Postoperative Complications (patf),CAUSES,Cessation of life (orgf),4.3e-06,80.54,5,11,0,7.27,11.0
Body mass index procedure (diap),DIAGNOSES,Postoperative Complications (patf),PROCESS_OF,"Recipient, Transplant (podg)",2.81e-06,81.89,5,10,0,7.5,1.0
Body mass index procedure (diap),DIAGNOSES,Postoperative Complications (patf),PROCESS_OF,cohort (humn),1.24e-07,82.05,5,30,0,5.83,1.0
Body mass index procedure (diap),DIAGNOSES,Postoperative Complications (patf),PROCESS_OF,Control Groups (humn),4.03e-07,79.2,5,16,0,6.56,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,African American (popg),2.99e-07,63.55,12,18,0,20.0,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.24e-17,65.99,12,77,0,13.87,21.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",ISA,Kidney Diseases (dsyn),8.23e-15,64.06,12,33,0,16.36,5.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,End stage renal failure (dsyn),1.72e-09,65.07,12,18,0,20.0,21.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Survivors (humn),2e-10,68.32,12,15,0,21.6,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,"Recipient, Transplant (podg)",1.24e-17,66.05,12,41,0,15.51,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),9.04e-15,64.59,12,30,0,16.8,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Glomerular Filtration Rate (ortf),3.17e-16,64.24,12,35,0,16.11,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Veterans (popg),1.27e-17,68.61,12,27,0,17.33,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Renal function (ortf),3.96e-06,63.34,12,16,0,21.0,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),6.32e-13,66.03,12,22,0,18.55,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Hospitalized Patients (humn),2.02e-08,64.28,12,18,0,20.0,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Population Group (humn),4.32e-13,68.15,12,19,0,19.58,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",AFFECTS,Anemia (dsyn),1e-07,67.13,12,12,0,24.0,7.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",CAUSES,Vascular calcification (patf),1.87e-07,72.84,12,9,0,15.75,11.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Participant (humn),1.24e-17,63.72,11,96,1,12.26,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,General Population (humn),1.24e-17,64.73,12,68,0,14.12,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.24e-17,77.74,12,27,0,17.33,21.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,High Risk Populations (popg),8.95e-07,67.88,12,10,0,18.33,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Heart failure (dsyn),4.5e-16,71.63,12,20,0,19.2,9.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Cardiovascular Diseases (dsyn),1.62e-13,68.72,12,19,0,19.58,9.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),1.24e-17,64.97,12,93,0,13.55,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",ISA,Chronic Disease (dsyn),3.21e-08,64.87,12,16,0,21.0,5.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,Outpatients (podg),4.83e-07,63.66,12,17,0,20.47,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PREDISPOSES,Heart failure (dsyn),6.63e-07,68.2,12,10,0,18.33,21.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",PROCESS_OF,cohort (humn),2.8e-09,63.76,12,22,0,18.55,1.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",CAUSES,Cessation of life (orgf),1.87e-13,65.58,12,24,0,18.0,11.0
Body mass index (clna),PREDISPOSES,"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),2.69e-06,66.8,12,10,0,18.33,9.0
hypercholesterolemia (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),5.04e-07,12.92,9,18,0,13.5,1.0
Large-for-dates fetus (fndg),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),8.68e-08,38.97,6,20,0,7.8,1.0
Large-for-dates fetus (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),8.84e-08,36.15,6,65,0,6.55,1.0
Large-for-dates fetus (fndg),PROCESS_OF,cohort (humn),USES,Treats (clas),4.61e-07,38.48,6,16,0,8.25,1.0
Large-for-dates fetus (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.18e-06,38.73,6,13,0,8.77,1.0
Large-for-dates fetus (fndg),PROCESS_OF,cohort (humn),USES,Classification (clas),9.81e-08,39.71,6,16,0,8.25,1.0
Large-for-dates fetus (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.56e-06,45.12,6,8,0,10.5,1.0
Large-for-dates fetus (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),8.6e-08,38.59,6,23,0,7.57,1.0
Large-for-dates fetus (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),8.58e-08,39.49,6,22,0,7.64,1.0
Large-for-dates fetus (fndg),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),9.7e-07,39.42,6,13,0,8.77,1.0
Large-for-dates fetus (fndg),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),8.74e-08,41.42,6,15,0,8.4,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,43.85,9,9,0,18.0,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.01e-11,42.91,9,194,0,9.42,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.47e-10,41.63,9,17,0,13.76,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),1.01e-11,42.9,9,29,0,11.79,11.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),2.09e-10,45.08,9,14,0,14.79,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,40.89,9,12,0,15.75,5.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),1.01e-11,39.71,9,48,0,10.69,11.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.01e-11,43.1,9,29,0,11.79,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.01e-11,40.15,9,98,0,9.83,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.34e-09,38.81,9,24,0,12.38,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,45.22,9,10,0,17.1,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.22e-08,37.58,9,37,0,11.19,7.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.74e-09,39.38,9,20,0,13.05,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.01e-11,41.04,9,94,0,9.86,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,46.83,9,8,0,15.11,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),1.04e-11,43.7,9,19,0,13.26,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),2.21e-11,40.86,9,21,0,12.86,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.79e-09,46.04,9,12,0,15.75,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.64e-09,53.75,9,10,0,17.1,21.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,46.34,9,10,0,17.1,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),3.26e-11,40.66,9,21,0,12.86,21.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),1.03e-11,42.27,9,21,0,12.86,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.01e-11,40.39,9,32,0,11.53,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,47.75,9,10,0,17.1,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),1.01e-11,46.72,9,39,0,11.08,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),1.01e-11,50.7,9,44,0,10.84,11.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.01e-11,43.57,9,113,0,9.72,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,41.1,9,11,0,16.36,11.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,40.83,9,11,0,16.36,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,41.29,9,12,0,15.75,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.28e-10,39.18,9,25,0,12.24,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.01e-11,44.86,9,87,0,9.93,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),1.01e-11,39.84,9,33,0,11.45,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.01e-11,42.58,9,41,0,10.98,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),1.02e-11,42.75,9,21,0,12.86,1.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",6.01e-11,40.41,9,21,0,12.86,9.0
Leptin|LEP (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.01e-11,41.36,9,1021,0,9.08,11.0
Total cholesterol (strd),ISA,Lipids (lipd),PART_OF,Stratum corneum (tisu),7.96e-07,12.95,45,2,0,2.09,3.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PREDISPOSES,CARDIAC EVENT (dsyn),2.63e-08,55.41,10,15,0,16.67,21.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Octogenarians (aggp),4.29e-08,57.76,10,12,0,18.33,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Vascular Diseases (dsyn),6.96e-09,56.06,10,15,0,16.67,5.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Death (finding) (fndg),4.23e-14,55.3,10,28,0,13.57,5.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Participant (humn),3.74e-11,53.46,10,28,0,13.57,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiovascular Diseases (dsyn),3.97e-14,56.25,10,66,0,11.52,5.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Outpatients (podg),3.97e-14,54.11,10,47,0,12.13,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetic (fndg),1.49e-10,53.39,10,27,0,13.7,9.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Heart failure (dsyn),8.95e-07,57.81,10,10,0,20.0,9.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Acute coronary syndrome (dsyn),4.26e-09,58.38,10,13,0,17.69,9.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",3.23e-11,53.8,10,26,0,13.85,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Heart Diseases (dsyn),1.43e-07,53.45,10,19,0,15.26,5.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Survivors (humn),1.03e-07,54.81,10,15,0,16.67,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,General Population (humn),8.9e-10,53.73,10,23,0,14.35,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,Young adult (aggp),3.12e-06,53.34,10,16,0,16.25,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Cardiomyopathies (dsyn),2.14e-06,54.49,10,13,0,17.69,5.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),ISA,Myocardial Ischemia (dsyn),2.35e-06,53.2,10,17,0,15.88,5.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.97e-14,53.84,10,51,0,11.96,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Cessation of life (orgf),3.97e-14,54.33,10,145,0,10.69,11.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),CAUSES,Heart failure (dsyn),3.97e-14,55.19,10,39,0,12.56,11.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),PROCESS_OF,cohort (humn),3.42e-06,54.81,10,12,0,18.33,1.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.76e-06,53.96,10,14,0,17.14,9.0
Waist circumference (fndg),PREDISPOSES,Coronary Arteriosclerosis (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",6.63e-07,58.14,10,10,0,20.0,9.0
Systolic blood pressure (ortf),PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),5.13e-12,17.48,12,136,0,13.06,1.0
Systolic blood pressure (ortf),PROCESS_OF,Caucasoid Race (popg),ISA,Ethnic group (popg),5.13e-12,16.61,12,188,0,12.77,1.0
Systolic blood pressure (ortf),PROCESS_OF,Caucasoid Race (popg),ISA,Population Group (humn),2.53e-06,17.49,12,20,0,19.2,1.0
"Sleep Apnea, Obstructive (dsyn)",OCCURS_IN,cohort (humn),USES,Medicare (rnlw),2.34e-09,48.16,7,20,0,9.45,6.0
"Sleep Apnea, Obstructive (dsyn)",OCCURS_IN,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.88e-09,45.34,7,65,0,7.75,2.0
"Sleep Apnea, Obstructive (dsyn)",OCCURS_IN,cohort (humn),USES,Treats (clas),3.77e-07,47.67,7,16,0,10.06,6.0
"Sleep Apnea, Obstructive (dsyn)",OCCURS_IN,cohort (humn),LOCATION_OF,Calcium (bacs),4.1e-06,47.92,7,13,0,10.77,2.0
"Sleep Apnea, Obstructive (dsyn)",OCCURS_IN,cohort (humn),USES,Classification (clas),1.36e-08,48.9,7,16,0,10.06,6.0
"Sleep Apnea, Obstructive (dsyn)",OCCURS_IN,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,54.31,7,8,0,13.12,2.0
"Sleep Apnea, Obstructive (dsyn)",OCCURS_IN,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.52e-09,47.79,7,23,0,9.13,2.0
"Sleep Apnea, Obstructive (dsyn)",OCCURS_IN,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.36e-09,48.68,7,22,0,9.23,2.0
"Sleep Apnea, Obstructive (dsyn)",OCCURS_IN,cohort (humn),USES,Tissue Microarray (resd),8.86e-07,48.61,7,13,0,10.77,6.0
"Sleep Apnea, Obstructive (dsyn)",OCCURS_IN,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),2.89e-09,50.61,7,15,0,10.27,2.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),ISA,Heart Diseases (dsyn),9.71e-07,55.84,12,20,0,19.2,5.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PRECEDES,"Death, Sudden, Cardiac (patf)",4.81e-16,58.69,12,28,0,17.14,21.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),CAUSES,Heart failure (dsyn),3.63e-17,56.32,12,48,0,15.0,11.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),CAUSES,Hospitalization (hlca),9.25e-12,61.12,12,17,0,20.47,11.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PROCESS_OF,cohort (humn),3.51e-17,59.26,12,114,0,13.26,1.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),CAUSES,Heart Arrest (patf),6.98e-08,59.27,12,13,0,23.08,11.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),OCCURS_IN,cohort (humn),4.86e-07,61.45,11,9,1,16.36,21.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PRECEDES,Myocardial rupture (dsyn),8.82e-14,58.33,12,25,0,17.76,21.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PROCESS_OF,Control Groups (humn),2.44e-06,55.56,12,21,0,18.86,1.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),ISA,Myocardial Ischemia (dsyn),3.51e-17,57.15,12,45,0,15.2,5.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PROCESS_OF,High Risk Populations (popg),9.31e-11,63.35,12,14,0,22.29,1.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PRECEDES,"Shock, Cardiogenic (patf)",6.29e-10,58.33,12,18,0,20.0,21.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),COEXISTS_WITH,Cerebrovascular accident (dsyn),6.71e-10,60.38,12,15,0,21.6,9.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),ISA,Coronary Arteriosclerosis (dsyn),3.51e-17,56.73,12,55,0,14.62,5.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),CAUSES,"Shock, Cardiogenic (patf)",1.56e-13,60.02,12,21,0,18.86,11.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PROCESS_OF,Octogenarians (aggp),4.19e-09,65.65,12,11,0,21.08,1.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),NEG_COEXISTS_WITH,Hemorrhage (fndg),3.04e-06,69.03,12,7,0,11.08,21.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),COEXISTS_WITH,Diabetic (fndg),5.75e-14,57.16,12,30,0,16.8,9.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PROCESS_OF,cohort (humn),5.28e-15,59.63,12,24,0,18.0,1.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PROCESS_OF,"Mice, Knockout (mamm)",5.59e-07,58.81,12,12,0,24.0,1.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),ISA,Cardiovascular Diseases (dsyn),3.51e-17,56.7,12,94,0,13.53,5.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PROCESS_OF,inpatient (humn),1.72e-11,60.74,12,17,0,20.47,1.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),CAUSES,Cessation of life (orgf),3.51e-17,56.87,12,123,0,13.17,11.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PRECEDES,Atrial Fibrillation (patf),4.72e-09,60.08,12,14,0,22.29,21.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),COEXISTS_WITH,Coronary Arteriosclerosis (dsyn),2.14e-06,57.45,12,13,0,23.08,9.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PRECEDES,"Death, Sudden (patf)",8.9e-10,56.69,12,23,0,18.26,21.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.12e-07,58.98,12,13,0,23.08,9.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),ISA,Death (finding) (fndg),3.51e-17,58.21,12,65,0,14.22,5.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),ISA,Coronary heart disease (dsyn),3.51e-17,57.7,12,78,0,13.85,5.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),ISA,Ischemia (dsyn),9.74e-08,56.5,12,19,0,19.58,5.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PRECEDES,Heart failure (dsyn),3.51e-17,57.12,12,110,0,13.31,21.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PROCESS_OF,Survivors (humn),3.51e-17,56.81,12,105,0,13.37,1.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),COEXISTS_WITH,Cardiac Death (patf),3.47e-06,63.56,12,8,0,13.33,9.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PROCESS_OF,Participant (humn),3.51e-17,57.1,12,53,0,14.72,1.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),COEXISTS_WITH,Thrombosis (patf),5.21e-07,59.87,12,11,0,21.08,9.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PROCESS_OF,network (popg),3.51e-17,61.73,12,31,0,16.65,1.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PROCESS_OF,General Population (humn),3.91e-17,58.56,12,32,0,16.5,1.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PROCESS_OF,Hospitalized Patients (humn),1.14e-14,59.36,12,24,0,18.0,1.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PRECEDES,Congestive heart failure (dsyn),2.82e-07,56.71,12,17,0,20.47,21.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.4e-06,59.1,12,11,0,21.08,21.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PRECEDES,Depressive disorder (mobd),1.76e-07,58.71,12,13,0,23.08,21.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PRECEDES,"Ventricular Dysfunction, Left (patf)",8.24e-13,56.03,12,36,0,16.0,21.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PROCESS_OF,Survivors (humn),1.88e-14,63.05,12,19,0,19.58,1.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PREDISPOSES,Cerebrovascular accident (dsyn),3.51e-17,59.73,12,38,0,15.79,21.0
Body mass index (clna),PREDISPOSES,Myocardial Infarction (dsyn),PRECEDES,Mitral Valve Insufficiency (dsyn),4.77e-07,57.18,12,15,0,21.6,21.0
Periodontal Diseases (dsyn),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.64e-09,19.93,10,18,0,15.56,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Pre-Eclampsia (dsyn),AFFECTS,Pathogenesis (patf),1.87e-06,22.11,16,25,0,26.24,7.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Pre-Eclampsia (dsyn),PROCESS_OF,Pregnant Women (popg),1.41e-12,21.33,16,105,0,18.44,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Pre-Eclampsia (dsyn),AFFECTS,Pregnancy (orgf),3.63e-08,23.17,16,21,0,28.19,7.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Pre-Eclampsia (dsyn),ISA,Hypertension induced by pregnancy (dsyn),3.66e-08,22.15,16,31,0,24.26,5.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Pre-Eclampsia (dsyn),PROCESS_OF,Pregnant Women (popg),4.89e-09,22.36,16,31,0,24.26,1.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Pre-Eclampsia (dsyn),ISA,Pregnancy Complications (dsyn),9.31e-16,22.77,16,46,0,21.57,5.0
Leptin|LEP (aapp),ASSOCIATED_WITH,Pre-Eclampsia (dsyn),CAUSES,"Morbidity, perinatal (patf)",3.47e-06,30.41,16,8,0,12.0,8.0
Vitamin D (phsu),TREATS,Participant (humn),USES,Medicare (rnlw),1.27e-09,22.81,10,18,0,15.56,4.0
dietary intervention (topp),TREATS,Body Weight decreased (fndg),PROCESS_OF,Survivors (humn),1.06e-06,26.89,17,12,0,20.47,1.0
dietary intervention (topp),TREATS,Body Weight decreased (fndg),ISA,Physical findings (sosy),7.03e-08,24.26,17,24,0,29.04,4.0
Assessment procedure (hlca),TREATS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",4.59e-08,33.38,179,16,0,17.43,4.0
Assessment procedure (hlca),TREATS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),9.39e-07,38.55,179,9,0,9.45,4.0
Assessment procedure (hlca),TREATS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),1.17e-07,30.93,179,31,0,36.37,4.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,21.67,16,9,0,14.06,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.17e-15,20.73,16,194,0,17.32,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,19.45,16,17,0,31.06,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.17e-15,20.72,16,29,0,24.83,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,22.9,16,14,0,26.25,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,18.71,16,12,0,21.0,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),2.17e-15,17.53,16,48,0,21.33,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.17e-15,20.92,16,29,0,24.83,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.17e-15,17.97,16,98,0,18.61,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,16.63,16,24,0,26.67,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,23.04,16,10,0,16.25,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,15.4,16,37,0,22.92,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,17.2,16,20,0,28.8,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),2.17e-15,18.86,16,94,0,18.72,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,24.65,16,8,0,12.0,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.15e-13,21.52,16,19,0,29.47,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,18.68,16,21,0,28.19,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,23.86,16,12,0,21.0,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,31.57,16,10,0,16.25,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,24.16,16,10,0,16.25,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,18.48,16,21,0,28.19,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.72e-13,20.09,16,21,0,28.19,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),2.26e-15,18.21,16,32,0,24.0,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,25.57,16,10,0,16.25,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.17e-15,24.54,16,39,0,22.56,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),2.17e-15,28.52,16,44,0,21.82,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.17e-15,21.39,16,113,0,18.27,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,18.92,16,11,0,18.56,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,18.65,16,11,0,18.56,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,19.11,16,12,0,21.0,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,17.0,16,25,0,26.24,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",2.17e-15,22.68,16,87,0,18.94,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),2.78e-15,17.67,16,33,0,23.76,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),2.17e-15,20.4,16,41,0,22.24,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),9.09e-14,20.57,16,21,0,28.19,1.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,18.24,16,21,0,28.19,5.0
"Sleep Apnea, Obstructive (dsyn)",ISA,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),2.17e-15,19.18,15,1020,1,15.22,5.0
Serum specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Ischemic stroke (dsyn),4.17e-06,17.66,16,11,0,18.56,2.0
Serum specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Cardiovascular Diseases (dsyn),3.01e-10,14.89,16,34,0,23.53,2.0
Serum specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Septicemia (dsyn),8.39e-13,19.25,16,20,0,28.8,2.0
Serum specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),ISA,Albumins (aapp),5.5e-14,16.49,16,30,0,24.53,2.0
Serum specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),ASSOCIATED_WITH,Acute coronary syndrome (dsyn),1.24e-07,17.01,16,15,0,29.06,2.0
Serum specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),ISA,Acute-Phase Proteins (aapp),1.62e-13,14.08,16,77,0,19.32,2.0
Serum specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),compared_with,procalcitonin (aapp),1.82e-08,17.3,16,16,0,32.0,2.0
Serum specimen (bdsu),LOCATION_OF,C-reactive protein (aapp),PREDISPOSES,Myocardial Infarction (dsyn),2.06e-06,16.34,16,14,0,26.25,2.0
Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),LOCATION_OF,Interleukin-6 (aapp),2.93e-19,13.84,43,25,0,39.53,1.0
Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),LOCATION_OF,C-reactive protein (aapp),5.88e-09,11.64,43,13,0,16.93,1.0
Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (humn),LOCATION_OF,procalcitonin (aapp),3.99e-21,16.1,43,32,0,55.81,1.0
Alanine Transaminase (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.75e-10,25.26,10,33,0,13.03,1.0
Alanine Transaminase (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,25.81,10,16,0,16.25,8.0
Alanine Transaminase (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),1.64e-11,25.61,10,71,0,11.41,5.0
Alanine Transaminase (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.64e-11,39.45,10,35,0,12.86,8.0
Alanine Transaminase (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),1.64e-11,25.54,10,110,0,10.91,8.0
Alanine Transaminase (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.37e-09,24.87,10,37,0,12.7,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,22.33,80,20,0,25.0,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,19.51,80,65,0,117.81,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,21.84,80,16,0,19.2,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,22.09,80,13,0,15.11,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,23.07,80,16,0,19.2,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,28.48,80,8,0,8.8,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,21.96,80,23,0,29.61,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,22.85,80,22,0,28.05,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,22.78,80,13,0,15.11,1.0
Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,24.78,80,15,0,17.81,1.0
Roux-en-Y Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Gastric Adenocarcinoma (neop),1.87e-32,34.42,27,64,0,38.39,4.0
Roux-en-Y Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Malignant neoplasm of stomach (neop),1.87e-32,31.28,27,578,0,28.26,4.0
Roux-en-Y Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Advanced cancer (neop),1.2e-16,33.98,27,24,0,45.33,4.0
Roux-en-Y Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Adenocarcinoma (neop),8.38e-19,32.48,27,30,0,51.3,4.0
Roux-en-Y Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,"Obesity, Morbid (dsyn)",1.87e-32,30.16,25,78,2,33.01,4.0
Roux-en-Y Gastric Bypass (topp),compared_with,Gastrectomy (topp),USES,Sleeves (medd),1.87e-32,27.23,24,530,3,25.09,6.0
Roux-en-Y Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Body Weight decreased (fndg),5.27e-15,30.45,27,30,0,51.3,4.0
Roux-en-Y Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Stomach Carcinoma (neop),4.1e-27,31.17,27,49,0,41.88,4.0
Roux-en-Y Gastric Bypass (topp),compared_with,Gastrectomy (topp),ADMINISTERED_TO,Surgeon (humn),2e-09,33.54,27,14,0,21.26,15.0
Roux-en-Y Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Malignant neoplasm of stomach stage III (neop),2.07e-06,32.79,27,10,0,13.7,4.0
Roux-en-Y Gastric Bypass (topp),compared_with,Gastrectomy (topp),TREATS,Early gastric cancer (neop),2.24e-31,29.72,27,71,0,37.27,4.0
Exercise (dora),TREATS,Participant (humn),USES,Medicare (rnlw),6e-07,10.26,11,18,0,17.72,4.0
Laparoscopic Colectomy (topp),compared_with,Colectomy (topp),TREATS,Malignant tumor of colon (neop),6.67e-07,11.09,8,42,2,9.52,4.0
Laparoscopic Colectomy (topp),compared_with,Colectomy (topp),TREATS,Clostridium difficile colitis (dsyn),6.67e-07,16.8,10,18,0,15.56,4.0
Laparoscopic Colectomy (topp),compared_with,Colectomy (topp),TREATS,Ulcerative Colitis (dsyn),2.3e-06,7.85,10,36,0,12.78,4.0
Laparoscopic Colectomy (topp),compared_with,Colectomy (topp),TREATS,Carcinoma of the Large Intestine (neop),9.92e-07,10.04,10,16,0,16.25,4.0
Laparoscopic Colectomy (topp),compared_with,Colectomy (topp),TREATS,Diverticulitis (dsyn),6.73e-07,12.98,10,14,0,17.14,4.0
Leptin|LEP (aapp),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.48e-07,23.93,7,16,0,10.06,7.0
Leptin|LEP (aapp),AFFECTS,Insulin Resistance (patf),COEXISTS_WITH,Critical Illness (dsyn),1.04e-06,29.1,7,9,0,12.44,7.0
Leptin|LEP (aapp),AFFECTS,Insulin Resistance (patf),PREDISPOSES,Cardiovascular Diseases (dsyn),2.2e-07,21.48,7,31,0,8.58,7.0
Leptin|LEP (aapp),PART_OF,Adipocytes (cell),PART_OF,Caucasoid Race (popg),6.05e-07,6.51,10,4,0,5.6,3.0
Leptin|LEP (aapp),PART_OF,Adipocytes (cell),PART_OF,Stroma (bpoc),5.92e-07,6.53,10,7,0,11.9,3.0
Hip Fractures (inpo),ISA,Wounds and Injuries (inpo),PROCESS_OF,Surgical Patients (podg),3.5e-07,12.53,9,22,0,12.68,1.0
Hip Fractures (inpo),ISA,Wounds and Injuries (inpo),PROCESS_OF,VICTIM (humn),3.5e-07,11.31,9,322,0,9.25,1.0
Hip Fractures (inpo),ISA,Wounds and Injuries (inpo),CAUSES,Multiple Organ Failure (patf),3.5e-07,16.21,9,15,0,14.4,5.0
Hip Fractures (inpo),ISA,Wounds and Injuries (inpo),PROCESS_OF,cohort (humn),3.5e-07,12.49,9,32,0,11.53,1.0
Hip Fractures (inpo),ISA,Wounds and Injuries (inpo),CAUSES,Heart Arrest (patf),4.74e-06,14.49,9,10,0,17.1,5.0
Hip Fractures (inpo),ISA,Wounds and Injuries (inpo),PROCESS_OF,Pedestrian (humn),4.81e-07,15.04,9,12,0,15.75,1.0
Hip Fractures (inpo),ISA,Wounds and Injuries (inpo),PROCESS_OF,network (popg),3.5e-07,11.35,9,46,0,10.76,1.0
Hip Fractures (inpo),ISA,Wounds and Injuries (inpo),PROCESS_OF,Geriatric Patients (humn),3.5e-07,14.06,9,85,0,9.95,1.0
Hip Fractures (inpo),ISA,Wounds and Injuries (inpo),PROCESS_OF,Teams (humn),3.5e-07,11.35,9,133,0,9.61,1.0
Hip Fractures (inpo),ISA,Wounds and Injuries (inpo),PROCESS_OF,General Population (humn),9.28e-07,12.0,9,16,0,14.06,1.0
Hip Fractures (inpo),ISA,Wounds and Injuries (inpo),PROCESS_OF,civilian (humn),3.5e-07,12.36,9,58,0,10.4,1.0
Hip Fractures (inpo),ISA,Wounds and Injuries (inpo),PROCESS_OF,Hospitalized Patients (humn),3.5e-07,13.45,9,35,0,11.31,1.0
Hip Fractures (inpo),ISA,Wounds and Injuries (inpo),CAUSES,Blood Coagulation Disorders (dsyn),3.5e-07,16.21,9,18,0,13.5,5.0
Triglycerides (bacs),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),4.2e-07,12.9,9,77,0,10.05,1.0
Triglycerides (bacs),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),4.3e-07,13.25,9,16,0,14.06,1.0
Triglycerides (bacs),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Young adult (aggp),4.5e-06,12.69,9,12,0,15.75,1.0
Triglycerides (bacs),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Middle Aged (aggp),4.2e-07,13.03,9,19,0,13.26,1.0
Triglycerides (bacs),PREDISPOSES,Coronary heart disease (dsyn),PREDISPOSES,Atherosclerosis (dsyn),4.21e-07,11.82,9,22,0,12.68,21.0
Triglycerides (bacs),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Outpatients (podg),4.77e-07,10.82,9,24,0,12.38,1.0
Triglycerides (bacs),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,General Population (humn),4.2e-07,12.53,9,42,0,10.93,1.0
Triglycerides (bacs),PREDISPOSES,Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),4.2e-07,13.78,9,102,0,9.79,5.0
Triglycerides (bacs),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Heart failure (dsyn),7.54e-07,13.37,9,13,0,15.23,11.0
Triglycerides (bacs),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),4.2e-07,13.12,9,83,0,9.98,1.0
Triglycerides (bacs),PREDISPOSES,Coronary heart disease (dsyn),ISA,Death (finding) (fndg),4.2e-07,15.7,9,250,0,9.32,5.0
Triglycerides (bacs),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),4.2e-07,12.88,9,194,0,9.42,11.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Glomerular Filtration Rate (ortf),2.59e-06,15.47,54,9,0,10.5,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),1.18e-39,14.53,54,194,0,69.03,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Middle Aged (aggp),3.37e-10,13.26,54,17,0,22.35,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Hospitalization (hlca),2.76e-19,14.52,54,29,0,44.57,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Western society (popg),1.99e-10,16.71,54,14,0,17.63,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),ISA,Heart failure (dsyn),1.06e-06,12.52,54,12,0,14.67,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Disability NOS (patf),9.81e-23,11.34,54,48,0,90.67,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.51e-19,14.73,54,29,0,44.57,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),1.18e-39,11.77,52,96,2,80.17,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Metabolic syndrome (dsyn),2.33e-09,10.44,54,24,0,34.67,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Long-Term Survivors (podg),1.76e-07,16.85,54,10,0,11.85,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),AFFECTS,Pathogenesis (patf),1.21e-08,9.21,54,37,0,62.35,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetes Mellitus (dsyn),6.73e-09,11.01,54,20,0,27.41,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,cohort (humn),1.18e-39,12.66,54,94,0,85.02,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Coronary heart disease (dsyn),2.34e-06,18.45,54,8,0,9.19,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Population Group (humn),3.13e-13,15.33,54,19,0,25.69,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Survivors (humn),1.2e-11,12.48,54,21,0,29.17,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Death (finding) (fndg),2.78e-09,17.66,54,12,0,14.67,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),2.63e-09,25.38,54,10,0,11.85,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Cancer Survivor (podg),8.18e-08,17.96,54,10,0,11.85,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PREDISPOSES,Atherosclerosis (dsyn),2.25e-11,12.28,54,21,0,29.17,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Chronic Obstructive Airway Disease (dsyn),2.69e-13,13.89,54,21,0,29.17,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Participant (humn),9.02e-17,12.02,54,32,0,50.96,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,modern society (popg),3.53e-08,19.38,54,10,0,11.85,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,End stage renal failure (dsyn),2.28e-31,18.34,54,39,0,67.17,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,follow-up (hlca),2.52e-39,22.32,54,44,0,79.85,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",1.18e-39,15.2,54,113,0,79.81,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Myocardial Infarction (dsyn),2.75e-06,12.72,54,11,0,13.24,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),4.17e-06,12.45,54,11,0,13.24,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,Japanese Population (popg),5.59e-07,12.91,54,12,0,14.67,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,African American (popg),1.18e-10,10.81,54,25,0,36.57,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,"Recipient, Transplant (podg)",1.18e-39,16.48,54,87,0,87.52,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,Diabetic (fndg),6.16e-16,11.47,54,33,0,53.17,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,General Population (humn),9.09e-27,14.21,54,41,0,72.13,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),PROCESS_OF,High Risk Populations (popg),8.87e-14,14.37,54,21,0,29.17,1.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),COEXISTS_WITH,"Diabetes Mellitus, Insulin-Dependent (dsyn)",5e-11,12.04,54,21,0,29.17,5.0
Cerebrovascular accident (dsyn),ISA,Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),1.18e-39,12.99,52,1019,2,54.65,5.0
Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,cohort (humn),6.23e-11,16.38,12,77,0,13.87,1.0
Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),1.01e-08,16.73,12,16,0,21.0,1.0
Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Young adult (aggp),4.08e-06,16.17,12,12,0,24.0,1.0
Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Middle Aged (aggp),4.97e-10,16.51,12,19,0,19.58,1.0
Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PREDISPOSES,Atherosclerosis (dsyn),1.44e-09,15.3,12,22,0,18.55,21.0
Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Outpatients (podg),5.77e-08,14.3,12,24,0,18.0,1.0
Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,General Population (humn),6.23e-11,16.01,12,42,0,15.43,1.0
Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),ISA,Cardiovascular Diseases (dsyn),6.23e-11,17.26,12,102,0,13.41,5.0
Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Heart failure (dsyn),3.34e-07,16.85,12,13,0,23.08,11.0
Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),PROCESS_OF,Participant (humn),6.23e-11,16.6,12,83,0,13.73,1.0
Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),ISA,Death (finding) (fndg),6.23e-11,19.18,12,250,0,12.58,5.0
Cerebrovascular accident (dsyn),PREDISPOSES,Coronary heart disease (dsyn),CAUSES,Cessation of life (orgf),6.23e-11,16.36,12,194,0,12.74,11.0
Sports (dora),ISA,Physical activity (dora),TREATS,Cardiovascular Diseases (dsyn),1.72e-08,14.89,20,18,0,34.2,4.0
Sports (dora),ISA,Physical activity (dora),TREATS,Survivors (humn),4.06e-12,13.53,20,36,0,31.11,4.0
Sports (dora),ISA,Physical activity (dora),TREATS,General Population (humn),4.11e-11,15.04,20,23,0,37.39,4.0
Sports (dora),ISA,Physical activity (dora),TREATS,Chronic Obstructive Airway Disease (dsyn),1.66e-07,12.82,20,31,0,32.9,4.0
Sports (dora),ISA,Physical activity (dora),PREVENTS,Cardiovascular Diseases (dsyn),6.41e-10,15.56,20,19,0,37.05,5.0
Sports (dora),ISA,Physical activity (dora),TREATS,"Kidney Failure, Chronic (dsyn)",6.74e-07,17.33,20,11,0,17.05,4.0
Intervention regimes (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.2e-14,22.28,26,22,0,40.62,4.0
Intervention regimes (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),1.23e-10,21.71,26,17,0,28.12,1.0
Intervention regimes (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.29e-08,17.77,26,27,0,51.04,1.0
Intervention regimes (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.38e-08,20.73,26,15,0,23.65,1.0
Intervention regimes (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),1.37e-10,18.93,26,24,0,46.15,4.0
Intervention regimes (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),8.91e-14,18.55,26,34,0,45.88,1.0
Intervention regimes (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),5.21e-21,19.98,26,40,0,42.9,1.0
Intervention regimes (hlca),TREATS,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),1.22e-09,26.7,26,12,0,17.54,4.0
Physical activity (dora),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.67e-10,14.08,13,33,0,18.12,1.0
Physical activity (dora),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,14.62,13,16,0,23.56,4.0
Physical activity (dora),TREATS,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),8.63e-12,14.42,13,71,0,15.38,4.0
Physical activity (dora),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),8.63e-12,28.27,13,35,0,17.83,4.0
Physical activity (dora),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),8.63e-12,14.35,13,110,0,14.54,4.0
Physical activity (dora),TREATS,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.36e-09,13.69,13,37,0,17.57,1.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),1.84e-08,68.39,31,20,0,32.9,1.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),CAUSES,Disability NOS (patf),5.78e-23,71.54,30,35,1,55.71,11.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),ISA,Respiration Disorders (dsyn),1e-23,68.17,31,59,0,47.29,5.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Respiratory physiology (ortf),2.06e-08,67.83,31,23,0,40.06,1.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),CAUSES,Acute respiratory failure (dsyn),3.54e-07,70.83,31,12,0,16.65,11.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,cohort (humn),1.33e-31,68.54,31,72,0,44.35,1.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),ISA,Lung diseases (dsyn),3.92e-28,68.01,31,73,0,44.16,5.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Hospitalized Patients (humn),3.22e-25,69.34,31,50,0,50.22,1.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospital admission (hlca),3.35e-09,71.13,31,15,0,22.26,11.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),CAUSES,Cessation of life (orgf),1.03e-46,71.06,30,183,1,34.92,11.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Outpatients (podg),1.87e-08,66.6,31,43,0,53.35,1.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,General Population (humn),7.58e-12,68.57,31,27,0,50.52,1.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),CAUSES,Diagnosis (hlca),1.7e-07,72.61,30,10,1,13.33,11.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),CAUSES,Hospitalization (hlca),2e-18,70.75,31,31,0,62.0,11.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),PROCESS_OF,Participant (humn),3.56e-26,67.9,31,70,0,44.73,1.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),COEXISTS_WITH,Smoker (fndg),2.39e-07,67.08,31,27,0,50.52,9.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),ISA,Chronic Disease (dsyn),3.84e-22,69.05,31,46,0,51.89,5.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Malignant neoplasm of lung (neop),8.79e-08,68.77,31,17,0,26.32,18.0
Body mass index procedure (diap),DIAGNOSES,Chronic Obstructive Airway Disease (dsyn),PREDISPOSES,Pneumonia (dsyn),4.46e-07,70.68,31,12,0,16.65,18.0
Irregular menstrual cycle NOS (patf),PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.22e-08,61.44,6,18,0,8.0,1.0
Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,13.57,26,20,0,35.38,1.0
Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,10.76,26,65,0,36.4,1.0
Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,13.08,26,16,0,25.85,1.0
Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,13.34,26,13,0,19.5,1.0
Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,14.32,26,16,0,25.85,1.0
Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,19.72,26,8,0,10.46,1.0
Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,13.2,26,23,0,43.35,1.0
Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,14.09,26,22,0,40.62,1.0
Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,14.02,26,13,0,19.5,1.0
Diabetes Mellitus (dsyn),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,16.02,26,15,0,23.65,1.0
"ATPase, Aminophospholipid Transporter-Like, Class I, Type 8A, Member 2|ATP8A2 (aapp)",PART_OF,Extracellular (celc),LOCATION_OF,Vesicle (acab),6.26e-08,0.24,2,57,0,2.07,2.0
"ATPase, Aminophospholipid Transporter-Like, Class I, Type 8A, Member 2|ATP8A2 (aapp)",PART_OF,Extracellular (celc),LOCATION_OF,Polysaccharides (carb),6.26e-08,0.06,2,3,0,3.33,2.0
Supplementation (topp),USES,Vitamin D (phsu),ASSOCIATED_WITH,Carcinoma of the Large Intestine (neop),3.03e-07,12.34,97,11,0,12.25,6.0
Supplementation (topp),USES,Vitamin D (phsu),ASSOCIATED_WITH,Cardiovascular Diseases (dsyn),6.05e-11,9.88,97,21,0,25.55,6.0
Supplementation (topp),USES,Vitamin D (phsu),TREATS,Cardiovascular Diseases (dsyn),2.69e-06,11.7,97,10,0,11.03,4.0
Supplementation (topp),USES,Vitamin D (phsu),TREATS,"Hyperparathyroidism, Secondary (dsyn)",8.83e-09,9.42,97,18,0,21.34,4.0
Supplementation (topp),USES,Vitamin D (phsu),TREATS,Critical Illness (dsyn),9.08e-08,13.52,96,10,1,11.04,4.0
Supplementation (topp),USES,Vitamin D (phsu),TREATS,"Kidney Failure, Chronic (dsyn)",6.32e-12,9.55,97,24,0,29.94,4.0
Supplementation (topp),USES,Vitamin D (phsu),ASSOCIATED_WITH,"Kidney Failure, Chronic (dsyn)",9.54e-14,9.47,97,28,0,36.08,6.0
Shock (patf),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cerebrovascular accident (dsyn),5.01e-07,17.44,16,16,0,32.0,9.0
Shock (patf),COEXISTS_WITH,"Sleep Apnea, Obstructive (dsyn)",PREDISPOSES,Cardiovascular morbidity (dsyn),1.59e-15,27.65,16,26,0,25.85,9.0
Respiration (phsf),PROCESS_OF,cohort (humn),USES,Medicare (rnlw),9.97e-10,23.33,15,20,0,26.25,1.0
Respiration (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.54e-09,20.51,15,65,0,18.46,1.0
Respiration (phsf),PROCESS_OF,cohort (humn),USES,Treats (clas),3.75e-07,22.83,15,16,0,29.06,1.0
Respiration (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,Calcium (bacs),4.09e-06,23.09,15,13,0,24.27,1.0
Respiration (phsf),PROCESS_OF,cohort (humn),USES,Classification (clas),1.22e-08,24.07,15,16,0,29.06,1.0
Respiration (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,Sodium (elii),3.47e-06,29.48,15,8,0,12.27,1.0
Respiration (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,C-reactive protein (aapp),1.77e-10,22.95,15,23,0,24.78,1.0
Respiration (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,TP53 gene|TP53 (aapp),1.53e-11,23.85,15,22,0,25.23,1.0
Respiration (phsf),PROCESS_OF,cohort (humn),USES,Tissue Microarray (resd),8.85e-07,23.78,15,13,0,24.27,1.0
Respiration (phsf),PROCESS_OF,cohort (humn),LOCATION_OF,ERBB2 gene|ERBB2 (aapp),1.54e-09,25.77,15,15,0,30.0,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,General Population (humn),2.59e-10,25.98,45,33,0,57.2,1.0
C-reactive protein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Cardiovascular Diseases (dsyn),4.43e-06,26.53,45,16,0,21.69,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),ISA,Cardiovascular Diseases (dsyn),3.33e-25,26.33,45,71,0,73.52,5.0
C-reactive protein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular morbidity (dsyn),1.96e-32,40.17,45,35,0,62.22,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Cardiovascular Diseases (dsyn),3.09e-38,26.26,45,110,0,63.41,8.0
C-reactive protein (aapp),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PROCESS_OF,cohort (humn),1.35e-09,25.59,45,37,0,67.42,1.0
Neck (blor),LOCATION_OF,Scanning (diap),USES,Calcium (bacs),2.38e-07,6.19,14,32,0,20.12,2.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Survivors (humn),1.59e-15,67.33,16,34,0,23.53,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Fibrosis (patf),3.08e-10,67.71,16,21,0,28.19,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Septicemia (dsyn),8.64e-24,71.07,16,38,0,22.74,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Critical Illness (dsyn),1.04e-13,66.64,16,35,0,23.31,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,cohort (humn),9.34e-13,65.57,16,49,0,21.22,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Pneumonia (dsyn),7.6e-17,70.93,16,25,0,26.24,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Acute heart failure (dsyn),1.34e-06,72.55,16,9,0,14.06,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Surgical Patients (podg),5.48e-08,67.48,16,17,0,31.06,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Chronic Obstructive Airway Disease (dsyn),3.74e-10,65.91,16,33,0,23.76,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,End stage renal failure (dsyn),8.3e-11,69.44,16,18,0,30.22,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Pancreatitis (dsyn),2.98e-06,67.59,16,13,0,23.56,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Pulmonary Embolism (dsyn),4.76e-07,67.9,16,14,0,26.25,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Aortic Valve Stenosis (dsyn),4.77e-07,67.47,16,15,0,29.06,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Coronary heart disease (dsyn),8.81e-09,66.9,16,21,0,28.19,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Frailty (fndg),1.88e-06,72.08,16,9,0,14.06,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),USES,Brain natriuretic peptide (aapp),6.59e-09,68.7,16,16,0,32.0,5.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Chronic heart failure (dsyn),2.07e-09,68.18,16,18,0,30.22,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Heart failure (dsyn),8.58e-24,67.49,16,67,0,19.82,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,CARDIAC EVENT (dsyn),3.47e-06,73.84,16,8,0,12.0,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,Acute coronary syndrome (dsyn),7.06e-10,67.79,16,20,0,28.8,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),TREATS,End stage liver disease (dsyn),2.79e-14,76.31,16,17,0,31.06,4.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),METHOD_OF,Transplantation (topp),9.45e-10,66.14,16,29,0,24.83,5.0
Body mass index procedure (diap),ISA,Assessment procedure (hlca),METHOD_OF,Percutaneous coronary intervention (topp),3.47e-06,73.84,16,8,0,12.0,5.0
Atherosclerosis (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,"Kidney Failure, Chronic (dsyn)",2.36e-09,23.52,9,22,0,12.68,9.0
Atherosclerosis (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Survivors (humn),2.48e-09,22.94,9,17,0,13.76,1.0
Atherosclerosis (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,cohort (humn),1.52e-08,19.01,9,27,0,12.0,1.0
Atherosclerosis (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),1.62e-08,21.97,9,15,0,14.4,1.0
Atherosclerosis (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PREDISPOSES,Cardiovascular Diseases (dsyn),2.49e-09,20.17,9,24,0,12.38,9.0
Atherosclerosis (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,Participant (humn),2.36e-09,19.79,9,34,0,11.38,1.0
Atherosclerosis (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",PROCESS_OF,General Population (humn),2.36e-09,21.21,9,40,0,11.03,1.0
Atherosclerosis (dsyn),COEXISTS_WITH,"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,End stage renal failure (dsyn),3.57e-09,27.94,9,12,0,15.75,9.0
"Hypertrophy, Left Ventricular (patf)",PROCESS_OF,Participant (humn),USES,Medicare (rnlw),1.24e-09,19.15,11,18,0,17.72,1.0
